<pre>
<pre>2017-03-23_21-56-58 Restart Xvfb...
2017-03-23 21:56:59 start...
2017-03-23 21:56:59 reset updateRequest
2017-03-23 21:57:04  - 23147  http://www.lymphomahub.com/
2017-03-23 21:57:08  - 23147  http://www.lymphomahub.com/about
2017-03-23 21:57:12  - 23147  http://www.lymphomahub.com/terms
2017-03-23 21:57:15  - 23147  http://www.lymphomahub.com/undefined
2017-03-23 21:57:15  - 23147  http://www.lymphomahub.com/therapies
2017-03-23 21:57:21  - 23147  http://www.lymphomahub.com/newsletter
2017-03-23 21:57:24  - 23147  http://www.lymphomahub.com/cookie-policy
2017-03-23 21:57:27  - 23147  http://www.lymphomahub.com/therapies/afm13
2017-03-23 21:57:31  - 23147  http://www.lymphomahub.com/therapies/ags67e
2017-03-23 21:57:35  - 23147  http://www.lymphomahub.com/therapies/cc-292
2017-03-23 21:57:39  - 23147  http://www.lymphomahub.com/therapies/cc-223
2017-03-23 21:57:43  - 23147  http://www.lymphomahub.com/therapies/sd-101
2017-03-23 21:57:47  - 23147  http://www.lymphomahub.com/therapies/rp6530
2017-03-23 21:57:51  - 23147  http://www.lymphomahub.com/therapies/abt199
2017-03-23 21:57:52  - 23147  http://www.lymphomahub.com/therapies/mor208
2017-03-23 21:57:56  - 23147  http://www.lymphomahub.com/therapies/cc-122
2017-03-23 21:58:00  - 23147  http://www.lymphomahub.com/therapies/at-101
2017-03-23 21:58:03  - 23147  http://www.lymphomahub.com/therapies/bl8040
2017-03-23 21:58:07  - 23147  http://www.lymphomahub.com/therapies/bcl201
2017-03-23 21:58:11  - 23147  http://www.lymphomahub.com/therapies/azd3965
2017-03-23 21:58:15  - 23147  http://www.lymphomahub.com/therapies/imgn529
2017-03-23 21:58:19  - 23147  http://www.lymphomahub.com/therapies/azd2014
2017-03-23 21:58:23  - 23147  http://www.lymphomahub.com/therapies/mt-3724
2017-03-23 21:58:27  - 23147  http://www.lymphomahub.com/therapies/actr087
2017-03-23 21:58:31  - 23147  http://www.lymphomahub.com/therapies/epz6438
2017-03-23 21:58:35  - 23147  http://www.lymphomahub.com/therapies/kte-c19
2017-03-23 21:58:39  - 23147  http://www.lymphomahub.com/about/secretariat
2017-03-23 21:58:42  - 23147  http://www.lymphomahub.com/therapies/alt-803
2017-03-23 21:58:46  - 23147  http://www.lymphomahub.com/therapies/regn1979
2017-03-23 21:58:50  - 23147  http://www.lymphomahub.com/therapies/immu-114
2017-03-23 21:58:54  - 23147  http://www.lymphomahub.com/therapies/incb7839
2017-03-23 21:58:58  - 23147  http://www.lymphomahub.com/therapies/adct-301
<pre>2017-03-23_21-58-58 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/adct-301?_prerender {"code":"ECONNRESET"}
<pre>2017-03-23_22-00-58 Restart Xvfb...
2017-03-23 22:01:03  - 23147  http://www.lymphomahub.com/therapies/adct-301
2017-03-23 22:01:07  - 23147  http://www.lymphomahub.com/therapies/ixazomib
2017-03-23 22:01:11  - 23147  http://www.lymphomahub.com/therapies/avelumab
2017-03-23 22:01:15  - 23147  http://www.lymphomahub.com/therapies/bi836826
2017-03-23 22:01:19  - 23147  http://www.lymphomahub.com/therapies/medi-570
2017-03-23 22:01:23  - 23147  http://www.lymphomahub.com/therapies/ds-3201b
2017-03-23 22:01:27  - 23147  http://www.lymphomahub.com/therapies/sea-cd40
2017-03-23 22:01:30  - 23147  http://www.lymphomahub.com/therapies/adct-402
2017-03-23 22:01:34  - 23147  http://www.lymphomahub.com/therapies/acy-1215
2017-03-23 22:01:38  - 23147  http://www.lymphomahub.com/therapies/cudc-907
2017-03-23 22:01:43  - 23147  http://www.lymphomahub.com/therapies/tgr-1202
2017-03-23 22:01:47  - 23147  http://www.lymphomahub.com/therapies/axitinib
2017-03-23 22:01:52  - 23147  http://www.lymphomahub.com/therapies/imatinib
2017-03-23 22:01:56  - 23147  http://www.lymphomahub.com/therapies/edo-s101
2017-03-23 22:02:00  - 23147  http://www.lymphomahub.com/therapies/btct4465a
2017-03-23 22:02:05  - 23147  http://www.lymphomahub.com/therapies/alisertib
2017-03-23 22:02:10  - 23147  http://www.lymphomahub.com/therapies/lirilumab
2017-03-23 22:02:15  - 23147  http://www.lymphomahub.com/therapies/ibrutinib
2017-03-23 22:02:15  - 23147  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-03-23 22:02:20  - 23147  http://www.lymphomahub.com/therapies/rituximab
2017-03-23 22:02:24  - 23147  http://www.lymphomahub.com/therapies/veliparib
2017-03-23 22:02:29  - 23147  http://www.lymphomahub.com/therapies/sunitinib
2017-03-23 22:02:34  - 23147  http://www.lymphomahub.com/therapies/nivolumab
2017-03-23 22:02:34  - 23147  http://www.lymphomahub.com/therapies/sirolimus
2017-03-23 22:02:39  - 23147  http://www.lymphomahub.com/medical-information
2017-03-23 22:02:42  - 23147  http://www.lymphomahub.com/therapies/selinexor
2017-03-23 22:02:47  - 23147  http://www.lymphomahub.com/therapies/abc294640
2017-03-23 22:02:51  - 23147  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-03-23 22:02:56  - 23147  http://www.lymphomahub.com/therapies/tenofovir
<pre>2017-03-23_22-02-58 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/tenofovir?_prerender {"code":"ECONNRESET"}
<pre>2017-03-23_22-04-58 Restart Xvfb...
2017-03-23 22:05:01  - 23147  http://www.lymphomahub.com/therapies/tenofovir
2017-03-23 22:05:05  - 23147  http://www.lymphomahub.com/therapies/betalutin
2017-03-23 22:05:10  - 23147  http://www.lymphomahub.com/therapies/chidamide
2017-03-23 22:05:14  - 23147  http://www.lymphomahub.com/therapies/duvelisib
2017-03-23 22:05:19  - 23147  http://www.lymphomahub.com/therapies/dasatinib
2017-03-23 22:05:23  - 23147  http://www.lymphomahub.com/therapies/everolimus
2017-03-23 22:05:28  - 23147  http://www.lymphomahub.com/therapies/incb039110
2017-03-23 22:05:32  - 23147  http://www.lymphomahub.com/therapies/durvalumab
2017-03-23 22:05:37  - 23147  http://www.lymphomahub.com/therapies/romidepsin
2017-03-23 22:05:42  - 23147  http://www.lymphomahub.com/therapies/bortezomib
2017-03-23 22:05:46  - 23147  http://www.lymphomahub.com/therapies/idelalisib
2017-03-23 22:05:47  - 23147  http://www.lymphomahub.com/therapies/tipifarnib
2017-03-23 22:05:51  - 23147  http://www.lymphomahub.com/therapies/ipilimumab
2017-03-23 22:05:56  - 23147  http://www.lymphomahub.com/therapies/crizotinib
2017-03-23 22:06:00  - 23147  http://www.lymphomahub.com/therapies/gsk2816126
2017-03-23 22:06:05  - 23147  http://www.lymphomahub.com/therapies/copanlisib
2017-03-23 22:06:09  - 23147  http://www.lymphomahub.com/therapies/buparlisib
2017-03-23 22:06:13  - 23147  http://www.lymphomahub.com/therapies/belinostat
2017-03-23 22:06:18  - 23147  http://www.lymphomahub.com/therapies/vorinostat
2017-03-23 22:06:23  - 23147  http://www.lymphomahub.com/therapies/plerixafor
2017-03-23 22:06:23  - 23147  http://www.lymphomahub.com/therapies/ofatumumab
2017-03-23 22:06:28  - 23147  http://www.lymphomahub.com/therapies/pf-06801591
2017-03-23 22:06:32  - 23147  http://www.lymphomahub.com/therapies/tocilizumab
2017-03-23 22:06:37  - 23147  http://www.lymphomahub.com/therapies/msc2490484a
2017-03-23 22:06:41  - 23147  http://www.lymphomahub.com/therapies/carfilzomib
2017-03-23 22:06:46  - 23147  http://www.lymphomahub.com/therapies/ruxolitinib
2017-03-23 22:06:50  - 23147  http://www.lymphomahub.com/therapies/palbociclib
2017-03-23 22:06:55  - 23147  http://www.lymphomahub.com/therapies/fenretinide
<pre>2017-03-23_22-06-58 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/fenretinide?_prerender {"code":"ECONNRESET"}
<pre>2017-03-23_22-08-58 Restart Xvfb...
2017-03-23 22:09:00  - 23147  http://www.lymphomahub.com/therapies/fenretinide
2017-03-23 22:09:04  - 23147  http://www.lymphomahub.com/therapies/daratumumab
2017-03-23 22:09:09  - 23147  http://www.lymphomahub.com/therapies/pf-05082566
2017-03-23 22:09:13  - 23147  http://www.lymphomahub.com/therapies/ramucirumab
2017-03-23 22:09:18  - 23147  http://www.lymphomahub.com/therapies/tositumomab
2017-03-23 22:09:22  - 23147  http://www.lymphomahub.com/therapies/ublituximab
2017-03-23 22:09:26  - 23147  http://www.lymphomahub.com/therapies/epacadostat
2017-03-23 22:09:31  - 23147  http://www.lymphomahub.com/therapies/alemtuzumab
2017-03-23 22:09:32  - 23147  http://www.lymphomahub.com/therapies/otlertuzumab
2017-03-23 22:09:36  - 23147  http://www.lymphomahub.com/therapies/panobinostat
2017-03-23 22:09:40  - 23147  http://www.lymphomahub.com/therapies/mocetinostat
2017-03-23 22:09:45  - 23147  http://www.lymphomahub.com/therapies/atezolizumab
2017-03-23 22:09:49  - 23147  http://www.lymphomahub.com/therapies/temsirolimus
2017-03-23 22:09:54  - 23147  http://www.lymphomahub.com/therapies/lenalidomide
2017-03-23 22:09:59  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab
2017-03-23 22:10:04  - 23147  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-03-23 22:10:08  - 23147  http://www.lymphomahub.com/therapies/blinatumomab
2017-03-23 22:10:13  - 23147  http://www.lymphomahub.com/therapies/jnj-64052781
2017-03-23 22:10:17  - 23147  http://www.lymphomahub.com/therapies/entospletinib
2017-03-23 22:10:22  - 23147  http://www.lymphomahub.com/therapies/pembrolizumab
2017-03-23 22:10:26  - 23147  http://www.lymphomahub.com/therapies/acalabrutinib
2017-03-23 22:10:31  - 23147  http://www.lymphomahub.com/about/innovation-committee
2017-03-23 22:10:36  - 23147  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-03-23 22:10:37  - 23147  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-03-23 22:10:41  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-03-23 22:10:45  - 23147  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-03-23 22:10:50  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-03-23 22:10:54  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-03-23 22:10:55  - 23147  http://www.lymphomahub.com/therapies/denileukin-diftitox
<pre>2017-03-23_22-10-58 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/denileukin-diftitox?_prerender {"code":"ECONNRESET"}
<pre>2017-03-23_22-12-58 Restart Xvfb...
2017-03-23 22:13:00  - 23147  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-03-23 22:13:04  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-03-23 22:13:09  - 23147  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-03-23 22:13:13  - 23147  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-03-23 22:13:17  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board
2017-03-23 22:13:20  - 23147  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-03-23 22:13:25  - 23147  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-03-23 22:13:28  - 23147  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-03-23 22:13:32  - 23147  http://www.lymphomahub.com/about/executive-steering-committee
2017-03-23 22:13:36  - 23147  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-03-23 22:13:39  - 23147  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-03-23 22:13:45  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-03-23 22:13:49  - 23147  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-03-23 22:13:53  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-03-23 22:13:57  - 23147  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-03-23 22:14:01  - 23147  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-03-23 22:14:02  - 23147  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-03-23 22:14:06  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-03-23 22:14:11  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-03-23 22:14:16  - 23147  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-03-23 22:14:19  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-03-23 22:14:24  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-03-23 22:14:29  - 23147  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-03-23 22:14:33  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-03-23 22:14:36  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-03-23 22:14:40  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-03-23 22:14:44  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-03-23 22:14:48  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-03-23 22:14:51  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-03-23 22:14:55  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
<pre>2017-03-23_22-14-58 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule?_prerender {"code":"ECONNRESET"}
<pre>2017-03-23_22-16-58 Restart Xvfb...
2017-03-23 22:17:00  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-03-23 22:17:04  - 23147  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-03-23 22:17:09  - 23147  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-03-23 22:17:13  - 23147  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-03-23 22:17:18  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-03-23 22:17:21  - 23147  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-03-23 22:17:25  - 23147  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-03-23 22:17:29  - 23147  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-03-23 22:17:34  - 23147  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-03-23 22:17:39  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-03-23 22:17:43  - 23147  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-03-23 22:17:48  - 23147  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-03-23 22:17:53  - 23147  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-03-23 22:17:57  - 23147  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-03-23 22:18:02  - 23147  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-03-23 22:18:06  - 23147  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-03-23 22:18:11  - 23147  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-03-23 22:18:16  - 23147  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-03-23 22:18:20  - 23147  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-03-23 22:18:24  - 23147  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-03-23 22:18:29  - 23147  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-03-23 22:18:33  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-03-23 22:18:37  - 23147  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-03-23 22:18:42  - 23147  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-03-23 22:18:46  - 23147  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-03-23 22:18:50  - 23147  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-03-23 22:18:55  - 23147  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
<pre>2017-03-23_22-18-58 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/?_prerender {"code":"ECONNRESET"}
<pre>2017-03-23_22-20-58 Restart Xvfb...
2017-03-23 22:21:00  - 23147  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-03-23 22:21:03  - 23147  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-03-23 22:21:07  - 23147  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-03-23 22:21:11  - 23147  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-03-23 22:21:16  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-03-23 22:21:20  - 23147  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-03-23 22:21:24  - 23147  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-03-23 22:21:29  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-03-23 22:21:33  - 23147  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-03-23 22:21:37  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-03-23 22:21:41  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-03-23 22:21:45  - 23147  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-03-23 22:21:49  - 23147  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-03-23 22:21:54  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-03-23 22:21:58  - 23147  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-03-23 22:22:03  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-03-23 22:22:07  - 23147  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-03-23 22:22:12  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-03-23 22:22:16  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-03-23 22:22:21  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-03-23 22:22:24  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-03-23 22:22:29  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-03-23 22:22:34  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-03-23 22:22:37  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-03-23 22:22:41  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-03-23 22:22:46  - 23147  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-03-23 22:22:51  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-03-23 22:22:56  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
<pre>2017-03-23_22-22-59 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma?_prerender {"code":"ECONNRESET"}
<pre>2017-03-23_22-24-59 Restart Xvfb...
2017-03-23 22:25:01  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-03-23 22:25:06  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-03-23 22:25:11  - 23147  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-23 22:25:12  - 23147  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-03-23 22:25:17  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-03-23 22:25:21  - 23147  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-03-23 22:25:26  - 23147  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-03-23 22:25:36  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-03-23 22:25:41  - 23147  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-03-23 22:25:45  - 23147  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-03-23 22:25:55  - 23147  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-03-23 22:26:00  - 23147  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-03-23 22:26:05  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-03-23 22:26:10  - 23147  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-03-23 22:26:14  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-03-23 22:26:19  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-03-23 22:26:23  - 23147  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-03-23 22:26:28  - 23147  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-03-23 22:26:32  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-03-23 22:26:37  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-03-23 22:26:42  - 23147  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-03-23 22:26:47  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-03-23 22:26:52  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-03-23 22:26:56  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
<pre>2017-03-23_22-26-59 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen?_prerender {"code":"ECONNRESET"}
<pre>2017-03-23_22-28-59 Restart Xvfb...
2017-03-23 22:29:02  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-03-23 22:29:07  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-03-23 22:29:12  - 23147  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-23 22:29:16  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-03-23 22:29:21  - 23147  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-03-23 22:29:26  - 23147  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-03-23 22:29:30  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-03-23 22:29:35  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-03-23 22:29:40  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-03-23 22:29:44  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-03-23 22:29:49  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-03-23 22:29:54  - 23147  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-03-23 22:29:59  - 23147  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-03-23 22:30:03  - 23147  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-03-23 22:30:08  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-03-23 22:30:14  - 23147  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-03-23 22:30:20  - 23147  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-03-23 22:30:25  - 23147  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-03-23 22:30:25  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-03-23 22:30:30  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-03-23 22:30:34  - 23147  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-03-23 22:30:39  - 23147  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-03-23 22:30:44  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-03-23 22:30:49  - 23147  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-03-23 22:30:54  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-03-23 22:30:58  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
<pre>2017-03-23_22-30-59 Restart Xvfb...
2017-03-23 22:31:03  - 23147  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-03-23 22:31:08  - 23147  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-03-23 22:31:13  - 23147  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-03-23 22:31:18  - 23147  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-03-23 22:31:23  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-03-23 22:31:27  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-03-23 22:31:32  - 23147  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-03-23 22:31:37  - 23147  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-03-23 22:31:41  - 23147  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-03-23 22:31:46  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-03-23 22:31:50  - 23147  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-03-23 22:31:55  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-03-23 22:32:00  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-03-23 22:32:03  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-03-23 22:32:09  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-03-23 22:32:13  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-03-23 22:32:17  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-03-23 22:32:21  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-03-23 22:32:25  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-03-23 22:32:29  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-03-23 22:32:33  - 23147  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-03-23 22:32:34  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-03-23 22:32:39  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-03-23 22:32:43  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-03-23 22:32:47  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-03-23 22:32:51  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-03-23 22:32:54  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
<pre>2017-03-23_22-32-59 Restart Xvfb...
2017-03-23 22:32:59  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-03-23 22:33:02  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-03-23 22:33:06  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-03-23 22:33:10  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-03-23 22:33:13  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-03-23 22:33:17  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-03-23 22:33:20  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-03-23 22:33:24  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-03-23 22:33:28  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-03-23 22:33:32  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-03-23 22:33:36  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-03-23 22:33:40  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-03-23 22:33:43  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-03-23 22:33:47  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-03-23 22:33:51  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-03-23 22:33:55  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-03-23 22:33:59  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-03-23 22:34:02  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-03-23 22:34:06  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-03-23 22:34:10  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-03-23 22:34:13  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-03-23 22:34:17  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-03-23 22:34:21  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-03-23 22:34:25  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-03-23 22:34:28  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-03-23 22:34:32  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-03-23 22:34:36  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-03-23 22:34:39  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-03-23 22:34:43  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-03-23 22:34:47  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-03-23 22:34:50  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-03-23 22:34:54  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-03-23 22:34:58  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
<pre>2017-03-23_22-34-59 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/?_prerender {"code":"ECONNRESET"}
<pre>2017-03-23_22-36-59 Restart Xvfb...
2017-03-23 22:37:03  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-03-23 22:37:07  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-03-23 22:37:10  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-03-23 22:37:14  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-03-23 22:37:17  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-03-23 22:37:21  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-03-23 22:37:25  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-03-23 22:37:29  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-03-23 22:37:32  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-03-23 22:37:36  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-03-23 22:37:40  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-03-23 22:37:43  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-03-23 22:37:48  - 23147  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-03-23 22:37:53  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-03-23 22:37:58  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-03-23 22:38:02  - 23147  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-03-23 22:38:03  - 23147  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-03-23 22:38:07  - 23147  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-03-23 22:38:12  - 23147  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-03-23 22:38:16  - 23147  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-03-23 22:38:21  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-03-23 22:38:25  - 23147  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-03-23 22:38:30  - 23147  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-03-23 22:38:34  - 23147  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-03-23 22:38:39  - 23147  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-03-23 22:38:43  - 23147  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-03-23 22:38:48  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-03-23 22:38:53  - 23147  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-03-23 22:38:57  - 23147  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
<pre>2017-03-23_22-38-59 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs?_prerender {"code":"ECONNRESET"}
<pre>2017-03-23_22-40-59 Restart Xvfb...
2017-03-23 22:41:02  - 23147  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-03-23 22:41:07  - 23147  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-03-23 22:41:12  - 23147  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-03-23 22:41:16  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-03-23 22:41:21  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-03-23 22:41:26  - 23147  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-03-23 22:41:30  - 23147  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-03-23 22:41:35  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-03-23 22:41:40  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-03-23 22:41:44  - 23147  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-23 22:41:49  - 23147  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-03-23 22:41:53  - 23147  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-03-23 22:41:58  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-03-23 22:42:03  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-03-23 22:42:08  - 23147  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-03-23 22:42:13  - 23147  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-03-23 22:42:17  - 23147  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-03-23 22:42:22  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-03-23 22:42:26  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-03-23 22:42:31  - 23147  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-23 22:42:35  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-03-23 22:42:40  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-03-23 22:42:44  - 23147  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-03-23 22:42:49  - 23147  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-03-23 22:42:54  - 23147  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-03-23 22:42:58  - 23147  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
<pre>2017-03-23_22-42-59 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll?_prerender {"code":"ECONNRESET"}
<pre>2017-03-23_22-44-59 Restart Xvfb...
2017-03-23 22:45:03  - 23147  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-03-23 22:45:08  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-03-23 22:45:13  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-03-23 22:45:17  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-03-23 22:45:22  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-03-23 22:45:26  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-03-23 22:45:31  - 23147  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-03-23 22:45:36  - 23147  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-03-23 22:45:41  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-03-23 22:45:45  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-03-23 22:45:50  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-03-23 22:45:54  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-03-23 22:45:59  - 23147  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-03-23 22:46:03  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-03-23 22:46:08  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-03-23 22:46:12  - 23147  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-03-23 22:46:17  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-03-23 22:46:21  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-03-23 22:46:26  - 23147  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-03-23 22:46:31  - 23147  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-03-23 22:46:35  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-03-23 22:46:40  - 23147  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-03-23 22:46:44  - 23147  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-03-23 22:46:49  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-03-23 22:46:54  - 23147  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-03-23 22:46:59  - 23147  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
<pre>2017-03-23_22-46-59 Restart Xvfb...
2017-03-23 22:47:03  - 23147  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-03-23 22:47:08  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-03-23 22:47:12  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-03-23 22:47:17  - 23147  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-03-23 22:47:21  - 23147  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-03-23 22:47:26  - 23147  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-03-23 22:47:30  - 23147  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-03-23 22:47:35  - 23147  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-03-23 22:47:40  - 23147  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-03-23 22:47:44  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-03-23 22:47:49  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-03-23 22:47:54  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-03-23 22:47:58  - 23147  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-03-23 22:48:03  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-03-23 22:48:08  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-03-23 22:48:13  - 23147  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-03-23 22:48:17  - 23147  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-03-23 22:48:22  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-03-23 22:48:26  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-03-23 22:48:31  - 23147  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-03-23 22:48:35  - 23147  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-03-23 22:48:40  - 23147  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-03-23 22:48:44  - 23147  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-03-23 22:48:48  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-03-23 22:48:53  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-03-23 22:48:58  - 23147  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
<pre>2017-03-23_22-48-59 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd?_prerender {"code":"ECONNRESET"}
<pre>2017-03-23_22-50-59 Restart Xvfb...
2017-03-23 22:51:03  - 23147  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-03-23 22:51:07  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-03-23 22:51:12  - 23147  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-03-23 22:51:17  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-03-23 22:51:21  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-03-23 22:51:26  - 23147  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-03-23 22:51:31  - 23147  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-03-23 22:51:35  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-03-23 22:51:40  - 23147  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-03-23 22:51:46  - 23147  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-03-23 22:51:51  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-03-23 22:51:56  - 23147  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-03-23 22:52:00  - 23147  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-03-23 22:52:05  - 23147  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-03-23 22:52:10  - 23147  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-03-23 22:52:14  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-03-23 22:52:19  - 23147  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-03-23 22:52:23  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-03-23 22:52:28  - 23147  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-03-23 22:52:33  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-03-23 22:52:37  - 23147  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-03-23 22:52:43  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-03-23 22:52:48  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-03-23 22:52:53  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-03-23 22:52:58  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
<pre>2017-03-23_22-52-59 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl?_prerender {"code":"ECONNRESET"}
<pre>2017-03-23_22-54-59 Restart Xvfb...
2017-03-23 22:55:03  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-03-23 22:55:08  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-03-23 22:55:13  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-03-23 22:55:17  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-03-23 22:55:22  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-03-23 22:55:27  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-03-23 22:55:31  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-03-23 22:55:36  - 23147  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-03-23 22:55:41  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-03-23 22:55:45  - 23147  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-03-23 22:55:49  - 23147  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-03-23 22:55:54  - 23147  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-03-23 22:55:59  - 23147  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-03-23 22:56:04  - 23147  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-03-23 22:56:08  - 23147  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-03-23 22:56:13  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-03-23 22:56:18  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-03-23 22:56:23  - 23147  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-03-23 22:56:27  - 23147  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-03-23 22:56:32  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-03-23 22:56:37  - 23147  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-03-23 22:56:42  - 23147  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-03-23 22:56:46  - 23147  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-03-23 22:56:51  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-03-23 22:56:56  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
<pre>2017-03-23_22-56-59 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study?_prerender {"code":"ECONNRESET"}
<pre>2017-03-23_22-58-59 Restart Xvfb...
2017-03-23 22:59:01  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-03-23 22:59:05  - 23147  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-03-23 22:59:10  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-03-23 22:59:15  - 23147  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-03-23 22:59:19  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-03-23 22:59:24  - 23147  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-03-23 22:59:29  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-03-23 22:59:33  - 23147  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-03-23 22:59:38  - 23147  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-03-23 22:59:42  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-03-23 22:59:47  - 23147  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-03-23 22:59:51  - 23147  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-03-23 22:59:56  - 23147  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-03-23 23:00:00  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-03-23 23:00:06  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-03-23 23:00:10  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-03-23 23:00:15  - 23147  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-03-23 23:00:20  - 23147  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-03-23 23:00:24  - 23147  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-03-23 23:00:28  - 23147  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-03-23 23:00:32  - 23147  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-03-23 23:00:37  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-03-23 23:00:41  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-03-23 23:00:46  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-03-23 23:00:50  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-03-23 23:00:55  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
<pre>2017-03-23_23-00-59 Restart Xvfb...
2017-03-23 23:00:59  - 23147  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-03-23 23:01:04  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-03-23 23:01:09  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-03-23 23:01:13  - 23147  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-03-23 23:01:18  - 23147  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-03-23 23:01:22  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-03-23 23:01:25  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-03-23 23:01:30  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-03-23 23:01:34  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-03-23 23:01:39  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-03-23 23:01:44  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-03-23 23:01:48  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-03-23 23:01:52  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-03-23 23:01:57  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-03-23 23:02:01  - 23147  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-03-23 23:02:05  - 23147  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-03-23 23:02:09  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-03-23 23:02:14  - 23147  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-03-23 23:02:18  - 23147  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-03-23 23:02:22  - 23147  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-03-23 23:02:27  - 23147  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-03-23 23:02:32  - 23147  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-03-23 23:02:36  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-03-23 23:02:42  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-03-23 23:02:46  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-03-23 23:02:51  - 23147  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-03-23 23:02:55  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
<pre>2017-03-23_23-02-59 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas?_prerender {"code":"ECONNRESET"}
<pre>2017-03-23_23-04-59 Restart Xvfb...
2017-03-23 23:05:01  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-03-23 23:05:05  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-03-23 23:05:09  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-03-23 23:05:13  - 23147  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-03-23 23:05:18  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-03-23 23:05:22  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-03-23 23:05:27  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-03-23 23:05:31  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-03-23 23:05:36  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-03-23 23:05:40  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-03-23 23:05:44  - 23147  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-03-23 23:05:49  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-03-23 23:05:53  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-03-23 23:05:57  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-03-23 23:06:02  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-03-23 23:06:07  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-03-23 23:06:11  - 23147  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-03-23 23:06:16  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-03-23 23:06:20  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-03-23 23:06:24  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-03-23 23:06:28  - 23147  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-03-23 23:06:33  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-03-23 23:06:38  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-03-23 23:06:42  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-03-23 23:06:47  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-03-23 23:06:51  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-03-23 23:06:55  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-03-23 23:06:59  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
<pre>2017-03-23_23-06-59 Restart Xvfb...
2017-03-23 23:07:03  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-03-23 23:07:07  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-03-23 23:07:12  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-03-23 23:07:17  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-03-23 23:07:20  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-03-23 23:07:24  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-03-23 23:07:29  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-03-23 23:07:33  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-03-23 23:07:36  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-03-23 23:07:40  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-03-23 23:07:45  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-03-23 23:07:49  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-03-23 23:07:53  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-03-23 23:07:58  - 23147  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-03-23 23:08:02  - 23147  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-03-23 23:08:06  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-03-23 23:08:10  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-03-23 23:08:14  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-03-23 23:08:19  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-03-23 23:08:23  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-03-23 23:08:28  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-03-23 23:08:32  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-03-23 23:08:37  - 23147  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-03-23 23:08:41  - 23147  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-03-23 23:08:45  - 23147  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-03-23 23:08:49  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-03-23 23:08:54  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-03-23 23:08:58  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
<pre>2017-03-23_23-08-59 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy?_prerender {"code":"ECONNRESET"}
<pre>2017-03-23_23-10-59 Restart Xvfb...
2017-03-23 23:11:03  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-03-23 23:11:07  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-03-23 23:11:12  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-03-23 23:11:16  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-23 23:11:20  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-23 23:11:24  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-23 23:11:28  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-23 23:11:32  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-03-23 23:11:36  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-23 23:11:40  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-23 23:11:44  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-03-23 23:11:48  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-03-23 23:11:52  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-03-23 23:11:56  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-03-23 23:12:00  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-03-23 23:12:05  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-03-23 23:12:09  - 23147  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-03-23 23:12:13  - 23147  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-03-23 23:12:17  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-03-23 23:12:21  - 23147  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-03-23 23:12:25  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-03-23 23:12:30  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-03-23 23:12:34  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-03-23 23:12:38  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-03-23 23:12:42  - 23147  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-03-23 23:12:46  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-03-23 23:12:50  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-03-23 23:12:54  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-03-23 23:12:58  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
<pre>2017-03-23_23-12-59 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities?_prerender {"code":"ECONNRESET"}
<pre>2017-03-23_23-14-59 Restart Xvfb...
2017-03-23 23:15:04  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-03-23 23:15:08  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-03-23 23:15:12  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-23 23:15:16  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-23 23:15:20  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-23 23:15:24  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-23 23:15:28  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-23 23:15:32  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-03-23 23:15:36  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-23 23:15:40  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-23 23:15:45  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-23 23:15:49  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-23 23:15:53  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-03-23 23:15:57  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-23 23:16:01  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-23 23:16:05  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-23 23:16:10  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-03-23 23:16:14  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
<pre>2017-03-23_23-16-59 Restart Xvfb...
<pre>2017-03-23_23-18-59 Restart Xvfb...
<pre>2017-03-23_23-20-59 Restart Xvfb...
<pre>2017-03-23_23-22-59 Restart Xvfb...
<pre>2017-03-23_23-24-59 Restart Xvfb...
<pre>2017-03-23_23-26-59 Restart Xvfb...
<pre>2017-03-23_23-28-59 Restart Xvfb...
<pre>2017-03-23_23-30-59 Restart Xvfb...
<pre>2017-03-23_23-32-59 Restart Xvfb...
<pre>2017-03-23_23-34-59 Restart Xvfb...
<pre>2017-03-23_23-36-59 Restart Xvfb...
<pre>2017-03-23_23-38-59 Restart Xvfb...
<pre>2017-03-23_23-40-59 Restart Xvfb...
<pre>2017-03-23_23-42-59 Restart Xvfb...
<pre>2017-03-23_23-45-00 Restart Xvfb...
<pre>2017-03-23_23-47-00 Restart Xvfb...
<pre>2017-03-23_23-49-00 Restart Xvfb...
<pre>2017-03-23_23-51-00 Restart Xvfb...
<pre>2017-03-23_23-53-00 Restart Xvfb...
<pre>2017-03-23_23-55-00 Restart Xvfb...
<pre>2017-03-23_23-57-00 Restart Xvfb...
<pre>2017-03-23_23-59-00 Restart Xvfb...
<pre>2017-03-24_00-01-00 Restart Xvfb...
<pre>2017-03-24_00-03-00 Restart Xvfb...
<pre>2017-03-24_00-05-00 Restart Xvfb...
<pre>2017-03-24_00-07-00 Restart Xvfb...
<pre>2017-03-24_00-09-00 Restart Xvfb...
<pre>2017-03-24_00-11-00 Restart Xvfb...
<pre>2017-03-24_00-13-00 Restart Xvfb...
<pre>2017-03-24_00-15-00 Restart Xvfb...
<pre>2017-03-24_00-17-00 Restart Xvfb...
<pre>2017-03-24_00-19-00 Restart Xvfb...
<pre>2017-03-24_00-21-00 Restart Xvfb...
<pre>2017-03-24_00-23-00 Restart Xvfb...
<pre>2017-03-24_00-25-00 Restart Xvfb...
<pre>2017-03-24_00-27-00 Restart Xvfb...
<pre>2017-03-24_00-29-00 Restart Xvfb...
<pre>2017-03-24_00-31-00 Restart Xvfb...
<pre>2017-03-24_00-33-00 Restart Xvfb...
<pre>2017-03-24_00-35-00 Restart Xvfb...
<pre>2017-03-24_00-37-00 Restart Xvfb...
<pre>2017-03-24_00-39-00 Restart Xvfb...
<pre>2017-03-24_00-41-00 Restart Xvfb...
<pre>2017-03-24_00-43-00 Restart Xvfb...
<pre>2017-03-24_00-45-00 Restart Xvfb...
<pre>2017-03-24_00-47-00 Restart Xvfb...
<pre>2017-03-24_00-49-00 Restart Xvfb...
<pre>2017-03-24_00-51-00 Restart Xvfb...
<pre>2017-03-24_00-53-00 Restart Xvfb...
<pre>2017-03-24_00-55-00 Restart Xvfb...
2017-03-24 00:56:59 reset updateRequest
<pre>2017-03-24_00-57-00 Restart Xvfb...
2017-03-24 00:57:01  - 23147  http://www.lymphomahub.com/
2017-03-24 00:57:04  - 23147  http://www.lymphomahub.com/
2017-03-24 00:57:06  - 23147  http://www.lymphomahub.com/about
2017-03-24 00:57:08  - 23147  http://www.lymphomahub.com/about
2017-03-24 00:57:12  - 23147  http://www.lymphomahub.com/terms
2017-03-24 00:57:12  - 23147  http://www.lymphomahub.com/terms
2017-03-24 00:57:16  - 23147  http://www.lymphomahub.com/undefined
2017-03-24 00:57:16  - 23147  http://www.lymphomahub.com/undefined
2017-03-24 00:57:17  - 23147  http://www.lymphomahub.com/therapies
2017-03-24 00:57:17  - 23147  http://www.lymphomahub.com/therapies
2017-03-24 00:57:26  - 23147  http://www.lymphomahub.com/newsletter
2017-03-24 00:57:27  - 23147  http://www.lymphomahub.com/newsletter
2017-03-24 00:57:31  - 23147  http://www.lymphomahub.com/cookie-policy
2017-03-24 00:57:31  - 23147  http://www.lymphomahub.com/cookie-policy
2017-03-24 00:57:34  - 23147  http://www.lymphomahub.com/therapies/afm13
2017-03-24 00:57:35  - 23147  http://www.lymphomahub.com/therapies/afm13
2017-03-24 00:57:40  - 23147  http://www.lymphomahub.com/therapies/ags67e
2017-03-24 00:57:40  - 23147  http://www.lymphomahub.com/therapies/ags67e
2017-03-24 00:57:46  - 23147  http://www.lymphomahub.com/therapies/cc-292
2017-03-24 00:57:46  - 23147  http://www.lymphomahub.com/therapies/cc-292
2017-03-24 00:57:51  - 23147  http://www.lymphomahub.com/therapies/cc-223
2017-03-24 00:57:51  - 23147  http://www.lymphomahub.com/therapies/cc-223
2017-03-24 00:57:57  - 23147  http://www.lymphomahub.com/therapies/sd-101
2017-03-24 00:58:01  - 23147  http://www.lymphomahub.com/therapies/rp6530
2017-03-24 00:58:06  - 23147  http://www.lymphomahub.com/therapies/abt199
2017-03-24 00:58:06  - 23147  http://www.lymphomahub.com/therapies/mor208
2017-03-24 00:58:11  - 23147  http://www.lymphomahub.com/therapies/cc-122
2017-03-24 00:58:15  - 23147  http://www.lymphomahub.com/therapies/at-101
2017-03-24 00:58:20  - 23147  http://www.lymphomahub.com/therapies/bl8040
2017-03-24 00:58:24  - 23147  http://www.lymphomahub.com/therapies/bcl201
2017-03-24 00:58:29  - 23147  http://www.lymphomahub.com/therapies/azd3965
2017-03-24 00:58:33  - 23147  http://www.lymphomahub.com/therapies/imgn529
2017-03-24 00:58:38  - 23147  http://www.lymphomahub.com/therapies/azd2014
2017-03-24 00:58:42  - 23147  http://www.lymphomahub.com/therapies/mt-3724
2017-03-24 00:58:46  - 23147  http://www.lymphomahub.com/therapies/actr087
2017-03-24 00:58:51  - 23147  http://www.lymphomahub.com/therapies/epz6438
2017-03-24 00:58:55  - 23147  http://www.lymphomahub.com/therapies/kte-c19
2017-03-24 00:59:00  - 23147  http://www.lymphomahub.com/about/secretariat
<pre>2017-03-24_00-59-00 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about/secretariat?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_01-01-00 Restart Xvfb...
2017-03-24 01:01:05  - 23147  http://www.lymphomahub.com/about/secretariat
2017-03-24 01:01:09  - 23147  http://www.lymphomahub.com/therapies/alt-803
2017-03-24 01:01:13  - 23147  http://www.lymphomahub.com/therapies/regn1979
2017-03-24 01:01:17  - 23147  http://www.lymphomahub.com/therapies/immu-114
2017-03-24 01:01:22  - 23147  http://www.lymphomahub.com/therapies/incb7839
2017-03-24 01:01:26  - 23147  http://www.lymphomahub.com/therapies/adct-301
2017-03-24 01:01:31  - 23147  http://www.lymphomahub.com/therapies/ixazomib
2017-03-24 01:01:35  - 23147  http://www.lymphomahub.com/therapies/avelumab
2017-03-24 01:01:40  - 23147  http://www.lymphomahub.com/therapies/bi836826
2017-03-24 01:01:44  - 23147  http://www.lymphomahub.com/therapies/medi-570
2017-03-24 01:01:49  - 23147  http://www.lymphomahub.com/therapies/ds-3201b
2017-03-24 01:01:53  - 23147  http://www.lymphomahub.com/therapies/sea-cd40
2017-03-24 01:01:58  - 23147  http://www.lymphomahub.com/therapies/adct-402
2017-03-24 01:02:02  - 23147  http://www.lymphomahub.com/therapies/acy-1215
2017-03-24 01:02:07  - 23147  http://www.lymphomahub.com/therapies/cudc-907
2017-03-24 01:02:11  - 23147  http://www.lymphomahub.com/therapies/tgr-1202
2017-03-24 01:02:16  - 23147  http://www.lymphomahub.com/therapies/axitinib
2017-03-24 01:02:20  - 23147  http://www.lymphomahub.com/therapies/imatinib
2017-03-24 01:02:24  - 23147  http://www.lymphomahub.com/therapies/edo-s101
2017-03-24 01:02:29  - 23147  http://www.lymphomahub.com/therapies/btct4465a
2017-03-24 01:02:33  - 23147  http://www.lymphomahub.com/therapies/alisertib
2017-03-24 01:02:38  - 23147  http://www.lymphomahub.com/therapies/lirilumab
2017-03-24 01:02:42  - 23147  http://www.lymphomahub.com/therapies/ibrutinib
2017-03-24 01:02:43  - 23147  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-03-24 01:02:47  - 23147  http://www.lymphomahub.com/therapies/rituximab
2017-03-24 01:02:52  - 23147  http://www.lymphomahub.com/therapies/veliparib
2017-03-24 01:02:56  - 23147  http://www.lymphomahub.com/therapies/sunitinib
<pre>2017-03-24_01-03-00 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/sunitinib?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_01-05-00 Restart Xvfb...
2017-03-24 01:05:01  - 23147  http://www.lymphomahub.com/therapies/sunitinib
2017-03-24 01:05:05  - 23147  http://www.lymphomahub.com/therapies/nivolumab
2017-03-24 01:05:06  - 23147  http://www.lymphomahub.com/therapies/sirolimus
2017-03-24 01:05:11  - 23147  http://www.lymphomahub.com/medical-information
2017-03-24 01:05:14  - 23147  http://www.lymphomahub.com/therapies/selinexor
2017-03-24 01:05:19  - 23147  http://www.lymphomahub.com/therapies/abc294640
2017-03-24 01:05:23  - 23147  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-03-24 01:05:28  - 23147  http://www.lymphomahub.com/therapies/tenofovir
2017-03-24 01:05:32  - 23147  http://www.lymphomahub.com/therapies/betalutin
2017-03-24 01:05:37  - 23147  http://www.lymphomahub.com/therapies/chidamide
2017-03-24 01:05:41  - 23147  http://www.lymphomahub.com/therapies/duvelisib
2017-03-24 01:05:46  - 23147  http://www.lymphomahub.com/therapies/dasatinib
2017-03-24 01:05:50  - 23147  http://www.lymphomahub.com/therapies/everolimus
2017-03-24 01:05:55  - 23147  http://www.lymphomahub.com/therapies/incb039110
2017-03-24 01:05:59  - 23147  http://www.lymphomahub.com/therapies/durvalumab
2017-03-24 01:06:04  - 23147  http://www.lymphomahub.com/therapies/romidepsin
2017-03-24 01:06:08  - 23147  http://www.lymphomahub.com/therapies/bortezomib
2017-03-24 01:06:13  - 23147  http://www.lymphomahub.com/therapies/idelalisib
2017-03-24 01:06:14  - 23147  http://www.lymphomahub.com/therapies/tipifarnib
2017-03-24 01:06:18  - 23147  http://www.lymphomahub.com/therapies/ipilimumab
2017-03-24 01:06:23  - 23147  http://www.lymphomahub.com/therapies/crizotinib
2017-03-24 01:06:27  - 23147  http://www.lymphomahub.com/therapies/gsk2816126
2017-03-24 01:06:31  - 23147  http://www.lymphomahub.com/therapies/copanlisib
2017-03-24 01:06:36  - 23147  http://www.lymphomahub.com/therapies/buparlisib
2017-03-24 01:06:41  - 23147  http://www.lymphomahub.com/therapies/belinostat
2017-03-24 01:06:45  - 23147  http://www.lymphomahub.com/therapies/vorinostat
2017-03-24 01:06:50  - 23147  http://www.lymphomahub.com/therapies/plerixafor
2017-03-24 01:06:51  - 23147  http://www.lymphomahub.com/therapies/ofatumumab
2017-03-24 01:06:55  - 23147  http://www.lymphomahub.com/therapies/pf-06801591
2017-03-24 01:07:00  - 23147  http://www.lymphomahub.com/therapies/tocilizumab
<pre>2017-03-24_01-07-00 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/tocilizumab?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_01-09-00 Restart Xvfb...
2017-03-24 01:09:05  - 23147  http://www.lymphomahub.com/therapies/tocilizumab
2017-03-24 01:09:09  - 23147  http://www.lymphomahub.com/therapies/msc2490484a
2017-03-24 01:09:14  - 23147  http://www.lymphomahub.com/therapies/carfilzomib
2017-03-24 01:09:18  - 23147  http://www.lymphomahub.com/therapies/ruxolitinib
2017-03-24 01:09:23  - 23147  http://www.lymphomahub.com/therapies/palbociclib
2017-03-24 01:09:27  - 23147  http://www.lymphomahub.com/therapies/fenretinide
2017-03-24 01:09:31  - 23147  http://www.lymphomahub.com/therapies/daratumumab
2017-03-24 01:09:36  - 23147  http://www.lymphomahub.com/therapies/pf-05082566
2017-03-24 01:09:41  - 23147  http://www.lymphomahub.com/therapies/ramucirumab
2017-03-24 01:09:45  - 23147  http://www.lymphomahub.com/therapies/tositumomab
2017-03-24 01:09:50  - 23147  http://www.lymphomahub.com/therapies/ublituximab
2017-03-24 01:09:55  - 23147  http://www.lymphomahub.com/therapies/epacadostat
2017-03-24 01:09:59  - 23147  http://www.lymphomahub.com/therapies/alemtuzumab
2017-03-24 01:10:00  - 23147  http://www.lymphomahub.com/therapies/otlertuzumab
2017-03-24 01:10:04  - 23147  http://www.lymphomahub.com/therapies/panobinostat
2017-03-24 01:10:09  - 23147  http://www.lymphomahub.com/therapies/mocetinostat
2017-03-24 01:10:13  - 23147  http://www.lymphomahub.com/therapies/atezolizumab
2017-03-24 01:10:18  - 23147  http://www.lymphomahub.com/therapies/temsirolimus
2017-03-24 01:10:22  - 23147  http://www.lymphomahub.com/therapies/lenalidomide
2017-03-24 01:10:27  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab
2017-03-24 01:10:31  - 23147  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-03-24 01:10:36  - 23147  http://www.lymphomahub.com/therapies/blinatumomab
2017-03-24 01:10:40  - 23147  http://www.lymphomahub.com/therapies/jnj-64052781
2017-03-24 01:10:45  - 23147  http://www.lymphomahub.com/therapies/entospletinib
2017-03-24 01:10:49  - 23147  http://www.lymphomahub.com/therapies/pembrolizumab
2017-03-24 01:10:54  - 23147  http://www.lymphomahub.com/therapies/acalabrutinib
2017-03-24 01:10:58  - 23147  http://www.lymphomahub.com/about/innovation-committee
<pre>2017-03-24_01-11-00 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about/innovation-committee?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_01-13-00 Restart Xvfb...
2017-03-24 01:13:04  - 23147  http://www.lymphomahub.com/about/innovation-committee
2017-03-24 01:13:09  - 23147  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-03-24 01:13:10  - 23147  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-03-24 01:13:14  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-03-24 01:13:18  - 23147  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-03-24 01:13:23  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-03-24 01:13:27  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-03-24 01:13:28  - 23147  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-03-24 01:13:32  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-03-24 01:13:37  - 23147  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-03-24 01:13:41  - 23147  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-03-24 01:13:45  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board
2017-03-24 01:13:49  - 23147  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-03-24 01:13:54  - 23147  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-03-24 01:13:57  - 23147  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-03-24 01:14:01  - 23147  http://www.lymphomahub.com/about/executive-steering-committee
2017-03-24 01:14:05  - 23147  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-03-24 01:14:08  - 23147  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-03-24 01:14:13  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-03-24 01:14:17  - 23147  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-03-24 01:14:21  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-03-24 01:14:26  - 23147  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-03-24 01:14:30  - 23147  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-03-24 01:14:30  - 23147  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-03-24 01:14:34  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-03-24 01:14:38  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-03-24 01:14:43  - 23147  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-03-24 01:14:47  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-03-24 01:14:52  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-03-24 01:14:56  - 23147  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-03-24 01:15:00  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
<pre>2017-03-24_01-15-00 Restart Xvfb...
2017-03-24 01:15:04  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-03-24 01:15:08  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-03-24 01:15:12  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-03-24 01:15:16  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-03-24 01:15:19  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-03-24 01:15:23  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-03-24 01:15:27  - 23147  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-03-24 01:15:31  - 23147  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-03-24 01:15:36  - 23147  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-03-24 01:15:40  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-03-24 01:15:44  - 23147  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-03-24 01:15:48  - 23147  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-03-24 01:15:52  - 23147  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-03-24 01:15:57  - 23147  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-03-24 01:16:01  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-03-24 01:16:05  - 23147  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-03-24 01:16:10  - 23147  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-03-24 01:16:14  - 23147  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-03-24 01:16:19  - 23147  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-03-24 01:16:24  - 23147  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-03-24 01:16:28  - 23147  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-03-24 01:16:33  - 23147  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-03-24 01:16:38  - 23147  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-03-24 01:16:42  - 23147  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-03-24 01:16:46  - 23147  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-03-24 01:16:51  - 23147  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-03-24 01:16:55  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-03-24 01:16:59  - 23147  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
<pre>2017-03-24_01-17-00 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_01-19-00 Restart Xvfb...
2017-03-24 01:19:04  - 23147  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-03-24 01:19:09  - 23147  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-03-24 01:19:13  - 23147  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-03-24 01:19:17  - 23147  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-03-24 01:19:22  - 23147  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-03-24 01:19:26  - 23147  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-03-24 01:19:30  - 23147  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-03-24 01:19:35  - 23147  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-03-24 01:19:39  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-03-24 01:19:43  - 23147  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-03-24 01:19:47  - 23147  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-03-24 01:19:52  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-03-24 01:19:56  - 23147  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-03-24 01:20:00  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-03-24 01:20:04  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-03-24 01:20:08  - 23147  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-03-24 01:20:12  - 23147  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-03-24 01:20:17  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-03-24 01:20:21  - 23147  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-03-24 01:20:26  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-03-24 01:20:29  - 23147  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-03-24 01:20:34  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-03-24 01:20:38  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-03-24 01:20:43  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-03-24 01:20:46  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-03-24 01:20:50  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-03-24 01:20:54  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-03-24 01:20:58  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
<pre>2017-03-24_01-21-01 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_01-23-01 Restart Xvfb...
2017-03-24 01:23:03  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-03-24 01:23:06  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-03-24 01:23:11  - 23147  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-03-24 01:23:16  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-03-24 01:23:21  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-03-24 01:23:25  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-03-24 01:23:30  - 23147  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-24 01:23:31  - 23147  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-03-24 01:23:35  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-03-24 01:23:40  - 23147  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-03-24 01:23:44  - 23147  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-03-24 01:23:49  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-03-24 01:23:54  - 23147  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-03-24 01:23:58  - 23147  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-03-24 01:24:03  - 23147  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-03-24 01:24:08  - 23147  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-03-24 01:24:12  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-03-24 01:24:17  - 23147  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-03-24 01:24:22  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-03-24 01:24:26  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-03-24 01:24:31  - 23147  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-03-24 01:24:35  - 23147  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-03-24 01:24:40  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-03-24 01:24:44  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-03-24 01:24:49  - 23147  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-03-24 01:24:54  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-03-24 01:24:59  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
<pre>2017-03-24_01-25-01 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_01-27-01 Restart Xvfb...
2017-03-24 01:27:04  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-03-24 01:27:09  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-03-24 01:27:13  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-03-24 01:27:19  - 23147  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-24 01:27:23  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-03-24 01:27:28  - 23147  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-03-24 01:27:32  - 23147  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-03-24 01:27:37  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-03-24 01:27:42  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-03-24 01:27:46  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-03-24 01:27:51  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-03-24 01:27:55  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-03-24 01:28:00  - 23147  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-03-24 01:28:05  - 23147  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-03-24 01:28:09  - 23147  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-03-24 01:28:14  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-03-24 01:28:19  - 23147  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-03-24 01:28:23  - 23147  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-03-24 01:28:28  - 23147  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-03-24 01:28:29  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-03-24 01:28:33  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-03-24 01:28:38  - 23147  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-03-24 01:28:43  - 23147  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-03-24 01:28:48  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-03-24 01:28:52  - 23147  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-03-24 01:28:57  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
<pre>2017-03-24_01-29-01 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_01-31-01 Restart Xvfb...
2017-03-24 01:31:02  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-03-24 01:31:06  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-03-24 01:31:11  - 23147  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-03-24 01:31:16  - 23147  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-03-24 01:31:20  - 23147  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-03-24 01:31:25  - 23147  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-03-24 01:31:29  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-03-24 01:31:34  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-03-24 01:31:39  - 23147  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-03-24 01:31:44  - 23147  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-03-24 01:31:48  - 23147  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-03-24 01:31:53  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-03-24 01:31:58  - 23147  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-03-24 01:32:03  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-03-24 01:32:07  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-03-24 01:32:11  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-03-24 01:32:17  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-03-24 01:32:21  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-03-24 01:32:25  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-03-24 01:32:28  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-03-24 01:32:32  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-03-24 01:32:36  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-03-24 01:32:41  - 23147  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-03-24 01:32:41  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-03-24 01:32:46  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-03-24 01:32:50  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-03-24 01:32:54  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-03-24 01:32:57  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
<pre>2017-03-24_01-33-01 Restart Xvfb...
2017-03-24 01:33:01  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-03-24 01:33:05  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-03-24 01:33:08  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-03-24 01:33:12  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-03-24 01:33:16  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-03-24 01:33:19  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-03-24 01:33:23  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-03-24 01:33:26  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-03-24 01:33:30  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-03-24 01:33:34  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-03-24 01:33:37  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-03-24 01:33:42  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-03-24 01:33:45  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-03-24 01:33:49  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-03-24 01:33:53  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-03-24 01:33:56  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-03-24 01:34:00  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-03-24 01:34:04  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-03-24 01:34:07  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-03-24 01:34:11  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-03-24 01:34:15  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-03-24 01:34:18  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-03-24 01:34:22  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-03-24 01:34:25  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-03-24 01:34:29  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-03-24 01:34:33  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-03-24 01:34:36  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-03-24 01:34:40  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-03-24 01:34:43  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-03-24 01:34:47  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-03-24 01:34:50  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-03-24 01:34:54  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-03-24 01:34:58  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
<pre>2017-03-24_01-35-01 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_01-37-01 Restart Xvfb...
2017-03-24 01:37:03  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-03-24 01:37:07  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-03-24 01:37:10  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-03-24 01:37:14  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-03-24 01:37:18  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-03-24 01:37:21  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-03-24 01:37:25  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-03-24 01:37:29  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-03-24 01:37:32  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-03-24 01:37:36  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-03-24 01:37:40  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-03-24 01:37:43  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-03-24 01:37:47  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-03-24 01:37:51  - 23147  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-03-24 01:37:56  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-03-24 01:38:01  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-03-24 01:38:06  - 23147  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-03-24 01:38:06  - 23147  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-03-24 01:38:11  - 23147  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-03-24 01:38:16  - 23147  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-03-24 01:38:20  - 23147  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-03-24 01:38:24  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-03-24 01:38:29  - 23147  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-03-24 01:38:34  - 23147  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-03-24 01:38:38  - 23147  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-03-24 01:38:43  - 23147  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-03-24 01:38:47  - 23147  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-03-24 01:38:52  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-03-24 01:38:57  - 23147  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
<pre>2017-03-24_01-39-01 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_01-41-01 Restart Xvfb...
2017-03-24 01:41:02  - 23147  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-03-24 01:41:07  - 23147  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-03-24 01:41:12  - 23147  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-03-24 01:41:17  - 23147  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-03-24 01:41:21  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-03-24 01:41:26  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-03-24 01:41:31  - 23147  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-03-24 01:41:36  - 23147  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-03-24 01:41:40  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-03-24 01:41:45  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-03-24 01:41:49  - 23147  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-24 01:41:54  - 23147  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-03-24 01:41:58  - 23147  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-03-24 01:42:03  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-03-24 01:42:07  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-03-24 01:42:12  - 23147  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-03-24 01:42:16  - 23147  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-03-24 01:42:21  - 23147  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-03-24 01:42:26  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-03-24 01:42:30  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-03-24 01:42:35  - 23147  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-24 01:42:39  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-03-24 01:42:44  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-03-24 01:42:48  - 23147  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-03-24 01:42:53  - 23147  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-03-24 01:42:57  - 23147  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
<pre>2017-03-24_01-43-01 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_01-45-01 Restart Xvfb...
2017-03-24 01:45:03  - 23147  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-03-24 01:45:07  - 23147  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-03-24 01:45:12  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-03-24 01:45:16  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-03-24 01:45:21  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-03-24 01:45:25  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-03-24 01:45:30  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-03-24 01:45:35  - 23147  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-03-24 01:45:39  - 23147  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-03-24 01:45:44  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-03-24 01:45:49  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-03-24 01:45:53  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-03-24 01:45:57  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-03-24 01:46:02  - 23147  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-03-24 01:46:07  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-03-24 01:46:11  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-03-24 01:46:16  - 23147  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-03-24 01:46:21  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-03-24 01:46:25  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-03-24 01:46:30  - 23147  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-03-24 01:46:35  - 23147  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-03-24 01:46:39  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-03-24 01:46:44  - 23147  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-03-24 01:46:48  - 23147  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-03-24 01:46:53  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-03-24 01:46:58  - 23147  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
<pre>2017-03-24_01-47-01 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_01-49-01 Restart Xvfb...
2017-03-24 01:49:03  - 23147  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-03-24 01:49:07  - 23147  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-03-24 01:49:12  - 23147  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-03-24 01:49:16  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-03-24 01:49:21  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-03-24 01:49:26  - 23147  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-03-24 01:49:30  - 23147  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-03-24 01:49:35  - 23147  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-03-24 01:49:40  - 23147  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-03-24 01:49:44  - 23147  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-03-24 01:49:49  - 23147  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-03-24 01:49:53  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-03-24 01:49:58  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-03-24 01:50:02  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-03-24 01:50:07  - 23147  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-03-24 01:50:11  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-03-24 01:50:16  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-03-24 01:50:20  - 23147  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-03-24 01:50:25  - 23147  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-03-24 01:50:30  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-03-24 01:50:35  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-03-24 01:50:39  - 23147  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-03-24 01:50:44  - 23147  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-03-24 01:50:49  - 23147  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-03-24 01:50:53  - 23147  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-03-24 01:50:57  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
<pre>2017-03-24_01-51-01 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_01-53-01 Restart Xvfb...
2017-03-24 01:53:02  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-03-24 01:53:07  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-03-24 01:53:11  - 23147  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-03-24 01:53:16  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-03-24 01:53:21  - 23147  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-03-24 01:53:25  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-03-24 01:53:30  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-03-24 01:53:35  - 23147  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-03-24 01:53:39  - 23147  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-03-24 01:53:44  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-03-24 01:53:48  - 23147  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-03-24 01:53:53  - 23147  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-03-24 01:53:58  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-03-24 01:54:02  - 23147  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-03-24 01:54:07  - 23147  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-03-24 01:54:11  - 23147  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-03-24 01:54:16  - 23147  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-03-24 01:54:21  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-03-24 01:54:25  - 23147  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-03-24 01:54:29  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-03-24 01:54:34  - 23147  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-03-24 01:54:38  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-03-24 01:54:43  - 23147  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-03-24 01:54:48  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-03-24 01:54:52  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-03-24 01:54:58  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
<pre>2017-03-24_01-55-01 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_01-57-01 Restart Xvfb...
2017-03-24 01:57:03  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-03-24 01:57:08  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-03-24 01:57:13  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-03-24 01:57:18  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-03-24 01:57:22  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-03-24 01:57:27  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-03-24 01:57:32  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-03-24 01:57:36  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-03-24 01:57:42  - 23147  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-03-24 01:57:46  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-03-24 01:57:50  - 23147  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-03-24 01:57:55  - 23147  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-03-24 01:57:59  - 23147  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-03-24 01:58:04  - 23147  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-03-24 01:58:08  - 23147  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-03-24 01:58:13  - 23147  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-03-24 01:58:18  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-03-24 01:58:22  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-03-24 01:58:27  - 23147  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-03-24 01:58:33  - 23147  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-03-24 01:58:37  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-03-24 01:58:42  - 23147  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-03-24 01:58:47  - 23147  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-03-24 01:58:51  - 23147  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-03-24 01:58:56  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-03-24 01:59:01  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
<pre>2017-03-24_01-59-01 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_02-01-01 Restart Xvfb...
2017-03-24 02:01:06  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-03-24 02:01:11  - 23147  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-03-24 02:01:15  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-03-24 02:01:20  - 23147  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-03-24 02:01:25  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-03-24 02:01:29  - 23147  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-03-24 02:01:34  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-03-24 02:01:38  - 23147  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-03-24 02:01:43  - 23147  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-03-24 02:01:47  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-03-24 02:01:52  - 23147  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-03-24 02:01:56  - 23147  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-03-24 02:02:00  - 23147  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-03-24 02:02:05  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-03-24 02:02:10  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-03-24 02:02:14  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-03-24 02:02:19  - 23147  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-03-24 02:02:23  - 23147  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-03-24 02:02:28  - 23147  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-03-24 02:02:32  - 23147  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-03-24 02:02:36  - 23147  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-03-24 02:02:40  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-03-24 02:02:45  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-03-24 02:02:49  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-03-24 02:02:53  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-03-24 02:02:58  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
<pre>2017-03-24_02-03-01 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_02-05-01 Restart Xvfb...
2017-03-24 02:05:04  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-03-24 02:05:07  - 23147  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-03-24 02:05:12  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-03-24 02:05:17  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-03-24 02:05:22  - 23147  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-03-24 02:05:27  - 23147  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-03-24 02:05:31  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-03-24 02:05:35  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-03-24 02:05:40  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-03-24 02:05:44  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-03-24 02:05:49  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-03-24 02:05:53  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-03-24 02:05:57  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-03-24 02:06:02  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-03-24 02:06:06  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-03-24 02:06:10  - 23147  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-03-24 02:06:15  - 23147  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-03-24 02:06:19  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-03-24 02:06:23  - 23147  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-03-24 02:06:27  - 23147  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-03-24 02:06:32  - 23147  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-03-24 02:06:37  - 23147  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-03-24 02:06:41  - 23147  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-03-24 02:06:46  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-03-24 02:06:51  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-03-24 02:06:55  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-03-24 02:07:00  - 23147  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
<pre>2017-03-24_02-07-01 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_02-09-01 Restart Xvfb...
2017-03-24 02:09:05  - 23147  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-03-24 02:09:10  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-03-24 02:09:15  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-03-24 02:09:19  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-03-24 02:09:23  - 23147  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-03-24 02:09:28  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-03-24 02:09:32  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-03-24 02:09:37  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-03-24 02:09:41  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-03-24 02:09:45  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-03-24 02:09:50  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-03-24 02:09:54  - 23147  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-03-24 02:09:59  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-03-24 02:10:04  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-03-24 02:10:08  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-03-24 02:10:12  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-03-24 02:10:17  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-03-24 02:10:22  - 23147  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-03-24 02:10:26  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-03-24 02:10:30  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-03-24 02:10:35  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-03-24 02:10:39  - 23147  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-03-24 02:10:44  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-03-24 02:10:48  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-03-24 02:10:53  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-03-24 02:10:57  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
<pre>2017-03-24_02-11-01 Restart Xvfb...
2017-03-24 02:11:01  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-03-24 02:11:05  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-03-24 02:11:09  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-03-24 02:11:14  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-03-24 02:11:18  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-03-24 02:11:22  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-03-24 02:11:27  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-03-24 02:11:31  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-03-24 02:11:35  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-03-24 02:11:39  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-03-24 02:11:43  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-03-24 02:11:47  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-03-24 02:11:51  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-03-24 02:11:55  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-03-24 02:12:00  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-03-24 02:12:04  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-03-24 02:12:08  - 23147  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-03-24 02:12:12  - 23147  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-03-24 02:12:16  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-03-24 02:12:21  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-03-24 02:12:25  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-03-24 02:12:29  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-03-24 02:12:34  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-03-24 02:12:38  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-03-24 02:12:43  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-03-24 02:12:48  - 23147  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-03-24 02:12:52  - 23147  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-03-24 02:12:56  - 23147  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-03-24 02:13:00  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
<pre>2017-03-24_02-13-01 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_02-15-01 Restart Xvfb...
2017-03-24 02:15:05  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-03-24 02:15:10  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-03-24 02:15:14  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-03-24 02:15:18  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-03-24 02:15:23  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-03-24 02:15:27  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-24 02:15:31  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-24 02:15:34  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-24 02:15:38  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-24 02:15:43  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-03-24 02:15:47  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-24 02:15:51  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-24 02:15:56  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-03-24 02:16:00  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-03-24 02:16:04  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-03-24 02:16:08  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-03-24 02:16:12  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-03-24 02:16:17  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-03-24 02:16:21  - 23147  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-03-24 02:16:25  - 23147  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-03-24 02:16:29  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-03-24 02:16:33  - 23147  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-03-24 02:16:37  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-03-24 02:16:41  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-03-24 02:16:46  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-03-24 02:16:50  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-03-24 02:16:54  - 23147  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-03-24 02:16:58  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
<pre>2017-03-24_02-17-01 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_02-19-01 Restart Xvfb...
2017-03-24 02:19:03  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-03-24 02:19:07  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-03-24 02:19:11  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-03-24 02:19:15  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-03-24 02:19:19  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-03-24 02:19:23  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-24 02:19:27  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-24 02:19:31  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-24 02:19:35  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-24 02:19:39  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-24 02:19:43  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-03-24 02:19:47  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-24 02:19:51  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-24 02:19:55  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-24 02:19:59  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-24 02:20:03  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-03-24 02:20:09  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-24 02:20:13  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-24 02:20:17  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-24 02:20:21  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-03-24 02:20:25  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
<pre>2017-03-24_02-21-01 Restart Xvfb...
<pre>2017-03-24_02-23-01 Restart Xvfb...
<pre>2017-03-24_02-25-01 Restart Xvfb...
<pre>2017-03-24_02-27-01 Restart Xvfb...
<pre>2017-03-24_02-29-01 Restart Xvfb...
<pre>2017-03-24_02-31-01 Restart Xvfb...
<pre>2017-03-24_02-33-01 Restart Xvfb...
<pre>2017-03-24_02-35-01 Restart Xvfb...
<pre>2017-03-24_02-37-01 Restart Xvfb...
<pre>2017-03-24_02-39-01 Restart Xvfb...
<pre>2017-03-24_02-41-01 Restart Xvfb...
<pre>2017-03-24_02-43-01 Restart Xvfb...
<pre>2017-03-24_02-45-02 Restart Xvfb...
<pre>2017-03-24_02-47-02 Restart Xvfb...
<pre>2017-03-24_02-49-02 Restart Xvfb...
<pre>2017-03-24_02-51-02 Restart Xvfb...
<pre>2017-03-24_02-53-02 Restart Xvfb...
<pre>2017-03-24_02-55-02 Restart Xvfb...
<pre>2017-03-24_02-57-02 Restart Xvfb...
<pre>2017-03-24_02-59-02 Restart Xvfb...
<pre>2017-03-24_03-01-02 Restart Xvfb...
<pre>2017-03-24_03-03-02 Restart Xvfb...
<pre>2017-03-24_03-05-02 Restart Xvfb...
<pre>2017-03-24_03-07-02 Restart Xvfb...
<pre>2017-03-24_03-09-02 Restart Xvfb...
<pre>2017-03-24_03-11-02 Restart Xvfb...
<pre>2017-03-24_03-13-02 Restart Xvfb...
<pre>2017-03-24_03-15-02 Restart Xvfb...
<pre>2017-03-24_03-17-02 Restart Xvfb...
<pre>2017-03-24_03-19-02 Restart Xvfb...
<pre>2017-03-24_03-21-02 Restart Xvfb...
<pre>2017-03-24_03-23-02 Restart Xvfb...
<pre>2017-03-24_03-25-02 Restart Xvfb...
<pre>2017-03-24_03-27-02 Restart Xvfb...
<pre>2017-03-24_03-29-02 Restart Xvfb...
<pre>2017-03-24_03-31-02 Restart Xvfb...
<pre>2017-03-24_03-33-02 Restart Xvfb...
<pre>2017-03-24_03-35-02 Restart Xvfb...
<pre>2017-03-24_03-37-02 Restart Xvfb...
<pre>2017-03-24_03-39-02 Restart Xvfb...
<pre>2017-03-24_03-41-02 Restart Xvfb...
<pre>2017-03-24_03-43-02 Restart Xvfb...
<pre>2017-03-24_03-45-02 Restart Xvfb...
<pre>2017-03-24_03-47-02 Restart Xvfb...
<pre>2017-03-24_03-49-02 Restart Xvfb...
<pre>2017-03-24_03-51-02 Restart Xvfb...
<pre>2017-03-24_03-53-02 Restart Xvfb...
<pre>2017-03-24_03-55-02 Restart Xvfb...
2017-03-24 03:56:59 reset updateRequest
2017-03-24 03:57:01  - 23147  http://www.lymphomahub.com/
<pre>2017-03-24_03-57-02 Restart Xvfb...
2017-03-24 03:57:04  - 23147  http://www.lymphomahub.com/
2017-03-24 03:57:08  - 23147  http://www.lymphomahub.com/about
2017-03-24 03:57:14  - 23147  http://www.lymphomahub.com/terms
2017-03-24 03:57:17  - 23147  http://www.lymphomahub.com/undefined
2017-03-24 03:57:18  - 23147  http://www.lymphomahub.com/therapies
2017-03-24 03:57:24  - 23147  http://www.lymphomahub.com/newsletter
2017-03-24 03:57:28  - 23147  http://www.lymphomahub.com/cookie-policy
2017-03-24 03:57:32  - 23147  http://www.lymphomahub.com/therapies/afm13
2017-03-24 03:57:36  - 23147  http://www.lymphomahub.com/therapies/ags67e
2017-03-24 03:57:41  - 23147  http://www.lymphomahub.com/therapies/cc-292
2017-03-24 03:57:45  - 23147  http://www.lymphomahub.com/therapies/cc-223
2017-03-24 03:57:51  - 23147  http://www.lymphomahub.com/therapies/sd-101
2017-03-24 03:57:58  - 23147  http://www.lymphomahub.com/therapies/rp6530
2017-03-24 03:58:03  - 23147  http://www.lymphomahub.com/therapies/abt199
2017-03-24 03:58:04  - 23147  http://www.lymphomahub.com/therapies/mor208
2017-03-24 03:58:08  - 23147  http://www.lymphomahub.com/therapies/cc-122
2017-03-24 03:58:12  - 23147  http://www.lymphomahub.com/therapies/at-101
2017-03-24 03:58:17  - 23147  http://www.lymphomahub.com/therapies/bl8040
2017-03-24 03:58:25  - 23147  http://www.lymphomahub.com/therapies/bcl201
2017-03-24 03:58:30  - 23147  http://www.lymphomahub.com/therapies/azd3965
2017-03-24 03:58:33  - 23147  http://www.lymphomahub.com/therapies/imgn529
2017-03-24 03:58:37  - 23147  http://www.lymphomahub.com/therapies/azd2014
2017-03-24 03:58:45  - 23147  http://www.lymphomahub.com/therapies/mt-3724
2017-03-24 03:58:50  - 23147  http://www.lymphomahub.com/therapies/actr087
2017-03-24 03:58:55  - 23147  http://www.lymphomahub.com/therapies/epz6438
2017-03-24 03:59:00  - 23147  http://www.lymphomahub.com/therapies/kte-c19
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_03-59-02 Restart Xvfb...
2017-03-24 03:59:06  - 23147  http://www.lymphomahub.com/therapies/kte-c19
2017-03-24 03:59:10  - 23147  http://www.lymphomahub.com/about/secretariat
2017-03-24 03:59:14  - 23147  http://www.lymphomahub.com/therapies/alt-803
2017-03-24 03:59:19  - 23147  http://www.lymphomahub.com/therapies/regn1979
2017-03-24 03:59:23  - 23147  http://www.lymphomahub.com/therapies/immu-114
2017-03-24 03:59:27  - 23147  http://www.lymphomahub.com/therapies/incb7839
2017-03-24 03:59:32  - 23147  http://www.lymphomahub.com/therapies/adct-301
2017-03-24 03:59:36  - 23147  http://www.lymphomahub.com/therapies/ixazomib
2017-03-24 03:59:40  - 23147  http://www.lymphomahub.com/therapies/avelumab
2017-03-24 03:59:45  - 23147  http://www.lymphomahub.com/therapies/bi836826
2017-03-24 03:59:49  - 23147  http://www.lymphomahub.com/therapies/medi-570
2017-03-24 03:59:54  - 23147  http://www.lymphomahub.com/therapies/ds-3201b
2017-03-24 03:59:59  - 23147  http://www.lymphomahub.com/therapies/sea-cd40
2017-03-24 04:00:03  - 23147  http://www.lymphomahub.com/therapies/adct-402
2017-03-24 04:00:11  - 23147  http://www.lymphomahub.com/therapies/acy-1215
2017-03-24 04:00:15  - 23147  http://www.lymphomahub.com/therapies/cudc-907
2017-03-24 04:00:23  - 23147  http://www.lymphomahub.com/therapies/tgr-1202
2017-03-24 04:00:27  - 23147  http://www.lymphomahub.com/therapies/axitinib
2017-03-24 04:00:32  - 23147  http://www.lymphomahub.com/therapies/imatinib
2017-03-24 04:00:39  - 23147  http://www.lymphomahub.com/therapies/edo-s101
2017-03-24 04:00:44  - 23147  http://www.lymphomahub.com/therapies/btct4465a
2017-03-24 04:00:48  - 23147  http://www.lymphomahub.com/therapies/alisertib
2017-03-24 04:00:52  - 23147  http://www.lymphomahub.com/therapies/lirilumab
2017-03-24 04:00:57  - 23147  http://www.lymphomahub.com/therapies/ibrutinib
2017-03-24 04:00:58  - 23147  http://www.lymphomahub.com/therapies/sgn-cd70a
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/kte-c19?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_04-01-02 Restart Xvfb...
2017-03-24 04:01:02  - 23147  http://www.lymphomahub.com/therapies/rituximab
2017-03-24 04:01:05  - 23147  http://www.lymphomahub.com/therapies/rituximab
2017-03-24 04:01:07  - 23147  http://www.lymphomahub.com/therapies/veliparib
2017-03-24 04:01:09  - 23147  http://www.lymphomahub.com/therapies/veliparib
2017-03-24 04:01:12  - 23147  http://www.lymphomahub.com/therapies/sunitinib
2017-03-24 04:01:13  - 23147  http://www.lymphomahub.com/therapies/sunitinib
2017-03-24 04:01:16  - 23147  http://www.lymphomahub.com/therapies/nivolumab
2017-03-24 04:01:17  - 23147  http://www.lymphomahub.com/therapies/sirolimus
2017-03-24 04:01:18  - 23147  http://www.lymphomahub.com/therapies/sirolimus
2017-03-24 04:01:22  - 23147  http://www.lymphomahub.com/medical-information
2017-03-24 04:01:22  - 23147  http://www.lymphomahub.com/medical-information
2017-03-24 04:01:28  - 23147  http://www.lymphomahub.com/therapies/selinexor
2017-03-24 04:01:28  - 23147  http://www.lymphomahub.com/therapies/selinexor
2017-03-24 04:01:34  - 23147  http://www.lymphomahub.com/therapies/abc294640
2017-03-24 04:01:34  - 23147  http://www.lymphomahub.com/therapies/abc294640
2017-03-24 04:01:40  - 23147  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-03-24 04:01:44  - 23147  http://www.lymphomahub.com/therapies/tenofovir
2017-03-24 04:01:49  - 23147  http://www.lymphomahub.com/therapies/betalutin
2017-03-24 04:01:53  - 23147  http://www.lymphomahub.com/therapies/chidamide
2017-03-24 04:01:58  - 23147  http://www.lymphomahub.com/therapies/duvelisib
2017-03-24 04:02:02  - 23147  http://www.lymphomahub.com/therapies/dasatinib
2017-03-24 04:02:07  - 23147  http://www.lymphomahub.com/therapies/everolimus
2017-03-24 04:02:11  - 23147  http://www.lymphomahub.com/therapies/incb039110
2017-03-24 04:02:16  - 23147  http://www.lymphomahub.com/therapies/durvalumab
2017-03-24 04:02:20  - 23147  http://www.lymphomahub.com/therapies/romidepsin
2017-03-24 04:02:24  - 23147  http://www.lymphomahub.com/therapies/bortezomib
2017-03-24 04:02:29  - 23147  http://www.lymphomahub.com/therapies/idelalisib
2017-03-24 04:02:29  - 23147  http://www.lymphomahub.com/therapies/tipifarnib
2017-03-24 04:02:34  - 23147  http://www.lymphomahub.com/therapies/ipilimumab
2017-03-24 04:02:38  - 23147  http://www.lymphomahub.com/therapies/crizotinib
2017-03-24 04:02:42  - 23147  http://www.lymphomahub.com/therapies/gsk2816126
2017-03-24 04:02:47  - 23147  http://www.lymphomahub.com/therapies/copanlisib
2017-03-24 04:02:51  - 23147  http://www.lymphomahub.com/therapies/buparlisib
2017-03-24 04:02:56  - 23147  http://www.lymphomahub.com/therapies/belinostat
2017-03-24 04:03:01  - 23147  http://www.lymphomahub.com/therapies/vorinostat
<pre>2017-03-24_04-03-02 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/vorinostat?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_04-05-02 Restart Xvfb...
2017-03-24 04:05:06  - 23147  http://www.lymphomahub.com/therapies/vorinostat
2017-03-24 04:05:10  - 23147  http://www.lymphomahub.com/therapies/plerixafor
2017-03-24 04:05:11  - 23147  http://www.lymphomahub.com/therapies/ofatumumab
2017-03-24 04:05:15  - 23147  http://www.lymphomahub.com/therapies/pf-06801591
2017-03-24 04:05:20  - 23147  http://www.lymphomahub.com/therapies/tocilizumab
2017-03-24 04:05:24  - 23147  http://www.lymphomahub.com/therapies/msc2490484a
2017-03-24 04:05:29  - 23147  http://www.lymphomahub.com/therapies/carfilzomib
2017-03-24 04:05:33  - 23147  http://www.lymphomahub.com/therapies/ruxolitinib
2017-03-24 04:05:38  - 23147  http://www.lymphomahub.com/therapies/palbociclib
2017-03-24 04:05:42  - 23147  http://www.lymphomahub.com/therapies/fenretinide
2017-03-24 04:05:46  - 23147  http://www.lymphomahub.com/therapies/daratumumab
2017-03-24 04:05:51  - 23147  http://www.lymphomahub.com/therapies/pf-05082566
2017-03-24 04:05:55  - 23147  http://www.lymphomahub.com/therapies/ramucirumab
2017-03-24 04:05:59  - 23147  http://www.lymphomahub.com/therapies/tositumomab
2017-03-24 04:06:04  - 23147  http://www.lymphomahub.com/therapies/ublituximab
2017-03-24 04:06:08  - 23147  http://www.lymphomahub.com/therapies/epacadostat
2017-03-24 04:06:13  - 23147  http://www.lymphomahub.com/therapies/alemtuzumab
2017-03-24 04:06:13  - 23147  http://www.lymphomahub.com/therapies/otlertuzumab
2017-03-24 04:06:18  - 23147  http://www.lymphomahub.com/therapies/panobinostat
2017-03-24 04:06:22  - 23147  http://www.lymphomahub.com/therapies/mocetinostat
2017-03-24 04:06:26  - 23147  http://www.lymphomahub.com/therapies/atezolizumab
2017-03-24 04:06:31  - 23147  http://www.lymphomahub.com/therapies/temsirolimus
2017-03-24 04:06:35  - 23147  http://www.lymphomahub.com/therapies/lenalidomide
2017-03-24 04:06:40  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab
2017-03-24 04:06:44  - 23147  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-03-24 04:06:49  - 23147  http://www.lymphomahub.com/therapies/blinatumomab
2017-03-24 04:06:53  - 23147  http://www.lymphomahub.com/therapies/jnj-64052781
2017-03-24 04:06:58  - 23147  http://www.lymphomahub.com/therapies/entospletinib
<pre>2017-03-24_04-07-02 Restart Xvfb...
2017-03-24 04:07:02  - 23147  http://www.lymphomahub.com/therapies/pembrolizumab
2017-03-24 04:07:07  - 23147  http://www.lymphomahub.com/therapies/acalabrutinib
2017-03-24 04:07:12  - 23147  http://www.lymphomahub.com/about/innovation-committee
2017-03-24 04:07:15  - 23147  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-03-24 04:07:16  - 23147  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-03-24 04:07:20  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-03-24 04:07:25  - 23147  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-03-24 04:07:29  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-03-24 04:07:33  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-03-24 04:07:34  - 23147  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-03-24 04:07:38  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-03-24 04:07:43  - 23147  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-03-24 04:07:47  - 23147  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-03-24 04:07:51  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board
2017-03-24 04:07:55  - 23147  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-03-24 04:08:00  - 23147  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-03-24 04:08:03  - 23147  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-03-24 04:08:07  - 23147  http://www.lymphomahub.com/about/executive-steering-committee
2017-03-24 04:08:11  - 23147  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-03-24 04:08:15  - 23147  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-03-24 04:08:20  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-03-24 04:08:23  - 23147  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-03-24 04:08:28  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-03-24 04:08:32  - 23147  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-03-24 04:08:36  - 23147  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-03-24 04:08:37  - 23147  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-03-24 04:08:40  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-03-24 04:08:45  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-03-24 04:08:50  - 23147  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-03-24 04:08:54  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-03-24 04:08:59  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
<pre>2017-03-24_04-09-02 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_04-11-02 Restart Xvfb...
2017-03-24 04:11:04  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-03-24 04:11:08  - 23147  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-03-24 04:11:12  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-03-24 04:11:16  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-03-24 04:11:19  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-03-24 04:11:23  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-03-24 04:11:27  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-03-24 04:11:31  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-03-24 04:11:34  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-03-24 04:11:38  - 23147  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-03-24 04:11:42  - 23147  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-03-24 04:11:47  - 23147  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-03-24 04:11:52  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-03-24 04:11:56  - 23147  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-03-24 04:11:59  - 23147  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-03-24 04:12:05  - 23147  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-03-24 04:12:10  - 23147  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-03-24 04:12:14  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-03-24 04:12:19  - 23147  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-03-24 04:12:24  - 23147  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-03-24 04:12:28  - 23147  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-03-24 04:12:33  - 23147  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-03-24 04:12:38  - 23147  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-03-24 04:12:42  - 23147  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-03-24 04:12:47  - 23147  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-03-24 04:12:52  - 23147  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-03-24 04:12:56  - 23147  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-03-24 04:13:00  - 23147  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
<pre>2017-03-24_04-13-02 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_04-15-02 Restart Xvfb...
2017-03-24 04:15:06  - 23147  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-03-24 04:15:09  - 23147  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-03-24 04:15:13  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-03-24 04:15:17  - 23147  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-03-24 04:15:22  - 23147  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-03-24 04:15:26  - 23147  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-03-24 04:15:31  - 23147  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-03-24 04:15:35  - 23147  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-03-24 04:15:39  - 23147  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-03-24 04:15:43  - 23147  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-03-24 04:15:48  - 23147  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-03-24 04:15:52  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-03-24 04:15:56  - 23147  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-03-24 04:16:00  - 23147  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-03-24 04:16:05  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-03-24 04:16:09  - 23147  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-03-24 04:16:13  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-03-24 04:16:17  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-03-24 04:16:21  - 23147  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-03-24 04:16:25  - 23147  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-03-24 04:16:30  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-03-24 04:16:34  - 23147  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-03-24 04:16:39  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-03-24 04:16:43  - 23147  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-03-24 04:16:47  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-03-24 04:16:51  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-03-24 04:16:56  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-03-24 04:17:00  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
<pre>2017-03-24_04-17-02 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_04-19-02 Restart Xvfb...
2017-03-24 04:19:05  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-03-24 04:19:08  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-03-24 04:19:12  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-03-24 04:19:16  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-03-24 04:19:20  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-03-24 04:19:25  - 23147  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-03-24 04:19:29  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-03-24 04:19:34  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-03-24 04:19:39  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-03-24 04:19:44  - 23147  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-24 04:19:45  - 23147  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-03-24 04:19:49  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-03-24 04:19:54  - 23147  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-03-24 04:19:59  - 23147  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-03-24 04:20:03  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-03-24 04:20:08  - 23147  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-03-24 04:20:12  - 23147  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-03-24 04:20:17  - 23147  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-03-24 04:20:22  - 23147  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-03-24 04:20:27  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-03-24 04:20:31  - 23147  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-03-24 04:20:36  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-03-24 04:20:40  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-03-24 04:20:44  - 23147  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-03-24 04:20:49  - 23147  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-03-24 04:20:54  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-03-24 04:20:59  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
<pre>2017-03-24_04-21-03 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_04-23-03 Restart Xvfb...
2017-03-24 04:23:04  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-03-24 04:23:09  - 23147  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-03-24 04:23:13  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-03-24 04:23:18  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-03-24 04:23:22  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-03-24 04:23:28  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-03-24 04:23:33  - 23147  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-24 04:23:38  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-03-24 04:23:42  - 23147  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-03-24 04:23:47  - 23147  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-03-24 04:23:51  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-03-24 04:23:56  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-03-24 04:24:01  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-03-24 04:24:05  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-03-24 04:24:10  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-03-24 04:24:15  - 23147  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-03-24 04:24:19  - 23147  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-03-24 04:24:24  - 23147  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-03-24 04:24:28  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-03-24 04:24:33  - 23147  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-03-24 04:24:38  - 23147  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-03-24 04:24:42  - 23147  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-03-24 04:24:43  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-03-24 04:24:47  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-03-24 04:24:52  - 23147  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-03-24 04:24:57  - 23147  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-03-24 04:25:02  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
<pre>2017-03-24_04-25-03 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_04-27-03 Restart Xvfb...
2017-03-24 04:27:07  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-03-24 04:27:11  - 23147  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-03-24 04:27:16  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-03-24 04:27:21  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-03-24 04:27:26  - 23147  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-03-24 04:27:31  - 23147  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-03-24 04:27:35  - 23147  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-03-24 04:27:40  - 23147  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-03-24 04:27:44  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-03-24 04:27:49  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-03-24 04:27:54  - 23147  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-03-24 04:27:59  - 23147  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-03-24 04:28:04  - 23147  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-03-24 04:28:08  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-03-24 04:28:13  - 23147  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-03-24 04:28:18  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-03-24 04:28:22  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-03-24 04:28:26  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-03-24 04:28:32  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-03-24 04:28:36  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-03-24 04:28:40  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-03-24 04:28:44  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-03-24 04:28:48  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-03-24 04:28:52  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-03-24 04:28:56  - 23147  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-03-24 04:28:56  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-03-24 04:29:01  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
<pre>2017-03-24_04-29-03 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_04-31-03 Restart Xvfb...
2017-03-24 04:31:06  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-03-24 04:31:11  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-03-24 04:31:15  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-03-24 04:31:18  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-03-24 04:31:22  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-03-24 04:31:26  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-03-24 04:31:29  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-03-24 04:31:33  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-03-24 04:31:37  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-03-24 04:31:40  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-03-24 04:31:44  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-03-24 04:31:47  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-03-24 04:31:51  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-03-24 04:31:55  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-03-24 04:31:58  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-03-24 04:32:03  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-03-24 04:32:07  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-03-24 04:32:11  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-03-24 04:32:14  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-03-24 04:32:18  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-03-24 04:32:21  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-03-24 04:32:25  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-03-24 04:32:29  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-03-24 04:32:32  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-03-24 04:32:36  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-03-24 04:32:39  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-03-24 04:32:43  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-03-24 04:32:47  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-03-24 04:32:51  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-03-24 04:32:54  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-03-24 04:32:58  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-03-24 04:33:02  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
<pre>2017-03-24_04-33-03 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_04-35-03 Restart Xvfb...
2017-03-24 04:35:07  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-03-24 04:35:10  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-03-24 04:35:14  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-03-24 04:35:18  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-03-24 04:35:21  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-03-24 04:35:25  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-03-24 04:35:28  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-03-24 04:35:32  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-03-24 04:35:36  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-03-24 04:35:39  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-03-24 04:35:43  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-03-24 04:35:46  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-03-24 04:35:50  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-03-24 04:35:54  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-03-24 04:35:57  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-03-24 04:36:01  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-03-24 04:36:05  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-03-24 04:36:08  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-03-24 04:36:13  - 23147  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-03-24 04:36:18  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-03-24 04:36:22  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-03-24 04:36:28  - 23147  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-03-24 04:36:28  - 23147  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-03-24 04:36:33  - 23147  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-03-24 04:36:38  - 23147  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-03-24 04:36:42  - 23147  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-03-24 04:36:47  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-03-24 04:36:52  - 23147  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-03-24 04:36:56  - 23147  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-03-24 04:37:01  - 23147  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
<pre>2017-03-24_04-37-03 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_04-39-03 Restart Xvfb...
2017-03-24 04:39:06  - 23147  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-03-24 04:39:11  - 23147  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-03-24 04:39:15  - 23147  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-03-24 04:39:20  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-03-24 04:39:24  - 23147  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-03-24 04:39:29  - 23147  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-03-24 04:39:34  - 23147  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-03-24 04:39:38  - 23147  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-03-24 04:39:43  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-03-24 04:39:48  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-03-24 04:39:52  - 23147  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-03-24 04:39:57  - 23147  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-03-24 04:40:02  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-03-24 04:40:06  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-03-24 04:40:11  - 23147  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-24 04:40:15  - 23147  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-03-24 04:40:20  - 23147  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-03-24 04:40:25  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-03-24 04:40:29  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-03-24 04:40:34  - 23147  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-03-24 04:40:38  - 23147  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-03-24 04:40:43  - 23147  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-03-24 04:40:48  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-03-24 04:40:52  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-03-24 04:40:57  - 23147  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-24 04:41:02  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
<pre>2017-03-24_04-41-03 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_04-43-03 Restart Xvfb...
2017-03-24 04:43:07  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-03-24 04:43:12  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-03-24 04:43:16  - 23147  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-03-24 04:43:21  - 23147  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-03-24 04:43:25  - 23147  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-03-24 04:43:30  - 23147  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-03-24 04:43:35  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-03-24 04:43:40  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-03-24 04:43:44  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-03-24 04:43:49  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-03-24 04:43:54  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-03-24 04:43:58  - 23147  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-03-24 04:44:03  - 23147  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-03-24 04:44:07  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-03-24 04:44:12  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-03-24 04:44:16  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-03-24 04:44:21  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-03-24 04:44:26  - 23147  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-03-24 04:44:30  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-03-24 04:44:35  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-03-24 04:44:40  - 23147  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-03-24 04:44:44  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-03-24 04:44:49  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-03-24 04:44:54  - 23147  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-03-24 04:44:58  - 23147  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-03-24 04:45:03  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
<pre>2017-03-24_04-45-03 Restart Xvfb...
2017-03-24 04:45:07  - 23147  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-03-24 04:45:12  - 23147  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-03-24 04:45:16  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-03-24 04:45:21  - 23147  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-03-24 04:45:26  - 23147  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-03-24 04:45:30  - 23147  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-03-24 04:45:35  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-03-24 04:45:39  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-03-24 04:45:44  - 23147  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-03-24 04:45:48  - 23147  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-03-24 04:45:53  - 23147  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-03-24 04:45:58  - 23147  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-03-24 04:46:02  - 23147  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-03-24 04:46:07  - 23147  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-03-24 04:46:11  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-03-24 04:46:16  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-03-24 04:46:21  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-03-24 04:46:25  - 23147  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-03-24 04:46:30  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-03-24 04:46:34  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-03-24 04:46:39  - 23147  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-03-24 04:46:43  - 23147  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-03-24 04:46:48  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-03-24 04:46:52  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-03-24 04:46:57  - 23147  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-03-24 04:47:01  - 23147  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
<pre>2017-03-24_04-47-03 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_04-49-03 Restart Xvfb...
2017-03-24 04:49:06  - 23147  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-03-24 04:49:11  - 23147  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-03-24 04:49:15  - 23147  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-03-24 04:49:20  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-03-24 04:49:25  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-03-24 04:49:29  - 23147  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-03-24 04:49:34  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-03-24 04:49:38  - 23147  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-03-24 04:49:43  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-03-24 04:49:48  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-03-24 04:49:52  - 23147  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-03-24 04:49:57  - 23147  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-03-24 04:50:02  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-03-24 04:50:06  - 23147  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-03-24 04:50:11  - 23147  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-03-24 04:50:16  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-03-24 04:50:20  - 23147  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-03-24 04:50:25  - 23147  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-03-24 04:50:30  - 23147  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-03-24 04:50:34  - 23147  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-03-24 04:50:39  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-03-24 04:50:43  - 23147  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-03-24 04:50:48  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-03-24 04:50:52  - 23147  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-03-24 04:50:57  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-03-24 04:51:02  - 23147  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
<pre>2017-03-24_04-51-03 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_04-53-03 Restart Xvfb...
2017-03-24 04:53:07  - 23147  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-03-24 04:53:12  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-03-24 04:53:17  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-03-24 04:53:21  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-03-24 04:53:26  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-03-24 04:53:31  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-03-24 04:53:35  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-03-24 04:53:40  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-03-24 04:53:44  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-03-24 04:53:49  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-03-24 04:53:53  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-03-24 04:53:58  - 23147  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-03-24 04:54:02  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-03-24 04:54:06  - 23147  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-03-24 04:54:11  - 23147  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-03-24 04:54:16  - 23147  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-03-24 04:54:20  - 23147  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-03-24 04:54:25  - 23147  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-03-24 04:54:30  - 23147  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-03-24 04:54:34  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-03-24 04:54:39  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-03-24 04:54:44  - 23147  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-03-24 04:54:48  - 23147  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-03-24 04:54:53  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-03-24 04:54:57  - 23147  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-03-24 04:55:02  - 23147  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
<pre>2017-03-24_04-55-03 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_04-57-03 Restart Xvfb...
2017-03-24 04:57:07  - 23147  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-03-24 04:57:12  - 23147  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-03-24 04:57:16  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-03-24 04:57:21  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-03-24 04:57:26  - 23147  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-03-24 04:57:30  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-03-24 04:57:35  - 23147  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-03-24 04:57:40  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-03-24 04:57:45  - 23147  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-03-24 04:57:49  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-03-24 04:57:54  - 23147  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-03-24 04:57:59  - 23147  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-03-24 04:58:03  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-03-24 04:58:07  - 23147  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-03-24 04:58:11  - 23147  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-03-24 04:58:16  - 23147  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-03-24 04:58:21  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-03-24 04:58:25  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-03-24 04:58:29  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-03-24 04:58:34  - 23147  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-03-24 04:58:38  - 23147  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-03-24 04:58:43  - 23147  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-03-24 04:58:48  - 23147  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-03-24 04:58:52  - 23147  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-03-24 04:58:56  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-03-24 04:59:01  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
<pre>2017-03-24_04-59-03 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_05-01-03 Restart Xvfb...
2017-03-24 05:01:06  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-03-24 05:01:10  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-03-24 05:01:15  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-03-24 05:01:19  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-03-24 05:01:24  - 23147  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-03-24 05:01:28  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-03-24 05:01:33  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-03-24 05:01:37  - 23147  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-03-24 05:01:42  - 23147  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-03-24 05:01:46  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-03-24 05:01:50  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-03-24 05:01:55  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-03-24 05:02:00  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-03-24 05:02:04  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-03-24 05:02:09  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-03-24 05:02:13  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-03-24 05:02:17  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-03-24 05:02:22  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-03-24 05:02:26  - 23147  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-03-24 05:02:30  - 23147  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-03-24 05:02:35  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-03-24 05:02:39  - 23147  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-03-24 05:02:44  - 23147  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-03-24 05:02:48  - 23147  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-03-24 05:02:53  - 23147  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-03-24 05:02:58  - 23147  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-03-24 05:03:03  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
<pre>2017-03-24_05-03-03 Restart Xvfb...
2017-03-24 05:03:07  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-03-24 05:03:12  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-03-24 05:03:17  - 23147  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-03-24 05:03:21  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-03-24 05:03:26  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-03-24 05:03:30  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-03-24 05:03:34  - 23147  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-03-24 05:03:39  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-03-24 05:03:43  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-03-24 05:03:49  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-03-24 05:03:53  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-03-24 05:03:57  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-03-24 05:04:02  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-03-24 05:04:06  - 23147  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-03-24 05:04:11  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-03-24 05:04:16  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-03-24 05:04:20  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-03-24 05:04:24  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-03-24 05:04:29  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-03-24 05:04:33  - 23147  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-03-24 05:04:38  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-03-24 05:04:42  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-03-24 05:04:46  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-03-24 05:04:51  - 23147  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-03-24 05:04:55  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-03-24 05:05:00  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
<pre>2017-03-24_05-05-03 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_05-07-03 Restart Xvfb...
2017-03-24 05:07:05  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-03-24 05:07:09  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-03-24 05:07:14  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-03-24 05:07:18  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-03-24 05:07:22  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-03-24 05:07:26  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-03-24 05:07:30  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-03-24 05:07:34  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-03-24 05:07:39  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-03-24 05:07:43  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-03-24 05:07:47  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-03-24 05:07:51  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-03-24 05:07:55  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-03-24 05:08:00  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-03-24 05:08:04  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-03-24 05:08:08  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-03-24 05:08:12  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-03-24 05:08:17  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-03-24 05:08:21  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-03-24 05:08:25  - 23147  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-03-24 05:08:29  - 23147  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-03-24 05:08:33  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-03-24 05:08:38  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-03-24 05:08:42  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-03-24 05:08:46  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-03-24 05:08:51  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-03-24 05:08:56  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-03-24 05:09:00  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
<pre>2017-03-24_05-09-03 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_05-11-03 Restart Xvfb...
2017-03-24 05:11:05  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-03-24 05:11:10  - 23147  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-03-24 05:11:14  - 23147  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-03-24 05:11:18  - 23147  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-03-24 05:11:22  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-03-24 05:11:27  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-03-24 05:11:31  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-03-24 05:11:35  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-03-24 05:11:39  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-03-24 05:11:43  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-24 05:11:47  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-24 05:11:51  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-24 05:11:56  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-24 05:12:00  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-03-24 05:12:04  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-24 05:12:08  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-24 05:12:12  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-03-24 05:12:16  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-03-24 05:12:20  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-03-24 05:12:24  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-03-24 05:12:28  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-03-24 05:12:33  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-03-24 05:12:37  - 23147  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-03-24 05:12:41  - 23147  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-03-24 05:12:45  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-03-24 05:12:49  - 23147  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-03-24 05:12:54  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-03-24 05:12:58  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-03-24 05:13:02  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
<pre>2017-03-24_05-13-03 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_05-15-03 Restart Xvfb...
2017-03-24 05:15:07  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-03-24 05:15:11  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-03-24 05:15:15  - 23147  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-03-24 05:15:19  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-03-24 05:15:24  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-03-24 05:15:28  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-03-24 05:15:32  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-03-24 05:15:36  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-03-24 05:15:40  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-24 05:15:44  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-24 05:15:48  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-24 05:15:52  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-24 05:15:56  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-24 05:16:00  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-03-24 05:16:04  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-24 05:16:08  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-24 05:16:12  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-24 05:16:16  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-24 05:16:21  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-03-24 05:16:24  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-24 05:16:28  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-24 05:16:32  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-24 05:16:37  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-03-24 05:16:41  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
<pre>2017-03-24_05-17-03 Restart Xvfb...
<pre>2017-03-24_05-19-03 Restart Xvfb...
<pre>2017-03-24_05-21-03 Restart Xvfb...
<pre>2017-03-24_05-23-03 Restart Xvfb...
<pre>2017-03-24_05-25-03 Restart Xvfb...
<pre>2017-03-24_05-27-03 Restart Xvfb...
<pre>2017-03-24_05-29-03 Restart Xvfb...
<pre>2017-03-24_05-31-03 Restart Xvfb...
<pre>2017-03-24_05-33-03 Restart Xvfb...
<pre>2017-03-24_05-35-03 Restart Xvfb...
<pre>2017-03-24_05-37-03 Restart Xvfb...
<pre>2017-03-24_05-39-03 Restart Xvfb...
<pre>2017-03-24_05-41-03 Restart Xvfb...
<pre>2017-03-24_05-43-03 Restart Xvfb...
<pre>2017-03-24_05-45-04 Restart Xvfb...
<pre>2017-03-24_05-47-04 Restart Xvfb...
<pre>2017-03-24_05-49-04 Restart Xvfb...
<pre>2017-03-24_05-51-04 Restart Xvfb...
<pre>2017-03-24_05-53-04 Restart Xvfb...
<pre>2017-03-24_05-55-04 Restart Xvfb...
<pre>2017-03-24_05-57-04 Restart Xvfb...
<pre>2017-03-24_05-59-04 Restart Xvfb...
<pre>2017-03-24_06-01-04 Restart Xvfb...
<pre>2017-03-24_06-03-04 Restart Xvfb...
<pre>2017-03-24_06-05-04 Restart Xvfb...
<pre>2017-03-24_06-07-04 Restart Xvfb...
<pre>2017-03-24_06-09-04 Restart Xvfb...
<pre>2017-03-24_06-11-04 Restart Xvfb...
<pre>2017-03-24_06-13-04 Restart Xvfb...
<pre>2017-03-24_06-15-04 Restart Xvfb...
<pre>2017-03-24_06-17-04 Restart Xvfb...
<pre>2017-03-24_06-19-04 Restart Xvfb...
<pre>2017-03-24_06-21-04 Restart Xvfb...
<pre>2017-03-24_06-23-04 Restart Xvfb...
<pre>2017-03-24_06-25-04 Restart Xvfb...
<pre>2017-03-24_06-27-04 Restart Xvfb...
<pre>2017-03-24_06-29-04 Restart Xvfb...
<pre>2017-03-24_06-31-04 Restart Xvfb...
<pre>2017-03-24_06-33-04 Restart Xvfb...
<pre>2017-03-24_06-35-04 Restart Xvfb...
<pre>2017-03-24_06-37-04 Restart Xvfb...
<pre>2017-03-24_06-39-04 Restart Xvfb...
<pre>2017-03-24_06-41-04 Restart Xvfb...
<pre>2017-03-24_06-43-04 Restart Xvfb...
<pre>2017-03-24_06-45-04 Restart Xvfb...
<pre>2017-03-24_06-47-04 Restart Xvfb...
<pre>2017-03-24_06-49-04 Restart Xvfb...
<pre>2017-03-24_06-51-04 Restart Xvfb...
<pre>2017-03-24_06-53-04 Restart Xvfb...
<pre>2017-03-24_06-55-04 Restart Xvfb...
2017-03-24 06:56:59 reset updateRequest
2017-03-24 06:57:02  - 23147  http://www.lymphomahub.com/
2017-03-24 06:57:04  - 23147  http://www.lymphomahub.com/
<pre>2017-03-24_06-57-04 Restart Xvfb...
2017-03-24 06:57:09  - 23147  http://www.lymphomahub.com/about
2017-03-24 06:57:14  - 23147  http://www.lymphomahub.com/terms
2017-03-24 06:57:18  - 23147  http://www.lymphomahub.com/undefined
2017-03-24 06:57:19  - 23147  http://www.lymphomahub.com/therapies
2017-03-24 06:57:24  - 23147  http://www.lymphomahub.com/newsletter
2017-03-24 06:57:28  - 23147  http://www.lymphomahub.com/cookie-policy
2017-03-24 06:57:31  - 23147  http://www.lymphomahub.com/therapies/afm13
2017-03-24 06:57:36  - 23147  http://www.lymphomahub.com/therapies/ags67e
2017-03-24 06:57:41  - 23147  http://www.lymphomahub.com/therapies/cc-292
2017-03-24 06:57:45  - 23147  http://www.lymphomahub.com/therapies/cc-223
2017-03-24 06:57:50  - 23147  http://www.lymphomahub.com/therapies/sd-101
2017-03-24 06:57:55  - 23147  http://www.lymphomahub.com/therapies/rp6530
2017-03-24 06:57:59  - 23147  http://www.lymphomahub.com/therapies/abt199
2017-03-24 06:58:00  - 23147  http://www.lymphomahub.com/therapies/mor208
2017-03-24 06:58:05  - 23147  http://www.lymphomahub.com/therapies/cc-122
2017-03-24 06:58:09  - 23147  http://www.lymphomahub.com/therapies/at-101
2017-03-24 06:58:14  - 23147  http://www.lymphomahub.com/therapies/bl8040
2017-03-24 06:58:18  - 23147  http://www.lymphomahub.com/therapies/bcl201
2017-03-24 06:58:23  - 23147  http://www.lymphomahub.com/therapies/azd3965
2017-03-24 06:58:28  - 23147  http://www.lymphomahub.com/therapies/imgn529
2017-03-24 06:58:32  - 23147  http://www.lymphomahub.com/therapies/azd2014
2017-03-24 06:58:37  - 23147  http://www.lymphomahub.com/therapies/mt-3724
2017-03-24 06:58:41  - 23147  http://www.lymphomahub.com/therapies/actr087
2017-03-24 06:58:46  - 23147  http://www.lymphomahub.com/therapies/epz6438
2017-03-24 06:58:51  - 23147  http://www.lymphomahub.com/therapies/kte-c19
2017-03-24 06:58:56  - 23147  http://www.lymphomahub.com/about/secretariat
2017-03-24 06:58:59  - 23147  http://www.lymphomahub.com/therapies/alt-803
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/?_prerender {"code":"ECONNRESET"}
2017-03-24 06:59:04  - 23147  http://www.lymphomahub.com/therapies/regn1979
<pre>2017-03-24_06-59-04 Restart Xvfb...
2017-03-24 06:59:08  - 23147  http://www.lymphomahub.com/therapies/regn1979
2017-03-24 06:59:12  - 23147  http://www.lymphomahub.com/therapies/immu-114
2017-03-24 06:59:16  - 23147  http://www.lymphomahub.com/therapies/incb7839
2017-03-24 06:59:21  - 23147  http://www.lymphomahub.com/therapies/adct-301
2017-03-24 06:59:25  - 23147  http://www.lymphomahub.com/therapies/ixazomib
2017-03-24 06:59:29  - 23147  http://www.lymphomahub.com/therapies/avelumab
2017-03-24 06:59:34  - 23147  http://www.lymphomahub.com/therapies/bi836826
2017-03-24 06:59:38  - 23147  http://www.lymphomahub.com/therapies/medi-570
2017-03-24 06:59:43  - 23147  http://www.lymphomahub.com/therapies/ds-3201b
2017-03-24 06:59:47  - 23147  http://www.lymphomahub.com/therapies/sea-cd40
2017-03-24 06:59:52  - 23147  http://www.lymphomahub.com/therapies/adct-402
2017-03-24 06:59:56  - 23147  http://www.lymphomahub.com/therapies/acy-1215
2017-03-24 07:00:03  - 23147  http://www.lymphomahub.com/therapies/cudc-907
2017-03-24 07:00:07  - 23147  http://www.lymphomahub.com/therapies/tgr-1202
2017-03-24 07:00:12  - 23147  http://www.lymphomahub.com/therapies/axitinib
2017-03-24 07:00:16  - 23147  http://www.lymphomahub.com/therapies/imatinib
2017-03-24 07:00:20  - 23147  http://www.lymphomahub.com/therapies/edo-s101
2017-03-24 07:00:28  - 23147  http://www.lymphomahub.com/therapies/btct4465a
2017-03-24 07:00:32  - 23147  http://www.lymphomahub.com/therapies/alisertib
2017-03-24 07:00:37  - 23147  http://www.lymphomahub.com/therapies/lirilumab
2017-03-24 07:00:42  - 23147  http://www.lymphomahub.com/therapies/ibrutinib
2017-03-24 07:00:43  - 23147  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-03-24 07:00:47  - 23147  http://www.lymphomahub.com/therapies/rituximab
2017-03-24 07:00:52  - 23147  http://www.lymphomahub.com/therapies/veliparib
2017-03-24 07:00:56  - 23147  http://www.lymphomahub.com/therapies/sunitinib
2017-03-24 07:01:01  - 23147  http://www.lymphomahub.com/therapies/nivolumab
2017-03-24 07:01:01  - 23147  http://www.lymphomahub.com/therapies/sirolimus
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/regn1979?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_07-01-04 Restart Xvfb...
2017-03-24 07:01:09  - 23147  http://www.lymphomahub.com/therapies/sirolimus
2017-03-24 07:01:13  - 23147  http://www.lymphomahub.com/medical-information
2017-03-24 07:01:17  - 23147  http://www.lymphomahub.com/therapies/selinexor
2017-03-24 07:01:22  - 23147  http://www.lymphomahub.com/therapies/abc294640
2017-03-24 07:01:27  - 23147  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-03-24 07:01:31  - 23147  http://www.lymphomahub.com/therapies/tenofovir
2017-03-24 07:01:35  - 23147  http://www.lymphomahub.com/therapies/betalutin
2017-03-24 07:01:40  - 23147  http://www.lymphomahub.com/therapies/chidamide
2017-03-24 07:01:44  - 23147  http://www.lymphomahub.com/therapies/duvelisib
2017-03-24 07:01:49  - 23147  http://www.lymphomahub.com/therapies/dasatinib
2017-03-24 07:01:54  - 23147  http://www.lymphomahub.com/therapies/everolimus
2017-03-24 07:01:58  - 23147  http://www.lymphomahub.com/therapies/incb039110
2017-03-24 07:02:03  - 23147  http://www.lymphomahub.com/therapies/durvalumab
2017-03-24 07:02:07  - 23147  http://www.lymphomahub.com/therapies/romidepsin
2017-03-24 07:02:12  - 23147  http://www.lymphomahub.com/therapies/bortezomib
2017-03-24 07:02:16  - 23147  http://www.lymphomahub.com/therapies/idelalisib
2017-03-24 07:02:17  - 23147  http://www.lymphomahub.com/therapies/tipifarnib
2017-03-24 07:02:21  - 23147  http://www.lymphomahub.com/therapies/ipilimumab
2017-03-24 07:02:26  - 23147  http://www.lymphomahub.com/therapies/crizotinib
2017-03-24 07:02:30  - 23147  http://www.lymphomahub.com/therapies/gsk2816126
2017-03-24 07:02:34  - 23147  http://www.lymphomahub.com/therapies/copanlisib
2017-03-24 07:02:39  - 23147  http://www.lymphomahub.com/therapies/buparlisib
2017-03-24 07:02:43  - 23147  http://www.lymphomahub.com/therapies/belinostat
2017-03-24 07:02:48  - 23147  http://www.lymphomahub.com/therapies/vorinostat
2017-03-24 07:02:52  - 23147  http://www.lymphomahub.com/therapies/plerixafor
2017-03-24 07:02:53  - 23147  http://www.lymphomahub.com/therapies/ofatumumab
2017-03-24 07:02:57  - 23147  http://www.lymphomahub.com/therapies/pf-06801591
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/sirolimus?_prerender {"code":"ECONNRESET"}
2017-03-24 07:03:02  - 23147  http://www.lymphomahub.com/therapies/tocilizumab
<pre>2017-03-24_07-03-04 Restart Xvfb...
2017-03-24 07:03:07  - 23147  http://www.lymphomahub.com/therapies/tocilizumab
2017-03-24 07:03:11  - 23147  http://www.lymphomahub.com/therapies/msc2490484a
2017-03-24 07:03:15  - 23147  http://www.lymphomahub.com/therapies/carfilzomib
2017-03-24 07:03:20  - 23147  http://www.lymphomahub.com/therapies/ruxolitinib
2017-03-24 07:03:24  - 23147  http://www.lymphomahub.com/therapies/palbociclib
2017-03-24 07:03:28  - 23147  http://www.lymphomahub.com/therapies/fenretinide
2017-03-24 07:03:33  - 23147  http://www.lymphomahub.com/therapies/daratumumab
2017-03-24 07:03:38  - 23147  http://www.lymphomahub.com/therapies/pf-05082566
2017-03-24 07:03:42  - 23147  http://www.lymphomahub.com/therapies/ramucirumab
2017-03-24 07:03:47  - 23147  http://www.lymphomahub.com/therapies/tositumomab
2017-03-24 07:03:51  - 23147  http://www.lymphomahub.com/therapies/ublituximab
2017-03-24 07:03:56  - 23147  http://www.lymphomahub.com/therapies/epacadostat
2017-03-24 07:04:01  - 23147  http://www.lymphomahub.com/therapies/alemtuzumab
2017-03-24 07:04:01  - 23147  http://www.lymphomahub.com/therapies/otlertuzumab
2017-03-24 07:04:06  - 23147  http://www.lymphomahub.com/therapies/panobinostat
2017-03-24 07:04:10  - 23147  http://www.lymphomahub.com/therapies/mocetinostat
2017-03-24 07:04:15  - 23147  http://www.lymphomahub.com/therapies/atezolizumab
2017-03-24 07:04:19  - 23147  http://www.lymphomahub.com/therapies/temsirolimus
2017-03-24 07:04:24  - 23147  http://www.lymphomahub.com/therapies/lenalidomide
2017-03-24 07:04:28  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab
2017-03-24 07:04:33  - 23147  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-03-24 07:04:37  - 23147  http://www.lymphomahub.com/therapies/blinatumomab
2017-03-24 07:04:42  - 23147  http://www.lymphomahub.com/therapies/jnj-64052781
2017-03-24 07:04:46  - 23147  http://www.lymphomahub.com/therapies/entospletinib
2017-03-24 07:04:51  - 23147  http://www.lymphomahub.com/therapies/pembrolizumab
2017-03-24 07:04:56  - 23147  http://www.lymphomahub.com/therapies/acalabrutinib
2017-03-24 07:05:00  - 23147  http://www.lymphomahub.com/about/innovation-committee
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/tocilizumab?_prerender {"code":"ECONNRESET"}
2017-03-24 07:05:04  - 23147  http://www.lymphomahub.com/mailto:info@lymphomahub.com
<pre>2017-03-24_07-05-04 Restart Xvfb...
2017-03-24 07:05:05  - 23147  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-03-24 07:05:07  - 23147  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-03-24 07:05:09  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-03-24 07:05:12  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-03-24 07:05:15  - 23147  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-03-24 07:05:16  - 23147  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-03-24 07:05:20  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-03-24 07:05:21  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-03-24 07:05:25  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-03-24 07:05:26  - 23147  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-03-24 07:05:31  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-03-24 07:05:35  - 23147  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-03-24 07:05:40  - 23147  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-03-24 07:05:43  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board
2017-03-24 07:05:48  - 23147  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-03-24 07:05:53  - 23147  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-03-24 07:05:57  - 23147  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-03-24 07:06:00  - 23147  http://www.lymphomahub.com/about/executive-steering-committee
2017-03-24 07:06:04  - 23147  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-03-24 07:06:08  - 23147  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-03-24 07:06:13  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-03-24 07:06:17  - 23147  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-03-24 07:06:21  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-03-24 07:06:25  - 23147  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-03-24 07:06:29  - 23147  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-03-24 07:06:30  - 23147  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-03-24 07:06:33  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-03-24 07:06:38  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-03-24 07:06:43  - 23147  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-03-24 07:06:47  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-03-24 07:06:51  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-03-24 07:06:56  - 23147  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-03-24 07:07:00  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-03-24 07:07:04  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
<pre>2017-03-24_07-07-04 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_07-09-04 Restart Xvfb...
2017-03-24 07:09:09  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-03-24 07:09:13  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-03-24 07:09:16  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-03-24 07:09:20  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-03-24 07:09:24  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-03-24 07:09:28  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-03-24 07:09:31  - 23147  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-03-24 07:09:36  - 23147  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-03-24 07:09:40  - 23147  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-03-24 07:09:45  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-03-24 07:09:49  - 23147  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-03-24 07:09:52  - 23147  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-03-24 07:09:57  - 23147  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-03-24 07:10:01  - 23147  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-03-24 07:10:06  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-03-24 07:10:09  - 23147  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-03-24 07:10:14  - 23147  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-03-24 07:10:19  - 23147  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-03-24 07:10:23  - 23147  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-03-24 07:10:28  - 23147  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-03-24 07:10:33  - 23147  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-03-24 07:10:37  - 23147  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-03-24 07:10:42  - 23147  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-03-24 07:10:46  - 23147  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-03-24 07:10:50  - 23147  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-03-24 07:10:55  - 23147  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-03-24 07:11:00  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-03-24 07:11:04  - 23147  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
<pre>2017-03-24_07-11-04 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_07-13-04 Restart Xvfb...
2017-03-24 07:13:09  - 23147  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-03-24 07:13:14  - 23147  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-03-24 07:13:18  - 23147  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-03-24 07:13:22  - 23147  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-03-24 07:13:27  - 23147  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-03-24 07:13:31  - 23147  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-03-24 07:13:35  - 23147  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-03-24 07:13:39  - 23147  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-03-24 07:13:43  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-03-24 07:13:49  - 23147  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-03-24 07:13:53  - 23147  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-03-24 07:13:58  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-03-24 07:14:02  - 23147  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-03-24 07:14:06  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-03-24 07:14:10  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-03-24 07:14:14  - 23147  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-03-24 07:14:19  - 23147  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-03-24 07:14:23  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-03-24 07:14:27  - 23147  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-03-24 07:14:31  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-03-24 07:14:35  - 23147  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-03-24 07:14:40  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-03-24 07:14:43  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-03-24 07:14:48  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-03-24 07:14:52  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-03-24 07:14:55  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-03-24 07:15:00  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-03-24 07:15:03  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
<pre>2017-03-24_07-15-05 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_07-17-05 Restart Xvfb...
2017-03-24 07:17:08  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-03-24 07:17:12  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-03-24 07:17:17  - 23147  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-03-24 07:17:22  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-03-24 07:17:26  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-03-24 07:17:31  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-03-24 07:17:36  - 23147  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-24 07:17:36  - 23147  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-03-24 07:17:41  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-03-24 07:17:45  - 23147  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-03-24 07:17:50  - 23147  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-03-24 07:17:55  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-03-24 07:18:00  - 23147  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-03-24 07:18:04  - 23147  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-03-24 07:18:09  - 23147  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-03-24 07:18:14  - 23147  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-03-24 07:18:18  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-03-24 07:18:23  - 23147  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-03-24 07:18:27  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-03-24 07:18:32  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-03-24 07:18:37  - 23147  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-03-24 07:18:41  - 23147  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-03-24 07:18:46  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-03-24 07:18:51  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-03-24 07:18:56  - 23147  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-03-24 07:19:00  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
<pre>2017-03-24_07-19-05 Restart Xvfb...
2017-03-24 07:19:05  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
<pre>2017-03-24_07-21-05 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma?_prerender {"code":"ECONNRESET"}
2017-03-24 07:21:10  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-03-24 07:21:15  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-03-24 07:21:19  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-03-24 07:21:25  - 23147  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-24 07:21:29  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-03-24 07:21:34  - 23147  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-03-24 07:21:39  - 23147  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-03-24 07:21:43  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-03-24 07:21:48  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-03-24 07:21:53  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-03-24 07:21:57  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-03-24 07:22:01  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-03-24 07:22:06  - 23147  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-03-24 07:22:11  - 23147  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-03-24 07:22:15  - 23147  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-03-24 07:22:20  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-03-24 07:22:25  - 23147  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-03-24 07:22:29  - 23147  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-03-24 07:22:34  - 23147  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-03-24 07:22:35  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-03-24 07:22:39  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-03-24 07:22:44  - 23147  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-03-24 07:22:48  - 23147  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-03-24 07:22:53  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-03-24 07:22:58  - 23147  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-03-24 07:23:03  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
<pre>2017-03-24_07-23-05 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_07-25-05 Restart Xvfb...
2017-03-24 07:25:08  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-03-24 07:25:12  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-03-24 07:25:17  - 23147  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-03-24 07:25:22  - 23147  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-03-24 07:25:26  - 23147  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-03-24 07:25:31  - 23147  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-03-24 07:25:35  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-03-24 07:25:40  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-03-24 07:25:45  - 23147  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-03-24 07:25:49  - 23147  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-03-24 07:25:54  - 23147  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-03-24 07:25:59  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-03-24 07:26:03  - 23147  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-03-24 07:26:08  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-03-24 07:26:13  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-03-24 07:26:16  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-03-24 07:26:22  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-03-24 07:26:26  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-03-24 07:26:30  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-03-24 07:26:34  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-03-24 07:26:38  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-03-24 07:26:41  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-03-24 07:26:46  - 23147  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-03-24 07:26:46  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-03-24 07:26:51  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-03-24 07:26:56  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-03-24 07:27:00  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-03-24 07:27:03  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
<pre>2017-03-24_07-27-05 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_07-29-05 Restart Xvfb...
2017-03-24 07:29:08  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-03-24 07:29:12  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-03-24 07:29:17  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-03-24 07:29:20  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-03-24 07:29:24  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-03-24 07:29:27  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-03-24 07:29:31  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-03-24 07:29:35  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-03-24 07:29:38  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-03-24 07:29:42  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-03-24 07:29:46  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-03-24 07:29:49  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-03-24 07:29:54  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-03-24 07:29:58  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-03-24 07:30:01  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-03-24 07:30:05  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-03-24 07:30:09  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-03-24 07:30:13  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-03-24 07:30:16  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-03-24 07:30:20  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-03-24 07:30:24  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-03-24 07:30:28  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-03-24 07:30:31  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-03-24 07:30:35  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-03-24 07:30:38  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-03-24 07:30:42  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-03-24 07:30:46  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-03-24 07:30:49  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-03-24 07:30:53  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-03-24 07:30:56  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-03-24 07:31:00  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-03-24 07:31:04  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
<pre>2017-03-24_07-31-05 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_07-33-05 Restart Xvfb...
2017-03-24 07:33:09  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-03-24 07:33:12  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-03-24 07:33:16  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-03-24 07:33:20  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-03-24 07:33:24  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-03-24 07:33:27  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-03-24 07:33:31  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-03-24 07:33:35  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-03-24 07:33:39  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-03-24 07:33:42  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-03-24 07:33:46  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-03-24 07:33:50  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-03-24 07:33:53  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-03-24 07:33:57  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-03-24 07:34:01  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-03-24 07:34:06  - 23147  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-03-24 07:34:11  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-03-24 07:34:16  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-03-24 07:34:21  - 23147  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-03-24 07:34:21  - 23147  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-03-24 07:34:26  - 23147  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-03-24 07:34:30  - 23147  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-03-24 07:34:35  - 23147  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-03-24 07:34:40  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-03-24 07:34:44  - 23147  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-03-24 07:34:49  - 23147  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-03-24 07:34:54  - 23147  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-03-24 07:34:59  - 23147  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-03-24 07:35:03  - 23147  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
<pre>2017-03-24_07-35-05 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_07-37-05 Restart Xvfb...
2017-03-24 07:37:08  - 23147  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-03-24 07:37:13  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-03-24 07:37:18  - 23147  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-03-24 07:37:23  - 23147  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-03-24 07:37:28  - 23147  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-03-24 07:37:32  - 23147  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-03-24 07:37:37  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-03-24 07:37:41  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-03-24 07:37:46  - 23147  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-03-24 07:37:50  - 23147  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-03-24 07:37:55  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-03-24 07:37:59  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-03-24 07:38:04  - 23147  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-24 07:38:08  - 23147  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-03-24 07:38:13  - 23147  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-03-24 07:38:18  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-03-24 07:38:22  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-03-24 07:38:27  - 23147  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-03-24 07:38:31  - 23147  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-03-24 07:38:36  - 23147  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-03-24 07:38:41  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-03-24 07:38:45  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-03-24 07:38:50  - 23147  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-24 07:38:54  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-03-24 07:38:59  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-03-24 07:39:04  - 23147  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
<pre>2017-03-24_07-39-05 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_07-41-05 Restart Xvfb...
2017-03-24 07:41:09  - 23147  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-03-24 07:41:14  - 23147  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-03-24 07:41:18  - 23147  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-03-24 07:41:23  - 23147  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-03-24 07:41:28  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-03-24 07:41:33  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-03-24 07:41:37  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-03-24 07:41:42  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-03-24 07:41:46  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-03-24 07:41:51  - 23147  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-03-24 07:41:56  - 23147  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-03-24 07:42:00  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-03-24 07:42:05  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-03-24 07:42:10  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-03-24 07:42:14  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-03-24 07:42:19  - 23147  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-03-24 07:42:24  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-03-24 07:42:28  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-03-24 07:42:33  - 23147  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-03-24 07:42:38  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-03-24 07:42:42  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-03-24 07:42:47  - 23147  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-03-24 07:42:52  - 23147  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-03-24 07:42:56  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-03-24 07:43:01  - 23147  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
<pre>2017-03-24_07-43-05 Restart Xvfb...
2017-03-24 07:43:05  - 23147  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-03-24 07:43:10  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-03-24 07:43:14  - 23147  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-03-24 07:43:19  - 23147  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-03-24 07:43:24  - 23147  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-03-24 07:43:28  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-03-24 07:43:33  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-03-24 07:43:37  - 23147  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-03-24 07:43:42  - 23147  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-03-24 07:43:47  - 23147  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-03-24 07:43:51  - 23147  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-03-24 07:43:56  - 23147  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-03-24 07:44:01  - 23147  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-03-24 07:44:05  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-03-24 07:44:10  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-03-24 07:44:15  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-03-24 07:44:19  - 23147  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-03-24 07:44:24  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-03-24 07:44:28  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-03-24 07:44:33  - 23147  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-03-24 07:44:37  - 23147  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-03-24 07:44:42  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-03-24 07:44:47  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-03-24 07:44:51  - 23147  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-03-24 07:44:56  - 23147  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-03-24 07:45:01  - 23147  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-03-24 07:45:04  - 23147  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
<pre>2017-03-24_07-45-05 Restart Xvfb...
2017-03-24 07:45:09  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-03-24 07:45:14  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-03-24 07:45:19  - 23147  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-03-24 07:45:23  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-03-24 07:45:28  - 23147  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-03-24 07:45:32  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-03-24 07:45:37  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-03-24 07:45:42  - 23147  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-03-24 07:45:46  - 23147  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-03-24 07:45:51  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-03-24 07:45:56  - 23147  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-03-24 07:46:01  - 23147  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-03-24 07:46:05  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-03-24 07:46:10  - 23147  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-03-24 07:46:15  - 23147  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-03-24 07:46:19  - 23147  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-03-24 07:46:24  - 23147  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-03-24 07:46:29  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-03-24 07:46:33  - 23147  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-03-24 07:46:38  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-03-24 07:46:42  - 23147  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-03-24 07:46:47  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-03-24 07:46:52  - 23147  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-03-24 07:46:57  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-03-24 07:47:01  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
<pre>2017-03-24_07-47-05 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_07-49-05 Restart Xvfb...
2017-03-24 07:49:06  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-03-24 07:49:11  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-03-24 07:49:16  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-03-24 07:49:21  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-03-24 07:49:25  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-03-24 07:49:30  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-03-24 07:49:35  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-03-24 07:49:39  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-03-24 07:49:44  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-03-24 07:49:48  - 23147  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-03-24 07:49:53  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-03-24 07:49:57  - 23147  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-03-24 07:50:01  - 23147  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-03-24 07:50:06  - 23147  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-03-24 07:50:11  - 23147  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-03-24 07:50:17  - 23147  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-03-24 07:50:22  - 23147  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-03-24 07:50:27  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-03-24 07:50:32  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-03-24 07:50:36  - 23147  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-03-24 07:50:41  - 23147  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-03-24 07:50:46  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-03-24 07:50:50  - 23147  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-03-24 07:50:55  - 23147  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-03-24 07:51:00  - 23147  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-03-24 07:51:05  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
<pre>2017-03-24_07-51-05 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_07-53-05 Restart Xvfb...
2017-03-24 07:53:10  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-03-24 07:53:14  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-03-24 07:53:19  - 23147  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-03-24 07:53:24  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-03-24 07:53:29  - 23147  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-03-24 07:53:33  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-03-24 07:53:38  - 23147  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-03-24 07:53:43  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-03-24 07:53:47  - 23147  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-03-24 07:53:52  - 23147  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-03-24 07:53:56  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-03-24 07:54:01  - 23147  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-03-24 07:54:05  - 23147  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-03-24 07:54:09  - 23147  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-03-24 07:54:14  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-03-24 07:54:19  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-03-24 07:54:23  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-03-24 07:54:27  - 23147  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-03-24 07:54:32  - 23147  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-03-24 07:54:37  - 23147  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-03-24 07:54:41  - 23147  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-03-24 07:54:45  - 23147  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-03-24 07:54:49  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-03-24 07:54:54  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-03-24 07:54:59  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-03-24 07:55:03  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
<pre>2017-03-24_07-55-05 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_07-57-05 Restart Xvfb...
2017-03-24 07:57:08  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-03-24 07:57:12  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-03-24 07:57:17  - 23147  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-03-24 07:57:21  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-03-24 07:57:26  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-03-24 07:57:31  - 23147  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-03-24 07:57:36  - 23147  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-03-24 07:57:40  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-03-24 07:57:44  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-03-24 07:57:48  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-03-24 07:57:53  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-03-24 07:57:58  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-03-24 07:58:02  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-03-24 07:58:07  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-03-24 07:58:11  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-03-24 07:58:16  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-03-24 07:58:20  - 23147  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-03-24 07:58:25  - 23147  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-03-24 07:58:29  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-03-24 07:58:33  - 23147  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-03-24 07:58:37  - 23147  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-03-24 07:58:42  - 23147  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-03-24 07:58:46  - 23147  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-03-24 07:58:51  - 23147  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-03-24 07:58:56  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-03-24 07:59:00  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-03-24 07:59:05  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
<pre>2017-03-24_07-59-05 Restart Xvfb...
2017-03-24 07:59:10  - 23147  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-03-24 07:59:14  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-03-24 07:59:19  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-03-24 07:59:24  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-03-24 07:59:28  - 23147  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-03-24 07:59:33  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-03-24 07:59:37  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-03-24 07:59:42  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-03-24 07:59:46  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-03-24 07:59:50  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-03-24 07:59:55  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-03-24 07:59:59  - 23147  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-03-24 08:00:04  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-03-24 08:00:09  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-03-24 08:00:13  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-03-24 08:00:23  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-03-24 08:00:27  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-03-24 08:00:32  - 23147  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-03-24 08:00:39  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-03-24 08:00:43  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-03-24 08:00:48  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-03-24 08:00:52  - 23147  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-03-24 08:00:57  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-03-24 08:01:01  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
<pre>2017-03-24_08-01-05 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_08-03-05 Restart Xvfb...
2017-03-24 08:03:06  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-03-24 08:03:11  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-03-24 08:03:15  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-03-24 08:03:19  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-03-24 08:03:23  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-03-24 08:03:28  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-03-24 08:03:32  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-03-24 08:03:36  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-03-24 08:03:40  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-03-24 08:03:45  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-03-24 08:03:49  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-03-24 08:03:53  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-03-24 08:03:57  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-03-24 08:04:01  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-03-24 08:04:06  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-03-24 08:04:10  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-03-24 08:04:15  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-03-24 08:04:20  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-03-24 08:04:24  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-03-24 08:04:28  - 23147  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-03-24 08:04:32  - 23147  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-03-24 08:04:36  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-03-24 08:04:41  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-03-24 08:04:45  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-03-24 08:04:49  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-03-24 08:04:54  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-03-24 08:04:59  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-03-24 08:05:03  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
<pre>2017-03-24_08-05-05 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_08-07-05 Restart Xvfb...
2017-03-24 08:07:08  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-03-24 08:07:13  - 23147  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-03-24 08:07:17  - 23147  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-03-24 08:07:21  - 23147  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-03-24 08:07:25  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-03-24 08:07:30  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-03-24 08:07:34  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-03-24 08:07:38  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-03-24 08:07:43  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-03-24 08:07:47  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-24 08:07:51  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-24 08:07:55  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-24 08:07:59  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-24 08:08:04  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-03-24 08:08:08  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-24 08:08:12  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-24 08:08:16  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-03-24 08:08:22  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-03-24 08:08:26  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-03-24 08:08:30  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-03-24 08:08:35  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-03-24 08:08:39  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-03-24 08:08:43  - 23147  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-03-24 08:08:48  - 23147  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-03-24 08:08:52  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-03-24 08:08:57  - 23147  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-03-24 08:09:01  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-03-24 08:09:05  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
<pre>2017-03-24_08-09-05 Restart Xvfb...
2017-03-24 08:09:10  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-03-24 08:09:14  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-03-24 08:09:18  - 23147  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-03-24 08:09:22  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-03-24 08:09:26  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-03-24 08:09:31  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-03-24 08:09:35  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-03-24 08:09:39  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-03-24 08:09:43  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-24 08:09:47  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-24 08:09:51  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-24 08:09:55  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-24 08:09:59  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-24 08:10:04  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-03-24 08:10:08  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-24 08:10:12  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-24 08:10:16  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-24 08:10:20  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-24 08:10:24  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-03-24 08:10:28  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-24 08:10:32  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-24 08:10:37  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-24 08:10:41  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-03-24 08:10:45  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
<pre>2017-03-24_08-11-05 Restart Xvfb...
<pre>2017-03-24_08-13-05 Restart Xvfb...
<pre>2017-03-24_08-15-05 Restart Xvfb...
<pre>2017-03-24_08-17-05 Restart Xvfb...
<pre>2017-03-24_08-19-05 Restart Xvfb...
<pre>2017-03-24_08-21-05 Restart Xvfb...
<pre>2017-03-24_08-23-05 Restart Xvfb...
<pre>2017-03-24_08-25-05 Restart Xvfb...
<pre>2017-03-24_08-27-05 Restart Xvfb...
<pre>2017-03-24_08-29-05 Restart Xvfb...
<pre>2017-03-24_08-31-05 Restart Xvfb...
<pre>2017-03-24_08-33-05 Restart Xvfb...
<pre>2017-03-24_08-35-05 Restart Xvfb...
<pre>2017-03-24_08-37-06 Restart Xvfb...
<pre>2017-03-24_08-39-06 Restart Xvfb...
<pre>2017-03-24_08-41-06 Restart Xvfb...
<pre>2017-03-24_08-43-06 Restart Xvfb...
<pre>2017-03-24_08-45-06 Restart Xvfb...
<pre>2017-03-24_08-47-06 Restart Xvfb...
<pre>2017-03-24_08-49-06 Restart Xvfb...
<pre>2017-03-24_08-51-06 Restart Xvfb...
<pre>2017-03-24_08-53-06 Restart Xvfb...
<pre>2017-03-24_08-55-06 Restart Xvfb...
<pre>2017-03-24_08-57-06 Restart Xvfb...
<pre>2017-03-24_08-59-06 Restart Xvfb...
<pre>2017-03-24_09-01-06 Restart Xvfb...
<pre>2017-03-24_09-03-06 Restart Xvfb...
<pre>2017-03-24_09-05-06 Restart Xvfb...
<pre>2017-03-24_09-07-06 Restart Xvfb...
<pre>2017-03-24_09-09-06 Restart Xvfb...
<pre>2017-03-24_09-11-06 Restart Xvfb...
<pre>2017-03-24_09-13-06 Restart Xvfb...
<pre>2017-03-24_09-15-06 Restart Xvfb...
<pre>2017-03-24_09-17-06 Restart Xvfb...
<pre>2017-03-24_09-19-06 Restart Xvfb...
<pre>2017-03-24_09-21-06 Restart Xvfb...
<pre>2017-03-24_09-23-06 Restart Xvfb...
<pre>2017-03-24_09-25-06 Restart Xvfb...
<pre>2017-03-24_09-27-06 Restart Xvfb...
<pre>2017-03-24_09-29-06 Restart Xvfb...
<pre>2017-03-24_09-31-06 Restart Xvfb...
<pre>2017-03-24_09-33-06 Restart Xvfb...
<pre>2017-03-24_09-35-06 Restart Xvfb...
<pre>2017-03-24_09-37-06 Restart Xvfb...
<pre>2017-03-24_09-39-06 Restart Xvfb...
<pre>2017-03-24_09-41-06 Restart Xvfb...
<pre>2017-03-24_09-43-06 Restart Xvfb...
<pre>2017-03-24_09-45-06 Restart Xvfb...
<pre>2017-03-24_09-47-06 Restart Xvfb...
<pre>2017-03-24_09-49-06 Restart Xvfb...
<pre>2017-03-24_09-51-06 Restart Xvfb...
<pre>2017-03-24_09-53-06 Restart Xvfb...
<pre>2017-03-24_09-55-06 Restart Xvfb...
2017-03-24 09:56:59 reset updateRequest
2017-03-24 09:57:03  - 23147  http://www.lymphomahub.com/
2017-03-24 09:57:04  - 23147  http://www.lymphomahub.com/
<pre>2017-03-24_09-57-06 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/?_prerender {"code":"ECONNRESET"}
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_09-59-06 Restart Xvfb...
2017-03-24 09:59:08  - 23147  http://www.lymphomahub.com/
2017-03-24 09:59:09  - 23147  http://www.lymphomahub.com/
2017-03-24 09:59:12  - 23147  http://www.lymphomahub.com/about
2017-03-24 09:59:13  - 23147  http://www.lymphomahub.com/about
2017-03-24 09:59:18  - 23147  http://www.lymphomahub.com/terms
2017-03-24 09:59:18  - 23147  http://www.lymphomahub.com/terms
2017-03-24 09:59:23  - 23147  http://www.lymphomahub.com/undefined
2017-03-24 09:59:23  - 23147  http://www.lymphomahub.com/undefined
2017-03-24 09:59:23  - 23147  http://www.lymphomahub.com/therapies
2017-03-24 09:59:23  - 23147  http://www.lymphomahub.com/therapies
2017-03-24 09:59:34  - 23147  http://www.lymphomahub.com/newsletter
2017-03-24 09:59:37  - 23147  http://www.lymphomahub.com/cookie-policy
2017-03-24 09:59:40  - 23147  http://www.lymphomahub.com/therapies/afm13
2017-03-24 09:59:45  - 23147  http://www.lymphomahub.com/therapies/ags67e
2017-03-24 09:59:49  - 23147  http://www.lymphomahub.com/therapies/cc-292
2017-03-24 09:59:54  - 23147  http://www.lymphomahub.com/therapies/cc-223
2017-03-24 09:59:59  - 23147  http://www.lymphomahub.com/therapies/sd-101
2017-03-24 10:00:03  - 23147  http://www.lymphomahub.com/therapies/rp6530
2017-03-24 10:00:08  - 23147  http://www.lymphomahub.com/therapies/abt199
2017-03-24 10:00:08  - 23147  http://www.lymphomahub.com/therapies/mor208
2017-03-24 10:00:15  - 23147  http://www.lymphomahub.com/therapies/cc-122
2017-03-24 10:00:20  - 23147  http://www.lymphomahub.com/therapies/at-101
2017-03-24 10:00:24  - 23147  http://www.lymphomahub.com/therapies/bl8040
2017-03-24 10:00:29  - 23147  http://www.lymphomahub.com/therapies/bcl201
2017-03-24 10:00:32  - 23147  http://www.lymphomahub.com/therapies/azd3965
2017-03-24 10:00:40  - 23147  http://www.lymphomahub.com/therapies/imgn529
2017-03-24 10:00:44  - 23147  http://www.lymphomahub.com/therapies/azd2014
2017-03-24 10:00:49  - 23147  http://www.lymphomahub.com/therapies/mt-3724
2017-03-24 10:00:54  - 23147  http://www.lymphomahub.com/therapies/actr087
2017-03-24 10:00:59  - 23147  http://www.lymphomahub.com/therapies/epz6438
2017-03-24 10:01:03  - 23147  http://www.lymphomahub.com/therapies/kte-c19
<pre>2017-03-24_10-01-06 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/kte-c19?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_10-03-06 Restart Xvfb...
2017-03-24 10:03:08  - 23147  http://www.lymphomahub.com/therapies/kte-c19
2017-03-24 10:03:12  - 23147  http://www.lymphomahub.com/about/secretariat
2017-03-24 10:03:16  - 23147  http://www.lymphomahub.com/therapies/alt-803
2017-03-24 10:03:20  - 23147  http://www.lymphomahub.com/therapies/regn1979
2017-03-24 10:03:25  - 23147  http://www.lymphomahub.com/therapies/immu-114
2017-03-24 10:03:29  - 23147  http://www.lymphomahub.com/therapies/incb7839
2017-03-24 10:03:34  - 23147  http://www.lymphomahub.com/therapies/adct-301
2017-03-24 10:03:38  - 23147  http://www.lymphomahub.com/therapies/ixazomib
2017-03-24 10:03:43  - 23147  http://www.lymphomahub.com/therapies/avelumab
2017-03-24 10:03:47  - 23147  http://www.lymphomahub.com/therapies/bi836826
2017-03-24 10:03:52  - 23147  http://www.lymphomahub.com/therapies/medi-570
2017-03-24 10:03:57  - 23147  http://www.lymphomahub.com/therapies/ds-3201b
2017-03-24 10:04:01  - 23147  http://www.lymphomahub.com/therapies/sea-cd40
2017-03-24 10:04:06  - 23147  http://www.lymphomahub.com/therapies/adct-402
2017-03-24 10:04:10  - 23147  http://www.lymphomahub.com/therapies/acy-1215
2017-03-24 10:04:15  - 23147  http://www.lymphomahub.com/therapies/cudc-907
2017-03-24 10:04:20  - 23147  http://www.lymphomahub.com/therapies/tgr-1202
2017-03-24 10:04:25  - 23147  http://www.lymphomahub.com/therapies/axitinib
2017-03-24 10:04:29  - 23147  http://www.lymphomahub.com/therapies/imatinib
2017-03-24 10:04:34  - 23147  http://www.lymphomahub.com/therapies/edo-s101
2017-03-24 10:04:39  - 23147  http://www.lymphomahub.com/therapies/btct4465a
2017-03-24 10:04:43  - 23147  http://www.lymphomahub.com/therapies/alisertib
2017-03-24 10:04:48  - 23147  http://www.lymphomahub.com/therapies/lirilumab
2017-03-24 10:04:52  - 23147  http://www.lymphomahub.com/therapies/ibrutinib
2017-03-24 10:04:53  - 23147  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-03-24 10:04:57  - 23147  http://www.lymphomahub.com/therapies/rituximab
2017-03-24 10:05:02  - 23147  http://www.lymphomahub.com/therapies/veliparib
<pre>2017-03-24_10-05-06 Restart Xvfb...
2017-03-24 10:05:06  - 23147  http://www.lymphomahub.com/therapies/sunitinib
2017-03-24 10:05:11  - 23147  http://www.lymphomahub.com/therapies/nivolumab
2017-03-24 10:05:12  - 23147  http://www.lymphomahub.com/therapies/sirolimus
2017-03-24 10:05:16  - 23147  http://www.lymphomahub.com/medical-information
2017-03-24 10:05:21  - 23147  http://www.lymphomahub.com/therapies/selinexor
2017-03-24 10:05:25  - 23147  http://www.lymphomahub.com/therapies/abc294640
2017-03-24 10:05:30  - 23147  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-03-24 10:05:34  - 23147  http://www.lymphomahub.com/therapies/tenofovir
2017-03-24 10:05:39  - 23147  http://www.lymphomahub.com/therapies/betalutin
2017-03-24 10:05:44  - 23147  http://www.lymphomahub.com/therapies/chidamide
2017-03-24 10:05:49  - 23147  http://www.lymphomahub.com/therapies/duvelisib
2017-03-24 10:05:54  - 23147  http://www.lymphomahub.com/therapies/dasatinib
2017-03-24 10:05:59  - 23147  http://www.lymphomahub.com/therapies/everolimus
2017-03-24 10:06:03  - 23147  http://www.lymphomahub.com/therapies/incb039110
2017-03-24 10:06:08  - 23147  http://www.lymphomahub.com/therapies/durvalumab
2017-03-24 10:06:12  - 23147  http://www.lymphomahub.com/therapies/romidepsin
2017-03-24 10:06:16  - 23147  http://www.lymphomahub.com/therapies/bortezomib
2017-03-24 10:06:21  - 23147  http://www.lymphomahub.com/therapies/idelalisib
2017-03-24 10:06:22  - 23147  http://www.lymphomahub.com/therapies/tipifarnib
2017-03-24 10:06:27  - 23147  http://www.lymphomahub.com/therapies/ipilimumab
2017-03-24 10:06:31  - 23147  http://www.lymphomahub.com/therapies/crizotinib
2017-03-24 10:06:35  - 23147  http://www.lymphomahub.com/therapies/gsk2816126
2017-03-24 10:06:40  - 23147  http://www.lymphomahub.com/therapies/copanlisib
2017-03-24 10:06:44  - 23147  http://www.lymphomahub.com/therapies/buparlisib
2017-03-24 10:06:49  - 23147  http://www.lymphomahub.com/therapies/belinostat
2017-03-24 10:06:53  - 23147  http://www.lymphomahub.com/therapies/vorinostat
2017-03-24 10:06:58  - 23147  http://www.lymphomahub.com/therapies/plerixafor
2017-03-24 10:06:59  - 23147  http://www.lymphomahub.com/therapies/ofatumumab
2017-03-24 10:07:03  - 23147  http://www.lymphomahub.com/therapies/pf-06801591
<pre>2017-03-24_10-07-06 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/pf-06801591?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_10-09-06 Restart Xvfb...
2017-03-24 10:09:08  - 23147  http://www.lymphomahub.com/therapies/pf-06801591
2017-03-24 10:09:12  - 23147  http://www.lymphomahub.com/therapies/tocilizumab
2017-03-24 10:09:17  - 23147  http://www.lymphomahub.com/therapies/msc2490484a
2017-03-24 10:09:22  - 23147  http://www.lymphomahub.com/therapies/carfilzomib
2017-03-24 10:09:26  - 23147  http://www.lymphomahub.com/therapies/ruxolitinib
2017-03-24 10:09:30  - 23147  http://www.lymphomahub.com/therapies/palbociclib
2017-03-24 10:09:35  - 23147  http://www.lymphomahub.com/therapies/fenretinide
2017-03-24 10:09:39  - 23147  http://www.lymphomahub.com/therapies/daratumumab
2017-03-24 10:09:44  - 23147  http://www.lymphomahub.com/therapies/pf-05082566
2017-03-24 10:09:48  - 23147  http://www.lymphomahub.com/therapies/ramucirumab
2017-03-24 10:09:53  - 23147  http://www.lymphomahub.com/therapies/tositumomab
2017-03-24 10:09:57  - 23147  http://www.lymphomahub.com/therapies/ublituximab
2017-03-24 10:10:01  - 23147  http://www.lymphomahub.com/therapies/epacadostat
2017-03-24 10:10:07  - 23147  http://www.lymphomahub.com/therapies/alemtuzumab
2017-03-24 10:10:07  - 23147  http://www.lymphomahub.com/therapies/otlertuzumab
2017-03-24 10:10:12  - 23147  http://www.lymphomahub.com/therapies/panobinostat
2017-03-24 10:10:17  - 23147  http://www.lymphomahub.com/therapies/mocetinostat
2017-03-24 10:10:21  - 23147  http://www.lymphomahub.com/therapies/atezolizumab
2017-03-24 10:10:26  - 23147  http://www.lymphomahub.com/therapies/temsirolimus
2017-03-24 10:10:31  - 23147  http://www.lymphomahub.com/therapies/lenalidomide
2017-03-24 10:10:36  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab
2017-03-24 10:10:40  - 23147  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-03-24 10:10:45  - 23147  http://www.lymphomahub.com/therapies/blinatumomab
2017-03-24 10:10:49  - 23147  http://www.lymphomahub.com/therapies/jnj-64052781
2017-03-24 10:10:54  - 23147  http://www.lymphomahub.com/therapies/entospletinib
2017-03-24 10:10:58  - 23147  http://www.lymphomahub.com/therapies/pembrolizumab
2017-03-24 10:11:02  - 23147  http://www.lymphomahub.com/therapies/acalabrutinib
<pre>2017-03-24_10-11-06 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/acalabrutinib?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_10-13-06 Restart Xvfb...
2017-03-24 10:13:08  - 23147  http://www.lymphomahub.com/therapies/acalabrutinib
2017-03-24 10:13:12  - 23147  http://www.lymphomahub.com/about/innovation-committee
2017-03-24 10:13:16  - 23147  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-03-24 10:13:16  - 23147  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-03-24 10:13:21  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-03-24 10:13:25  - 23147  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-03-24 10:13:30  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-03-24 10:13:34  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-03-24 10:13:35  - 23147  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-03-24 10:13:39  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-03-24 10:13:44  - 23147  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-03-24 10:13:48  - 23147  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-03-24 10:13:52  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board
2017-03-24 10:13:56  - 23147  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-03-24 10:14:01  - 23147  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-03-24 10:14:05  - 23147  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-03-24 10:14:09  - 23147  http://www.lymphomahub.com/about/executive-steering-committee
2017-03-24 10:14:13  - 23147  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-03-24 10:14:16  - 23147  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-03-24 10:14:21  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-03-24 10:14:27  - 23147  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-03-24 10:14:31  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-03-24 10:14:36  - 23147  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-03-24 10:14:40  - 23147  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-03-24 10:14:41  - 23147  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-03-24 10:14:44  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-03-24 10:14:49  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-03-24 10:14:54  - 23147  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-03-24 10:14:58  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-03-24 10:15:03  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
<pre>2017-03-24_10-15-06 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_10-17-07 Restart Xvfb...
2017-03-24 10:17:08  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-03-24 10:17:12  - 23147  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-03-24 10:17:16  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-03-24 10:17:20  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-03-24 10:17:24  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-03-24 10:17:28  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-03-24 10:17:31  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-03-24 10:17:36  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-03-24 10:17:39  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-03-24 10:17:43  - 23147  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-03-24 10:17:47  - 23147  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-03-24 10:17:52  - 23147  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-03-24 10:17:57  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-03-24 10:18:00  - 23147  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-03-24 10:18:04  - 23147  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-03-24 10:18:09  - 23147  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-03-24 10:18:14  - 23147  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-03-24 10:18:18  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-03-24 10:18:22  - 23147  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-03-24 10:18:27  - 23147  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-03-24 10:18:32  - 23147  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-03-24 10:18:37  - 23147  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-03-24 10:18:41  - 23147  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-03-24 10:18:46  - 23147  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-03-24 10:18:51  - 23147  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-03-24 10:18:55  - 23147  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-03-24 10:19:00  - 23147  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-03-24 10:19:04  - 23147  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
<pre>2017-03-24_10-19-07 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_10-21-07 Restart Xvfb...
2017-03-24 10:21:09  - 23147  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-03-24 10:21:13  - 23147  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-03-24 10:21:17  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-03-24 10:21:21  - 23147  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-03-24 10:21:26  - 23147  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-03-24 10:21:31  - 23147  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-03-24 10:21:35  - 23147  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-03-24 10:21:40  - 23147  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-03-24 10:21:44  - 23147  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-03-24 10:21:48  - 23147  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-03-24 10:21:52  - 23147  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-03-24 10:21:57  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-03-24 10:22:00  - 23147  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-03-24 10:22:05  - 23147  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-03-24 10:22:10  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-03-24 10:22:14  - 23147  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-03-24 10:22:18  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-03-24 10:22:22  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-03-24 10:22:26  - 23147  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-03-24 10:22:31  - 23147  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-03-24 10:22:36  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-03-24 10:22:39  - 23147  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-03-24 10:22:44  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-03-24 10:22:48  - 23147  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-03-24 10:22:52  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-03-24 10:22:56  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-03-24 10:23:01  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-03-24 10:23:05  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
<pre>2017-03-24_10-23-07 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_10-25-07 Restart Xvfb...
2017-03-24 10:25:10  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-03-24 10:25:16  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-03-24 10:25:20  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-03-24 10:25:24  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-03-24 10:25:27  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-03-24 10:25:32  - 23147  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-03-24 10:25:38  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-03-24 10:25:43  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-03-24 10:25:48  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-03-24 10:25:53  - 23147  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-24 10:25:53  - 23147  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-03-24 10:25:58  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-03-24 10:26:03  - 23147  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-03-24 10:26:07  - 23147  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-03-24 10:26:12  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-03-24 10:26:16  - 23147  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-03-24 10:26:21  - 23147  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-03-24 10:26:26  - 23147  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-03-24 10:26:31  - 23147  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-03-24 10:26:36  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-03-24 10:26:40  - 23147  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-03-24 10:26:45  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-03-24 10:26:50  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-03-24 10:26:54  - 23147  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-03-24 10:26:59  - 23147  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-03-24 10:27:04  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
<pre>2017-03-24_10-27-07 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_10-29-07 Restart Xvfb...
2017-03-24 10:29:09  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-03-24 10:29:13  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-03-24 10:29:18  - 23147  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-03-24 10:29:23  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-03-24 10:29:27  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-03-24 10:29:32  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-03-24 10:29:37  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-03-24 10:29:42  - 23147  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-24 10:29:46  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-03-24 10:29:51  - 23147  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-03-24 10:29:56  - 23147  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-03-24 10:30:00  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-03-24 10:30:05  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-03-24 10:30:10  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-03-24 10:30:14  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-03-24 10:30:19  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-03-24 10:30:25  - 23147  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-03-24 10:30:30  - 23147  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-03-24 10:30:34  - 23147  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-03-24 10:30:39  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-03-24 10:30:44  - 23147  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-03-24 10:30:48  - 23147  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-03-24 10:30:53  - 23147  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-03-24 10:30:54  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-03-24 10:30:59  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-03-24 10:31:04  - 23147  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
<pre>2017-03-24_10-31-07 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_10-33-07 Restart Xvfb...
2017-03-24 10:33:09  - 23147  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-03-24 10:33:13  - 23147  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-03-24 10:33:18  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-03-24 10:33:23  - 23147  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-03-24 10:33:28  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-03-24 10:33:32  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-03-24 10:33:37  - 23147  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-03-24 10:33:41  - 23147  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-03-24 10:33:46  - 23147  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-03-24 10:33:50  - 23147  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-03-24 10:33:55  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-03-24 10:34:00  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-03-24 10:34:05  - 23147  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-03-24 10:34:09  - 23147  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-03-24 10:34:14  - 23147  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-03-24 10:34:18  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-03-24 10:34:23  - 23147  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-03-24 10:34:28  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-03-24 10:34:33  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-03-24 10:34:36  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-03-24 10:34:42  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-03-24 10:34:46  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-03-24 10:34:50  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-03-24 10:34:54  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-03-24 10:34:58  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-03-24 10:35:02  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
<pre>2017-03-24_10-35-07 Restart Xvfb...
2017-03-24 10:35:07  - 23147  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-03-24 10:35:07  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-03-24 10:35:13  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-03-24 10:35:17  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-03-24 10:35:21  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-03-24 10:35:25  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-03-24 10:35:28  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-03-24 10:35:32  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-03-24 10:35:35  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-03-24 10:35:39  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-03-24 10:35:42  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-03-24 10:35:46  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-03-24 10:35:50  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-03-24 10:35:53  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-03-24 10:35:57  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-03-24 10:36:01  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-03-24 10:36:04  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-03-24 10:36:09  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-03-24 10:36:13  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-03-24 10:36:16  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-03-24 10:36:20  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-03-24 10:36:23  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-03-24 10:36:27  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-03-24 10:36:31  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-03-24 10:36:34  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-03-24 10:36:38  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-03-24 10:36:41  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-03-24 10:36:45  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-03-24 10:36:49  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-03-24 10:36:53  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-03-24 10:36:56  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-03-24 10:37:00  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-03-24 10:37:03  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-03-24 10:37:07  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
<pre>2017-03-24_10-37-07 Restart Xvfb...
2017-03-24 10:37:10  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-03-24 10:37:14  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-03-24 10:37:17  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-03-24 10:37:21  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-03-24 10:37:25  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-03-24 10:37:28  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-03-24 10:37:32  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-03-24 10:37:35  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-03-24 10:37:39  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-03-24 10:37:43  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-03-24 10:37:46  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-03-24 10:37:51  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-03-24 10:37:55  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-03-24 10:37:59  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-03-24 10:38:02  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-03-24 10:38:06  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-03-24 10:38:10  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-03-24 10:38:15  - 23147  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-03-24 10:38:19  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-03-24 10:38:24  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-03-24 10:38:29  - 23147  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-03-24 10:38:30  - 23147  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-03-24 10:38:34  - 23147  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-03-24 10:38:39  - 23147  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-03-24 10:38:43  - 23147  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-03-24 10:38:48  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-03-24 10:38:53  - 23147  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-03-24 10:38:57  - 23147  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-03-24 10:39:02  - 23147  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-03-24 10:39:07  - 23147  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
<pre>2017-03-24_10-39-07 Restart Xvfb...
2017-03-24 10:39:11  - 23147  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-03-24 10:39:16  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-03-24 10:39:21  - 23147  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-03-24 10:39:26  - 23147  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-03-24 10:39:31  - 23147  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-03-24 10:39:35  - 23147  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-03-24 10:39:40  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-03-24 10:39:44  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-03-24 10:39:49  - 23147  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-03-24 10:39:53  - 23147  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-03-24 10:39:58  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-03-24 10:40:03  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-03-24 10:40:07  - 23147  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-24 10:40:12  - 23147  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-03-24 10:40:17  - 23147  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-03-24 10:40:21  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-03-24 10:40:26  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-03-24 10:40:30  - 23147  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-03-24 10:40:35  - 23147  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-03-24 10:40:39  - 23147  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-03-24 10:40:44  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-03-24 10:40:49  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-03-24 10:40:53  - 23147  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-24 10:40:58  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-03-24 10:41:03  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
<pre>2017-03-24_10-41-07 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_10-43-07 Restart Xvfb...
2017-03-24 10:43:08  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-03-24 10:43:12  - 23147  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-03-24 10:43:16  - 23147  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-03-24 10:43:21  - 23147  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-03-24 10:43:26  - 23147  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-03-24 10:43:30  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-03-24 10:43:35  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-03-24 10:43:40  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-03-24 10:43:45  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-03-24 10:43:49  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-03-24 10:43:54  - 23147  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-03-24 10:43:58  - 23147  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-03-24 10:44:03  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-03-24 10:44:08  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-03-24 10:44:12  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-03-24 10:44:17  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-03-24 10:44:22  - 23147  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-03-24 10:44:27  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-03-24 10:44:31  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-03-24 10:44:36  - 23147  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-03-24 10:44:40  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-03-24 10:44:45  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-03-24 10:44:50  - 23147  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-03-24 10:44:55  - 23147  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-03-24 10:44:59  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-03-24 10:45:04  - 23147  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
<pre>2017-03-24_10-45-07 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_10-47-07 Restart Xvfb...
2017-03-24 10:47:09  - 23147  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-03-24 10:47:13  - 23147  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-03-24 10:47:18  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-03-24 10:47:22  - 23147  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-03-24 10:47:27  - 23147  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-03-24 10:47:32  - 23147  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-03-24 10:47:37  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-03-24 10:47:41  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-03-24 10:47:46  - 23147  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-03-24 10:47:51  - 23147  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-03-24 10:47:55  - 23147  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-03-24 10:48:00  - 23147  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-03-24 10:48:05  - 23147  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-03-24 10:48:10  - 23147  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-03-24 10:48:14  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-03-24 10:48:19  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-03-24 10:48:24  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-03-24 10:48:28  - 23147  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-03-24 10:48:33  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-03-24 10:48:38  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-03-24 10:48:42  - 23147  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-03-24 10:48:47  - 23147  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-03-24 10:48:51  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-03-24 10:48:56  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-03-24 10:49:01  - 23147  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-03-24 10:49:06  - 23147  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
<pre>2017-03-24_10-49-07 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_10-51-07 Restart Xvfb...
2017-03-24 10:51:11  - 23147  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-03-24 10:51:16  - 23147  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-03-24 10:51:20  - 23147  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-03-24 10:51:24  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-03-24 10:51:29  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-03-24 10:51:34  - 23147  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-03-24 10:51:38  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-03-24 10:51:43  - 23147  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-03-24 10:51:47  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-03-24 10:51:52  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-03-24 10:51:57  - 23147  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-03-24 10:52:01  - 23147  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-03-24 10:52:06  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-03-24 10:52:11  - 23147  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-03-24 10:52:15  - 23147  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-03-24 10:52:20  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-03-24 10:52:25  - 23147  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-03-24 10:52:29  - 23147  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-03-24 10:52:34  - 23147  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-03-24 10:52:38  - 23147  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-03-24 10:52:43  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-03-24 10:52:48  - 23147  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-03-24 10:52:52  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-03-24 10:52:57  - 23147  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-03-24 10:53:01  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-03-24 10:53:06  - 23147  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
<pre>2017-03-24_10-53-07 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_10-55-07 Restart Xvfb...
2017-03-24 10:55:11  - 23147  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-03-24 10:55:16  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-03-24 10:55:21  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-03-24 10:55:26  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-03-24 10:55:30  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-03-24 10:55:35  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-03-24 10:55:39  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-03-24 10:55:44  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-03-24 10:55:49  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-03-24 10:55:53  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-03-24 10:55:58  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-03-24 10:56:02  - 23147  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-03-24 10:56:07  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-03-24 10:56:11  - 23147  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-03-24 10:56:16  - 23147  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-03-24 10:56:20  - 23147  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-03-24 10:56:25  - 23147  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-03-24 10:56:29  - 23147  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-03-24 10:56:34  - 23147  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-03-24 10:56:39  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-03-24 10:56:43  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-03-24 10:56:48  - 23147  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-03-24 10:56:52  - 23147  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-03-24 10:56:57  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-03-24 10:57:02  - 23147  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-03-24 10:57:06  - 23147  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
<pre>2017-03-24_10-57-07 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_10-59-07 Restart Xvfb...
2017-03-24 10:59:11  - 23147  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-03-24 10:59:16  - 23147  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-03-24 10:59:21  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-03-24 10:59:26  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-03-24 10:59:30  - 23147  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-03-24 10:59:35  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-03-24 10:59:40  - 23147  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-03-24 10:59:44  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-03-24 10:59:49  - 23147  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-03-24 10:59:53  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-03-24 10:59:59  - 23147  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-03-24 11:00:04  - 23147  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-03-24 11:00:08  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-03-24 11:00:12  - 23147  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-03-24 11:00:17  - 23147  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-03-24 11:00:21  - 23147  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-03-24 11:00:26  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-03-24 11:00:30  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-03-24 11:00:34  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-03-24 11:00:39  - 23147  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-03-24 11:00:43  - 23147  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-03-24 11:00:48  - 23147  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-03-24 11:00:53  - 23147  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-03-24 11:00:57  - 23147  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-03-24 11:01:01  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-03-24 11:01:05  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
<pre>2017-03-24_11-01-07 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_11-03-07 Restart Xvfb...
2017-03-24 11:03:10  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-03-24 11:03:15  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-03-24 11:03:19  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-03-24 11:03:24  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-03-24 11:03:29  - 23147  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-03-24 11:03:33  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-03-24 11:03:38  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-03-24 11:03:42  - 23147  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-03-24 11:03:47  - 23147  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-03-24 11:03:52  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-03-24 11:03:56  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-03-24 11:04:00  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-03-24 11:04:05  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-03-24 11:04:10  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-03-24 11:04:15  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-03-24 11:04:19  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-03-24 11:04:24  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-03-24 11:04:28  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-03-24 11:04:32  - 23147  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-03-24 11:04:37  - 23147  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-03-24 11:04:41  - 23147  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-03-24 11:04:46  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-03-24 11:04:50  - 23147  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-03-24 11:04:54  - 23147  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-03-24 11:04:59  - 23147  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-03-24 11:05:04  - 23147  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
<pre>2017-03-24_11-05-07 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_11-07-07 Restart Xvfb...
2017-03-24 11:07:09  - 23147  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-03-24 11:07:13  - 23147  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-03-24 11:07:18  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-03-24 11:07:22  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-03-24 11:07:27  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-03-24 11:07:31  - 23147  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-03-24 11:07:36  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-03-24 11:07:40  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-03-24 11:07:45  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-03-24 11:07:49  - 23147  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-03-24 11:07:54  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-03-24 11:07:58  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-03-24 11:08:03  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-03-24 11:08:07  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-03-24 11:08:11  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-03-24 11:08:16  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-03-24 11:08:20  - 23147  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-03-24 11:08:24  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-03-24 11:08:29  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-03-24 11:08:33  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-03-24 11:08:38  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-03-24 11:08:42  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-03-24 11:08:47  - 23147  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-03-24 11:08:51  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-03-24 11:08:55  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-03-24 11:09:00  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-03-24 11:09:04  - 23147  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
<pre>2017-03-24_11-09-07 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_11-11-07 Restart Xvfb...
2017-03-24 11:11:09  - 23147  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-03-24 11:11:14  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-03-24 11:11:19  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-03-24 11:11:24  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-03-24 11:11:28  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-03-24 11:11:33  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-03-24 11:11:37  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-03-24 11:11:41  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-03-24 11:11:45  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-03-24 11:11:49  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-03-24 11:11:54  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-03-24 11:11:58  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-03-24 11:12:02  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-03-24 11:12:06  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-03-24 11:12:10  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-03-24 11:12:14  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-03-24 11:12:18  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-03-24 11:12:22  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-03-24 11:12:27  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-03-24 11:12:31  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-03-24 11:12:35  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-03-24 11:12:39  - 23147  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-03-24 11:12:44  - 23147  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-03-24 11:12:48  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-03-24 11:12:52  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-03-24 11:12:56  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-03-24 11:13:01  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-03-24 11:13:06  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
<pre>2017-03-24_11-13-07 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_11-15-07 Restart Xvfb...
2017-03-24 11:15:11  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-03-24 11:15:16  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-03-24 11:15:20  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-03-24 11:15:25  - 23147  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-03-24 11:15:29  - 23147  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-03-24 11:15:33  - 23147  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-03-24 11:15:38  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-03-24 11:15:43  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-03-24 11:15:47  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-03-24 11:15:52  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-03-24 11:15:56  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-03-24 11:16:00  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-24 11:16:05  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-24 11:16:09  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-24 11:16:13  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-24 11:16:17  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-03-24 11:16:21  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-24 11:16:25  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-24 11:16:29  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-03-24 11:16:33  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-03-24 11:16:36  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-03-24 11:16:41  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-03-24 11:16:45  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-03-24 11:16:49  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-03-24 11:16:53  - 23147  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-03-24 11:16:57  - 23147  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-03-24 11:17:02  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-03-24 11:17:06  - 23147  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
<pre>2017-03-24_11-17-07 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_11-19-07 Restart Xvfb...
2017-03-24 11:19:11  - 23147  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-03-24 11:19:15  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-03-24 11:19:19  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-03-24 11:19:24  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-03-24 11:19:28  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-03-24 11:19:32  - 23147  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-03-24 11:19:36  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-03-24 11:19:40  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-03-24 11:19:44  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-03-24 11:19:48  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-03-24 11:19:53  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-03-24 11:19:57  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-24 11:20:01  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-24 11:20:05  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-24 11:20:09  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-24 11:20:13  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-24 11:20:18  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-03-24 11:20:23  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-24 11:20:28  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-24 11:20:32  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-24 11:20:36  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-24 11:20:40  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-03-24 11:20:45  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-24 11:20:49  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-24 11:20:53  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-24 11:20:57  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-03-24 11:21:01  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
<pre>2017-03-24_11-21-07 Restart Xvfb...
<pre>2017-03-24_11-23-07 Restart Xvfb...
<pre>2017-03-24_11-25-07 Restart Xvfb...
<pre>2017-03-24_11-27-07 Restart Xvfb...
<pre>2017-03-24_11-29-07 Restart Xvfb...
<pre>2017-03-24_11-31-07 Restart Xvfb...
<pre>2017-03-24_11-33-07 Restart Xvfb...
<pre>2017-03-24_11-35-08 Restart Xvfb...
<pre>2017-03-24_11-37-08 Restart Xvfb...
<pre>2017-03-24_11-39-08 Restart Xvfb...
<pre>2017-03-24_11-41-08 Restart Xvfb...
<pre>2017-03-24_11-43-08 Restart Xvfb...
<pre>2017-03-24_11-45-08 Restart Xvfb...
<pre>2017-03-24_11-47-08 Restart Xvfb...
<pre>2017-03-24_11-49-08 Restart Xvfb...
<pre>2017-03-24_11-51-08 Restart Xvfb...
<pre>2017-03-24_11-53-08 Restart Xvfb...
<pre>2017-03-24_11-55-08 Restart Xvfb...
<pre>2017-03-24_11-57-08 Restart Xvfb...
<pre>2017-03-24_11-59-08 Restart Xvfb...
<pre>2017-03-24_12-01-08 Restart Xvfb...
<pre>2017-03-24_12-03-08 Restart Xvfb...
<pre>2017-03-24_12-05-08 Restart Xvfb...
<pre>2017-03-24_12-07-08 Restart Xvfb...
<pre>2017-03-24_12-09-08 Restart Xvfb...
<pre>2017-03-24_12-11-08 Restart Xvfb...
<pre>2017-03-24_12-13-08 Restart Xvfb...
<pre>2017-03-24_12-15-08 Restart Xvfb...
<pre>2017-03-24_12-17-08 Restart Xvfb...
<pre>2017-03-24_12-19-08 Restart Xvfb...
<pre>2017-03-24_12-21-08 Restart Xvfb...
<pre>2017-03-24_12-23-08 Restart Xvfb...
<pre>2017-03-24_12-25-08 Restart Xvfb...
<pre>2017-03-24_12-27-08 Restart Xvfb...
<pre>2017-03-24_12-29-08 Restart Xvfb...
<pre>2017-03-24_12-31-08 Restart Xvfb...
<pre>2017-03-24_12-33-08 Restart Xvfb...
<pre>2017-03-24_12-35-08 Restart Xvfb...
<pre>2017-03-24_12-37-08 Restart Xvfb...
<pre>2017-03-24_12-39-08 Restart Xvfb...
<pre>2017-03-24_12-41-08 Restart Xvfb...
<pre>2017-03-24_12-43-08 Restart Xvfb...
<pre>2017-03-24_12-45-08 Restart Xvfb...
<pre>2017-03-24_12-47-08 Restart Xvfb...
<pre>2017-03-24_12-49-08 Restart Xvfb...
<pre>2017-03-24_12-51-08 Restart Xvfb...
<pre>2017-03-24_12-53-08 Restart Xvfb...
<pre>2017-03-24_12-55-08 Restart Xvfb...
2017-03-24 12:56:59 reset updateRequest
2017-03-24 12:57:02  - 23147  http://www.lymphomahub.com/
2017-03-24 12:57:04  - 23147  http://www.lymphomahub.com/
2017-03-24 12:57:07  - 23147  http://www.lymphomahub.com/about
<pre>2017-03-24_12-57-08 Restart Xvfb...
2017-03-24 12:57:09  - 23147  http://www.lymphomahub.com/about
2017-03-24 12:57:14  - 23147  http://www.lymphomahub.com/terms
2017-03-24 12:57:17  - 23147  http://www.lymphomahub.com/undefined
2017-03-24 12:57:18  - 23147  http://www.lymphomahub.com/therapies
2017-03-24 12:57:23  - 23147  http://www.lymphomahub.com/newsletter
2017-03-24 12:57:27  - 23147  http://www.lymphomahub.com/cookie-policy
2017-03-24 12:57:30  - 23147  http://www.lymphomahub.com/therapies/afm13
2017-03-24 12:57:35  - 23147  http://www.lymphomahub.com/therapies/afm11
2017-03-24 12:57:40  - 23147  http://www.lymphomahub.com/therapies/ags67e
2017-03-24 12:57:44  - 23147  http://www.lymphomahub.com/therapies/cc-292
2017-03-24 12:57:49  - 23147  http://www.lymphomahub.com/therapies/cc-223
2017-03-24 12:57:53  - 23147  http://www.lymphomahub.com/therapies/sd-101
2017-03-24 12:57:58  - 23147  http://www.lymphomahub.com/therapies/rp6530
2017-03-24 12:58:03  - 23147  http://www.lymphomahub.com/therapies/abt199
2017-03-24 12:58:03  - 23147  http://www.lymphomahub.com/therapies/mor208
2017-03-24 12:58:08  - 23147  http://www.lymphomahub.com/therapies/cc-122
2017-03-24 12:58:12  - 23147  http://www.lymphomahub.com/therapies/at-101
2017-03-24 12:58:17  - 23147  http://www.lymphomahub.com/therapies/bl8040
2017-03-24 12:58:21  - 23147  http://www.lymphomahub.com/therapies/bcl201
2017-03-24 12:58:25  - 23147  http://www.lymphomahub.com/therapies/azd3965
2017-03-24 12:58:30  - 23147  http://www.lymphomahub.com/therapies/imgn529
2017-03-24 12:58:34  - 23147  http://www.lymphomahub.com/therapies/azd2014
2017-03-24 12:58:39  - 23147  http://www.lymphomahub.com/therapies/mt-3724
2017-03-24 12:58:43  - 23147  http://www.lymphomahub.com/therapies/actr087
2017-03-24 12:58:48  - 23147  http://www.lymphomahub.com/therapies/epz6438
2017-03-24 12:58:53  - 23147  http://www.lymphomahub.com/therapies/kte-c19
2017-03-24 12:58:58  - 23147  http://www.lymphomahub.com/about/secretariat
2017-03-24 12:59:01  - 23147  http://www.lymphomahub.com/therapies/alt-803
2017-03-24 12:59:06  - 23147  http://www.lymphomahub.com/therapies/regn1979
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_12-59-08 Restart Xvfb...
2017-03-24 12:59:12  - 23147  http://www.lymphomahub.com/therapies/regn1979
2017-03-24 12:59:17  - 23147  http://www.lymphomahub.com/therapies/immu-114
2017-03-24 12:59:21  - 23147  http://www.lymphomahub.com/therapies/incb7839
2017-03-24 12:59:25  - 23147  http://www.lymphomahub.com/therapies/adct-301
2017-03-24 12:59:30  - 23147  http://www.lymphomahub.com/therapies/ixazomib
2017-03-24 12:59:34  - 23147  http://www.lymphomahub.com/therapies/avelumab
2017-03-24 12:59:39  - 23147  http://www.lymphomahub.com/therapies/bi836826
2017-03-24 12:59:43  - 23147  http://www.lymphomahub.com/therapies/medi-570
2017-03-24 12:59:48  - 23147  http://www.lymphomahub.com/therapies/ds-3201b
2017-03-24 12:59:52  - 23147  http://www.lymphomahub.com/therapies/sea-cd40
2017-03-24 12:59:57  - 23147  http://www.lymphomahub.com/therapies/adct-402
2017-03-24 13:00:01  - 23147  http://www.lymphomahub.com/therapies/acy-1215
2017-03-24 13:00:06  - 23147  http://www.lymphomahub.com/therapies/cudc-907
2017-03-24 13:00:11  - 23147  http://www.lymphomahub.com/therapies/tgr-1202
2017-03-24 13:00:15  - 23147  http://www.lymphomahub.com/therapies/axitinib
2017-03-24 13:00:19  - 23147  http://www.lymphomahub.com/therapies/imatinib
2017-03-24 13:00:24  - 23147  http://www.lymphomahub.com/therapies/edo-s101
2017-03-24 13:00:28  - 23147  http://www.lymphomahub.com/therapies/btct4465a
2017-03-24 13:00:33  - 23147  http://www.lymphomahub.com/therapies/alisertib
2017-03-24 13:00:37  - 23147  http://www.lymphomahub.com/therapies/lirilumab
2017-03-24 13:00:41  - 23147  http://www.lymphomahub.com/therapies/ibrutinib
2017-03-24 13:00:42  - 23147  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-03-24 13:00:47  - 23147  http://www.lymphomahub.com/therapies/rituximab
2017-03-24 13:00:51  - 23147  http://www.lymphomahub.com/therapies/veliparib
2017-03-24 13:00:56  - 23147  http://www.lymphomahub.com/therapies/sunitinib
2017-03-24 13:01:00  - 23147  http://www.lymphomahub.com/therapies/nivolumab
2017-03-24 13:01:01  - 23147  http://www.lymphomahub.com/therapies/sirolimus
2017-03-24 13:01:05  - 23147  http://www.lymphomahub.com/medical-information
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/regn1979?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_13-01-08 Restart Xvfb...
2017-03-24 13:01:11  - 23147  http://www.lymphomahub.com/medical-information
2017-03-24 13:01:14  - 23147  http://www.lymphomahub.com/therapies/selinexor
2017-03-24 13:01:19  - 23147  http://www.lymphomahub.com/therapies/abc294640
2017-03-24 13:01:23  - 23147  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-03-24 13:01:28  - 23147  http://www.lymphomahub.com/therapies/tenofovir
2017-03-24 13:01:32  - 23147  http://www.lymphomahub.com/therapies/betalutin
2017-03-24 13:01:36  - 23147  http://www.lymphomahub.com/therapies/chidamide
2017-03-24 13:01:41  - 23147  http://www.lymphomahub.com/therapies/duvelisib
2017-03-24 13:01:45  - 23147  http://www.lymphomahub.com/therapies/dasatinib
2017-03-24 13:01:50  - 23147  http://www.lymphomahub.com/therapies/everolimus
2017-03-24 13:01:54  - 23147  http://www.lymphomahub.com/therapies/incb039110
2017-03-24 13:01:59  - 23147  http://www.lymphomahub.com/therapies/durvalumab
2017-03-24 13:02:03  - 23147  http://www.lymphomahub.com/therapies/romidepsin
2017-03-24 13:02:08  - 23147  http://www.lymphomahub.com/therapies/bortezomib
2017-03-24 13:02:12  - 23147  http://www.lymphomahub.com/therapies/idelalisib
2017-03-24 13:02:13  - 23147  http://www.lymphomahub.com/therapies/tipifarnib
2017-03-24 13:02:18  - 23147  http://www.lymphomahub.com/therapies/ipilimumab
2017-03-24 13:02:22  - 23147  http://www.lymphomahub.com/therapies/crizotinib
2017-03-24 13:02:27  - 23147  http://www.lymphomahub.com/therapies/gsk2816126
2017-03-24 13:02:31  - 23147  http://www.lymphomahub.com/therapies/copanlisib
2017-03-24 13:02:36  - 23147  http://www.lymphomahub.com/therapies/buparlisib
2017-03-24 13:02:40  - 23147  http://www.lymphomahub.com/therapies/belinostat
2017-03-24 13:02:45  - 23147  http://www.lymphomahub.com/therapies/vorinostat
2017-03-24 13:02:49  - 23147  http://www.lymphomahub.com/therapies/plerixafor
2017-03-24 13:02:50  - 23147  http://www.lymphomahub.com/therapies/ofatumumab
2017-03-24 13:02:54  - 23147  http://www.lymphomahub.com/therapies/pf-06801591
2017-03-24 13:02:59  - 23147  http://www.lymphomahub.com/therapies/tocilizumab
2017-03-24 13:03:03  - 23147  http://www.lymphomahub.com/therapies/msc2490484a
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information?_prerender {"code":"ECONNRESET"}
2017-03-24 13:03:08  - 23147  http://www.lymphomahub.com/therapies/carfilzomib
<pre>2017-03-24_13-03-08 Restart Xvfb...
2017-03-24 13:03:10  - 23147  http://www.lymphomahub.com/therapies/carfilzomib
2017-03-24 13:03:15  - 23147  http://www.lymphomahub.com/therapies/ruxolitinib
2017-03-24 13:03:19  - 23147  http://www.lymphomahub.com/therapies/palbociclib
2017-03-24 13:03:24  - 23147  http://www.lymphomahub.com/therapies/fenretinide
2017-03-24 13:03:28  - 23147  http://www.lymphomahub.com/therapies/daratumumab
2017-03-24 13:03:32  - 23147  http://www.lymphomahub.com/therapies/pf-05082566
2017-03-24 13:03:37  - 23147  http://www.lymphomahub.com/therapies/ramucirumab
2017-03-24 13:03:41  - 23147  http://www.lymphomahub.com/therapies/tositumomab
2017-03-24 13:03:46  - 23147  http://www.lymphomahub.com/therapies/ublituximab
2017-03-24 13:03:50  - 23147  http://www.lymphomahub.com/therapies/epacadostat
2017-03-24 13:03:55  - 23147  http://www.lymphomahub.com/therapies/alemtuzumab
2017-03-24 13:03:55  - 23147  http://www.lymphomahub.com/therapies/otlertuzumab
2017-03-24 13:04:00  - 23147  http://www.lymphomahub.com/therapies/panobinostat
2017-03-24 13:04:04  - 23147  http://www.lymphomahub.com/therapies/mocetinostat
2017-03-24 13:04:09  - 23147  http://www.lymphomahub.com/therapies/atezolizumab
2017-03-24 13:04:13  - 23147  http://www.lymphomahub.com/therapies/temsirolimus
2017-03-24 13:04:18  - 23147  http://www.lymphomahub.com/therapies/lenalidomide
2017-03-24 13:04:22  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab
2017-03-24 13:04:26  - 23147  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-03-24 13:04:31  - 23147  http://www.lymphomahub.com/therapies/blinatumomab
2017-03-24 13:04:35  - 23147  http://www.lymphomahub.com/therapies/jnj-64052781
2017-03-24 13:04:40  - 23147  http://www.lymphomahub.com/therapies/entospletinib
2017-03-24 13:04:44  - 23147  http://www.lymphomahub.com/therapies/pembrolizumab
2017-03-24 13:04:49  - 23147  http://www.lymphomahub.com/therapies/acalabrutinib
2017-03-24 13:04:54  - 23147  http://www.lymphomahub.com/about/innovation-committee
2017-03-24 13:04:57  - 23147  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-03-24 13:04:58  - 23147  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-03-24 13:05:02  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-03-24 13:05:07  - 23147  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/carfilzomib?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_13-05-08 Restart Xvfb...
2017-03-24 13:05:13  - 23147  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-03-24 13:05:17  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-03-24 13:05:22  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-03-24 13:05:22  - 23147  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-03-24 13:05:27  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-03-24 13:05:31  - 23147  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-03-24 13:05:36  - 23147  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-03-24 13:05:40  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board
2017-03-24 13:05:44  - 23147  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-03-24 13:05:49  - 23147  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-03-24 13:05:52  - 23147  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-03-24 13:05:56  - 23147  http://www.lymphomahub.com/about/executive-steering-committee
2017-03-24 13:06:00  - 23147  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-03-24 13:06:04  - 23147  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-03-24 13:06:08  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-03-24 13:06:12  - 23147  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-03-24 13:06:16  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-03-24 13:06:21  - 23147  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-03-24 13:06:25  - 23147  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-03-24 13:06:25  - 23147  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-03-24 13:06:29  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-03-24 13:06:33  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-03-24 13:06:38  - 23147  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-03-24 13:06:42  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-03-24 13:06:47  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-03-24 13:06:51  - 23147  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-03-24 13:06:55  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-03-24 13:06:59  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-03-24 13:07:03  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-03-24 13:07:07  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/polatuzumab-vedotin?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_13-07-08 Restart Xvfb...
2017-03-24 13:07:12  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-03-24 13:07:16  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-03-24 13:07:20  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-03-24 13:07:24  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-03-24 13:07:28  - 23147  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-03-24 13:07:32  - 23147  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-03-24 13:07:37  - 23147  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-03-24 13:07:41  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-03-24 13:07:45  - 23147  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-03-24 13:07:49  - 23147  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-03-24 13:07:53  - 23147  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-03-24 13:07:58  - 23147  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-03-24 13:08:03  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-03-24 13:08:06  - 23147  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-03-24 13:08:11  - 23147  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-03-24 13:08:16  - 23147  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-03-24 13:08:20  - 23147  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-03-24 13:08:25  - 23147  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-03-24 13:08:29  - 23147  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-03-24 13:08:34  - 23147  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-03-24 13:08:38  - 23147  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-03-24 13:08:43  - 23147  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-03-24 13:08:48  - 23147  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-03-24 13:08:52  - 23147  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-03-24 13:08:56  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-03-24 13:09:00  - 23147  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-03-24 13:09:05  - 23147  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_13-09-08 Restart Xvfb...
2017-03-24 13:09:12  - 23147  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-03-24 13:09:17  - 23147  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-03-24 13:09:21  - 23147  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-03-24 13:09:26  - 23147  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-03-24 13:09:30  - 23147  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-03-24 13:09:34  - 23147  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-03-24 13:09:38  - 23147  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-03-24 13:09:43  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-03-24 13:09:47  - 23147  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-03-24 13:09:51  - 23147  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-03-24 13:09:56  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-03-24 13:10:00  - 23147  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-03-24 13:10:05  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-03-24 13:10:09  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-03-24 13:10:13  - 23147  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-03-24 13:10:17  - 23147  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-03-24 13:10:22  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-03-24 13:10:26  - 23147  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-03-24 13:10:30  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-03-24 13:10:34  - 23147  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-03-24 13:10:39  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-03-24 13:10:42  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-03-24 13:10:47  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-03-24 13:10:51  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-03-24 13:10:55  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-03-24 13:10:59  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-03-24 13:11:03  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/?_prerender {"code":"ECONNRESET"}
2017-03-24 13:11:07  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
<pre>2017-03-24_13-11-09 Restart Xvfb...
2017-03-24 13:11:10  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-03-24 13:11:15  - 23147  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-03-24 13:11:20  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-03-24 13:11:24  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-03-24 13:11:29  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-03-24 13:11:34  - 23147  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-24 13:11:34  - 23147  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-03-24 13:11:38  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-03-24 13:11:43  - 23147  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-03-24 13:11:48  - 23147  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-03-24 13:11:52  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-03-24 13:11:57  - 23147  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-03-24 13:12:02  - 23147  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-03-24 13:12:06  - 23147  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-03-24 13:12:11  - 23147  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-03-24 13:12:16  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-03-24 13:12:21  - 23147  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-03-24 13:12:25  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-03-24 13:12:30  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-03-24 13:12:35  - 23147  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-03-24 13:12:39  - 23147  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-03-24 13:12:44  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-03-24 13:12:49  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-03-24 13:12:54  - 23147  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-03-24 13:12:58  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-03-24 13:13:03  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc?_prerender {"code":"ECONNRESET"}
2017-03-24 13:13:07  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
<pre>2017-03-24_13-13-09 Restart Xvfb...
2017-03-24 13:13:12  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-03-24 13:13:16  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-03-24 13:13:21  - 23147  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-24 13:13:26  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-03-24 13:13:31  - 23147  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-03-24 13:13:36  - 23147  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-03-24 13:13:40  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-03-24 13:13:45  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-03-24 13:13:50  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-03-24 13:13:55  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-03-24 13:13:59  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-03-24 13:14:04  - 23147  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-03-24 13:14:09  - 23147  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-03-24 13:14:13  - 23147  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-03-24 13:14:18  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-03-24 13:14:23  - 23147  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-03-24 13:14:27  - 23147  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-03-24 13:14:32  - 23147  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-03-24 13:14:33  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-03-24 13:14:37  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-03-24 13:14:42  - 23147  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-03-24 13:14:46  - 23147  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-03-24 13:14:51  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-03-24 13:14:56  - 23147  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-03-24 13:15:01  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-03-24 13:15:05  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_13-15-09 Restart Xvfb...
2017-03-24 13:15:12  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-03-24 13:15:17  - 23147  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-03-24 13:15:21  - 23147  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-03-24 13:15:26  - 23147  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-03-24 13:15:30  - 23147  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-03-24 13:15:35  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-03-24 13:15:40  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-03-24 13:15:45  - 23147  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-03-24 13:15:50  - 23147  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-03-24 13:15:54  - 23147  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-03-24 13:15:59  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-03-24 13:16:03  - 23147  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-03-24 13:16:08  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-03-24 13:16:13  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-03-24 13:16:17  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-03-24 13:16:23  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-03-24 13:16:27  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-03-24 13:16:30  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-03-24 13:16:34  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-03-24 13:16:38  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-03-24 13:16:42  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-03-24 13:16:47  - 23147  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-03-24 13:16:47  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-03-24 13:16:52  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-03-24 13:16:56  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-03-24 13:17:00  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-03-24 13:17:04  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice?_prerender {"code":"ECONNRESET"}
2017-03-24 13:17:07  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
<pre>2017-03-24_13-17-09 Restart Xvfb...
2017-03-24 13:17:10  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-03-24 13:17:14  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-03-24 13:17:18  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-03-24 13:17:21  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-03-24 13:17:25  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-03-24 13:17:28  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-03-24 13:17:32  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-03-24 13:17:36  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-03-24 13:17:39  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-03-24 13:17:43  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-03-24 13:17:47  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-03-24 13:17:52  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-03-24 13:17:55  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-03-24 13:17:59  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-03-24 13:18:03  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-03-24 13:18:06  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-03-24 13:18:10  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-03-24 13:18:14  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-03-24 13:18:18  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-03-24 13:18:22  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-03-24 13:18:25  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-03-24 13:18:29  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-03-24 13:18:33  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-03-24 13:18:36  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-03-24 13:18:40  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-03-24 13:18:43  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-03-24 13:18:47  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-03-24 13:18:51  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-03-24 13:18:55  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-03-24 13:18:59  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-03-24 13:19:02  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-03-24 13:19:06  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_13-19-09 Restart Xvfb...
2017-03-24 13:19:12  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-03-24 13:19:16  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-03-24 13:19:19  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-03-24 13:19:23  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-03-24 13:19:28  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-03-24 13:19:32  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-03-24 13:19:36  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-03-24 13:19:39  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-03-24 13:19:43  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-03-24 13:19:47  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-03-24 13:19:50  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-03-24 13:19:54  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-03-24 13:19:58  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-03-24 13:20:01  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-03-24 13:20:07  - 23147  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-03-24 13:20:13  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-03-24 13:20:18  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-03-24 13:20:23  - 23147  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-03-24 13:20:23  - 23147  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-03-24 13:20:28  - 23147  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-03-24 13:20:32  - 23147  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-03-24 13:20:37  - 23147  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-03-24 13:20:47  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-03-24 13:20:51  - 23147  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-03-24 13:20:56  - 23147  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-03-24 13:21:02  - 23147  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/?_prerender {"code":"ECONNRESET"}
2017-03-24 13:21:06  - 23147  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
<pre>2017-03-24_13-21-09 Restart Xvfb...
2017-03-24 13:21:11  - 23147  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-03-24 13:21:16  - 23147  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-03-24 13:21:20  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-03-24 13:21:25  - 23147  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-03-24 13:21:30  - 23147  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-03-24 13:21:35  - 23147  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-03-24 13:21:39  - 23147  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-03-24 13:21:44  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-03-24 13:21:48  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-03-24 13:21:53  - 23147  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-03-24 13:21:58  - 23147  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-03-24 13:22:03  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-03-24 13:22:07  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-03-24 13:22:12  - 23147  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-24 13:22:17  - 23147  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-03-24 13:22:21  - 23147  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-03-24 13:22:26  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-03-24 13:22:31  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-03-24 13:22:35  - 23147  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-03-24 13:22:39  - 23147  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-03-24 13:22:44  - 23147  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-03-24 13:22:49  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-03-24 13:22:53  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-03-24 13:22:58  - 23147  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-24 13:23:02  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi?_prerender {"code":"ECONNRESET"}
2017-03-24 13:23:07  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
<pre>2017-03-24_13-23-09 Restart Xvfb...
2017-03-24 13:23:11  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-03-24 13:23:16  - 23147  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-03-24 13:23:21  - 23147  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-03-24 13:23:25  - 23147  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-03-24 13:23:30  - 23147  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-03-24 13:23:35  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-03-24 13:23:39  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-03-24 13:23:44  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-03-24 13:23:48  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-03-24 13:23:53  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-03-24 13:23:58  - 23147  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-03-24 13:24:03  - 23147  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-03-24 13:24:07  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-03-24 13:24:12  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-03-24 13:24:16  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-03-24 13:24:21  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-03-24 13:24:25  - 23147  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-03-24 13:24:30  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-03-24 13:24:34  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-03-24 13:24:39  - 23147  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-03-24 13:24:43  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-03-24 13:24:48  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-03-24 13:24:53  - 23147  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-03-24 13:24:57  - 23147  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-03-24 13:25:02  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-03-24 13:25:07  - 23147  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_13-25-09 Restart Xvfb...
2017-03-24 13:25:12  - 23147  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-03-24 13:25:17  - 23147  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-03-24 13:25:21  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-03-24 13:25:26  - 23147  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-03-24 13:25:32  - 23147  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-03-24 13:25:36  - 23147  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-03-24 13:25:41  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-03-24 13:25:46  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-03-24 13:25:50  - 23147  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-03-24 13:25:55  - 23147  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-03-24 13:26:00  - 23147  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-03-24 13:26:05  - 23147  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-03-24 13:26:09  - 23147  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-03-24 13:26:14  - 23147  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-03-24 13:26:19  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-03-24 13:26:25  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-03-24 13:26:29  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-03-24 13:26:34  - 23147  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-03-24 13:26:38  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-03-24 13:26:43  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-03-24 13:26:47  - 23147  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-03-24 13:26:52  - 23147  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-03-24 13:26:57  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-03-24 13:27:02  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-03-24 13:27:06  - 23147  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_13-27-09 Restart Xvfb...
2017-03-24 13:27:12  - 23147  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-03-24 13:27:16  - 23147  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-03-24 13:27:21  - 23147  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-03-24 13:27:25  - 23147  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-03-24 13:27:30  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-03-24 13:27:35  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-03-24 13:27:39  - 23147  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-03-24 13:27:44  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-03-24 13:27:48  - 23147  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-03-24 13:27:53  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-03-24 13:27:57  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-03-24 13:28:02  - 23147  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-03-24 13:28:07  - 23147  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-03-24 13:28:11  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-03-24 13:28:16  - 23147  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-03-24 13:28:21  - 23147  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-03-24 13:28:25  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-03-24 13:28:30  - 23147  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-03-24 13:28:34  - 23147  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-03-24 13:28:39  - 23147  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-03-24 13:28:43  - 23147  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-03-24 13:28:48  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-03-24 13:28:53  - 23147  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-03-24 13:28:58  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-03-24 13:29:02  - 23147  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients?_prerender {"code":"ECONNRESET"}
2017-03-24 13:29:07  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
<pre>2017-03-24_13-29-09 Restart Xvfb...
2017-03-24 13:29:12  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-03-24 13:29:16  - 23147  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-03-24 13:29:21  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-03-24 13:29:25  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-03-24 13:29:30  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-03-24 13:29:34  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-03-24 13:29:39  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-03-24 13:29:44  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-03-24 13:29:48  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-03-24 13:29:53  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-03-24 13:29:58  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-03-24 13:30:03  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-03-24 13:30:08  - 23147  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-03-24 13:30:12  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-03-24 13:30:16  - 23147  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-03-24 13:30:21  - 23147  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-03-24 13:30:28  - 23147  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-03-24 13:30:32  - 23147  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-03-24 13:30:37  - 23147  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-03-24 13:30:42  - 23147  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-03-24 13:30:46  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-03-24 13:30:51  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-03-24 13:30:56  - 23147  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-03-24 13:31:01  - 23147  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-03-24 13:31:05  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_13-31-09 Restart Xvfb...
2017-03-24 13:31:12  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-03-24 13:31:18  - 23147  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-03-24 13:31:22  - 23147  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-03-24 13:31:27  - 23147  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-03-24 13:31:32  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-03-24 13:31:36  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-03-24 13:31:41  - 23147  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-03-24 13:31:45  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-03-24 13:31:50  - 23147  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-03-24 13:31:55  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-03-24 13:31:59  - 23147  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-03-24 13:32:04  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-03-24 13:32:09  - 23147  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-03-24 13:32:13  - 23147  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-03-24 13:32:17  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-03-24 13:32:22  - 23147  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-03-24 13:32:26  - 23147  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-03-24 13:32:30  - 23147  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-03-24 13:32:35  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-03-24 13:32:39  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-03-24 13:32:44  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-03-24 13:32:48  - 23147  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-03-24 13:32:53  - 23147  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-03-24 13:32:58  - 23147  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-03-24 13:33:03  - 23147  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470?_prerender {"code":"ECONNRESET"}
2017-03-24 13:33:07  - 23147  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
<pre>2017-03-24_13-33-09 Restart Xvfb...
2017-03-24 13:33:10  - 23147  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-03-24 13:33:14  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-03-24 13:33:19  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-03-24 13:33:24  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-03-24 13:33:28  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-03-24 13:33:33  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-03-24 13:33:36  - 23147  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-03-24 13:33:41  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-03-24 13:33:45  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-03-24 13:33:50  - 23147  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-03-24 13:33:55  - 23147  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-03-24 13:33:59  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-03-24 13:34:03  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-03-24 13:34:08  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-03-24 13:34:12  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-03-24 13:34:17  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-03-24 13:34:22  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-03-24 13:34:26  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-03-24 13:34:30  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-03-24 13:34:35  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-03-24 13:34:39  - 23147  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-03-24 13:34:44  - 23147  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-03-24 13:34:48  - 23147  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-03-24 13:34:53  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-03-24 13:34:57  - 23147  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-03-24 13:35:01  - 23147  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-03-24 13:35:07  - 23147  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_13-35-09 Restart Xvfb...
2017-03-24 13:35:12  - 23147  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-03-24 13:35:17  - 23147  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-03-24 13:35:21  - 23147  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-03-24 13:35:26  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-03-24 13:35:30  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-03-24 13:35:35  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-03-24 13:35:40  - 23147  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-03-24 13:35:44  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-03-24 13:35:49  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-03-24 13:35:54  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-03-24 13:35:58  - 23147  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-03-24 13:36:03  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-03-24 13:36:07  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-03-24 13:36:11  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-03-24 13:36:15  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-03-24 13:36:20  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-03-24 13:36:24  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-03-24 13:36:29  - 23147  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-03-24 13:36:33  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-03-24 13:36:38  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-03-24 13:36:42  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-03-24 13:36:47  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-03-24 13:36:52  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-03-24 13:36:56  - 23147  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-03-24 13:37:01  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-03-24 13:37:05  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_13-37-09 Restart Xvfb...
2017-03-24 13:37:12  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-03-24 13:37:17  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-03-24 13:37:21  - 23147  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-03-24 13:37:26  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-03-24 13:37:31  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-03-24 13:37:36  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-03-24 13:37:41  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-03-24 13:37:45  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-03-24 13:37:49  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-03-24 13:37:53  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-03-24 13:37:58  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-03-24 13:38:02  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-03-24 13:38:06  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-03-24 13:38:11  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-03-24 13:38:15  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-03-24 13:38:19  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-03-24 13:38:23  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-03-24 13:38:27  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-03-24 13:38:32  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-03-24 13:38:36  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-03-24 13:38:40  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-03-24 13:38:45  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-03-24 13:38:49  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-03-24 13:38:53  - 23147  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-03-24 13:38:57  - 23147  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-03-24 13:39:01  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial?_prerender {"code":"ECONNRESET"}
2017-03-24 13:39:05  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
<pre>2017-03-24_13-39-09 Restart Xvfb...
2017-03-24 13:39:10  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-03-24 13:39:14  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-03-24 13:39:18  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-03-24 13:39:23  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-03-24 13:39:27  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-03-24 13:39:32  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-03-24 13:39:36  - 23147  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-03-24 13:39:41  - 23147  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-03-24 13:39:45  - 23147  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-03-24 13:39:49  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-03-24 13:39:54  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-03-24 13:39:58  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-03-24 13:40:02  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-03-24 13:40:06  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-03-24 13:40:12  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-24 13:40:17  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-24 13:40:21  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-24 13:40:25  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-24 13:40:29  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-03-24 13:40:33  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-24 13:40:37  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-24 13:40:41  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-03-24 13:40:45  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-03-24 13:40:49  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-03-24 13:40:54  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-03-24 13:40:58  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-03-24 13:41:02  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia?_prerender {"code":"ECONNRESET"}
2017-03-24 13:41:06  - 23147  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
<pre>2017-03-24_13-41-09 Restart Xvfb...
2017-03-24 13:41:10  - 23147  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-03-24 13:41:14  - 23147  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-03-24 13:41:18  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-03-24 13:41:23  - 23147  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-03-24 13:41:27  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-03-24 13:41:31  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-03-24 13:41:35  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-03-24 13:41:39  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-03-24 13:41:43  - 23147  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-03-24 13:41:48  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-03-24 13:41:52  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-03-24 13:41:56  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-03-24 13:42:00  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-03-24 13:42:04  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-03-24 13:42:08  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-24 13:42:12  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-24 13:42:16  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-24 13:42:20  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-24 13:42:24  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-24 13:42:28  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-03-24 13:42:32  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-24 13:42:36  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-24 13:42:40  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-24 13:42:44  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-24 13:42:48  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-03-24 13:42:52  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-24 13:42:56  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-24 13:43:00  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-24 13:43:05  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_13-43-09 Restart Xvfb...
2017-03-24 13:43:09  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-03-24 13:43:11  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
<pre>2017-03-24_13-45-09 Restart Xvfb...
<pre>2017-03-24_13-47-09 Restart Xvfb...
<pre>2017-03-24_13-49-09 Restart Xvfb...
<pre>2017-03-24_13-51-09 Restart Xvfb...
<pre>2017-03-24_13-53-09 Restart Xvfb...
<pre>2017-03-24_13-55-09 Restart Xvfb...
<pre>2017-03-24_13-57-09 Restart Xvfb...
<pre>2017-03-24_13-59-09 Restart Xvfb...
<pre>2017-03-24_14-01-09 Restart Xvfb...
<pre>2017-03-24_14-03-09 Restart Xvfb...
<pre>2017-03-24_14-05-09 Restart Xvfb...
<pre>2017-03-24_14-07-09 Restart Xvfb...
<pre>2017-03-24_14-09-09 Restart Xvfb...
<pre>2017-03-24_14-11-09 Restart Xvfb...
<pre>2017-03-24_14-13-09 Restart Xvfb...
<pre>2017-03-24_14-15-09 Restart Xvfb...
<pre>2017-03-24_14-17-09 Restart Xvfb...
<pre>2017-03-24_14-19-09 Restart Xvfb...
<pre>2017-03-24_14-21-09 Restart Xvfb...
<pre>2017-03-24_14-23-09 Restart Xvfb...
<pre>2017-03-24_14-25-09 Restart Xvfb...
<pre>2017-03-24_14-27-09 Restart Xvfb...
<pre>2017-03-24_14-29-10 Restart Xvfb...
<pre>2017-03-24_14-31-10 Restart Xvfb...
<pre>2017-03-24_14-33-10 Restart Xvfb...
<pre>2017-03-24_14-35-10 Restart Xvfb...
<pre>2017-03-24_14-37-10 Restart Xvfb...
<pre>2017-03-24_14-39-10 Restart Xvfb...
<pre>2017-03-24_14-41-10 Restart Xvfb...
<pre>2017-03-24_14-43-10 Restart Xvfb...
<pre>2017-03-24_14-45-10 Restart Xvfb...
<pre>2017-03-24_14-47-10 Restart Xvfb...
<pre>2017-03-24_14-49-10 Restart Xvfb...
<pre>2017-03-24_14-51-10 Restart Xvfb...
<pre>2017-03-24_14-53-10 Restart Xvfb...
<pre>2017-03-24_14-55-10 Restart Xvfb...
<pre>2017-03-24_14-57-10 Restart Xvfb...
<pre>2017-03-24_14-59-10 Restart Xvfb...
<pre>2017-03-24_15-01-10 Restart Xvfb...
<pre>2017-03-24_15-03-10 Restart Xvfb...
<pre>2017-03-24_15-05-10 Restart Xvfb...
<pre>2017-03-24_15-07-10 Restart Xvfb...
<pre>2017-03-24_15-09-10 Restart Xvfb...
<pre>2017-03-24_15-11-10 Restart Xvfb...
<pre>2017-03-24_15-13-10 Restart Xvfb...
<pre>2017-03-24_15-15-10 Restart Xvfb...
<pre>2017-03-24_15-17-10 Restart Xvfb...
<pre>2017-03-24_15-19-10 Restart Xvfb...
<pre>2017-03-24_15-21-10 Restart Xvfb...
<pre>2017-03-24_15-23-10 Restart Xvfb...
<pre>2017-03-24_15-25-10 Restart Xvfb...
<pre>2017-03-24_15-27-10 Restart Xvfb...
<pre>2017-03-24_15-29-10 Restart Xvfb...
<pre>2017-03-24_15-31-10 Restart Xvfb...
<pre>2017-03-24_15-33-10 Restart Xvfb...
<pre>2017-03-24_15-35-10 Restart Xvfb...
<pre>2017-03-24_15-37-10 Restart Xvfb...
<pre>2017-03-24_15-39-10 Restart Xvfb...
<pre>2017-03-24_15-41-10 Restart Xvfb...
<pre>2017-03-24_15-43-10 Restart Xvfb...
<pre>2017-03-24_15-45-10 Restart Xvfb...
<pre>2017-03-24_15-47-10 Restart Xvfb...
<pre>2017-03-24_15-49-10 Restart Xvfb...
<pre>2017-03-24_15-51-10 Restart Xvfb...
<pre>2017-03-24_15-53-10 Restart Xvfb...
<pre>2017-03-24_15-55-10 Restart Xvfb...
2017-03-24 15:56:59 reset updateRequest
2017-03-24 15:57:01  - 23147  http://www.lymphomahub.com/
2017-03-24 15:57:03  - 23147  http://www.lymphomahub.com/
2017-03-24 15:57:04  - 23147  http://www.lymphomahub.com/
2017-03-24 15:57:06  - 23147  http://www.lymphomahub.com/about
<pre>2017-03-24_15-57-10 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/?_prerender {"code":"ECONNRESET"}
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/?_prerender {"code":"ECONNRESET"}
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about?_prerender {"code":"ECONNRESET"}
2017-03-24 15:59:08  - 23147  http://www.lymphomahub.com/about
2017-03-24 15:59:09  - 23147  http://www.lymphomahub.com/about
<pre>2017-03-24_15-59-10 Restart Xvfb...
2017-03-24 15:59:11  - 23147  http://www.lymphomahub.com/about
2017-03-24 15:59:16  - 23147  http://www.lymphomahub.com/terms
2017-03-24 15:59:19  - 23147  http://www.lymphomahub.com/undefined
2017-03-24 15:59:20  - 23147  http://www.lymphomahub.com/therapies
2017-03-24 15:59:25  - 23147  http://www.lymphomahub.com/newsletter
2017-03-24 15:59:28  - 23147  http://www.lymphomahub.com/cookie-policy
2017-03-24 15:59:31  - 23147  http://www.lymphomahub.com/therapies/afm13
2017-03-24 15:59:36  - 23147  http://www.lymphomahub.com/therapies/afm11
2017-03-24 15:59:40  - 23147  http://www.lymphomahub.com/therapies/ags67e
2017-03-24 15:59:45  - 23147  http://www.lymphomahub.com/therapies/cc-292
2017-03-24 15:59:49  - 23147  http://www.lymphomahub.com/therapies/cc-223
2017-03-24 15:59:54  - 23147  http://www.lymphomahub.com/therapies/sd-101
2017-03-24 15:59:58  - 23147  http://www.lymphomahub.com/therapies/rp6530
2017-03-24 16:00:03  - 23147  http://www.lymphomahub.com/therapies/abt199
2017-03-24 16:00:04  - 23147  http://www.lymphomahub.com/therapies/mor208
2017-03-24 16:00:08  - 23147  http://www.lymphomahub.com/therapies/cc-122
2017-03-24 16:00:13  - 23147  http://www.lymphomahub.com/therapies/at-101
2017-03-24 16:00:17  - 23147  http://www.lymphomahub.com/therapies/bl8040
2017-03-24 16:00:21  - 23147  http://www.lymphomahub.com/therapies/bcl201
2017-03-24 16:00:29  - 23147  http://www.lymphomahub.com/therapies/azd3965
2017-03-24 16:00:36  - 23147  http://www.lymphomahub.com/therapies/imgn529
2017-03-24 16:00:41  - 23147  http://www.lymphomahub.com/therapies/azd2014
2017-03-24 16:00:45  - 23147  http://www.lymphomahub.com/therapies/mt-3724
2017-03-24 16:00:50  - 23147  http://www.lymphomahub.com/therapies/actr087
2017-03-24 16:00:55  - 23147  http://www.lymphomahub.com/therapies/epz6438
2017-03-24 16:01:00  - 23147  http://www.lymphomahub.com/therapies/kte-c19
2017-03-24 16:01:04  - 23147  http://www.lymphomahub.com/about/secretariat
2017-03-24 16:01:08  - 23147  http://www.lymphomahub.com/therapies/alt-803
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about?_prerender {"code":"ECONNRESET"}
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_16-01-10 Restart Xvfb...
2017-03-24 16:01:13  - 23147  http://www.lymphomahub.com/therapies/alt-803
2017-03-24 16:01:14  - 23147  http://www.lymphomahub.com/therapies/alt-803
2017-03-24 16:01:18  - 23147  http://www.lymphomahub.com/therapies/regn1979
2017-03-24 16:01:19  - 23147  http://www.lymphomahub.com/therapies/regn1979
2017-03-24 16:01:24  - 23147  http://www.lymphomahub.com/therapies/immu-114
2017-03-24 16:01:24  - 23147  http://www.lymphomahub.com/therapies/immu-114
2017-03-24 16:01:30  - 23147  http://www.lymphomahub.com/therapies/incb7839
2017-03-24 16:01:34  - 23147  http://www.lymphomahub.com/therapies/adct-301
2017-03-24 16:01:39  - 23147  http://www.lymphomahub.com/therapies/ixazomib
2017-03-24 16:01:43  - 23147  http://www.lymphomahub.com/therapies/avelumab
2017-03-24 16:01:48  - 23147  http://www.lymphomahub.com/therapies/bi836826
2017-03-24 16:01:52  - 23147  http://www.lymphomahub.com/therapies/medi-570
2017-03-24 16:01:57  - 23147  http://www.lymphomahub.com/therapies/ds-3201b
2017-03-24 16:02:01  - 23147  http://www.lymphomahub.com/therapies/sea-cd40
2017-03-24 16:02:06  - 23147  http://www.lymphomahub.com/therapies/adct-402
2017-03-24 16:02:10  - 23147  http://www.lymphomahub.com/therapies/acy-1215
2017-03-24 16:02:15  - 23147  http://www.lymphomahub.com/therapies/cudc-907
2017-03-24 16:02:20  - 23147  http://www.lymphomahub.com/therapies/tgr-1202
2017-03-24 16:02:24  - 23147  http://www.lymphomahub.com/therapies/axitinib
2017-03-24 16:02:28  - 23147  http://www.lymphomahub.com/therapies/imatinib
2017-03-24 16:02:33  - 23147  http://www.lymphomahub.com/therapies/edo-s101
2017-03-24 16:02:38  - 23147  http://www.lymphomahub.com/therapies/btct4465a
2017-03-24 16:02:42  - 23147  http://www.lymphomahub.com/therapies/alisertib
2017-03-24 16:02:47  - 23147  http://www.lymphomahub.com/therapies/lirilumab
2017-03-24 16:02:52  - 23147  http://www.lymphomahub.com/therapies/ibrutinib
2017-03-24 16:02:52  - 23147  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-03-24 16:02:57  - 23147  http://www.lymphomahub.com/therapies/rituximab
2017-03-24 16:03:01  - 23147  http://www.lymphomahub.com/therapies/veliparib
2017-03-24 16:03:06  - 23147  http://www.lymphomahub.com/therapies/sunitinib
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/alt-803?_prerender {"code":"ECONNRESET"}
2017-03-24 16:03:10  - 23147  http://www.lymphomahub.com/therapies/nivolumab
<pre>2017-03-24_16-03-10 Restart Xvfb...
2017-03-24 16:03:11  - 23147  http://www.lymphomahub.com/therapies/sirolimus
2017-03-24 16:03:13  - 23147  http://www.lymphomahub.com/therapies/sirolimus
2017-03-24 16:03:15  - 23147  http://www.lymphomahub.com/medical-information
2017-03-24 16:03:17  - 23147  http://www.lymphomahub.com/medical-information
2017-03-24 16:03:20  - 23147  http://www.lymphomahub.com/therapies/selinexor
2017-03-24 16:03:21  - 23147  http://www.lymphomahub.com/therapies/selinexor
2017-03-24 16:03:25  - 23147  http://www.lymphomahub.com/therapies/abc294640
2017-03-24 16:03:27  - 23147  http://www.lymphomahub.com/therapies/abc294640
2017-03-24 16:03:30  - 23147  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-03-24 16:03:31  - 23147  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-03-24 16:03:35  - 23147  http://www.lymphomahub.com/therapies/tenofovir
2017-03-24 16:03:36  - 23147  http://www.lymphomahub.com/therapies/tenofovir
2017-03-24 16:03:39  - 23147  http://www.lymphomahub.com/therapies/betalutin
2017-03-24 16:03:41  - 23147  http://www.lymphomahub.com/therapies/betalutin
2017-03-24 16:03:44  - 23147  http://www.lymphomahub.com/therapies/chidamide
2017-03-24 16:03:45  - 23147  http://www.lymphomahub.com/therapies/chidamide
2017-03-24 16:03:49  - 23147  http://www.lymphomahub.com/therapies/duvelisib
2017-03-24 16:03:50  - 23147  http://www.lymphomahub.com/therapies/duvelisib
2017-03-24 16:03:55  - 23147  http://www.lymphomahub.com/therapies/dasatinib
2017-03-24 16:03:56  - 23147  http://www.lymphomahub.com/therapies/dasatinib
2017-03-24 16:04:00  - 23147  http://www.lymphomahub.com/therapies/everolimus
2017-03-24 16:04:00  - 23147  http://www.lymphomahub.com/therapies/everolimus
2017-03-24 16:04:06  - 23147  http://www.lymphomahub.com/therapies/incb039110
2017-03-24 16:04:10  - 23147  http://www.lymphomahub.com/therapies/durvalumab
2017-03-24 16:04:15  - 23147  http://www.lymphomahub.com/therapies/romidepsin
2017-03-24 16:04:20  - 23147  http://www.lymphomahub.com/therapies/bortezomib
2017-03-24 16:04:24  - 23147  http://www.lymphomahub.com/therapies/idelalisib
2017-03-24 16:04:25  - 23147  http://www.lymphomahub.com/therapies/tipifarnib
2017-03-24 16:04:29  - 23147  http://www.lymphomahub.com/therapies/ipilimumab
2017-03-24 16:04:33  - 23147  http://www.lymphomahub.com/therapies/crizotinib
2017-03-24 16:04:38  - 23147  http://www.lymphomahub.com/therapies/gsk2816126
2017-03-24 16:04:42  - 23147  http://www.lymphomahub.com/therapies/copanlisib
2017-03-24 16:04:47  - 23147  http://www.lymphomahub.com/therapies/buparlisib
2017-03-24 16:04:51  - 23147  http://www.lymphomahub.com/therapies/belinostat
2017-03-24 16:04:56  - 23147  http://www.lymphomahub.com/therapies/vorinostat
2017-03-24 16:05:01  - 23147  http://www.lymphomahub.com/therapies/plerixafor
2017-03-24 16:05:01  - 23147  http://www.lymphomahub.com/therapies/ofatumumab
2017-03-24 16:05:06  - 23147  http://www.lymphomahub.com/therapies/pf-06801591
2017-03-24 16:05:10  - 23147  http://www.lymphomahub.com/therapies/tocilizumab
<pre>2017-03-24_16-05-10 Restart Xvfb...
2017-03-24 16:05:15  - 23147  http://www.lymphomahub.com/therapies/msc2490484a
2017-03-24 16:05:19  - 23147  http://www.lymphomahub.com/therapies/carfilzomib
2017-03-24 16:05:24  - 23147  http://www.lymphomahub.com/therapies/ruxolitinib
2017-03-24 16:05:29  - 23147  http://www.lymphomahub.com/therapies/palbociclib
2017-03-24 16:05:33  - 23147  http://www.lymphomahub.com/therapies/fenretinide
2017-03-24 16:05:38  - 23147  http://www.lymphomahub.com/therapies/daratumumab
2017-03-24 16:05:42  - 23147  http://www.lymphomahub.com/therapies/pf-05082566
2017-03-24 16:05:47  - 23147  http://www.lymphomahub.com/therapies/ramucirumab
2017-03-24 16:05:51  - 23147  http://www.lymphomahub.com/therapies/tositumomab
2017-03-24 16:05:56  - 23147  http://www.lymphomahub.com/therapies/ublituximab
2017-03-24 16:06:00  - 23147  http://www.lymphomahub.com/therapies/epacadostat
2017-03-24 16:06:05  - 23147  http://www.lymphomahub.com/therapies/alemtuzumab
2017-03-24 16:06:05  - 23147  http://www.lymphomahub.com/therapies/otlertuzumab
2017-03-24 16:06:10  - 23147  http://www.lymphomahub.com/therapies/panobinostat
2017-03-24 16:06:14  - 23147  http://www.lymphomahub.com/therapies/mocetinostat
2017-03-24 16:06:19  - 23147  http://www.lymphomahub.com/therapies/atezolizumab
2017-03-24 16:06:23  - 23147  http://www.lymphomahub.com/therapies/temsirolimus
2017-03-24 16:06:27  - 23147  http://www.lymphomahub.com/therapies/lenalidomide
2017-03-24 16:06:32  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab
2017-03-24 16:06:36  - 23147  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-03-24 16:06:41  - 23147  http://www.lymphomahub.com/therapies/blinatumomab
2017-03-24 16:06:46  - 23147  http://www.lymphomahub.com/therapies/jnj-64052781
2017-03-24 16:06:50  - 23147  http://www.lymphomahub.com/therapies/entospletinib
2017-03-24 16:06:55  - 23147  http://www.lymphomahub.com/therapies/pembrolizumab
2017-03-24 16:06:59  - 23147  http://www.lymphomahub.com/therapies/acalabrutinib
2017-03-24 16:07:04  - 23147  http://www.lymphomahub.com/about/innovation-committee
2017-03-24 16:07:07  - 23147  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-03-24 16:07:08  - 23147  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
<pre>2017-03-24_16-07-10 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/pinatuzumab-vedotin?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_16-09-11 Restart Xvfb...
2017-03-24 16:09:13  - 23147  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-03-24 16:09:17  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-03-24 16:09:22  - 23147  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-03-24 16:09:26  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-03-24 16:09:31  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-03-24 16:09:31  - 23147  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-03-24 16:09:36  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-03-24 16:09:40  - 23147  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-03-24 16:09:45  - 23147  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-03-24 16:09:49  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board
2017-03-24 16:09:53  - 23147  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-03-24 16:09:57  - 23147  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-03-24 16:10:01  - 23147  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-03-24 16:10:05  - 23147  http://www.lymphomahub.com/about/executive-steering-committee
2017-03-24 16:10:09  - 23147  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-03-24 16:10:13  - 23147  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-03-24 16:10:18  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-03-24 16:10:22  - 23147  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-03-24 16:10:26  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-03-24 16:10:31  - 23147  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-03-24 16:10:35  - 23147  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-03-24 16:10:35  - 23147  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-03-24 16:10:39  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-03-24 16:10:44  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-03-24 16:10:49  - 23147  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-03-24 16:10:53  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-03-24 16:10:58  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-03-24 16:11:02  - 23147  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-03-24 16:11:06  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-03-24 16:11:09  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
<pre>2017-03-24_16-11-11 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_16-13-11 Restart Xvfb...
2017-03-24 16:13:14  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-03-24 16:13:18  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-03-24 16:13:22  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-03-24 16:13:26  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-03-24 16:13:30  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-03-24 16:13:34  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-03-24 16:13:38  - 23147  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-03-24 16:13:43  - 23147  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-03-24 16:13:47  - 23147  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-03-24 16:13:52  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-03-24 16:13:56  - 23147  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-03-24 16:13:59  - 23147  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-03-24 16:14:04  - 23147  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-03-24 16:14:09  - 23147  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-03-24 16:14:13  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-03-24 16:14:19  - 23147  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-03-24 16:14:23  - 23147  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-03-24 16:14:28  - 23147  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-03-24 16:14:33  - 23147  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-03-24 16:14:38  - 23147  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-03-24 16:14:42  - 23147  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-03-24 16:14:47  - 23147  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-03-24 16:14:52  - 23147  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-03-24 16:14:56  - 23147  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-03-24 16:15:01  - 23147  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-03-24 16:15:06  - 23147  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-03-24 16:15:10  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
<pre>2017-03-24_16-15-11 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_16-17-11 Restart Xvfb...
2017-03-24 16:17:15  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-03-24 16:17:19  - 23147  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-03-24 16:17:24  - 23147  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-03-24 16:17:28  - 23147  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-03-24 16:17:32  - 23147  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-03-24 16:17:37  - 23147  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-03-24 16:17:41  - 23147  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-03-24 16:17:45  - 23147  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-03-24 16:17:50  - 23147  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-03-24 16:17:55  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-03-24 16:17:59  - 23147  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-03-24 16:18:04  - 23147  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-03-24 16:18:08  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-03-24 16:18:12  - 23147  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-03-24 16:18:17  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-03-24 16:18:20  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-03-24 16:18:24  - 23147  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-03-24 16:18:29  - 23147  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-03-24 16:18:34  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-03-24 16:18:37  - 23147  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-03-24 16:18:42  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-03-24 16:18:46  - 23147  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-03-24 16:18:50  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-03-24 16:18:54  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-03-24 16:18:59  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-03-24 16:19:03  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-03-24 16:19:07  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
<pre>2017-03-24_16-19-11 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_16-21-11 Restart Xvfb...
2017-03-24 16:21:12  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-03-24 16:21:15  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-03-24 16:21:19  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-03-24 16:21:23  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-03-24 16:21:28  - 23147  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-03-24 16:21:32  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-03-24 16:21:37  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-03-24 16:21:42  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-03-24 16:21:47  - 23147  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-24 16:21:47  - 23147  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-03-24 16:21:52  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-03-24 16:21:57  - 23147  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-03-24 16:22:02  - 23147  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-03-24 16:22:06  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-03-24 16:22:11  - 23147  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-03-24 16:22:16  - 23147  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-03-24 16:22:20  - 23147  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-03-24 16:22:25  - 23147  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-03-24 16:22:29  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-03-24 16:22:34  - 23147  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-03-24 16:22:39  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-03-24 16:22:44  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-03-24 16:22:49  - 23147  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-03-24 16:22:53  - 23147  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-03-24 16:22:58  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-03-24 16:23:03  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-03-24 16:23:08  - 23147  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
<pre>2017-03-24_16-23-11 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_16-25-11 Restart Xvfb...
2017-03-24 16:25:13  - 23147  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-03-24 16:25:18  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-03-24 16:25:24  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-03-24 16:25:28  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-03-24 16:25:33  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-03-24 16:25:38  - 23147  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-24 16:25:43  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-03-24 16:25:48  - 23147  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-03-24 16:25:52  - 23147  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-03-24 16:25:57  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-03-24 16:26:02  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-03-24 16:26:06  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-03-24 16:26:11  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-03-24 16:26:15  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-03-24 16:26:20  - 23147  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-03-24 16:26:25  - 23147  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-03-24 16:26:29  - 23147  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-03-24 16:26:34  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-03-24 16:26:39  - 23147  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-03-24 16:26:44  - 23147  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-03-24 16:26:48  - 23147  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-03-24 16:26:49  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-03-24 16:26:53  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-03-24 16:26:58  - 23147  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-03-24 16:27:03  - 23147  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-03-24 16:27:08  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
<pre>2017-03-24_16-27-11 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_16-29-11 Restart Xvfb...
2017-03-24 16:29:13  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-03-24 16:29:17  - 23147  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-03-24 16:29:22  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-03-24 16:29:27  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-03-24 16:29:32  - 23147  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-03-24 16:29:36  - 23147  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-03-24 16:29:41  - 23147  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-03-24 16:29:45  - 23147  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-03-24 16:29:50  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-03-24 16:29:55  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-03-24 16:30:00  - 23147  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-03-24 16:30:05  - 23147  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-03-24 16:30:09  - 23147  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-03-24 16:30:14  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-03-24 16:30:19  - 23147  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-03-24 16:30:23  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-03-24 16:30:28  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-03-24 16:30:32  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-03-24 16:30:37  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-03-24 16:30:41  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-03-24 16:30:45  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-03-24 16:30:49  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-03-24 16:30:53  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-03-24 16:30:57  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-03-24 16:31:01  - 23147  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-03-24 16:31:02  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-03-24 16:31:07  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-03-24 16:31:11  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
<pre>2017-03-24_16-31-11 Restart Xvfb...
2017-03-24 16:31:15  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-03-24 16:31:18  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-03-24 16:31:22  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-03-24 16:31:25  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-03-24 16:31:29  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-03-24 16:31:32  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-03-24 16:31:36  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-03-24 16:31:39  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-03-24 16:31:43  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-03-24 16:31:46  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-03-24 16:31:50  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-03-24 16:31:54  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-03-24 16:31:57  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-03-24 16:32:02  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-03-24 16:32:06  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-03-24 16:32:09  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-03-24 16:32:13  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-03-24 16:32:17  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-03-24 16:32:20  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-03-24 16:32:24  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-03-24 16:32:27  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-03-24 16:32:31  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-03-24 16:32:34  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-03-24 16:32:38  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-03-24 16:32:41  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-03-24 16:32:45  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-03-24 16:32:49  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-03-24 16:32:52  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-03-24 16:32:56  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-03-24 16:32:59  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-03-24 16:33:03  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-03-24 16:33:07  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-03-24 16:33:10  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
<pre>2017-03-24_16-33-11 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_16-35-11 Restart Xvfb...
2017-03-24 16:35:15  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-03-24 16:35:19  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-03-24 16:35:23  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-03-24 16:35:26  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-03-24 16:35:30  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-03-24 16:35:33  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-03-24 16:35:37  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-03-24 16:35:41  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-03-24 16:35:44  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-03-24 16:35:48  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-03-24 16:35:51  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-03-24 16:35:55  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-03-24 16:35:59  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-03-24 16:36:02  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-03-24 16:36:06  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-03-24 16:36:10  - 23147  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-03-24 16:36:15  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-03-24 16:36:20  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-03-24 16:36:25  - 23147  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-03-24 16:36:26  - 23147  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-03-24 16:36:30  - 23147  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-03-24 16:36:35  - 23147  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-03-24 16:36:40  - 23147  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-03-24 16:36:45  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-03-24 16:36:50  - 23147  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-03-24 16:36:54  - 23147  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-03-24 16:36:59  - 23147  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-03-24 16:37:03  - 23147  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-03-24 16:37:08  - 23147  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
<pre>2017-03-24_16-37-11 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_16-39-11 Restart Xvfb...
2017-03-24 16:39:13  - 23147  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-03-24 16:39:17  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-03-24 16:39:22  - 23147  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-03-24 16:39:27  - 23147  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-03-24 16:39:32  - 23147  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-03-24 16:39:37  - 23147  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-03-24 16:39:41  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-03-24 16:39:46  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-03-24 16:39:51  - 23147  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-03-24 16:39:55  - 23147  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-03-24 16:40:00  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-03-24 16:40:05  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-03-24 16:40:09  - 23147  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-24 16:40:14  - 23147  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-03-24 16:40:18  - 23147  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-03-24 16:40:23  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-03-24 16:40:28  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-03-24 16:40:32  - 23147  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-03-24 16:40:37  - 23147  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-03-24 16:40:41  - 23147  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-03-24 16:40:46  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-03-24 16:40:51  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-03-24 16:40:55  - 23147  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-24 16:41:00  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-03-24 16:41:05  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-03-24 16:41:09  - 23147  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
<pre>2017-03-24_16-41-11 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_16-43-11 Restart Xvfb...
2017-03-24 16:43:14  - 23147  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-03-24 16:43:19  - 23147  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-03-24 16:43:24  - 23147  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-03-24 16:43:28  - 23147  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-03-24 16:43:33  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-03-24 16:43:37  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-03-24 16:43:42  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-03-24 16:43:47  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-03-24 16:43:51  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-03-24 16:43:56  - 23147  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-03-24 16:44:01  - 23147  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-03-24 16:44:05  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-03-24 16:44:10  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-03-24 16:44:14  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-03-24 16:44:19  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-03-24 16:44:24  - 23147  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-03-24 16:44:28  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-03-24 16:44:33  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-03-24 16:44:37  - 23147  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-03-24 16:44:42  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-03-24 16:44:47  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-03-24 16:44:52  - 23147  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-03-24 16:44:56  - 23147  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-03-24 16:45:01  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-03-24 16:45:06  - 23147  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-03-24 16:45:10  - 23147  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
<pre>2017-03-24_16-45-11 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_16-47-11 Restart Xvfb...
2017-03-24 16:47:16  - 23147  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-03-24 16:47:20  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-03-24 16:47:25  - 23147  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-03-24 16:47:30  - 23147  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-03-24 16:47:35  - 23147  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-03-24 16:47:39  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-03-24 16:47:44  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-03-24 16:47:49  - 23147  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-03-24 16:47:53  - 23147  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-03-24 16:47:58  - 23147  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-03-24 16:48:03  - 23147  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-03-24 16:48:08  - 23147  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-03-24 16:48:12  - 23147  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-03-24 16:48:17  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-03-24 16:48:22  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-03-24 16:48:26  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-03-24 16:48:31  - 23147  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-03-24 16:48:36  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-03-24 16:48:40  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-03-24 16:48:45  - 23147  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-03-24 16:48:50  - 23147  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-03-24 16:48:54  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-03-24 16:48:59  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-03-24 16:49:03  - 23147  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-03-24 16:49:08  - 23147  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
<pre>2017-03-24_16-49-11 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_16-51-11 Restart Xvfb...
2017-03-24 16:51:13  - 23147  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-03-24 16:51:17  - 23147  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-03-24 16:51:21  - 23147  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-03-24 16:51:26  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-03-24 16:51:30  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-03-24 16:51:35  - 23147  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-03-24 16:51:40  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-03-24 16:51:44  - 23147  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-03-24 16:51:49  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-03-24 16:51:54  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-03-24 16:51:59  - 23147  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-03-24 16:52:03  - 23147  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-03-24 16:52:09  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-03-24 16:52:14  - 23147  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-03-24 16:52:18  - 23147  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-03-24 16:52:23  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-03-24 16:52:27  - 23147  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-03-24 16:52:32  - 23147  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-03-24 16:52:37  - 23147  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-03-24 16:52:41  - 23147  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-03-24 16:52:46  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-03-24 16:52:51  - 23147  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-03-24 16:52:55  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-03-24 16:53:00  - 23147  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-03-24 16:53:04  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-03-24 16:53:09  - 23147  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
<pre>2017-03-24_16-53-11 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_16-55-11 Restart Xvfb...
2017-03-24 16:55:14  - 23147  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-03-24 16:55:19  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-03-24 16:55:23  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-03-24 16:55:28  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-03-24 16:55:33  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-03-24 16:55:37  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-03-24 16:55:42  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-03-24 16:55:47  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-03-24 16:55:51  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-03-24 16:55:56  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-03-24 16:56:01  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-03-24 16:56:05  - 23147  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-03-24 16:56:10  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-03-24 16:56:14  - 23147  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-03-24 16:56:18  - 23147  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-03-24 16:56:23  - 23147  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-03-24 16:56:27  - 23147  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-03-24 16:56:32  - 23147  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-03-24 16:56:36  - 23147  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-03-24 16:56:41  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-03-24 16:56:46  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-03-24 16:56:50  - 23147  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-03-24 16:56:55  - 23147  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-03-24 16:56:59  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-03-24 16:57:04  - 23147  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-03-24 16:57:09  - 23147  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
<pre>2017-03-24_16-57-11 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_16-59-11 Restart Xvfb...
2017-03-24 16:59:14  - 23147  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-03-24 16:59:19  - 23147  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-03-24 16:59:23  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-03-24 16:59:28  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-03-24 16:59:33  - 23147  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-03-24 16:59:38  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-03-24 16:59:42  - 23147  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-03-24 16:59:47  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-03-24 16:59:51  - 23147  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-03-24 16:59:56  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-03-24 17:00:01  - 23147  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-03-24 17:00:06  - 23147  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-03-24 17:00:10  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-03-24 17:00:14  - 23147  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-03-24 17:00:18  - 23147  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-03-24 17:00:24  - 23147  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-03-24 17:00:28  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-03-24 17:00:33  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-03-24 17:00:38  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-03-24 17:00:42  - 23147  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-03-24 17:00:47  - 23147  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-03-24 17:00:53  - 23147  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-03-24 17:00:57  - 23147  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-03-24 17:01:01  - 23147  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-03-24 17:01:05  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-03-24 17:01:10  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
<pre>2017-03-24_17-01-11 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_17-03-11 Restart Xvfb...
2017-03-24 17:03:15  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-03-24 17:03:20  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-03-24 17:03:24  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-03-24 17:03:29  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-03-24 17:03:33  - 23147  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-03-24 17:03:37  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-03-24 17:03:42  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-03-24 17:03:47  - 23147  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-03-24 17:03:52  - 23147  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-03-24 17:03:56  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-03-24 17:04:00  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-03-24 17:04:05  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-03-24 17:04:09  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-03-24 17:04:14  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-03-24 17:04:19  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-03-24 17:04:23  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-03-24 17:04:27  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-03-24 17:04:32  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-03-24 17:04:36  - 23147  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-03-24 17:04:40  - 23147  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-03-24 17:04:45  - 23147  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-03-24 17:04:49  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-03-24 17:04:54  - 23147  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-03-24 17:04:59  - 23147  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-03-24 17:05:04  - 23147  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-03-24 17:05:08  - 23147  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
<pre>2017-03-24_17-05-11 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_17-07-11 Restart Xvfb...
2017-03-24 17:07:14  - 23147  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-03-24 17:07:18  - 23147  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-03-24 17:07:22  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-03-24 17:07:27  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-03-24 17:07:31  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-03-24 17:07:36  - 23147  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-03-24 17:07:41  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-03-24 17:07:45  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-03-24 17:07:50  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-03-24 17:07:54  - 23147  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-03-24 17:07:59  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-03-24 17:08:03  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-03-24 17:08:07  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-03-24 17:08:11  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-03-24 17:08:16  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-03-24 17:08:20  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-03-24 17:08:24  - 23147  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-03-24 17:08:29  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-03-24 17:08:33  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-03-24 17:08:37  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-03-24 17:08:42  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-03-24 17:08:47  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-03-24 17:08:52  - 23147  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-03-24 17:08:56  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-03-24 17:09:01  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-03-24 17:09:05  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-03-24 17:09:10  - 23147  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
<pre>2017-03-24_17-09-11 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_17-11-11 Restart Xvfb...
2017-03-24 17:11:15  - 23147  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-03-24 17:11:20  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-03-24 17:11:24  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-03-24 17:11:29  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-03-24 17:11:33  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-03-24 17:11:37  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-03-24 17:11:41  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-03-24 17:11:46  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-03-24 17:11:50  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-03-24 17:11:54  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-03-24 17:11:58  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-03-24 17:12:03  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-03-24 17:12:07  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-03-24 17:12:11  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-03-24 17:12:15  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-03-24 17:12:19  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-03-24 17:12:23  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-03-24 17:12:28  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-03-24 17:12:32  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-03-24 17:12:37  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-03-24 17:12:41  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-03-24 17:12:45  - 23147  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-03-24 17:12:49  - 23147  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-03-24 17:12:53  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-03-24 17:12:58  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-03-24 17:13:01  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-03-24 17:13:06  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-03-24 17:13:11  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
<pre>2017-03-24_17-13-11 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_17-15-11 Restart Xvfb...
2017-03-24 17:15:16  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-03-24 17:15:21  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-03-24 17:15:25  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-03-24 17:15:31  - 23147  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-03-24 17:15:35  - 23147  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-03-24 17:15:39  - 23147  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-03-24 17:15:43  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-03-24 17:15:48  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-03-24 17:15:52  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-03-24 17:15:56  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-03-24 17:16:01  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-03-24 17:16:05  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-24 17:16:09  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-24 17:16:13  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-24 17:16:17  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-24 17:16:21  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-03-24 17:16:25  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-24 17:16:29  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-24 17:16:33  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-03-24 17:16:37  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-03-24 17:16:41  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-03-24 17:16:45  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-03-24 17:16:50  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-03-24 17:16:54  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-03-24 17:16:58  - 23147  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-03-24 17:17:02  - 23147  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-03-24 17:17:06  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-03-24 17:17:10  - 23147  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
<pre>2017-03-24_17-17-11 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_17-19-11 Restart Xvfb...
2017-03-24 17:19:16  - 23147  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-03-24 17:19:20  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-03-24 17:19:24  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-03-24 17:19:29  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-03-24 17:19:33  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-03-24 17:19:37  - 23147  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-03-24 17:19:41  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-03-24 17:19:45  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-03-24 17:19:49  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-03-24 17:19:53  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-03-24 17:19:57  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-03-24 17:20:01  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-24 17:20:05  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-24 17:20:09  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-24 17:20:13  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-24 17:20:20  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-24 17:20:27  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-03-24 17:20:31  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-24 17:20:35  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-24 17:20:39  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-24 17:20:43  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-24 17:20:47  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-03-24 17:20:51  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-24 17:20:56  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-24 17:21:00  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-24 17:21:04  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-03-24 17:21:08  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
<pre>2017-03-24_17-21-12 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_17-23-12 Restart Xvfb...
2017-03-24 17:23:13  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
<pre>2017-03-24_17-25-12 Restart Xvfb...
<pre>2017-03-24_17-27-12 Restart Xvfb...
<pre>2017-03-24_17-29-12 Restart Xvfb...
<pre>2017-03-24_17-31-12 Restart Xvfb...
<pre>2017-03-24_17-33-12 Restart Xvfb...
<pre>2017-03-24_17-35-12 Restart Xvfb...
<pre>2017-03-24_17-37-12 Restart Xvfb...
<pre>2017-03-24_17-39-12 Restart Xvfb...
<pre>2017-03-24_17-41-12 Restart Xvfb...
<pre>2017-03-24_17-43-12 Restart Xvfb...
<pre>2017-03-24_17-45-12 Restart Xvfb...
<pre>2017-03-24_17-47-12 Restart Xvfb...
<pre>2017-03-24_17-49-12 Restart Xvfb...
<pre>2017-03-24_17-51-12 Restart Xvfb...
<pre>2017-03-24_17-53-12 Restart Xvfb...
<pre>2017-03-24_17-55-12 Restart Xvfb...
<pre>2017-03-24_17-57-12 Restart Xvfb...
<pre>2017-03-24_17-59-12 Restart Xvfb...
<pre>2017-03-24_18-01-12 Restart Xvfb...
<pre>2017-03-24_18-03-12 Restart Xvfb...
<pre>2017-03-24_18-05-12 Restart Xvfb...
<pre>2017-03-24_18-07-12 Restart Xvfb...
<pre>2017-03-24_18-09-12 Restart Xvfb...
<pre>2017-03-24_18-11-12 Restart Xvfb...
<pre>2017-03-24_18-13-12 Restart Xvfb...
<pre>2017-03-24_18-15-12 Restart Xvfb...
<pre>2017-03-24_18-17-12 Restart Xvfb...
<pre>2017-03-24_18-19-12 Restart Xvfb...
<pre>2017-03-24_18-21-12 Restart Xvfb...
<pre>2017-03-24_18-23-12 Restart Xvfb...
<pre>2017-03-24_18-25-12 Restart Xvfb...
<pre>2017-03-24_18-27-12 Restart Xvfb...
<pre>2017-03-24_18-29-12 Restart Xvfb...
<pre>2017-03-24_18-31-12 Restart Xvfb...
<pre>2017-03-24_18-33-12 Restart Xvfb...
<pre>2017-03-24_18-35-12 Restart Xvfb...
<pre>2017-03-24_18-37-12 Restart Xvfb...
<pre>2017-03-24_18-39-12 Restart Xvfb...
<pre>2017-03-24_18-41-12 Restart Xvfb...
<pre>2017-03-24_18-43-12 Restart Xvfb...
<pre>2017-03-24_18-45-12 Restart Xvfb...
<pre>2017-03-24_18-47-12 Restart Xvfb...
<pre>2017-03-24_18-49-12 Restart Xvfb...
<pre>2017-03-24_18-51-12 Restart Xvfb...
<pre>2017-03-24_18-53-12 Restart Xvfb...
<pre>2017-03-24_18-55-12 Restart Xvfb...
2017-03-24 18:56:59 reset updateRequest
2017-03-24 18:56:59  - 23147  http://www.lymphomahub.com/
2017-03-24 18:57:04  - 23147  http://www.lymphomahub.com/about
2017-03-24 18:57:04  - 23147  http://www.lymphomahub.com/about
2017-03-24 18:57:09  - 23147  http://www.lymphomahub.com/terms
2017-03-24 18:57:10  - 23147  http://www.lymphomahub.com/terms
<pre>2017-03-24_18-57-12 Restart Xvfb...
2017-03-24 18:57:13  - 23147  http://www.lymphomahub.com/undefined
2017-03-24 18:57:13  - 23147  http://www.lymphomahub.com/therapies
2017-03-24 18:57:20  - 23147  http://www.lymphomahub.com/newsletter
2017-03-24 18:57:23  - 23147  http://www.lymphomahub.com/cookie-policy
2017-03-24 18:57:26  - 23147  http://www.lymphomahub.com/therapies/afm13
2017-03-24 18:57:31  - 23147  http://www.lymphomahub.com/therapies/afm11
2017-03-24 18:57:36  - 23147  http://www.lymphomahub.com/therapies/ags67e
2017-03-24 18:57:40  - 23147  http://www.lymphomahub.com/therapies/cc-292
2017-03-24 18:57:45  - 23147  http://www.lymphomahub.com/therapies/cc-223
2017-03-24 18:57:49  - 23147  http://www.lymphomahub.com/therapies/sd-101
2017-03-24 18:57:54  - 23147  http://www.lymphomahub.com/therapies/rp6530
2017-03-24 18:57:58  - 23147  http://www.lymphomahub.com/therapies/abt199
2017-03-24 18:57:59  - 23147  http://www.lymphomahub.com/therapies/mor208
2017-03-24 18:58:04  - 23147  http://www.lymphomahub.com/therapies/cc-122
2017-03-24 18:58:08  - 23147  http://www.lymphomahub.com/therapies/at-101
2017-03-24 18:58:13  - 23147  http://www.lymphomahub.com/therapies/bl8040
2017-03-24 18:58:17  - 23147  http://www.lymphomahub.com/therapies/bcl201
2017-03-24 18:58:22  - 23147  http://www.lymphomahub.com/therapies/azd3965
2017-03-24 18:58:26  - 23147  http://www.lymphomahub.com/therapies/imgn529
2017-03-24 18:58:31  - 23147  http://www.lymphomahub.com/therapies/azd2014
2017-03-24 18:58:35  - 23147  http://www.lymphomahub.com/therapies/mt-3724
2017-03-24 18:58:40  - 23147  http://www.lymphomahub.com/therapies/actr087
2017-03-24 18:58:44  - 23147  http://www.lymphomahub.com/therapies/epz6438
2017-03-24 18:58:49  - 23147  http://www.lymphomahub.com/therapies/kte-c19
2017-03-24 18:58:53  - 23147  http://www.lymphomahub.com/about/secretariat
2017-03-24 18:58:57  - 23147  http://www.lymphomahub.com/therapies/alt-803
2017-03-24 18:59:02  - 23147  http://www.lymphomahub.com/therapies/regn1979
2017-03-24 18:59:07  - 23147  http://www.lymphomahub.com/therapies/immu-114
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/terms?_prerender {"code":"ECONNRESET"}
2017-03-24 18:59:11  - 23147  http://www.lymphomahub.com/therapies/incb7839
<pre>2017-03-24_18-59-12 Restart Xvfb...
2017-03-24 18:59:15  - 23147  http://www.lymphomahub.com/therapies/incb7839
2017-03-24 18:59:20  - 23147  http://www.lymphomahub.com/therapies/adct-301
2017-03-24 18:59:24  - 23147  http://www.lymphomahub.com/therapies/ixazomib
2017-03-24 18:59:28  - 23147  http://www.lymphomahub.com/therapies/avelumab
2017-03-24 18:59:33  - 23147  http://www.lymphomahub.com/therapies/bi836826
2017-03-24 18:59:37  - 23147  http://www.lymphomahub.com/therapies/medi-570
2017-03-24 18:59:42  - 23147  http://www.lymphomahub.com/therapies/ds-3201b
2017-03-24 18:59:46  - 23147  http://www.lymphomahub.com/therapies/sea-cd40
2017-03-24 18:59:50  - 23147  http://www.lymphomahub.com/therapies/adct-402
2017-03-24 18:59:55  - 23147  http://www.lymphomahub.com/therapies/acy-1215
2017-03-24 18:59:59  - 23147  http://www.lymphomahub.com/therapies/cudc-907
2017-03-24 19:00:04  - 23147  http://www.lymphomahub.com/therapies/tgr-1202
2017-03-24 19:00:08  - 23147  http://www.lymphomahub.com/therapies/axitinib
2017-03-24 19:00:13  - 23147  http://www.lymphomahub.com/therapies/imatinib
2017-03-24 19:00:18  - 23147  http://www.lymphomahub.com/therapies/edo-s101
2017-03-24 19:00:22  - 23147  http://www.lymphomahub.com/therapies/btct4465a
2017-03-24 19:00:27  - 23147  http://www.lymphomahub.com/therapies/alisertib
2017-03-24 19:00:31  - 23147  http://www.lymphomahub.com/therapies/lirilumab
2017-03-24 19:00:36  - 23147  http://www.lymphomahub.com/therapies/ibrutinib
2017-03-24 19:00:37  - 23147  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-03-24 19:00:42  - 23147  http://www.lymphomahub.com/therapies/rituximab
2017-03-24 19:00:46  - 23147  http://www.lymphomahub.com/therapies/veliparib
2017-03-24 19:00:51  - 23147  http://www.lymphomahub.com/therapies/sunitinib
2017-03-24 19:00:55  - 23147  http://www.lymphomahub.com/therapies/nivolumab
2017-03-24 19:00:56  - 23147  http://www.lymphomahub.com/therapies/sirolimus
2017-03-24 19:01:01  - 23147  http://www.lymphomahub.com/medical-information
2017-03-24 19:01:05  - 23147  http://www.lymphomahub.com/therapies/selinexor
2017-03-24 19:01:10  - 23147  http://www.lymphomahub.com/therapies/abc294640
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/incb7839?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_19-01-12 Restart Xvfb...
2017-03-24 19:01:17  - 23147  http://www.lymphomahub.com/therapies/abc294640
2017-03-24 19:01:20  - 23147  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-03-24 19:01:25  - 23147  http://www.lymphomahub.com/therapies/tenofovir
2017-03-24 19:01:29  - 23147  http://www.lymphomahub.com/therapies/betalutin
2017-03-24 19:01:34  - 23147  http://www.lymphomahub.com/therapies/chidamide
2017-03-24 19:01:38  - 23147  http://www.lymphomahub.com/therapies/duvelisib
2017-03-24 19:01:42  - 23147  http://www.lymphomahub.com/therapies/dasatinib
2017-03-24 19:01:47  - 23147  http://www.lymphomahub.com/therapies/everolimus
2017-03-24 19:01:52  - 23147  http://www.lymphomahub.com/therapies/incb039110
2017-03-24 19:01:56  - 23147  http://www.lymphomahub.com/therapies/durvalumab
2017-03-24 19:02:00  - 23147  http://www.lymphomahub.com/therapies/romidepsin
2017-03-24 19:02:05  - 23147  http://www.lymphomahub.com/therapies/bortezomib
2017-03-24 19:02:10  - 23147  http://www.lymphomahub.com/therapies/idelalisib
2017-03-24 19:02:10  - 23147  http://www.lymphomahub.com/therapies/tipifarnib
2017-03-24 19:02:15  - 23147  http://www.lymphomahub.com/therapies/ipilimumab
2017-03-24 19:02:19  - 23147  http://www.lymphomahub.com/therapies/crizotinib
2017-03-24 19:02:24  - 23147  http://www.lymphomahub.com/therapies/gsk2816126
2017-03-24 19:02:28  - 23147  http://www.lymphomahub.com/therapies/copanlisib
2017-03-24 19:02:32  - 23147  http://www.lymphomahub.com/therapies/buparlisib
2017-03-24 19:02:37  - 23147  http://www.lymphomahub.com/therapies/belinostat
2017-03-24 19:02:41  - 23147  http://www.lymphomahub.com/therapies/vorinostat
2017-03-24 19:02:46  - 23147  http://www.lymphomahub.com/therapies/plerixafor
2017-03-24 19:02:47  - 23147  http://www.lymphomahub.com/therapies/ofatumumab
2017-03-24 19:02:51  - 23147  http://www.lymphomahub.com/therapies/pf-06801591
2017-03-24 19:02:56  - 23147  http://www.lymphomahub.com/therapies/tocilizumab
2017-03-24 19:03:00  - 23147  http://www.lymphomahub.com/therapies/msc2490484a
2017-03-24 19:03:04  - 23147  http://www.lymphomahub.com/therapies/carfilzomib
2017-03-24 19:03:09  - 23147  http://www.lymphomahub.com/therapies/ruxolitinib
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/abc294640?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_19-03-13 Restart Xvfb...
2017-03-24 19:03:15  - 23147  http://www.lymphomahub.com/therapies/ruxolitinib
2017-03-24 19:03:19  - 23147  http://www.lymphomahub.com/therapies/palbociclib
2017-03-24 19:03:23  - 23147  http://www.lymphomahub.com/therapies/fenretinide
2017-03-24 19:03:27  - 23147  http://www.lymphomahub.com/therapies/daratumumab
2017-03-24 19:03:32  - 23147  http://www.lymphomahub.com/therapies/pf-05082566
2017-03-24 19:03:36  - 23147  http://www.lymphomahub.com/therapies/ramucirumab
2017-03-24 19:03:40  - 23147  http://www.lymphomahub.com/therapies/tositumomab
2017-03-24 19:03:45  - 23147  http://www.lymphomahub.com/therapies/ublituximab
2017-03-24 19:03:50  - 23147  http://www.lymphomahub.com/therapies/epacadostat
2017-03-24 19:03:54  - 23147  http://www.lymphomahub.com/therapies/alemtuzumab
2017-03-24 19:03:55  - 23147  http://www.lymphomahub.com/therapies/otlertuzumab
2017-03-24 19:03:59  - 23147  http://www.lymphomahub.com/therapies/panobinostat
2017-03-24 19:04:03  - 23147  http://www.lymphomahub.com/therapies/mocetinostat
2017-03-24 19:04:08  - 23147  http://www.lymphomahub.com/therapies/atezolizumab
2017-03-24 19:04:12  - 23147  http://www.lymphomahub.com/therapies/temsirolimus
2017-03-24 19:04:17  - 23147  http://www.lymphomahub.com/therapies/lenalidomide
2017-03-24 19:04:21  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab
2017-03-24 19:04:26  - 23147  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-03-24 19:04:30  - 23147  http://www.lymphomahub.com/therapies/blinatumomab
2017-03-24 19:04:35  - 23147  http://www.lymphomahub.com/therapies/jnj-64052781
2017-03-24 19:04:39  - 23147  http://www.lymphomahub.com/therapies/entospletinib
2017-03-24 19:04:44  - 23147  http://www.lymphomahub.com/therapies/pembrolizumab
2017-03-24 19:04:48  - 23147  http://www.lymphomahub.com/therapies/acalabrutinib
2017-03-24 19:04:53  - 23147  http://www.lymphomahub.com/about/innovation-committee
2017-03-24 19:04:56  - 23147  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-03-24 19:04:57  - 23147  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-03-24 19:05:01  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-03-24 19:05:06  - 23147  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/ruxolitinib?_prerender {"code":"ECONNRESET"}
2017-03-24 19:05:12  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b
<pre>2017-03-24_19-05-13 Restart Xvfb...
2017-03-24 19:05:14  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-03-24 19:05:18  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-03-24 19:05:19  - 23147  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-03-24 19:05:23  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-03-24 19:05:28  - 23147  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-03-24 19:05:32  - 23147  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-03-24 19:05:36  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board
2017-03-24 19:05:40  - 23147  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-03-24 19:05:45  - 23147  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-03-24 19:05:48  - 23147  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-03-24 19:05:52  - 23147  http://www.lymphomahub.com/about/executive-steering-committee
2017-03-24 19:05:57  - 23147  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-03-24 19:06:00  - 23147  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-03-24 19:06:05  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-03-24 19:06:09  - 23147  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-03-24 19:06:13  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-03-24 19:06:18  - 23147  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-03-24 19:06:22  - 23147  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-03-24 19:06:22  - 23147  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-03-24 19:06:26  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-03-24 19:06:31  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-03-24 19:06:36  - 23147  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-03-24 19:06:40  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-03-24 19:06:45  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-03-24 19:06:50  - 23147  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-03-24 19:06:53  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-03-24 19:06:57  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-03-24 19:07:01  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-03-24 19:07:05  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-03-24 19:07:08  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/interferon-alpha-2b?_prerender {"code":"ECONNRESET"}
2017-03-24 19:07:12  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
<pre>2017-03-24_19-07-13 Restart Xvfb...
2017-03-24 19:07:17  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-03-24 19:07:20  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-03-24 19:07:24  - 23147  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-03-24 19:07:29  - 23147  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-03-24 19:07:33  - 23147  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-03-24 19:07:38  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-03-24 19:07:41  - 23147  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-03-24 19:07:45  - 23147  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-03-24 19:07:50  - 23147  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-03-24 19:07:54  - 23147  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-03-24 19:07:59  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-03-24 19:08:03  - 23147  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-03-24 19:08:07  - 23147  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-03-24 19:08:12  - 23147  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-03-24 19:08:17  - 23147  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-03-24 19:08:21  - 23147  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-03-24 19:08:26  - 23147  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-03-24 19:08:30  - 23147  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-03-24 19:08:35  - 23147  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-03-24 19:08:39  - 23147  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-03-24 19:08:43  - 23147  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-03-24 19:08:48  - 23147  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-03-24 19:08:52  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-03-24 19:08:56  - 23147  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-03-24 19:09:01  - 23147  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-03-24 19:09:05  - 23147  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-03-24 19:09:09  - 23147  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_19-09-13 Restart Xvfb...
2017-03-24 19:09:17  - 23147  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-03-24 19:09:20  - 23147  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-03-24 19:09:25  - 23147  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-03-24 19:09:29  - 23147  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-03-24 19:09:33  - 23147  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-03-24 19:09:38  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-03-24 19:09:42  - 23147  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-03-24 19:09:47  - 23147  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-03-24 19:09:51  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-03-24 19:09:55  - 23147  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-03-24 19:10:00  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-03-24 19:10:04  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-03-24 19:10:08  - 23147  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-03-24 19:10:12  - 23147  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-03-24 19:10:17  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-03-24 19:10:21  - 23147  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-03-24 19:10:25  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-03-24 19:10:29  - 23147  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-03-24 19:10:34  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-03-24 19:10:38  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-03-24 19:10:43  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-03-24 19:10:46  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-03-24 19:10:50  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-03-24 19:10:54  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-03-24 19:10:58  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-03-24 19:11:02  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-03-24 19:11:07  - 23147  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/?_prerender {"code":"ECONNRESET"}
2017-03-24 19:11:11  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
<pre>2017-03-24_19-11-13 Restart Xvfb...
2017-03-24 19:11:14  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-03-24 19:11:19  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-03-24 19:11:24  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-03-24 19:11:29  - 23147  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-24 19:11:29  - 23147  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-03-24 19:11:34  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-03-24 19:11:38  - 23147  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-03-24 19:11:43  - 23147  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-03-24 19:11:48  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-03-24 19:11:53  - 23147  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-03-24 19:11:57  - 23147  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-03-24 19:12:02  - 23147  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-03-24 19:12:06  - 23147  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-03-24 19:12:11  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-03-24 19:12:16  - 23147  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-03-24 19:12:20  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-03-24 19:12:25  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-03-24 19:12:30  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-03-24 19:12:34  - 23147  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-03-24 19:12:39  - 23147  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-03-24 19:12:43  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-03-24 19:12:48  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-03-24 19:12:53  - 23147  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-03-24 19:12:58  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-03-24 19:13:03  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-03-24 19:13:07  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl?_prerender {"code":"ECONNRESET"}
2017-03-24 19:13:12  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
<pre>2017-03-24_19-13-13 Restart Xvfb...
2017-03-24 19:13:16  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-03-24 19:13:21  - 23147  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-24 19:13:26  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-03-24 19:13:30  - 23147  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-03-24 19:13:35  - 23147  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-03-24 19:13:39  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-03-24 19:13:44  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-03-24 19:13:48  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-03-24 19:13:53  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-03-24 19:13:58  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-03-24 19:14:02  - 23147  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-03-24 19:14:07  - 23147  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-03-24 19:14:12  - 23147  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-03-24 19:14:16  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-03-24 19:14:21  - 23147  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-03-24 19:14:26  - 23147  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-03-24 19:14:31  - 23147  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-03-24 19:14:32  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-03-24 19:14:36  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-03-24 19:14:41  - 23147  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-03-24 19:14:46  - 23147  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-03-24 19:14:51  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-03-24 19:14:56  - 23147  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-03-24 19:15:00  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-03-24 19:15:05  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-03-24 19:15:10  - 23147  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_19-15-13 Restart Xvfb...
2017-03-24 19:15:17  - 23147  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-03-24 19:15:22  - 23147  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-03-24 19:15:27  - 23147  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-03-24 19:15:31  - 23147  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-03-24 19:15:36  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-03-24 19:15:40  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-03-24 19:15:45  - 23147  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-03-24 19:15:50  - 23147  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-03-24 19:15:55  - 23147  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-03-24 19:15:59  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-03-24 19:16:04  - 23147  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-03-24 19:16:09  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-03-24 19:16:13  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-03-24 19:16:17  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-03-24 19:16:23  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-03-24 19:16:27  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-03-24 19:16:30  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-03-24 19:16:34  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-03-24 19:16:38  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-03-24 19:16:42  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-03-24 19:16:47  - 23147  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-03-24 19:16:47  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-03-24 19:16:52  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-03-24 19:16:56  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-03-24 19:17:00  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-03-24 19:17:04  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-03-24 19:17:07  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy?_prerender {"code":"ECONNRESET"}
2017-03-24 19:17:12  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
<pre>2017-03-24_19-17-13 Restart Xvfb...
2017-03-24 19:17:15  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-03-24 19:17:19  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-03-24 19:17:22  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-03-24 19:17:26  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-03-24 19:17:29  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-03-24 19:17:33  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-03-24 19:17:37  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-03-24 19:17:40  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-03-24 19:17:44  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-03-24 19:17:47  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-03-24 19:17:53  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-03-24 19:17:56  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-03-24 19:18:00  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-03-24 19:18:03  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-03-24 19:18:07  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-03-24 19:18:10  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-03-24 19:18:14  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-03-24 19:18:17  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-03-24 19:18:21  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-03-24 19:18:25  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-03-24 19:18:28  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-03-24 19:18:32  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-03-24 19:18:36  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-03-24 19:18:39  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-03-24 19:18:43  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-03-24 19:18:47  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-03-24 19:18:51  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-03-24 19:18:55  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-03-24 19:18:58  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-03-24 19:19:02  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-03-24 19:19:06  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-03-24 19:19:09  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_19-19-13 Restart Xvfb...
2017-03-24 19:19:13  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-03-24 19:19:16  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-03-24 19:19:17  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-03-24 19:19:22  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-03-24 19:19:22  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-03-24 19:19:27  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-03-24 19:19:27  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-03-24 19:19:33  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-03-24 19:19:33  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-03-24 19:19:38  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-03-24 19:19:38  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-03-24 19:19:43  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-03-24 19:19:43  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-03-24 19:19:48  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-03-24 19:19:48  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-03-24 19:19:53  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-03-24 19:19:54  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-03-24 19:19:59  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-03-24 19:19:59  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-03-24 19:20:04  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-03-24 19:20:04  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-03-24 19:20:09  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-03-24 19:20:09  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-03-24 19:20:14  - 23147  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-03-24 19:20:19  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-03-24 19:20:24  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-03-24 19:20:29  - 23147  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-03-24 19:20:29  - 23147  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-03-24 19:20:34  - 23147  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-03-24 19:20:39  - 23147  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-03-24 19:20:43  - 23147  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-03-24 19:20:48  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-03-24 19:20:53  - 23147  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-03-24 19:20:58  - 23147  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-03-24 19:21:03  - 23147  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-03-24 19:21:07  - 23147  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-03-24 19:21:12  - 23147  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
<pre>2017-03-24_19-21-13 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_19-23-13 Restart Xvfb...
2017-03-24 19:23:17  - 23147  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-03-24 19:23:22  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-03-24 19:23:26  - 23147  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-03-24 19:23:31  - 23147  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-03-24 19:23:36  - 23147  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-03-24 19:23:40  - 23147  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-03-24 19:23:45  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-03-24 19:23:49  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-03-24 19:23:54  - 23147  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-03-24 19:23:58  - 23147  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-03-24 19:24:03  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-03-24 19:24:08  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-03-24 19:24:13  - 23147  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-24 19:24:17  - 23147  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-03-24 19:24:22  - 23147  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-03-24 19:24:26  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-03-24 19:24:31  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-03-24 19:24:36  - 23147  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-03-24 19:24:40  - 23147  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-03-24 19:24:45  - 23147  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-03-24 19:24:49  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-03-24 19:24:54  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-03-24 19:24:59  - 23147  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-24 19:25:03  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-03-24 19:25:08  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-03-24 19:25:12  - 23147  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
<pre>2017-03-24_19-25-13 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_19-27-13 Restart Xvfb...
2017-03-24 19:27:17  - 23147  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-03-24 19:27:22  - 23147  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-03-24 19:27:27  - 23147  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-03-24 19:27:32  - 23147  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-03-24 19:27:36  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-03-24 19:27:41  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-03-24 19:27:47  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-03-24 19:27:52  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-03-24 19:27:57  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-03-24 19:28:01  - 23147  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-03-24 19:28:06  - 23147  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-03-24 19:28:11  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-03-24 19:28:16  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-03-24 19:28:20  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-03-24 19:28:25  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-03-24 19:28:30  - 23147  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-03-24 19:28:34  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-03-24 19:28:39  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-03-24 19:28:43  - 23147  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-03-24 19:28:48  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-03-24 19:28:52  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-03-24 19:28:57  - 23147  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-03-24 19:29:02  - 23147  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-03-24 19:29:07  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-03-24 19:29:12  - 23147  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
<pre>2017-03-24_19-29-13 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_19-31-13 Restart Xvfb...
2017-03-24 19:31:17  - 23147  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-03-24 19:31:22  - 23147  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-03-24 19:31:27  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-03-24 19:31:31  - 23147  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-03-24 19:31:36  - 23147  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-03-24 19:31:41  - 23147  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-03-24 19:31:46  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-03-24 19:31:50  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-03-24 19:31:55  - 23147  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-03-24 19:31:59  - 23147  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-03-24 19:32:04  - 23147  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-03-24 19:32:09  - 23147  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-03-24 19:32:14  - 23147  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-03-24 19:32:19  - 23147  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-03-24 19:32:23  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-03-24 19:32:28  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-03-24 19:32:33  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-03-24 19:32:37  - 23147  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-03-24 19:32:42  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-03-24 19:32:46  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-03-24 19:32:51  - 23147  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-03-24 19:32:56  - 23147  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-03-24 19:33:01  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-03-24 19:33:05  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-03-24 19:33:10  - 23147  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
<pre>2017-03-24_19-33-13 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_19-35-13 Restart Xvfb...
2017-03-24 19:35:15  - 23147  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-03-24 19:35:20  - 23147  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-03-24 19:35:24  - 23147  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-03-24 19:35:28  - 23147  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-03-24 19:35:33  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-03-24 19:35:38  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-03-24 19:35:42  - 23147  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-03-24 19:35:47  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-03-24 19:35:52  - 23147  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-03-24 19:35:56  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-03-24 19:36:01  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-03-24 19:36:06  - 23147  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-03-24 19:36:11  - 23147  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-03-24 19:36:16  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-03-24 19:36:21  - 23147  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-03-24 19:36:26  - 23147  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-03-24 19:36:30  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-03-24 19:36:35  - 23147  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-03-24 19:36:39  - 23147  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-03-24 19:36:44  - 23147  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-03-24 19:36:49  - 23147  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-03-24 19:36:53  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-03-24 19:36:58  - 23147  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-03-24 19:37:03  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-03-24 19:37:07  - 23147  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-03-24 19:37:12  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
<pre>2017-03-24_19-37-13 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_19-39-13 Restart Xvfb...
2017-03-24 19:39:17  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-03-24 19:39:21  - 23147  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-03-24 19:39:26  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-03-24 19:39:31  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-03-24 19:39:35  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-03-24 19:39:40  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-03-24 19:39:45  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-03-24 19:39:49  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-03-24 19:39:54  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-03-24 19:39:59  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-03-24 19:40:03  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-03-24 19:40:08  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-03-24 19:40:13  - 23147  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-03-24 19:40:18  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-03-24 19:40:21  - 23147  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-03-24 19:40:26  - 23147  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-03-24 19:40:31  - 23147  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-03-24 19:40:35  - 23147  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-03-24 19:40:40  - 23147  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-03-24 19:40:44  - 23147  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-03-24 19:40:49  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-03-24 19:40:53  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-03-24 19:40:58  - 23147  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-03-24 19:41:03  - 23147  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-03-24 19:41:07  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-03-24 19:41:12  - 23147  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
<pre>2017-03-24_19-41-13 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_19-43-13 Restart Xvfb...
2017-03-24 19:43:17  - 23147  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-03-24 19:43:22  - 23147  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-03-24 19:43:26  - 23147  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-03-24 19:43:32  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-03-24 19:43:36  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-03-24 19:43:41  - 23147  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-03-24 19:43:45  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-03-24 19:43:50  - 23147  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-03-24 19:43:55  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-03-24 19:44:00  - 23147  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-03-24 19:44:05  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-03-24 19:44:09  - 23147  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-03-24 19:44:14  - 23147  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-03-24 19:44:18  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-03-24 19:44:22  - 23147  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-03-24 19:44:26  - 23147  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-03-24 19:44:31  - 23147  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-03-24 19:44:36  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-03-24 19:44:41  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-03-24 19:44:45  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-03-24 19:44:49  - 23147  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-03-24 19:44:54  - 23147  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-03-24 19:44:59  - 23147  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-03-24 19:45:03  - 23147  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-03-24 19:45:08  - 23147  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-03-24 19:45:12  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
<pre>2017-03-24_19-45-13 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_19-47-13 Restart Xvfb...
2017-03-24 19:47:17  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-03-24 19:47:22  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-03-24 19:47:26  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-03-24 19:47:30  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-03-24 19:47:35  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-03-24 19:47:40  - 23147  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-03-24 19:47:44  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-03-24 19:47:49  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-03-24 19:47:53  - 23147  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-03-24 19:47:58  - 23147  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-03-24 19:48:02  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-03-24 19:48:07  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-03-24 19:48:11  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-03-24 19:48:16  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-03-24 19:48:20  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-03-24 19:48:25  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-03-24 19:48:29  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-03-24 19:48:33  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-03-24 19:48:38  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-03-24 19:48:42  - 23147  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-03-24 19:48:46  - 23147  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-03-24 19:48:51  - 23147  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-03-24 19:48:55  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-03-24 19:48:59  - 23147  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-03-24 19:49:03  - 23147  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-03-24 19:49:08  - 23147  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-03-24 19:49:13  - 23147  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
<pre>2017-03-24_19-49-13 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_19-51-13 Restart Xvfb...
2017-03-24 19:51:18  - 23147  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-03-24 19:51:22  - 23147  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-03-24 19:51:27  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-03-24 19:51:32  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-03-24 19:51:36  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-03-24 19:51:41  - 23147  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-03-24 19:51:45  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-03-24 19:51:49  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-03-24 19:51:54  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-03-24 19:51:58  - 23147  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-03-24 19:52:03  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-03-24 19:52:07  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-03-24 19:52:12  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-03-24 19:52:16  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-03-24 19:52:20  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-03-24 19:52:25  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-03-24 19:52:29  - 23147  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-03-24 19:52:33  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-03-24 19:52:38  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-03-24 19:52:42  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-03-24 19:52:47  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-03-24 19:52:51  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-03-24 19:52:56  - 23147  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-03-24 19:53:01  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-03-24 19:53:05  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-03-24 19:53:10  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
<pre>2017-03-24_19-53-13 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_19-55-13 Restart Xvfb...
2017-03-24 19:55:15  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-03-24 19:55:19  - 23147  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-03-24 19:55:24  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-03-24 19:55:28  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-03-24 19:55:33  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-03-24 19:55:37  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-03-24 19:55:42  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-03-24 19:55:46  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-03-24 19:55:50  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-03-24 19:55:54  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-03-24 19:55:58  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-03-24 19:56:03  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-03-24 19:56:07  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-03-24 19:56:11  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-03-24 19:56:15  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-03-24 19:56:19  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-03-24 19:56:24  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-03-24 19:56:28  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-03-24 19:56:32  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-03-24 19:56:36  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-03-24 19:56:41  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-03-24 19:56:45  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-03-24 19:56:50  - 23147  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-03-24 19:56:54  - 23147  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-03-24 19:56:58  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-03-24 19:57:03  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-03-24 19:57:07  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-03-24 19:57:11  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
<pre>2017-03-24_19-57-13 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_19-59-13 Restart Xvfb...
2017-03-24 19:59:16  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-03-24 19:59:21  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-03-24 19:59:26  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-03-24 19:59:31  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-03-24 19:59:36  - 23147  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-03-24 19:59:40  - 23147  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-03-24 19:59:44  - 23147  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-03-24 19:59:48  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-03-24 19:59:53  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-03-24 19:59:57  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-03-24 20:00:01  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-03-24 20:00:06  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-03-24 20:00:10  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-24 20:00:14  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-24 20:00:18  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-24 20:00:22  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-24 20:00:26  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-03-24 20:00:31  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-24 20:00:37  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-24 20:00:41  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-03-24 20:00:45  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-03-24 20:00:52  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-03-24 20:00:56  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-03-24 20:01:00  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-03-24 20:01:05  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-03-24 20:01:09  - 23147  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-03-24 20:01:13  - 23147  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
<pre>2017-03-24_20-01-13 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_20-03-13 Restart Xvfb...
2017-03-24 20:03:18  - 23147  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-03-24 20:03:22  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-03-24 20:03:26  - 23147  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-03-24 20:03:30  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-03-24 20:03:34  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-03-24 20:03:39  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-03-24 20:03:43  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-03-24 20:03:47  - 23147  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-03-24 20:03:52  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-03-24 20:03:56  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-03-24 20:04:00  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-03-24 20:04:04  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-03-24 20:04:10  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-03-24 20:04:14  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-24 20:04:18  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-24 20:04:22  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-24 20:04:27  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-24 20:04:31  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-24 20:04:35  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-03-24 20:04:39  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-24 20:04:43  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-24 20:04:48  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-24 20:04:52  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-24 20:04:56  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-03-24 20:05:01  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-24 20:05:05  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-24 20:05:09  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
<pre>2017-03-24_20-05-13 Restart Xvfb...
2017-03-24 20:05:13  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-03-24 20:05:18  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
<pre>2017-03-24_20-07-13 Restart Xvfb...
<pre>2017-03-24_20-09-13 Restart Xvfb...
<pre>2017-03-24_20-11-13 Restart Xvfb...
<pre>2017-03-24_20-13-14 Restart Xvfb...
<pre>2017-03-24_20-15-14 Restart Xvfb...
<pre>2017-03-24_20-17-14 Restart Xvfb...
<pre>2017-03-24_20-19-14 Restart Xvfb...
<pre>2017-03-24_20-21-14 Restart Xvfb...
<pre>2017-03-24_20-23-14 Restart Xvfb...
<pre>2017-03-24_20-25-14 Restart Xvfb...
<pre>2017-03-24_20-27-14 Restart Xvfb...
<pre>2017-03-24_20-29-14 Restart Xvfb...
<pre>2017-03-24_20-31-14 Restart Xvfb...
<pre>2017-03-24_20-33-14 Restart Xvfb...
<pre>2017-03-24_20-35-14 Restart Xvfb...
<pre>2017-03-24_20-37-14 Restart Xvfb...
<pre>2017-03-24_20-39-14 Restart Xvfb...
<pre>2017-03-24_20-41-14 Restart Xvfb...
<pre>2017-03-24_20-43-14 Restart Xvfb...
<pre>2017-03-24_20-45-14 Restart Xvfb...
<pre>2017-03-24_20-47-14 Restart Xvfb...
<pre>2017-03-24_20-49-14 Restart Xvfb...
<pre>2017-03-24_20-51-14 Restart Xvfb...
<pre>2017-03-24_20-53-14 Restart Xvfb...
<pre>2017-03-24_20-55-14 Restart Xvfb...
<pre>2017-03-24_20-57-14 Restart Xvfb...
<pre>2017-03-24_20-59-14 Restart Xvfb...
<pre>2017-03-24_21-01-14 Restart Xvfb...
<pre>2017-03-24_21-03-14 Restart Xvfb...
<pre>2017-03-24_21-05-14 Restart Xvfb...
<pre>2017-03-24_21-07-14 Restart Xvfb...
<pre>2017-03-24_21-09-14 Restart Xvfb...
<pre>2017-03-24_21-11-14 Restart Xvfb...
<pre>2017-03-24_21-13-14 Restart Xvfb...
<pre>2017-03-24_21-15-14 Restart Xvfb...
<pre>2017-03-24_21-17-14 Restart Xvfb...
<pre>2017-03-24_21-19-14 Restart Xvfb...
<pre>2017-03-24_21-21-14 Restart Xvfb...
<pre>2017-03-24_21-23-14 Restart Xvfb...
<pre>2017-03-24_21-25-14 Restart Xvfb...
<pre>2017-03-24_21-27-14 Restart Xvfb...
<pre>2017-03-24_21-29-14 Restart Xvfb...
<pre>2017-03-24_21-31-14 Restart Xvfb...
<pre>2017-03-24_21-33-14 Restart Xvfb...
<pre>2017-03-24_21-35-14 Restart Xvfb...
<pre>2017-03-24_21-37-14 Restart Xvfb...
<pre>2017-03-24_21-39-14 Restart Xvfb...
<pre>2017-03-24_21-41-14 Restart Xvfb...
<pre>2017-03-24_21-43-14 Restart Xvfb...
<pre>2017-03-24_21-45-14 Restart Xvfb...
<pre>2017-03-24_21-47-14 Restart Xvfb...
<pre>2017-03-24_21-49-14 Restart Xvfb...
<pre>2017-03-24_21-51-14 Restart Xvfb...
<pre>2017-03-24_21-53-14 Restart Xvfb...
<pre>2017-03-24_21-55-14 Restart Xvfb...
2017-03-24 21:56:59 reset updateRequest
2017-03-24 21:57:01  - 23147  http://www.lymphomahub.com/
2017-03-24 21:57:04  - 23147  http://www.lymphomahub.com/
2017-03-24 21:57:07  - 23147  http://www.lymphomahub.com/about
2017-03-24 21:57:08  - 23147  http://www.lymphomahub.com/about
2017-03-24 21:57:11  - 23147  http://www.lymphomahub.com/terms
2017-03-24 21:57:13  - 23147  http://www.lymphomahub.com/terms
<pre>2017-03-24_21-57-14 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/terms?_prerender {"code":"ECONNRESET"}
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/terms?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_21-59-14 Restart Xvfb...
2017-03-24 21:59:16  - 23147  http://www.lymphomahub.com/terms
2017-03-24 21:59:18  - 23147  http://www.lymphomahub.com/terms
2017-03-24 21:59:20  - 23147  http://www.lymphomahub.com/undefined
2017-03-24 21:59:20  - 23147  http://www.lymphomahub.com/therapies
2017-03-24 21:59:22  - 23147  http://www.lymphomahub.com/therapies
2017-03-24 21:59:29  - 23147  http://www.lymphomahub.com/newsletter
2017-03-24 21:59:31  - 23147  http://www.lymphomahub.com/newsletter
2017-03-24 21:59:33  - 23147  http://www.lymphomahub.com/cookie-policy
2017-03-24 21:59:34  - 23147  http://www.lymphomahub.com/cookie-policy
2017-03-24 21:59:37  - 23147  http://www.lymphomahub.com/therapies/afm13
2017-03-24 21:59:38  - 23147  http://www.lymphomahub.com/therapies/afm13
2017-03-24 21:59:43  - 23147  http://www.lymphomahub.com/therapies/afm11
2017-03-24 21:59:43  - 23147  http://www.lymphomahub.com/therapies/afm11
2017-03-24 21:59:48  - 23147  http://www.lymphomahub.com/therapies/ags67e
2017-03-24 21:59:48  - 23147  http://www.lymphomahub.com/therapies/ags67e
2017-03-24 21:59:53  - 23147  http://www.lymphomahub.com/therapies/cc-292
2017-03-24 21:59:58  - 23147  http://www.lymphomahub.com/therapies/cc-223
2017-03-24 22:00:02  - 23147  http://www.lymphomahub.com/therapies/sd-101
2017-03-24 22:00:09  - 23147  http://www.lymphomahub.com/therapies/rp6530
2017-03-24 22:00:13  - 23147  http://www.lymphomahub.com/therapies/abt199
2017-03-24 22:00:14  - 23147  http://www.lymphomahub.com/therapies/mor208
2017-03-24 22:00:18  - 23147  http://www.lymphomahub.com/therapies/cc-122
2017-03-24 22:00:23  - 23147  http://www.lymphomahub.com/therapies/at-101
2017-03-24 22:00:28  - 23147  http://www.lymphomahub.com/therapies/bl8040
2017-03-24 22:00:32  - 23147  http://www.lymphomahub.com/therapies/bcl201
2017-03-24 22:00:36  - 23147  http://www.lymphomahub.com/therapies/azd3965
2017-03-24 22:00:41  - 23147  http://www.lymphomahub.com/therapies/imgn529
2017-03-24 22:00:45  - 23147  http://www.lymphomahub.com/therapies/azd2014
2017-03-24 22:00:50  - 23147  http://www.lymphomahub.com/therapies/mt-3724
2017-03-24 22:00:55  - 23147  http://www.lymphomahub.com/therapies/actr087
2017-03-24 22:00:59  - 23147  http://www.lymphomahub.com/therapies/epz6438
2017-03-24 22:01:04  - 23147  http://www.lymphomahub.com/therapies/kte-c19
2017-03-24 22:01:09  - 23147  http://www.lymphomahub.com/about/secretariat
2017-03-24 22:01:12  - 23147  http://www.lymphomahub.com/therapies/alt-803
<pre>2017-03-24_22-01-14 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/alt-803?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_22-03-15 Restart Xvfb...
2017-03-24 22:03:17  - 23147  http://www.lymphomahub.com/therapies/alt-803
2017-03-24 22:03:22  - 23147  http://www.lymphomahub.com/therapies/regn1979
2017-03-24 22:03:27  - 23147  http://www.lymphomahub.com/therapies/immu-114
2017-03-24 22:03:31  - 23147  http://www.lymphomahub.com/therapies/incb7839
2017-03-24 22:03:36  - 23147  http://www.lymphomahub.com/therapies/adct-301
2017-03-24 22:03:40  - 23147  http://www.lymphomahub.com/therapies/ixazomib
2017-03-24 22:03:45  - 23147  http://www.lymphomahub.com/therapies/avelumab
2017-03-24 22:03:51  - 23147  http://www.lymphomahub.com/therapies/bi836826
2017-03-24 22:03:55  - 23147  http://www.lymphomahub.com/therapies/medi-570
2017-03-24 22:03:59  - 23147  http://www.lymphomahub.com/therapies/ds-3201b
2017-03-24 22:04:04  - 23147  http://www.lymphomahub.com/therapies/sea-cd40
2017-03-24 22:04:08  - 23147  http://www.lymphomahub.com/therapies/adct-402
2017-03-24 22:04:13  - 23147  http://www.lymphomahub.com/therapies/acy-1215
2017-03-24 22:04:17  - 23147  http://www.lymphomahub.com/therapies/cudc-907
2017-03-24 22:04:22  - 23147  http://www.lymphomahub.com/therapies/tgr-1202
2017-03-24 22:04:27  - 23147  http://www.lymphomahub.com/therapies/axitinib
2017-03-24 22:04:31  - 23147  http://www.lymphomahub.com/therapies/imatinib
2017-03-24 22:04:36  - 23147  http://www.lymphomahub.com/therapies/edo-s101
2017-03-24 22:04:41  - 23147  http://www.lymphomahub.com/therapies/btct4465a
2017-03-24 22:04:45  - 23147  http://www.lymphomahub.com/therapies/alisertib
2017-03-24 22:04:49  - 23147  http://www.lymphomahub.com/therapies/lirilumab
2017-03-24 22:04:54  - 23147  http://www.lymphomahub.com/therapies/ibrutinib
2017-03-24 22:04:55  - 23147  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-03-24 22:04:59  - 23147  http://www.lymphomahub.com/therapies/rituximab
2017-03-24 22:05:04  - 23147  http://www.lymphomahub.com/therapies/veliparib
2017-03-24 22:05:08  - 23147  http://www.lymphomahub.com/therapies/sunitinib
2017-03-24 22:05:12  - 23147  http://www.lymphomahub.com/therapies/nivolumab
2017-03-24 22:05:13  - 23147  http://www.lymphomahub.com/therapies/sirolimus
<pre>2017-03-24_22-05-15 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/sirolimus?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_22-07-15 Restart Xvfb...
2017-03-24 22:07:18  - 23147  http://www.lymphomahub.com/therapies/sirolimus
2017-03-24 22:07:23  - 23147  http://www.lymphomahub.com/medical-information
2017-03-24 22:07:26  - 23147  http://www.lymphomahub.com/therapies/selinexor
2017-03-24 22:07:31  - 23147  http://www.lymphomahub.com/therapies/abc294640
2017-03-24 22:07:35  - 23147  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-03-24 22:07:40  - 23147  http://www.lymphomahub.com/therapies/tenofovir
2017-03-24 22:07:44  - 23147  http://www.lymphomahub.com/therapies/betalutin
2017-03-24 22:07:49  - 23147  http://www.lymphomahub.com/therapies/chidamide
2017-03-24 22:07:54  - 23147  http://www.lymphomahub.com/therapies/duvelisib
2017-03-24 22:07:58  - 23147  http://www.lymphomahub.com/therapies/dasatinib
2017-03-24 22:08:03  - 23147  http://www.lymphomahub.com/therapies/everolimus
2017-03-24 22:08:07  - 23147  http://www.lymphomahub.com/therapies/incb039110
2017-03-24 22:08:12  - 23147  http://www.lymphomahub.com/therapies/durvalumab
2017-03-24 22:08:17  - 23147  http://www.lymphomahub.com/therapies/romidepsin
2017-03-24 22:08:21  - 23147  http://www.lymphomahub.com/therapies/bortezomib
2017-03-24 22:08:26  - 23147  http://www.lymphomahub.com/therapies/idelalisib
2017-03-24 22:08:26  - 23147  http://www.lymphomahub.com/therapies/tipifarnib
2017-03-24 22:08:31  - 23147  http://www.lymphomahub.com/therapies/ipilimumab
2017-03-24 22:08:35  - 23147  http://www.lymphomahub.com/therapies/crizotinib
2017-03-24 22:08:39  - 23147  http://www.lymphomahub.com/therapies/gsk2816126
2017-03-24 22:08:44  - 23147  http://www.lymphomahub.com/therapies/copanlisib
2017-03-24 22:08:48  - 23147  http://www.lymphomahub.com/therapies/buparlisib
2017-03-24 22:08:53  - 23147  http://www.lymphomahub.com/therapies/belinostat
2017-03-24 22:08:57  - 23147  http://www.lymphomahub.com/therapies/vorinostat
2017-03-24 22:09:02  - 23147  http://www.lymphomahub.com/therapies/plerixafor
2017-03-24 22:09:02  - 23147  http://www.lymphomahub.com/therapies/ofatumumab
2017-03-24 22:09:07  - 23147  http://www.lymphomahub.com/therapies/pf-06801591
2017-03-24 22:09:11  - 23147  http://www.lymphomahub.com/therapies/tocilizumab
<pre>2017-03-24_22-09-15 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/tocilizumab?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_22-11-15 Restart Xvfb...
2017-03-24 22:11:16  - 23147  http://www.lymphomahub.com/therapies/tocilizumab
2017-03-24 22:11:20  - 23147  http://www.lymphomahub.com/therapies/msc2490484a
2017-03-24 22:11:25  - 23147  http://www.lymphomahub.com/therapies/carfilzomib
2017-03-24 22:11:29  - 23147  http://www.lymphomahub.com/therapies/ruxolitinib
2017-03-24 22:11:34  - 23147  http://www.lymphomahub.com/therapies/palbociclib
2017-03-24 22:11:38  - 23147  http://www.lymphomahub.com/therapies/fenretinide
2017-03-24 22:11:43  - 23147  http://www.lymphomahub.com/therapies/daratumumab
2017-03-24 22:11:47  - 23147  http://www.lymphomahub.com/therapies/pf-05082566
2017-03-24 22:11:52  - 23147  http://www.lymphomahub.com/therapies/ramucirumab
2017-03-24 22:11:56  - 23147  http://www.lymphomahub.com/therapies/tositumomab
2017-03-24 22:12:01  - 23147  http://www.lymphomahub.com/therapies/ublituximab
2017-03-24 22:12:05  - 23147  http://www.lymphomahub.com/therapies/epacadostat
2017-03-24 22:12:10  - 23147  http://www.lymphomahub.com/therapies/alemtuzumab
2017-03-24 22:12:11  - 23147  http://www.lymphomahub.com/therapies/otlertuzumab
2017-03-24 22:12:15  - 23147  http://www.lymphomahub.com/therapies/panobinostat
2017-03-24 22:12:20  - 23147  http://www.lymphomahub.com/therapies/mocetinostat
2017-03-24 22:12:24  - 23147  http://www.lymphomahub.com/therapies/atezolizumab
2017-03-24 22:12:28  - 23147  http://www.lymphomahub.com/therapies/temsirolimus
2017-03-24 22:12:33  - 23147  http://www.lymphomahub.com/therapies/lenalidomide
2017-03-24 22:12:37  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab
2017-03-24 22:12:42  - 23147  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-03-24 22:12:46  - 23147  http://www.lymphomahub.com/therapies/blinatumomab
2017-03-24 22:12:51  - 23147  http://www.lymphomahub.com/therapies/jnj-64052781
2017-03-24 22:12:55  - 23147  http://www.lymphomahub.com/therapies/entospletinib
2017-03-24 22:13:00  - 23147  http://www.lymphomahub.com/therapies/pembrolizumab
2017-03-24 22:13:04  - 23147  http://www.lymphomahub.com/therapies/acalabrutinib
2017-03-24 22:13:08  - 23147  http://www.lymphomahub.com/about/innovation-committee
2017-03-24 22:13:14  - 23147  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-03-24 22:13:14  - 23147  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
<pre>2017-03-24_22-13-15 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/pinatuzumab-vedotin?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_22-15-15 Restart Xvfb...
2017-03-24 22:15:19  - 23147  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-03-24 22:15:24  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-03-24 22:15:28  - 23147  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-03-24 22:15:33  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-03-24 22:15:37  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-03-24 22:15:38  - 23147  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-03-24 22:15:42  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-03-24 22:15:47  - 23147  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-03-24 22:15:51  - 23147  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-03-24 22:15:55  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board
2017-03-24 22:15:59  - 23147  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-03-24 22:16:03  - 23147  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-03-24 22:16:07  - 23147  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-03-24 22:16:11  - 23147  http://www.lymphomahub.com/about/executive-steering-committee
2017-03-24 22:16:15  - 23147  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-03-24 22:16:18  - 23147  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-03-24 22:16:24  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-03-24 22:16:27  - 23147  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-03-24 22:16:31  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-03-24 22:16:36  - 23147  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-03-24 22:16:40  - 23147  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-03-24 22:16:40  - 23147  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-03-24 22:16:44  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-03-24 22:16:49  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-03-24 22:16:54  - 23147  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-03-24 22:16:57  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-03-24 22:17:02  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-03-24 22:17:07  - 23147  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-03-24 22:17:11  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-03-24 22:17:15  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
<pre>2017-03-24_22-17-15 Restart Xvfb...
2017-03-24 22:17:18  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-03-24 22:17:22  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-03-24 22:17:26  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-03-24 22:17:30  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-03-24 22:17:34  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-03-24 22:17:38  - 23147  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-03-24 22:17:42  - 23147  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-03-24 22:17:47  - 23147  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-03-24 22:17:52  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-03-24 22:17:56  - 23147  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-03-24 22:17:59  - 23147  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-03-24 22:18:04  - 23147  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-03-24 22:18:09  - 23147  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-03-24 22:18:13  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-03-24 22:18:17  - 23147  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-03-24 22:18:21  - 23147  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-03-24 22:18:25  - 23147  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-03-24 22:18:30  - 23147  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-03-24 22:18:35  - 23147  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-03-24 22:18:39  - 23147  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-03-24 22:18:43  - 23147  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-03-24 22:18:48  - 23147  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-03-24 22:18:52  - 23147  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-03-24 22:18:57  - 23147  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-03-24 22:19:01  - 23147  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-03-24 22:19:06  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-03-24 22:19:09  - 23147  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-03-24 22:19:14  - 23147  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
<pre>2017-03-24_22-19-15 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_22-21-15 Restart Xvfb...
2017-03-24 22:21:19  - 23147  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-03-24 22:21:23  - 23147  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-03-24 22:21:28  - 23147  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-03-24 22:21:32  - 23147  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-03-24 22:21:37  - 23147  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-03-24 22:21:41  - 23147  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-03-24 22:21:45  - 23147  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-03-24 22:21:50  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-03-24 22:21:53  - 23147  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-03-24 22:21:58  - 23147  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-03-24 22:22:02  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-03-24 22:22:06  - 23147  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-03-24 22:22:11  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-03-24 22:22:15  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-03-24 22:22:19  - 23147  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-03-24 22:22:24  - 23147  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-03-24 22:22:28  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-03-24 22:22:32  - 23147  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-03-24 22:22:37  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-03-24 22:22:40  - 23147  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-03-24 22:22:45  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-03-24 22:22:49  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-03-24 22:22:53  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-03-24 22:22:57  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-03-24 22:23:01  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-03-24 22:23:05  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-03-24 22:23:08  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-03-24 22:23:12  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
<pre>2017-03-24_22-23-15 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_22-25-15 Restart Xvfb...
2017-03-24 22:25:17  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-03-24 22:25:22  - 23147  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-03-24 22:25:27  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-03-24 22:25:31  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-03-24 22:25:36  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-03-24 22:25:41  - 23147  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-24 22:25:41  - 23147  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-03-24 22:25:46  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-03-24 22:25:50  - 23147  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-03-24 22:25:55  - 23147  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-03-24 22:26:00  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-03-24 22:26:04  - 23147  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-03-24 22:26:09  - 23147  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-03-24 22:26:13  - 23147  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-03-24 22:26:18  - 23147  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-03-24 22:26:22  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-03-24 22:26:27  - 23147  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-03-24 22:26:32  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-03-24 22:26:36  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-03-24 22:26:41  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-03-24 22:26:45  - 23147  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-03-24 22:26:50  - 23147  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-03-24 22:26:55  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-03-24 22:27:00  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-03-24 22:27:04  - 23147  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-03-24 22:27:09  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-03-24 22:27:14  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
<pre>2017-03-24_22-27-15 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_22-29-15 Restart Xvfb...
2017-03-24 22:29:19  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-03-24 22:29:24  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-03-24 22:29:29  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-03-24 22:29:34  - 23147  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-24 22:29:38  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-03-24 22:29:43  - 23147  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-03-24 22:29:48  - 23147  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-03-24 22:29:53  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-03-24 22:29:57  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-03-24 22:30:02  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-03-24 22:30:07  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-03-24 22:30:11  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-03-24 22:30:17  - 23147  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-03-24 22:30:21  - 23147  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-03-24 22:30:26  - 23147  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-03-24 22:30:31  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-03-24 22:30:36  - 23147  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-03-24 22:30:40  - 23147  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-03-24 22:30:45  - 23147  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-03-24 22:30:46  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-03-24 22:30:51  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-03-24 22:30:55  - 23147  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-03-24 22:31:00  - 23147  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-03-24 22:31:05  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-03-24 22:31:09  - 23147  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-03-24 22:31:14  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
<pre>2017-03-24_22-31-15 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_22-33-15 Restart Xvfb...
2017-03-24 22:33:19  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-03-24 22:33:24  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-03-24 22:33:29  - 23147  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-03-24 22:33:34  - 23147  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-03-24 22:33:39  - 23147  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-03-24 22:33:44  - 23147  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-03-24 22:33:48  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-03-24 22:33:53  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-03-24 22:33:58  - 23147  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-03-24 22:34:02  - 23147  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-03-24 22:34:07  - 23147  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-03-24 22:34:12  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-03-24 22:34:17  - 23147  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-03-24 22:34:21  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-03-24 22:34:26  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-03-24 22:34:30  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-03-24 22:34:35  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-03-24 22:34:39  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-03-24 22:34:43  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-03-24 22:34:47  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-03-24 22:34:51  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-03-24 22:34:54  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-03-24 22:34:59  - 23147  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-03-24 22:35:00  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-03-24 22:35:04  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-03-24 22:35:08  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-03-24 22:35:12  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
<pre>2017-03-24_22-35-15 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_22-37-15 Restart Xvfb...
2017-03-24 22:37:17  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-03-24 22:37:21  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-03-24 22:37:25  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-03-24 22:37:29  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-03-24 22:37:32  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-03-24 22:37:36  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-03-24 22:37:39  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-03-24 22:37:43  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-03-24 22:37:47  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-03-24 22:37:50  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-03-24 22:37:54  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-03-24 22:37:58  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-03-24 22:38:02  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-03-24 22:38:06  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-03-24 22:38:10  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-03-24 22:38:14  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-03-24 22:38:17  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-03-24 22:38:21  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-03-24 22:38:24  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-03-24 22:38:28  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-03-24 22:38:31  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-03-24 22:38:35  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-03-24 22:38:39  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-03-24 22:38:42  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-03-24 22:38:46  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-03-24 22:38:49  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-03-24 22:38:53  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-03-24 22:39:00  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-03-24 22:39:04  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-03-24 22:39:08  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-03-24 22:39:11  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-03-24 22:39:15  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
<pre>2017-03-24_22-39-15 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_22-41-15 Restart Xvfb...
2017-03-24 22:41:20  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-03-24 22:41:23  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-03-24 22:41:27  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-03-24 22:41:31  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-03-24 22:41:34  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-03-24 22:41:38  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-03-24 22:41:41  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-03-24 22:41:45  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-03-24 22:41:48  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-03-24 22:41:52  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-03-24 22:41:56  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-03-24 22:41:59  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-03-24 22:42:03  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-03-24 22:42:07  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-03-24 22:42:10  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-03-24 22:42:14  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-03-24 22:42:19  - 23147  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-03-24 22:42:23  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-03-24 22:42:28  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-03-24 22:42:33  - 23147  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-03-24 22:42:33  - 23147  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-03-24 22:42:38  - 23147  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-03-24 22:42:43  - 23147  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-03-24 22:42:47  - 23147  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-03-24 22:42:52  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-03-24 22:42:56  - 23147  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-03-24 22:43:01  - 23147  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-03-24 22:43:06  - 23147  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-03-24 22:43:10  - 23147  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-03-24 22:43:15  - 23147  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
<pre>2017-03-24_22-43-15 Restart Xvfb...
2017-03-24 22:43:20  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-03-24 22:43:24  - 23147  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-03-24 22:43:29  - 23147  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-03-24 22:43:33  - 23147  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-03-24 22:43:38  - 23147  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-03-24 22:43:42  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-03-24 22:43:47  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-03-24 22:43:51  - 23147  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-03-24 22:43:56  - 23147  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-03-24 22:44:01  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-03-24 22:44:05  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-03-24 22:44:10  - 23147  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-24 22:44:14  - 23147  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-03-24 22:44:19  - 23147  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-03-24 22:44:23  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-03-24 22:44:28  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-03-24 22:44:33  - 23147  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-03-24 22:44:37  - 23147  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-03-24 22:44:42  - 23147  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-03-24 22:44:46  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-03-24 22:44:51  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-03-24 22:44:55  - 23147  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-24 22:45:00  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-03-24 22:45:05  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-03-24 22:45:09  - 23147  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-03-24 22:45:14  - 23147  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
<pre>2017-03-24_22-45-15 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_22-47-15 Restart Xvfb...
2017-03-24 22:47:19  - 23147  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-03-24 22:47:24  - 23147  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-03-24 22:47:29  - 23147  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-03-24 22:47:33  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-03-24 22:47:38  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-03-24 22:47:43  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-03-24 22:47:48  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-03-24 22:47:52  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-03-24 22:47:57  - 23147  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-03-24 22:48:02  - 23147  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-03-24 22:48:06  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-03-24 22:48:11  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-03-24 22:48:15  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-03-24 22:48:20  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-03-24 22:48:25  - 23147  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-03-24 22:48:29  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-03-24 22:48:34  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-03-24 22:48:39  - 23147  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-03-24 22:48:43  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-03-24 22:48:48  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-03-24 22:48:52  - 23147  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-03-24 22:48:57  - 23147  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-03-24 22:49:02  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-03-24 22:49:07  - 23147  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-03-24 22:49:11  - 23147  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
<pre>2017-03-24_22-49-15 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_22-51-15 Restart Xvfb...
2017-03-24 22:51:16  - 23147  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-03-24 22:51:20  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-03-24 22:51:25  - 23147  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-03-24 22:51:30  - 23147  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-03-24 22:51:34  - 23147  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-03-24 22:51:39  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-03-24 22:51:44  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-03-24 22:51:48  - 23147  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-03-24 22:51:53  - 23147  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-03-24 22:51:58  - 23147  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-03-24 22:52:02  - 23147  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-03-24 22:52:07  - 23147  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-03-24 22:52:12  - 23147  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-03-24 22:52:16  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-03-24 22:52:21  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-03-24 22:52:26  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-03-24 22:52:30  - 23147  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-03-24 22:52:35  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-03-24 22:52:39  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-03-24 22:52:44  - 23147  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-03-24 22:52:48  - 23147  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-03-24 22:52:53  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-03-24 22:52:58  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-03-24 22:53:02  - 23147  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-03-24 22:53:07  - 23147  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-03-24 22:53:11  - 23147  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
<pre>2017-03-24_22-53-15 Restart Xvfb...
2017-03-24 22:53:15  - 23147  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-03-24 22:53:20  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-03-24 22:53:25  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-03-24 22:53:29  - 23147  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-03-24 22:53:34  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-03-24 22:53:38  - 23147  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-03-24 22:53:43  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-03-24 22:53:48  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-03-24 22:53:52  - 23147  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-03-24 22:53:57  - 23147  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-03-24 22:54:02  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-03-24 22:54:06  - 23147  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-03-24 22:54:11  - 23147  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-03-24 22:54:16  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-03-24 22:54:20  - 23147  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-03-24 22:54:25  - 23147  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-03-24 22:54:30  - 23147  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-03-24 22:54:34  - 23147  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-03-24 22:54:39  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-03-24 22:54:43  - 23147  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-03-24 22:54:48  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-03-24 22:54:52  - 23147  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-03-24 22:54:57  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-03-24 22:55:01  - 23147  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-03-24 22:55:06  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-03-24 22:55:11  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
<pre>2017-03-24_22-55-15 Restart Xvfb...
2017-03-24 22:55:15  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-03-24 22:55:20  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-03-24 22:55:25  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-03-24 22:55:29  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-03-24 22:55:34  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-03-24 22:55:38  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-03-24 22:55:43  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-03-24 22:55:48  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-03-24 22:55:52  - 23147  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-03-24 22:55:57  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-03-24 22:56:01  - 23147  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-03-24 22:56:05  - 23147  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-03-24 22:56:10  - 23147  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-03-24 22:56:15  - 23147  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-03-24 22:56:19  - 23147  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-03-24 22:56:24  - 23147  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-03-24 22:56:29  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-03-24 22:56:33  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-03-24 22:56:38  - 23147  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-03-24 22:56:43  - 23147  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-03-24 22:56:47  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-03-24 22:56:52  - 23147  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-03-24 22:56:57  - 23147  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-03-24 22:57:01  - 23147  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-03-24 22:57:06  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-03-24 22:57:10  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-03-24 22:57:15  - 23147  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
<pre>2017-03-24_22-57-15 Restart Xvfb...
2017-03-24 22:57:19  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-03-24 22:57:24  - 23147  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-03-24 22:57:28  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-03-24 22:57:33  - 23147  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-03-24 22:57:38  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-03-24 22:57:42  - 23147  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-03-24 22:57:47  - 23147  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-03-24 22:57:51  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-03-24 22:57:56  - 23147  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-03-24 22:58:00  - 23147  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-03-24 22:58:04  - 23147  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-03-24 22:58:09  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-03-24 22:58:13  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-03-24 22:58:18  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-03-24 22:58:22  - 23147  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-03-24 22:58:27  - 23147  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-03-24 22:58:31  - 23147  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-03-24 22:58:36  - 23147  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-03-24 22:58:40  - 23147  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-03-24 22:58:44  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-03-24 22:58:49  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-03-24 22:58:53  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-03-24 22:58:58  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-03-24 22:59:02  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-03-24 22:59:06  - 23147  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-03-24 22:59:11  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
<pre>2017-03-24_22-59-15 Restart Xvfb...
2017-03-24 22:59:16  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-03-24 22:59:20  - 23147  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-03-24 22:59:25  - 23147  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-03-24 22:59:29  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-03-24 22:59:33  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-03-24 22:59:37  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-03-24 22:59:42  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-03-24 22:59:47  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-03-24 22:59:51  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-03-24 22:59:55  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-03-24 23:00:00  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-03-24 23:00:05  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-03-24 23:00:09  - 23147  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-03-24 23:00:13  - 23147  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-03-24 23:00:21  - 23147  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-03-24 23:00:25  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-03-24 23:00:30  - 23147  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-03-24 23:00:34  - 23147  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-03-24 23:00:39  - 23147  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-03-24 23:00:44  - 23147  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-03-24 23:00:49  - 23147  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-03-24 23:00:54  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-03-24 23:00:58  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-03-24 23:01:03  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-03-24 23:01:07  - 23147  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-03-24 23:01:13  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
<pre>2017-03-24_23-01-15 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_23-03-15 Restart Xvfb...
2017-03-24 23:03:18  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-03-24 23:03:23  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-03-24 23:03:27  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-03-24 23:03:31  - 23147  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-03-24 23:03:36  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-03-24 23:03:40  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-03-24 23:03:44  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-03-24 23:03:48  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-03-24 23:03:53  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-03-24 23:03:58  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-03-24 23:04:02  - 23147  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-03-24 23:04:07  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-03-24 23:04:12  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-03-24 23:04:16  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-03-24 23:04:20  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-03-24 23:04:25  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-03-24 23:04:29  - 23147  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-03-24 23:04:34  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-03-24 23:04:38  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-03-24 23:04:43  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-03-24 23:04:47  - 23147  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-03-24 23:04:52  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-03-24 23:04:56  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-03-24 23:05:01  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-03-24 23:05:06  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-03-24 23:05:10  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-03-24 23:05:14  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
<pre>2017-03-24_23-05-15 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_23-07-15 Restart Xvfb...
2017-03-24 23:07:19  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-03-24 23:07:23  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-03-24 23:07:27  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-03-24 23:07:31  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-03-24 23:07:36  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-03-24 23:07:40  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-03-24 23:07:44  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-03-24 23:07:49  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-03-24 23:07:53  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-03-24 23:07:57  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-03-24 23:08:01  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-03-24 23:08:05  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-03-24 23:08:09  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-03-24 23:08:13  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-03-24 23:08:18  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-03-24 23:08:22  - 23147  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-03-24 23:08:26  - 23147  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-03-24 23:08:30  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-03-24 23:08:35  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-03-24 23:08:39  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-03-24 23:08:43  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-03-24 23:08:48  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-03-24 23:08:52  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-03-24 23:08:57  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-03-24 23:09:02  - 23147  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-03-24 23:09:06  - 23147  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-03-24 23:09:11  - 23147  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-03-24 23:09:15  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
<pre>2017-03-24_23-09-15 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_23-11-15 Restart Xvfb...
2017-03-24 23:11:20  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-03-24 23:11:25  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-03-24 23:11:29  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-03-24 23:11:33  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-03-24 23:11:38  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-03-24 23:11:42  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-24 23:11:46  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-24 23:11:50  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-24 23:11:54  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-24 23:11:59  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-03-24 23:12:03  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-24 23:12:06  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-24 23:12:10  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-03-24 23:12:15  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-03-24 23:12:19  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-03-24 23:12:23  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-03-24 23:12:27  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-03-24 23:12:32  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-03-24 23:12:36  - 23147  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-03-24 23:12:40  - 23147  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-03-24 23:12:44  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-03-24 23:12:48  - 23147  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-03-24 23:12:53  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-03-24 23:12:57  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-03-24 23:13:01  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-03-24 23:13:05  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-03-24 23:13:10  - 23147  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-03-24 23:13:14  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
<pre>2017-03-24_23-13-15 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy?_prerender {"code":"ECONNRESET"}
<pre>2017-03-24_23-15-15 Restart Xvfb...
2017-03-24 23:15:19  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-03-24 23:15:23  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-03-24 23:15:27  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-03-24 23:15:31  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-03-24 23:15:36  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-03-24 23:15:40  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-24 23:15:44  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-24 23:15:48  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-24 23:15:52  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-24 23:15:56  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-24 23:16:00  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-03-24 23:16:05  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-24 23:16:09  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-24 23:16:13  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-24 23:16:17  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-24 23:16:21  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-03-24 23:16:25  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-24 23:16:29  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-24 23:16:33  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-24 23:16:38  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-03-24 23:16:42  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
<pre>2017-03-24_23-17-15 Restart Xvfb...
<pre>2017-03-24_23-19-15 Restart Xvfb...
<pre>2017-03-24_23-21-15 Restart Xvfb...
<pre>2017-03-24_23-23-15 Restart Xvfb...
<pre>2017-03-24_23-25-16 Restart Xvfb...
<pre>2017-03-24_23-27-16 Restart Xvfb...
<pre>2017-03-24_23-29-16 Restart Xvfb...
<pre>2017-03-24_23-31-16 Restart Xvfb...
<pre>2017-03-24_23-33-16 Restart Xvfb...
<pre>2017-03-24_23-35-16 Restart Xvfb...
<pre>2017-03-24_23-37-16 Restart Xvfb...
<pre>2017-03-24_23-39-16 Restart Xvfb...
<pre>2017-03-24_23-41-16 Restart Xvfb...
<pre>2017-03-24_23-43-16 Restart Xvfb...
<pre>2017-03-24_23-45-16 Restart Xvfb...
<pre>2017-03-24_23-47-16 Restart Xvfb...
<pre>2017-03-24_23-49-16 Restart Xvfb...
<pre>2017-03-24_23-51-16 Restart Xvfb...
<pre>2017-03-24_23-53-16 Restart Xvfb...
<pre>2017-03-24_23-55-16 Restart Xvfb...
<pre>2017-03-24_23-57-16 Restart Xvfb...
<pre>2017-03-24_23-59-16 Restart Xvfb...
<pre>2017-03-25_00-01-16 Restart Xvfb...
<pre>2017-03-25_00-03-16 Restart Xvfb...
<pre>2017-03-25_00-05-16 Restart Xvfb...
<pre>2017-03-25_00-07-16 Restart Xvfb...
<pre>2017-03-25_00-09-16 Restart Xvfb...
<pre>2017-03-25_00-11-16 Restart Xvfb...
<pre>2017-03-25_00-13-16 Restart Xvfb...
<pre>2017-03-25_00-15-16 Restart Xvfb...
<pre>2017-03-25_00-17-16 Restart Xvfb...
<pre>2017-03-25_00-19-16 Restart Xvfb...
<pre>2017-03-25_00-21-16 Restart Xvfb...
<pre>2017-03-25_00-23-16 Restart Xvfb...
<pre>2017-03-25_00-25-16 Restart Xvfb...
<pre>2017-03-25_00-27-16 Restart Xvfb...
<pre>2017-03-25_00-29-16 Restart Xvfb...
<pre>2017-03-25_00-31-16 Restart Xvfb...
<pre>2017-03-25_00-33-16 Restart Xvfb...
<pre>2017-03-25_00-35-16 Restart Xvfb...
<pre>2017-03-25_00-37-16 Restart Xvfb...
<pre>2017-03-25_00-39-16 Restart Xvfb...
<pre>2017-03-25_00-41-16 Restart Xvfb...
<pre>2017-03-25_00-43-16 Restart Xvfb...
<pre>2017-03-25_00-45-16 Restart Xvfb...
<pre>2017-03-25_00-47-16 Restart Xvfb...
<pre>2017-03-25_00-49-16 Restart Xvfb...
<pre>2017-03-25_00-51-16 Restart Xvfb...
<pre>2017-03-25_00-53-16 Restart Xvfb...
<pre>2017-03-25_00-55-16 Restart Xvfb...
2017-03-25 00:56:59 reset updateRequest
2017-03-25 00:57:04  - 23147  http://www.lymphomahub.com/
2017-03-25 00:57:04  - 23147  http://www.lymphomahub.com/
2017-03-25 00:57:09  - 23147  http://www.lymphomahub.com/about
2017-03-25 00:57:09  - 23147  http://www.lymphomahub.com/about
2017-03-25 00:57:16  - 23147  http://www.lymphomahub.com/terms
2017-03-25 00:57:16  - 23147  http://www.lymphomahub.com/terms
<pre>2017-03-25_00-57-16 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/terms?_prerender {"code":"ECONNRESET"}
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/terms?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_00-59-16 Restart Xvfb...
2017-03-25 00:59:21  - 23147  http://www.lymphomahub.com/terms
2017-03-25 00:59:21  - 23147  http://www.lymphomahub.com/terms
2017-03-25 00:59:24  - 23147  http://www.lymphomahub.com/undefined
2017-03-25 00:59:25  - 23147  http://www.lymphomahub.com/therapies
2017-03-25 00:59:26  - 23147  http://www.lymphomahub.com/therapies
2017-03-25 00:59:34  - 23147  http://www.lymphomahub.com/newsletter
2017-03-25 00:59:35  - 23147  http://www.lymphomahub.com/newsletter
2017-03-25 00:59:39  - 23147  http://www.lymphomahub.com/cookie-policy
2017-03-25 00:59:39  - 23147  http://www.lymphomahub.com/cookie-policy
2017-03-25 00:59:42  - 23147  http://www.lymphomahub.com/therapies/afm13
2017-03-25 00:59:43  - 23147  http://www.lymphomahub.com/therapies/afm13
2017-03-25 00:59:48  - 23147  http://www.lymphomahub.com/therapies/afm11
2017-03-25 00:59:48  - 23147  http://www.lymphomahub.com/therapies/afm11
2017-03-25 00:59:54  - 23147  http://www.lymphomahub.com/therapies/ags67e
2017-03-25 00:59:58  - 23147  http://www.lymphomahub.com/therapies/cc-292
2017-03-25 01:00:03  - 23147  http://www.lymphomahub.com/therapies/cc-223
2017-03-25 01:00:07  - 23147  http://www.lymphomahub.com/therapies/sd-101
2017-03-25 01:00:15  - 23147  http://www.lymphomahub.com/therapies/rp6530
2017-03-25 01:00:19  - 23147  http://www.lymphomahub.com/therapies/abt199
2017-03-25 01:00:21  - 23147  http://www.lymphomahub.com/therapies/mor208
2017-03-25 01:00:25  - 23147  http://www.lymphomahub.com/therapies/cc-122
2017-03-25 01:00:29  - 23147  http://www.lymphomahub.com/therapies/at-101
2017-03-25 01:00:34  - 23147  http://www.lymphomahub.com/therapies/bl8040
2017-03-25 01:00:38  - 23147  http://www.lymphomahub.com/therapies/bcl201
2017-03-25 01:00:43  - 23147  http://www.lymphomahub.com/therapies/azd3965
2017-03-25 01:00:47  - 23147  http://www.lymphomahub.com/therapies/imgn529
2017-03-25 01:00:52  - 23147  http://www.lymphomahub.com/therapies/azd2014
2017-03-25 01:00:56  - 23147  http://www.lymphomahub.com/therapies/mt-3724
2017-03-25 01:01:02  - 23147  http://www.lymphomahub.com/therapies/actr087
2017-03-25 01:01:06  - 23147  http://www.lymphomahub.com/therapies/epz6438
2017-03-25 01:01:10  - 23147  http://www.lymphomahub.com/therapies/kte-c19
2017-03-25 01:01:15  - 23147  http://www.lymphomahub.com/about/secretariat
<pre>2017-03-25_01-01-16 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about/secretariat?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_01-03-16 Restart Xvfb...
2017-03-25 01:03:20  - 23147  http://www.lymphomahub.com/about/secretariat
2017-03-25 01:03:24  - 23147  http://www.lymphomahub.com/therapies/alt-803
2017-03-25 01:03:28  - 23147  http://www.lymphomahub.com/therapies/regn1979
2017-03-25 01:03:33  - 23147  http://www.lymphomahub.com/therapies/immu-114
2017-03-25 01:03:37  - 23147  http://www.lymphomahub.com/therapies/incb7839
2017-03-25 01:03:41  - 23147  http://www.lymphomahub.com/therapies/adct-301
2017-03-25 01:03:46  - 23147  http://www.lymphomahub.com/therapies/ixazomib
2017-03-25 01:03:50  - 23147  http://www.lymphomahub.com/therapies/avelumab
2017-03-25 01:03:55  - 23147  http://www.lymphomahub.com/therapies/bi836826
2017-03-25 01:03:59  - 23147  http://www.lymphomahub.com/therapies/medi-570
2017-03-25 01:04:03  - 23147  http://www.lymphomahub.com/therapies/ds-3201b
2017-03-25 01:04:08  - 23147  http://www.lymphomahub.com/therapies/sea-cd40
2017-03-25 01:04:12  - 23147  http://www.lymphomahub.com/therapies/adct-402
2017-03-25 01:04:17  - 23147  http://www.lymphomahub.com/therapies/acy-1215
2017-03-25 01:04:21  - 23147  http://www.lymphomahub.com/therapies/cudc-907
2017-03-25 01:04:26  - 23147  http://www.lymphomahub.com/therapies/tgr-1202
2017-03-25 01:04:30  - 23147  http://www.lymphomahub.com/therapies/axitinib
2017-03-25 01:04:35  - 23147  http://www.lymphomahub.com/therapies/imatinib
2017-03-25 01:04:39  - 23147  http://www.lymphomahub.com/therapies/edo-s101
2017-03-25 01:04:44  - 23147  http://www.lymphomahub.com/therapies/btct4465a
2017-03-25 01:04:48  - 23147  http://www.lymphomahub.com/therapies/alisertib
2017-03-25 01:04:53  - 23147  http://www.lymphomahub.com/therapies/lirilumab
2017-03-25 01:04:57  - 23147  http://www.lymphomahub.com/therapies/ibrutinib
2017-03-25 01:04:58  - 23147  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-03-25 01:05:02  - 23147  http://www.lymphomahub.com/therapies/rituximab
2017-03-25 01:05:07  - 23147  http://www.lymphomahub.com/therapies/veliparib
2017-03-25 01:05:12  - 23147  http://www.lymphomahub.com/therapies/sunitinib
2017-03-25 01:05:16  - 23147  http://www.lymphomahub.com/therapies/nivolumab
<pre>2017-03-25_01-05-17 Restart Xvfb...
2017-03-25 01:05:17  - 23147  http://www.lymphomahub.com/therapies/sirolimus
2017-03-25 01:05:21  - 23147  http://www.lymphomahub.com/medical-information
2017-03-25 01:05:26  - 23147  http://www.lymphomahub.com/therapies/selinexor
2017-03-25 01:05:30  - 23147  http://www.lymphomahub.com/therapies/abc294640
2017-03-25 01:05:35  - 23147  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-03-25 01:05:39  - 23147  http://www.lymphomahub.com/therapies/tenofovir
2017-03-25 01:05:43  - 23147  http://www.lymphomahub.com/therapies/betalutin
2017-03-25 01:05:48  - 23147  http://www.lymphomahub.com/therapies/chidamide
2017-03-25 01:05:53  - 23147  http://www.lymphomahub.com/therapies/duvelisib
2017-03-25 01:05:57  - 23147  http://www.lymphomahub.com/therapies/dasatinib
2017-03-25 01:06:02  - 23147  http://www.lymphomahub.com/therapies/everolimus
2017-03-25 01:06:06  - 23147  http://www.lymphomahub.com/therapies/incb039110
2017-03-25 01:06:10  - 23147  http://www.lymphomahub.com/therapies/durvalumab
2017-03-25 01:06:15  - 23147  http://www.lymphomahub.com/therapies/romidepsin
2017-03-25 01:06:19  - 23147  http://www.lymphomahub.com/therapies/bortezomib
2017-03-25 01:06:24  - 23147  http://www.lymphomahub.com/therapies/idelalisib
2017-03-25 01:06:24  - 23147  http://www.lymphomahub.com/therapies/tipifarnib
2017-03-25 01:06:29  - 23147  http://www.lymphomahub.com/therapies/ipilimumab
2017-03-25 01:06:33  - 23147  http://www.lymphomahub.com/therapies/crizotinib
2017-03-25 01:06:37  - 23147  http://www.lymphomahub.com/therapies/gsk2816126
2017-03-25 01:06:42  - 23147  http://www.lymphomahub.com/therapies/copanlisib
2017-03-25 01:06:46  - 23147  http://www.lymphomahub.com/therapies/buparlisib
2017-03-25 01:06:51  - 23147  http://www.lymphomahub.com/therapies/belinostat
2017-03-25 01:06:55  - 23147  http://www.lymphomahub.com/therapies/vorinostat
2017-03-25 01:07:00  - 23147  http://www.lymphomahub.com/therapies/plerixafor
2017-03-25 01:07:01  - 23147  http://www.lymphomahub.com/therapies/ofatumumab
2017-03-25 01:07:05  - 23147  http://www.lymphomahub.com/therapies/pf-06801591
2017-03-25 01:07:10  - 23147  http://www.lymphomahub.com/therapies/tocilizumab
2017-03-25 01:07:14  - 23147  http://www.lymphomahub.com/therapies/msc2490484a
<pre>2017-03-25_01-07-17 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/msc2490484a?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_01-09-17 Restart Xvfb...
2017-03-25 01:09:19  - 23147  http://www.lymphomahub.com/therapies/msc2490484a
2017-03-25 01:09:23  - 23147  http://www.lymphomahub.com/therapies/carfilzomib
2017-03-25 01:09:28  - 23147  http://www.lymphomahub.com/therapies/ruxolitinib
2017-03-25 01:09:32  - 23147  http://www.lymphomahub.com/therapies/palbociclib
2017-03-25 01:09:36  - 23147  http://www.lymphomahub.com/therapies/fenretinide
2017-03-25 01:09:41  - 23147  http://www.lymphomahub.com/therapies/daratumumab
2017-03-25 01:09:45  - 23147  http://www.lymphomahub.com/therapies/pf-05082566
2017-03-25 01:09:50  - 23147  http://www.lymphomahub.com/therapies/ramucirumab
2017-03-25 01:09:54  - 23147  http://www.lymphomahub.com/therapies/tositumomab
2017-03-25 01:09:59  - 23147  http://www.lymphomahub.com/therapies/ublituximab
2017-03-25 01:10:03  - 23147  http://www.lymphomahub.com/therapies/epacadostat
2017-03-25 01:10:08  - 23147  http://www.lymphomahub.com/therapies/alemtuzumab
2017-03-25 01:10:08  - 23147  http://www.lymphomahub.com/therapies/otlertuzumab
2017-03-25 01:10:13  - 23147  http://www.lymphomahub.com/therapies/panobinostat
2017-03-25 01:10:18  - 23147  http://www.lymphomahub.com/therapies/mocetinostat
2017-03-25 01:10:22  - 23147  http://www.lymphomahub.com/therapies/atezolizumab
2017-03-25 01:10:26  - 23147  http://www.lymphomahub.com/therapies/temsirolimus
2017-03-25 01:10:31  - 23147  http://www.lymphomahub.com/therapies/lenalidomide
2017-03-25 01:10:35  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab
2017-03-25 01:10:40  - 23147  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-03-25 01:10:44  - 23147  http://www.lymphomahub.com/therapies/blinatumomab
2017-03-25 01:10:49  - 23147  http://www.lymphomahub.com/therapies/jnj-64052781
2017-03-25 01:10:53  - 23147  http://www.lymphomahub.com/therapies/entospletinib
2017-03-25 01:10:58  - 23147  http://www.lymphomahub.com/therapies/pembrolizumab
2017-03-25 01:11:02  - 23147  http://www.lymphomahub.com/therapies/acalabrutinib
2017-03-25 01:11:07  - 23147  http://www.lymphomahub.com/about/innovation-committee
2017-03-25 01:11:10  - 23147  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-03-25 01:11:11  - 23147  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-03-25 01:11:15  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a
<pre>2017-03-25_01-11-17 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/interferon-alpha-2a?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_01-13-17 Restart Xvfb...
2017-03-25 01:13:20  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-03-25 01:13:25  - 23147  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-03-25 01:13:29  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-03-25 01:13:34  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-03-25 01:13:35  - 23147  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-03-25 01:13:39  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-03-25 01:13:44  - 23147  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-03-25 01:13:48  - 23147  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-03-25 01:13:53  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board
2017-03-25 01:13:58  - 23147  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-03-25 01:14:02  - 23147  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-03-25 01:14:06  - 23147  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-03-25 01:14:10  - 23147  http://www.lymphomahub.com/about/executive-steering-committee
2017-03-25 01:14:13  - 23147  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-03-25 01:14:17  - 23147  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-03-25 01:14:22  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-03-25 01:14:26  - 23147  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-03-25 01:14:29  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-03-25 01:14:34  - 23147  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-03-25 01:14:38  - 23147  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-03-25 01:14:38  - 23147  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-03-25 01:14:42  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-03-25 01:14:47  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-03-25 01:14:51  - 23147  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-03-25 01:14:55  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-03-25 01:15:00  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-03-25 01:15:05  - 23147  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-03-25 01:15:09  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-03-25 01:15:13  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-03-25 01:15:16  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
<pre>2017-03-25_01-15-17 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_01-17-17 Restart Xvfb...
2017-03-25 01:17:22  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-03-25 01:17:25  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-03-25 01:17:29  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-03-25 01:17:33  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-03-25 01:17:37  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-03-25 01:17:41  - 23147  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-03-25 01:17:46  - 23147  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-03-25 01:17:50  - 23147  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-03-25 01:17:55  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-03-25 01:17:59  - 23147  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-03-25 01:18:02  - 23147  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-03-25 01:18:07  - 23147  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-03-25 01:18:11  - 23147  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-03-25 01:18:16  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-03-25 01:18:20  - 23147  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-03-25 01:18:24  - 23147  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-03-25 01:18:29  - 23147  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-03-25 01:18:34  - 23147  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-03-25 01:18:38  - 23147  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-03-25 01:18:43  - 23147  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-03-25 01:18:47  - 23147  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-03-25 01:18:52  - 23147  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-03-25 01:18:56  - 23147  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-03-25 01:19:00  - 23147  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-03-25 01:19:05  - 23147  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-03-25 01:19:09  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-03-25 01:19:13  - 23147  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
<pre>2017-03-25_01-19-17 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_01-21-17 Restart Xvfb...
2017-03-25 01:21:18  - 23147  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-03-25 01:21:21  - 23147  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-03-25 01:21:26  - 23147  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-03-25 01:21:30  - 23147  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-03-25 01:21:35  - 23147  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-03-25 01:21:39  - 23147  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-03-25 01:21:43  - 23147  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-03-25 01:21:47  - 23147  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-03-25 01:21:52  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-03-25 01:21:56  - 23147  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-03-25 01:22:01  - 23147  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-03-25 01:22:05  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-03-25 01:22:09  - 23147  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-03-25 01:22:14  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-03-25 01:22:18  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-03-25 01:22:21  - 23147  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-03-25 01:22:26  - 23147  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-03-25 01:22:31  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-03-25 01:22:35  - 23147  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-03-25 01:22:40  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-03-25 01:22:43  - 23147  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-03-25 01:22:48  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-03-25 01:22:52  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-03-25 01:22:56  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-03-25 01:23:00  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-03-25 01:23:04  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-03-25 01:23:08  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-03-25 01:23:12  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-03-25 01:23:16  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
<pre>2017-03-25_01-23-17 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_01-25-17 Restart Xvfb...
2017-03-25 01:25:21  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-03-25 01:25:26  - 23147  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-03-25 01:25:30  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-03-25 01:25:35  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-03-25 01:25:40  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-03-25 01:25:44  - 23147  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-25 01:25:45  - 23147  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-03-25 01:25:49  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-03-25 01:25:54  - 23147  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-03-25 01:25:59  - 23147  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-03-25 01:26:03  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-03-25 01:26:08  - 23147  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-03-25 01:26:13  - 23147  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-03-25 01:26:17  - 23147  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-03-25 01:26:22  - 23147  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-03-25 01:26:26  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-03-25 01:26:31  - 23147  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-03-25 01:26:36  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-03-25 01:26:40  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-03-25 01:26:45  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-03-25 01:26:50  - 23147  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-03-25 01:26:54  - 23147  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-03-25 01:26:59  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-03-25 01:27:03  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-03-25 01:27:08  - 23147  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-03-25 01:27:13  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
<pre>2017-03-25_01-27-17 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_01-29-17 Restart Xvfb...
2017-03-25 01:29:18  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-03-25 01:29:22  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-03-25 01:29:27  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-03-25 01:29:32  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-03-25 01:29:36  - 23147  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-25 01:29:41  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-03-25 01:29:45  - 23147  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-03-25 01:29:50  - 23147  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-03-25 01:29:55  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-03-25 01:29:59  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-03-25 01:30:04  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-03-25 01:30:10  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-03-25 01:30:15  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-03-25 01:30:20  - 23147  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-03-25 01:30:24  - 23147  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-03-25 01:30:29  - 23147  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-03-25 01:30:33  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-03-25 01:30:38  - 23147  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-03-25 01:30:43  - 23147  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-03-25 01:30:47  - 23147  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-03-25 01:30:48  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-03-25 01:30:52  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-03-25 01:30:57  - 23147  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-03-25 01:31:02  - 23147  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-03-25 01:31:07  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-03-25 01:31:11  - 23147  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-03-25 01:31:16  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
<pre>2017-03-25_01-31-17 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_01-33-17 Restart Xvfb...
2017-03-25 01:33:21  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-03-25 01:33:26  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-03-25 01:33:31  - 23147  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-03-25 01:33:36  - 23147  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-03-25 01:33:41  - 23147  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-03-25 01:33:45  - 23147  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-03-25 01:33:50  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-03-25 01:33:55  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-03-25 01:34:00  - 23147  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-03-25 01:34:04  - 23147  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-03-25 01:34:09  - 23147  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-03-25 01:34:13  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-03-25 01:34:18  - 23147  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-03-25 01:34:22  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-03-25 01:34:27  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-03-25 01:34:31  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-03-25 01:34:36  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-03-25 01:34:40  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-03-25 01:34:44  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-03-25 01:34:48  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-03-25 01:34:52  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-03-25 01:34:56  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-03-25 01:35:00  - 23147  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-03-25 01:35:01  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-03-25 01:35:06  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-03-25 01:35:10  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-03-25 01:35:13  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
<pre>2017-03-25_01-35-17 Restart Xvfb...
2017-03-25 01:35:17  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-03-25 01:35:20  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-03-25 01:35:24  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-03-25 01:35:28  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-03-25 01:35:31  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-03-25 01:35:35  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-03-25 01:35:39  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-03-25 01:35:42  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-03-25 01:35:46  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-03-25 01:35:49  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-03-25 01:35:53  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-03-25 01:35:56  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-03-25 01:36:01  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-03-25 01:36:05  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-03-25 01:36:09  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-03-25 01:36:12  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-03-25 01:36:16  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-03-25 01:36:20  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-03-25 01:36:23  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-03-25 01:36:27  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-03-25 01:36:30  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-03-25 01:36:34  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-03-25 01:36:37  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-03-25 01:36:41  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-03-25 01:36:45  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-03-25 01:36:48  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-03-25 01:36:52  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-03-25 01:36:56  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-03-25 01:36:59  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-03-25 01:37:03  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-03-25 01:37:06  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-03-25 01:37:10  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-03-25 01:37:13  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
<pre>2017-03-25_01-37-17 Restart Xvfb...
2017-03-25 01:37:17  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-03-25 01:37:21  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-03-25 01:37:24  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-03-25 01:37:28  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-03-25 01:37:31  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-03-25 01:37:35  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-03-25 01:37:38  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-03-25 01:37:42  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-03-25 01:37:46  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-03-25 01:37:49  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-03-25 01:37:53  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-03-25 01:37:57  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-03-25 01:38:00  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-03-25 01:38:05  - 23147  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-03-25 01:38:10  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-03-25 01:38:15  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-03-25 01:38:19  - 23147  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-03-25 01:38:20  - 23147  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-03-25 01:38:24  - 23147  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-03-25 01:38:29  - 23147  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-03-25 01:38:33  - 23147  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-03-25 01:38:38  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-03-25 01:38:43  - 23147  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-03-25 01:38:48  - 23147  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-03-25 01:38:53  - 23147  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-03-25 01:38:57  - 23147  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-03-25 01:39:02  - 23147  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-03-25 01:39:07  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-03-25 01:39:11  - 23147  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-03-25 01:39:16  - 23147  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
<pre>2017-03-25_01-39-17 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_01-41-17 Restart Xvfb...
2017-03-25 01:41:21  - 23147  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-03-25 01:41:26  - 23147  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-03-25 01:41:31  - 23147  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-03-25 01:41:36  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-03-25 01:41:40  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-03-25 01:41:45  - 23147  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-03-25 01:41:49  - 23147  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-03-25 01:41:54  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-03-25 01:41:59  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-03-25 01:42:03  - 23147  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-25 01:42:08  - 23147  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-03-25 01:42:12  - 23147  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-03-25 01:42:17  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-03-25 01:42:21  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-03-25 01:42:26  - 23147  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-03-25 01:42:31  - 23147  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-03-25 01:42:35  - 23147  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-03-25 01:42:40  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-03-25 01:42:44  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-03-25 01:42:49  - 23147  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-25 01:42:54  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-03-25 01:42:58  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-03-25 01:43:03  - 23147  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-03-25 01:43:08  - 23147  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-03-25 01:43:12  - 23147  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-03-25 01:43:17  - 23147  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
<pre>2017-03-25_01-43-17 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_01-45-17 Restart Xvfb...
2017-03-25 01:45:22  - 23147  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-03-25 01:45:27  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-03-25 01:45:31  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-03-25 01:45:36  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-03-25 01:45:41  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-03-25 01:45:45  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-03-25 01:45:50  - 23147  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-03-25 01:45:54  - 23147  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-03-25 01:45:59  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-03-25 01:46:04  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-03-25 01:46:08  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-03-25 01:46:13  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-03-25 01:46:17  - 23147  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-03-25 01:46:22  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-03-25 01:46:27  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-03-25 01:46:31  - 23147  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-03-25 01:46:36  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-03-25 01:46:40  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-03-25 01:46:45  - 23147  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-03-25 01:46:50  - 23147  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-03-25 01:46:54  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-03-25 01:46:59  - 23147  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-03-25 01:47:04  - 23147  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-03-25 01:47:08  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-03-25 01:47:13  - 23147  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
<pre>2017-03-25_01-47-17 Restart Xvfb...
2017-03-25 01:47:17  - 23147  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-03-25 01:47:22  - 23147  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-03-25 01:47:26  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-03-25 01:47:31  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-03-25 01:47:35  - 23147  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-03-25 01:47:40  - 23147  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-03-25 01:47:44  - 23147  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-03-25 01:47:49  - 23147  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-03-25 01:47:54  - 23147  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-03-25 01:47:59  - 23147  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-03-25 01:48:03  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-03-25 01:48:09  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-03-25 01:48:13  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-03-25 01:48:18  - 23147  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-03-25 01:48:22  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-03-25 01:48:27  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-03-25 01:48:32  - 23147  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-03-25 01:48:36  - 23147  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-03-25 01:48:41  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-03-25 01:48:45  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-03-25 01:48:50  - 23147  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-03-25 01:48:54  - 23147  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-03-25 01:48:59  - 23147  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-03-25 01:49:04  - 23147  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-03-25 01:49:08  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-03-25 01:49:13  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
<pre>2017-03-25_01-49-17 Restart Xvfb...
2017-03-25 01:49:17  - 23147  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-03-25 01:49:22  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-03-25 01:49:26  - 23147  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-03-25 01:49:31  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-03-25 01:49:35  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-03-25 01:49:40  - 23147  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-03-25 01:49:45  - 23147  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-03-25 01:49:49  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-03-25 01:49:54  - 23147  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-03-25 01:49:59  - 23147  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-03-25 01:50:04  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-03-25 01:50:09  - 23147  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-03-25 01:50:13  - 23147  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-03-25 01:50:18  - 23147  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-03-25 01:50:22  - 23147  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-03-25 01:50:27  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-03-25 01:50:31  - 23147  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-03-25 01:50:37  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-03-25 01:50:41  - 23147  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-03-25 01:50:46  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-03-25 01:50:51  - 23147  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-03-25 01:50:55  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-03-25 01:51:00  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-03-25 01:51:05  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-03-25 01:51:09  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-03-25 01:51:14  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
<pre>2017-03-25_01-51-17 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_01-53-17 Restart Xvfb...
2017-03-25 01:53:19  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-03-25 01:53:24  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-03-25 01:53:28  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-03-25 01:53:33  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-03-25 01:53:37  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-03-25 01:53:42  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-03-25 01:53:47  - 23147  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-03-25 01:53:52  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-03-25 01:53:56  - 23147  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-03-25 01:54:01  - 23147  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-03-25 01:54:05  - 23147  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-03-25 01:54:10  - 23147  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-03-25 01:54:14  - 23147  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-03-25 01:54:19  - 23147  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-03-25 01:54:23  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-03-25 01:54:28  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-03-25 01:54:33  - 23147  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-03-25 01:54:37  - 23147  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-03-25 01:54:41  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-03-25 01:54:46  - 23147  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-03-25 01:54:51  - 23147  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-03-25 01:54:55  - 23147  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-03-25 01:55:00  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-03-25 01:55:05  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-03-25 01:55:09  - 23147  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-03-25 01:55:14  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
<pre>2017-03-25_01-55-17 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_01-57-17 Restart Xvfb...
2017-03-25 01:57:19  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-03-25 01:57:23  - 23147  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-03-25 01:57:28  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-03-25 01:57:33  - 23147  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-03-25 01:57:37  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-03-25 01:57:42  - 23147  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-03-25 01:57:46  - 23147  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-03-25 01:57:50  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-03-25 01:57:55  - 23147  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-03-25 01:57:59  - 23147  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-03-25 01:58:04  - 23147  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-03-25 01:58:08  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-03-25 01:58:13  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-03-25 01:58:17  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-03-25 01:58:22  - 23147  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-03-25 01:58:26  - 23147  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-03-25 01:58:31  - 23147  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-03-25 01:58:36  - 23147  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-03-25 01:58:40  - 23147  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-03-25 01:58:44  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-03-25 01:58:48  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-03-25 01:58:53  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-03-25 01:58:57  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-03-25 01:59:02  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-03-25 01:59:06  - 23147  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-03-25 01:59:10  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-03-25 01:59:15  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
<pre>2017-03-25_01-59-17 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_02-01-17 Restart Xvfb...
2017-03-25 02:01:20  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-03-25 02:01:25  - 23147  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-03-25 02:01:30  - 23147  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-03-25 02:01:34  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-03-25 02:01:38  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-03-25 02:01:43  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-03-25 02:01:48  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-03-25 02:01:53  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-03-25 02:01:58  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-03-25 02:02:02  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-03-25 02:02:07  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-03-25 02:02:11  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-03-25 02:02:15  - 23147  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-03-25 02:02:20  - 23147  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-03-25 02:02:25  - 23147  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-03-25 02:02:29  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-03-25 02:02:33  - 23147  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-03-25 02:02:37  - 23147  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-03-25 02:02:42  - 23147  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-03-25 02:02:47  - 23147  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-03-25 02:02:52  - 23147  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-03-25 02:02:56  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-03-25 02:03:01  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-03-25 02:03:06  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-03-25 02:03:10  - 23147  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-03-25 02:03:15  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
<pre>2017-03-25_02-03-17 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_02-05-17 Restart Xvfb...
2017-03-25 02:05:20  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-03-25 02:05:25  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-03-25 02:05:30  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-03-25 02:05:34  - 23147  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-03-25 02:05:38  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-03-25 02:05:43  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-03-25 02:05:48  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-03-25 02:05:52  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-03-25 02:05:57  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-03-25 02:06:02  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-03-25 02:06:06  - 23147  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-03-25 02:06:10  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-03-25 02:06:15  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-03-25 02:06:19  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-03-25 02:06:24  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-03-25 02:06:28  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-03-25 02:06:33  - 23147  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-03-25 02:06:37  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-03-25 02:06:41  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-03-25 02:06:46  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-03-25 02:06:50  - 23147  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-03-25 02:06:55  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-03-25 02:07:00  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-03-25 02:07:04  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-03-25 02:07:09  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-03-25 02:07:13  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-03-25 02:07:17  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
<pre>2017-03-25_02-07-17 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_02-09-17 Restart Xvfb...
2017-03-25 02:09:22  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-03-25 02:09:27  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-03-25 02:09:32  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-03-25 02:09:36  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-03-25 02:09:41  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-03-25 02:09:45  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-03-25 02:09:49  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-03-25 02:09:53  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-03-25 02:09:57  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-03-25 02:10:01  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-03-25 02:10:06  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-03-25 02:10:10  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-03-25 02:10:14  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-03-25 02:10:19  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-03-25 02:10:23  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-03-25 02:10:27  - 23147  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-03-25 02:10:31  - 23147  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-03-25 02:10:36  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-03-25 02:10:40  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-03-25 02:10:44  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-03-25 02:10:49  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-03-25 02:10:53  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-03-25 02:10:58  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-03-25 02:11:03  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-03-25 02:11:07  - 23147  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-03-25 02:11:11  - 23147  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-03-25 02:11:15  - 23147  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
<pre>2017-03-25_02-11-17 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_02-13-17 Restart Xvfb...
2017-03-25 02:13:21  - 23147  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-03-25 02:13:25  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-03-25 02:13:30  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-03-25 02:13:34  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-03-25 02:13:38  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-03-25 02:13:42  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-03-25 02:13:46  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-25 02:13:50  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-25 02:13:55  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-25 02:13:58  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-25 02:14:03  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-03-25 02:14:07  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-25 02:14:11  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-25 02:14:15  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-03-25 02:14:19  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-03-25 02:14:23  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-03-25 02:14:27  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-03-25 02:14:32  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-03-25 02:14:36  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-03-25 02:14:40  - 23147  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-03-25 02:14:44  - 23147  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-03-25 02:14:48  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-03-25 02:14:52  - 23147  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-03-25 02:14:56  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-03-25 02:15:00  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-03-25 02:15:05  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-03-25 02:15:09  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-03-25 02:15:13  - 23147  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-03-25 02:15:17  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
<pre>2017-03-25_02-15-17 Restart Xvfb...
2017-03-25 02:15:21  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-03-25 02:15:26  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-03-25 02:15:30  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-03-25 02:15:34  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-03-25 02:15:38  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-25 02:15:42  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-25 02:15:46  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-25 02:15:50  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-25 02:15:54  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-25 02:15:58  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-03-25 02:16:02  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-25 02:16:06  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-25 02:16:10  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-25 02:16:14  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-25 02:16:18  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-03-25 02:16:22  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-25 02:16:26  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-25 02:16:30  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-25 02:16:34  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-03-25 02:16:38  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
<pre>2017-03-25_02-17-17 Restart Xvfb...
<pre>2017-03-25_02-19-17 Restart Xvfb...
<pre>2017-03-25_02-21-17 Restart Xvfb...
<pre>2017-03-25_02-23-17 Restart Xvfb...
<pre>2017-03-25_02-25-17 Restart Xvfb...
<pre>2017-03-25_02-27-18 Restart Xvfb...
<pre>2017-03-25_02-29-18 Restart Xvfb...
<pre>2017-03-25_02-31-18 Restart Xvfb...
<pre>2017-03-25_02-33-18 Restart Xvfb...
<pre>2017-03-25_02-35-18 Restart Xvfb...
<pre>2017-03-25_02-37-18 Restart Xvfb...
<pre>2017-03-25_02-39-18 Restart Xvfb...
<pre>2017-03-25_02-41-18 Restart Xvfb...
<pre>2017-03-25_02-43-18 Restart Xvfb...
<pre>2017-03-25_02-45-18 Restart Xvfb...
<pre>2017-03-25_02-47-18 Restart Xvfb...
<pre>2017-03-25_02-49-18 Restart Xvfb...
<pre>2017-03-25_02-51-18 Restart Xvfb...
<pre>2017-03-25_02-53-18 Restart Xvfb...
<pre>2017-03-25_02-55-18 Restart Xvfb...
<pre>2017-03-25_02-57-18 Restart Xvfb...
<pre>2017-03-25_02-59-18 Restart Xvfb...
<pre>2017-03-25_03-01-18 Restart Xvfb...
<pre>2017-03-25_03-03-18 Restart Xvfb...
<pre>2017-03-25_03-05-18 Restart Xvfb...
<pre>2017-03-25_03-07-18 Restart Xvfb...
<pre>2017-03-25_03-09-18 Restart Xvfb...
<pre>2017-03-25_03-11-18 Restart Xvfb...
<pre>2017-03-25_03-13-18 Restart Xvfb...
<pre>2017-03-25_03-15-18 Restart Xvfb...
<pre>2017-03-25_03-17-18 Restart Xvfb...
<pre>2017-03-25_03-19-18 Restart Xvfb...
<pre>2017-03-25_03-21-18 Restart Xvfb...
<pre>2017-03-25_03-23-18 Restart Xvfb...
<pre>2017-03-25_03-25-18 Restart Xvfb...
<pre>2017-03-25_03-27-18 Restart Xvfb...
<pre>2017-03-25_03-29-18 Restart Xvfb...
<pre>2017-03-25_03-31-18 Restart Xvfb...
<pre>2017-03-25_03-33-18 Restart Xvfb...
<pre>2017-03-25_03-35-18 Restart Xvfb...
<pre>2017-03-25_03-37-18 Restart Xvfb...
<pre>2017-03-25_03-39-18 Restart Xvfb...
<pre>2017-03-25_03-41-18 Restart Xvfb...
<pre>2017-03-25_03-43-18 Restart Xvfb...
<pre>2017-03-25_03-45-18 Restart Xvfb...
<pre>2017-03-25_03-47-18 Restart Xvfb...
<pre>2017-03-25_03-49-18 Restart Xvfb...
<pre>2017-03-25_03-51-18 Restart Xvfb...
<pre>2017-03-25_03-53-18 Restart Xvfb...
<pre>2017-03-25_03-55-18 Restart Xvfb...
2017-03-25 03:56:59 reset updateRequest
2017-03-25 03:57:00  - 23147  http://www.lymphomahub.com/
2017-03-25 03:57:04  - 23147  http://www.lymphomahub.com/
2017-03-25 03:57:05  - 23147  http://www.lymphomahub.com/about
2017-03-25 03:57:09  - 23147  http://www.lymphomahub.com/about
2017-03-25 03:57:12  - 23147  http://www.lymphomahub.com/terms
2017-03-25 03:57:13  - 23147  http://www.lymphomahub.com/terms
2017-03-25 03:57:15  - 23147  http://www.lymphomahub.com/undefined
2017-03-25 03:57:16  - 23147  http://www.lymphomahub.com/therapies
2017-03-25 03:57:17  - 23147  http://www.lymphomahub.com/therapies
<pre>2017-03-25_03-57-18 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies?_prerender {"code":"ECONNRESET"}
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_03-59-18 Restart Xvfb...
2017-03-25 03:59:21  - 23147  http://www.lymphomahub.com/therapies
2017-03-25 03:59:22  - 23147  http://www.lymphomahub.com/therapies
2017-03-25 03:59:31  - 23147  http://www.lymphomahub.com/newsletter
2017-03-25 03:59:31  - 23147  http://www.lymphomahub.com/newsletter
2017-03-25 03:59:35  - 23147  http://www.lymphomahub.com/cookie-policy
2017-03-25 03:59:36  - 23147  http://www.lymphomahub.com/cookie-policy
2017-03-25 03:59:39  - 23147  http://www.lymphomahub.com/therapies/afm13
2017-03-25 03:59:40  - 23147  http://www.lymphomahub.com/therapies/afm13
2017-03-25 03:59:45  - 23147  http://www.lymphomahub.com/therapies/afm11
2017-03-25 03:59:45  - 23147  http://www.lymphomahub.com/therapies/afm11
2017-03-25 03:59:50  - 23147  http://www.lymphomahub.com/therapies/ags67e
2017-03-25 03:59:55  - 23147  http://www.lymphomahub.com/therapies/cc-292
2017-03-25 03:59:59  - 23147  http://www.lymphomahub.com/therapies/cc-223
2017-03-25 04:00:04  - 23147  http://www.lymphomahub.com/therapies/sd-101
2017-03-25 04:00:08  - 23147  http://www.lymphomahub.com/therapies/rp6530
2017-03-25 04:00:13  - 23147  http://www.lymphomahub.com/therapies/abt199
2017-03-25 04:00:17  - 23147  http://www.lymphomahub.com/therapies/mor208
2017-03-25 04:00:21  - 23147  http://www.lymphomahub.com/therapies/cc-122
2017-03-25 04:00:25  - 23147  http://www.lymphomahub.com/therapies/at-101
2017-03-25 04:00:32  - 23147  http://www.lymphomahub.com/therapies/bl8040
2017-03-25 04:00:37  - 23147  http://www.lymphomahub.com/therapies/bcl201
2017-03-25 04:00:41  - 23147  http://www.lymphomahub.com/therapies/azd3965
2017-03-25 04:00:45  - 23147  http://www.lymphomahub.com/therapies/imgn529
2017-03-25 04:00:50  - 23147  http://www.lymphomahub.com/therapies/azd2014
2017-03-25 04:00:54  - 23147  http://www.lymphomahub.com/therapies/mt-3724
2017-03-25 04:00:59  - 23147  http://www.lymphomahub.com/therapies/actr087
2017-03-25 04:01:04  - 23147  http://www.lymphomahub.com/therapies/epz6438
2017-03-25 04:01:08  - 23147  http://www.lymphomahub.com/therapies/kte-c19
2017-03-25 04:01:12  - 23147  http://www.lymphomahub.com/about/secretariat
2017-03-25 04:01:16  - 23147  http://www.lymphomahub.com/therapies/alt-803
<pre>2017-03-25_04-01-18 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/alt-803?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_04-03-18 Restart Xvfb...
2017-03-25 04:03:21  - 23147  http://www.lymphomahub.com/therapies/alt-803
2017-03-25 04:03:26  - 23147  http://www.lymphomahub.com/therapies/regn1979
2017-03-25 04:03:30  - 23147  http://www.lymphomahub.com/therapies/immu-114
2017-03-25 04:03:35  - 23147  http://www.lymphomahub.com/therapies/incb7839
2017-03-25 04:03:39  - 23147  http://www.lymphomahub.com/therapies/adct-301
2017-03-25 04:03:44  - 23147  http://www.lymphomahub.com/therapies/ixazomib
2017-03-25 04:03:48  - 23147  http://www.lymphomahub.com/therapies/avelumab
2017-03-25 04:03:52  - 23147  http://www.lymphomahub.com/therapies/bi836826
2017-03-25 04:03:57  - 23147  http://www.lymphomahub.com/therapies/medi-570
2017-03-25 04:04:01  - 23147  http://www.lymphomahub.com/therapies/ds-3201b
2017-03-25 04:04:06  - 23147  http://www.lymphomahub.com/therapies/sea-cd40
2017-03-25 04:04:10  - 23147  http://www.lymphomahub.com/therapies/adct-402
2017-03-25 04:04:15  - 23147  http://www.lymphomahub.com/therapies/acy-1215
2017-03-25 04:04:19  - 23147  http://www.lymphomahub.com/therapies/cudc-907
2017-03-25 04:04:24  - 23147  http://www.lymphomahub.com/therapies/tgr-1202
2017-03-25 04:04:28  - 23147  http://www.lymphomahub.com/therapies/axitinib
2017-03-25 04:04:32  - 23147  http://www.lymphomahub.com/therapies/imatinib
2017-03-25 04:04:37  - 23147  http://www.lymphomahub.com/therapies/edo-s101
2017-03-25 04:04:41  - 23147  http://www.lymphomahub.com/therapies/btct4465a
2017-03-25 04:04:46  - 23147  http://www.lymphomahub.com/therapies/alisertib
2017-03-25 04:04:50  - 23147  http://www.lymphomahub.com/therapies/lirilumab
2017-03-25 04:04:55  - 23147  http://www.lymphomahub.com/therapies/ibrutinib
2017-03-25 04:04:55  - 23147  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-03-25 04:05:00  - 23147  http://www.lymphomahub.com/therapies/rituximab
2017-03-25 04:05:04  - 23147  http://www.lymphomahub.com/therapies/veliparib
2017-03-25 04:05:08  - 23147  http://www.lymphomahub.com/therapies/sunitinib
2017-03-25 04:05:12  - 23147  http://www.lymphomahub.com/therapies/nivolumab
2017-03-25 04:05:13  - 23147  http://www.lymphomahub.com/therapies/sirolimus
2017-03-25 04:05:17  - 23147  http://www.lymphomahub.com/medical-information
<pre>2017-03-25_04-05-18 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_04-07-18 Restart Xvfb...
2017-03-25 04:07:22  - 23147  http://www.lymphomahub.com/medical-information
2017-03-25 04:07:27  - 23147  http://www.lymphomahub.com/therapies/selinexor
2017-03-25 04:07:32  - 23147  http://www.lymphomahub.com/therapies/abc294640
2017-03-25 04:07:36  - 23147  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-03-25 04:07:40  - 23147  http://www.lymphomahub.com/therapies/tenofovir
2017-03-25 04:07:44  - 23147  http://www.lymphomahub.com/therapies/betalutin
2017-03-25 04:07:49  - 23147  http://www.lymphomahub.com/therapies/chidamide
2017-03-25 04:07:54  - 23147  http://www.lymphomahub.com/therapies/duvelisib
2017-03-25 04:07:59  - 23147  http://www.lymphomahub.com/therapies/dasatinib
2017-03-25 04:08:03  - 23147  http://www.lymphomahub.com/therapies/everolimus
2017-03-25 04:08:08  - 23147  http://www.lymphomahub.com/therapies/incb039110
2017-03-25 04:08:13  - 23147  http://www.lymphomahub.com/therapies/durvalumab
2017-03-25 04:08:17  - 23147  http://www.lymphomahub.com/therapies/romidepsin
2017-03-25 04:08:22  - 23147  http://www.lymphomahub.com/therapies/bortezomib
2017-03-25 04:08:26  - 23147  http://www.lymphomahub.com/therapies/idelalisib
2017-03-25 04:08:27  - 23147  http://www.lymphomahub.com/therapies/tipifarnib
2017-03-25 04:08:31  - 23147  http://www.lymphomahub.com/therapies/ipilimumab
2017-03-25 04:08:36  - 23147  http://www.lymphomahub.com/therapies/crizotinib
2017-03-25 04:08:40  - 23147  http://www.lymphomahub.com/therapies/gsk2816126
2017-03-25 04:08:44  - 23147  http://www.lymphomahub.com/therapies/copanlisib
2017-03-25 04:08:49  - 23147  http://www.lymphomahub.com/therapies/buparlisib
2017-03-25 04:08:53  - 23147  http://www.lymphomahub.com/therapies/belinostat
2017-03-25 04:08:58  - 23147  http://www.lymphomahub.com/therapies/vorinostat
2017-03-25 04:09:02  - 23147  http://www.lymphomahub.com/therapies/plerixafor
2017-03-25 04:09:03  - 23147  http://www.lymphomahub.com/therapies/ofatumumab
2017-03-25 04:09:07  - 23147  http://www.lymphomahub.com/therapies/pf-06801591
2017-03-25 04:09:12  - 23147  http://www.lymphomahub.com/therapies/tocilizumab
2017-03-25 04:09:16  - 23147  http://www.lymphomahub.com/therapies/msc2490484a
<pre>2017-03-25_04-09-19 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/msc2490484a?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_04-11-19 Restart Xvfb...
2017-03-25 04:11:22  - 23147  http://www.lymphomahub.com/therapies/msc2490484a
2017-03-25 04:11:26  - 23147  http://www.lymphomahub.com/therapies/carfilzomib
2017-03-25 04:11:30  - 23147  http://www.lymphomahub.com/therapies/ruxolitinib
2017-03-25 04:11:35  - 23147  http://www.lymphomahub.com/therapies/palbociclib
2017-03-25 04:11:39  - 23147  http://www.lymphomahub.com/therapies/fenretinide
2017-03-25 04:11:43  - 23147  http://www.lymphomahub.com/therapies/daratumumab
2017-03-25 04:11:48  - 23147  http://www.lymphomahub.com/therapies/pf-05082566
2017-03-25 04:11:52  - 23147  http://www.lymphomahub.com/therapies/ramucirumab
2017-03-25 04:11:57  - 23147  http://www.lymphomahub.com/therapies/tositumomab
2017-03-25 04:12:01  - 23147  http://www.lymphomahub.com/therapies/ublituximab
2017-03-25 04:12:05  - 23147  http://www.lymphomahub.com/therapies/epacadostat
2017-03-25 04:12:10  - 23147  http://www.lymphomahub.com/therapies/alemtuzumab
2017-03-25 04:12:11  - 23147  http://www.lymphomahub.com/therapies/otlertuzumab
2017-03-25 04:12:15  - 23147  http://www.lymphomahub.com/therapies/panobinostat
2017-03-25 04:12:19  - 23147  http://www.lymphomahub.com/therapies/mocetinostat
2017-03-25 04:12:24  - 23147  http://www.lymphomahub.com/therapies/atezolizumab
2017-03-25 04:12:28  - 23147  http://www.lymphomahub.com/therapies/temsirolimus
2017-03-25 04:12:33  - 23147  http://www.lymphomahub.com/therapies/lenalidomide
2017-03-25 04:12:37  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab
2017-03-25 04:12:42  - 23147  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-03-25 04:12:46  - 23147  http://www.lymphomahub.com/therapies/blinatumomab
2017-03-25 04:12:51  - 23147  http://www.lymphomahub.com/therapies/jnj-64052781
2017-03-25 04:12:55  - 23147  http://www.lymphomahub.com/therapies/entospletinib
2017-03-25 04:12:59  - 23147  http://www.lymphomahub.com/therapies/pembrolizumab
2017-03-25 04:13:04  - 23147  http://www.lymphomahub.com/therapies/acalabrutinib
2017-03-25 04:13:08  - 23147  http://www.lymphomahub.com/about/innovation-committee
2017-03-25 04:13:13  - 23147  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-03-25 04:13:14  - 23147  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-03-25 04:13:18  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a
<pre>2017-03-25_04-13-19 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/interferon-alpha-2a?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_04-15-19 Restart Xvfb...
2017-03-25 04:15:23  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-03-25 04:15:28  - 23147  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-03-25 04:15:32  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-03-25 04:15:37  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-03-25 04:15:37  - 23147  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-03-25 04:15:42  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-03-25 04:15:46  - 23147  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-03-25 04:15:51  - 23147  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-03-25 04:15:55  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board
2017-03-25 04:15:59  - 23147  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-03-25 04:16:04  - 23147  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-03-25 04:16:07  - 23147  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-03-25 04:16:11  - 23147  http://www.lymphomahub.com/about/executive-steering-committee
2017-03-25 04:16:15  - 23147  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-03-25 04:16:19  - 23147  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-03-25 04:16:24  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-03-25 04:16:28  - 23147  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-03-25 04:16:32  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-03-25 04:16:37  - 23147  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-03-25 04:16:41  - 23147  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-03-25 04:16:41  - 23147  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-03-25 04:16:45  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-03-25 04:16:50  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-03-25 04:16:54  - 23147  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-03-25 04:16:58  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-03-25 04:17:03  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-03-25 04:17:08  - 23147  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-03-25 04:17:11  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-03-25 04:17:15  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
<pre>2017-03-25_04-17-19 Restart Xvfb...
2017-03-25 04:17:19  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-03-25 04:17:23  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-03-25 04:17:26  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-03-25 04:17:30  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-03-25 04:17:34  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-03-25 04:17:38  - 23147  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-03-25 04:17:43  - 23147  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-03-25 04:17:48  - 23147  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-03-25 04:17:53  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-03-25 04:17:56  - 23147  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-03-25 04:18:00  - 23147  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-03-25 04:18:05  - 23147  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-03-25 04:18:09  - 23147  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-03-25 04:18:14  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-03-25 04:18:17  - 23147  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-03-25 04:18:22  - 23147  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-03-25 04:18:26  - 23147  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-03-25 04:18:31  - 23147  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-03-25 04:18:36  - 23147  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-03-25 04:18:40  - 23147  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-03-25 04:18:45  - 23147  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-03-25 04:18:49  - 23147  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-03-25 04:18:54  - 23147  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-03-25 04:18:58  - 23147  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-03-25 04:19:03  - 23147  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-03-25 04:19:07  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-03-25 04:19:11  - 23147  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-03-25 04:19:15  - 23147  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
<pre>2017-03-25_04-19-19 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_04-21-19 Restart Xvfb...
2017-03-25 04:21:21  - 23147  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-03-25 04:21:24  - 23147  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-03-25 04:21:29  - 23147  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-03-25 04:21:33  - 23147  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-03-25 04:21:38  - 23147  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-03-25 04:21:41  - 23147  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-03-25 04:21:46  - 23147  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-03-25 04:21:50  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-03-25 04:21:54  - 23147  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-03-25 04:21:59  - 23147  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-03-25 04:22:03  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-03-25 04:22:07  - 23147  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-03-25 04:22:12  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-03-25 04:22:16  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-03-25 04:22:19  - 23147  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-03-25 04:22:24  - 23147  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-03-25 04:22:29  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-03-25 04:22:32  - 23147  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-03-25 04:22:37  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-03-25 04:22:41  - 23147  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-03-25 04:22:45  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-03-25 04:22:49  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-03-25 04:22:54  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-03-25 04:22:58  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-03-25 04:23:01  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-03-25 04:23:05  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-03-25 04:23:09  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-03-25 04:23:13  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-03-25 04:23:18  - 23147  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
<pre>2017-03-25_04-23-19 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_04-25-19 Restart Xvfb...
2017-03-25 04:25:23  - 23147  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-03-25 04:25:27  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-03-25 04:25:32  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-03-25 04:25:37  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-03-25 04:25:42  - 23147  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-25 04:25:42  - 23147  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-03-25 04:25:47  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-03-25 04:25:52  - 23147  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-03-25 04:25:56  - 23147  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-03-25 04:26:01  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-03-25 04:26:05  - 23147  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-03-25 04:26:10  - 23147  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-03-25 04:26:14  - 23147  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-03-25 04:26:19  - 23147  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-03-25 04:26:24  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-03-25 04:26:28  - 23147  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-03-25 04:26:33  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-03-25 04:26:37  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-03-25 04:26:42  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-03-25 04:26:47  - 23147  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-03-25 04:26:52  - 23147  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-03-25 04:26:56  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-03-25 04:27:01  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-03-25 04:27:09  - 23147  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-03-25 04:27:16  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
<pre>2017-03-25_04-27-19 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_04-29-19 Restart Xvfb...
2017-03-25 04:29:21  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-03-25 04:29:25  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-03-25 04:29:30  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-03-25 04:29:35  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-03-25 04:29:40  - 23147  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-25 04:29:45  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-03-25 04:29:50  - 23147  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-03-25 04:29:55  - 23147  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-03-25 04:29:59  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-03-25 04:30:04  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-03-25 04:30:09  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-03-25 04:30:14  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-03-25 04:30:19  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-03-25 04:30:24  - 23147  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-03-25 04:30:28  - 23147  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-03-25 04:30:33  - 23147  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-03-25 04:30:38  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-03-25 04:30:43  - 23147  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-03-25 04:30:47  - 23147  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-03-25 04:30:52  - 23147  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-03-25 04:30:52  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-03-25 04:30:57  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-03-25 04:31:02  - 23147  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-03-25 04:31:06  - 23147  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-03-25 04:31:11  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-03-25 04:31:16  - 23147  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
<pre>2017-03-25_04-31-19 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_04-33-19 Restart Xvfb...
2017-03-25 04:33:21  - 23147  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-03-25 04:33:25  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-03-25 04:33:30  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-03-25 04:33:34  - 23147  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-03-25 04:33:39  - 23147  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-03-25 04:33:43  - 23147  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-03-25 04:33:48  - 23147  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-03-25 04:33:53  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-03-25 04:33:58  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-03-25 04:34:03  - 23147  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-03-25 04:34:07  - 23147  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-03-25 04:34:12  - 23147  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-03-25 04:34:17  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-03-25 04:34:21  - 23147  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-03-25 04:34:26  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-03-25 04:34:31  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-03-25 04:34:34  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-03-25 04:34:40  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-03-25 04:34:44  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-03-25 04:34:48  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-03-25 04:34:51  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-03-25 04:34:55  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-03-25 04:34:59  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-03-25 04:35:04  - 23147  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-03-25 04:35:04  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-03-25 04:35:09  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-03-25 04:35:13  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-03-25 04:35:17  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
<pre>2017-03-25_04-35-19 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_04-37-19 Restart Xvfb...
2017-03-25 04:37:22  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-03-25 04:37:26  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-03-25 04:37:29  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-03-25 04:37:34  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-03-25 04:37:37  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-03-25 04:37:41  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-03-25 04:37:45  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-03-25 04:37:48  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-03-25 04:37:52  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-03-25 04:37:55  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-03-25 04:37:59  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-03-25 04:38:03  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-03-25 04:38:06  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-03-25 04:38:11  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-03-25 04:38:15  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-03-25 04:38:18  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-03-25 04:38:22  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-03-25 04:38:26  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-03-25 04:38:29  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-03-25 04:38:33  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-03-25 04:38:36  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-03-25 04:38:40  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-03-25 04:38:43  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-03-25 04:38:47  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-03-25 04:38:51  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-03-25 04:38:54  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-03-25 04:38:58  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-03-25 04:39:01  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-03-25 04:39:05  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-03-25 04:39:08  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-03-25 04:39:12  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-03-25 04:39:16  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
<pre>2017-03-25_04-39-19 Restart Xvfb...
2017-03-25 04:39:19  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-03-25 04:39:23  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-03-25 04:39:26  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-03-25 04:39:30  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-03-25 04:39:34  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-03-25 04:39:37  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-03-25 04:39:41  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-03-25 04:39:45  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-03-25 04:39:48  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-03-25 04:39:52  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-03-25 04:39:55  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-03-25 04:39:59  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-03-25 04:40:02  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-03-25 04:40:06  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-03-25 04:40:09  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-03-25 04:40:14  - 23147  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-03-25 04:40:19  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-03-25 04:40:24  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-03-25 04:40:28  - 23147  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-03-25 04:40:29  - 23147  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-03-25 04:40:33  - 23147  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-03-25 04:40:38  - 23147  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-03-25 04:40:43  - 23147  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-03-25 04:40:47  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-03-25 04:40:52  - 23147  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-03-25 04:40:57  - 23147  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-03-25 04:41:02  - 23147  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-03-25 04:41:06  - 23147  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-03-25 04:41:11  - 23147  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-03-25 04:41:15  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
<pre>2017-03-25_04-41-19 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_04-43-19 Restart Xvfb...
2017-03-25 04:43:20  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-03-25 04:43:25  - 23147  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-03-25 04:43:29  - 23147  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-03-25 04:43:34  - 23147  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-03-25 04:43:39  - 23147  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-03-25 04:43:44  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-03-25 04:43:48  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-03-25 04:43:53  - 23147  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-03-25 04:43:57  - 23147  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-03-25 04:44:02  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-03-25 04:44:07  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-03-25 04:44:11  - 23147  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-25 04:44:16  - 23147  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-03-25 04:44:21  - 23147  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-03-25 04:44:25  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-03-25 04:44:30  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-03-25 04:44:35  - 23147  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-03-25 04:44:39  - 23147  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-03-25 04:44:44  - 23147  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-03-25 04:44:48  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-03-25 04:44:53  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-03-25 04:44:58  - 23147  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-25 04:45:03  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-03-25 04:45:08  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-03-25 04:45:12  - 23147  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-03-25 04:45:17  - 23147  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
<pre>2017-03-25_04-45-19 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_04-47-19 Restart Xvfb...
2017-03-25 04:47:22  - 23147  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-03-25 04:47:27  - 23147  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-03-25 04:47:32  - 23147  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-03-25 04:47:36  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-03-25 04:47:41  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-03-25 04:47:46  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-03-25 04:47:50  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-03-25 04:47:55  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-03-25 04:48:00  - 23147  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-03-25 04:48:05  - 23147  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-03-25 04:48:09  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-03-25 04:48:14  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-03-25 04:48:18  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-03-25 04:48:23  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-03-25 04:48:28  - 23147  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-03-25 04:48:32  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-03-25 04:48:37  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-03-25 04:48:41  - 23147  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-03-25 04:48:46  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-03-25 04:48:51  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-03-25 04:48:56  - 23147  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-03-25 04:49:01  - 23147  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-03-25 04:49:05  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-03-25 04:49:10  - 23147  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-03-25 04:49:14  - 23147  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
<pre>2017-03-25_04-49-19 Restart Xvfb...
2017-03-25 04:49:19  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-03-25 04:49:24  - 23147  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-03-25 04:49:29  - 23147  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-03-25 04:49:33  - 23147  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-03-25 04:49:38  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-03-25 04:49:42  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-03-25 04:49:47  - 23147  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-03-25 04:49:52  - 23147  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-03-25 04:49:57  - 23147  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-03-25 04:50:02  - 23147  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-03-25 04:50:06  - 23147  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-03-25 04:50:11  - 23147  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-03-25 04:50:16  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-03-25 04:50:20  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-03-25 04:50:25  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-03-25 04:50:30  - 23147  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-03-25 04:50:34  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-03-25 04:50:39  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-03-25 04:50:43  - 23147  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-03-25 04:50:48  - 23147  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-03-25 04:50:53  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-03-25 04:50:57  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-03-25 04:51:02  - 23147  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-03-25 04:51:07  - 23147  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-03-25 04:51:11  - 23147  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-03-25 04:51:15  - 23147  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
<pre>2017-03-25_04-51-19 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_04-53-19 Restart Xvfb...
2017-03-25 04:53:20  - 23147  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-03-25 04:53:25  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-03-25 04:53:30  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-03-25 04:53:35  - 23147  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-03-25 04:53:39  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-03-25 04:53:44  - 23147  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-03-25 04:53:48  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-03-25 04:53:53  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-03-25 04:53:58  - 23147  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-03-25 04:54:02  - 23147  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-03-25 04:54:07  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-03-25 04:54:12  - 23147  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-03-25 04:54:16  - 23147  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-03-25 04:54:21  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-03-25 04:54:26  - 23147  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-03-25 04:54:30  - 23147  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-03-25 04:54:35  - 23147  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-03-25 04:54:40  - 23147  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-03-25 04:54:44  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-03-25 04:54:49  - 23147  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-03-25 04:54:53  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-03-25 04:54:58  - 23147  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-03-25 04:55:02  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-03-25 04:55:07  - 23147  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-03-25 04:55:12  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-03-25 04:55:16  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
<pre>2017-03-25_04-55-19 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_04-57-19 Restart Xvfb...
2017-03-25 04:57:21  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-03-25 04:57:25  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-03-25 04:57:30  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-03-25 04:57:35  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-03-25 04:57:39  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-03-25 04:57:44  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-03-25 04:57:49  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-03-25 04:57:53  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-03-25 04:57:58  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-03-25 04:58:02  - 23147  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-03-25 04:58:07  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-03-25 04:58:11  - 23147  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-03-25 04:58:15  - 23147  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-03-25 04:58:20  - 23147  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-03-25 04:58:24  - 23147  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-03-25 04:58:29  - 23147  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-03-25 04:58:34  - 23147  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-03-25 04:58:38  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-03-25 04:58:43  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-03-25 04:58:48  - 23147  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-03-25 04:58:52  - 23147  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-03-25 04:58:57  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-03-25 04:59:02  - 23147  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-03-25 04:59:07  - 23147  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-03-25 04:59:11  - 23147  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-03-25 04:59:16  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
<pre>2017-03-25_04-59-19 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_05-01-19 Restart Xvfb...
2017-03-25 05:01:21  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-03-25 05:01:25  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-03-25 05:01:30  - 23147  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-03-25 05:01:35  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-03-25 05:01:40  - 23147  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-03-25 05:01:44  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-03-25 05:01:49  - 23147  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-03-25 05:01:54  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-03-25 05:01:59  - 23147  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-03-25 05:02:03  - 23147  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-03-25 05:02:07  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-03-25 05:02:12  - 23147  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-03-25 05:02:16  - 23147  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-03-25 05:02:20  - 23147  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-03-25 05:02:25  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-03-25 05:02:30  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-03-25 05:02:34  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-03-25 05:02:39  - 23147  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-03-25 05:02:44  - 23147  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-03-25 05:02:48  - 23147  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-03-25 05:02:53  - 23147  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-03-25 05:02:57  - 23147  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-03-25 05:03:01  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-03-25 05:03:06  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-03-25 05:03:10  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-03-25 05:03:14  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-03-25 05:03:19  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
<pre>2017-03-25_05-03-19 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_05-05-19 Restart Xvfb...
2017-03-25 05:05:24  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-03-25 05:05:28  - 23147  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-03-25 05:05:33  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-03-25 05:05:37  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-03-25 05:05:42  - 23147  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-03-25 05:05:47  - 23147  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-03-25 05:05:51  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-03-25 05:05:55  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-03-25 05:05:59  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-03-25 05:06:04  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-03-25 05:06:09  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-03-25 05:06:13  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-03-25 05:06:18  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-03-25 05:06:22  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-03-25 05:06:27  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-03-25 05:06:31  - 23147  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-03-25 05:06:36  - 23147  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-03-25 05:06:40  - 23147  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-03-25 05:06:44  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-03-25 05:06:49  - 23147  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-03-25 05:06:53  - 23147  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-03-25 05:06:58  - 23147  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-03-25 05:07:03  - 23147  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-03-25 05:07:07  - 23147  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-03-25 05:07:12  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-03-25 05:07:17  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
<pre>2017-03-25_05-07-19 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_05-09-19 Restart Xvfb...
2017-03-25 05:09:22  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-03-25 05:09:27  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-03-25 05:09:32  - 23147  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-03-25 05:09:36  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-03-25 05:09:41  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-03-25 05:09:46  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-03-25 05:09:50  - 23147  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-03-25 05:09:56  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-03-25 05:10:00  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-03-25 05:10:04  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-03-25 05:10:08  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-03-25 05:10:13  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-03-25 05:10:17  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-03-25 05:10:21  - 23147  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-03-25 05:10:26  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-03-25 05:10:30  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-03-25 05:10:34  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-03-25 05:10:39  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-03-25 05:10:43  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-03-25 05:10:48  - 23147  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-03-25 05:10:53  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-03-25 05:10:57  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-03-25 05:11:02  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-03-25 05:11:06  - 23147  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-03-25 05:11:11  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-03-25 05:11:16  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
<pre>2017-03-25_05-11-19 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_05-13-19 Restart Xvfb...
2017-03-25 05:13:21  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-03-25 05:13:25  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-03-25 05:13:30  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-03-25 05:13:34  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-03-25 05:13:38  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-03-25 05:13:42  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-03-25 05:13:46  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-03-25 05:13:50  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-03-25 05:13:54  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-03-25 05:13:59  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-03-25 05:14:03  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-03-25 05:14:07  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-03-25 05:14:11  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-03-25 05:14:15  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-03-25 05:14:20  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-03-25 05:14:24  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-03-25 05:14:28  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-03-25 05:14:33  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-03-25 05:14:36  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-03-25 05:14:40  - 23147  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-03-25 05:14:45  - 23147  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-03-25 05:14:49  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-03-25 05:14:53  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-03-25 05:14:58  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-03-25 05:15:02  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-03-25 05:15:07  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-03-25 05:15:11  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-03-25 05:15:16  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
<pre>2017-03-25_05-15-19 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_05-17-19 Restart Xvfb...
2017-03-25 05:17:21  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-03-25 05:17:25  - 23147  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-03-25 05:17:29  - 23147  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-03-25 05:17:33  - 23147  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-03-25 05:17:37  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-03-25 05:17:42  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-03-25 05:17:46  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-03-25 05:17:50  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-03-25 05:17:54  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-03-25 05:17:58  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-25 05:18:03  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-25 05:18:07  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-25 05:18:11  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-25 05:18:15  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-03-25 05:18:19  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-25 05:18:23  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-25 05:18:27  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-03-25 05:18:31  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-03-25 05:18:35  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-03-25 05:18:39  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-03-25 05:18:43  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-03-25 05:18:48  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-03-25 05:18:52  - 23147  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-03-25 05:18:56  - 23147  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-03-25 05:19:00  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-03-25 05:19:04  - 23147  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-03-25 05:19:08  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-03-25 05:19:12  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-03-25 05:19:17  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
<pre>2017-03-25_05-19-19 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_05-21-19 Restart Xvfb...
2017-03-25 05:21:22  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-03-25 05:21:26  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-03-25 05:21:30  - 23147  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-03-25 05:21:34  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-03-25 05:21:38  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-03-25 05:21:42  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-03-25 05:21:46  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-03-25 05:21:50  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-03-25 05:21:54  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-25 05:21:58  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-25 05:22:03  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-25 05:22:07  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-25 05:22:11  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-25 05:22:15  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-03-25 05:22:19  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-25 05:22:23  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-25 05:22:27  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-25 05:22:31  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-25 05:22:35  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-03-25 05:22:39  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-25 05:22:43  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-25 05:22:47  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-25 05:22:52  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-03-25 05:22:56  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
<pre>2017-03-25_05-23-19 Restart Xvfb...
<pre>2017-03-25_05-25-19 Restart Xvfb...
<pre>2017-03-25_05-27-19 Restart Xvfb...
<pre>2017-03-25_05-29-20 Restart Xvfb...
<pre>2017-03-25_05-31-20 Restart Xvfb...
<pre>2017-03-25_05-33-20 Restart Xvfb...
<pre>2017-03-25_05-35-20 Restart Xvfb...
<pre>2017-03-25_05-37-20 Restart Xvfb...
<pre>2017-03-25_05-39-20 Restart Xvfb...
<pre>2017-03-25_05-41-20 Restart Xvfb...
<pre>2017-03-25_05-43-20 Restart Xvfb...
<pre>2017-03-25_05-45-20 Restart Xvfb...
<pre>2017-03-25_05-47-20 Restart Xvfb...
<pre>2017-03-25_05-49-20 Restart Xvfb...
<pre>2017-03-25_05-51-20 Restart Xvfb...
<pre>2017-03-25_05-53-20 Restart Xvfb...
<pre>2017-03-25_05-55-20 Restart Xvfb...
<pre>2017-03-25_05-57-20 Restart Xvfb...
<pre>2017-03-25_05-59-20 Restart Xvfb...
<pre>2017-03-25_06-01-20 Restart Xvfb...
<pre>2017-03-25_06-03-20 Restart Xvfb...
<pre>2017-03-25_06-05-20 Restart Xvfb...
<pre>2017-03-25_06-07-20 Restart Xvfb...
<pre>2017-03-25_06-09-20 Restart Xvfb...
<pre>2017-03-25_06-11-20 Restart Xvfb...
<pre>2017-03-25_06-13-20 Restart Xvfb...
<pre>2017-03-25_06-15-20 Restart Xvfb...
<pre>2017-03-25_06-17-20 Restart Xvfb...
<pre>2017-03-25_06-19-20 Restart Xvfb...
<pre>2017-03-25_06-21-20 Restart Xvfb...
<pre>2017-03-25_06-23-20 Restart Xvfb...
<pre>2017-03-25_06-25-20 Restart Xvfb...
<pre>2017-03-25_06-27-20 Restart Xvfb...
<pre>2017-03-25_06-29-20 Restart Xvfb...
<pre>2017-03-25_06-31-20 Restart Xvfb...
<pre>2017-03-25_06-33-20 Restart Xvfb...
<pre>2017-03-25_06-35-20 Restart Xvfb...
<pre>2017-03-25_06-37-20 Restart Xvfb...
<pre>2017-03-25_06-39-20 Restart Xvfb...
<pre>2017-03-25_06-41-20 Restart Xvfb...
<pre>2017-03-25_06-43-20 Restart Xvfb...
<pre>2017-03-25_06-45-20 Restart Xvfb...
<pre>2017-03-25_06-47-20 Restart Xvfb...
<pre>2017-03-25_06-49-20 Restart Xvfb...
<pre>2017-03-25_06-51-20 Restart Xvfb...
<pre>2017-03-25_06-53-20 Restart Xvfb...
<pre>2017-03-25_06-55-20 Restart Xvfb...
2017-03-25 06:56:59 reset updateRequest
2017-03-25 06:57:02  - 23147  http://www.lymphomahub.com/
2017-03-25 06:57:04  - 23147  http://www.lymphomahub.com/
2017-03-25 06:57:08  - 23147  http://www.lymphomahub.com/about
2017-03-25 06:57:09  - 23147  http://www.lymphomahub.com/about
2017-03-25 06:57:15  - 23147  http://www.lymphomahub.com/terms
2017-03-25 06:57:18  - 23147  http://www.lymphomahub.com/undefined
2017-03-25 06:57:19  - 23147  http://www.lymphomahub.com/therapies
<pre>2017-03-25_06-57-20 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_06-59-20 Restart Xvfb...
2017-03-25 06:59:24  - 23147  http://www.lymphomahub.com/therapies
2017-03-25 06:59:30  - 23147  http://www.lymphomahub.com/newsletter
2017-03-25 06:59:33  - 23147  http://www.lymphomahub.com/cookie-policy
2017-03-25 06:59:36  - 23147  http://www.lymphomahub.com/therapies/afm13
2017-03-25 06:59:40  - 23147  http://www.lymphomahub.com/therapies/afm11
2017-03-25 06:59:45  - 23147  http://www.lymphomahub.com/therapies/ags67e
2017-03-25 06:59:50  - 23147  http://www.lymphomahub.com/therapies/cc-292
2017-03-25 06:59:54  - 23147  http://www.lymphomahub.com/therapies/cc-223
2017-03-25 06:59:58  - 23147  http://www.lymphomahub.com/therapies/sd-101
2017-03-25 07:00:03  - 23147  http://www.lymphomahub.com/therapies/rp6530
2017-03-25 07:00:10  - 23147  http://www.lymphomahub.com/therapies/abt199
2017-03-25 07:00:14  - 23147  http://www.lymphomahub.com/therapies/mor208
2017-03-25 07:00:19  - 23147  http://www.lymphomahub.com/therapies/cc-122
2017-03-25 07:00:25  - 23147  http://www.lymphomahub.com/therapies/at-101
2017-03-25 07:00:30  - 23147  http://www.lymphomahub.com/therapies/bl8040
2017-03-25 07:00:35  - 23147  http://www.lymphomahub.com/therapies/bcl201
2017-03-25 07:00:40  - 23147  http://www.lymphomahub.com/therapies/azd3965
2017-03-25 07:00:44  - 23147  http://www.lymphomahub.com/therapies/imgn529
2017-03-25 07:00:49  - 23147  http://www.lymphomahub.com/therapies/azd2014
2017-03-25 07:00:53  - 23147  http://www.lymphomahub.com/therapies/mt-3724
2017-03-25 07:00:58  - 23147  http://www.lymphomahub.com/therapies/actr087
2017-03-25 07:01:02  - 23147  http://www.lymphomahub.com/therapies/epz6438
2017-03-25 07:01:07  - 23147  http://www.lymphomahub.com/therapies/kte-c19
2017-03-25 07:01:11  - 23147  http://www.lymphomahub.com/about/secretariat
2017-03-25 07:01:15  - 23147  http://www.lymphomahub.com/therapies/alt-803
2017-03-25 07:01:19  - 23147  http://www.lymphomahub.com/therapies/regn1979
<pre>2017-03-25_07-01-20 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/regn1979?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_07-03-20 Restart Xvfb...
2017-03-25 07:03:24  - 23147  http://www.lymphomahub.com/therapies/regn1979
2017-03-25 07:03:28  - 23147  http://www.lymphomahub.com/therapies/immu-114
2017-03-25 07:03:33  - 23147  http://www.lymphomahub.com/therapies/incb7839
2017-03-25 07:03:37  - 23147  http://www.lymphomahub.com/therapies/adct-301
2017-03-25 07:03:42  - 23147  http://www.lymphomahub.com/therapies/ixazomib
2017-03-25 07:03:47  - 23147  http://www.lymphomahub.com/therapies/avelumab
2017-03-25 07:03:51  - 23147  http://www.lymphomahub.com/therapies/bi836826
2017-03-25 07:03:55  - 23147  http://www.lymphomahub.com/therapies/medi-570
2017-03-25 07:04:00  - 23147  http://www.lymphomahub.com/therapies/ds-3201b
2017-03-25 07:04:04  - 23147  http://www.lymphomahub.com/therapies/sea-cd40
2017-03-25 07:04:09  - 23147  http://www.lymphomahub.com/therapies/adct-402
2017-03-25 07:04:13  - 23147  http://www.lymphomahub.com/therapies/acy-1215
2017-03-25 07:04:17  - 23147  http://www.lymphomahub.com/therapies/cudc-907
2017-03-25 07:04:22  - 23147  http://www.lymphomahub.com/therapies/tgr-1202
2017-03-25 07:04:26  - 23147  http://www.lymphomahub.com/therapies/axitinib
2017-03-25 07:04:31  - 23147  http://www.lymphomahub.com/therapies/imatinib
2017-03-25 07:04:35  - 23147  http://www.lymphomahub.com/therapies/edo-s101
2017-03-25 07:04:39  - 23147  http://www.lymphomahub.com/therapies/btct4465a
2017-03-25 07:04:44  - 23147  http://www.lymphomahub.com/therapies/alisertib
2017-03-25 07:04:48  - 23147  http://www.lymphomahub.com/therapies/lirilumab
2017-03-25 07:04:53  - 23147  http://www.lymphomahub.com/therapies/ibrutinib
2017-03-25 07:04:54  - 23147  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-03-25 07:04:58  - 23147  http://www.lymphomahub.com/therapies/rituximab
2017-03-25 07:05:02  - 23147  http://www.lymphomahub.com/therapies/veliparib
2017-03-25 07:05:07  - 23147  http://www.lymphomahub.com/therapies/sunitinib
2017-03-25 07:05:11  - 23147  http://www.lymphomahub.com/therapies/nivolumab
2017-03-25 07:05:12  - 23147  http://www.lymphomahub.com/therapies/sirolimus
2017-03-25 07:05:16  - 23147  http://www.lymphomahub.com/medical-information
<pre>2017-03-25_07-05-20 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_07-07-20 Restart Xvfb...
2017-03-25 07:07:22  - 23147  http://www.lymphomahub.com/medical-information
2017-03-25 07:07:25  - 23147  http://www.lymphomahub.com/therapies/selinexor
2017-03-25 07:07:30  - 23147  http://www.lymphomahub.com/therapies/abc294640
2017-03-25 07:07:34  - 23147  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-03-25 07:07:38  - 23147  http://www.lymphomahub.com/therapies/tenofovir
2017-03-25 07:07:43  - 23147  http://www.lymphomahub.com/therapies/betalutin
2017-03-25 07:07:47  - 23147  http://www.lymphomahub.com/therapies/chidamide
2017-03-25 07:07:52  - 23147  http://www.lymphomahub.com/therapies/duvelisib
2017-03-25 07:07:56  - 23147  http://www.lymphomahub.com/therapies/dasatinib
2017-03-25 07:08:01  - 23147  http://www.lymphomahub.com/therapies/everolimus
2017-03-25 07:08:06  - 23147  http://www.lymphomahub.com/therapies/incb039110
2017-03-25 07:08:10  - 23147  http://www.lymphomahub.com/therapies/durvalumab
2017-03-25 07:08:15  - 23147  http://www.lymphomahub.com/therapies/romidepsin
2017-03-25 07:08:19  - 23147  http://www.lymphomahub.com/therapies/bortezomib
2017-03-25 07:08:23  - 23147  http://www.lymphomahub.com/therapies/idelalisib
2017-03-25 07:08:24  - 23147  http://www.lymphomahub.com/therapies/tipifarnib
2017-03-25 07:08:29  - 23147  http://www.lymphomahub.com/therapies/ipilimumab
2017-03-25 07:08:33  - 23147  http://www.lymphomahub.com/therapies/crizotinib
2017-03-25 07:08:37  - 23147  http://www.lymphomahub.com/therapies/gsk2816126
2017-03-25 07:08:42  - 23147  http://www.lymphomahub.com/therapies/copanlisib
2017-03-25 07:08:46  - 23147  http://www.lymphomahub.com/therapies/buparlisib
2017-03-25 07:08:50  - 23147  http://www.lymphomahub.com/therapies/belinostat
2017-03-25 07:08:55  - 23147  http://www.lymphomahub.com/therapies/vorinostat
2017-03-25 07:08:59  - 23147  http://www.lymphomahub.com/therapies/plerixafor
2017-03-25 07:09:00  - 23147  http://www.lymphomahub.com/therapies/ofatumumab
2017-03-25 07:09:04  - 23147  http://www.lymphomahub.com/therapies/pf-06801591
2017-03-25 07:09:09  - 23147  http://www.lymphomahub.com/therapies/tocilizumab
2017-03-25 07:09:13  - 23147  http://www.lymphomahub.com/therapies/msc2490484a
2017-03-25 07:09:18  - 23147  http://www.lymphomahub.com/therapies/carfilzomib
<pre>2017-03-25_07-09-20 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/carfilzomib?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_07-11-21 Restart Xvfb...
2017-03-25 07:11:23  - 23147  http://www.lymphomahub.com/therapies/carfilzomib
2017-03-25 07:11:27  - 23147  http://www.lymphomahub.com/therapies/ruxolitinib
2017-03-25 07:11:32  - 23147  http://www.lymphomahub.com/therapies/palbociclib
2017-03-25 07:11:36  - 23147  http://www.lymphomahub.com/therapies/fenretinide
2017-03-25 07:11:40  - 23147  http://www.lymphomahub.com/therapies/daratumumab
2017-03-25 07:11:45  - 23147  http://www.lymphomahub.com/therapies/pf-05082566
2017-03-25 07:11:49  - 23147  http://www.lymphomahub.com/therapies/ramucirumab
2017-03-25 07:11:54  - 23147  http://www.lymphomahub.com/therapies/tositumomab
2017-03-25 07:11:58  - 23147  http://www.lymphomahub.com/therapies/ublituximab
2017-03-25 07:12:03  - 23147  http://www.lymphomahub.com/therapies/epacadostat
2017-03-25 07:12:07  - 23147  http://www.lymphomahub.com/therapies/alemtuzumab
2017-03-25 07:12:08  - 23147  http://www.lymphomahub.com/therapies/otlertuzumab
2017-03-25 07:12:13  - 23147  http://www.lymphomahub.com/therapies/panobinostat
2017-03-25 07:12:17  - 23147  http://www.lymphomahub.com/therapies/mocetinostat
2017-03-25 07:12:21  - 23147  http://www.lymphomahub.com/therapies/atezolizumab
2017-03-25 07:12:26  - 23147  http://www.lymphomahub.com/therapies/temsirolimus
2017-03-25 07:12:30  - 23147  http://www.lymphomahub.com/therapies/lenalidomide
2017-03-25 07:12:35  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab
2017-03-25 07:12:39  - 23147  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-03-25 07:12:43  - 23147  http://www.lymphomahub.com/therapies/blinatumomab
2017-03-25 07:12:48  - 23147  http://www.lymphomahub.com/therapies/jnj-64052781
2017-03-25 07:12:52  - 23147  http://www.lymphomahub.com/therapies/entospletinib
2017-03-25 07:12:57  - 23147  http://www.lymphomahub.com/therapies/pembrolizumab
2017-03-25 07:13:01  - 23147  http://www.lymphomahub.com/therapies/acalabrutinib
2017-03-25 07:13:05  - 23147  http://www.lymphomahub.com/about/innovation-committee
2017-03-25 07:13:10  - 23147  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-03-25 07:13:11  - 23147  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-03-25 07:13:15  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-03-25 07:13:20  - 23147  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
<pre>2017-03-25_07-13-21 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/polatuzumab-vedotin?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_07-15-21 Restart Xvfb...
2017-03-25 07:15:25  - 23147  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-03-25 07:15:29  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-03-25 07:15:34  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-03-25 07:15:34  - 23147  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-03-25 07:15:39  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-03-25 07:15:43  - 23147  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-03-25 07:15:48  - 23147  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-03-25 07:15:51  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board
2017-03-25 07:15:56  - 23147  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-03-25 07:16:00  - 23147  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-03-25 07:16:04  - 23147  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-03-25 07:16:07  - 23147  http://www.lymphomahub.com/about/executive-steering-committee
2017-03-25 07:16:11  - 23147  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-03-25 07:16:15  - 23147  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-03-25 07:16:20  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-03-25 07:16:24  - 23147  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-03-25 07:16:27  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-03-25 07:16:32  - 23147  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-03-25 07:16:36  - 23147  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-03-25 07:16:37  - 23147  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-03-25 07:16:40  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-03-25 07:16:45  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-03-25 07:16:50  - 23147  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-03-25 07:16:54  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-03-25 07:16:58  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-03-25 07:17:03  - 23147  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-03-25 07:17:07  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-03-25 07:17:11  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-03-25 07:17:15  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-03-25 07:17:19  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
<pre>2017-03-25_07-17-21 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_07-19-21 Restart Xvfb...
2017-03-25 07:19:24  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-03-25 07:19:28  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-03-25 07:19:32  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-03-25 07:19:35  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-03-25 07:19:39  - 23147  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-03-25 07:19:44  - 23147  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-03-25 07:19:48  - 23147  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-03-25 07:19:53  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-03-25 07:19:57  - 23147  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-03-25 07:20:00  - 23147  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-03-25 07:20:05  - 23147  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-03-25 07:20:09  - 23147  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-03-25 07:20:14  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-03-25 07:20:17  - 23147  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-03-25 07:20:20  - 23147  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-03-25 07:20:25  - 23147  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-03-25 07:20:30  - 23147  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-03-25 07:20:34  - 23147  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-03-25 07:20:39  - 23147  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-03-25 07:20:43  - 23147  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-03-25 07:20:48  - 23147  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-03-25 07:20:52  - 23147  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-03-25 07:20:57  - 23147  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-03-25 07:21:01  - 23147  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-03-25 07:21:05  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-03-25 07:21:09  - 23147  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-03-25 07:21:13  - 23147  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-03-25 07:21:18  - 23147  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
<pre>2017-03-25_07-21-21 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_07-23-21 Restart Xvfb...
2017-03-25 07:23:23  - 23147  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-03-25 07:23:26  - 23147  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-03-25 07:23:31  - 23147  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-03-25 07:23:35  - 23147  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-03-25 07:23:39  - 23147  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-03-25 07:23:43  - 23147  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-03-25 07:23:48  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-03-25 07:23:52  - 23147  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-03-25 07:23:56  - 23147  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-03-25 07:24:01  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-03-25 07:24:04  - 23147  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-03-25 07:24:09  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-03-25 07:24:13  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-03-25 07:24:16  - 23147  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-03-25 07:24:21  - 23147  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-03-25 07:24:26  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-03-25 07:24:30  - 23147  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-03-25 07:24:34  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-03-25 07:24:38  - 23147  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-03-25 07:24:43  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-03-25 07:24:46  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-03-25 07:24:51  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-03-25 07:24:55  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-03-25 07:24:58  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-03-25 07:25:02  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-03-25 07:25:06  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-03-25 07:25:10  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-03-25 07:25:14  - 23147  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-03-25 07:25:19  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
<pre>2017-03-25_07-25-21 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_07-27-21 Restart Xvfb...
2017-03-25 07:27:24  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-03-25 07:27:29  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-03-25 07:27:34  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-03-25 07:27:38  - 23147  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-25 07:27:39  - 23147  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-03-25 07:27:43  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-03-25 07:27:48  - 23147  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-03-25 07:27:52  - 23147  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-03-25 07:27:57  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-03-25 07:28:02  - 23147  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-03-25 07:28:06  - 23147  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-03-25 07:28:11  - 23147  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-03-25 07:28:16  - 23147  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-03-25 07:28:20  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-03-25 07:28:25  - 23147  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-03-25 07:28:30  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-03-25 07:28:35  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-03-25 07:28:40  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-03-25 07:28:44  - 23147  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-03-25 07:28:49  - 23147  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-03-25 07:28:53  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-03-25 07:28:58  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-03-25 07:29:03  - 23147  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-03-25 07:29:08  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-03-25 07:29:12  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-03-25 07:29:17  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
<pre>2017-03-25_07-29-21 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_07-31-21 Restart Xvfb...
2017-03-25 07:31:22  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-03-25 07:31:26  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-03-25 07:31:31  - 23147  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-25 07:31:36  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-03-25 07:31:40  - 23147  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-03-25 07:31:45  - 23147  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-03-25 07:31:50  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-03-25 07:31:55  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-03-25 07:31:59  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-03-25 07:32:04  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-03-25 07:32:09  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-03-25 07:32:13  - 23147  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-03-25 07:32:18  - 23147  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-03-25 07:32:23  - 23147  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-03-25 07:32:27  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-03-25 07:32:32  - 23147  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-03-25 07:32:37  - 23147  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-03-25 07:32:41  - 23147  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-03-25 07:32:42  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-03-25 07:32:47  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-03-25 07:32:51  - 23147  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-03-25 07:32:56  - 23147  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-03-25 07:33:01  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-03-25 07:33:06  - 23147  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-03-25 07:33:11  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-03-25 07:33:15  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-03-25 07:33:20  - 23147  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
<pre>2017-03-25_07-33-21 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_07-35-21 Restart Xvfb...
2017-03-25 07:35:25  - 23147  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-03-25 07:35:30  - 23147  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-03-25 07:35:35  - 23147  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-03-25 07:35:39  - 23147  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-03-25 07:35:44  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-03-25 07:35:48  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-03-25 07:35:53  - 23147  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-03-25 07:35:58  - 23147  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-03-25 07:36:02  - 23147  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-03-25 07:36:07  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-03-25 07:36:12  - 23147  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-03-25 07:36:16  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-03-25 07:36:21  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-03-25 07:36:25  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-03-25 07:36:30  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-03-25 07:36:34  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-03-25 07:36:38  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-03-25 07:36:42  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-03-25 07:36:46  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-03-25 07:36:50  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-03-25 07:36:54  - 23147  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-03-25 07:36:54  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-03-25 07:36:59  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-03-25 07:37:03  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-03-25 07:37:07  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-03-25 07:37:11  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-03-25 07:37:14  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-03-25 07:37:18  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
<pre>2017-03-25_07-37-21 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_07-39-21 Restart Xvfb...
2017-03-25 07:39:23  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-03-25 07:39:27  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-03-25 07:39:30  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-03-25 07:39:34  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-03-25 07:39:38  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-03-25 07:39:41  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-03-25 07:39:46  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-03-25 07:39:49  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-03-25 07:39:53  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-03-25 07:39:56  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-03-25 07:40:01  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-03-25 07:40:05  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-03-25 07:40:09  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-03-25 07:40:12  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-03-25 07:40:16  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-03-25 07:40:19  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-03-25 07:40:23  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-03-25 07:40:27  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-03-25 07:40:30  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-03-25 07:40:34  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-03-25 07:40:38  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-03-25 07:40:41  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-03-25 07:40:45  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-03-25 07:40:49  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-03-25 07:40:52  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-03-25 07:40:56  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-03-25 07:40:59  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-03-25 07:41:03  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-03-25 07:41:06  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-03-25 07:41:11  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-03-25 07:41:14  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-03-25 07:41:18  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
<pre>2017-03-25_07-41-21 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_07-43-21 Restart Xvfb...
2017-03-25 07:43:23  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-03-25 07:43:27  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-03-25 07:43:30  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-03-25 07:43:34  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-03-25 07:43:38  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-03-25 07:43:42  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-03-25 07:43:46  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-03-25 07:43:49  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-03-25 07:43:53  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-03-25 07:43:56  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-03-25 07:44:00  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-03-25 07:44:03  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-03-25 07:44:07  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-03-25 07:44:12  - 23147  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-03-25 07:44:16  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-03-25 07:44:21  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-03-25 07:44:26  - 23147  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-03-25 07:44:26  - 23147  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-03-25 07:44:31  - 23147  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-03-25 07:44:35  - 23147  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-03-25 07:44:40  - 23147  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-03-25 07:44:45  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-03-25 07:44:49  - 23147  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-03-25 07:44:54  - 23147  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-03-25 07:44:59  - 23147  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-03-25 07:45:03  - 23147  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-03-25 07:45:08  - 23147  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-03-25 07:45:12  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-03-25 07:45:17  - 23147  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
<pre>2017-03-25_07-45-21 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_07-47-21 Restart Xvfb...
2017-03-25 07:47:22  - 23147  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-03-25 07:47:27  - 23147  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-03-25 07:47:31  - 23147  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-03-25 07:47:36  - 23147  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-03-25 07:47:41  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-03-25 07:47:45  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-03-25 07:47:50  - 23147  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-03-25 07:47:55  - 23147  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-03-25 07:47:59  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-03-25 07:48:04  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-03-25 07:48:08  - 23147  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-25 07:48:13  - 23147  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-03-25 07:48:18  - 23147  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-03-25 07:48:22  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-03-25 07:48:27  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-03-25 07:48:31  - 23147  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-03-25 07:48:36  - 23147  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-03-25 07:48:41  - 23147  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-03-25 07:48:46  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-03-25 07:48:50  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-03-25 07:48:55  - 23147  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-25 07:49:00  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-03-25 07:49:04  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-03-25 07:49:09  - 23147  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-03-25 07:49:14  - 23147  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-03-25 07:49:18  - 23147  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
<pre>2017-03-25_07-49-21 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_07-51-21 Restart Xvfb...
2017-03-25 07:51:23  - 23147  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-03-25 07:51:27  - 23147  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-03-25 07:51:32  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-03-25 07:51:36  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-03-25 07:51:41  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-03-25 07:51:46  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-03-25 07:51:50  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-03-25 07:51:55  - 23147  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-03-25 07:52:00  - 23147  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-03-25 07:52:04  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-03-25 07:52:09  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-03-25 07:52:13  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-03-25 07:52:18  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-03-25 07:52:22  - 23147  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-03-25 07:52:27  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-03-25 07:52:32  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-03-25 07:52:36  - 23147  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-03-25 07:52:41  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-03-25 07:52:45  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-03-25 07:52:50  - 23147  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-03-25 07:52:55  - 23147  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-03-25 07:53:00  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-03-25 07:53:04  - 23147  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-03-25 07:53:09  - 23147  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-03-25 07:53:14  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-03-25 07:53:18  - 23147  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
<pre>2017-03-25_07-53-21 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_07-55-21 Restart Xvfb...
2017-03-25 07:55:23  - 23147  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-03-25 07:55:29  - 23147  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-03-25 07:55:33  - 23147  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-03-25 07:55:38  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-03-25 07:55:43  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-03-25 07:55:47  - 23147  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-03-25 07:55:52  - 23147  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-03-25 07:55:56  - 23147  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-03-25 07:56:01  - 23147  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-03-25 07:56:05  - 23147  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-03-25 07:56:10  - 23147  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-03-25 07:56:15  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-03-25 07:56:19  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-03-25 07:56:24  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-03-25 07:56:29  - 23147  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-03-25 07:56:33  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-03-25 07:56:38  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-03-25 07:56:43  - 23147  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-03-25 07:56:47  - 23147  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-03-25 07:56:52  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-03-25 07:56:56  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-03-25 07:57:01  - 23147  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-03-25 07:57:06  - 23147  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-03-25 07:57:10  - 23147  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-03-25 07:57:14  - 23147  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-03-25 07:57:19  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
<pre>2017-03-25_07-57-21 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_07-59-21 Restart Xvfb...
2017-03-25 07:59:24  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-03-25 07:59:29  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-03-25 07:59:33  - 23147  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-03-25 07:59:38  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-03-25 07:59:43  - 23147  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-03-25 07:59:47  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-03-25 07:59:52  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-03-25 07:59:57  - 23147  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-03-25 08:00:01  - 23147  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-03-25 08:00:06  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-03-25 08:00:11  - 23147  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-03-25 08:00:16  - 23147  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-03-25 08:00:20  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-03-25 08:00:28  - 23147  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-03-25 08:00:32  - 23147  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-03-25 08:00:37  - 23147  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-03-25 08:00:41  - 23147  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-03-25 08:00:46  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-03-25 08:00:51  - 23147  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-03-25 08:00:55  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-03-25 08:01:00  - 23147  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-03-25 08:01:04  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-03-25 08:01:09  - 23147  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-03-25 08:01:14  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-03-25 08:01:18  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
<pre>2017-03-25_08-01-21 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_08-03-21 Restart Xvfb...
2017-03-25 08:03:23  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-03-25 08:03:28  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-03-25 08:03:33  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-03-25 08:03:37  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-03-25 08:03:42  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-03-25 08:03:46  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-03-25 08:03:51  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-03-25 08:03:55  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-03-25 08:04:00  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-03-25 08:04:05  - 23147  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-03-25 08:04:10  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-03-25 08:04:14  - 23147  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-03-25 08:04:18  - 23147  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-03-25 08:04:23  - 23147  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-03-25 08:04:27  - 23147  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-03-25 08:04:32  - 23147  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-03-25 08:04:36  - 23147  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-03-25 08:04:41  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-03-25 08:04:45  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-03-25 08:04:50  - 23147  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-03-25 08:04:55  - 23147  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-03-25 08:04:59  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-03-25 08:05:04  - 23147  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-03-25 08:05:09  - 23147  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-03-25 08:05:13  - 23147  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-03-25 08:05:18  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
<pre>2017-03-25_08-05-21 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_08-07-21 Restart Xvfb...
2017-03-25 08:07:23  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-03-25 08:07:27  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-03-25 08:07:32  - 23147  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-03-25 08:07:36  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-03-25 08:07:41  - 23147  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-03-25 08:07:46  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-03-25 08:07:50  - 23147  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-03-25 08:07:55  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-03-25 08:08:00  - 23147  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-03-25 08:08:04  - 23147  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-03-25 08:08:09  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-03-25 08:08:13  - 23147  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-03-25 08:08:17  - 23147  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-03-25 08:08:22  - 23147  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-03-25 08:08:27  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-03-25 08:08:32  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-03-25 08:08:36  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-03-25 08:08:40  - 23147  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-03-25 08:08:45  - 23147  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-03-25 08:08:50  - 23147  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-03-25 08:08:55  - 23147  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-03-25 08:08:59  - 23147  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-03-25 08:09:03  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-03-25 08:09:08  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-03-25 08:09:13  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-03-25 08:09:17  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
<pre>2017-03-25_08-09-21 Restart Xvfb...
2017-03-25 08:09:22  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-03-25 08:09:26  - 23147  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-03-25 08:09:30  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-03-25 08:09:35  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-03-25 08:09:40  - 23147  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-03-25 08:09:44  - 23147  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-03-25 08:09:48  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-03-25 08:09:52  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-03-25 08:09:57  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-03-25 08:10:02  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-03-25 08:10:07  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-03-25 08:10:11  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-03-25 08:10:15  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-03-25 08:10:20  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-03-25 08:10:24  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-03-25 08:10:29  - 23147  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-03-25 08:10:33  - 23147  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-03-25 08:10:38  - 23147  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-03-25 08:10:42  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-03-25 08:10:46  - 23147  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-03-25 08:10:50  - 23147  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-03-25 08:10:55  - 23147  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-03-25 08:11:00  - 23147  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-03-25 08:11:04  - 23147  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-03-25 08:11:09  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-03-25 08:11:14  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-03-25 08:11:18  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
<pre>2017-03-25_08-11-21 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_08-13-21 Restart Xvfb...
2017-03-25 08:13:23  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-03-25 08:13:28  - 23147  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-03-25 08:13:33  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-03-25 08:13:37  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-03-25 08:13:42  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-03-25 08:13:46  - 23147  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-03-25 08:13:51  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-03-25 08:13:55  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-03-25 08:14:00  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-03-25 08:14:04  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-03-25 08:14:09  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-03-25 08:14:13  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-03-25 08:14:18  - 23147  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-03-25 08:14:22  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-03-25 08:14:27  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-03-25 08:14:31  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-03-25 08:14:36  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-03-25 08:14:40  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-03-25 08:14:45  - 23147  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-03-25 08:14:50  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-03-25 08:14:54  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-03-25 08:14:58  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-03-25 08:15:03  - 23147  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-03-25 08:15:08  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-03-25 08:15:12  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-03-25 08:15:17  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
<pre>2017-03-25_08-15-21 Restart Xvfb...
2017-03-25 08:15:22  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
<pre>2017-03-25_08-17-21 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-?_prerender {"code":"ECONNRESET"}
2017-03-25 08:17:27  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-03-25 08:17:31  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-03-25 08:17:35  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-03-25 08:17:39  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-03-25 08:17:43  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-03-25 08:17:47  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-03-25 08:17:52  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-03-25 08:17:56  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-03-25 08:18:01  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-03-25 08:18:05  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-03-25 08:18:09  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-03-25 08:18:13  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-03-25 08:18:17  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-03-25 08:18:21  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-03-25 08:18:26  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-03-25 08:18:30  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-03-25 08:18:34  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-03-25 08:18:38  - 23147  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-03-25 08:18:42  - 23147  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-03-25 08:18:46  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-03-25 08:18:51  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-03-25 08:18:55  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-03-25 08:19:00  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-03-25 08:19:04  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-03-25 08:19:09  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-03-25 08:19:14  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-03-25 08:19:18  - 23147  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
<pre>2017-03-25_08-19-21 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_08-21-21 Restart Xvfb...
2017-03-25 08:21:23  - 23147  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-03-25 08:21:27  - 23147  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-03-25 08:21:31  - 23147  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-03-25 08:21:35  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-03-25 08:21:39  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-03-25 08:21:43  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-03-25 08:21:47  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-03-25 08:21:52  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-03-25 08:21:56  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-25 08:22:03  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-25 08:22:07  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-25 08:22:11  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-25 08:22:19  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-03-25 08:22:23  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-25 08:22:26  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-25 08:22:33  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-03-25 08:22:37  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-03-25 08:22:41  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-03-25 08:22:46  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-03-25 08:22:50  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-03-25 08:22:55  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-03-25 08:22:59  - 23147  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-03-25 08:23:04  - 23147  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-03-25 08:23:08  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-03-25 08:23:13  - 23147  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-03-25 08:23:17  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-03-25 08:23:21  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
<pre>2017-03-25_08-23-21 Restart Xvfb...
2017-03-25 08:23:26  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-03-25 08:23:30  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-03-25 08:23:34  - 23147  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-03-25 08:23:38  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-03-25 08:23:43  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-03-25 08:23:47  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-03-25 08:23:51  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-03-25 08:23:55  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-03-25 08:23:59  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-25 08:24:03  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-25 08:24:08  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-25 08:24:12  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-25 08:24:16  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-25 08:24:20  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-03-25 08:24:24  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-25 08:24:28  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-25 08:24:32  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-25 08:24:35  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-25 08:24:39  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-03-25 08:24:43  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-25 08:24:48  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-25 08:24:52  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-25 08:24:56  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-03-25 08:25:00  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
<pre>2017-03-25_08-25-21 Restart Xvfb...
<pre>2017-03-25_08-27-22 Restart Xvfb...
<pre>2017-03-25_08-29-22 Restart Xvfb...
<pre>2017-03-25_08-31-22 Restart Xvfb...
<pre>2017-03-25_08-33-22 Restart Xvfb...
<pre>2017-03-25_08-35-22 Restart Xvfb...
<pre>2017-03-25_08-37-22 Restart Xvfb...
<pre>2017-03-25_08-39-22 Restart Xvfb...
<pre>2017-03-25_08-41-22 Restart Xvfb...
<pre>2017-03-25_08-43-22 Restart Xvfb...
<pre>2017-03-25_08-45-22 Restart Xvfb...
<pre>2017-03-25_08-47-22 Restart Xvfb...
<pre>2017-03-25_08-49-22 Restart Xvfb...
<pre>2017-03-25_08-51-22 Restart Xvfb...
<pre>2017-03-25_08-53-22 Restart Xvfb...
<pre>2017-03-25_08-55-22 Restart Xvfb...
<pre>2017-03-25_08-57-22 Restart Xvfb...
<pre>2017-03-25_08-59-22 Restart Xvfb...
<pre>2017-03-25_09-01-22 Restart Xvfb...
<pre>2017-03-25_09-03-22 Restart Xvfb...
<pre>2017-03-25_09-05-22 Restart Xvfb...
<pre>2017-03-25_09-07-22 Restart Xvfb...
<pre>2017-03-25_09-09-22 Restart Xvfb...
<pre>2017-03-25_09-11-22 Restart Xvfb...
<pre>2017-03-25_09-13-22 Restart Xvfb...
<pre>2017-03-25_09-15-22 Restart Xvfb...
<pre>2017-03-25_09-17-22 Restart Xvfb...
<pre>2017-03-25_09-19-22 Restart Xvfb...
<pre>2017-03-25_09-21-22 Restart Xvfb...
<pre>2017-03-25_09-23-22 Restart Xvfb...
<pre>2017-03-25_09-25-22 Restart Xvfb...
<pre>2017-03-25_09-27-22 Restart Xvfb...
<pre>2017-03-25_09-29-22 Restart Xvfb...
<pre>2017-03-25_09-31-22 Restart Xvfb...
<pre>2017-03-25_09-33-22 Restart Xvfb...
<pre>2017-03-25_09-35-22 Restart Xvfb...
<pre>2017-03-25_09-37-22 Restart Xvfb...
<pre>2017-03-25_09-39-22 Restart Xvfb...
<pre>2017-03-25_09-41-22 Restart Xvfb...
<pre>2017-03-25_09-43-22 Restart Xvfb...
<pre>2017-03-25_09-45-22 Restart Xvfb...
<pre>2017-03-25_09-47-22 Restart Xvfb...
<pre>2017-03-25_09-49-22 Restart Xvfb...
<pre>2017-03-25_09-51-22 Restart Xvfb...
<pre>2017-03-25_09-53-22 Restart Xvfb...
<pre>2017-03-25_09-55-22 Restart Xvfb...
2017-03-25 09:56:59 reset updateRequest
2017-03-25 09:57:01  - 23147  http://www.lymphomahub.com/
2017-03-25 09:57:04  - 23147  http://www.lymphomahub.com/
2017-03-25 09:57:06  - 23147  http://www.lymphomahub.com/about
2017-03-25 09:57:09  - 23147  http://www.lymphomahub.com/about
2017-03-25 09:57:12  - 23147  http://www.lymphomahub.com/terms
2017-03-25 09:57:13  - 23147  http://www.lymphomahub.com/terms
2017-03-25 09:57:16  - 23147  http://www.lymphomahub.com/undefined
2017-03-25 09:57:17  - 23147  http://www.lymphomahub.com/therapies
2017-03-25 09:57:17  - 23147  http://www.lymphomahub.com/therapies
<pre>2017-03-25_09-57-22 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies?_prerender {"code":"ECONNRESET"}
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies?_prerender {"code":"ECONNRESET"}
2017-03-25 09:59:22  - 23147  http://www.lymphomahub.com/therapies
2017-03-25 09:59:22  - 23147  http://www.lymphomahub.com/therapies
<pre>2017-03-25_09-59-22 Restart Xvfb...
2017-03-25 09:59:28  - 23147  http://www.lymphomahub.com/newsletter
2017-03-25 09:59:31  - 23147  http://www.lymphomahub.com/cookie-policy
2017-03-25 09:59:34  - 23147  http://www.lymphomahub.com/therapies/afm13
2017-03-25 09:59:38  - 23147  http://www.lymphomahub.com/therapies/afm11
2017-03-25 09:59:43  - 23147  http://www.lymphomahub.com/therapies/ags67e
2017-03-25 09:59:48  - 23147  http://www.lymphomahub.com/therapies/cc-292
2017-03-25 09:59:52  - 23147  http://www.lymphomahub.com/therapies/cc-223
2017-03-25 09:59:57  - 23147  http://www.lymphomahub.com/therapies/sd-101
2017-03-25 10:00:01  - 23147  http://www.lymphomahub.com/therapies/rp6530
2017-03-25 10:00:06  - 23147  http://www.lymphomahub.com/therapies/abt199
2017-03-25 10:00:07  - 23147  http://www.lymphomahub.com/therapies/mor208
2017-03-25 10:00:11  - 23147  http://www.lymphomahub.com/therapies/cc-122
2017-03-25 10:00:19  - 23147  http://www.lymphomahub.com/therapies/at-101
2017-03-25 10:00:23  - 23147  http://www.lymphomahub.com/therapies/bl8040
2017-03-25 10:00:28  - 23147  http://www.lymphomahub.com/therapies/bcl201
2017-03-25 10:00:32  - 23147  http://www.lymphomahub.com/therapies/azd3965
2017-03-25 10:00:37  - 23147  http://www.lymphomahub.com/therapies/imgn529
2017-03-25 10:00:42  - 23147  http://www.lymphomahub.com/therapies/azd2014
2017-03-25 10:00:51  - 23147  http://www.lymphomahub.com/therapies/mt-3724
2017-03-25 10:00:55  - 23147  http://www.lymphomahub.com/therapies/actr087
2017-03-25 10:01:00  - 23147  http://www.lymphomahub.com/therapies/epz6438
2017-03-25 10:01:05  - 23147  http://www.lymphomahub.com/therapies/kte-c19
2017-03-25 10:01:09  - 23147  http://www.lymphomahub.com/about/secretariat
2017-03-25 10:01:13  - 23147  http://www.lymphomahub.com/therapies/alt-803
2017-03-25 10:01:17  - 23147  http://www.lymphomahub.com/therapies/regn1979
2017-03-25 10:01:22  - 23147  http://www.lymphomahub.com/therapies/immu-114
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_10-01-22 Restart Xvfb...
2017-03-25 10:01:27  - 23147  http://www.lymphomahub.com/therapies/immu-114
2017-03-25 10:01:31  - 23147  http://www.lymphomahub.com/therapies/incb7839
2017-03-25 10:01:36  - 23147  http://www.lymphomahub.com/therapies/adct-301
2017-03-25 10:01:40  - 23147  http://www.lymphomahub.com/therapies/ixazomib
2017-03-25 10:01:45  - 23147  http://www.lymphomahub.com/therapies/avelumab
2017-03-25 10:01:49  - 23147  http://www.lymphomahub.com/therapies/bi836826
2017-03-25 10:01:53  - 23147  http://www.lymphomahub.com/therapies/medi-570
2017-03-25 10:01:58  - 23147  http://www.lymphomahub.com/therapies/ds-3201b
2017-03-25 10:02:02  - 23147  http://www.lymphomahub.com/therapies/sea-cd40
2017-03-25 10:02:07  - 23147  http://www.lymphomahub.com/therapies/adct-402
2017-03-25 10:02:11  - 23147  http://www.lymphomahub.com/therapies/acy-1215
2017-03-25 10:02:15  - 23147  http://www.lymphomahub.com/therapies/cudc-907
2017-03-25 10:02:20  - 23147  http://www.lymphomahub.com/therapies/tgr-1202
2017-03-25 10:02:25  - 23147  http://www.lymphomahub.com/therapies/axitinib
2017-03-25 10:02:30  - 23147  http://www.lymphomahub.com/therapies/imatinib
2017-03-25 10:02:34  - 23147  http://www.lymphomahub.com/therapies/edo-s101
2017-03-25 10:02:39  - 23147  http://www.lymphomahub.com/therapies/btct4465a
2017-03-25 10:02:43  - 23147  http://www.lymphomahub.com/therapies/alisertib
2017-03-25 10:02:48  - 23147  http://www.lymphomahub.com/therapies/lirilumab
2017-03-25 10:02:52  - 23147  http://www.lymphomahub.com/therapies/ibrutinib
2017-03-25 10:02:53  - 23147  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-03-25 10:02:57  - 23147  http://www.lymphomahub.com/therapies/rituximab
2017-03-25 10:03:02  - 23147  http://www.lymphomahub.com/therapies/veliparib
2017-03-25 10:03:06  - 23147  http://www.lymphomahub.com/therapies/sunitinib
2017-03-25 10:03:11  - 23147  http://www.lymphomahub.com/therapies/nivolumab
2017-03-25 10:03:11  - 23147  http://www.lymphomahub.com/therapies/sirolimus
2017-03-25 10:03:16  - 23147  http://www.lymphomahub.com/medical-information
2017-03-25 10:03:20  - 23147  http://www.lymphomahub.com/therapies/selinexor
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/immu-114?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_10-03-22 Restart Xvfb...
2017-03-25 10:03:27  - 23147  http://www.lymphomahub.com/therapies/selinexor
2017-03-25 10:03:31  - 23147  http://www.lymphomahub.com/therapies/abc294640
2017-03-25 10:03:35  - 23147  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-03-25 10:03:40  - 23147  http://www.lymphomahub.com/therapies/tenofovir
2017-03-25 10:03:44  - 23147  http://www.lymphomahub.com/therapies/betalutin
2017-03-25 10:03:49  - 23147  http://www.lymphomahub.com/therapies/chidamide
2017-03-25 10:03:53  - 23147  http://www.lymphomahub.com/therapies/duvelisib
2017-03-25 10:03:58  - 23147  http://www.lymphomahub.com/therapies/dasatinib
2017-03-25 10:04:02  - 23147  http://www.lymphomahub.com/therapies/everolimus
2017-03-25 10:04:07  - 23147  http://www.lymphomahub.com/therapies/incb039110
2017-03-25 10:04:11  - 23147  http://www.lymphomahub.com/therapies/durvalumab
2017-03-25 10:04:16  - 23147  http://www.lymphomahub.com/therapies/romidepsin
2017-03-25 10:04:21  - 23147  http://www.lymphomahub.com/therapies/bortezomib
2017-03-25 10:04:25  - 23147  http://www.lymphomahub.com/therapies/idelalisib
2017-03-25 10:04:26  - 23147  http://www.lymphomahub.com/therapies/tipifarnib
2017-03-25 10:04:31  - 23147  http://www.lymphomahub.com/therapies/ipilimumab
2017-03-25 10:04:35  - 23147  http://www.lymphomahub.com/therapies/crizotinib
2017-03-25 10:04:39  - 23147  http://www.lymphomahub.com/therapies/gsk2816126
2017-03-25 10:04:44  - 23147  http://www.lymphomahub.com/therapies/copanlisib
2017-03-25 10:04:48  - 23147  http://www.lymphomahub.com/therapies/buparlisib
2017-03-25 10:04:53  - 23147  http://www.lymphomahub.com/therapies/belinostat
2017-03-25 10:04:57  - 23147  http://www.lymphomahub.com/therapies/vorinostat
2017-03-25 10:05:02  - 23147  http://www.lymphomahub.com/therapies/plerixafor
2017-03-25 10:05:02  - 23147  http://www.lymphomahub.com/therapies/ofatumumab
2017-03-25 10:05:07  - 23147  http://www.lymphomahub.com/therapies/pf-06801591
2017-03-25 10:05:12  - 23147  http://www.lymphomahub.com/therapies/tocilizumab
2017-03-25 10:05:16  - 23147  http://www.lymphomahub.com/therapies/msc2490484a
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/selinexor?_prerender {"code":"ECONNRESET"}
2017-03-25 10:05:20  - 23147  http://www.lymphomahub.com/therapies/carfilzomib
<pre>2017-03-25_10-05-22 Restart Xvfb...
2017-03-25 10:05:25  - 23147  http://www.lymphomahub.com/therapies/carfilzomib
2017-03-25 10:05:30  - 23147  http://www.lymphomahub.com/therapies/ruxolitinib
2017-03-25 10:05:34  - 23147  http://www.lymphomahub.com/therapies/palbociclib
2017-03-25 10:05:39  - 23147  http://www.lymphomahub.com/therapies/fenretinide
2017-03-25 10:05:43  - 23147  http://www.lymphomahub.com/therapies/daratumumab
2017-03-25 10:05:48  - 23147  http://www.lymphomahub.com/therapies/pf-05082566
2017-03-25 10:05:53  - 23147  http://www.lymphomahub.com/therapies/ramucirumab
2017-03-25 10:05:57  - 23147  http://www.lymphomahub.com/therapies/tositumomab
2017-03-25 10:06:02  - 23147  http://www.lymphomahub.com/therapies/ublituximab
2017-03-25 10:06:06  - 23147  http://www.lymphomahub.com/therapies/epacadostat
2017-03-25 10:06:11  - 23147  http://www.lymphomahub.com/therapies/alemtuzumab
2017-03-25 10:06:11  - 23147  http://www.lymphomahub.com/therapies/otlertuzumab
2017-03-25 10:06:16  - 23147  http://www.lymphomahub.com/therapies/panobinostat
2017-03-25 10:06:20  - 23147  http://www.lymphomahub.com/therapies/mocetinostat
2017-03-25 10:06:24  - 23147  http://www.lymphomahub.com/therapies/atezolizumab
2017-03-25 10:06:29  - 23147  http://www.lymphomahub.com/therapies/temsirolimus
2017-03-25 10:06:33  - 23147  http://www.lymphomahub.com/therapies/lenalidomide
2017-03-25 10:06:38  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab
2017-03-25 10:06:43  - 23147  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-03-25 10:06:47  - 23147  http://www.lymphomahub.com/therapies/blinatumomab
2017-03-25 10:06:52  - 23147  http://www.lymphomahub.com/therapies/jnj-64052781
2017-03-25 10:06:57  - 23147  http://www.lymphomahub.com/therapies/entospletinib
2017-03-25 10:07:01  - 23147  http://www.lymphomahub.com/therapies/pembrolizumab
2017-03-25 10:07:06  - 23147  http://www.lymphomahub.com/therapies/acalabrutinib
2017-03-25 10:07:10  - 23147  http://www.lymphomahub.com/about/innovation-committee
2017-03-25 10:07:14  - 23147  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-03-25 10:07:14  - 23147  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-03-25 10:07:19  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/carfilzomib?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_10-07-23 Restart Xvfb...
2017-03-25 10:07:25  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-03-25 10:07:29  - 23147  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-03-25 10:07:34  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-03-25 10:07:39  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-03-25 10:07:39  - 23147  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-03-25 10:07:44  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-03-25 10:07:48  - 23147  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-03-25 10:07:53  - 23147  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-03-25 10:07:57  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board
2017-03-25 10:08:01  - 23147  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-03-25 10:08:05  - 23147  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-03-25 10:08:09  - 23147  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-03-25 10:08:13  - 23147  http://www.lymphomahub.com/about/executive-steering-committee
2017-03-25 10:08:16  - 23147  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-03-25 10:08:20  - 23147  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-03-25 10:08:25  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-03-25 10:08:29  - 23147  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-03-25 10:08:33  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-03-25 10:08:38  - 23147  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-03-25 10:08:42  - 23147  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-03-25 10:08:43  - 23147  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-03-25 10:08:46  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-03-25 10:08:51  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-03-25 10:08:56  - 23147  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-03-25 10:09:00  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-03-25 10:09:05  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-03-25 10:09:10  - 23147  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-03-25 10:09:13  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-03-25 10:09:17  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/interferon-alpha-2a?_prerender {"code":"ECONNRESET"}
2017-03-25 10:09:21  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
<pre>2017-03-25_10-09-23 Restart Xvfb...
2017-03-25 10:09:24  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-03-25 10:09:28  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-03-25 10:09:32  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-03-25 10:09:35  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-03-25 10:09:39  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-03-25 10:09:43  - 23147  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-03-25 10:09:48  - 23147  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-03-25 10:09:52  - 23147  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-03-25 10:09:57  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-03-25 10:10:00  - 23147  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-03-25 10:10:04  - 23147  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-03-25 10:10:08  - 23147  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-03-25 10:10:13  - 23147  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-03-25 10:10:18  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-03-25 10:10:21  - 23147  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-03-25 10:10:26  - 23147  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-03-25 10:10:30  - 23147  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-03-25 10:10:35  - 23147  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-03-25 10:10:40  - 23147  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-03-25 10:10:44  - 23147  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-03-25 10:10:49  - 23147  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-03-25 10:10:53  - 23147  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-03-25 10:10:58  - 23147  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-03-25 10:11:02  - 23147  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-03-25 10:11:07  - 23147  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-03-25 10:11:11  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-03-25 10:11:15  - 23147  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-03-25 10:11:19  - 23147  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_10-11-23 Restart Xvfb...
2017-03-25 10:11:26  - 23147  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-03-25 10:11:29  - 23147  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-03-25 10:11:34  - 23147  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-03-25 10:11:38  - 23147  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-03-25 10:11:42  - 23147  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-03-25 10:11:46  - 23147  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-03-25 10:11:51  - 23147  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-03-25 10:11:55  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-03-25 10:11:59  - 23147  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-03-25 10:12:04  - 23147  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-03-25 10:12:08  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-03-25 10:12:13  - 23147  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-03-25 10:12:18  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-03-25 10:12:22  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-03-25 10:12:25  - 23147  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-03-25 10:12:30  - 23147  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-03-25 10:12:35  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-03-25 10:12:39  - 23147  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-03-25 10:12:43  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-03-25 10:12:48  - 23147  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-03-25 10:12:53  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-03-25 10:12:57  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-03-25 10:13:02  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-03-25 10:13:06  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-03-25 10:13:10  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-03-25 10:13:14  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-03-25 10:13:18  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/?_prerender {"code":"ECONNRESET"}
2017-03-25 10:13:21  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
<pre>2017-03-25_10-13-23 Restart Xvfb...
2017-03-25 10:13:24  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-03-25 10:13:29  - 23147  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-03-25 10:13:34  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-03-25 10:13:39  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-03-25 10:13:43  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-03-25 10:13:48  - 23147  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-25 10:13:48  - 23147  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-03-25 10:13:53  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-03-25 10:13:57  - 23147  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-03-25 10:14:02  - 23147  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-03-25 10:14:07  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-03-25 10:14:11  - 23147  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-03-25 10:14:16  - 23147  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-03-25 10:14:21  - 23147  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-03-25 10:14:26  - 23147  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-03-25 10:14:30  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-03-25 10:14:35  - 23147  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-03-25 10:14:40  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-03-25 10:14:44  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-03-25 10:14:49  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-03-25 10:14:53  - 23147  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-03-25 10:14:58  - 23147  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-03-25 10:15:03  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-03-25 10:15:08  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-03-25 10:15:12  - 23147  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-03-25 10:15:17  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc?_prerender {"code":"ECONNRESET"}
2017-03-25 10:15:22  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
<pre>2017-03-25_10-15-23 Restart Xvfb...
2017-03-25 10:15:26  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-03-25 10:15:31  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-03-25 10:15:36  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-03-25 10:15:41  - 23147  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-25 10:15:45  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-03-25 10:15:50  - 23147  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-03-25 10:15:55  - 23147  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-03-25 10:15:59  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-03-25 10:16:04  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-03-25 10:16:08  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-03-25 10:16:13  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-03-25 10:16:18  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-03-25 10:16:22  - 23147  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-03-25 10:16:27  - 23147  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-03-25 10:16:32  - 23147  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-03-25 10:16:36  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-03-25 10:16:41  - 23147  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-03-25 10:16:45  - 23147  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-03-25 10:16:50  - 23147  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-03-25 10:16:51  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-03-25 10:16:55  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-03-25 10:17:00  - 23147  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-03-25 10:17:05  - 23147  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-03-25 10:17:10  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-03-25 10:17:14  - 23147  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-03-25 10:17:19  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_10-17-23 Restart Xvfb...
2017-03-25 10:17:27  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-03-25 10:17:31  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-03-25 10:17:36  - 23147  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-03-25 10:17:41  - 23147  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-03-25 10:17:45  - 23147  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-03-25 10:17:50  - 23147  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-03-25 10:17:54  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-03-25 10:17:59  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-03-25 10:18:04  - 23147  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-03-25 10:18:09  - 23147  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-03-25 10:18:13  - 23147  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-03-25 10:18:18  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-03-25 10:18:23  - 23147  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-03-25 10:18:27  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-03-25 10:18:32  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-03-25 10:18:36  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-03-25 10:18:41  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-03-25 10:18:45  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-03-25 10:18:49  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-03-25 10:18:53  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-03-25 10:18:57  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-03-25 10:19:01  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-03-25 10:19:05  - 23147  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-03-25 10:19:06  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-03-25 10:19:10  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-03-25 10:19:15  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-03-25 10:19:19  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct?_prerender {"code":"ECONNRESET"}
2017-03-25 10:19:22  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
<pre>2017-03-25_10-19-23 Restart Xvfb...
2017-03-25 10:19:24  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-03-25 10:19:28  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-03-25 10:19:31  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-03-25 10:19:35  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-03-25 10:19:38  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-03-25 10:19:42  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-03-25 10:19:45  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-03-25 10:19:49  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-03-25 10:19:53  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-03-25 10:19:56  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-03-25 10:20:00  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-03-25 10:20:03  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-03-25 10:20:08  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-03-25 10:20:12  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-03-25 10:20:16  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-03-25 10:20:19  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-03-25 10:20:23  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-03-25 10:20:26  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-03-25 10:20:30  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-03-25 10:20:34  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-03-25 10:20:37  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-03-25 10:20:41  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-03-25 10:20:44  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-03-25 10:20:48  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-03-25 10:20:52  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-03-25 10:20:55  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-03-25 10:20:59  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-03-25 10:21:03  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-03-25 10:21:06  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-03-25 10:21:10  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-03-25 10:21:14  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-03-25 10:21:17  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-03-25 10:21:21  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_10-21-23 Restart Xvfb...
2017-03-25 10:21:27  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-03-25 10:21:31  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-03-25 10:21:35  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-03-25 10:21:38  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-03-25 10:21:42  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-03-25 10:21:46  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-03-25 10:21:49  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-03-25 10:21:53  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-03-25 10:21:57  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-03-25 10:22:00  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-03-25 10:22:04  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-03-25 10:22:08  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-03-25 10:22:11  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-03-25 10:22:15  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-03-25 10:22:20  - 23147  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-03-25 10:22:25  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-03-25 10:22:29  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-03-25 10:22:34  - 23147  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-03-25 10:22:35  - 23147  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-03-25 10:22:39  - 23147  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-03-25 10:22:44  - 23147  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-03-25 10:22:49  - 23147  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-03-25 10:22:54  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-03-25 10:22:59  - 23147  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-03-25 10:23:04  - 23147  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-03-25 10:23:09  - 23147  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-03-25 10:23:13  - 23147  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-03-25 10:23:18  - 23147  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/?_prerender {"code":"ECONNRESET"}
2017-03-25 10:23:22  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
<pre>2017-03-25_10-23-23 Restart Xvfb...
2017-03-25 10:23:26  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-03-25 10:23:31  - 23147  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-03-25 10:23:35  - 23147  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-03-25 10:23:40  - 23147  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-03-25 10:23:45  - 23147  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-03-25 10:23:49  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-03-25 10:23:54  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-03-25 10:23:59  - 23147  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-03-25 10:24:03  - 23147  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-03-25 10:24:08  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-03-25 10:24:13  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-03-25 10:24:17  - 23147  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-25 10:24:22  - 23147  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-03-25 10:24:26  - 23147  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-03-25 10:24:31  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-03-25 10:24:35  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-03-25 10:24:40  - 23147  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-03-25 10:24:45  - 23147  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-03-25 10:24:49  - 23147  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-03-25 10:24:54  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-03-25 10:24:58  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-03-25 10:25:05  - 23147  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-25 10:25:09  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-03-25 10:25:14  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-03-25 10:25:19  - 23147  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_10-25-23 Restart Xvfb...
2017-03-25 10:25:27  - 23147  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-03-25 10:25:32  - 23147  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-03-25 10:25:36  - 23147  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-03-25 10:25:41  - 23147  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-03-25 10:25:45  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-03-25 10:25:50  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-03-25 10:25:55  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-03-25 10:25:59  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-03-25 10:26:04  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-03-25 10:26:08  - 23147  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-03-25 10:26:13  - 23147  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-03-25 10:26:18  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-03-25 10:26:23  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-03-25 10:26:27  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-03-25 10:26:31  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-03-25 10:26:36  - 23147  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-03-25 10:26:41  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-03-25 10:26:45  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-03-25 10:26:50  - 23147  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-03-25 10:26:54  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-03-25 10:26:59  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-03-25 10:27:04  - 23147  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-03-25 10:27:09  - 23147  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-03-25 10:27:13  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-03-25 10:27:18  - 23147  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501?_prerender {"code":"ECONNRESET"}
2017-03-25 10:27:23  - 23147  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
<pre>2017-03-25_10-27-23 Restart Xvfb...
2017-03-25 10:27:24  - 23147  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-03-25 10:27:28  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-03-25 10:27:29  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-03-25 10:27:33  - 23147  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-03-25 10:27:34  - 23147  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-03-25 10:27:40  - 23147  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-03-25 10:27:40  - 23147  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-03-25 10:27:45  - 23147  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-03-25 10:27:45  - 23147  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-03-25 10:27:50  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-03-25 10:27:50  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-03-25 10:27:56  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-03-25 10:28:01  - 23147  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-03-25 10:28:05  - 23147  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-03-25 10:28:10  - 23147  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-03-25 10:28:15  - 23147  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-03-25 10:28:19  - 23147  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-03-25 10:28:24  - 23147  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-03-25 10:28:29  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-03-25 10:28:34  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-03-25 10:28:38  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-03-25 10:28:43  - 23147  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-03-25 10:28:47  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-03-25 10:28:51  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-03-25 10:28:56  - 23147  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-03-25 10:29:01  - 23147  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-03-25 10:29:05  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-03-25 10:29:10  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-03-25 10:29:14  - 23147  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-03-25 10:29:19  - 23147  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
<pre>2017-03-25_10-29-23 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_10-31-23 Restart Xvfb...
2017-03-25 10:31:24  - 23147  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-03-25 10:31:28  - 23147  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-03-25 10:31:33  - 23147  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-03-25 10:31:37  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-03-25 10:31:42  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-03-25 10:31:47  - 23147  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-03-25 10:31:52  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-03-25 10:31:57  - 23147  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-03-25 10:32:01  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-03-25 10:32:06  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-03-25 10:32:11  - 23147  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-03-25 10:32:15  - 23147  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-03-25 10:32:20  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-03-25 10:32:25  - 23147  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-03-25 10:32:29  - 23147  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-03-25 10:32:34  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-03-25 10:32:38  - 23147  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-03-25 10:32:43  - 23147  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-03-25 10:32:47  - 23147  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-03-25 10:32:52  - 23147  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-03-25 10:32:57  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-03-25 10:33:01  - 23147  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-03-25 10:33:06  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-03-25 10:33:10  - 23147  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-03-25 10:33:15  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-03-25 10:33:20  - 23147  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
<pre>2017-03-25_10-33-23 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_10-35-23 Restart Xvfb...
2017-03-25 10:35:25  - 23147  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-03-25 10:35:29  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-03-25 10:35:34  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-03-25 10:35:38  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-03-25 10:35:43  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-03-25 10:35:48  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-03-25 10:35:53  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-03-25 10:35:58  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-03-25 10:36:03  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-03-25 10:36:07  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-03-25 10:36:12  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-03-25 10:36:17  - 23147  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-03-25 10:36:21  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-03-25 10:36:25  - 23147  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-03-25 10:36:30  - 23147  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-03-25 10:36:34  - 23147  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-03-25 10:36:39  - 23147  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-03-25 10:36:43  - 23147  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-03-25 10:36:48  - 23147  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-03-25 10:36:53  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-03-25 10:36:57  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-03-25 10:37:02  - 23147  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-03-25 10:37:07  - 23147  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-03-25 10:37:11  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-03-25 10:37:16  - 23147  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-03-25 10:37:21  - 23147  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
<pre>2017-03-25_10-37-23 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_10-39-23 Restart Xvfb...
2017-03-25 10:39:26  - 23147  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-03-25 10:39:31  - 23147  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-03-25 10:39:36  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-03-25 10:39:40  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-03-25 10:39:45  - 23147  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-03-25 10:39:50  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-03-25 10:39:54  - 23147  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-03-25 10:39:59  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-03-25 10:40:04  - 23147  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-03-25 10:40:08  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-03-25 10:40:13  - 23147  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-03-25 10:40:18  - 23147  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-03-25 10:40:22  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-03-25 10:40:26  - 23147  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-03-25 10:40:30  - 23147  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-03-25 10:40:35  - 23147  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-03-25 10:40:39  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-03-25 10:40:44  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-03-25 10:40:48  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-03-25 10:40:53  - 23147  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-03-25 10:40:57  - 23147  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-03-25 10:41:02  - 23147  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-03-25 10:41:07  - 23147  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-03-25 10:41:11  - 23147  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-03-25 10:41:15  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-03-25 10:41:19  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
<pre>2017-03-25_10-41-23 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_10-43-23 Restart Xvfb...
2017-03-25 10:43:24  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-03-25 10:43:28  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-03-25 10:43:33  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-03-25 10:43:37  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-03-25 10:43:41  - 23147  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-03-25 10:43:46  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-03-25 10:43:51  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-03-25 10:43:55  - 23147  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-03-25 10:44:00  - 23147  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-03-25 10:44:04  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-03-25 10:44:08  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-03-25 10:44:12  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-03-25 10:44:17  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-03-25 10:44:22  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-03-25 10:44:26  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-03-25 10:44:31  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-03-25 10:44:35  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-03-25 10:44:40  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-03-25 10:44:44  - 23147  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-03-25 10:44:49  - 23147  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-03-25 10:44:53  - 23147  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-03-25 10:44:57  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-03-25 10:45:02  - 23147  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-03-25 10:45:06  - 23147  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-03-25 10:45:11  - 23147  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-03-25 10:45:16  - 23147  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-03-25 10:45:20  - 23147  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
<pre>2017-03-25_10-45-23 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_10-47-23 Restart Xvfb...
2017-03-25 10:47:25  - 23147  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-03-25 10:47:29  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-03-25 10:47:34  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-03-25 10:47:39  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-03-25 10:47:44  - 23147  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-03-25 10:47:48  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-03-25 10:47:53  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-03-25 10:47:58  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-03-25 10:48:02  - 23147  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-03-25 10:48:07  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-03-25 10:48:11  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-03-25 10:48:15  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-03-25 10:48:19  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-03-25 10:48:24  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-03-25 10:48:29  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-03-25 10:48:33  - 23147  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-03-25 10:48:37  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-03-25 10:48:42  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-03-25 10:48:46  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-03-25 10:48:50  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-03-25 10:48:55  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-03-25 10:49:00  - 23147  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-03-25 10:49:04  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-03-25 10:49:08  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-03-25 10:49:13  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-03-25 10:49:17  - 23147  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-03-25 10:49:22  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
<pre>2017-03-25_10-49-23 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_10-51-23 Restart Xvfb...
2017-03-25 10:51:27  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-03-25 10:51:32  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-03-25 10:51:36  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-03-25 10:51:41  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-03-25 10:51:45  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-03-25 10:51:49  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-03-25 10:51:53  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-03-25 10:51:58  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-03-25 10:52:02  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-03-25 10:52:07  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-03-25 10:52:11  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-03-25 10:52:15  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-03-25 10:52:19  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-03-25 10:52:23  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-03-25 10:52:28  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-03-25 10:52:32  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-03-25 10:52:36  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-03-25 10:52:40  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-03-25 10:52:45  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-03-25 10:52:49  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-03-25 10:52:53  - 23147  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-03-25 10:52:57  - 23147  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-03-25 10:53:01  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-03-25 10:53:06  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-03-25 10:53:11  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-03-25 10:53:15  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-03-25 10:53:20  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
<pre>2017-03-25_10-53-23 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_10-55-23 Restart Xvfb...
2017-03-25 10:55:25  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-03-25 10:55:29  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-03-25 10:55:34  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-03-25 10:55:38  - 23147  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-03-25 10:55:42  - 23147  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-03-25 10:55:46  - 23147  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-03-25 10:55:50  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-03-25 10:55:55  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-03-25 10:56:00  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-03-25 10:56:04  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-03-25 10:56:08  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-03-25 10:56:12  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-25 10:56:16  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-25 10:56:20  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-25 10:56:24  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-25 10:56:28  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-03-25 10:56:32  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-25 10:56:36  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-25 10:56:40  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-03-25 10:56:44  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-03-25 10:56:48  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-03-25 10:56:52  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-03-25 10:56:57  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-03-25 10:57:01  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-03-25 10:57:05  - 23147  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-03-25 10:57:09  - 23147  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-03-25 10:57:13  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-03-25 10:57:17  - 23147  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-03-25 10:57:22  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
<pre>2017-03-25_10-57-23 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_10-59-23 Restart Xvfb...
2017-03-25 10:59:27  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-03-25 10:59:31  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-03-25 10:59:35  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-03-25 10:59:40  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-03-25 10:59:44  - 23147  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-03-25 10:59:48  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-03-25 10:59:52  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-03-25 10:59:56  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-03-25 11:00:00  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-03-25 11:00:05  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-03-25 11:00:09  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-25 11:00:14  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-25 11:00:18  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-25 11:00:23  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-25 11:00:27  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-25 11:00:31  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-03-25 11:00:35  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-25 11:00:39  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-25 11:00:43  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-25 11:00:47  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-25 11:00:51  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-03-25 11:00:55  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-25 11:01:00  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-25 11:01:04  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-25 11:01:08  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-03-25 11:01:12  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
<pre>2017-03-25_11-01-23 Restart Xvfb...
<pre>2017-03-25_11-03-23 Restart Xvfb...
<pre>2017-03-25_11-05-23 Restart Xvfb...
<pre>2017-03-25_11-07-23 Restart Xvfb...
<pre>2017-03-25_11-09-23 Restart Xvfb...
<pre>2017-03-25_11-11-23 Restart Xvfb...
<pre>2017-03-25_11-13-23 Restart Xvfb...
<pre>2017-03-25_11-15-23 Restart Xvfb...
<pre>2017-03-25_11-17-24 Restart Xvfb...
<pre>2017-03-25_11-19-24 Restart Xvfb...
<pre>2017-03-25_11-21-24 Restart Xvfb...
<pre>2017-03-25_11-23-24 Restart Xvfb...
<pre>2017-03-25_11-25-24 Restart Xvfb...
<pre>2017-03-25_11-27-24 Restart Xvfb...
<pre>2017-03-25_11-29-24 Restart Xvfb...
<pre>2017-03-25_11-31-24 Restart Xvfb...
<pre>2017-03-25_11-33-24 Restart Xvfb...
<pre>2017-03-25_11-35-24 Restart Xvfb...
<pre>2017-03-25_11-37-24 Restart Xvfb...
<pre>2017-03-25_11-39-24 Restart Xvfb...
<pre>2017-03-25_11-41-24 Restart Xvfb...
<pre>2017-03-25_11-43-24 Restart Xvfb...
<pre>2017-03-25_11-45-24 Restart Xvfb...
<pre>2017-03-25_11-47-24 Restart Xvfb...
<pre>2017-03-25_11-49-24 Restart Xvfb...
<pre>2017-03-25_11-51-24 Restart Xvfb...
<pre>2017-03-25_11-53-24 Restart Xvfb...
<pre>2017-03-25_11-55-24 Restart Xvfb...
<pre>2017-03-25_11-57-24 Restart Xvfb...
<pre>2017-03-25_11-59-24 Restart Xvfb...
<pre>2017-03-25_12-01-24 Restart Xvfb...
<pre>2017-03-25_12-03-24 Restart Xvfb...
<pre>2017-03-25_12-05-24 Restart Xvfb...
<pre>2017-03-25_12-07-24 Restart Xvfb...
<pre>2017-03-25_12-09-24 Restart Xvfb...
<pre>2017-03-25_12-11-24 Restart Xvfb...
<pre>2017-03-25_12-13-24 Restart Xvfb...
<pre>2017-03-25_12-15-24 Restart Xvfb...
<pre>2017-03-25_12-17-24 Restart Xvfb...
<pre>2017-03-25_12-19-24 Restart Xvfb...
<pre>2017-03-25_12-21-24 Restart Xvfb...
<pre>2017-03-25_12-23-24 Restart Xvfb...
<pre>2017-03-25_12-25-24 Restart Xvfb...
<pre>2017-03-25_12-27-24 Restart Xvfb...
<pre>2017-03-25_12-29-24 Restart Xvfb...
<pre>2017-03-25_12-31-24 Restart Xvfb...
<pre>2017-03-25_12-33-24 Restart Xvfb...
<pre>2017-03-25_12-35-24 Restart Xvfb...
<pre>2017-03-25_12-37-24 Restart Xvfb...
<pre>2017-03-25_12-39-24 Restart Xvfb...
<pre>2017-03-25_12-41-24 Restart Xvfb...
<pre>2017-03-25_12-43-24 Restart Xvfb...
<pre>2017-03-25_12-45-24 Restart Xvfb...
<pre>2017-03-25_12-47-24 Restart Xvfb...
<pre>2017-03-25_12-49-24 Restart Xvfb...
<pre>2017-03-25_12-51-24 Restart Xvfb...
<pre>2017-03-25_12-53-24 Restart Xvfb...
<pre>2017-03-25_12-55-24 Restart Xvfb...
2017-03-25 12:56:59 reset updateRequest
2017-03-25 12:57:01  - 23147  http://www.lymphomahub.com/
2017-03-25 12:57:04  - 23147  http://www.lymphomahub.com/
2017-03-25 12:57:05  - 23147  http://www.lymphomahub.com/about
2017-03-25 12:57:09  - 23147  http://www.lymphomahub.com/about
2017-03-25 12:57:13  - 23147  http://www.lymphomahub.com/terms
2017-03-25 12:57:14  - 23147  http://www.lymphomahub.com/terms
2017-03-25 12:57:18  - 23147  http://www.lymphomahub.com/undefined
2017-03-25 12:57:18  - 23147  http://www.lymphomahub.com/undefined
2017-03-25 12:57:18  - 23147  http://www.lymphomahub.com/therapies
2017-03-25 12:57:24  - 23147  http://www.lymphomahub.com/newsletter
<pre>2017-03-25_12-57-24 Restart Xvfb...
2017-03-25 12:57:27  - 23147  http://www.lymphomahub.com/cookie-policy
2017-03-25 12:57:31  - 23147  http://www.lymphomahub.com/therapies/afm13
2017-03-25 12:57:35  - 23147  http://www.lymphomahub.com/therapies/afm11
2017-03-25 12:57:40  - 23147  http://www.lymphomahub.com/therapies/ags67e
2017-03-25 12:57:44  - 23147  http://www.lymphomahub.com/therapies/cc-292
2017-03-25 12:57:49  - 23147  http://www.lymphomahub.com/therapies/cc-223
2017-03-25 12:57:53  - 23147  http://www.lymphomahub.com/therapies/sd-101
2017-03-25 12:57:58  - 23147  http://www.lymphomahub.com/therapies/rp6530
2017-03-25 12:58:02  - 23147  http://www.lymphomahub.com/therapies/abt199
2017-03-25 12:58:03  - 23147  http://www.lymphomahub.com/therapies/mor208
2017-03-25 12:58:07  - 23147  http://www.lymphomahub.com/therapies/cc-122
2017-03-25 12:58:11  - 23147  http://www.lymphomahub.com/therapies/at-101
2017-03-25 12:58:16  - 23147  http://www.lymphomahub.com/therapies/bl8040
2017-03-25 12:58:21  - 23147  http://www.lymphomahub.com/therapies/bcl201
2017-03-25 12:58:25  - 23147  http://www.lymphomahub.com/therapies/azd3965
2017-03-25 12:58:30  - 23147  http://www.lymphomahub.com/therapies/imgn529
2017-03-25 12:58:34  - 23147  http://www.lymphomahub.com/therapies/azd2014
2017-03-25 12:58:38  - 23147  http://www.lymphomahub.com/therapies/mt-3724
2017-03-25 12:58:43  - 23147  http://www.lymphomahub.com/therapies/actr087
2017-03-25 12:58:48  - 23147  http://www.lymphomahub.com/therapies/epz6438
2017-03-25 12:58:52  - 23147  http://www.lymphomahub.com/therapies/kte-c19
2017-03-25 12:58:56  - 23147  http://www.lymphomahub.com/about/secretariat
2017-03-25 12:59:00  - 23147  http://www.lymphomahub.com/therapies/alt-803
2017-03-25 12:59:04  - 23147  http://www.lymphomahub.com/therapies/regn1979
2017-03-25 12:59:09  - 23147  http://www.lymphomahub.com/therapies/immu-114
2017-03-25 12:59:13  - 23147  http://www.lymphomahub.com/therapies/incb7839
2017-03-25 12:59:18  - 23147  http://www.lymphomahub.com/therapies/adct-301
2017-03-25 12:59:22  - 23147  http://www.lymphomahub.com/therapies/ixazomib
<pre>2017-03-25_12-59-24 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/ixazomib?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_13-01-25 Restart Xvfb...
2017-03-25 13:01:27  - 23147  http://www.lymphomahub.com/therapies/ixazomib
2017-03-25 13:01:32  - 23147  http://www.lymphomahub.com/therapies/avelumab
2017-03-25 13:01:36  - 23147  http://www.lymphomahub.com/therapies/bi836826
2017-03-25 13:01:40  - 23147  http://www.lymphomahub.com/therapies/medi-570
2017-03-25 13:01:45  - 23147  http://www.lymphomahub.com/therapies/ds-3201b
2017-03-25 13:01:49  - 23147  http://www.lymphomahub.com/therapies/sea-cd40
2017-03-25 13:01:54  - 23147  http://www.lymphomahub.com/therapies/adct-402
2017-03-25 13:01:58  - 23147  http://www.lymphomahub.com/therapies/acy-1215
2017-03-25 13:02:03  - 23147  http://www.lymphomahub.com/therapies/cudc-907
2017-03-25 13:02:07  - 23147  http://www.lymphomahub.com/therapies/tgr-1202
2017-03-25 13:02:12  - 23147  http://www.lymphomahub.com/therapies/axitinib
2017-03-25 13:02:16  - 23147  http://www.lymphomahub.com/therapies/imatinib
2017-03-25 13:02:20  - 23147  http://www.lymphomahub.com/therapies/edo-s101
2017-03-25 13:02:25  - 23147  http://www.lymphomahub.com/therapies/btct4465a
2017-03-25 13:02:30  - 23147  http://www.lymphomahub.com/therapies/alisertib
2017-03-25 13:02:34  - 23147  http://www.lymphomahub.com/therapies/lirilumab
2017-03-25 13:02:38  - 23147  http://www.lymphomahub.com/therapies/ibrutinib
2017-03-25 13:02:39  - 23147  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-03-25 13:02:44  - 23147  http://www.lymphomahub.com/therapies/rituximab
2017-03-25 13:02:48  - 23147  http://www.lymphomahub.com/therapies/veliparib
2017-03-25 13:02:52  - 23147  http://www.lymphomahub.com/therapies/sunitinib
2017-03-25 13:02:57  - 23147  http://www.lymphomahub.com/therapies/nivolumab
2017-03-25 13:02:58  - 23147  http://www.lymphomahub.com/therapies/sirolimus
2017-03-25 13:03:02  - 23147  http://www.lymphomahub.com/medical-information
2017-03-25 13:03:06  - 23147  http://www.lymphomahub.com/therapies/selinexor
2017-03-25 13:03:10  - 23147  http://www.lymphomahub.com/therapies/abc294640
2017-03-25 13:03:14  - 23147  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-03-25 13:03:19  - 23147  http://www.lymphomahub.com/therapies/tenofovir
2017-03-25 13:03:23  - 23147  http://www.lymphomahub.com/therapies/betalutin
<pre>2017-03-25_13-03-25 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/betalutin?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_13-05-25 Restart Xvfb...
2017-03-25 13:05:28  - 23147  http://www.lymphomahub.com/therapies/betalutin
2017-03-25 13:05:33  - 23147  http://www.lymphomahub.com/therapies/chidamide
2017-03-25 13:05:37  - 23147  http://www.lymphomahub.com/therapies/duvelisib
2017-03-25 13:05:42  - 23147  http://www.lymphomahub.com/therapies/dasatinib
2017-03-25 13:05:46  - 23147  http://www.lymphomahub.com/therapies/everolimus
2017-03-25 13:05:51  - 23147  http://www.lymphomahub.com/therapies/incb039110
2017-03-25 13:05:55  - 23147  http://www.lymphomahub.com/therapies/durvalumab
2017-03-25 13:06:00  - 23147  http://www.lymphomahub.com/therapies/romidepsin
2017-03-25 13:06:04  - 23147  http://www.lymphomahub.com/therapies/bortezomib
2017-03-25 13:06:09  - 23147  http://www.lymphomahub.com/therapies/idelalisib
2017-03-25 13:06:09  - 23147  http://www.lymphomahub.com/therapies/tipifarnib
2017-03-25 13:06:14  - 23147  http://www.lymphomahub.com/therapies/ipilimumab
2017-03-25 13:06:19  - 23147  http://www.lymphomahub.com/therapies/crizotinib
2017-03-25 13:06:23  - 23147  http://www.lymphomahub.com/therapies/gsk2816126
2017-03-25 13:06:27  - 23147  http://www.lymphomahub.com/therapies/copanlisib
2017-03-25 13:06:32  - 23147  http://www.lymphomahub.com/therapies/buparlisib
2017-03-25 13:06:37  - 23147  http://www.lymphomahub.com/therapies/belinostat
2017-03-25 13:06:41  - 23147  http://www.lymphomahub.com/therapies/vorinostat
2017-03-25 13:06:45  - 23147  http://www.lymphomahub.com/therapies/plerixafor
2017-03-25 13:06:46  - 23147  http://www.lymphomahub.com/therapies/ofatumumab
2017-03-25 13:06:51  - 23147  http://www.lymphomahub.com/therapies/pf-06801591
2017-03-25 13:06:55  - 23147  http://www.lymphomahub.com/therapies/tocilizumab
2017-03-25 13:07:00  - 23147  http://www.lymphomahub.com/therapies/msc2490484a
2017-03-25 13:07:04  - 23147  http://www.lymphomahub.com/therapies/carfilzomib
2017-03-25 13:07:09  - 23147  http://www.lymphomahub.com/therapies/ruxolitinib
2017-03-25 13:07:13  - 23147  http://www.lymphomahub.com/therapies/palbociclib
2017-03-25 13:07:18  - 23147  http://www.lymphomahub.com/therapies/fenretinide
2017-03-25 13:07:22  - 23147  http://www.lymphomahub.com/therapies/daratumumab
<pre>2017-03-25_13-07-25 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/daratumumab?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_13-09-25 Restart Xvfb...
2017-03-25 13:09:27  - 23147  http://www.lymphomahub.com/therapies/daratumumab
2017-03-25 13:09:31  - 23147  http://www.lymphomahub.com/therapies/pf-05082566
2017-03-25 13:09:35  - 23147  http://www.lymphomahub.com/therapies/ramucirumab
2017-03-25 13:09:40  - 23147  http://www.lymphomahub.com/therapies/tositumomab
2017-03-25 13:09:44  - 23147  http://www.lymphomahub.com/therapies/ublituximab
2017-03-25 13:09:49  - 23147  http://www.lymphomahub.com/therapies/epacadostat
2017-03-25 13:09:53  - 23147  http://www.lymphomahub.com/therapies/alemtuzumab
2017-03-25 13:09:54  - 23147  http://www.lymphomahub.com/therapies/otlertuzumab
2017-03-25 13:09:58  - 23147  http://www.lymphomahub.com/therapies/panobinostat
2017-03-25 13:10:03  - 23147  http://www.lymphomahub.com/therapies/mocetinostat
2017-03-25 13:10:08  - 23147  http://www.lymphomahub.com/therapies/atezolizumab
2017-03-25 13:10:12  - 23147  http://www.lymphomahub.com/therapies/temsirolimus
2017-03-25 13:10:16  - 23147  http://www.lymphomahub.com/therapies/lenalidomide
2017-03-25 13:10:21  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab
2017-03-25 13:10:25  - 23147  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-03-25 13:10:30  - 23147  http://www.lymphomahub.com/therapies/blinatumomab
2017-03-25 13:10:34  - 23147  http://www.lymphomahub.com/therapies/jnj-64052781
2017-03-25 13:10:39  - 23147  http://www.lymphomahub.com/therapies/entospletinib
2017-03-25 13:10:44  - 23147  http://www.lymphomahub.com/therapies/pembrolizumab
2017-03-25 13:10:48  - 23147  http://www.lymphomahub.com/therapies/acalabrutinib
2017-03-25 13:10:53  - 23147  http://www.lymphomahub.com/about/innovation-committee
2017-03-25 13:10:56  - 23147  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-03-25 13:10:57  - 23147  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-03-25 13:11:01  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-03-25 13:11:06  - 23147  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-03-25 13:11:10  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-03-25 13:11:14  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-03-25 13:11:15  - 23147  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-03-25 13:11:20  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-03-25 13:11:24  - 23147  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
<pre>2017-03-25_13-11-25 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_13-13-25 Restart Xvfb...
2017-03-25 13:13:29  - 23147  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-03-25 13:13:33  - 23147  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-03-25 13:13:38  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board
2017-03-25 13:13:42  - 23147  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-03-25 13:13:47  - 23147  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-03-25 13:13:50  - 23147  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-03-25 13:13:54  - 23147  http://www.lymphomahub.com/about/executive-steering-committee
2017-03-25 13:13:58  - 23147  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-03-25 13:14:02  - 23147  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-03-25 13:14:07  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-03-25 13:14:11  - 23147  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-03-25 13:14:15  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-03-25 13:14:20  - 23147  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-03-25 13:14:24  - 23147  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-03-25 13:14:24  - 23147  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-03-25 13:14:28  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-03-25 13:14:33  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-03-25 13:14:38  - 23147  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-03-25 13:14:42  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-03-25 13:14:48  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-03-25 13:14:52  - 23147  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-03-25 13:14:56  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-03-25 13:15:00  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-03-25 13:15:04  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-03-25 13:15:08  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-03-25 13:15:11  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-03-25 13:15:15  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-03-25 13:15:19  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-03-25 13:15:23  - 23147  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
<pre>2017-03-25_13-15-25 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_13-17-25 Restart Xvfb...
2017-03-25 13:17:28  - 23147  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-03-25 13:17:31  - 23147  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-03-25 13:17:36  - 23147  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-03-25 13:17:40  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-03-25 13:17:44  - 23147  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-03-25 13:17:48  - 23147  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-03-25 13:17:53  - 23147  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-03-25 13:17:58  - 23147  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-03-25 13:18:02  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-03-25 13:18:06  - 23147  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-03-25 13:18:11  - 23147  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-03-25 13:18:15  - 23147  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-03-25 13:18:20  - 23147  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-03-25 13:18:24  - 23147  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-03-25 13:18:29  - 23147  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-03-25 13:18:33  - 23147  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-03-25 13:18:38  - 23147  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-03-25 13:18:42  - 23147  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-03-25 13:18:46  - 23147  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-03-25 13:18:51  - 23147  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-03-25 13:18:55  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-03-25 13:18:59  - 23147  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-03-25 13:19:04  - 23147  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-03-25 13:19:09  - 23147  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-03-25 13:19:13  - 23147  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-03-25 13:19:18  - 23147  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-03-25 13:19:22  - 23147  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
<pre>2017-03-25_13-19-25 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_13-21-25 Restart Xvfb...
2017-03-25 13:21:27  - 23147  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-03-25 13:21:31  - 23147  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-03-25 13:21:36  - 23147  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-03-25 13:21:40  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-03-25 13:21:44  - 23147  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-03-25 13:21:49  - 23147  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-03-25 13:21:53  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-03-25 13:21:57  - 23147  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-03-25 13:22:02  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-03-25 13:22:05  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-03-25 13:22:09  - 23147  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-03-25 13:22:14  - 23147  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-03-25 13:22:18  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-03-25 13:22:22  - 23147  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-03-25 13:22:27  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-03-25 13:22:31  - 23147  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-03-25 13:22:35  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-03-25 13:22:39  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-03-25 13:22:44  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-03-25 13:22:47  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-03-25 13:22:51  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-03-25 13:22:55  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-03-25 13:22:59  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-03-25 13:23:03  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-03-25 13:23:08  - 23147  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-03-25 13:23:13  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-03-25 13:23:18  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-03-25 13:23:23  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
<pre>2017-03-25_13-23-25 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_13-25-25 Restart Xvfb...
2017-03-25 13:25:28  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-03-25 13:25:33  - 23147  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-25 13:25:33  - 23147  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-03-25 13:25:38  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-03-25 13:25:42  - 23147  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-03-25 13:25:46  - 23147  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-03-25 13:25:51  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-03-25 13:25:55  - 23147  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-03-25 13:26:00  - 23147  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-03-25 13:26:05  - 23147  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-03-25 13:26:09  - 23147  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-03-25 13:26:14  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-03-25 13:26:19  - 23147  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-03-25 13:26:24  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-03-25 13:26:28  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-03-25 13:26:33  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-03-25 13:26:38  - 23147  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-03-25 13:26:42  - 23147  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-03-25 13:26:47  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-03-25 13:26:51  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-03-25 13:26:56  - 23147  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-03-25 13:27:01  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-03-25 13:27:05  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-03-25 13:27:10  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-03-25 13:27:14  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-03-25 13:27:19  - 23147  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-25 13:27:24  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
<pre>2017-03-25_13-27-25 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_13-29-25 Restart Xvfb...
2017-03-25 13:29:29  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-03-25 13:29:34  - 23147  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-03-25 13:29:39  - 23147  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-03-25 13:29:43  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-03-25 13:29:48  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-03-25 13:29:53  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-03-25 13:29:58  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-03-25 13:30:02  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-03-25 13:30:07  - 23147  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-03-25 13:30:14  - 23147  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-03-25 13:30:19  - 23147  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-03-25 13:30:24  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-03-25 13:30:29  - 23147  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-03-25 13:30:33  - 23147  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-03-25 13:30:38  - 23147  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-03-25 13:30:39  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-03-25 13:30:43  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-03-25 13:30:48  - 23147  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-03-25 13:30:53  - 23147  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-03-25 13:30:58  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-03-25 13:31:02  - 23147  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-03-25 13:31:07  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-03-25 13:31:11  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-03-25 13:31:16  - 23147  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-03-25 13:31:21  - 23147  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
<pre>2017-03-25_13-31-25 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_13-33-25 Restart Xvfb...
2017-03-25 13:33:26  - 23147  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-03-25 13:33:30  - 23147  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-03-25 13:33:35  - 23147  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-03-25 13:33:39  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-03-25 13:33:44  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-03-25 13:33:49  - 23147  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-03-25 13:33:53  - 23147  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-03-25 13:33:58  - 23147  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-03-25 13:34:02  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-03-25 13:34:07  - 23147  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-03-25 13:34:12  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-03-25 13:34:17  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-03-25 13:34:20  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-03-25 13:34:26  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-03-25 13:34:30  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-03-25 13:34:34  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-03-25 13:34:38  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-03-25 13:34:42  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-03-25 13:34:45  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-03-25 13:34:50  - 23147  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-03-25 13:34:50  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-03-25 13:34:55  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-03-25 13:34:59  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-03-25 13:35:03  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-03-25 13:35:07  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-03-25 13:35:11  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-03-25 13:35:15  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-03-25 13:35:19  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-03-25 13:35:23  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
<pre>2017-03-25_13-35-25 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_13-37-25 Restart Xvfb...
2017-03-25 13:37:28  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-03-25 13:37:31  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-03-25 13:37:35  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-03-25 13:37:38  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-03-25 13:37:42  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-03-25 13:37:45  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-03-25 13:37:49  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-03-25 13:37:53  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-03-25 13:37:58  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-03-25 13:38:01  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-03-25 13:38:05  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-03-25 13:38:09  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-03-25 13:38:13  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-03-25 13:38:16  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-03-25 13:38:20  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-03-25 13:38:23  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-03-25 13:38:27  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-03-25 13:38:30  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-03-25 13:38:34  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-03-25 13:38:37  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-03-25 13:38:41  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-03-25 13:38:45  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-03-25 13:38:48  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-03-25 13:38:52  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-03-25 13:38:55  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-03-25 13:38:59  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-03-25 13:39:03  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-03-25 13:39:06  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-03-25 13:39:10  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-03-25 13:39:13  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-03-25 13:39:17  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-03-25 13:39:21  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-03-25 13:39:24  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
<pre>2017-03-25_13-39-25 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_13-41-25 Restart Xvfb...
2017-03-25 13:41:29  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-03-25 13:41:33  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-03-25 13:41:37  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-03-25 13:41:40  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-03-25 13:41:44  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-03-25 13:41:48  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-03-25 13:41:52  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-03-25 13:41:55  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-03-25 13:41:59  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-03-25 13:42:03  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-03-25 13:42:07  - 23147  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-03-25 13:42:12  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-03-25 13:42:17  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-03-25 13:42:22  - 23147  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-03-25 13:42:22  - 23147  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-03-25 13:42:27  - 23147  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-03-25 13:42:32  - 23147  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-03-25 13:42:37  - 23147  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-03-25 13:42:42  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-03-25 13:42:46  - 23147  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-03-25 13:42:51  - 23147  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-03-25 13:42:56  - 23147  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-03-25 13:43:00  - 23147  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-03-25 13:43:05  - 23147  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-03-25 13:43:09  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-03-25 13:43:14  - 23147  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-03-25 13:43:19  - 23147  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-03-25 13:43:23  - 23147  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
<pre>2017-03-25_13-43-25 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_13-45-25 Restart Xvfb...
2017-03-25 13:45:29  - 23147  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-03-25 13:45:34  - 23147  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-03-25 13:45:38  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-03-25 13:45:43  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-03-25 13:45:48  - 23147  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-03-25 13:45:52  - 23147  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-03-25 13:45:57  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-03-25 13:46:02  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-03-25 13:46:06  - 23147  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-25 13:46:11  - 23147  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-03-25 13:46:15  - 23147  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-03-25 13:46:20  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-03-25 13:46:25  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-03-25 13:46:29  - 23147  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-03-25 13:46:34  - 23147  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-03-25 13:46:39  - 23147  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-03-25 13:46:44  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-03-25 13:46:48  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-03-25 13:46:53  - 23147  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-25 13:46:58  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-03-25 13:47:02  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-03-25 13:47:07  - 23147  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-03-25 13:47:12  - 23147  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-03-25 13:47:16  - 23147  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-03-25 13:47:21  - 23147  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
<pre>2017-03-25_13-47-25 Restart Xvfb...
2017-03-25 13:47:25  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-03-25 13:47:30  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-03-25 13:47:34  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-03-25 13:47:39  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-03-25 13:47:43  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-03-25 13:47:48  - 23147  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-03-25 13:47:52  - 23147  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-03-25 13:47:57  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-03-25 13:48:01  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-03-25 13:48:06  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-03-25 13:48:10  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-03-25 13:48:15  - 23147  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-03-25 13:48:19  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-03-25 13:48:24  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-03-25 13:48:29  - 23147  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-03-25 13:48:33  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-03-25 13:48:38  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-03-25 13:48:42  - 23147  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-03-25 13:48:47  - 23147  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-03-25 13:48:52  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-03-25 13:48:56  - 23147  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-03-25 13:49:01  - 23147  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-03-25 13:49:05  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-03-25 13:49:10  - 23147  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-03-25 13:49:15  - 23147  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-03-25 13:49:20  - 23147  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-03-25 13:49:24  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
<pre>2017-03-25_13-49-25 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_13-51-25 Restart Xvfb...
2017-03-25 13:51:29  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-03-25 13:51:34  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-03-25 13:51:38  - 23147  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-03-25 13:51:43  - 23147  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-03-25 13:51:48  - 23147  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-03-25 13:51:53  - 23147  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-03-25 13:51:57  - 23147  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-03-25 13:52:02  - 23147  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-03-25 13:52:07  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-03-25 13:52:12  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-03-25 13:52:16  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-03-25 13:52:21  - 23147  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-03-25 13:52:25  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-03-25 13:52:32  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-03-25 13:52:36  - 23147  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-03-25 13:52:42  - 23147  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-03-25 13:52:46  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-03-25 13:52:51  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-03-25 13:52:56  - 23147  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-03-25 13:53:00  - 23147  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-03-25 13:53:05  - 23147  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-03-25 13:53:09  - 23147  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-03-25 13:53:14  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-03-25 13:53:18  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-03-25 13:53:23  - 23147  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
<pre>2017-03-25_13-53-25 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_13-55-25 Restart Xvfb...
2017-03-25 13:55:28  - 23147  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-03-25 13:55:33  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-03-25 13:55:38  - 23147  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-03-25 13:55:42  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-03-25 13:55:47  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-03-25 13:55:52  - 23147  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-03-25 13:55:56  - 23147  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-03-25 13:56:01  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-03-25 13:56:06  - 23147  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-03-25 13:56:11  - 23147  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-03-25 13:56:15  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-03-25 13:56:20  - 23147  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-03-25 13:56:24  - 23147  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-03-25 13:56:29  - 23147  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-03-25 13:56:34  - 23147  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-03-25 13:56:38  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-03-25 13:56:43  - 23147  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-03-25 13:56:47  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-03-25 13:56:52  - 23147  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-03-25 13:56:56  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-03-25 13:57:01  - 23147  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-03-25 13:57:05  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-03-25 13:57:10  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-03-25 13:57:15  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-03-25 13:57:19  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-03-25 13:57:24  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
<pre>2017-03-25_13-57-25 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_13-59-25 Restart Xvfb...
2017-03-25 13:59:29  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-03-25 13:59:34  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-03-25 13:59:39  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-03-25 13:59:43  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-03-25 13:59:48  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-03-25 13:59:53  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-03-25 13:59:57  - 23147  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-03-25 14:00:02  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-03-25 14:00:09  - 23147  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-03-25 14:00:13  - 23147  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-03-25 14:00:18  - 23147  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-03-25 14:00:23  - 23147  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-03-25 14:00:27  - 23147  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-03-25 14:00:32  - 23147  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-03-25 14:00:37  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-03-25 14:00:42  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-03-25 14:00:46  - 23147  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-03-25 14:00:51  - 23147  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-03-25 14:00:56  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-03-25 14:01:00  - 23147  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-03-25 14:01:05  - 23147  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-03-25 14:01:09  - 23147  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-03-25 14:01:14  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-03-25 14:01:19  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-03-25 14:01:24  - 23147  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
<pre>2017-03-25_14-01-25 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_14-03-25 Restart Xvfb...
2017-03-25 14:03:29  - 23147  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-03-25 14:03:34  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-03-25 14:03:38  - 23147  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-03-25 14:03:43  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-03-25 14:03:48  - 23147  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-03-25 14:03:52  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-03-25 14:03:57  - 23147  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-03-25 14:04:02  - 23147  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-03-25 14:04:06  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-03-25 14:04:11  - 23147  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-03-25 14:04:15  - 23147  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-03-25 14:04:19  - 23147  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-03-25 14:04:24  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-03-25 14:04:29  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-03-25 14:04:33  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-03-25 14:04:37  - 23147  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-03-25 14:04:42  - 23147  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-03-25 14:04:46  - 23147  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-03-25 14:04:51  - 23147  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-03-25 14:04:56  - 23147  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-03-25 14:05:00  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-03-25 14:05:04  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-03-25 14:05:09  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-03-25 14:05:13  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-03-25 14:05:18  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-03-25 14:05:22  - 23147  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
<pre>2017-03-25_14-05-25 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_14-07-25 Restart Xvfb...
2017-03-25 14:07:27  - 23147  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-03-25 14:07:31  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-03-25 14:07:36  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-03-25 14:07:40  - 23147  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-03-25 14:07:45  - 23147  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-03-25 14:07:49  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-03-25 14:07:53  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-03-25 14:07:58  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-03-25 14:08:03  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-03-25 14:08:07  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-03-25 14:08:12  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-03-25 14:08:16  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-03-25 14:08:20  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-03-25 14:08:25  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-03-25 14:08:29  - 23147  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-03-25 14:08:34  - 23147  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-03-25 14:08:39  - 23147  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-03-25 14:08:44  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-03-25 14:08:48  - 23147  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-03-25 14:08:52  - 23147  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-03-25 14:08:57  - 23147  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-03-25 14:09:02  - 23147  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-03-25 14:09:07  - 23147  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-03-25 14:09:11  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-03-25 14:09:16  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-03-25 14:09:20  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-03-25 14:09:25  - 23147  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
<pre>2017-03-25_14-09-25 Restart Xvfb...
2017-03-25 14:09:30  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-03-25 14:09:35  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-03-25 14:09:39  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-03-25 14:09:43  - 23147  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-03-25 14:09:48  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-03-25 14:09:52  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-03-25 14:09:57  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-03-25 14:10:01  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-03-25 14:10:05  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-03-25 14:10:10  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-03-25 14:10:14  - 23147  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-03-25 14:10:18  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-03-25 14:10:23  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-03-25 14:10:27  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-03-25 14:10:32  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-03-25 14:10:36  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-03-25 14:10:41  - 23147  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-03-25 14:10:45  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-03-25 14:10:49  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-03-25 14:10:54  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-03-25 14:10:58  - 23147  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-03-25 14:11:03  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-03-25 14:11:07  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-03-25 14:11:12  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-03-25 14:11:17  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-03-25 14:11:21  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-03-25 14:11:25  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
<pre>2017-03-25_14-11-25 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_14-13-25 Restart Xvfb...
2017-03-25 14:13:30  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-03-25 14:13:34  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-03-25 14:13:38  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-03-25 14:13:42  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-03-25 14:13:47  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-03-25 14:13:51  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-03-25 14:13:55  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-03-25 14:13:59  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-03-25 14:14:03  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-03-25 14:14:07  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-03-25 14:14:12  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-03-25 14:14:16  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-03-25 14:14:20  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-03-25 14:14:25  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-03-25 14:14:29  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-03-25 14:14:33  - 23147  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-03-25 14:14:37  - 23147  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-03-25 14:14:41  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-03-25 14:14:45  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-03-25 14:14:49  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-03-25 14:14:54  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-03-25 14:14:59  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-03-25 14:15:04  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-03-25 14:15:09  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-03-25 14:15:13  - 23147  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-03-25 14:15:18  - 23147  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-03-25 14:15:22  - 23147  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
<pre>2017-03-25_14-15-25 Restart Xvfb...
2017-03-25 14:15:26  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-03-25 14:15:30  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-03-25 14:15:34  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-03-25 14:15:38  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-03-25 14:15:43  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-03-25 14:15:47  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-25 14:15:51  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-25 14:15:55  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-25 14:15:59  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-25 14:16:03  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-03-25 14:16:07  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-25 14:16:11  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-25 14:16:15  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-03-25 14:16:19  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-03-25 14:16:23  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-03-25 14:16:27  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-03-25 14:16:31  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-03-25 14:16:36  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-03-25 14:16:40  - 23147  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-03-25 14:16:44  - 23147  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-03-25 14:16:48  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-03-25 14:16:52  - 23147  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-03-25 14:16:56  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-03-25 14:17:00  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-03-25 14:17:05  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-03-25 14:17:09  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-03-25 14:17:13  - 23147  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-03-25 14:17:17  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-03-25 14:17:21  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-03-25 14:17:25  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
<pre>2017-03-25_14-17-25 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_14-19-25 Restart Xvfb...
2017-03-25 14:19:30  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-03-25 14:19:34  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-03-25 14:19:38  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-03-25 14:19:42  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-25 14:19:46  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-25 14:19:50  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-25 14:19:54  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-25 14:19:58  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-25 14:20:02  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-03-25 14:20:07  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-25 14:20:11  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-25 14:20:15  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-25 14:20:19  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-25 14:20:23  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-03-25 14:20:27  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-25 14:20:31  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-25 14:20:36  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-25 14:20:40  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-03-25 14:20:44  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
<pre>2017-03-25_14-21-26 Restart Xvfb...
<pre>2017-03-25_14-23-26 Restart Xvfb...
<pre>2017-03-25_14-25-26 Restart Xvfb...
<pre>2017-03-25_14-27-26 Restart Xvfb...
<pre>2017-03-25_14-29-26 Restart Xvfb...
<pre>2017-03-25_14-31-26 Restart Xvfb...
<pre>2017-03-25_14-33-26 Restart Xvfb...
<pre>2017-03-25_14-35-26 Restart Xvfb...
<pre>2017-03-25_14-37-26 Restart Xvfb...
<pre>2017-03-25_14-39-26 Restart Xvfb...
<pre>2017-03-25_14-41-26 Restart Xvfb...
<pre>2017-03-25_14-43-26 Restart Xvfb...
<pre>2017-03-25_14-45-26 Restart Xvfb...
<pre>2017-03-25_14-47-26 Restart Xvfb...
<pre>2017-03-25_14-49-26 Restart Xvfb...
<pre>2017-03-25_14-51-26 Restart Xvfb...
<pre>2017-03-25_14-53-26 Restart Xvfb...
<pre>2017-03-25_14-55-26 Restart Xvfb...
<pre>2017-03-25_14-57-26 Restart Xvfb...
<pre>2017-03-25_14-59-26 Restart Xvfb...
<pre>2017-03-25_15-01-26 Restart Xvfb...
<pre>2017-03-25_15-03-26 Restart Xvfb...
<pre>2017-03-25_15-05-26 Restart Xvfb...
<pre>2017-03-25_15-07-26 Restart Xvfb...
<pre>2017-03-25_15-09-26 Restart Xvfb...
<pre>2017-03-25_15-11-26 Restart Xvfb...
<pre>2017-03-25_15-13-26 Restart Xvfb...
<pre>2017-03-25_15-15-26 Restart Xvfb...
<pre>2017-03-25_15-17-26 Restart Xvfb...
<pre>2017-03-25_15-19-26 Restart Xvfb...
<pre>2017-03-25_15-21-26 Restart Xvfb...
<pre>2017-03-25_15-23-26 Restart Xvfb...
<pre>2017-03-25_15-25-26 Restart Xvfb...
<pre>2017-03-25_15-27-26 Restart Xvfb...
<pre>2017-03-25_15-29-26 Restart Xvfb...
<pre>2017-03-25_15-31-26 Restart Xvfb...
<pre>2017-03-25_15-33-26 Restart Xvfb...
<pre>2017-03-25_15-35-26 Restart Xvfb...
<pre>2017-03-25_15-37-26 Restart Xvfb...
<pre>2017-03-25_15-39-26 Restart Xvfb...
<pre>2017-03-25_15-41-26 Restart Xvfb...
<pre>2017-03-25_15-43-26 Restart Xvfb...
<pre>2017-03-25_15-45-26 Restart Xvfb...
<pre>2017-03-25_15-47-26 Restart Xvfb...
<pre>2017-03-25_15-49-26 Restart Xvfb...
<pre>2017-03-25_15-51-26 Restart Xvfb...
<pre>2017-03-25_15-53-26 Restart Xvfb...
<pre>2017-03-25_15-55-26 Restart Xvfb...
2017-03-25 15:56:59 reset updateRequest
2017-03-25 15:57:01  - 23147  http://www.lymphomahub.com/
2017-03-25 15:57:04  - 23147  http://www.lymphomahub.com/
2017-03-25 15:57:05  - 23147  http://www.lymphomahub.com/about
2017-03-25 15:57:08  - 23147  http://www.lymphomahub.com/about
2017-03-25 15:57:09  - 23147  http://www.lymphomahub.com/terms
2017-03-25 15:57:12  - 23147  http://www.lymphomahub.com/terms
2017-03-25 15:57:14  - 23147  http://www.lymphomahub.com/undefined
2017-03-25 15:57:14  - 23147  http://www.lymphomahub.com/therapies
2017-03-25 15:57:15  - 23147  http://www.lymphomahub.com/therapies
2017-03-25 15:57:25  - 23147  http://www.lymphomahub.com/newsletter
2017-03-25 15:57:26  - 23147  http://www.lymphomahub.com/newsletter
<pre>2017-03-25_15-57-26 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/newsletter?_prerender {"code":"ECONNRESET"}
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/newsletter?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_15-59-26 Restart Xvfb...
2017-03-25 15:59:30  - 23147  http://www.lymphomahub.com/newsletter
2017-03-25 15:59:31  - 23147  http://www.lymphomahub.com/newsletter
2017-03-25 15:59:35  - 23147  http://www.lymphomahub.com/cookie-policy
2017-03-25 15:59:36  - 23147  http://www.lymphomahub.com/cookie-policy
2017-03-25 15:59:39  - 23147  http://www.lymphomahub.com/therapies/afm13
2017-03-25 15:59:40  - 23147  http://www.lymphomahub.com/therapies/afm13
2017-03-25 15:59:43  - 23147  http://www.lymphomahub.com/therapies/afm11
2017-03-25 15:59:45  - 23147  http://www.lymphomahub.com/therapies/afm11
2017-03-25 15:59:48  - 23147  http://www.lymphomahub.com/therapies/ags67e
2017-03-25 15:59:49  - 23147  http://www.lymphomahub.com/therapies/ags67e
2017-03-25 15:59:53  - 23147  http://www.lymphomahub.com/therapies/cc-292
2017-03-25 15:59:54  - 23147  http://www.lymphomahub.com/therapies/cc-292
2017-03-25 15:59:58  - 23147  http://www.lymphomahub.com/therapies/cc-223
2017-03-25 15:59:59  - 23147  http://www.lymphomahub.com/therapies/cc-223
2017-03-25 16:00:04  - 23147  http://www.lymphomahub.com/therapies/sd-101
2017-03-25 16:00:09  - 23147  http://www.lymphomahub.com/therapies/rp6530
2017-03-25 16:00:13  - 23147  http://www.lymphomahub.com/therapies/abt199
2017-03-25 16:00:18  - 23147  http://www.lymphomahub.com/therapies/mor208
2017-03-25 16:00:24  - 23147  http://www.lymphomahub.com/therapies/cc-122
2017-03-25 16:00:28  - 23147  http://www.lymphomahub.com/therapies/at-101
2017-03-25 16:00:33  - 23147  http://www.lymphomahub.com/therapies/bl8040
2017-03-25 16:00:37  - 23147  http://www.lymphomahub.com/therapies/bcl201
2017-03-25 16:00:41  - 23147  http://www.lymphomahub.com/therapies/azd3965
2017-03-25 16:00:46  - 23147  http://www.lymphomahub.com/therapies/imgn529
2017-03-25 16:00:50  - 23147  http://www.lymphomahub.com/therapies/azd2014
2017-03-25 16:00:54  - 23147  http://www.lymphomahub.com/therapies/mt-3724
2017-03-25 16:00:59  - 23147  http://www.lymphomahub.com/therapies/actr087
2017-03-25 16:01:04  - 23147  http://www.lymphomahub.com/therapies/epz6438
2017-03-25 16:01:08  - 23147  http://www.lymphomahub.com/therapies/kte-c19
2017-03-25 16:01:13  - 23147  http://www.lymphomahub.com/about/secretariat
2017-03-25 16:01:17  - 23147  http://www.lymphomahub.com/therapies/alt-803
2017-03-25 16:01:21  - 23147  http://www.lymphomahub.com/therapies/regn1979
2017-03-25 16:01:25  - 23147  http://www.lymphomahub.com/therapies/immu-114
<pre>2017-03-25_16-01-26 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/immu-114?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_16-03-26 Restart Xvfb...
2017-03-25 16:03:31  - 23147  http://www.lymphomahub.com/therapies/immu-114
2017-03-25 16:03:35  - 23147  http://www.lymphomahub.com/therapies/incb7839
2017-03-25 16:03:40  - 23147  http://www.lymphomahub.com/therapies/adct-301
2017-03-25 16:03:44  - 23147  http://www.lymphomahub.com/therapies/ixazomib
2017-03-25 16:03:48  - 23147  http://www.lymphomahub.com/therapies/avelumab
2017-03-25 16:03:53  - 23147  http://www.lymphomahub.com/therapies/bi836826
2017-03-25 16:03:58  - 23147  http://www.lymphomahub.com/therapies/medi-570
2017-03-25 16:04:02  - 23147  http://www.lymphomahub.com/therapies/ds-3201b
2017-03-25 16:04:06  - 23147  http://www.lymphomahub.com/therapies/sea-cd40
2017-03-25 16:04:11  - 23147  http://www.lymphomahub.com/therapies/adct-402
2017-03-25 16:04:15  - 23147  http://www.lymphomahub.com/therapies/acy-1215
2017-03-25 16:04:20  - 23147  http://www.lymphomahub.com/therapies/cudc-907
2017-03-25 16:04:24  - 23147  http://www.lymphomahub.com/therapies/tgr-1202
2017-03-25 16:04:29  - 23147  http://www.lymphomahub.com/therapies/axitinib
2017-03-25 16:04:33  - 23147  http://www.lymphomahub.com/therapies/imatinib
2017-03-25 16:04:37  - 23147  http://www.lymphomahub.com/therapies/edo-s101
2017-03-25 16:04:42  - 23147  http://www.lymphomahub.com/therapies/btct4465a
2017-03-25 16:04:47  - 23147  http://www.lymphomahub.com/therapies/alisertib
2017-03-25 16:04:51  - 23147  http://www.lymphomahub.com/therapies/lirilumab
2017-03-25 16:04:56  - 23147  http://www.lymphomahub.com/therapies/ibrutinib
2017-03-25 16:04:57  - 23147  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-03-25 16:05:01  - 23147  http://www.lymphomahub.com/therapies/rituximab
2017-03-25 16:05:06  - 23147  http://www.lymphomahub.com/therapies/veliparib
2017-03-25 16:05:10  - 23147  http://www.lymphomahub.com/therapies/sunitinib
2017-03-25 16:05:15  - 23147  http://www.lymphomahub.com/therapies/nivolumab
2017-03-25 16:05:15  - 23147  http://www.lymphomahub.com/therapies/sirolimus
2017-03-25 16:05:20  - 23147  http://www.lymphomahub.com/medical-information
2017-03-25 16:05:24  - 23147  http://www.lymphomahub.com/therapies/selinexor
<pre>2017-03-25_16-05-27 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/selinexor?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_16-07-27 Restart Xvfb...
2017-03-25 16:07:29  - 23147  http://www.lymphomahub.com/therapies/selinexor
2017-03-25 16:07:34  - 23147  http://www.lymphomahub.com/therapies/abc294640
2017-03-25 16:07:38  - 23147  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-03-25 16:07:42  - 23147  http://www.lymphomahub.com/therapies/tenofovir
2017-03-25 16:07:47  - 23147  http://www.lymphomahub.com/therapies/betalutin
2017-03-25 16:07:51  - 23147  http://www.lymphomahub.com/therapies/chidamide
2017-03-25 16:07:56  - 23147  http://www.lymphomahub.com/therapies/duvelisib
2017-03-25 16:08:01  - 23147  http://www.lymphomahub.com/therapies/dasatinib
2017-03-25 16:08:05  - 23147  http://www.lymphomahub.com/therapies/everolimus
2017-03-25 16:08:10  - 23147  http://www.lymphomahub.com/therapies/incb039110
2017-03-25 16:08:14  - 23147  http://www.lymphomahub.com/therapies/durvalumab
2017-03-25 16:08:18  - 23147  http://www.lymphomahub.com/therapies/romidepsin
2017-03-25 16:08:23  - 23147  http://www.lymphomahub.com/therapies/bortezomib
2017-03-25 16:08:27  - 23147  http://www.lymphomahub.com/therapies/idelalisib
2017-03-25 16:08:28  - 23147  http://www.lymphomahub.com/therapies/tipifarnib
2017-03-25 16:08:32  - 23147  http://www.lymphomahub.com/therapies/ipilimumab
2017-03-25 16:08:37  - 23147  http://www.lymphomahub.com/therapies/crizotinib
2017-03-25 16:08:41  - 23147  http://www.lymphomahub.com/therapies/gsk2816126
2017-03-25 16:08:46  - 23147  http://www.lymphomahub.com/therapies/copanlisib
2017-03-25 16:08:50  - 23147  http://www.lymphomahub.com/therapies/buparlisib
2017-03-25 16:08:55  - 23147  http://www.lymphomahub.com/therapies/belinostat
2017-03-25 16:08:59  - 23147  http://www.lymphomahub.com/therapies/vorinostat
2017-03-25 16:09:04  - 23147  http://www.lymphomahub.com/therapies/plerixafor
2017-03-25 16:09:04  - 23147  http://www.lymphomahub.com/therapies/ofatumumab
2017-03-25 16:09:09  - 23147  http://www.lymphomahub.com/therapies/pf-06801591
2017-03-25 16:09:13  - 23147  http://www.lymphomahub.com/therapies/tocilizumab
2017-03-25 16:09:18  - 23147  http://www.lymphomahub.com/therapies/msc2490484a
2017-03-25 16:09:22  - 23147  http://www.lymphomahub.com/therapies/carfilzomib
2017-03-25 16:09:26  - 23147  http://www.lymphomahub.com/therapies/ruxolitinib
<pre>2017-03-25_16-09-27 Restart Xvfb...
2017-03-25 16:09:31  - 23147  http://www.lymphomahub.com/therapies/palbociclib
2017-03-25 16:09:35  - 23147  http://www.lymphomahub.com/therapies/fenretinide
2017-03-25 16:09:40  - 23147  http://www.lymphomahub.com/therapies/daratumumab
2017-03-25 16:09:44  - 23147  http://www.lymphomahub.com/therapies/pf-05082566
2017-03-25 16:09:48  - 23147  http://www.lymphomahub.com/therapies/ramucirumab
2017-03-25 16:09:53  - 23147  http://www.lymphomahub.com/therapies/tositumomab
2017-03-25 16:09:57  - 23147  http://www.lymphomahub.com/therapies/ublituximab
2017-03-25 16:10:02  - 23147  http://www.lymphomahub.com/therapies/epacadostat
2017-03-25 16:10:06  - 23147  http://www.lymphomahub.com/therapies/alemtuzumab
2017-03-25 16:10:08  - 23147  http://www.lymphomahub.com/therapies/otlertuzumab
2017-03-25 16:10:13  - 23147  http://www.lymphomahub.com/therapies/panobinostat
2017-03-25 16:10:17  - 23147  http://www.lymphomahub.com/therapies/mocetinostat
2017-03-25 16:10:22  - 23147  http://www.lymphomahub.com/therapies/atezolizumab
2017-03-25 16:10:26  - 23147  http://www.lymphomahub.com/therapies/temsirolimus
2017-03-25 16:10:31  - 23147  http://www.lymphomahub.com/therapies/lenalidomide
2017-03-25 16:10:35  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab
2017-03-25 16:10:40  - 23147  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-03-25 16:10:44  - 23147  http://www.lymphomahub.com/therapies/blinatumomab
2017-03-25 16:10:48  - 23147  http://www.lymphomahub.com/therapies/jnj-64052781
2017-03-25 16:10:53  - 23147  http://www.lymphomahub.com/therapies/entospletinib
2017-03-25 16:10:58  - 23147  http://www.lymphomahub.com/therapies/pembrolizumab
2017-03-25 16:11:03  - 23147  http://www.lymphomahub.com/therapies/acalabrutinib
2017-03-25 16:11:07  - 23147  http://www.lymphomahub.com/about/innovation-committee
2017-03-25 16:11:11  - 23147  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-03-25 16:11:11  - 23147  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-03-25 16:11:16  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-03-25 16:11:20  - 23147  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-03-25 16:11:24  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b
<pre>2017-03-25_16-11-27 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/interferon-alpha-2b?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_16-13-27 Restart Xvfb...
2017-03-25 16:13:29  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-03-25 16:13:34  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-03-25 16:13:35  - 23147  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-03-25 16:13:39  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-03-25 16:13:43  - 23147  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-03-25 16:13:48  - 23147  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-03-25 16:13:53  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board
2017-03-25 16:13:57  - 23147  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-03-25 16:14:01  - 23147  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-03-25 16:14:05  - 23147  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-03-25 16:14:09  - 23147  http://www.lymphomahub.com/about/executive-steering-committee
2017-03-25 16:14:13  - 23147  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-03-25 16:14:16  - 23147  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-03-25 16:14:22  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-03-25 16:14:26  - 23147  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-03-25 16:14:30  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-03-25 16:14:34  - 23147  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-03-25 16:14:38  - 23147  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-03-25 16:14:39  - 23147  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-03-25 16:14:43  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-03-25 16:14:47  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-03-25 16:14:52  - 23147  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-03-25 16:14:56  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-03-25 16:15:01  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-03-25 16:15:06  - 23147  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-03-25 16:15:10  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-03-25 16:15:13  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-03-25 16:15:17  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-03-25 16:15:21  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-03-25 16:15:25  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
<pre>2017-03-25_16-15-27 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_16-17-27 Restart Xvfb...
2017-03-25 16:17:30  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-03-25 16:17:34  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-03-25 16:17:38  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-03-25 16:17:41  - 23147  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-03-25 16:17:46  - 23147  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-03-25 16:17:51  - 23147  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-03-25 16:17:55  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-03-25 16:17:59  - 23147  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-03-25 16:18:02  - 23147  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-03-25 16:18:07  - 23147  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-03-25 16:18:12  - 23147  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-03-25 16:18:16  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-03-25 16:18:20  - 23147  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-03-25 16:18:25  - 23147  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-03-25 16:18:29  - 23147  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-03-25 16:18:34  - 23147  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-03-25 16:18:38  - 23147  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-03-25 16:18:43  - 23147  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-03-25 16:18:47  - 23147  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-03-25 16:18:52  - 23147  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-03-25 16:18:56  - 23147  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-03-25 16:19:01  - 23147  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-03-25 16:19:05  - 23147  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-03-25 16:19:10  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-03-25 16:19:14  - 23147  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-03-25 16:19:18  - 23147  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-03-25 16:19:22  - 23147  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
<pre>2017-03-25_16-19-27 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_16-21-27 Restart Xvfb...
2017-03-25 16:21:28  - 23147  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-03-25 16:21:31  - 23147  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-03-25 16:21:36  - 23147  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-03-25 16:21:40  - 23147  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-03-25 16:21:45  - 23147  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-03-25 16:21:49  - 23147  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-03-25 16:21:54  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-03-25 16:21:57  - 23147  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-03-25 16:22:02  - 23147  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-03-25 16:22:07  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-03-25 16:22:10  - 23147  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-03-25 16:22:15  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-03-25 16:22:19  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-03-25 16:22:23  - 23147  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-03-25 16:22:28  - 23147  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-03-25 16:22:32  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-03-25 16:22:36  - 23147  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-03-25 16:22:41  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-03-25 16:22:45  - 23147  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-03-25 16:22:49  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-03-25 16:22:53  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-03-25 16:22:58  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-03-25 16:23:02  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-03-25 16:23:06  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-03-25 16:23:10  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-03-25 16:23:13  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-03-25 16:23:18  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-03-25 16:23:22  - 23147  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
<pre>2017-03-25_16-23-27 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_16-25-27 Restart Xvfb...
2017-03-25 16:25:28  - 23147  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-03-25 16:25:32  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-03-25 16:25:36  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-03-25 16:25:41  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-03-25 16:25:46  - 23147  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-25 16:25:46  - 23147  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-03-25 16:25:51  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-03-25 16:25:56  - 23147  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-03-25 16:26:00  - 23147  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-03-25 16:26:05  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-03-25 16:26:09  - 23147  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-03-25 16:26:14  - 23147  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-03-25 16:26:18  - 23147  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-03-25 16:26:23  - 23147  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-03-25 16:26:27  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-03-25 16:26:32  - 23147  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-03-25 16:26:37  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-03-25 16:26:42  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-03-25 16:26:47  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-03-25 16:26:51  - 23147  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-03-25 16:26:56  - 23147  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-03-25 16:27:00  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-03-25 16:27:05  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-03-25 16:27:10  - 23147  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-03-25 16:27:15  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-03-25 16:27:20  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-03-25 16:27:25  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
<pre>2017-03-25_16-27-27 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_16-29-27 Restart Xvfb...
2017-03-25 16:29:30  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-03-25 16:29:35  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-03-25 16:29:41  - 23147  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-25 16:29:46  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-03-25 16:29:50  - 23147  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-03-25 16:29:55  - 23147  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-03-25 16:30:00  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-03-25 16:30:04  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-03-25 16:30:09  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-03-25 16:30:15  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-03-25 16:30:22  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-03-25 16:30:27  - 23147  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-03-25 16:30:32  - 23147  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-03-25 16:30:36  - 23147  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-03-25 16:30:41  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-03-25 16:30:46  - 23147  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-03-25 16:30:51  - 23147  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-03-25 16:30:56  - 23147  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-03-25 16:30:57  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-03-25 16:31:02  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-03-25 16:31:06  - 23147  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-03-25 16:31:11  - 23147  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-03-25 16:31:16  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-03-25 16:31:20  - 23147  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-03-25 16:31:25  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
<pre>2017-03-25_16-31-27 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_16-33-27 Restart Xvfb...
2017-03-25 16:33:30  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-03-25 16:33:35  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-03-25 16:33:39  - 23147  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-03-25 16:33:44  - 23147  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-03-25 16:33:49  - 23147  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-03-25 16:33:53  - 23147  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-03-25 16:33:58  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-03-25 16:34:03  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-03-25 16:34:07  - 23147  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-03-25 16:34:12  - 23147  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-03-25 16:34:17  - 23147  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-03-25 16:34:21  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-03-25 16:34:27  - 23147  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-03-25 16:34:31  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-03-25 16:34:36  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-03-25 16:34:39  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-03-25 16:34:45  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-03-25 16:34:49  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-03-25 16:34:53  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-03-25 16:34:57  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-03-25 16:35:01  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-03-25 16:35:05  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-03-25 16:35:09  - 23147  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-03-25 16:35:10  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-03-25 16:35:15  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-03-25 16:35:19  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-03-25 16:35:23  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-03-25 16:35:26  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
<pre>2017-03-25_16-35-27 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_16-37-27 Restart Xvfb...
2017-03-25 16:37:31  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-03-25 16:37:35  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-03-25 16:37:39  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-03-25 16:37:42  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-03-25 16:37:46  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-03-25 16:37:49  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-03-25 16:37:53  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-03-25 16:37:57  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-03-25 16:38:00  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-03-25 16:38:04  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-03-25 16:38:08  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-03-25 16:38:11  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-03-25 16:38:16  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-03-25 16:38:20  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-03-25 16:38:24  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-03-25 16:38:27  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-03-25 16:38:31  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-03-25 16:38:35  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-03-25 16:38:38  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-03-25 16:38:42  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-03-25 16:38:46  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-03-25 16:38:49  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-03-25 16:38:53  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-03-25 16:38:57  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-03-25 16:39:01  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-03-25 16:39:05  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-03-25 16:39:08  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-03-25 16:39:12  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-03-25 16:39:15  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-03-25 16:39:19  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-03-25 16:39:22  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-03-25 16:39:26  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
<pre>2017-03-25_16-39-27 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_16-41-27 Restart Xvfb...
2017-03-25 16:41:31  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-03-25 16:41:35  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-03-25 16:41:38  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-03-25 16:41:42  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-03-25 16:41:45  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-03-25 16:41:49  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-03-25 16:41:53  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-03-25 16:41:56  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-03-25 16:42:00  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-03-25 16:42:03  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-03-25 16:42:07  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-03-25 16:42:11  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-03-25 16:42:15  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-03-25 16:42:18  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-03-25 16:42:22  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-03-25 16:42:27  - 23147  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-03-25 16:42:32  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-03-25 16:42:37  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-03-25 16:42:41  - 23147  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-03-25 16:42:42  - 23147  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-03-25 16:42:46  - 23147  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-03-25 16:42:51  - 23147  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-03-25 16:42:56  - 23147  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-03-25 16:43:01  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-03-25 16:43:05  - 23147  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-03-25 16:43:10  - 23147  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-03-25 16:43:14  - 23147  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-03-25 16:43:19  - 23147  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-03-25 16:43:24  - 23147  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
<pre>2017-03-25_16-43-27 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_16-45-27 Restart Xvfb...
2017-03-25 16:45:29  - 23147  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-03-25 16:45:33  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-03-25 16:45:38  - 23147  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-03-25 16:45:43  - 23147  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-03-25 16:45:48  - 23147  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-03-25 16:45:52  - 23147  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-03-25 16:45:57  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-03-25 16:46:01  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-03-25 16:46:06  - 23147  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-03-25 16:46:11  - 23147  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-03-25 16:46:16  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-03-25 16:46:20  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-03-25 16:46:25  - 23147  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-25 16:46:29  - 23147  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-03-25 16:46:34  - 23147  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-03-25 16:46:39  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-03-25 16:46:43  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-03-25 16:46:48  - 23147  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-03-25 16:46:53  - 23147  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-03-25 16:46:57  - 23147  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-03-25 16:47:02  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-03-25 16:47:07  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-03-25 16:47:11  - 23147  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-25 16:47:16  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-03-25 16:47:20  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-03-25 16:47:25  - 23147  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
<pre>2017-03-25_16-47-27 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_16-49-27 Restart Xvfb...
2017-03-25 16:49:30  - 23147  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-03-25 16:49:35  - 23147  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-03-25 16:49:39  - 23147  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-03-25 16:49:44  - 23147  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-03-25 16:49:49  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-03-25 16:49:53  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-03-25 16:49:58  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-03-25 16:50:03  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-03-25 16:50:07  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-03-25 16:50:12  - 23147  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-03-25 16:50:17  - 23147  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-03-25 16:50:21  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-03-25 16:50:26  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-03-25 16:50:30  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-03-25 16:50:35  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-03-25 16:50:39  - 23147  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-03-25 16:50:44  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-03-25 16:50:49  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-03-25 16:50:53  - 23147  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-03-25 16:50:58  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-03-25 16:51:03  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-03-25 16:51:07  - 23147  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-03-25 16:51:12  - 23147  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-03-25 16:51:16  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-03-25 16:51:21  - 23147  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-03-25 16:51:25  - 23147  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
<pre>2017-03-25_16-51-27 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_16-53-27 Restart Xvfb...
2017-03-25 16:53:31  - 23147  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-03-25 16:53:36  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-03-25 16:53:40  - 23147  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-03-25 16:53:45  - 23147  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-03-25 16:53:50  - 23147  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-03-25 16:53:55  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-03-25 16:53:59  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-03-25 16:54:04  - 23147  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-03-25 16:54:09  - 23147  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-03-25 16:54:13  - 23147  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-03-25 16:54:18  - 23147  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-03-25 16:54:23  - 23147  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-03-25 16:54:28  - 23147  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-03-25 16:54:32  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-03-25 16:54:37  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-03-25 16:54:42  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-03-25 16:54:46  - 23147  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-03-25 16:54:51  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-03-25 16:54:55  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-03-25 16:55:00  - 23147  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-03-25 16:55:05  - 23147  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-03-25 16:55:09  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-03-25 16:55:14  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-03-25 16:55:19  - 23147  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-03-25 16:55:23  - 23147  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
<pre>2017-03-25_16-55-27 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_16-57-27 Restart Xvfb...
2017-03-25 16:57:28  - 23147  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-03-25 16:57:33  - 23147  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-03-25 16:57:37  - 23147  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-03-25 16:57:41  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-03-25 16:57:46  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-03-25 16:57:50  - 23147  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-03-25 16:57:55  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-03-25 16:58:00  - 23147  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-03-25 16:58:04  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-03-25 16:58:09  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-03-25 16:58:14  - 23147  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-03-25 16:58:18  - 23147  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-03-25 16:58:23  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-03-25 16:58:28  - 23147  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-03-25 16:58:33  - 23147  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-03-25 16:58:37  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-03-25 16:58:42  - 23147  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-03-25 16:58:46  - 23147  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-03-25 16:58:51  - 23147  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-03-25 16:58:56  - 23147  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-03-25 16:59:00  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-03-25 16:59:05  - 23147  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-03-25 16:59:09  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-03-25 16:59:14  - 23147  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-03-25 16:59:18  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-03-25 16:59:23  - 23147  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
<pre>2017-03-25_16-59-27 Restart Xvfb...
2017-03-25 16:59:27  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-03-25 16:59:32  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-03-25 16:59:37  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-03-25 16:59:42  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-03-25 16:59:46  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-03-25 16:59:51  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-03-25 16:59:55  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-03-25 17:00:00  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-03-25 17:00:05  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-03-25 17:00:09  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-03-25 17:00:17  - 23147  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-03-25 17:00:22  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-03-25 17:00:26  - 23147  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-03-25 17:00:30  - 23147  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-03-25 17:00:35  - 23147  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-03-25 17:00:40  - 23147  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-03-25 17:00:44  - 23147  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-03-25 17:00:49  - 23147  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-03-25 17:00:53  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-03-25 17:00:58  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-03-25 17:01:03  - 23147  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-03-25 17:01:07  - 23147  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-03-25 17:01:12  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-03-25 17:01:17  - 23147  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-03-25 17:01:21  - 23147  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-03-25 17:01:26  - 23147  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
<pre>2017-03-25_17-01-27 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_17-03-27 Restart Xvfb...
2017-03-25 17:03:31  - 23147  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-03-25 17:03:36  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-03-25 17:03:41  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-03-25 17:03:46  - 23147  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-03-25 17:03:51  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-03-25 17:03:55  - 23147  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-03-25 17:04:00  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-03-25 17:04:05  - 23147  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-03-25 17:04:10  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-03-25 17:04:14  - 23147  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-03-25 17:04:19  - 23147  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-03-25 17:04:22  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-03-25 17:04:27  - 23147  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-03-25 17:04:31  - 23147  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-03-25 17:04:35  - 23147  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-03-25 17:04:40  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-03-25 17:04:45  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-03-25 17:04:49  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-03-25 17:04:53  - 23147  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-03-25 17:04:58  - 23147  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-03-25 17:05:03  - 23147  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-03-25 17:05:08  - 23147  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-03-25 17:05:12  - 23147  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-03-25 17:05:16  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-03-25 17:05:21  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-03-25 17:05:25  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
<pre>2017-03-25_17-05-27 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_17-07-27 Restart Xvfb...
2017-03-25 17:07:31  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-03-25 17:07:35  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-03-25 17:07:39  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-03-25 17:07:43  - 23147  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-03-25 17:07:48  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-03-25 17:07:53  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-03-25 17:07:57  - 23147  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-03-25 17:08:02  - 23147  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-03-25 17:08:06  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-03-25 17:08:11  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-03-25 17:08:15  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-03-25 17:08:20  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-03-25 17:08:25  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-03-25 17:08:29  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-03-25 17:08:33  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-03-25 17:08:38  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-03-25 17:08:43  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-03-25 17:08:47  - 23147  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-03-25 17:08:51  - 23147  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-03-25 17:08:56  - 23147  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-03-25 17:09:00  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-03-25 17:09:05  - 23147  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-03-25 17:09:09  - 23147  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-03-25 17:09:14  - 23147  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-03-25 17:09:19  - 23147  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-03-25 17:09:23  - 23147  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
<pre>2017-03-25_17-09-27 Restart Xvfb...
2017-03-25 17:09:27  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-03-25 17:09:32  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-03-25 17:09:37  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-03-25 17:09:41  - 23147  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-03-25 17:09:46  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-03-25 17:09:50  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-03-25 17:09:55  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-03-25 17:09:59  - 23147  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-03-25 17:10:04  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-03-25 17:10:08  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-03-25 17:10:13  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-03-25 17:10:17  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-03-25 17:10:21  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-03-25 17:10:26  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-03-25 17:10:30  - 23147  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-03-25 17:10:35  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-03-25 17:10:40  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-03-25 17:10:44  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-03-25 17:10:48  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-03-25 17:10:53  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-03-25 17:10:57  - 23147  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-03-25 17:11:02  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-03-25 17:11:06  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-03-25 17:11:11  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-03-25 17:11:15  - 23147  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-03-25 17:11:20  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-03-25 17:11:24  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
<pre>2017-03-25_17-11-27 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_17-13-27 Restart Xvfb...
2017-03-25 17:13:29  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-03-25 17:13:34  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-03-25 17:13:39  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-03-25 17:13:43  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-03-25 17:13:47  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-03-25 17:13:52  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-03-25 17:13:56  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-03-25 17:14:00  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-03-25 17:14:04  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-03-25 17:14:10  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-03-25 17:14:14  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-03-25 17:14:18  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-03-25 17:14:24  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-03-25 17:14:29  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-03-25 17:14:34  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-03-25 17:14:38  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-03-25 17:14:43  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-03-25 17:14:47  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-03-25 17:14:52  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-03-25 17:14:56  - 23147  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-03-25 17:15:00  - 23147  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-03-25 17:15:05  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-03-25 17:15:09  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-03-25 17:15:13  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-03-25 17:15:18  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-03-25 17:15:23  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
<pre>2017-03-25_17-15-27 Restart Xvfb...
2017-03-25 17:15:27  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-03-25 17:15:32  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-03-25 17:15:37  - 23147  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-03-25 17:15:41  - 23147  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-03-25 17:15:45  - 23147  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-03-25 17:15:49  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-03-25 17:15:55  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-03-25 17:15:59  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-03-25 17:16:03  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-03-25 17:16:07  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-03-25 17:16:12  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-25 17:16:16  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-25 17:16:20  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-25 17:16:24  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-25 17:16:28  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-03-25 17:16:32  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-25 17:16:36  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-25 17:16:42  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-03-25 17:16:46  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-03-25 17:16:50  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-03-25 17:16:54  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-03-25 17:16:58  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-03-25 17:17:03  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-03-25 17:17:07  - 23147  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-03-25 17:17:11  - 23147  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-03-25 17:17:15  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-03-25 17:17:19  - 23147  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-03-25 17:17:23  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-03-25 17:17:27  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
<pre>2017-03-25_17-17-27 Restart Xvfb...
2017-03-25 17:17:32  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-03-25 17:17:36  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-03-25 17:17:40  - 23147  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-03-25 17:17:44  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-03-25 17:17:48  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-03-25 17:17:52  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-03-25 17:17:57  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-03-25 17:18:01  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-03-25 17:18:05  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-25 17:18:09  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-25 17:18:13  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-25 17:18:17  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-25 17:18:21  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-25 17:18:26  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-03-25 17:18:30  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-25 17:18:34  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-25 17:18:38  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-25 17:18:42  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-25 17:18:46  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-03-25 17:18:50  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-25 17:18:54  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-25 17:18:58  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-25 17:19:02  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-03-25 17:19:06  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
<pre>2017-03-25_17-19-27 Restart Xvfb...
<pre>2017-03-25_17-21-27 Restart Xvfb...
<pre>2017-03-25_17-23-27 Restart Xvfb...
<pre>2017-03-25_17-25-28 Restart Xvfb...
<pre>2017-03-25_17-27-28 Restart Xvfb...
<pre>2017-03-25_17-29-28 Restart Xvfb...
<pre>2017-03-25_17-31-28 Restart Xvfb...
<pre>2017-03-25_17-33-28 Restart Xvfb...
<pre>2017-03-25_17-35-28 Restart Xvfb...
<pre>2017-03-25_17-37-28 Restart Xvfb...
<pre>2017-03-25_17-39-28 Restart Xvfb...
<pre>2017-03-25_17-41-28 Restart Xvfb...
<pre>2017-03-25_17-43-28 Restart Xvfb...
<pre>2017-03-25_17-45-28 Restart Xvfb...
<pre>2017-03-25_17-47-28 Restart Xvfb...
<pre>2017-03-25_17-49-28 Restart Xvfb...
<pre>2017-03-25_17-51-28 Restart Xvfb...
<pre>2017-03-25_17-53-28 Restart Xvfb...
<pre>2017-03-25_17-55-28 Restart Xvfb...
<pre>2017-03-25_17-57-28 Restart Xvfb...
<pre>2017-03-25_17-59-28 Restart Xvfb...
<pre>2017-03-25_18-01-28 Restart Xvfb...
<pre>2017-03-25_18-03-28 Restart Xvfb...
<pre>2017-03-25_18-05-28 Restart Xvfb...
<pre>2017-03-25_18-07-28 Restart Xvfb...
<pre>2017-03-25_18-09-28 Restart Xvfb...
<pre>2017-03-25_18-11-28 Restart Xvfb...
<pre>2017-03-25_18-13-28 Restart Xvfb...
<pre>2017-03-25_18-15-28 Restart Xvfb...
<pre>2017-03-25_18-17-28 Restart Xvfb...
<pre>2017-03-25_18-19-28 Restart Xvfb...
<pre>2017-03-25_18-21-28 Restart Xvfb...
<pre>2017-03-25_18-23-28 Restart Xvfb...
<pre>2017-03-25_18-25-28 Restart Xvfb...
<pre>2017-03-25_18-27-28 Restart Xvfb...
<pre>2017-03-25_18-29-28 Restart Xvfb...
<pre>2017-03-25_18-31-28 Restart Xvfb...
<pre>2017-03-25_18-33-28 Restart Xvfb...
<pre>2017-03-25_18-35-28 Restart Xvfb...
<pre>2017-03-25_18-37-28 Restart Xvfb...
<pre>2017-03-25_18-39-28 Restart Xvfb...
<pre>2017-03-25_18-41-28 Restart Xvfb...
<pre>2017-03-25_18-43-28 Restart Xvfb...
<pre>2017-03-25_18-45-28 Restart Xvfb...
<pre>2017-03-25_18-47-28 Restart Xvfb...
<pre>2017-03-25_18-49-28 Restart Xvfb...
<pre>2017-03-25_18-51-28 Restart Xvfb...
<pre>2017-03-25_18-53-28 Restart Xvfb...
<pre>2017-03-25_18-55-28 Restart Xvfb...
2017-03-25 18:56:59 reset updateRequest
2017-03-25 18:57:03  - 23147  http://www.lymphomahub.com/
2017-03-25 18:57:04  - 23147  http://www.lymphomahub.com/
2017-03-25 18:57:09  - 23147  http://www.lymphomahub.com/about
2017-03-25 18:57:13  - 23147  http://www.lymphomahub.com/about
<pre>2017-03-25_18-57-28 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about?_prerender {"code":"ECONNRESET"}
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about?_prerender {"code":"ECONNRESET"}
2017-03-25 18:59:14  - 23147  http://www.lymphomahub.com/about
2017-03-25 18:59:19  - 23147  http://www.lymphomahub.com/about
<pre>2017-03-25_18-59-28 Restart Xvfb...
2017-03-25 18:59:54  - 23147  http://www.lymphomahub.com/terms
2017-03-25 18:59:59  - 23147  http://www.lymphomahub.com/terms
2017-03-25 19:00:35  - 23147  http://www.lymphomahub.com/undefined
2017-03-25 19:00:39  - 23147  http://www.lymphomahub.com/undefined
2017-03-25 19:01:15  - 23147  http://www.lymphomahub.com/therapies
2017-03-25 19:01:20  - 23147  http://www.lymphomahub.com/therapies
<pre>2017-03-25_19-01-28 Restart Xvfb...
2017-03-25 19:01:50  - 23147  http://www.lymphomahub.com/newsletter
2017-03-25 19:01:51  - 23147  http://www.lymphomahub.com/newsletter
2017-03-25 19:01:56  - 23147  http://www.lymphomahub.com/cookie-policy
2017-03-25 19:01:56  - 23147  http://www.lymphomahub.com/cookie-policy
2017-03-25 19:02:00  - 23147  http://www.lymphomahub.com/therapies/afm13
2017-03-25 19:02:10  - 23147  http://www.lymphomahub.com/therapies/afm13
2017-03-25 19:02:19  - 23147  http://www.lymphomahub.com/therapies/afm11
2017-03-25 19:02:24  - 23147  http://www.lymphomahub.com/therapies/ags67e
2017-03-25 19:02:25  - 23147  http://www.lymphomahub.com/therapies/ags67e
2017-03-25 19:02:29  - 23147  http://www.lymphomahub.com/therapies/cc-292
2017-03-25 19:02:30  - 23147  http://www.lymphomahub.com/therapies/cc-292
2017-03-25 19:02:35  - 23147  http://www.lymphomahub.com/therapies/cc-223
2017-03-25 19:02:35  - 23147  http://www.lymphomahub.com/therapies/cc-223
2017-03-25 19:02:40  - 23147  http://www.lymphomahub.com/therapies/sd-101
2017-03-25 19:02:40  - 23147  http://www.lymphomahub.com/therapies/sd-101
2017-03-25 19:02:46  - 23147  http://www.lymphomahub.com/therapies/rp6530
2017-03-25 19:02:50  - 23147  http://www.lymphomahub.com/therapies/abt199
2017-03-25 19:02:51  - 23147  http://www.lymphomahub.com/therapies/mor208
2017-03-25 19:02:55  - 23147  http://www.lymphomahub.com/therapies/cc-122
2017-03-25 19:03:00  - 23147  http://www.lymphomahub.com/therapies/at-101
2017-03-25 19:03:05  - 23147  http://www.lymphomahub.com/therapies/bl8040
2017-03-25 19:03:10  - 23147  http://www.lymphomahub.com/therapies/bcl201
2017-03-25 19:03:21  - 23147  http://www.lymphomahub.com/therapies/azd3965
<pre>2017-03-25_19-03-28 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/azd3965?_prerender {"code":"ECONNRESET"}
2017-03-25 19:05:26  - 23147  http://www.lymphomahub.com/therapies/azd3965
<pre>2017-03-25_19-05-29 Restart Xvfb...
2017-03-25 19:05:47  - 23147  http://www.lymphomahub.com/therapies/imgn529
2017-03-25 19:05:52  - 23147  http://www.lymphomahub.com/therapies/azd2014
2017-03-25 19:06:02  - 23147  http://www.lymphomahub.com/therapies/mt-3724
2017-03-25 19:06:07  - 23147  http://www.lymphomahub.com/therapies/actr087
2017-03-25 19:06:12  - 23147  http://www.lymphomahub.com/therapies/epz6438
2017-03-25 19:06:16  - 23147  http://www.lymphomahub.com/therapies/kte-c19
2017-03-25 19:06:22  - 23147  http://www.lymphomahub.com/about/secretariat
2017-03-25 19:06:25  - 23147  http://www.lymphomahub.com/therapies/alt-803
2017-03-25 19:06:30  - 23147  http://www.lymphomahub.com/therapies/regn1979
2017-03-25 19:06:35  - 23147  http://www.lymphomahub.com/therapies/immu-114
2017-03-25 19:06:39  - 23147  http://www.lymphomahub.com/therapies/incb7839
2017-03-25 19:06:49  - 23147  http://www.lymphomahub.com/therapies/adct-301
2017-03-25 19:06:58  - 23147  http://www.lymphomahub.com/therapies/ixazomib
2017-03-25 19:07:03  - 23147  http://www.lymphomahub.com/therapies/avelumab
2017-03-25 19:07:07  - 23147  http://www.lymphomahub.com/therapies/bi836826
2017-03-25 19:07:12  - 23147  http://www.lymphomahub.com/therapies/medi-570
2017-03-25 19:07:16  - 23147  http://www.lymphomahub.com/therapies/ds-3201b
<pre>2017-03-25_19-07-29 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/ds-3201b?_prerender {"code":"ECONNRESET"}
2017-03-25 19:09:21  - 23147  http://www.lymphomahub.com/therapies/ds-3201b
<pre>2017-03-25_19-09-29 Restart Xvfb...
2017-03-25 19:10:02  - 23147  http://www.lymphomahub.com/therapies/sea-cd40
2017-03-25 19:10:44  - 23147  http://www.lymphomahub.com/therapies/adct-402
2017-03-25 19:10:49  - 23147  http://www.lymphomahub.com/therapies/acy-1215
2017-03-25 19:11:26  - 23147  http://www.lymphomahub.com/therapies/cudc-907
<pre>2017-03-25_19-11-29 Restart Xvfb...
2017-03-25 19:11:35  - 23147  http://www.lymphomahub.com/therapies/tgr-1202
2017-03-25 19:11:40  - 23147  http://www.lymphomahub.com/therapies/axitinib
2017-03-25 19:11:45  - 23147  http://www.lymphomahub.com/therapies/imatinib
2017-03-25 19:11:49  - 23147  http://www.lymphomahub.com/therapies/edo-s101
2017-03-25 19:11:54  - 23147  http://www.lymphomahub.com/therapies/btct4465a
2017-03-25 19:11:59  - 23147  http://www.lymphomahub.com/therapies/alisertib
2017-03-25 19:12:05  - 23147  http://www.lymphomahub.com/therapies/lirilumab
2017-03-25 19:12:14  - 23147  http://www.lymphomahub.com/therapies/ibrutinib
2017-03-25 19:12:19  - 23147  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-03-25 19:12:23  - 23147  http://www.lymphomahub.com/therapies/rituximab
2017-03-25 19:12:28  - 23147  http://www.lymphomahub.com/therapies/veliparib
2017-03-25 19:13:07  - 23147  http://www.lymphomahub.com/therapies/sunitinib
2017-03-25 19:13:12  - 23147  http://www.lymphomahub.com/therapies/nivolumab
2017-03-25 19:13:12  - 23147  http://www.lymphomahub.com/therapies/sirolimus
2017-03-25 19:13:17  - 23147  http://www.lymphomahub.com/medical-information
2017-03-25 19:13:21  - 23147  http://www.lymphomahub.com/therapies/selinexor
2017-03-25 19:13:26  - 23147  http://www.lymphomahub.com/therapies/abc294640
<pre>2017-03-25_19-13-29 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/abc294640?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_19-15-29 Restart Xvfb...
2017-03-25 19:15:31  - 23147  http://www.lymphomahub.com/therapies/abc294640
2017-03-25 19:15:50  - 23147  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-03-25 19:15:54  - 23147  http://www.lymphomahub.com/therapies/tenofovir
2017-03-25 19:15:59  - 23147  http://www.lymphomahub.com/therapies/betalutin
2017-03-25 19:16:04  - 23147  http://www.lymphomahub.com/therapies/chidamide
2017-03-25 19:16:19  - 23147  http://www.lymphomahub.com/therapies/duvelisib
2017-03-25 19:16:24  - 23147  http://www.lymphomahub.com/therapies/dasatinib
2017-03-25 19:16:29  - 23147  http://www.lymphomahub.com/therapies/everolimus
2017-03-25 19:16:34  - 23147  http://www.lymphomahub.com/therapies/incb039110
2017-03-25 19:16:39  - 23147  http://www.lymphomahub.com/therapies/durvalumab
2017-03-25 19:16:44  - 23147  http://www.lymphomahub.com/therapies/romidepsin
2017-03-25 19:16:48  - 23147  http://www.lymphomahub.com/therapies/bortezomib
2017-03-25 19:16:53  - 23147  http://www.lymphomahub.com/therapies/idelalisib
2017-03-25 19:16:54  - 23147  http://www.lymphomahub.com/therapies/tipifarnib
2017-03-25 19:16:58  - 23147  http://www.lymphomahub.com/therapies/ipilimumab
2017-03-25 19:17:03  - 23147  http://www.lymphomahub.com/therapies/crizotinib
2017-03-25 19:17:07  - 23147  http://www.lymphomahub.com/therapies/gsk2816126
2017-03-25 19:17:12  - 23147  http://www.lymphomahub.com/therapies/copanlisib
2017-03-25 19:17:17  - 23147  http://www.lymphomahub.com/therapies/buparlisib
2017-03-25 19:17:21  - 23147  http://www.lymphomahub.com/therapies/belinostat
2017-03-25 19:17:26  - 23147  http://www.lymphomahub.com/therapies/vorinostat
<pre>2017-03-25_19-17-29 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/vorinostat?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_19-19-29 Restart Xvfb...
2017-03-25 19:19:31  - 23147  http://www.lymphomahub.com/therapies/vorinostat
2017-03-25 19:20:11  - 23147  http://www.lymphomahub.com/therapies/plerixafor
2017-03-25 19:20:48  - 23147  http://www.lymphomahub.com/therapies/ofatumumab
2017-03-25 19:21:08  - 23147  http://www.lymphomahub.com/therapies/pf-06801591
2017-03-25 19:21:13  - 23147  http://www.lymphomahub.com/therapies/tocilizumab
2017-03-25 19:21:18  - 23147  http://www.lymphomahub.com/therapies/msc2490484a
2017-03-25 19:21:28  - 23147  http://www.lymphomahub.com/therapies/carfilzomib
<pre>2017-03-25_19-21-29 Restart Xvfb...
2017-03-25 19:21:37  - 23147  http://www.lymphomahub.com/therapies/ruxolitinib
2017-03-25 19:21:46  - 23147  http://www.lymphomahub.com/therapies/palbociclib
2017-03-25 19:21:51  - 23147  http://www.lymphomahub.com/therapies/fenretinide
2017-03-25 19:21:56  - 23147  http://www.lymphomahub.com/therapies/daratumumab
2017-03-25 19:22:00  - 23147  http://www.lymphomahub.com/therapies/pf-05082566
2017-03-25 19:22:05  - 23147  http://www.lymphomahub.com/therapies/ramucirumab
2017-03-25 19:22:09  - 23147  http://www.lymphomahub.com/therapies/tositumomab
2017-03-25 19:22:14  - 23147  http://www.lymphomahub.com/therapies/ublituximab
2017-03-25 19:22:19  - 23147  http://www.lymphomahub.com/therapies/epacadostat
2017-03-25 19:22:23  - 23147  http://www.lymphomahub.com/therapies/alemtuzumab
2017-03-25 19:22:24  - 23147  http://www.lymphomahub.com/therapies/otlertuzumab
2017-03-25 19:22:28  - 23147  http://www.lymphomahub.com/therapies/panobinostat
2017-03-25 19:22:37  - 23147  http://www.lymphomahub.com/therapies/mocetinostat
2017-03-25 19:23:10  - 23147  http://www.lymphomahub.com/therapies/atezolizumab
<pre>2017-03-25_19-23-29 Restart Xvfb...
2017-03-25 19:23:50  - 23147  http://www.lymphomahub.com/therapies/temsirolimus
2017-03-25 19:24:28  - 23147  http://www.lymphomahub.com/therapies/lenalidomide
2017-03-25 19:24:42  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab
2017-03-25 19:24:46  - 23147  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-03-25 19:24:51  - 23147  http://www.lymphomahub.com/therapies/blinatumomab
2017-03-25 19:25:23  - 23147  http://www.lymphomahub.com/therapies/jnj-64052781
<pre>2017-03-25_19-25-29 Restart Xvfb...
2017-03-25 19:25:38  - 23147  http://www.lymphomahub.com/therapies/entospletinib
2017-03-25 19:25:42  - 23147  http://www.lymphomahub.com/therapies/pembrolizumab
2017-03-25 19:25:47  - 23147  http://www.lymphomahub.com/therapies/acalabrutinib
2017-03-25 19:25:51  - 23147  http://www.lymphomahub.com/about/innovation-committee
2017-03-25 19:25:56  - 23147  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-03-25 19:26:02  - 23147  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-03-25 19:26:07  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-03-25 19:26:17  - 23147  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-03-25 19:26:22  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-03-25 19:26:32  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-03-25 19:26:33  - 23147  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-03-25 19:26:37  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-03-25 19:26:42  - 23147  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-03-25 19:26:47  - 23147  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-03-25 19:26:54  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board
2017-03-25 19:27:01  - 23147  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-03-25 19:27:05  - 23147  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
<pre>2017-03-25_19-27-29 Restart Xvfb...
2017-03-25 19:27:45  - 23147  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-03-25 19:28:26  - 23147  http://www.lymphomahub.com/about/executive-steering-committee
2017-03-25 19:29:06  - 23147  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-03-25 19:29:21  - 23147  http://www.lymphomahub.com/medical-information/know-your-subtype
<pre>2017-03-25_19-29-29 Restart Xvfb...
2017-03-25 19:29:50  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-03-25 19:29:54  - 23147  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-03-25 19:30:04  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-03-25 19:30:20  - 23147  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-03-25 19:30:24  - 23147  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-03-25 19:30:24  - 23147  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-03-25 19:30:32  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-03-25 19:30:37  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-03-25 19:30:42  - 23147  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-03-25 19:30:46  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-03-25 19:30:51  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-03-25 19:30:56  - 23147  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-03-25 19:31:00  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-03-25 19:31:04  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-03-25 19:31:08  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-03-25 19:31:12  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-03-25 19:31:21  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-03-25 19:31:28  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
<pre>2017-03-25_19-31-29 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_19-33-29 Restart Xvfb...
2017-03-25 19:33:34  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-03-25 19:34:14  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-03-25 19:34:52  - 23147  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-03-25 19:35:09  - 23147  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-03-25 19:35:19  - 23147  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-03-25 19:35:28  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
<pre>2017-03-25_19-35-29 Restart Xvfb...
2017-03-25 19:35:36  - 23147  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-03-25 19:35:45  - 23147  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-03-25 19:35:48  - 23147  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-03-25 19:35:53  - 23147  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-03-25 19:35:56  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-03-25 19:36:00  - 23147  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-03-25 19:36:04  - 23147  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-03-25 19:36:08  - 23147  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-03-25 19:36:13  - 23147  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-03-25 19:36:18  - 23147  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-03-25 19:36:23  - 23147  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-03-25 19:36:27  - 23147  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-03-25 19:36:32  - 23147  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-03-25 19:36:36  - 23147  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-03-25 19:36:46  - 23147  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-03-25 19:36:51  - 23147  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-03-25 19:36:56  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-03-25 19:37:04  - 23147  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
<pre>2017-03-25_19-37-29 Restart Xvfb...
2017-03-25 19:37:44  - 23147  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-03-25 19:38:12  - 23147  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-03-25 19:38:52  - 23147  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
<pre>2017-03-25_19-39-29 Restart Xvfb...
2017-03-25 19:39:38  - 23147  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-03-25 19:40:03  - 23147  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-03-25 19:40:18  - 23147  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-03-25 19:40:25  - 23147  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-03-25 19:40:35  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-03-25 19:40:39  - 23147  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-03-25 19:40:45  - 23147  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-03-25 19:40:57  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-03-25 19:41:02  - 23147  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-03-25 19:41:07  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-03-25 19:41:11  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-03-25 19:41:15  - 23147  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-03-25 19:41:19  - 23147  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-03-25 19:41:24  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-03-25 19:41:28  - 23147  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
<pre>2017-03-25_19-41-29 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_19-43-29 Restart Xvfb...
2017-03-25 19:43:33  - 23147  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-03-25 19:44:05  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-03-25 19:44:46  - 23147  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
<pre>2017-03-25_19-45-29 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index?_prerender {"code":"ECONNRESET"}
2017-03-25 19:46:51  - 23147  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-03-25 19:47:25  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
<pre>2017-03-25_19-47-29 Restart Xvfb...
2017-03-25 19:47:29  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-03-25 19:47:34  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-03-25 19:47:38  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-03-25 19:47:47  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-03-25 19:47:53  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-03-25 19:47:57  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-03-25 19:48:01  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-03-25 19:48:06  - 23147  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-03-25 19:48:11  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-03-25 19:48:16  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-03-25 19:48:21  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-03-25 19:48:26  - 23147  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-25 19:48:27  - 23147  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-03-25 19:48:31  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-03-25 19:48:36  - 23147  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-03-25 19:48:41  - 23147  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-03-25 19:48:45  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-03-25 19:48:51  - 23147  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-03-25 19:49:00  - 23147  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-03-25 19:49:11  - 23147  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
<pre>2017-03-25_19-49-29 Restart Xvfb...
2017-03-25 19:49:51  - 23147  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-03-25 19:50:31  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-03-25 19:51:12  - 23147  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
<pre>2017-03-25_19-51-29 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging?_prerender {"code":"ECONNRESET"}
2017-03-25 19:53:17  - 23147  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
<pre>2017-03-25_19-53-29 Restart Xvfb...
2017-03-25 19:53:57  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-03-25 19:54:23  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-03-25 19:54:34  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-03-25 19:54:43  - 23147  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-03-25 19:54:51  - 23147  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-03-25 19:55:05  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-03-25 19:55:10  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
<pre>2017-03-25_19-55-29 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide?_prerender {"code":"ECONNRESET"}
2017-03-25 19:57:15  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
<pre>2017-03-25_19-57-29 Restart Xvfb...
2017-03-25 19:58:06  - 23147  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-03-25 19:58:46  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-03-25 19:59:26  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
<pre>2017-03-25_19-59-29 Restart Xvfb...
2017-03-25 19:59:52  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-03-25 19:59:57  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-03-25 20:00:12  - 23147  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-25 20:00:47  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-03-25 20:00:58  - 23147  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-03-25 20:01:02  - 23147  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-03-25 20:01:07  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-03-25 20:01:15  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-03-25 20:01:20  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-03-25 20:01:25  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
<pre>2017-03-25_20-01-29 Restart Xvfb...
2017-03-25 20:01:29  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-03-25 20:01:34  - 23147  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-03-25 20:01:39  - 23147  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-03-25 20:02:16  - 23147  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-03-25 20:02:31  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-03-25 20:02:36  - 23147  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-03-25 20:02:41  - 23147  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-03-25 20:02:46  - 23147  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-03-25 20:02:46  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-03-25 20:02:51  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-03-25 20:02:56  - 23147  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-03-25 20:03:05  - 23147  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-03-25 20:03:10  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-03-25 20:03:14  - 23147  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-03-25 20:03:24  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-03-25 20:03:29  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
<pre>2017-03-25_20-03-29 Restart Xvfb...
2017-03-25 20:03:34  - 23147  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-03-25 20:03:39  - 23147  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-03-25 20:03:44  - 23147  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-03-25 20:03:48  - 23147  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-03-25 20:03:53  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-03-25 20:03:58  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-03-25 20:04:02  - 23147  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-03-25 20:04:09  - 23147  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-03-25 20:04:13  - 23147  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-03-25 20:04:18  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-03-25 20:04:23  - 23147  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-03-25 20:04:28  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-03-25 20:04:32  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-03-25 20:04:36  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-03-25 20:04:42  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-03-25 20:04:51  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-03-25 20:04:59  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-03-25 20:05:03  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-03-25 20:05:06  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-03-25 20:05:16  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-03-25 20:05:20  - 23147  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-03-25 20:05:22  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
<pre>2017-03-25_20-05-29 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146?_prerender {"code":"ECONNRESET"}
2017-03-25 20:07:27  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
<pre>2017-03-25_20-07-29 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_20-09-29 Restart Xvfb...
2017-03-25 20:09:32  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-03-25 20:09:37  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-03-25 20:09:42  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-03-25 20:09:45  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-03-25 20:09:49  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-03-25 20:09:53  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-03-25 20:09:56  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-03-25 20:10:00  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-03-25 20:10:04  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-03-25 20:10:12  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-03-25 20:10:18  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-03-25 20:10:21  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-03-25 20:10:25  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-03-25 20:10:30  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-03-25 20:10:34  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-03-25 20:10:38  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-03-25 20:10:43  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-03-25 20:10:47  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-03-25 20:10:52  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-03-25 20:10:55  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-03-25 20:10:59  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-03-25 20:11:03  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-03-25 20:11:06  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-03-25 20:11:10  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-03-25 20:11:14  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-03-25 20:11:18  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-03-25 20:11:22  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-03-25 20:11:25  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-03-25 20:11:29  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
<pre>2017-03-25_20-11-29 Restart Xvfb...
2017-03-25 20:11:33  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-03-25 20:11:37  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-03-25 20:11:40  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-03-25 20:11:49  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-03-25 20:11:53  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-03-25 20:11:57  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-03-25 20:12:01  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-03-25 20:12:05  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-03-25 20:12:11  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-03-25 20:12:15  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-03-25 20:12:19  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-03-25 20:12:28  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-03-25 20:12:32  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-03-25 20:12:35  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-03-25 20:12:44  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-03-25 20:12:48  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-03-25 20:12:51  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-03-25 20:12:55  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-03-25 20:12:59  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-03-25 20:13:03  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-03-25 20:13:07  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-03-25 20:13:12  - 23147  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-03-25 20:13:16  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-03-25 20:13:21  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-03-25 20:13:26  - 23147  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-03-25 20:13:26  - 23147  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
<pre>2017-03-25_20-13-29 Restart Xvfb...
2017-03-25 20:13:34  - 23147  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-03-25 20:13:39  - 23147  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-03-25 20:13:45  - 23147  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-03-25 20:13:49  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-03-25 20:13:58  - 23147  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-03-25 20:14:08  - 23147  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-03-25 20:14:18  - 23147  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-03-25 20:14:23  - 23147  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-03-25 20:14:28  - 23147  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-03-25 20:14:32  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-03-25 20:14:37  - 23147  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-03-25 20:14:42  - 23147  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-03-25 20:14:47  - 23147  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-03-25 20:14:52  - 23147  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-03-25 20:14:56  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-03-25 20:15:01  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-03-25 20:15:05  - 23147  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-03-25 20:15:25  - 23147  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
<pre>2017-03-25_20-15-29 Restart Xvfb...
2017-03-25 20:15:34  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-03-25 20:15:44  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-03-25 20:15:54  - 23147  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-25 20:16:06  - 23147  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-03-25 20:16:13  - 23147  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-03-25 20:16:23  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-03-25 20:16:27  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-03-25 20:16:32  - 23147  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-03-25 20:16:37  - 23147  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-03-25 20:16:42  - 23147  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-03-25 20:16:46  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-03-25 20:16:51  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-03-25 20:16:56  - 23147  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-25 20:17:00  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-03-25 20:17:05  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-03-25 20:17:18  - 23147  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-03-25 20:17:28  - 23147  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
<pre>2017-03-25_20-17-29 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_20-19-29 Restart Xvfb...
2017-03-25 20:19:33  - 23147  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-03-25 20:19:38  - 23147  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-03-25 20:19:43  - 23147  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-03-25 20:19:48  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-03-25 20:19:54  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-03-25 20:19:58  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-03-25 20:20:03  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-03-25 20:20:08  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-03-25 20:20:12  - 23147  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-03-25 20:20:17  - 23147  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-03-25 20:20:32  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-03-25 20:20:41  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-03-25 20:20:49  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-03-25 20:20:59  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-03-25 20:21:04  - 23147  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-03-25 20:21:17  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-03-25 20:21:22  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-03-25 20:21:27  - 23147  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
<pre>2017-03-25_20-21-29 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_20-23-29 Restart Xvfb...
2017-03-25 20:23:32  - 23147  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-03-25 20:23:37  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-03-25 20:23:42  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-03-25 20:23:47  - 23147  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-03-25 20:23:52  - 23147  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-03-25 20:23:56  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-03-25 20:24:04  - 23147  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-03-25 20:24:14  - 23147  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-03-25 20:24:23  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-03-25 20:24:28  - 23147  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-03-25 20:24:33  - 23147  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-03-25 20:24:49  - 23147  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-03-25 20:24:54  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-03-25 20:24:58  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-03-25 20:25:03  - 23147  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-03-25 20:25:08  - 23147  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-03-25 20:25:13  - 23147  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-03-25 20:25:17  - 23147  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-03-25 20:25:22  - 23147  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-03-25 20:25:27  - 23147  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
<pre>2017-03-25_20-25-29 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_20-27-29 Restart Xvfb...
2017-03-25 20:27:32  - 23147  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-03-25 20:27:41  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-03-25 20:27:46  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-03-25 20:27:51  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-03-25 20:27:57  - 23147  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-03-25 20:28:01  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-03-25 20:28:07  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-03-25 20:28:11  - 23147  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-03-25 20:28:16  - 23147  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-03-25 20:28:22  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-03-25 20:28:27  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-03-25 20:28:32  - 23147  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-03-25 20:28:37  - 23147  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-03-25 20:28:41  - 23147  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-03-25 20:28:45  - 23147  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-03-25 20:28:50  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-03-25 20:28:55  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-03-25 20:29:00  - 23147  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-03-25 20:29:04  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-03-25 20:29:09  - 23147  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-03-25 20:29:13  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-03-25 20:29:23  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
<pre>2017-03-25_20-29-29 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl?_prerender {"code":"ECONNRESET"}
2017-03-25 20:31:28  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
<pre>2017-03-25_20-31-29 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_20-33-30 Restart Xvfb...
2017-03-25 20:33:33  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-03-25 20:33:38  - 23147  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-03-25 20:33:43  - 23147  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-03-25 20:33:48  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-03-25 20:33:53  - 23147  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-03-25 20:33:58  - 23147  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-03-25 20:34:03  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-03-25 20:34:07  - 23147  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-03-25 20:34:12  - 23147  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-03-25 20:34:17  - 23147  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-03-25 20:34:21  - 23147  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-03-25 20:34:26  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-03-25 20:34:30  - 23147  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-03-25 20:34:43  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-03-25 20:34:48  - 23147  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-03-25 20:35:00  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-03-25 20:35:08  - 23147  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-03-25 20:35:13  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-03-25 20:35:25  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
<pre>2017-03-25_20-35-30 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_20-37-30 Restart Xvfb...
2017-03-25 20:37:30  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-03-25 20:37:35  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-03-25 20:37:40  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-03-25 20:37:44  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-03-25 20:37:49  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-03-25 20:37:56  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-03-25 20:38:00  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-03-25 20:38:05  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-03-25 20:38:21  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-03-25 20:38:30  - 23147  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-03-25 20:38:35  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-03-25 20:38:40  - 23147  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-03-25 20:38:47  - 23147  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-03-25 20:38:52  - 23147  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-03-25 20:38:57  - 23147  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-03-25 20:39:02  - 23147  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-03-25 20:39:07  - 23147  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-03-25 20:39:12  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-03-25 20:39:16  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-03-25 20:39:21  - 23147  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-03-25 20:39:26  - 23147  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
<pre>2017-03-25_20-39-30 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_20-41-30 Restart Xvfb...
2017-03-25 20:41:31  - 23147  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-03-25 20:41:35  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-03-25 20:41:50  - 23147  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-03-25 20:42:03  - 23147  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-03-25 20:42:08  - 23147  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-03-25 20:42:14  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-03-25 20:42:24  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-03-25 20:42:29  - 23147  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-03-25 20:42:34  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-03-25 20:42:39  - 23147  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-03-25 20:42:43  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-03-25 20:42:48  - 23147  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-03-25 20:42:53  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-03-25 20:42:58  - 23147  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-03-25 20:43:02  - 23147  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-03-25 20:43:06  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-03-25 20:43:11  - 23147  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-03-25 20:43:15  - 23147  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-03-25 20:43:20  - 23147  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-03-25 20:43:29  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
<pre>2017-03-25_20-43-30 Restart Xvfb...
2017-03-25 20:43:34  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-03-25 20:43:45  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-03-25 20:43:49  - 23147  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-03-25 20:43:54  - 23147  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-03-25 20:43:59  - 23147  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-03-25 20:44:04  - 23147  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-03-25 20:44:08  - 23147  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-03-25 20:44:12  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-03-25 20:44:17  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-03-25 20:44:22  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-03-25 20:44:26  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-03-25 20:44:31  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-03-25 20:44:35  - 23147  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-03-25 20:44:40  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-03-25 20:44:44  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-03-25 20:44:49  - 23147  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-03-25 20:44:57  - 23147  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-03-25 20:45:01  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-03-25 20:45:05  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-03-25 20:45:12  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-03-25 20:45:21  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-03-25 20:45:27  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
<pre>2017-03-25_20-45-30 Restart Xvfb...
2017-03-25 20:45:36  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-03-25 20:45:40  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-03-25 20:45:50  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-03-25 20:45:55  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-03-25 20:45:59  - 23147  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-03-25 20:46:04  - 23147  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-03-25 20:46:08  - 23147  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-03-25 20:46:13  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-03-25 20:46:17  - 23147  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-03-25 20:46:21  - 23147  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-03-25 20:46:26  - 23147  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-03-25 20:46:31  - 23147  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-03-25 20:46:35  - 23147  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-03-25 20:46:40  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-03-25 20:46:44  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-03-25 20:46:57  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-03-25 20:47:02  - 23147  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-03-25 20:47:07  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-03-25 20:47:16  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-03-25 20:47:22  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-03-25 20:47:26  - 23147  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
<pre>2017-03-25_20-47-30 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_20-49-30 Restart Xvfb...
2017-03-25 20:49:31  - 23147  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-03-25 20:49:36  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-03-25 20:49:41  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-03-25 20:49:45  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-03-25 20:49:49  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-03-25 20:49:54  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-03-25 20:49:59  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-03-25 20:50:03  - 23147  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-03-25 20:50:08  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-03-25 20:50:12  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-03-25 20:50:22  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-03-25 20:50:30  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-03-25 20:50:35  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-03-25 20:50:44  - 23147  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-03-25 20:50:49  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-03-25 20:50:53  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-03-25 20:51:03  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-03-25 20:51:08  - 23147  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-03-25 20:51:12  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-03-25 20:51:17  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-03-25 20:51:22  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-03-25 20:51:27  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
<pre>2017-03-25_20-51-30 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_20-53-30 Restart Xvfb...
2017-03-25 20:53:32  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-03-25 20:53:35  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-03-25 20:53:40  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-03-25 20:53:44  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-03-25 20:53:48  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-03-25 20:53:57  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-03-25 20:54:05  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-03-25 20:54:10  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-03-25 20:54:14  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-03-25 20:54:25  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-03-25 20:54:29  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-03-25 20:54:33  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-03-25 20:54:37  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-03-25 20:54:41  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-03-25 20:54:46  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-03-25 20:54:51  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-03-25 20:54:55  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-03-25 20:54:59  - 23147  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-03-25 20:55:03  - 23147  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-03-25 20:55:08  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-03-25 20:55:13  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-03-25 20:55:17  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-03-25 20:55:22  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-03-25 20:55:27  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
<pre>2017-03-25_20-55-30 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_20-57-30 Restart Xvfb...
2017-03-25 20:57:32  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-03-25 20:57:36  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-03-25 20:57:41  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-03-25 20:57:45  - 23147  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-03-25 20:57:50  - 23147  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-03-25 20:57:54  - 23147  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-03-25 20:57:58  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-03-25 20:58:08  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-03-25 20:58:12  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-03-25 20:58:16  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-03-25 20:58:21  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-03-25 20:58:25  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-25 20:58:29  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-25 20:58:33  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-25 20:58:37  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-25 20:58:41  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-03-25 20:58:45  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-25 20:58:50  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-25 20:58:54  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-03-25 20:58:58  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-03-25 20:59:02  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-03-25 20:59:06  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-03-25 20:59:19  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-03-25 20:59:23  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
<pre>2017-03-25_20-59-30 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-?_prerender {"code":"ECONNRESET"}
2017-03-25 21:01:28  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
<pre>2017-03-25_21-01-30 Restart Xvfb...
2017-03-25 21:01:37  - 23147  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-03-25 21:01:41  - 23147  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-03-25 21:01:45  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-03-25 21:01:49  - 23147  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-03-25 21:01:54  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-03-25 21:01:58  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-03-25 21:02:03  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-03-25 21:02:07  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-03-25 21:02:11  - 23147  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-03-25 21:02:15  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-03-25 21:02:20  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-03-25 21:02:24  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-03-25 21:02:28  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-03-25 21:02:31  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-03-25 21:02:36  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-25 21:02:45  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-25 21:02:49  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-25 21:02:53  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-25 21:02:59  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-25 21:03:09  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-03-25 21:03:13  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-25 21:03:17  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-25 21:03:21  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-25 21:03:29  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
<pre>2017-03-25_21-03-30 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_21-05-30 Restart Xvfb...
2017-03-25 21:05:34  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-25 21:05:38  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-03-25 21:05:42  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-25 21:05:46  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-25 21:05:51  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-25 21:05:55  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-03-25 21:05:59  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
<pre>2017-03-25_21-07-30 Restart Xvfb...
<pre>2017-03-25_21-09-30 Restart Xvfb...
<pre>2017-03-25_21-11-30 Restart Xvfb...
<pre>2017-03-25_21-13-30 Restart Xvfb...
<pre>2017-03-25_21-15-30 Restart Xvfb...
<pre>2017-03-25_21-17-30 Restart Xvfb...
<pre>2017-03-25_21-19-30 Restart Xvfb...
<pre>2017-03-25_21-21-30 Restart Xvfb...
<pre>2017-03-25_21-23-30 Restart Xvfb...
<pre>2017-03-25_21-25-30 Restart Xvfb...
<pre>2017-03-25_21-27-30 Restart Xvfb...
<pre>2017-03-25_21-29-30 Restart Xvfb...
<pre>2017-03-25_21-31-30 Restart Xvfb...
<pre>2017-03-25_21-33-30 Restart Xvfb...
<pre>2017-03-25_21-35-30 Restart Xvfb...
<pre>2017-03-25_21-37-30 Restart Xvfb...
<pre>2017-03-25_21-39-30 Restart Xvfb...
<pre>2017-03-25_21-41-30 Restart Xvfb...
<pre>2017-03-25_21-43-30 Restart Xvfb...
<pre>2017-03-25_21-45-30 Restart Xvfb...
<pre>2017-03-25_21-47-30 Restart Xvfb...
<pre>2017-03-25_21-49-30 Restart Xvfb...
<pre>2017-03-25_21-51-30 Restart Xvfb...
<pre>2017-03-25_21-53-30 Restart Xvfb...
<pre>2017-03-25_21-55-30 Restart Xvfb...
2017-03-25 21:56:59 reset updateRequest
2017-03-25 21:56:59  - 23147  http://www.lymphomahub.com/
2017-03-25 21:57:04  - 23147  http://www.lymphomahub.com/
2017-03-25 21:57:07  - 23147  http://www.lymphomahub.com/about
2017-03-25 21:57:12  - 23147  http://www.lymphomahub.com/terms
2017-03-25 21:57:13  - 23147  http://www.lymphomahub.com/terms
2017-03-25 21:57:20  - 23147  http://www.lymphomahub.com/undefined
2017-03-25 21:57:21  - 23147  http://www.lymphomahub.com/therapies
2017-03-25 21:57:27  - 23147  http://www.lymphomahub.com/therapies
2017-03-25 21:57:28  - 23147  http://www.lymphomahub.com/newsletter
<pre>2017-03-25_21-57-30 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies?_prerender {"code":"ECONNRESET"}
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/newsletter?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_21-59-30 Restart Xvfb...
2017-03-25 21:59:32  - 23147  http://www.lymphomahub.com/newsletter
2017-03-25 21:59:33  - 23147  http://www.lymphomahub.com/newsletter
2017-03-25 21:59:36  - 23147  http://www.lymphomahub.com/cookie-policy
2017-03-25 21:59:40  - 23147  http://www.lymphomahub.com/cookie-policy
2017-03-25 21:59:43  - 23147  http://www.lymphomahub.com/therapies/afm13
2017-03-25 21:59:44  - 23147  http://www.lymphomahub.com/therapies/afm13
2017-03-25 21:59:48  - 23147  http://www.lymphomahub.com/therapies/afm11
2017-03-25 21:59:49  - 23147  http://www.lymphomahub.com/therapies/afm11
2017-03-25 21:59:53  - 23147  http://www.lymphomahub.com/therapies/ags67e
2017-03-25 21:59:54  - 23147  http://www.lymphomahub.com/therapies/ags67e
2017-03-25 21:59:58  - 23147  http://www.lymphomahub.com/therapies/cc-292
2017-03-25 21:59:59  - 23147  http://www.lymphomahub.com/therapies/cc-292
2017-03-25 22:00:04  - 23147  http://www.lymphomahub.com/therapies/cc-223
2017-03-25 22:00:04  - 23147  http://www.lymphomahub.com/therapies/cc-223
2017-03-25 22:00:09  - 23147  http://www.lymphomahub.com/therapies/sd-101
2017-03-25 22:00:10  - 23147  http://www.lymphomahub.com/therapies/sd-101
2017-03-25 22:00:15  - 23147  http://www.lymphomahub.com/therapies/rp6530
2017-03-25 22:00:20  - 23147  http://www.lymphomahub.com/therapies/abt199
2017-03-25 22:00:20  - 23147  http://www.lymphomahub.com/therapies/mor208
2017-03-25 22:00:25  - 23147  http://www.lymphomahub.com/therapies/cc-122
2017-03-25 22:00:29  - 23147  http://www.lymphomahub.com/therapies/at-101
2017-03-25 22:00:34  - 23147  http://www.lymphomahub.com/therapies/bl8040
2017-03-25 22:00:54  - 23147  http://www.lymphomahub.com/therapies/bcl201
2017-03-25 22:00:58  - 23147  http://www.lymphomahub.com/therapies/azd3965
2017-03-25 22:01:04  - 23147  http://www.lymphomahub.com/therapies/imgn529
2017-03-25 22:01:09  - 23147  http://www.lymphomahub.com/therapies/azd2014
2017-03-25 22:01:19  - 23147  http://www.lymphomahub.com/therapies/mt-3724
2017-03-25 22:01:25  - 23147  http://www.lymphomahub.com/therapies/actr087
<pre>2017-03-25_22-01-30 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/actr087?_prerender {"code":"ECONNRESET"}
2017-03-25 22:03:30  - 23147  http://www.lymphomahub.com/therapies/actr087
<pre>2017-03-25_22-03-30 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/actr087?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_22-05-31 Restart Xvfb...
2017-03-25 22:05:35  - 23147  http://www.lymphomahub.com/therapies/actr087
2017-03-25 22:05:39  - 23147  http://www.lymphomahub.com/therapies/epz6438
2017-03-25 22:05:44  - 23147  http://www.lymphomahub.com/therapies/kte-c19
2017-03-25 22:05:48  - 23147  http://www.lymphomahub.com/about/secretariat
2017-03-25 22:05:57  - 23147  http://www.lymphomahub.com/therapies/alt-803
2017-03-25 22:06:10  - 23147  http://www.lymphomahub.com/therapies/regn1979
2017-03-25 22:06:14  - 23147  http://www.lymphomahub.com/therapies/immu-114
2017-03-25 22:06:19  - 23147  http://www.lymphomahub.com/therapies/incb7839
2017-03-25 22:06:29  - 23147  http://www.lymphomahub.com/therapies/adct-301
2017-03-25 22:06:38  - 23147  http://www.lymphomahub.com/therapies/ixazomib
2017-03-25 22:06:44  - 23147  http://www.lymphomahub.com/therapies/avelumab
2017-03-25 22:06:53  - 23147  http://www.lymphomahub.com/therapies/bi836826
2017-03-25 22:06:58  - 23147  http://www.lymphomahub.com/therapies/medi-570
2017-03-25 22:07:04  - 23147  http://www.lymphomahub.com/therapies/ds-3201b
2017-03-25 22:07:08  - 23147  http://www.lymphomahub.com/therapies/sea-cd40
2017-03-25 22:07:13  - 23147  http://www.lymphomahub.com/therapies/adct-402
2017-03-25 22:07:17  - 23147  http://www.lymphomahub.com/therapies/acy-1215
2017-03-25 22:07:21  - 23147  http://www.lymphomahub.com/therapies/cudc-907
2017-03-25 22:07:26  - 23147  http://www.lymphomahub.com/therapies/tgr-1202
2017-03-25 22:07:30  - 23147  http://www.lymphomahub.com/therapies/axitinib
<pre>2017-03-25_22-07-31 Restart Xvfb...
2017-03-25 22:07:43  - 23147  http://www.lymphomahub.com/therapies/imatinib
2017-03-25 22:07:51  - 23147  http://www.lymphomahub.com/therapies/edo-s101
2017-03-25 22:07:56  - 23147  http://www.lymphomahub.com/therapies/btct4465a
2017-03-25 22:08:00  - 23147  http://www.lymphomahub.com/therapies/alisertib
2017-03-25 22:08:09  - 23147  http://www.lymphomahub.com/therapies/lirilumab
2017-03-25 22:08:15  - 23147  http://www.lymphomahub.com/therapies/ibrutinib
2017-03-25 22:08:16  - 23147  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-03-25 22:08:25  - 23147  http://www.lymphomahub.com/therapies/rituximab
2017-03-25 22:08:30  - 23147  http://www.lymphomahub.com/therapies/veliparib
2017-03-25 22:08:34  - 23147  http://www.lymphomahub.com/therapies/sunitinib
2017-03-25 22:08:39  - 23147  http://www.lymphomahub.com/therapies/nivolumab
2017-03-25 22:08:40  - 23147  http://www.lymphomahub.com/therapies/sirolimus
2017-03-25 22:08:44  - 23147  http://www.lymphomahub.com/medical-information
2017-03-25 22:08:48  - 23147  http://www.lymphomahub.com/therapies/selinexor
2017-03-25 22:08:53  - 23147  http://www.lymphomahub.com/therapies/abc294640
2017-03-25 22:08:58  - 23147  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-03-25 22:09:02  - 23147  http://www.lymphomahub.com/therapies/tenofovir
2017-03-25 22:09:07  - 23147  http://www.lymphomahub.com/therapies/betalutin
2017-03-25 22:09:11  - 23147  http://www.lymphomahub.com/therapies/chidamide
2017-03-25 22:09:16  - 23147  http://www.lymphomahub.com/therapies/duvelisib
2017-03-25 22:09:21  - 23147  http://www.lymphomahub.com/therapies/dasatinib
2017-03-25 22:09:25  - 23147  http://www.lymphomahub.com/therapies/everolimus
2017-03-25 22:09:30  - 23147  http://www.lymphomahub.com/therapies/incb039110
<pre>2017-03-25_22-09-31 Restart Xvfb...
2017-03-25 22:09:44  - 23147  http://www.lymphomahub.com/therapies/durvalumab
2017-03-25 22:09:54  - 23147  http://www.lymphomahub.com/therapies/romidepsin
2017-03-25 22:10:00  - 23147  http://www.lymphomahub.com/therapies/bortezomib
2017-03-25 22:10:09  - 23147  http://www.lymphomahub.com/therapies/idelalisib
2017-03-25 22:10:10  - 23147  http://www.lymphomahub.com/therapies/tipifarnib
2017-03-25 22:10:14  - 23147  http://www.lymphomahub.com/therapies/ipilimumab
2017-03-25 22:10:19  - 23147  http://www.lymphomahub.com/therapies/crizotinib
2017-03-25 22:10:23  - 23147  http://www.lymphomahub.com/therapies/gsk2816126
2017-03-25 22:10:27  - 23147  http://www.lymphomahub.com/therapies/copanlisib
2017-03-25 22:10:32  - 23147  http://www.lymphomahub.com/therapies/buparlisib
2017-03-25 22:10:37  - 23147  http://www.lymphomahub.com/therapies/belinostat
2017-03-25 22:10:41  - 23147  http://www.lymphomahub.com/therapies/vorinostat
2017-03-25 22:10:46  - 23147  http://www.lymphomahub.com/therapies/plerixafor
2017-03-25 22:10:46  - 23147  http://www.lymphomahub.com/therapies/ofatumumab
2017-03-25 22:10:51  - 23147  http://www.lymphomahub.com/therapies/pf-06801591
2017-03-25 22:10:56  - 23147  http://www.lymphomahub.com/therapies/tocilizumab
2017-03-25 22:11:00  - 23147  http://www.lymphomahub.com/therapies/msc2490484a
2017-03-25 22:11:09  - 23147  http://www.lymphomahub.com/therapies/carfilzomib
2017-03-25 22:11:14  - 23147  http://www.lymphomahub.com/therapies/ruxolitinib
2017-03-25 22:11:18  - 23147  http://www.lymphomahub.com/therapies/palbociclib
2017-03-25 22:11:28  - 23147  http://www.lymphomahub.com/therapies/fenretinide
<pre>2017-03-25_22-11-31 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/fenretinide?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_22-13-31 Restart Xvfb...
2017-03-25 22:13:33  - 23147  http://www.lymphomahub.com/therapies/fenretinide
2017-03-25 22:13:37  - 23147  http://www.lymphomahub.com/therapies/daratumumab
2017-03-25 22:13:42  - 23147  http://www.lymphomahub.com/therapies/pf-05082566
2017-03-25 22:13:48  - 23147  http://www.lymphomahub.com/therapies/ramucirumab
2017-03-25 22:13:52  - 23147  http://www.lymphomahub.com/therapies/tositumomab
2017-03-25 22:13:56  - 23147  http://www.lymphomahub.com/therapies/ublituximab
2017-03-25 22:14:01  - 23147  http://www.lymphomahub.com/therapies/epacadostat
2017-03-25 22:14:06  - 23147  http://www.lymphomahub.com/therapies/alemtuzumab
2017-03-25 22:14:06  - 23147  http://www.lymphomahub.com/therapies/otlertuzumab
2017-03-25 22:14:11  - 23147  http://www.lymphomahub.com/therapies/panobinostat
2017-03-25 22:14:15  - 23147  http://www.lymphomahub.com/therapies/mocetinostat
2017-03-25 22:14:20  - 23147  http://www.lymphomahub.com/therapies/atezolizumab
2017-03-25 22:14:24  - 23147  http://www.lymphomahub.com/therapies/temsirolimus
2017-03-25 22:14:29  - 23147  http://www.lymphomahub.com/therapies/lenalidomide
2017-03-25 22:14:34  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab
2017-03-25 22:14:38  - 23147  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-03-25 22:14:51  - 23147  http://www.lymphomahub.com/therapies/blinatumomab
2017-03-25 22:14:55  - 23147  http://www.lymphomahub.com/therapies/jnj-64052781
2017-03-25 22:15:00  - 23147  http://www.lymphomahub.com/therapies/entospletinib
2017-03-25 22:15:06  - 23147  http://www.lymphomahub.com/therapies/pembrolizumab
2017-03-25 22:15:10  - 23147  http://www.lymphomahub.com/therapies/acalabrutinib
2017-03-25 22:15:19  - 23147  http://www.lymphomahub.com/about/innovation-committee
2017-03-25 22:15:24  - 23147  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-03-25 22:15:24  - 23147  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-03-25 22:15:29  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a
<pre>2017-03-25_22-15-31 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/interferon-alpha-2a?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_22-17-31 Restart Xvfb...
2017-03-25 22:17:34  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-03-25 22:17:39  - 23147  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-03-25 22:17:44  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-03-25 22:17:48  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-03-25 22:17:49  - 23147  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-03-25 22:17:54  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-03-25 22:17:58  - 23147  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-03-25 22:18:08  - 23147  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-03-25 22:18:20  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board
2017-03-25 22:18:39  - 23147  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-03-25 22:18:51  - 23147  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-03-25 22:19:05  - 23147  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-03-25 22:19:11  - 23147  http://www.lymphomahub.com/about/executive-steering-committee
2017-03-25 22:19:18  - 23147  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-03-25 22:19:22  - 23147  http://www.lymphomahub.com/medical-information/know-your-subtype
<pre>2017-03-25_22-19-31 Restart Xvfb...
2017-03-25 22:19:47  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-03-25 22:19:51  - 23147  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-03-25 22:19:59  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-03-25 22:20:19  - 23147  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-03-25 22:20:23  - 23147  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-03-25 22:20:28  - 23147  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-03-25 22:20:36  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-03-25 22:20:46  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-03-25 22:20:56  - 23147  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-03-25 22:21:00  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-03-25 22:21:05  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-03-25 22:21:09  - 23147  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-03-25 22:21:13  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-03-25 22:21:17  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-03-25 22:21:21  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-03-25 22:21:24  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-03-25 22:21:28  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
<pre>2017-03-25_22-21-31 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_22-23-31 Restart Xvfb...
2017-03-25 22:23:33  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-03-25 22:23:42  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-03-25 22:23:46  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-03-25 22:23:54  - 23147  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-03-25 22:24:04  - 23147  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-03-25 22:24:13  - 23147  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-03-25 22:24:23  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-03-25 22:24:27  - 23147  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-03-25 22:24:31  - 23147  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-03-25 22:24:34  - 23147  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-03-25 22:24:39  - 23147  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-03-25 22:24:43  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-03-25 22:24:52  - 23147  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-03-25 22:25:02  - 23147  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-03-25 22:25:09  - 23147  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-03-25 22:25:24  - 23147  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
<pre>2017-03-25_22-25-31 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/?_prerender {"code":"ECONNRESET"}
2017-03-25 22:27:29  - 23147  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
<pre>2017-03-25_22-27-31 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_22-29-31 Restart Xvfb...
2017-03-25 22:29:34  - 23147  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-03-25 22:29:38  - 23147  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-03-25 22:29:44  - 23147  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-03-25 22:29:49  - 23147  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-03-25 22:29:54  - 23147  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-03-25 22:29:58  - 23147  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-03-25 22:30:03  - 23147  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-03-25 22:30:08  - 23147  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-03-25 22:30:15  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-03-25 22:30:22  - 23147  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-03-25 22:30:26  - 23147  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-03-25 22:30:31  - 23147  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-03-25 22:30:43  - 23147  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-03-25 22:30:52  - 23147  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-03-25 22:30:57  - 23147  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-03-25 22:31:01  - 23147  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-03-25 22:31:06  - 23147  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-03-25 22:31:16  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-03-25 22:31:21  - 23147  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-03-25 22:31:26  - 23147  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-03-25 22:31:30  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
<pre>2017-03-25_22-31-31 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_22-33-31 Restart Xvfb...
2017-03-25 22:33:36  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-03-25 22:33:40  - 23147  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-03-25 22:33:44  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-03-25 22:33:48  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-03-25 22:33:52  - 23147  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-03-25 22:33:57  - 23147  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-03-25 22:34:01  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-03-25 22:34:05  - 23147  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-03-25 22:34:10  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-03-25 22:34:14  - 23147  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-03-25 22:34:24  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-03-25 22:34:28  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-03-25 22:34:38  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-03-25 22:34:52  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-03-25 22:34:56  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-03-25 22:35:04  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-03-25 22:35:09  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-03-25 22:35:13  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-03-25 22:35:17  - 23147  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-03-25 22:35:22  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-03-25 22:35:27  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
<pre>2017-03-25_22-35-31 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_22-37-31 Restart Xvfb...
2017-03-25 22:37:32  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-03-25 22:37:36  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-03-25 22:37:41  - 23147  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-25 22:37:41  - 23147  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-03-25 22:37:46  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-03-25 22:37:54  - 23147  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-03-25 22:37:59  - 23147  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-03-25 22:38:04  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-03-25 22:38:09  - 23147  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-03-25 22:38:14  - 23147  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-03-25 22:38:19  - 23147  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-03-25 22:38:23  - 23147  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-03-25 22:38:28  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-03-25 22:38:32  - 23147  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-03-25 22:38:37  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-03-25 22:38:42  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-03-25 22:38:46  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-03-25 22:38:51  - 23147  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-03-25 22:38:56  - 23147  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-03-25 22:39:01  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-03-25 22:39:06  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-03-25 22:39:10  - 23147  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-03-25 22:39:15  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-03-25 22:39:20  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-03-25 22:39:24  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-03-25 22:39:29  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
<pre>2017-03-25_22-39-31 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_22-41-31 Restart Xvfb...
2017-03-25 22:41:34  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-03-25 22:41:44  - 23147  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-25 22:41:49  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-03-25 22:41:54  - 23147  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-03-25 22:41:59  - 23147  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-03-25 22:42:04  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-03-25 22:42:09  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-03-25 22:42:13  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-03-25 22:42:18  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-03-25 22:42:23  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-03-25 22:42:28  - 23147  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-03-25 22:42:32  - 23147  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-03-25 22:42:37  - 23147  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-03-25 22:42:42  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-03-25 22:42:47  - 23147  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-03-25 22:42:51  - 23147  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-03-25 22:42:56  - 23147  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-03-25 22:42:56  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-03-25 22:43:01  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-03-25 22:43:06  - 23147  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-03-25 22:43:11  - 23147  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-03-25 22:43:16  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-03-25 22:43:26  - 23147  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
<pre>2017-03-25_22-43-31 Restart Xvfb...
2017-03-25 22:43:46  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-03-25 22:43:51  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-03-25 22:43:56  - 23147  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-03-25 22:44:01  - 23147  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-03-25 22:44:06  - 23147  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-03-25 22:44:10  - 23147  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-03-25 22:44:23  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-03-25 22:44:33  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-03-25 22:44:43  - 23147  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-03-25 22:44:58  - 23147  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-03-25 22:45:08  - 23147  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-03-25 22:45:12  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-03-25 22:45:22  - 23147  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-03-25 22:45:30  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
<pre>2017-03-25_22-45-31 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_22-47-31 Restart Xvfb...
2017-03-25 22:47:35  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-03-25 22:47:40  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-03-25 22:47:44  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-03-25 22:47:50  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-03-25 22:47:54  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-03-25 22:47:58  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-03-25 22:48:02  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-03-25 22:48:06  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-03-25 22:48:14  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-03-25 22:48:19  - 23147  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-03-25 22:48:22  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-03-25 22:48:32  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-03-25 22:48:36  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-03-25 22:48:44  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-03-25 22:48:56  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-03-25 22:49:05  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-03-25 22:49:09  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-03-25 22:49:13  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-03-25 22:49:17  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-03-25 22:49:20  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-03-25 22:49:24  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-03-25 22:49:27  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
<pre>2017-03-25_22-49-31 Restart Xvfb...
2017-03-25 22:49:31  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-03-25 22:49:35  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-03-25 22:49:38  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-03-25 22:49:42  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-03-25 22:49:47  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-03-25 22:49:50  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-03-25 22:49:54  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-03-25 22:49:58  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-03-25 22:50:02  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-03-25 22:50:06  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-03-25 22:50:10  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-03-25 22:50:14  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-03-25 22:50:18  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-03-25 22:50:28  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-03-25 22:50:32  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-03-25 22:50:35  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-03-25 22:50:39  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-03-25 22:50:43  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-03-25 22:50:47  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-03-25 22:50:51  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-03-25 22:50:54  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-03-25 22:50:58  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-03-25 22:51:03  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-03-25 22:51:06  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-03-25 22:51:10  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-03-25 22:51:14  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-03-25 22:51:17  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-03-25 22:51:21  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-03-25 22:51:25  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
<pre>2017-03-25_22-51-31 Restart Xvfb...
2017-03-25 22:51:43  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-03-25 22:51:47  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-03-25 22:51:50  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-03-25 22:51:59  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-03-25 22:52:03  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-03-25 22:52:12  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-03-25 22:52:15  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-03-25 22:52:19  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-03-25 22:52:28  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-03-25 22:52:32  - 23147  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-03-25 22:52:37  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-03-25 22:52:43  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-03-25 22:52:47  - 23147  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-03-25 22:52:48  - 23147  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-03-25 22:52:52  - 23147  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-03-25 22:52:57  - 23147  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-03-25 22:53:06  - 23147  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-03-25 22:53:11  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-03-25 22:53:16  - 23147  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-03-25 22:53:21  - 23147  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-03-25 22:53:25  - 23147  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-03-25 22:53:30  - 23147  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
<pre>2017-03-25_22-53-31 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_22-55-31 Restart Xvfb...
2017-03-25 22:55:35  - 23147  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-03-25 22:55:40  - 23147  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-03-25 22:55:45  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-03-25 22:55:50  - 23147  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-03-25 22:55:54  - 23147  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-03-25 22:55:59  - 23147  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-03-25 22:56:04  - 23147  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-03-25 22:56:09  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-03-25 22:56:13  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-03-25 22:56:18  - 23147  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-03-25 22:56:23  - 23147  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-03-25 22:56:27  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-03-25 22:56:32  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-03-25 22:56:37  - 23147  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-25 22:56:41  - 23147  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-03-25 22:56:46  - 23147  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-03-25 22:56:51  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-03-25 22:56:56  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-03-25 22:57:00  - 23147  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-03-25 22:57:05  - 23147  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-03-25 22:57:10  - 23147  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-03-25 22:57:14  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-03-25 22:57:19  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-03-25 22:57:24  - 23147  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-25 22:57:28  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
<pre>2017-03-25_22-57-31 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_22-59-31 Restart Xvfb...
2017-03-25 22:59:33  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-03-25 22:59:38  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-03-25 22:59:42  - 23147  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-03-25 22:59:47  - 23147  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-03-25 22:59:52  - 23147  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-03-25 22:59:56  - 23147  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-03-25 23:00:01  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-03-25 23:00:08  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-03-25 23:00:13  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-03-25 23:00:18  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-03-25 23:00:25  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-03-25 23:00:30  - 23147  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-03-25 23:00:34  - 23147  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-03-25 23:00:39  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-03-25 23:00:44  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-03-25 23:00:53  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-03-25 23:00:58  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-03-25 23:01:02  - 23147  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-03-25 23:01:07  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-03-25 23:01:12  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-03-25 23:01:17  - 23147  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-03-25 23:01:22  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-03-25 23:01:27  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
<pre>2017-03-25_23-01-31 Restart Xvfb...
2017-03-25 23:01:31  - 23147  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-03-25 23:01:36  - 23147  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-03-25 23:01:40  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-03-25 23:01:45  - 23147  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-03-25 23:01:50  - 23147  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-03-25 23:01:54  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-03-25 23:01:59  - 23147  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-03-25 23:02:04  - 23147  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-03-25 23:02:08  - 23147  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-03-25 23:02:13  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-03-25 23:02:18  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-03-25 23:02:22  - 23147  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-03-25 23:02:27  - 23147  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-03-25 23:02:31  - 23147  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-03-25 23:02:39  - 23147  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-03-25 23:02:49  - 23147  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-03-25 23:02:54  - 23147  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-03-25 23:02:58  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-03-25 23:03:03  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-03-25 23:03:08  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-03-25 23:03:13  - 23147  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-03-25 23:03:17  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-03-25 23:03:22  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-03-25 23:03:26  - 23147  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-03-25 23:03:31  - 23147  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
<pre>2017-03-25_23-03-31 Restart Xvfb...
2017-03-25 23:03:35  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-03-25 23:03:40  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-03-25 23:03:45  - 23147  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-03-25 23:03:49  - 23147  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-03-25 23:03:54  - 23147  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-03-25 23:03:58  - 23147  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-03-25 23:04:02  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-03-25 23:04:07  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-03-25 23:04:15  - 23147  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-03-25 23:04:19  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-03-25 23:04:24  - 23147  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-03-25 23:04:28  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-03-25 23:04:33  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-03-25 23:04:38  - 23147  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-03-25 23:04:42  - 23147  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-03-25 23:04:47  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-03-25 23:04:52  - 23147  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-03-25 23:04:57  - 23147  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-03-25 23:05:01  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-03-25 23:05:06  - 23147  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-03-25 23:05:11  - 23147  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-03-25 23:05:15  - 23147  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-03-25 23:05:20  - 23147  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-03-25 23:05:25  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-03-25 23:05:29  - 23147  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
<pre>2017-03-25_23-05-31 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_23-07-31 Restart Xvfb...
2017-03-25 23:07:34  - 23147  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-03-25 23:07:40  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-03-25 23:07:45  - 23147  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-03-25 23:07:49  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-03-25 23:07:54  - 23147  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-03-25 23:08:04  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-03-25 23:08:14  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-03-25 23:08:18  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-03-25 23:08:25  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-03-25 23:08:31  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-03-25 23:08:36  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-03-25 23:08:40  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-03-25 23:08:45  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-03-25 23:08:50  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-03-25 23:08:54  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-03-25 23:08:59  - 23147  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-03-25 23:09:04  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-03-25 23:09:08  - 23147  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-03-25 23:09:13  - 23147  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-03-25 23:09:18  - 23147  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-03-25 23:09:25  - 23147  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
<pre>2017-03-25_23-09-31 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options?_prerender {"code":"ECONNRESET"}
2017-03-25 23:11:30  - 23147  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
<pre>2017-03-25_23-11-31 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_23-13-31 Restart Xvfb...
2017-03-25 23:13:35  - 23147  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-03-25 23:13:39  - 23147  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-03-25 23:13:44  - 23147  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-03-25 23:13:49  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-03-25 23:13:54  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-03-25 23:13:59  - 23147  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-03-25 23:14:04  - 23147  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-03-25 23:14:09  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-03-25 23:14:14  - 23147  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-03-25 23:14:18  - 23147  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-03-25 23:14:23  - 23147  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-03-25 23:14:28  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-03-25 23:14:32  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-03-25 23:14:37  - 23147  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-03-25 23:14:42  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-03-25 23:14:47  - 23147  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-03-25 23:14:52  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-03-25 23:14:56  - 23147  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-03-25 23:15:01  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-03-25 23:15:06  - 23147  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-03-25 23:15:11  - 23147  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-03-25 23:15:15  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-03-25 23:15:20  - 23147  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-03-25 23:15:24  - 23147  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-03-25 23:15:29  - 23147  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
<pre>2017-03-25_23-15-31 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_23-17-31 Restart Xvfb...
2017-03-25 23:17:34  - 23147  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-03-25 23:17:39  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-03-25 23:17:43  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-03-25 23:17:48  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-03-25 23:17:52  - 23147  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-03-25 23:17:57  - 23147  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-03-25 23:18:02  - 23147  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-03-25 23:18:06  - 23147  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-03-25 23:18:15  - 23147  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-03-25 23:18:19  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-03-25 23:18:24  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-03-25 23:18:29  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-03-25 23:18:33  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-03-25 23:18:37  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-03-25 23:18:45  - 23147  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-03-25 23:18:50  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-03-25 23:18:55  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-03-25 23:18:59  - 23147  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-03-25 23:19:04  - 23147  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-03-25 23:19:08  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-03-25 23:19:12  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-03-25 23:19:16  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-03-25 23:19:21  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-03-25 23:19:25  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-03-25 23:19:30  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
<pre>2017-03-25_23-19-31 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_23-21-31 Restart Xvfb...
2017-03-25 23:21:35  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-03-25 23:21:45  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-03-25 23:21:49  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-03-25 23:21:54  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-03-25 23:21:58  - 23147  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-03-25 23:22:03  - 23147  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-03-25 23:22:07  - 23147  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-03-25 23:22:11  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-03-25 23:22:16  - 23147  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-03-25 23:22:20  - 23147  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-03-25 23:22:25  - 23147  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-03-25 23:22:30  - 23147  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-03-25 23:22:34  - 23147  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-03-25 23:22:39  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-03-25 23:22:43  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-03-25 23:22:48  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-03-25 23:22:53  - 23147  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-03-25 23:22:57  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-03-25 23:23:02  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-03-25 23:23:06  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-03-25 23:23:10  - 23147  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-03-25 23:23:25  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-03-25 23:23:29  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
<pre>2017-03-25_23-23-31 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_23-25-31 Restart Xvfb...
2017-03-25 23:25:34  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-03-25 23:25:42  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-03-25 23:25:51  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-03-25 23:25:56  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-03-25 23:26:01  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-03-25 23:26:05  - 23147  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-03-25 23:26:09  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-03-25 23:26:14  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-03-25 23:26:18  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-03-25 23:26:23  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-03-25 23:26:28  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-03-25 23:26:33  - 23147  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-03-25 23:26:37  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-03-25 23:26:41  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-03-25 23:26:46  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-03-25 23:26:51  - 23147  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-03-25 23:26:55  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-03-25 23:27:00  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-03-25 23:27:08  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-03-25 23:27:13  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-03-25 23:27:22  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-03-25 23:27:26  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-03-25 23:27:30  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
<pre>2017-03-25_23-27-32 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_23-29-32 Restart Xvfb...
2017-03-25 23:29:35  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-03-25 23:29:39  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-03-25 23:29:43  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-03-25 23:29:48  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-03-25 23:29:52  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-03-25 23:29:56  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-03-25 23:30:00  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-03-25 23:30:05  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-03-25 23:30:11  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-03-25 23:30:15  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-03-25 23:30:19  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-03-25 23:30:24  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-03-25 23:30:29  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-03-25 23:30:33  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-03-25 23:30:37  - 23147  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-03-25 23:30:41  - 23147  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-03-25 23:30:46  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-03-25 23:30:56  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-03-25 23:31:01  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-03-25 23:31:06  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-03-25 23:31:13  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-03-25 23:31:18  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-03-25 23:31:23  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-03-25 23:31:27  - 23147  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-03-25 23:31:31  - 23147  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
<pre>2017-03-25_23-31-32 Restart Xvfb...
2017-03-25 23:31:36  - 23147  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-03-25 23:31:40  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-03-25 23:31:44  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-03-25 23:31:48  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-03-25 23:31:53  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-03-25 23:31:57  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-03-25 23:32:01  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-25 23:32:05  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-25 23:32:14  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-25 23:32:18  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-25 23:32:23  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-03-25 23:32:27  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-25 23:32:31  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-25 23:32:35  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-03-25 23:32:39  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-03-25 23:32:43  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-03-25 23:32:52  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-03-25 23:32:56  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-03-25 23:33:00  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-03-25 23:33:04  - 23147  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-03-25 23:33:08  - 23147  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-03-25 23:33:12  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-03-25 23:33:16  - 23147  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-03-25 23:33:20  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-03-25 23:33:24  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-03-25 23:33:29  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
<pre>2017-03-25_23-33-32 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy?_prerender {"code":"ECONNRESET"}
<pre>2017-03-25_23-35-32 Restart Xvfb...
2017-03-25 23:35:34  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-03-25 23:35:38  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-03-25 23:35:43  - 23147  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-03-25 23:35:47  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-03-25 23:35:56  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-03-25 23:36:00  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-03-25 23:36:04  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-03-25 23:36:08  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-03-25 23:36:12  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-25 23:36:17  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-25 23:36:21  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-25 23:36:25  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-25 23:36:29  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-25 23:36:33  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-03-25 23:36:37  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-25 23:36:41  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-25 23:36:45  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-25 23:36:49  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-25 23:36:53  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-03-25 23:36:57  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-25 23:37:01  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-25 23:37:05  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-25 23:37:09  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-03-25 23:37:13  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
<pre>2017-03-25_23-37-32 Restart Xvfb...
<pre>2017-03-25_23-39-32 Restart Xvfb...
<pre>2017-03-25_23-41-32 Restart Xvfb...
<pre>2017-03-25_23-43-32 Restart Xvfb...
<pre>2017-03-25_23-45-32 Restart Xvfb...
<pre>2017-03-25_23-47-32 Restart Xvfb...
<pre>2017-03-25_23-49-32 Restart Xvfb...
<pre>2017-03-25_23-51-32 Restart Xvfb...
<pre>2017-03-25_23-53-32 Restart Xvfb...
<pre>2017-03-25_23-55-32 Restart Xvfb...
<pre>2017-03-25_23-57-32 Restart Xvfb...
<pre>2017-03-25_23-59-32 Restart Xvfb...
<pre>2017-03-26_00-01-32 Restart Xvfb...
<pre>2017-03-26_00-03-32 Restart Xvfb...
<pre>2017-03-26_00-05-32 Restart Xvfb...
<pre>2017-03-26_00-07-32 Restart Xvfb...
<pre>2017-03-26_00-09-32 Restart Xvfb...
<pre>2017-03-26_00-11-32 Restart Xvfb...
<pre>2017-03-26_00-13-32 Restart Xvfb...
<pre>2017-03-26_00-15-32 Restart Xvfb...
<pre>2017-03-26_00-17-32 Restart Xvfb...
<pre>2017-03-26_00-19-32 Restart Xvfb...
<pre>2017-03-26_00-21-32 Restart Xvfb...
<pre>2017-03-26_00-23-32 Restart Xvfb...
<pre>2017-03-26_00-25-32 Restart Xvfb...
<pre>2017-03-26_00-27-32 Restart Xvfb...
<pre>2017-03-26_00-29-32 Restart Xvfb...
<pre>2017-03-26_00-31-32 Restart Xvfb...
<pre>2017-03-26_00-33-32 Restart Xvfb...
<pre>2017-03-26_00-35-32 Restart Xvfb...
<pre>2017-03-26_00-37-32 Restart Xvfb...
<pre>2017-03-26_00-39-32 Restart Xvfb...
<pre>2017-03-26_00-41-32 Restart Xvfb...
<pre>2017-03-26_00-43-32 Restart Xvfb...
<pre>2017-03-26_00-45-32 Restart Xvfb...
<pre>2017-03-26_00-47-32 Restart Xvfb...
<pre>2017-03-26_00-49-32 Restart Xvfb...
<pre>2017-03-26_00-51-32 Restart Xvfb...
<pre>2017-03-26_00-53-32 Restart Xvfb...
<pre>2017-03-26_00-55-32 Restart Xvfb...
2017-03-26 00:56:59 reset updateRequest
2017-03-26 00:57:03  - 23147  http://www.lymphomahub.com/
2017-03-26 00:57:04  - 23147  http://www.lymphomahub.com/
2017-03-26 00:57:08  - 23147  http://www.lymphomahub.com/about
2017-03-26 00:57:09  - 23147  http://www.lymphomahub.com/about
2017-03-26 00:57:15  - 23147  http://www.lymphomahub.com/terms
2017-03-26 00:57:18  - 23147  http://www.lymphomahub.com/undefined
2017-03-26 00:57:18  - 23147  http://www.lymphomahub.com/therapies
2017-03-26 00:57:24  - 23147  http://www.lymphomahub.com/newsletter
2017-03-26 00:57:27  - 23147  http://www.lymphomahub.com/cookie-policy
2017-03-26 00:57:30  - 23147  http://www.lymphomahub.com/therapies/afm13
<pre>2017-03-26_00-57-32 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/afm13?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_00-59-32 Restart Xvfb...
2017-03-26 00:59:36  - 23147  http://www.lymphomahub.com/therapies/afm13
2017-03-26 00:59:40  - 23147  http://www.lymphomahub.com/therapies/afm11
2017-03-26 00:59:45  - 23147  http://www.lymphomahub.com/therapies/ags67e
2017-03-26 00:59:49  - 23147  http://www.lymphomahub.com/therapies/cc-292
2017-03-26 00:59:54  - 23147  http://www.lymphomahub.com/therapies/cc-223
2017-03-26 00:59:58  - 23147  http://www.lymphomahub.com/therapies/sd-101
2017-03-26 01:00:03  - 23147  http://www.lymphomahub.com/therapies/rp6530
2017-03-26 01:00:11  - 23147  http://www.lymphomahub.com/therapies/abt199
2017-03-26 01:00:11  - 23147  http://www.lymphomahub.com/therapies/mor208
2017-03-26 01:00:18  - 23147  http://www.lymphomahub.com/therapies/cc-122
2017-03-26 01:00:27  - 23147  http://www.lymphomahub.com/therapies/at-101
2017-03-26 01:00:32  - 23147  http://www.lymphomahub.com/therapies/bl8040
2017-03-26 01:00:41  - 23147  http://www.lymphomahub.com/therapies/bcl201
2017-03-26 01:00:46  - 23147  http://www.lymphomahub.com/therapies/azd3965
2017-03-26 01:00:50  - 23147  http://www.lymphomahub.com/therapies/imgn529
2017-03-26 01:00:55  - 23147  http://www.lymphomahub.com/therapies/azd2014
2017-03-26 01:00:59  - 23147  http://www.lymphomahub.com/therapies/mt-3724
2017-03-26 01:01:04  - 23147  http://www.lymphomahub.com/therapies/actr087
2017-03-26 01:01:08  - 23147  http://www.lymphomahub.com/therapies/epz6438
2017-03-26 01:01:13  - 23147  http://www.lymphomahub.com/therapies/kte-c19
2017-03-26 01:01:17  - 23147  http://www.lymphomahub.com/about/secretariat
2017-03-26 01:01:21  - 23147  http://www.lymphomahub.com/therapies/alt-803
2017-03-26 01:01:25  - 23147  http://www.lymphomahub.com/therapies/regn1979
2017-03-26 01:01:29  - 23147  http://www.lymphomahub.com/therapies/immu-114
<pre>2017-03-26_01-01-32 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/immu-114?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_01-03-32 Restart Xvfb...
2017-03-26 01:03:34  - 23147  http://www.lymphomahub.com/therapies/immu-114
2017-03-26 01:03:38  - 23147  http://www.lymphomahub.com/therapies/incb7839
2017-03-26 01:03:43  - 23147  http://www.lymphomahub.com/therapies/adct-301
2017-03-26 01:03:48  - 23147  http://www.lymphomahub.com/therapies/ixazomib
2017-03-26 01:03:52  - 23147  http://www.lymphomahub.com/therapies/avelumab
2017-03-26 01:03:57  - 23147  http://www.lymphomahub.com/therapies/bi836826
2017-03-26 01:04:02  - 23147  http://www.lymphomahub.com/therapies/medi-570
2017-03-26 01:04:06  - 23147  http://www.lymphomahub.com/therapies/ds-3201b
2017-03-26 01:04:11  - 23147  http://www.lymphomahub.com/therapies/sea-cd40
2017-03-26 01:04:15  - 23147  http://www.lymphomahub.com/therapies/adct-402
2017-03-26 01:04:20  - 23147  http://www.lymphomahub.com/therapies/acy-1215
2017-03-26 01:04:24  - 23147  http://www.lymphomahub.com/therapies/cudc-907
2017-03-26 01:04:29  - 23147  http://www.lymphomahub.com/therapies/tgr-1202
2017-03-26 01:04:33  - 23147  http://www.lymphomahub.com/therapies/axitinib
2017-03-26 01:04:37  - 23147  http://www.lymphomahub.com/therapies/imatinib
2017-03-26 01:04:42  - 23147  http://www.lymphomahub.com/therapies/edo-s101
2017-03-26 01:04:47  - 23147  http://www.lymphomahub.com/therapies/btct4465a
2017-03-26 01:04:51  - 23147  http://www.lymphomahub.com/therapies/alisertib
2017-03-26 01:04:56  - 23147  http://www.lymphomahub.com/therapies/lirilumab
2017-03-26 01:05:00  - 23147  http://www.lymphomahub.com/therapies/ibrutinib
2017-03-26 01:05:01  - 23147  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-03-26 01:05:06  - 23147  http://www.lymphomahub.com/therapies/rituximab
2017-03-26 01:05:10  - 23147  http://www.lymphomahub.com/therapies/veliparib
2017-03-26 01:05:15  - 23147  http://www.lymphomahub.com/therapies/sunitinib
2017-03-26 01:05:19  - 23147  http://www.lymphomahub.com/therapies/nivolumab
2017-03-26 01:05:20  - 23147  http://www.lymphomahub.com/therapies/sirolimus
2017-03-26 01:05:25  - 23147  http://www.lymphomahub.com/medical-information
2017-03-26 01:05:29  - 23147  http://www.lymphomahub.com/therapies/selinexor
<pre>2017-03-26_01-05-32 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/selinexor?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_01-07-32 Restart Xvfb...
2017-03-26 01:07:34  - 23147  http://www.lymphomahub.com/therapies/selinexor
2017-03-26 01:07:39  - 23147  http://www.lymphomahub.com/therapies/abc294640
2017-03-26 01:07:43  - 23147  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-03-26 01:07:47  - 23147  http://www.lymphomahub.com/therapies/tenofovir
2017-03-26 01:07:52  - 23147  http://www.lymphomahub.com/therapies/betalutin
2017-03-26 01:07:56  - 23147  http://www.lymphomahub.com/therapies/chidamide
2017-03-26 01:08:01  - 23147  http://www.lymphomahub.com/therapies/duvelisib
2017-03-26 01:08:06  - 23147  http://www.lymphomahub.com/therapies/dasatinib
2017-03-26 01:08:10  - 23147  http://www.lymphomahub.com/therapies/everolimus
2017-03-26 01:08:15  - 23147  http://www.lymphomahub.com/therapies/incb039110
2017-03-26 01:08:19  - 23147  http://www.lymphomahub.com/therapies/durvalumab
2017-03-26 01:08:24  - 23147  http://www.lymphomahub.com/therapies/romidepsin
2017-03-26 01:08:29  - 23147  http://www.lymphomahub.com/therapies/bortezomib
2017-03-26 01:08:33  - 23147  http://www.lymphomahub.com/therapies/idelalisib
2017-03-26 01:08:34  - 23147  http://www.lymphomahub.com/therapies/tipifarnib
2017-03-26 01:08:39  - 23147  http://www.lymphomahub.com/therapies/ipilimumab
2017-03-26 01:08:43  - 23147  http://www.lymphomahub.com/therapies/crizotinib
2017-03-26 01:08:47  - 23147  http://www.lymphomahub.com/therapies/gsk2816126
2017-03-26 01:08:52  - 23147  http://www.lymphomahub.com/therapies/copanlisib
2017-03-26 01:08:56  - 23147  http://www.lymphomahub.com/therapies/buparlisib
2017-03-26 01:09:00  - 23147  http://www.lymphomahub.com/therapies/belinostat
2017-03-26 01:09:05  - 23147  http://www.lymphomahub.com/therapies/vorinostat
2017-03-26 01:09:10  - 23147  http://www.lymphomahub.com/therapies/plerixafor
2017-03-26 01:09:10  - 23147  http://www.lymphomahub.com/therapies/ofatumumab
2017-03-26 01:09:15  - 23147  http://www.lymphomahub.com/therapies/pf-06801591
2017-03-26 01:09:20  - 23147  http://www.lymphomahub.com/therapies/tocilizumab
2017-03-26 01:09:24  - 23147  http://www.lymphomahub.com/therapies/msc2490484a
2017-03-26 01:09:29  - 23147  http://www.lymphomahub.com/therapies/carfilzomib
<pre>2017-03-26_01-09-32 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/carfilzomib?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_01-11-33 Restart Xvfb...
2017-03-26 01:11:34  - 23147  http://www.lymphomahub.com/therapies/carfilzomib
2017-03-26 01:11:38  - 23147  http://www.lymphomahub.com/therapies/ruxolitinib
2017-03-26 01:11:42  - 23147  http://www.lymphomahub.com/therapies/palbociclib
2017-03-26 01:11:47  - 23147  http://www.lymphomahub.com/therapies/fenretinide
2017-03-26 01:11:51  - 23147  http://www.lymphomahub.com/therapies/daratumumab
2017-03-26 01:11:56  - 23147  http://www.lymphomahub.com/therapies/pf-05082566
2017-03-26 01:12:00  - 23147  http://www.lymphomahub.com/therapies/ramucirumab
2017-03-26 01:12:05  - 23147  http://www.lymphomahub.com/therapies/tositumomab
2017-03-26 01:12:09  - 23147  http://www.lymphomahub.com/therapies/ublituximab
2017-03-26 01:12:14  - 23147  http://www.lymphomahub.com/therapies/epacadostat
2017-03-26 01:12:18  - 23147  http://www.lymphomahub.com/therapies/alemtuzumab
2017-03-26 01:12:19  - 23147  http://www.lymphomahub.com/therapies/otlertuzumab
2017-03-26 01:12:23  - 23147  http://www.lymphomahub.com/therapies/panobinostat
2017-03-26 01:12:28  - 23147  http://www.lymphomahub.com/therapies/mocetinostat
2017-03-26 01:12:32  - 23147  http://www.lymphomahub.com/therapies/atezolizumab
2017-03-26 01:12:37  - 23147  http://www.lymphomahub.com/therapies/temsirolimus
2017-03-26 01:12:41  - 23147  http://www.lymphomahub.com/therapies/lenalidomide
2017-03-26 01:12:46  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab
2017-03-26 01:12:50  - 23147  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-03-26 01:12:54  - 23147  http://www.lymphomahub.com/therapies/blinatumomab
2017-03-26 01:12:59  - 23147  http://www.lymphomahub.com/therapies/jnj-64052781
2017-03-26 01:13:03  - 23147  http://www.lymphomahub.com/therapies/entospletinib
2017-03-26 01:13:08  - 23147  http://www.lymphomahub.com/therapies/pembrolizumab
2017-03-26 01:13:12  - 23147  http://www.lymphomahub.com/therapies/acalabrutinib
2017-03-26 01:13:16  - 23147  http://www.lymphomahub.com/about/innovation-committee
2017-03-26 01:13:22  - 23147  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-03-26 01:13:22  - 23147  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-03-26 01:13:27  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-03-26 01:13:31  - 23147  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
<pre>2017-03-26_01-13-33 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/polatuzumab-vedotin?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_01-15-33 Restart Xvfb...
2017-03-26 01:15:36  - 23147  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-03-26 01:15:41  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-03-26 01:15:45  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-03-26 01:15:46  - 23147  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-03-26 01:15:50  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-03-26 01:15:55  - 23147  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-03-26 01:15:59  - 23147  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-03-26 01:16:03  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board
2017-03-26 01:16:07  - 23147  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-03-26 01:16:12  - 23147  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-03-26 01:16:15  - 23147  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-03-26 01:16:19  - 23147  http://www.lymphomahub.com/about/executive-steering-committee
2017-03-26 01:16:24  - 23147  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-03-26 01:16:27  - 23147  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-03-26 01:16:32  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-03-26 01:16:36  - 23147  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-03-26 01:16:40  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-03-26 01:16:45  - 23147  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-03-26 01:16:49  - 23147  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-03-26 01:16:49  - 23147  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-03-26 01:16:53  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-03-26 01:16:58  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-03-26 01:17:03  - 23147  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-03-26 01:17:07  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-03-26 01:17:12  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-03-26 01:17:16  - 23147  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-03-26 01:17:20  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-03-26 01:17:24  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-03-26 01:17:28  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-03-26 01:17:31  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
<pre>2017-03-26_01-17-33 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_01-19-33 Restart Xvfb...
2017-03-26 01:19:37  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-03-26 01:19:41  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-03-26 01:19:44  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-03-26 01:19:48  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-03-26 01:19:52  - 23147  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-03-26 01:19:57  - 23147  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-03-26 01:20:01  - 23147  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-03-26 01:20:06  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-03-26 01:20:10  - 23147  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-03-26 01:20:13  - 23147  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-03-26 01:20:18  - 23147  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-03-26 01:20:22  - 23147  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-03-26 01:20:27  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-03-26 01:20:31  - 23147  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-03-26 01:20:35  - 23147  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-03-26 01:20:40  - 23147  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-03-26 01:20:45  - 23147  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-03-26 01:20:49  - 23147  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-03-26 01:20:54  - 23147  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-03-26 01:20:58  - 23147  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-03-26 01:21:03  - 23147  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-03-26 01:21:07  - 23147  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-03-26 01:21:12  - 23147  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-03-26 01:21:16  - 23147  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-03-26 01:21:21  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-03-26 01:21:25  - 23147  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-03-26 01:21:29  - 23147  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
<pre>2017-03-26_01-21-33 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_01-23-33 Restart Xvfb...
2017-03-26 01:23:34  - 23147  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-03-26 01:23:38  - 23147  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-03-26 01:23:42  - 23147  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-03-26 01:23:47  - 23147  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-03-26 01:23:52  - 23147  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-03-26 01:23:55  - 23147  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-03-26 01:24:00  - 23147  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-03-26 01:24:04  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-03-26 01:24:08  - 23147  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-03-26 01:24:13  - 23147  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-03-26 01:24:17  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-03-26 01:24:21  - 23147  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-03-26 01:24:26  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-03-26 01:24:29  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-03-26 01:24:33  - 23147  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-03-26 01:24:38  - 23147  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-03-26 01:24:43  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-03-26 01:24:46  - 23147  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-03-26 01:24:51  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-03-26 01:24:55  - 23147  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-03-26 01:24:59  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-03-26 01:25:03  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-03-26 01:25:08  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-03-26 01:25:12  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-03-26 01:25:16  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-03-26 01:25:20  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-03-26 01:25:24  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-03-26 01:25:27  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-03-26 01:25:32  - 23147  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
<pre>2017-03-26_01-25-33 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_01-27-33 Restart Xvfb...
2017-03-26 01:27:37  - 23147  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-03-26 01:27:42  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-03-26 01:27:47  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-03-26 01:27:51  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-03-26 01:27:56  - 23147  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-26 01:27:57  - 23147  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-03-26 01:28:02  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-03-26 01:28:06  - 23147  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-03-26 01:28:11  - 23147  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-03-26 01:28:16  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-03-26 01:28:21  - 23147  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-03-26 01:28:25  - 23147  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-03-26 01:28:30  - 23147  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-03-26 01:28:35  - 23147  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-03-26 01:28:39  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-03-26 01:28:44  - 23147  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-03-26 01:28:49  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-03-26 01:28:53  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-03-26 01:28:58  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-03-26 01:29:02  - 23147  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-03-26 01:29:07  - 23147  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-03-26 01:29:12  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-03-26 01:29:17  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-03-26 01:29:21  - 23147  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-03-26 01:29:26  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-03-26 01:29:30  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
<pre>2017-03-26_01-29-33 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_01-31-33 Restart Xvfb...
2017-03-26 01:31:36  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-03-26 01:31:40  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-03-26 01:31:45  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-03-26 01:31:50  - 23147  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-26 01:31:54  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-03-26 01:31:59  - 23147  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-03-26 01:32:04  - 23147  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-03-26 01:32:08  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-03-26 01:32:13  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-03-26 01:32:18  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-03-26 01:32:22  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-03-26 01:32:27  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-03-26 01:32:31  - 23147  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-03-26 01:32:36  - 23147  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-03-26 01:32:41  - 23147  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-03-26 01:32:45  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-03-26 01:32:50  - 23147  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-03-26 01:32:55  - 23147  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-03-26 01:33:00  - 23147  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-03-26 01:33:00  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-03-26 01:33:05  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-03-26 01:33:09  - 23147  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-03-26 01:33:14  - 23147  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-03-26 01:33:19  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-03-26 01:33:23  - 23147  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-03-26 01:33:28  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-03-26 01:33:32  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
<pre>2017-03-26_01-33-33 Restart Xvfb...
2017-03-26 01:33:37  - 23147  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-03-26 01:33:42  - 23147  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-03-26 01:33:47  - 23147  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-03-26 01:33:51  - 23147  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-03-26 01:33:56  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-03-26 01:34:01  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-03-26 01:34:05  - 23147  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-03-26 01:34:10  - 23147  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-03-26 01:34:14  - 23147  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-03-26 01:34:19  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-03-26 01:34:24  - 23147  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-03-26 01:34:28  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-03-26 01:34:33  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-03-26 01:34:37  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-03-26 01:34:42  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-03-26 01:34:46  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-03-26 01:34:50  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-03-26 01:34:54  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-03-26 01:34:58  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-03-26 01:35:01  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-03-26 01:35:06  - 23147  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-03-26 01:35:06  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-03-26 01:35:11  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-03-26 01:35:16  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-03-26 01:35:19  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-03-26 01:35:23  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-03-26 01:35:26  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-03-26 01:35:30  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
<pre>2017-03-26_01-35-33 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_01-37-33 Restart Xvfb...
2017-03-26 01:37:35  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-03-26 01:37:39  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-03-26 01:37:42  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-03-26 01:37:46  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-03-26 01:37:49  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-03-26 01:37:53  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-03-26 01:37:57  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-03-26 01:38:00  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-03-26 01:38:04  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-03-26 01:38:07  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-03-26 01:38:12  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-03-26 01:38:16  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-03-26 01:38:19  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-03-26 01:38:23  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-03-26 01:38:26  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-03-26 01:38:30  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-03-26 01:38:34  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-03-26 01:38:37  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-03-26 01:38:41  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-03-26 01:38:44  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-03-26 01:38:48  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-03-26 01:38:52  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-03-26 01:38:56  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-03-26 01:38:59  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-03-26 01:39:03  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-03-26 01:39:06  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-03-26 01:39:10  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-03-26 01:39:14  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-03-26 01:39:17  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-03-26 01:39:21  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-03-26 01:39:24  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-03-26 01:39:28  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-03-26 01:39:32  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
<pre>2017-03-26_01-39-33 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_01-41-33 Restart Xvfb...
2017-03-26 01:41:37  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-03-26 01:41:41  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-03-26 01:41:44  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-03-26 01:41:48  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-03-26 01:41:51  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-03-26 01:41:55  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-03-26 01:41:58  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-03-26 01:42:02  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-03-26 01:42:06  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-03-26 01:42:09  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-03-26 01:42:13  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-03-26 01:42:17  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-03-26 01:42:22  - 23147  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-03-26 01:42:26  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-03-26 01:42:31  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-03-26 01:42:36  - 23147  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-03-26 01:42:37  - 23147  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-03-26 01:42:41  - 23147  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-03-26 01:42:46  - 23147  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-03-26 01:42:50  - 23147  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-03-26 01:42:55  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-03-26 01:43:00  - 23147  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-03-26 01:43:04  - 23147  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-03-26 01:43:09  - 23147  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-03-26 01:43:13  - 23147  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-03-26 01:43:18  - 23147  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-03-26 01:43:23  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-03-26 01:43:27  - 23147  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-03-26 01:43:32  - 23147  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
<pre>2017-03-26_01-43-33 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_01-45-33 Restart Xvfb...
2017-03-26 01:45:37  - 23147  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-03-26 01:45:41  - 23147  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-03-26 01:45:46  - 23147  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-03-26 01:45:51  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-03-26 01:45:55  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-03-26 01:46:00  - 23147  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-03-26 01:46:04  - 23147  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-03-26 01:46:09  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-03-26 01:46:13  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-03-26 01:46:18  - 23147  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-26 01:46:23  - 23147  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-03-26 01:46:27  - 23147  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-03-26 01:46:32  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-03-26 01:46:36  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-03-26 01:46:41  - 23147  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-03-26 01:46:45  - 23147  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-03-26 01:46:50  - 23147  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-03-26 01:46:55  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-03-26 01:47:00  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-03-26 01:47:04  - 23147  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-26 01:47:09  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-03-26 01:47:13  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-03-26 01:47:18  - 23147  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-03-26 01:47:23  - 23147  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-03-26 01:47:28  - 23147  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-03-26 01:47:32  - 23147  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
<pre>2017-03-26_01-47-33 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_01-49-33 Restart Xvfb...
2017-03-26 01:49:37  - 23147  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-03-26 01:49:42  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-03-26 01:49:47  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-03-26 01:49:51  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-03-26 01:49:56  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-03-26 01:50:01  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-03-26 01:50:06  - 23147  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-03-26 01:50:10  - 23147  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-03-26 01:50:15  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-03-26 01:50:19  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-03-26 01:50:23  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-03-26 01:50:28  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-03-26 01:50:33  - 23147  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-03-26 01:50:37  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-03-26 01:50:42  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-03-26 01:50:46  - 23147  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-03-26 01:50:51  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-03-26 01:50:56  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-03-26 01:51:00  - 23147  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-03-26 01:51:05  - 23147  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-03-26 01:51:09  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-03-26 01:51:14  - 23147  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-03-26 01:51:19  - 23147  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-03-26 01:51:23  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-03-26 01:51:28  - 23147  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-03-26 01:51:33  - 23147  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
<pre>2017-03-26_01-51-33 Restart Xvfb...
2017-03-26 01:51:37  - 23147  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-03-26 01:51:42  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-03-26 01:51:47  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-03-26 01:51:51  - 23147  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-03-26 01:51:56  - 23147  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-03-26 01:52:01  - 23147  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-03-26 01:52:05  - 23147  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-03-26 01:52:10  - 23147  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-03-26 01:52:14  - 23147  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-03-26 01:52:19  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-03-26 01:52:24  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-03-26 01:52:28  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-03-26 01:52:33  - 23147  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-03-26 01:52:37  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-03-26 01:52:42  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-03-26 01:52:47  - 23147  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-03-26 01:52:51  - 23147  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-03-26 01:52:56  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-03-26 01:53:01  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-03-26 01:53:05  - 23147  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-03-26 01:53:10  - 23147  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-03-26 01:53:14  - 23147  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-03-26 01:53:19  - 23147  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-03-26 01:53:23  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-03-26 01:53:27  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-03-26 01:53:32  - 23147  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
<pre>2017-03-26_01-53-33 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_01-55-33 Restart Xvfb...
2017-03-26 01:55:37  - 23147  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-03-26 01:55:42  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-03-26 01:55:46  - 23147  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-03-26 01:55:51  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-03-26 01:55:55  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-03-26 01:56:00  - 23147  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-03-26 01:56:05  - 23147  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-03-26 01:56:09  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-03-26 01:56:14  - 23147  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-03-26 01:56:19  - 23147  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-03-26 01:56:23  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-03-26 01:56:28  - 23147  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-03-26 01:56:32  - 23147  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-03-26 01:56:37  - 23147  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-03-26 01:56:42  - 23147  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-03-26 01:56:46  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-03-26 01:56:51  - 23147  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-03-26 01:56:55  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-03-26 01:57:00  - 23147  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-03-26 01:57:04  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-03-26 01:57:09  - 23147  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-03-26 01:57:14  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-03-26 01:57:18  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-03-26 01:57:23  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-03-26 01:57:28  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-03-26 01:57:33  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
<pre>2017-03-26_01-57-33 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_01-59-33 Restart Xvfb...
2017-03-26 01:59:38  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-03-26 01:59:42  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-03-26 01:59:47  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-03-26 01:59:52  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-03-26 01:59:57  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-03-26 02:00:01  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-03-26 02:00:06  - 23147  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-03-26 02:00:11  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-03-26 02:00:18  - 23147  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-03-26 02:00:25  - 23147  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-03-26 02:00:30  - 23147  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-03-26 02:00:34  - 23147  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-03-26 02:00:39  - 23147  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-03-26 02:00:43  - 23147  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-03-26 02:00:48  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-03-26 02:00:52  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-03-26 02:00:57  - 23147  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-03-26 02:01:01  - 23147  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-03-26 02:01:06  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-03-26 02:01:11  - 23147  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-03-26 02:01:15  - 23147  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-03-26 02:01:20  - 23147  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-03-26 02:01:25  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-03-26 02:01:29  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
<pre>2017-03-26_02-01-33 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_02-03-33 Restart Xvfb...
2017-03-26 02:03:34  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-03-26 02:03:39  - 23147  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-03-26 02:03:43  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-03-26 02:03:48  - 23147  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-03-26 02:03:53  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-03-26 02:03:57  - 23147  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-03-26 02:04:02  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-03-26 02:04:07  - 23147  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-03-26 02:04:12  - 23147  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-03-26 02:04:16  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-03-26 02:04:21  - 23147  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-03-26 02:04:25  - 23147  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-03-26 02:04:29  - 23147  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-03-26 02:04:34  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-03-26 02:04:39  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-03-26 02:04:43  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-03-26 02:04:48  - 23147  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-03-26 02:04:52  - 23147  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-03-26 02:04:57  - 23147  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-03-26 02:05:01  - 23147  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-03-26 02:05:05  - 23147  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-03-26 02:05:09  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-03-26 02:05:14  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-03-26 02:05:19  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-03-26 02:05:22  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-03-26 02:05:27  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-03-26 02:05:31  - 23147  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
<pre>2017-03-26_02-05-33 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_02-07-33 Restart Xvfb...
2017-03-26 02:07:36  - 23147  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-03-26 02:07:41  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-03-26 02:07:46  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-03-26 02:07:50  - 23147  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-03-26 02:07:55  - 23147  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-03-26 02:07:59  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-03-26 02:08:03  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-03-26 02:08:08  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-03-26 02:08:12  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-03-26 02:08:17  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-03-26 02:08:22  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-03-26 02:08:26  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-03-26 02:08:30  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-03-26 02:08:35  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-03-26 02:08:39  - 23147  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-03-26 02:08:44  - 23147  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-03-26 02:08:48  - 23147  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-03-26 02:08:52  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-03-26 02:08:57  - 23147  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-03-26 02:09:01  - 23147  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-03-26 02:09:06  - 23147  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-03-26 02:09:11  - 23147  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-03-26 02:09:16  - 23147  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-03-26 02:09:20  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-03-26 02:09:25  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-03-26 02:09:29  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
<pre>2017-03-26_02-09-33 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_02-11-33 Restart Xvfb...
2017-03-26 02:11:35  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-03-26 02:11:39  - 23147  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-03-26 02:11:43  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-03-26 02:11:48  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-03-26 02:11:53  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-03-26 02:11:57  - 23147  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-03-26 02:12:01  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-03-26 02:12:05  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-03-26 02:12:10  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-03-26 02:12:14  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-03-26 02:12:18  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-03-26 02:12:23  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-03-26 02:12:27  - 23147  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-03-26 02:12:32  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-03-26 02:12:36  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-03-26 02:12:40  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-03-26 02:12:45  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-03-26 02:12:50  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-03-26 02:12:54  - 23147  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-03-26 02:12:59  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-03-26 02:13:03  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-03-26 02:13:08  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-03-26 02:13:12  - 23147  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-03-26 02:13:16  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-03-26 02:13:21  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-03-26 02:13:26  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-03-26 02:13:30  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
<pre>2017-03-26_02-13-33 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_02-15-33 Restart Xvfb...
2017-03-26 02:15:35  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-03-26 02:15:39  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-03-26 02:15:43  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-03-26 02:15:47  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-03-26 02:15:51  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-03-26 02:15:56  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-03-26 02:16:01  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-03-26 02:16:05  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-03-26 02:16:09  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-03-26 02:16:13  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-03-26 02:16:17  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-03-26 02:16:21  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-03-26 02:16:25  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-03-26 02:16:29  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-03-26 02:16:34  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-03-26 02:16:38  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-03-26 02:16:42  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-03-26 02:16:46  - 23147  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-03-26 02:16:50  - 23147  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-03-26 02:16:55  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-03-26 02:16:59  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-03-26 02:17:03  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-03-26 02:17:08  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-03-26 02:17:12  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-03-26 02:17:17  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-03-26 02:17:22  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-03-26 02:17:26  - 23147  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-03-26 02:17:30  - 23147  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
<pre>2017-03-26_02-17-33 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_02-19-33 Restart Xvfb...
2017-03-26 02:19:36  - 23147  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-03-26 02:19:39  - 23147  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-03-26 02:19:43  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-03-26 02:19:48  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-03-26 02:19:52  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-03-26 02:19:56  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-03-26 02:20:01  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-03-26 02:20:05  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-26 02:20:09  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-26 02:20:14  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-26 02:20:18  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-26 02:20:22  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-03-26 02:20:26  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-26 02:20:30  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-26 02:20:34  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-03-26 02:20:38  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-03-26 02:20:42  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-03-26 02:20:46  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-03-26 02:20:50  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-03-26 02:20:55  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-03-26 02:20:59  - 23147  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-03-26 02:21:03  - 23147  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-03-26 02:21:07  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-03-26 02:21:11  - 23147  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-03-26 02:21:15  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-03-26 02:21:19  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-03-26 02:21:24  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-03-26 02:21:28  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-03-26 02:21:32  - 23147  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
<pre>2017-03-26_02-21-33 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_02-23-33 Restart Xvfb...
2017-03-26 02:23:37  - 23147  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-03-26 02:23:41  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-03-26 02:23:45  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-03-26 02:23:49  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-03-26 02:23:53  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-03-26 02:23:57  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-03-26 02:24:01  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-26 02:24:05  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-26 02:24:09  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-26 02:24:13  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-26 02:24:17  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-26 02:24:21  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-03-26 02:24:25  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-26 02:24:29  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-26 02:24:33  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-26 02:24:37  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-26 02:24:41  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-03-26 02:24:45  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-26 02:24:49  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-26 02:24:53  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-26 02:24:57  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-03-26 02:25:01  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
<pre>2017-03-26_02-25-33 Restart Xvfb...
<pre>2017-03-26_02-27-34 Restart Xvfb...
<pre>2017-03-26_02-29-34 Restart Xvfb...
<pre>2017-03-26_02-31-34 Restart Xvfb...
<pre>2017-03-26_02-33-34 Restart Xvfb...
<pre>2017-03-26_02-35-34 Restart Xvfb...
<pre>2017-03-26_02-37-34 Restart Xvfb...
<pre>2017-03-26_02-39-34 Restart Xvfb...
<pre>2017-03-26_02-41-34 Restart Xvfb...
<pre>2017-03-26_02-43-34 Restart Xvfb...
<pre>2017-03-26_02-45-34 Restart Xvfb...
<pre>2017-03-26_02-47-34 Restart Xvfb...
<pre>2017-03-26_02-49-34 Restart Xvfb...
<pre>2017-03-26_02-51-34 Restart Xvfb...
<pre>2017-03-26_02-53-34 Restart Xvfb...
<pre>2017-03-26_02-55-34 Restart Xvfb...
<pre>2017-03-26_02-57-34 Restart Xvfb...
<pre>2017-03-26_02-59-34 Restart Xvfb...
<pre>2017-03-26_03-01-34 Restart Xvfb...
<pre>2017-03-26_03-03-34 Restart Xvfb...
<pre>2017-03-26_03-05-34 Restart Xvfb...
<pre>2017-03-26_03-07-34 Restart Xvfb...
<pre>2017-03-26_03-09-34 Restart Xvfb...
<pre>2017-03-26_03-11-34 Restart Xvfb...
<pre>2017-03-26_03-13-34 Restart Xvfb...
<pre>2017-03-26_03-15-34 Restart Xvfb...
<pre>2017-03-26_03-17-34 Restart Xvfb...
<pre>2017-03-26_03-19-34 Restart Xvfb...
<pre>2017-03-26_03-21-34 Restart Xvfb...
<pre>2017-03-26_03-23-34 Restart Xvfb...
<pre>2017-03-26_03-25-34 Restart Xvfb...
<pre>2017-03-26_03-27-34 Restart Xvfb...
<pre>2017-03-26_03-29-34 Restart Xvfb...
<pre>2017-03-26_03-31-34 Restart Xvfb...
<pre>2017-03-26_03-33-34 Restart Xvfb...
<pre>2017-03-26_03-35-34 Restart Xvfb...
<pre>2017-03-26_03-37-34 Restart Xvfb...
<pre>2017-03-26_03-39-34 Restart Xvfb...
<pre>2017-03-26_03-41-34 Restart Xvfb...
<pre>2017-03-26_03-43-34 Restart Xvfb...
<pre>2017-03-26_03-45-34 Restart Xvfb...
<pre>2017-03-26_03-47-34 Restart Xvfb...
<pre>2017-03-26_03-49-34 Restart Xvfb...
<pre>2017-03-26_03-51-34 Restart Xvfb...
<pre>2017-03-26_03-53-34 Restart Xvfb...
<pre>2017-03-26_03-55-34 Restart Xvfb...
2017-03-26 03:56:59 reset updateRequest
2017-03-26 03:57:02  - 23147  http://www.lymphomahub.com/
2017-03-26 03:57:04  - 23147  http://www.lymphomahub.com/
2017-03-26 03:57:06  - 23147  http://www.lymphomahub.com/about
2017-03-26 03:57:09  - 23147  http://www.lymphomahub.com/about
2017-03-26 03:57:13  - 23147  http://www.lymphomahub.com/terms
2017-03-26 03:57:13  - 23147  http://www.lymphomahub.com/terms
2017-03-26 03:57:17  - 23147  http://www.lymphomahub.com/undefined
2017-03-26 03:57:17  - 23147  http://www.lymphomahub.com/therapies
2017-03-26 03:57:17  - 23147  http://www.lymphomahub.com/therapies
2017-03-26 03:57:27  - 23147  http://www.lymphomahub.com/newsletter
2017-03-26 03:57:27  - 23147  http://www.lymphomahub.com/newsletter
2017-03-26 03:57:31  - 23147  http://www.lymphomahub.com/cookie-policy
2017-03-26 03:57:31  - 23147  http://www.lymphomahub.com/cookie-policy
<pre>2017-03-26_03-57-34 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/cookie-policy?_prerender {"code":"ECONNRESET"}
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/cookie-policy?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_03-59-34 Restart Xvfb...
2017-03-26 03:59:36  - 23147  http://www.lymphomahub.com/cookie-policy
2017-03-26 03:59:36  - 23147  http://www.lymphomahub.com/cookie-policy
2017-03-26 03:59:40  - 23147  http://www.lymphomahub.com/therapies/afm13
2017-03-26 03:59:40  - 23147  http://www.lymphomahub.com/therapies/afm13
2017-03-26 03:59:45  - 23147  http://www.lymphomahub.com/therapies/afm11
2017-03-26 03:59:45  - 23147  http://www.lymphomahub.com/therapies/afm11
2017-03-26 03:59:50  - 23147  http://www.lymphomahub.com/therapies/ags67e
2017-03-26 03:59:55  - 23147  http://www.lymphomahub.com/therapies/cc-292
2017-03-26 03:59:59  - 23147  http://www.lymphomahub.com/therapies/cc-223
2017-03-26 04:00:04  - 23147  http://www.lymphomahub.com/therapies/sd-101
2017-03-26 04:00:09  - 23147  http://www.lymphomahub.com/therapies/rp6530
2017-03-26 04:00:14  - 23147  http://www.lymphomahub.com/therapies/abt199
2017-03-26 04:00:14  - 23147  http://www.lymphomahub.com/therapies/mor208
2017-03-26 04:00:20  - 23147  http://www.lymphomahub.com/therapies/cc-122
2017-03-26 04:00:26  - 23147  http://www.lymphomahub.com/therapies/at-101
2017-03-26 04:00:30  - 23147  http://www.lymphomahub.com/therapies/bl8040
2017-03-26 04:00:34  - 23147  http://www.lymphomahub.com/therapies/bcl201
2017-03-26 04:00:39  - 23147  http://www.lymphomahub.com/therapies/azd3965
2017-03-26 04:00:43  - 23147  http://www.lymphomahub.com/therapies/imgn529
2017-03-26 04:00:47  - 23147  http://www.lymphomahub.com/therapies/azd2014
2017-03-26 04:00:51  - 23147  http://www.lymphomahub.com/therapies/mt-3724
2017-03-26 04:00:56  - 23147  http://www.lymphomahub.com/therapies/actr087
2017-03-26 04:01:00  - 23147  http://www.lymphomahub.com/therapies/epz6438
2017-03-26 04:01:05  - 23147  http://www.lymphomahub.com/therapies/kte-c19
2017-03-26 04:01:09  - 23147  http://www.lymphomahub.com/about/secretariat
2017-03-26 04:01:12  - 23147  http://www.lymphomahub.com/therapies/alt-803
2017-03-26 04:01:17  - 23147  http://www.lymphomahub.com/therapies/regn1979
2017-03-26 04:01:21  - 23147  http://www.lymphomahub.com/therapies/immu-114
2017-03-26 04:01:25  - 23147  http://www.lymphomahub.com/therapies/incb7839
2017-03-26 04:01:29  - 23147  http://www.lymphomahub.com/therapies/adct-301
2017-03-26 04:01:34  - 23147  http://www.lymphomahub.com/therapies/ixazomib
<pre>2017-03-26_04-01-34 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/ixazomib?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_04-03-34 Restart Xvfb...
2017-03-26 04:03:39  - 23147  http://www.lymphomahub.com/therapies/ixazomib
2017-03-26 04:03:43  - 23147  http://www.lymphomahub.com/therapies/avelumab
2017-03-26 04:03:47  - 23147  http://www.lymphomahub.com/therapies/bi836826
2017-03-26 04:03:52  - 23147  http://www.lymphomahub.com/therapies/medi-570
2017-03-26 04:03:56  - 23147  http://www.lymphomahub.com/therapies/ds-3201b
2017-03-26 04:04:00  - 23147  http://www.lymphomahub.com/therapies/sea-cd40
2017-03-26 04:04:05  - 23147  http://www.lymphomahub.com/therapies/adct-402
2017-03-26 04:04:09  - 23147  http://www.lymphomahub.com/therapies/acy-1215
2017-03-26 04:04:14  - 23147  http://www.lymphomahub.com/therapies/cudc-907
2017-03-26 04:04:18  - 23147  http://www.lymphomahub.com/therapies/tgr-1202
2017-03-26 04:04:22  - 23147  http://www.lymphomahub.com/therapies/axitinib
2017-03-26 04:04:26  - 23147  http://www.lymphomahub.com/therapies/imatinib
2017-03-26 04:04:30  - 23147  http://www.lymphomahub.com/therapies/edo-s101
2017-03-26 04:04:35  - 23147  http://www.lymphomahub.com/therapies/btct4465a
2017-03-26 04:04:39  - 23147  http://www.lymphomahub.com/therapies/alisertib
2017-03-26 04:04:43  - 23147  http://www.lymphomahub.com/therapies/lirilumab
2017-03-26 04:04:48  - 23147  http://www.lymphomahub.com/therapies/ibrutinib
2017-03-26 04:04:48  - 23147  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-03-26 04:04:53  - 23147  http://www.lymphomahub.com/therapies/rituximab
2017-03-26 04:04:57  - 23147  http://www.lymphomahub.com/therapies/veliparib
2017-03-26 04:05:01  - 23147  http://www.lymphomahub.com/therapies/sunitinib
2017-03-26 04:05:06  - 23147  http://www.lymphomahub.com/therapies/nivolumab
2017-03-26 04:05:06  - 23147  http://www.lymphomahub.com/therapies/sirolimus
2017-03-26 04:05:10  - 23147  http://www.lymphomahub.com/medical-information
2017-03-26 04:05:15  - 23147  http://www.lymphomahub.com/therapies/selinexor
2017-03-26 04:05:19  - 23147  http://www.lymphomahub.com/therapies/abc294640
2017-03-26 04:05:24  - 23147  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-03-26 04:05:28  - 23147  http://www.lymphomahub.com/therapies/tenofovir
2017-03-26 04:05:32  - 23147  http://www.lymphomahub.com/therapies/betalutin
<pre>2017-03-26_04-05-34 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/betalutin?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_04-07-34 Restart Xvfb...
2017-03-26 04:07:37  - 23147  http://www.lymphomahub.com/therapies/betalutin
2017-03-26 04:07:41  - 23147  http://www.lymphomahub.com/therapies/chidamide
2017-03-26 04:07:46  - 23147  http://www.lymphomahub.com/therapies/duvelisib
2017-03-26 04:07:50  - 23147  http://www.lymphomahub.com/therapies/dasatinib
2017-03-26 04:07:55  - 23147  http://www.lymphomahub.com/therapies/everolimus
2017-03-26 04:07:59  - 23147  http://www.lymphomahub.com/therapies/incb039110
2017-03-26 04:08:04  - 23147  http://www.lymphomahub.com/therapies/durvalumab
2017-03-26 04:08:08  - 23147  http://www.lymphomahub.com/therapies/romidepsin
2017-03-26 04:08:12  - 23147  http://www.lymphomahub.com/therapies/bortezomib
2017-03-26 04:08:17  - 23147  http://www.lymphomahub.com/therapies/idelalisib
2017-03-26 04:08:17  - 23147  http://www.lymphomahub.com/therapies/tipifarnib
2017-03-26 04:08:22  - 23147  http://www.lymphomahub.com/therapies/ipilimumab
2017-03-26 04:08:26  - 23147  http://www.lymphomahub.com/therapies/crizotinib
2017-03-26 04:08:30  - 23147  http://www.lymphomahub.com/therapies/gsk2816126
2017-03-26 04:08:34  - 23147  http://www.lymphomahub.com/therapies/copanlisib
2017-03-26 04:08:38  - 23147  http://www.lymphomahub.com/therapies/buparlisib
2017-03-26 04:08:43  - 23147  http://www.lymphomahub.com/therapies/belinostat
2017-03-26 04:08:47  - 23147  http://www.lymphomahub.com/therapies/vorinostat
2017-03-26 04:08:52  - 23147  http://www.lymphomahub.com/therapies/plerixafor
2017-03-26 04:08:52  - 23147  http://www.lymphomahub.com/therapies/ofatumumab
2017-03-26 04:08:56  - 23147  http://www.lymphomahub.com/therapies/pf-06801591
2017-03-26 04:09:01  - 23147  http://www.lymphomahub.com/therapies/tocilizumab
2017-03-26 04:09:05  - 23147  http://www.lymphomahub.com/therapies/msc2490484a
2017-03-26 04:09:09  - 23147  http://www.lymphomahub.com/therapies/carfilzomib
2017-03-26 04:09:14  - 23147  http://www.lymphomahub.com/therapies/ruxolitinib
2017-03-26 04:09:18  - 23147  http://www.lymphomahub.com/therapies/palbociclib
2017-03-26 04:09:22  - 23147  http://www.lymphomahub.com/therapies/fenretinide
2017-03-26 04:09:26  - 23147  http://www.lymphomahub.com/therapies/daratumumab
2017-03-26 04:09:31  - 23147  http://www.lymphomahub.com/therapies/pf-05082566
<pre>2017-03-26_04-09-35 Restart Xvfb...
2017-03-26 04:09:35  - 23147  http://www.lymphomahub.com/therapies/ramucirumab
2017-03-26 04:09:39  - 23147  http://www.lymphomahub.com/therapies/tositumomab
2017-03-26 04:09:44  - 23147  http://www.lymphomahub.com/therapies/ublituximab
2017-03-26 04:09:48  - 23147  http://www.lymphomahub.com/therapies/epacadostat
2017-03-26 04:09:53  - 23147  http://www.lymphomahub.com/therapies/alemtuzumab
2017-03-26 04:09:54  - 23147  http://www.lymphomahub.com/therapies/otlertuzumab
2017-03-26 04:09:58  - 23147  http://www.lymphomahub.com/therapies/panobinostat
2017-03-26 04:10:02  - 23147  http://www.lymphomahub.com/therapies/mocetinostat
2017-03-26 04:10:06  - 23147  http://www.lymphomahub.com/therapies/atezolizumab
2017-03-26 04:10:11  - 23147  http://www.lymphomahub.com/therapies/temsirolimus
2017-03-26 04:10:15  - 23147  http://www.lymphomahub.com/therapies/lenalidomide
2017-03-26 04:10:19  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab
2017-03-26 04:10:24  - 23147  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-03-26 04:10:28  - 23147  http://www.lymphomahub.com/therapies/blinatumomab
2017-03-26 04:10:32  - 23147  http://www.lymphomahub.com/therapies/jnj-64052781
2017-03-26 04:10:36  - 23147  http://www.lymphomahub.com/therapies/entospletinib
2017-03-26 04:10:40  - 23147  http://www.lymphomahub.com/therapies/pembrolizumab
2017-03-26 04:10:45  - 23147  http://www.lymphomahub.com/therapies/acalabrutinib
2017-03-26 04:10:49  - 23147  http://www.lymphomahub.com/about/innovation-committee
2017-03-26 04:10:53  - 23147  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-03-26 04:10:53  - 23147  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-03-26 04:10:57  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-03-26 04:11:02  - 23147  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-03-26 04:11:06  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-03-26 04:11:10  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-03-26 04:11:11  - 23147  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-03-26 04:11:15  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-03-26 04:11:19  - 23147  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-03-26 04:11:24  - 23147  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-03-26 04:11:27  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board
2017-03-26 04:11:32  - 23147  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
<pre>2017-03-26_04-11-35 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/denintuzumab-mafodotin?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_04-13-35 Restart Xvfb...
2017-03-26 04:13:37  - 23147  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-03-26 04:13:40  - 23147  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-03-26 04:13:45  - 23147  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-03-26 04:13:49  - 23147  http://www.lymphomahub.com/about/executive-steering-committee
2017-03-26 04:13:53  - 23147  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-03-26 04:13:57  - 23147  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-03-26 04:14:02  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-03-26 04:14:05  - 23147  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-03-26 04:14:09  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-03-26 04:14:14  - 23147  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-03-26 04:14:18  - 23147  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-03-26 04:14:18  - 23147  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-03-26 04:14:22  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-03-26 04:14:27  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-03-26 04:14:31  - 23147  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-03-26 04:14:35  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-03-26 04:14:40  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-03-26 04:14:44  - 23147  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-03-26 04:14:48  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-03-26 04:14:52  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-03-26 04:14:55  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-03-26 04:14:59  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-03-26 04:15:03  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-03-26 04:15:07  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-03-26 04:15:11  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-03-26 04:15:14  - 23147  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-03-26 04:15:19  - 23147  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-03-26 04:15:24  - 23147  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-03-26 04:15:28  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-03-26 04:15:32  - 23147  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
<pre>2017-03-26_04-15-35 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_04-17-35 Restart Xvfb...
2017-03-26 04:17:37  - 23147  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-03-26 04:17:40  - 23147  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-03-26 04:17:45  - 23147  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-03-26 04:17:49  - 23147  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-03-26 04:17:54  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-03-26 04:17:58  - 23147  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-03-26 04:18:02  - 23147  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-03-26 04:18:07  - 23147  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-03-26 04:18:12  - 23147  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-03-26 04:18:16  - 23147  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-03-26 04:18:21  - 23147  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-03-26 04:18:26  - 23147  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-03-26 04:18:30  - 23147  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-03-26 04:18:34  - 23147  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-03-26 04:18:39  - 23147  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-03-26 04:18:43  - 23147  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-03-26 04:18:47  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-03-26 04:18:51  - 23147  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-03-26 04:18:56  - 23147  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-03-26 04:19:00  - 23147  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-03-26 04:19:04  - 23147  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-03-26 04:19:09  - 23147  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-03-26 04:19:13  - 23147  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-03-26 04:19:17  - 23147  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-03-26 04:19:22  - 23147  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-03-26 04:19:26  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-03-26 04:19:30  - 23147  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-03-26 04:19:34  - 23147  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
<pre>2017-03-26_04-19-35 Restart Xvfb...
2017-03-26 04:19:39  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-03-26 04:19:43  - 23147  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-03-26 04:19:47  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-03-26 04:19:51  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-03-26 04:19:54  - 23147  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-03-26 04:19:59  - 23147  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-03-26 04:20:04  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-03-26 04:20:07  - 23147  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-03-26 04:20:12  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-03-26 04:20:15  - 23147  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-03-26 04:20:20  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-03-26 04:20:24  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-03-26 04:20:29  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-03-26 04:20:32  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-03-26 04:20:36  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-03-26 04:20:40  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-03-26 04:20:43  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-03-26 04:20:47  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-03-26 04:20:51  - 23147  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-03-26 04:20:56  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-03-26 04:21:01  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-03-26 04:21:05  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-03-26 04:21:10  - 23147  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-26 04:21:10  - 23147  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-03-26 04:21:15  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-03-26 04:21:19  - 23147  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-03-26 04:21:23  - 23147  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-03-26 04:21:28  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-03-26 04:21:32  - 23147  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
<pre>2017-03-26_04-21-35 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_04-23-35 Restart Xvfb...
2017-03-26 04:23:37  - 23147  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-03-26 04:23:41  - 23147  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-03-26 04:23:46  - 23147  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-03-26 04:23:50  - 23147  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-03-26 04:23:54  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-03-26 04:23:59  - 23147  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-03-26 04:24:03  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-03-26 04:24:08  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-03-26 04:24:12  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-03-26 04:24:17  - 23147  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-03-26 04:24:21  - 23147  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-03-26 04:24:26  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-03-26 04:24:30  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-03-26 04:24:35  - 23147  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-03-26 04:24:39  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-03-26 04:24:44  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-03-26 04:24:48  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-03-26 04:24:52  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-03-26 04:24:57  - 23147  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-26 04:25:01  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-03-26 04:25:06  - 23147  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-03-26 04:25:11  - 23147  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-03-26 04:25:15  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-03-26 04:25:19  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-03-26 04:25:24  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-03-26 04:25:28  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-03-26 04:25:32  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
<pre>2017-03-26_04-25-35 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_04-27-35 Restart Xvfb...
2017-03-26 04:27:38  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-03-26 04:27:42  - 23147  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-03-26 04:27:47  - 23147  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-03-26 04:27:51  - 23147  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-03-26 04:27:56  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-03-26 04:28:00  - 23147  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-03-26 04:28:05  - 23147  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-03-26 04:28:10  - 23147  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-03-26 04:28:10  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-03-26 04:28:15  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-03-26 04:28:19  - 23147  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-03-26 04:28:24  - 23147  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-03-26 04:28:28  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-03-26 04:28:33  - 23147  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-03-26 04:28:37  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-03-26 04:28:41  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-03-26 04:28:46  - 23147  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-03-26 04:28:51  - 23147  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-03-26 04:28:55  - 23147  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-03-26 04:29:00  - 23147  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-03-26 04:29:04  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-03-26 04:29:09  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-03-26 04:29:13  - 23147  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-03-26 04:29:18  - 23147  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-03-26 04:29:22  - 23147  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-03-26 04:29:26  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-03-26 04:29:31  - 23147  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
<pre>2017-03-26_04-29-35 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_04-31-35 Restart Xvfb...
2017-03-26 04:31:36  - 23147  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-03-26 04:31:40  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-03-26 04:31:44  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-03-26 04:31:48  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-03-26 04:31:54  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-03-26 04:31:58  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-03-26 04:32:02  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-03-26 04:32:06  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-03-26 04:32:10  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-03-26 04:32:13  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-03-26 04:32:18  - 23147  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-03-26 04:32:18  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-03-26 04:32:23  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-03-26 04:32:27  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-03-26 04:32:31  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-03-26 04:32:35  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-03-26 04:32:38  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-03-26 04:32:42  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-03-26 04:32:45  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-03-26 04:32:49  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-03-26 04:32:53  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-03-26 04:32:56  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-03-26 04:33:00  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-03-26 04:33:03  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-03-26 04:33:07  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-03-26 04:33:10  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-03-26 04:33:14  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-03-26 04:33:18  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-03-26 04:33:22  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-03-26 04:33:26  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-03-26 04:33:29  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-03-26 04:33:33  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
<pre>2017-03-26_04-33-35 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_04-35-35 Restart Xvfb...
2017-03-26 04:35:38  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-03-26 04:35:41  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-03-26 04:35:45  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-03-26 04:35:48  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-03-26 04:35:52  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-03-26 04:35:56  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-03-26 04:35:59  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-03-26 04:36:03  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-03-26 04:36:06  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-03-26 04:36:10  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-03-26 04:36:14  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-03-26 04:36:17  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-03-26 04:36:21  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-03-26 04:36:24  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-03-26 04:36:28  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-03-26 04:36:31  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-03-26 04:36:35  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-03-26 04:36:39  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-03-26 04:36:42  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-03-26 04:36:46  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-03-26 04:36:50  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-03-26 04:36:53  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-03-26 04:36:57  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-03-26 04:37:00  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-03-26 04:37:04  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-03-26 04:37:07  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-03-26 04:37:11  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-03-26 04:37:15  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-03-26 04:37:18  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-03-26 04:37:22  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-03-26 04:37:27  - 23147  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-03-26 04:37:32  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
<pre>2017-03-26_04-37-35 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_04-39-35 Restart Xvfb...
2017-03-26 04:39:37  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-03-26 04:39:41  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-03-26 04:39:46  - 23147  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-03-26 04:39:46  - 23147  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-03-26 04:39:51  - 23147  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-03-26 04:39:56  - 23147  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-03-26 04:40:00  - 23147  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-03-26 04:40:05  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-03-26 04:40:10  - 23147  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-03-26 04:40:14  - 23147  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-03-26 04:40:19  - 23147  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-03-26 04:40:23  - 23147  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-03-26 04:40:28  - 23147  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-03-26 04:40:32  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-03-26 04:40:36  - 23147  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-03-26 04:40:41  - 23147  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-03-26 04:40:45  - 23147  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-03-26 04:40:49  - 23147  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-03-26 04:40:54  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-03-26 04:40:58  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-03-26 04:41:02  - 23147  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-03-26 04:41:07  - 23147  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-03-26 04:41:12  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-03-26 04:41:16  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-03-26 04:41:20  - 23147  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-26 04:41:25  - 23147  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-03-26 04:41:29  - 23147  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-03-26 04:41:33  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
<pre>2017-03-26_04-41-35 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_04-43-35 Restart Xvfb...
2017-03-26 04:43:39  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-03-26 04:43:43  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-03-26 04:43:47  - 23147  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-03-26 04:43:52  - 23147  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-03-26 04:43:56  - 23147  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-03-26 04:44:01  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-03-26 04:44:05  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-03-26 04:44:10  - 23147  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-26 04:44:14  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-03-26 04:44:19  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-03-26 04:44:23  - 23147  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-03-26 04:44:28  - 23147  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-03-26 04:44:32  - 23147  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-03-26 04:44:37  - 23147  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-03-26 04:44:42  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-03-26 04:44:46  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-03-26 04:44:50  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-03-26 04:44:55  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-03-26 04:44:59  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-03-26 04:45:04  - 23147  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-03-26 04:45:08  - 23147  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-03-26 04:45:13  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-03-26 04:45:18  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-03-26 04:45:22  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-03-26 04:45:26  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-03-26 04:45:30  - 23147  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-03-26 04:45:35  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
<pre>2017-03-26_04-45-35 Restart Xvfb...
2017-03-26 04:45:39  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-03-26 04:45:43  - 23147  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-03-26 04:45:48  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-03-26 04:45:52  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-03-26 04:45:56  - 23147  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-03-26 04:46:01  - 23147  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-03-26 04:46:05  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-03-26 04:46:10  - 23147  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-03-26 04:46:14  - 23147  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-03-26 04:46:18  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-03-26 04:46:23  - 23147  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-03-26 04:46:28  - 23147  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-03-26 04:46:32  - 23147  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-03-26 04:46:36  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-03-26 04:46:41  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-03-26 04:46:45  - 23147  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-03-26 04:46:49  - 23147  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-03-26 04:46:54  - 23147  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-03-26 04:46:58  - 23147  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-03-26 04:47:02  - 23147  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-03-26 04:47:07  - 23147  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-03-26 04:47:11  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-03-26 04:47:16  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-03-26 04:47:20  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-03-26 04:47:25  - 23147  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-03-26 04:47:29  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-03-26 04:47:34  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
<pre>2017-03-26_04-47-35 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_04-49-35 Restart Xvfb...
2017-03-26 04:49:39  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-03-26 04:49:44  - 23147  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-03-26 04:49:48  - 23147  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-03-26 04:49:53  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-03-26 04:49:57  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-03-26 04:50:01  - 23147  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-03-26 04:50:06  - 23147  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-03-26 04:50:11  - 23147  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-03-26 04:50:15  - 23147  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-03-26 04:50:19  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-03-26 04:50:23  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-03-26 04:50:28  - 23147  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-03-26 04:50:32  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-03-26 04:50:37  - 23147  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-03-26 04:50:41  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-03-26 04:50:45  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-03-26 04:50:50  - 23147  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-03-26 04:50:54  - 23147  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-03-26 04:50:59  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-03-26 04:51:03  - 23147  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-03-26 04:51:08  - 23147  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-03-26 04:51:12  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-03-26 04:51:17  - 23147  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-03-26 04:51:21  - 23147  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-03-26 04:51:25  - 23147  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-03-26 04:51:30  - 23147  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-03-26 04:51:34  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
<pre>2017-03-26_04-51-35 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_04-53-35 Restart Xvfb...
2017-03-26 04:53:40  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-03-26 04:53:44  - 23147  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-03-26 04:53:49  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-03-26 04:53:53  - 23147  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-03-26 04:53:57  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-03-26 04:54:02  - 23147  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-03-26 04:54:06  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-03-26 04:54:11  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-03-26 04:54:15  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-03-26 04:54:20  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-03-26 04:54:24  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-03-26 04:54:29  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-03-26 04:54:33  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-03-26 04:54:38  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-03-26 04:54:42  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-03-26 04:54:46  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-03-26 04:54:51  - 23147  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-03-26 04:54:55  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-03-26 04:54:59  - 23147  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-03-26 04:55:04  - 23147  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-03-26 04:55:08  - 23147  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-03-26 04:55:13  - 23147  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-03-26 04:55:17  - 23147  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-03-26 04:55:21  - 23147  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-03-26 04:55:26  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-03-26 04:55:30  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-03-26 04:55:35  - 23147  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
<pre>2017-03-26_04-55-35 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_04-57-35 Restart Xvfb...
2017-03-26 04:57:40  - 23147  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-03-26 04:57:44  - 23147  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-03-26 04:57:49  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-03-26 04:57:53  - 23147  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-03-26 04:57:58  - 23147  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-03-26 04:58:02  - 23147  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-03-26 04:58:07  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-03-26 04:58:12  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-03-26 04:58:16  - 23147  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-03-26 04:58:21  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-03-26 04:58:25  - 23147  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-03-26 04:58:30  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-03-26 04:58:34  - 23147  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-03-26 04:58:39  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-03-26 04:58:43  - 23147  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-03-26 04:58:47  - 23147  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-03-26 04:58:52  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-03-26 04:58:56  - 23147  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-03-26 04:59:00  - 23147  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-03-26 04:59:05  - 23147  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-03-26 04:59:10  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-03-26 04:59:14  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-03-26 04:59:18  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-03-26 04:59:22  - 23147  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-03-26 04:59:27  - 23147  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-03-26 04:59:31  - 23147  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
<pre>2017-03-26_04-59-35 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_05-01-35 Restart Xvfb...
2017-03-26 05:01:36  - 23147  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-03-26 05:01:40  - 23147  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-03-26 05:01:44  - 23147  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-03-26 05:01:48  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-03-26 05:01:53  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-03-26 05:01:57  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-03-26 05:02:01  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-03-26 05:02:06  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-03-26 05:02:10  - 23147  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-03-26 05:02:15  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-03-26 05:02:19  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-03-26 05:02:24  - 23147  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-03-26 05:02:28  - 23147  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-03-26 05:02:32  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-03-26 05:02:36  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-03-26 05:02:40  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-03-26 05:02:45  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-03-26 05:02:49  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-03-26 05:02:54  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-03-26 05:02:58  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-03-26 05:03:02  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-03-26 05:03:07  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-03-26 05:03:11  - 23147  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-03-26 05:03:15  - 23147  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-03-26 05:03:20  - 23147  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-03-26 05:03:24  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-03-26 05:03:28  - 23147  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-03-26 05:03:32  - 23147  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
<pre>2017-03-26_05-03-35 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_05-05-35 Restart Xvfb...
2017-03-26 05:05:37  - 23147  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-03-26 05:05:41  - 23147  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-03-26 05:05:46  - 23147  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-03-26 05:05:50  - 23147  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-03-26 05:05:55  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-03-26 05:05:59  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-03-26 05:06:03  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-03-26 05:06:08  - 23147  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-03-26 05:06:12  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-03-26 05:06:17  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-03-26 05:06:22  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-03-26 05:06:26  - 23147  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-03-26 05:06:30  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-03-26 05:06:34  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-03-26 05:06:38  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-03-26 05:06:42  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-03-26 05:06:47  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-03-26 05:06:51  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-03-26 05:06:55  - 23147  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-03-26 05:07:00  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-03-26 05:07:04  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-03-26 05:07:08  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-03-26 05:07:12  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-03-26 05:07:17  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-03-26 05:07:21  - 23147  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-03-26 05:07:26  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-03-26 05:07:30  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-03-26 05:07:34  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
<pre>2017-03-26_05-07-35 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_05-09-35 Restart Xvfb...
2017-03-26 05:09:39  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-03-26 05:09:43  - 23147  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-03-26 05:09:48  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-03-26 05:09:52  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-03-26 05:09:57  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-03-26 05:10:01  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-03-26 05:10:07  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-03-26 05:10:11  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-03-26 05:10:15  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-03-26 05:10:19  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-03-26 05:10:23  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-03-26 05:10:27  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-03-26 05:10:31  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-03-26 05:10:36  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-03-26 05:10:39  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-03-26 05:10:43  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-03-26 05:10:47  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-03-26 05:10:51  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-03-26 05:10:55  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-03-26 05:11:00  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-03-26 05:11:04  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-03-26 05:11:08  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-03-26 05:11:12  - 23147  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-03-26 05:11:16  - 23147  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-03-26 05:11:20  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-03-26 05:11:24  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-03-26 05:11:28  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-03-26 05:11:33  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
<pre>2017-03-26_05-11-35 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_05-13-35 Restart Xvfb...
2017-03-26 05:13:38  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-03-26 05:13:42  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-03-26 05:13:47  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-03-26 05:13:51  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-03-26 05:13:56  - 23147  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-03-26 05:14:00  - 23147  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-03-26 05:14:04  - 23147  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-03-26 05:14:08  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-03-26 05:14:13  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-03-26 05:14:17  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-03-26 05:14:21  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-03-26 05:14:25  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-03-26 05:14:29  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-26 05:14:33  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-26 05:14:37  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-26 05:14:41  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-26 05:14:45  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-03-26 05:14:49  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-26 05:14:53  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-26 05:14:57  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-03-26 05:15:01  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-03-26 05:15:05  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-03-26 05:15:09  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-03-26 05:15:13  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-03-26 05:15:17  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-03-26 05:15:21  - 23147  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-03-26 05:15:25  - 23147  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-03-26 05:15:29  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-03-26 05:15:33  - 23147  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
<pre>2017-03-26_05-15-35 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_05-17-35 Restart Xvfb...
2017-03-26 05:17:38  - 23147  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-03-26 05:17:42  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-03-26 05:17:46  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-03-26 05:17:50  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-03-26 05:17:54  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-03-26 05:17:58  - 23147  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-03-26 05:18:02  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-03-26 05:18:06  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-03-26 05:18:10  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-03-26 05:18:14  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-03-26 05:18:18  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-03-26 05:18:22  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-26 05:18:26  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-26 05:18:30  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-26 05:18:34  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-26 05:18:38  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-26 05:18:41  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-03-26 05:18:45  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-26 05:18:49  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-26 05:18:53  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-26 05:18:57  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-26 05:19:01  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-03-26 05:19:05  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-26 05:19:09  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-26 05:19:13  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-26 05:19:17  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-03-26 05:19:21  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
<pre>2017-03-26_05-19-35 Restart Xvfb...
<pre>2017-03-26_05-21-35 Restart Xvfb...
<pre>2017-03-26_05-23-35 Restart Xvfb...
<pre>2017-03-26_05-25-35 Restart Xvfb...
<pre>2017-03-26_05-27-35 Restart Xvfb...
<pre>2017-03-26_05-29-36 Restart Xvfb...
<pre>2017-03-26_05-31-36 Restart Xvfb...
<pre>2017-03-26_05-33-36 Restart Xvfb...
<pre>2017-03-26_05-35-36 Restart Xvfb...
<pre>2017-03-26_05-37-36 Restart Xvfb...
<pre>2017-03-26_05-39-36 Restart Xvfb...
<pre>2017-03-26_05-41-36 Restart Xvfb...
<pre>2017-03-26_05-43-36 Restart Xvfb...
<pre>2017-03-26_05-45-36 Restart Xvfb...
<pre>2017-03-26_05-47-36 Restart Xvfb...
<pre>2017-03-26_05-49-36 Restart Xvfb...
<pre>2017-03-26_05-51-36 Restart Xvfb...
<pre>2017-03-26_05-53-36 Restart Xvfb...
<pre>2017-03-26_05-55-36 Restart Xvfb...
<pre>2017-03-26_05-57-36 Restart Xvfb...
<pre>2017-03-26_05-59-36 Restart Xvfb...
<pre>2017-03-26_06-01-36 Restart Xvfb...
<pre>2017-03-26_06-03-36 Restart Xvfb...
<pre>2017-03-26_06-05-36 Restart Xvfb...
<pre>2017-03-26_06-07-36 Restart Xvfb...
<pre>2017-03-26_06-09-36 Restart Xvfb...
<pre>2017-03-26_06-11-36 Restart Xvfb...
<pre>2017-03-26_06-13-36 Restart Xvfb...
<pre>2017-03-26_06-15-36 Restart Xvfb...
<pre>2017-03-26_06-17-36 Restart Xvfb...
<pre>2017-03-26_06-19-36 Restart Xvfb...
<pre>2017-03-26_06-21-36 Restart Xvfb...
<pre>2017-03-26_06-23-36 Restart Xvfb...
<pre>2017-03-26_06-25-36 Restart Xvfb...
<pre>2017-03-26_06-27-36 Restart Xvfb...
<pre>2017-03-26_06-29-36 Restart Xvfb...
<pre>2017-03-26_06-31-36 Restart Xvfb...
<pre>2017-03-26_06-33-36 Restart Xvfb...
<pre>2017-03-26_06-35-36 Restart Xvfb...
<pre>2017-03-26_06-37-36 Restart Xvfb...
<pre>2017-03-26_06-39-36 Restart Xvfb...
<pre>2017-03-26_06-41-36 Restart Xvfb...
<pre>2017-03-26_06-43-36 Restart Xvfb...
<pre>2017-03-26_06-45-36 Restart Xvfb...
<pre>2017-03-26_06-47-36 Restart Xvfb...
<pre>2017-03-26_06-49-36 Restart Xvfb...
<pre>2017-03-26_06-51-36 Restart Xvfb...
<pre>2017-03-26_06-53-36 Restart Xvfb...
<pre>2017-03-26_06-55-36 Restart Xvfb...
2017-03-26 06:56:59 reset updateRequest
2017-03-26 06:57:03  - 23147  http://www.lymphomahub.com/
2017-03-26 06:57:04  - 23147  http://www.lymphomahub.com/
2017-03-26 06:57:08  - 23147  http://www.lymphomahub.com/about
2017-03-26 06:57:09  - 23147  http://www.lymphomahub.com/about
2017-03-26 06:57:14  - 23147  http://www.lymphomahub.com/terms
2017-03-26 06:57:17  - 23147  http://www.lymphomahub.com/undefined
2017-03-26 06:57:17  - 23147  http://www.lymphomahub.com/therapies
2017-03-26 06:57:23  - 23147  http://www.lymphomahub.com/newsletter
2017-03-26 06:57:26  - 23147  http://www.lymphomahub.com/cookie-policy
2017-03-26 06:57:29  - 23147  http://www.lymphomahub.com/therapies/afm13
2017-03-26 06:57:34  - 23147  http://www.lymphomahub.com/therapies/afm11
<pre>2017-03-26_06-57-36 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/afm11?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_06-59-36 Restart Xvfb...
2017-03-26 06:59:39  - 23147  http://www.lymphomahub.com/therapies/afm11
2017-03-26 06:59:43  - 23147  http://www.lymphomahub.com/therapies/ags67e
2017-03-26 06:59:47  - 23147  http://www.lymphomahub.com/therapies/cc-292
2017-03-26 06:59:51  - 23147  http://www.lymphomahub.com/therapies/cc-223
2017-03-26 06:59:56  - 23147  http://www.lymphomahub.com/therapies/sd-101
2017-03-26 07:00:00  - 23147  http://www.lymphomahub.com/therapies/rp6530
2017-03-26 07:00:05  - 23147  http://www.lymphomahub.com/therapies/abt199
2017-03-26 07:00:06  - 23147  http://www.lymphomahub.com/therapies/mor208
2017-03-26 07:00:10  - 23147  http://www.lymphomahub.com/therapies/cc-122
2017-03-26 07:00:18  - 23147  http://www.lymphomahub.com/therapies/at-101
2017-03-26 07:00:22  - 23147  http://www.lymphomahub.com/therapies/bl8040
2017-03-26 07:00:28  - 23147  http://www.lymphomahub.com/therapies/bcl201
2017-03-26 07:00:32  - 23147  http://www.lymphomahub.com/therapies/azd3965
2017-03-26 07:00:36  - 23147  http://www.lymphomahub.com/therapies/imgn529
2017-03-26 07:00:40  - 23147  http://www.lymphomahub.com/therapies/azd2014
2017-03-26 07:00:45  - 23147  http://www.lymphomahub.com/therapies/mt-3724
2017-03-26 07:00:49  - 23147  http://www.lymphomahub.com/therapies/actr087
2017-03-26 07:00:54  - 23147  http://www.lymphomahub.com/therapies/epz6438
2017-03-26 07:00:58  - 23147  http://www.lymphomahub.com/therapies/kte-c19
2017-03-26 07:01:02  - 23147  http://www.lymphomahub.com/about/secretariat
2017-03-26 07:01:06  - 23147  http://www.lymphomahub.com/therapies/alt-803
2017-03-26 07:01:10  - 23147  http://www.lymphomahub.com/therapies/regn1979
2017-03-26 07:01:14  - 23147  http://www.lymphomahub.com/therapies/immu-114
2017-03-26 07:01:18  - 23147  http://www.lymphomahub.com/therapies/incb7839
2017-03-26 07:01:23  - 23147  http://www.lymphomahub.com/therapies/adct-301
2017-03-26 07:01:27  - 23147  http://www.lymphomahub.com/therapies/ixazomib
2017-03-26 07:01:31  - 23147  http://www.lymphomahub.com/therapies/avelumab
2017-03-26 07:01:35  - 23147  http://www.lymphomahub.com/therapies/bi836826
<pre>2017-03-26_07-01-36 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/bi836826?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_07-03-36 Restart Xvfb...
2017-03-26 07:03:40  - 23147  http://www.lymphomahub.com/therapies/bi836826
2017-03-26 07:03:44  - 23147  http://www.lymphomahub.com/therapies/medi-570
2017-03-26 07:03:49  - 23147  http://www.lymphomahub.com/therapies/ds-3201b
2017-03-26 07:03:53  - 23147  http://www.lymphomahub.com/therapies/sea-cd40
2017-03-26 07:03:57  - 23147  http://www.lymphomahub.com/therapies/adct-402
2017-03-26 07:04:02  - 23147  http://www.lymphomahub.com/therapies/acy-1215
2017-03-26 07:04:06  - 23147  http://www.lymphomahub.com/therapies/cudc-907
2017-03-26 07:04:11  - 23147  http://www.lymphomahub.com/therapies/tgr-1202
2017-03-26 07:04:15  - 23147  http://www.lymphomahub.com/therapies/axitinib
2017-03-26 07:04:20  - 23147  http://www.lymphomahub.com/therapies/imatinib
2017-03-26 07:04:24  - 23147  http://www.lymphomahub.com/therapies/edo-s101
2017-03-26 07:04:28  - 23147  http://www.lymphomahub.com/therapies/btct4465a
2017-03-26 07:04:33  - 23147  http://www.lymphomahub.com/therapies/alisertib
2017-03-26 07:04:37  - 23147  http://www.lymphomahub.com/therapies/lirilumab
2017-03-26 07:04:41  - 23147  http://www.lymphomahub.com/therapies/ibrutinib
2017-03-26 07:04:42  - 23147  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-03-26 07:04:46  - 23147  http://www.lymphomahub.com/therapies/rituximab
2017-03-26 07:04:51  - 23147  http://www.lymphomahub.com/therapies/veliparib
2017-03-26 07:04:55  - 23147  http://www.lymphomahub.com/therapies/sunitinib
2017-03-26 07:04:59  - 23147  http://www.lymphomahub.com/therapies/nivolumab
2017-03-26 07:05:00  - 23147  http://www.lymphomahub.com/therapies/sirolimus
2017-03-26 07:05:04  - 23147  http://www.lymphomahub.com/medical-information
2017-03-26 07:05:09  - 23147  http://www.lymphomahub.com/therapies/selinexor
2017-03-26 07:05:13  - 23147  http://www.lymphomahub.com/therapies/abc294640
2017-03-26 07:05:18  - 23147  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-03-26 07:05:22  - 23147  http://www.lymphomahub.com/therapies/tenofovir
2017-03-26 07:05:26  - 23147  http://www.lymphomahub.com/therapies/betalutin
2017-03-26 07:05:30  - 23147  http://www.lymphomahub.com/therapies/chidamide
2017-03-26 07:05:34  - 23147  http://www.lymphomahub.com/therapies/duvelisib
<pre>2017-03-26_07-05-36 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/duvelisib?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_07-07-36 Restart Xvfb...
2017-03-26 07:07:40  - 23147  http://www.lymphomahub.com/therapies/duvelisib
2017-03-26 07:07:44  - 23147  http://www.lymphomahub.com/therapies/dasatinib
2017-03-26 07:07:48  - 23147  http://www.lymphomahub.com/therapies/everolimus
2017-03-26 07:07:52  - 23147  http://www.lymphomahub.com/therapies/incb039110
2017-03-26 07:07:57  - 23147  http://www.lymphomahub.com/therapies/durvalumab
2017-03-26 07:08:01  - 23147  http://www.lymphomahub.com/therapies/romidepsin
2017-03-26 07:08:05  - 23147  http://www.lymphomahub.com/therapies/bortezomib
2017-03-26 07:08:10  - 23147  http://www.lymphomahub.com/therapies/idelalisib
2017-03-26 07:08:10  - 23147  http://www.lymphomahub.com/therapies/tipifarnib
2017-03-26 07:08:14  - 23147  http://www.lymphomahub.com/therapies/ipilimumab
2017-03-26 07:08:19  - 23147  http://www.lymphomahub.com/therapies/crizotinib
2017-03-26 07:08:23  - 23147  http://www.lymphomahub.com/therapies/gsk2816126
2017-03-26 07:08:27  - 23147  http://www.lymphomahub.com/therapies/copanlisib
2017-03-26 07:08:31  - 23147  http://www.lymphomahub.com/therapies/buparlisib
2017-03-26 07:08:35  - 23147  http://www.lymphomahub.com/therapies/belinostat
2017-03-26 07:08:40  - 23147  http://www.lymphomahub.com/therapies/vorinostat
2017-03-26 07:08:44  - 23147  http://www.lymphomahub.com/therapies/plerixafor
2017-03-26 07:08:45  - 23147  http://www.lymphomahub.com/therapies/ofatumumab
2017-03-26 07:08:49  - 23147  http://www.lymphomahub.com/therapies/pf-06801591
2017-03-26 07:08:53  - 23147  http://www.lymphomahub.com/therapies/tocilizumab
2017-03-26 07:08:58  - 23147  http://www.lymphomahub.com/therapies/msc2490484a
2017-03-26 07:09:02  - 23147  http://www.lymphomahub.com/therapies/carfilzomib
2017-03-26 07:09:06  - 23147  http://www.lymphomahub.com/therapies/ruxolitinib
2017-03-26 07:09:11  - 23147  http://www.lymphomahub.com/therapies/palbociclib
2017-03-26 07:09:15  - 23147  http://www.lymphomahub.com/therapies/fenretinide
2017-03-26 07:09:19  - 23147  http://www.lymphomahub.com/therapies/daratumumab
2017-03-26 07:09:24  - 23147  http://www.lymphomahub.com/therapies/pf-05082566
2017-03-26 07:09:28  - 23147  http://www.lymphomahub.com/therapies/ramucirumab
2017-03-26 07:09:32  - 23147  http://www.lymphomahub.com/therapies/tositumomab
<pre>2017-03-26_07-09-36 Restart Xvfb...
2017-03-26 07:09:36  - 23147  http://www.lymphomahub.com/therapies/ublituximab
2017-03-26 07:09:41  - 23147  http://www.lymphomahub.com/therapies/epacadostat
2017-03-26 07:09:45  - 23147  http://www.lymphomahub.com/therapies/alemtuzumab
2017-03-26 07:09:46  - 23147  http://www.lymphomahub.com/therapies/otlertuzumab
2017-03-26 07:09:50  - 23147  http://www.lymphomahub.com/therapies/panobinostat
2017-03-26 07:09:54  - 23147  http://www.lymphomahub.com/therapies/mocetinostat
2017-03-26 07:09:59  - 23147  http://www.lymphomahub.com/therapies/atezolizumab
2017-03-26 07:10:04  - 23147  http://www.lymphomahub.com/therapies/temsirolimus
2017-03-26 07:10:08  - 23147  http://www.lymphomahub.com/therapies/lenalidomide
2017-03-26 07:10:13  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab
2017-03-26 07:10:17  - 23147  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-03-26 07:10:21  - 23147  http://www.lymphomahub.com/therapies/blinatumomab
2017-03-26 07:10:25  - 23147  http://www.lymphomahub.com/therapies/jnj-64052781
2017-03-26 07:10:30  - 23147  http://www.lymphomahub.com/therapies/entospletinib
2017-03-26 07:10:34  - 23147  http://www.lymphomahub.com/therapies/pembrolizumab
2017-03-26 07:10:38  - 23147  http://www.lymphomahub.com/therapies/acalabrutinib
2017-03-26 07:10:42  - 23147  http://www.lymphomahub.com/about/innovation-committee
2017-03-26 07:10:46  - 23147  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-03-26 07:10:47  - 23147  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-03-26 07:10:51  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-03-26 07:10:55  - 23147  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-03-26 07:10:59  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-03-26 07:11:04  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-03-26 07:11:04  - 23147  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-03-26 07:11:09  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-03-26 07:11:13  - 23147  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-03-26 07:11:17  - 23147  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-03-26 07:11:21  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board
2017-03-26 07:11:25  - 23147  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-03-26 07:11:29  - 23147  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-03-26 07:11:33  - 23147  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
<pre>2017-03-26_07-11-36 Restart Xvfb...
2017-03-26 07:11:37  - 23147  http://www.lymphomahub.com/about/executive-steering-committee
2017-03-26 07:11:40  - 23147  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-03-26 07:11:44  - 23147  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-03-26 07:11:49  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-03-26 07:11:52  - 23147  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-03-26 07:11:56  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-03-26 07:12:00  - 23147  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-03-26 07:12:04  - 23147  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-03-26 07:12:05  - 23147  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-03-26 07:12:08  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-03-26 07:12:13  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-03-26 07:12:17  - 23147  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-03-26 07:12:22  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-03-26 07:12:27  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-03-26 07:12:31  - 23147  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-03-26 07:12:35  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-03-26 07:12:39  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-03-26 07:12:43  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-03-26 07:12:46  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-03-26 07:12:50  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-03-26 07:12:54  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-03-26 07:12:58  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-03-26 07:13:01  - 23147  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-03-26 07:13:06  - 23147  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-03-26 07:13:10  - 23147  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-03-26 07:13:15  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-03-26 07:13:18  - 23147  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-03-26 07:13:22  - 23147  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-03-26 07:13:26  - 23147  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-03-26 07:13:31  - 23147  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-03-26 07:13:36  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
<pre>2017-03-26_07-13-36 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_07-15-37 Restart Xvfb...
2017-03-26 07:15:41  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-03-26 07:15:45  - 23147  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-03-26 07:15:50  - 23147  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-03-26 07:15:54  - 23147  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-03-26 07:15:59  - 23147  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-03-26 07:16:04  - 23147  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-03-26 07:16:08  - 23147  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-03-26 07:16:13  - 23147  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-03-26 07:16:17  - 23147  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-03-26 07:16:22  - 23147  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-03-26 07:16:26  - 23147  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-03-26 07:16:30  - 23147  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-03-26 07:16:35  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-03-26 07:16:39  - 23147  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-03-26 07:16:44  - 23147  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-03-26 07:16:48  - 23147  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-03-26 07:16:53  - 23147  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-03-26 07:16:57  - 23147  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-03-26 07:17:01  - 23147  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-03-26 07:17:05  - 23147  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-03-26 07:17:10  - 23147  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-03-26 07:17:14  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-03-26 07:17:18  - 23147  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-03-26 07:17:22  - 23147  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-03-26 07:17:27  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-03-26 07:17:30  - 23147  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-03-26 07:17:35  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
<pre>2017-03-26_07-17-37 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_07-19-37 Restart Xvfb...
2017-03-26 07:19:40  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-03-26 07:19:44  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-03-26 07:19:48  - 23147  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-03-26 07:19:52  - 23147  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-03-26 07:19:57  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-03-26 07:20:00  - 23147  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-03-26 07:20:05  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-03-26 07:20:09  - 23147  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-03-26 07:20:14  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-03-26 07:20:18  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-03-26 07:20:23  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-03-26 07:20:26  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-03-26 07:20:30  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-03-26 07:20:34  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-03-26 07:20:38  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-03-26 07:20:42  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-03-26 07:20:46  - 23147  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-03-26 07:20:51  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-03-26 07:20:56  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-03-26 07:21:00  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-03-26 07:21:05  - 23147  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-26 07:21:06  - 23147  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-03-26 07:21:10  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-03-26 07:21:15  - 23147  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-03-26 07:21:20  - 23147  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-03-26 07:21:24  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-03-26 07:21:29  - 23147  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-03-26 07:21:33  - 23147  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
<pre>2017-03-26_07-21-37 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_07-23-37 Restart Xvfb...
2017-03-26 07:23:38  - 23147  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-03-26 07:23:42  - 23147  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-03-26 07:23:47  - 23147  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-03-26 07:23:51  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-03-26 07:23:56  - 23147  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-03-26 07:24:00  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-03-26 07:24:05  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-03-26 07:24:10  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-03-26 07:24:14  - 23147  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-03-26 07:24:19  - 23147  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-03-26 07:24:23  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-03-26 07:24:28  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-03-26 07:24:33  - 23147  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-03-26 07:24:37  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-03-26 07:24:42  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-03-26 07:24:46  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-03-26 07:24:51  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-03-26 07:24:56  - 23147  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-26 07:25:00  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-03-26 07:25:05  - 23147  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-03-26 07:25:09  - 23147  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-03-26 07:25:14  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-03-26 07:25:18  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-03-26 07:25:23  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-03-26 07:25:27  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-03-26 07:25:31  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-03-26 07:25:36  - 23147  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
<pre>2017-03-26_07-25-37 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_07-27-37 Restart Xvfb...
2017-03-26 07:27:41  - 23147  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-03-26 07:27:46  - 23147  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-03-26 07:27:50  - 23147  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-03-26 07:27:55  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-03-26 07:27:59  - 23147  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-03-26 07:28:04  - 23147  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-03-26 07:28:09  - 23147  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-03-26 07:28:09  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-03-26 07:28:14  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-03-26 07:28:19  - 23147  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-03-26 07:28:23  - 23147  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-03-26 07:28:28  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-03-26 07:28:32  - 23147  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-03-26 07:28:37  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-03-26 07:28:42  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-03-26 07:28:46  - 23147  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-03-26 07:28:50  - 23147  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-03-26 07:28:55  - 23147  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-03-26 07:28:59  - 23147  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-03-26 07:29:04  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-03-26 07:29:09  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-03-26 07:29:13  - 23147  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-03-26 07:29:17  - 23147  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-03-26 07:29:22  - 23147  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-03-26 07:29:27  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-03-26 07:29:31  - 23147  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-03-26 07:29:36  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
<pre>2017-03-26_07-29-37 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_07-31-37 Restart Xvfb...
2017-03-26 07:31:41  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-03-26 07:31:45  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-03-26 07:31:49  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-03-26 07:31:55  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-03-26 07:31:59  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-03-26 07:32:02  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-03-26 07:32:06  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-03-26 07:32:10  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-03-26 07:32:14  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-03-26 07:32:19  - 23147  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-03-26 07:32:19  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-03-26 07:32:24  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-03-26 07:32:28  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-03-26 07:32:31  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-03-26 07:32:35  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-03-26 07:32:39  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-03-26 07:32:42  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-03-26 07:32:46  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-03-26 07:32:49  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-03-26 07:32:53  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-03-26 07:32:56  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-03-26 07:33:00  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-03-26 07:33:04  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-03-26 07:33:07  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-03-26 07:33:11  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-03-26 07:33:14  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-03-26 07:33:19  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-03-26 07:33:22  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-03-26 07:33:26  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-03-26 07:33:30  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-03-26 07:33:33  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
<pre>2017-03-26_07-33-37 Restart Xvfb...
2017-03-26 07:33:37  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
<pre>2017-03-26_07-35-37 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/?_prerender {"code":"ECONNRESET"}
2017-03-26 07:35:42  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-03-26 07:35:46  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-03-26 07:35:50  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-03-26 07:35:53  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-03-26 07:35:57  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-03-26 07:36:00  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-03-26 07:36:04  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-03-26 07:36:08  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-03-26 07:36:11  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-03-26 07:36:15  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-03-26 07:36:19  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-03-26 07:36:22  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-03-26 07:36:26  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-03-26 07:36:29  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-03-26 07:36:33  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-03-26 07:36:37  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-03-26 07:36:40  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-03-26 07:36:44  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-03-26 07:36:48  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-03-26 07:36:52  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-03-26 07:36:55  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-03-26 07:36:59  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-03-26 07:37:03  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-03-26 07:37:06  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-03-26 07:37:10  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-03-26 07:37:14  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-03-26 07:37:17  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-03-26 07:37:21  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-03-26 07:37:24  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-03-26 07:37:29  - 23147  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-03-26 07:37:34  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
<pre>2017-03-26_07-37-37 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_07-39-37 Restart Xvfb...
2017-03-26 07:39:39  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-03-26 07:39:43  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-03-26 07:39:48  - 23147  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-03-26 07:39:49  - 23147  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-03-26 07:39:53  - 23147  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-03-26 07:39:58  - 23147  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-03-26 07:40:02  - 23147  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-03-26 07:40:07  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-03-26 07:40:11  - 23147  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-03-26 07:40:16  - 23147  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-03-26 07:40:20  - 23147  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-03-26 07:40:24  - 23147  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-03-26 07:40:29  - 23147  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-03-26 07:40:33  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-03-26 07:40:37  - 23147  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-03-26 07:40:42  - 23147  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-03-26 07:40:46  - 23147  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-03-26 07:40:51  - 23147  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-03-26 07:40:55  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-03-26 07:40:59  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-03-26 07:41:04  - 23147  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-03-26 07:41:08  - 23147  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-03-26 07:41:13  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-03-26 07:41:17  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-03-26 07:41:22  - 23147  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-26 07:41:26  - 23147  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-03-26 07:41:30  - 23147  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-03-26 07:41:34  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
<pre>2017-03-26_07-41-37 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_07-43-37 Restart Xvfb...
2017-03-26 07:43:40  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-03-26 07:43:44  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-03-26 07:43:49  - 23147  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-03-26 07:43:53  - 23147  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-03-26 07:43:58  - 23147  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-03-26 07:44:02  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-03-26 07:44:07  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-03-26 07:44:11  - 23147  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-26 07:44:16  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-03-26 07:44:20  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-03-26 07:44:24  - 23147  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-03-26 07:44:29  - 23147  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-03-26 07:44:33  - 23147  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-03-26 07:44:37  - 23147  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-03-26 07:44:42  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-03-26 07:44:46  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-03-26 07:44:51  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-03-26 07:44:55  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-03-26 07:44:59  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-03-26 07:45:04  - 23147  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-03-26 07:45:08  - 23147  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-03-26 07:45:13  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-03-26 07:45:17  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-03-26 07:45:21  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-03-26 07:45:26  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-03-26 07:45:30  - 23147  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-03-26 07:45:34  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
<pre>2017-03-26_07-45-37 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_07-47-37 Restart Xvfb...
2017-03-26 07:47:39  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-03-26 07:47:44  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-03-26 07:47:48  - 23147  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-03-26 07:47:53  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-03-26 07:47:57  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-03-26 07:48:01  - 23147  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-03-26 07:48:06  - 23147  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-03-26 07:48:10  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-03-26 07:48:15  - 23147  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-03-26 07:48:19  - 23147  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-03-26 07:48:24  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-03-26 07:48:28  - 23147  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-03-26 07:48:33  - 23147  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-03-26 07:48:37  - 23147  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-03-26 07:48:42  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-03-26 07:48:46  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-03-26 07:48:50  - 23147  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-03-26 07:48:55  - 23147  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-03-26 07:48:59  - 23147  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-03-26 07:49:04  - 23147  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-03-26 07:49:08  - 23147  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-03-26 07:49:13  - 23147  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-03-26 07:49:17  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-03-26 07:49:22  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-03-26 07:49:26  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-03-26 07:49:30  - 23147  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-03-26 07:49:35  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
<pre>2017-03-26_07-49-37 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_07-51-37 Restart Xvfb...
2017-03-26 07:51:40  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-03-26 07:51:44  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-03-26 07:51:49  - 23147  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-03-26 07:51:53  - 23147  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-03-26 07:51:57  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-03-26 07:52:02  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-03-26 07:52:07  - 23147  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-03-26 07:52:11  - 23147  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-03-26 07:52:16  - 23147  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-03-26 07:52:20  - 23147  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-03-26 07:52:24  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-03-26 07:52:29  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-03-26 07:52:34  - 23147  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-03-26 07:52:38  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-03-26 07:52:42  - 23147  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-03-26 07:52:47  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-03-26 07:52:51  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-03-26 07:52:56  - 23147  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-03-26 07:53:00  - 23147  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-03-26 07:53:05  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-03-26 07:53:09  - 23147  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-03-26 07:53:14  - 23147  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-03-26 07:53:18  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-03-26 07:53:22  - 23147  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-03-26 07:53:27  - 23147  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-03-26 07:53:32  - 23147  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-03-26 07:53:36  - 23147  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
<pre>2017-03-26_07-53-37 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_07-55-37 Restart Xvfb...
2017-03-26 07:55:41  - 23147  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-03-26 07:55:46  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-03-26 07:55:50  - 23147  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-03-26 07:55:54  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-03-26 07:55:59  - 23147  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-03-26 07:56:03  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-03-26 07:56:08  - 23147  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-03-26 07:56:12  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-03-26 07:56:16  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-03-26 07:56:21  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-03-26 07:56:26  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-03-26 07:56:30  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-03-26 07:56:35  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-03-26 07:56:39  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-03-26 07:56:44  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-03-26 07:56:48  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-03-26 07:56:52  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-03-26 07:56:57  - 23147  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-03-26 07:57:01  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-03-26 07:57:05  - 23147  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-03-26 07:57:09  - 23147  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-03-26 07:57:14  - 23147  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-03-26 07:57:18  - 23147  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-03-26 07:57:22  - 23147  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-03-26 07:57:27  - 23147  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-03-26 07:57:31  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-03-26 07:57:35  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
<pre>2017-03-26_07-57-37 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_07-59-37 Restart Xvfb...
2017-03-26 07:59:40  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-03-26 07:59:45  - 23147  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-03-26 07:59:50  - 23147  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-03-26 07:59:54  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-03-26 07:59:59  - 23147  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-03-26 08:00:04  - 23147  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-03-26 08:00:08  - 23147  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-03-26 08:00:16  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-03-26 08:00:20  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-03-26 08:00:25  - 23147  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-03-26 08:00:30  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-03-26 08:00:34  - 23147  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-03-26 08:00:38  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-03-26 08:00:43  - 23147  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-03-26 08:00:47  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-03-26 08:00:52  - 23147  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-03-26 08:00:56  - 23147  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-03-26 08:01:00  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-03-26 08:01:05  - 23147  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-03-26 08:01:09  - 23147  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-03-26 08:01:13  - 23147  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-03-26 08:01:18  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-03-26 08:01:22  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-03-26 08:01:26  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-03-26 08:01:31  - 23147  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-03-26 08:01:35  - 23147  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
<pre>2017-03-26_08-01-37 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_08-03-37 Restart Xvfb...
2017-03-26 08:03:40  - 23147  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-03-26 08:03:45  - 23147  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-03-26 08:03:49  - 23147  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-03-26 08:03:53  - 23147  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-03-26 08:03:57  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-03-26 08:04:02  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-03-26 08:04:06  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-03-26 08:04:10  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-03-26 08:04:15  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-03-26 08:04:18  - 23147  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-03-26 08:04:23  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-03-26 08:04:27  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-03-26 08:04:32  - 23147  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-03-26 08:04:37  - 23147  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-03-26 08:04:41  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-03-26 08:04:45  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-03-26 08:04:49  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-03-26 08:04:54  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-03-26 08:04:58  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-03-26 08:05:03  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-03-26 08:05:07  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-03-26 08:05:11  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-03-26 08:05:16  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-03-26 08:05:20  - 23147  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-03-26 08:05:24  - 23147  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-03-26 08:05:29  - 23147  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-03-26 08:05:33  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-03-26 08:05:37  - 23147  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
<pre>2017-03-26_08-05-37 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_08-07-37 Restart Xvfb...
2017-03-26 08:07:42  - 23147  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-03-26 08:07:46  - 23147  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-03-26 08:07:51  - 23147  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-03-26 08:07:55  - 23147  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-03-26 08:08:00  - 23147  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-03-26 08:08:04  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-03-26 08:08:09  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-03-26 08:08:13  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-03-26 08:08:17  - 23147  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-03-26 08:08:22  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-03-26 08:08:27  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-03-26 08:08:31  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-03-26 08:08:35  - 23147  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-03-26 08:08:39  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-03-26 08:08:43  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-03-26 08:08:48  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-03-26 08:08:52  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-03-26 08:08:56  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-03-26 08:09:01  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-03-26 08:09:05  - 23147  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-03-26 08:09:09  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-03-26 08:09:14  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-03-26 08:09:18  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-03-26 08:09:22  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-03-26 08:09:27  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-03-26 08:09:31  - 23147  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-03-26 08:09:35  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
<pre>2017-03-26_08-09-37 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_08-11-37 Restart Xvfb...
2017-03-26 08:11:40  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-03-26 08:11:44  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-03-26 08:11:49  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-03-26 08:11:53  - 23147  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-03-26 08:11:58  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-03-26 08:12:02  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-03-26 08:12:07  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-03-26 08:12:11  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-03-26 08:12:15  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-03-26 08:12:19  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-03-26 08:12:23  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-03-26 08:12:27  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-03-26 08:12:31  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-03-26 08:12:36  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-03-26 08:12:40  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-03-26 08:12:44  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-03-26 08:12:48  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-03-26 08:12:52  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-03-26 08:12:56  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-03-26 08:13:00  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-03-26 08:13:04  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-03-26 08:13:08  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-03-26 08:13:13  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-03-26 08:13:17  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-03-26 08:13:21  - 23147  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-03-26 08:13:25  - 23147  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-03-26 08:13:29  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-03-26 08:13:33  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-03-26 08:13:37  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
<pre>2017-03-26_08-13-37 Restart Xvfb...
2017-03-26 08:13:42  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-03-26 08:13:46  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-03-26 08:13:50  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-03-26 08:13:55  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-03-26 08:13:59  - 23147  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-03-26 08:14:03  - 23147  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-03-26 08:14:07  - 23147  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-03-26 08:14:11  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-03-26 08:14:16  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-03-26 08:14:20  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-03-26 08:14:24  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-03-26 08:14:28  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-03-26 08:14:32  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-26 08:14:36  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-26 08:14:40  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-26 08:14:44  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-26 08:14:48  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-03-26 08:14:52  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-26 08:14:56  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-26 08:15:00  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-03-26 08:15:05  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-03-26 08:15:09  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-03-26 08:15:13  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-03-26 08:15:17  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-03-26 08:15:22  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-03-26 08:15:26  - 23147  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-03-26 08:15:29  - 23147  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-03-26 08:15:33  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
<pre>2017-03-26_08-15-37 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_08-17-37 Restart Xvfb...
2017-03-26 08:17:39  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-03-26 08:17:42  - 23147  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-03-26 08:17:46  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-03-26 08:17:50  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-03-26 08:17:54  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-03-26 08:17:58  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-03-26 08:18:02  - 23147  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-03-26 08:18:06  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-03-26 08:18:10  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-03-26 08:18:14  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-03-26 08:18:19  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-03-26 08:18:23  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-03-26 08:18:27  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-26 08:18:31  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-26 08:18:35  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-26 08:18:39  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-26 08:18:43  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-26 08:18:47  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-03-26 08:18:50  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-26 08:18:54  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-26 08:18:58  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-26 08:19:02  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-26 08:19:06  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-03-26 08:19:10  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-26 08:19:14  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-26 08:19:18  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-26 08:19:22  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-03-26 08:19:26  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
<pre>2017-03-26_08-19-37 Restart Xvfb...
<pre>2017-03-26_08-21-37 Restart Xvfb...
<pre>2017-03-26_08-23-37 Restart Xvfb...
<pre>2017-03-26_08-25-37 Restart Xvfb...
<pre>2017-03-26_08-27-37 Restart Xvfb...
<pre>2017-03-26_08-29-37 Restart Xvfb...
<pre>2017-03-26_08-31-37 Restart Xvfb...
<pre>2017-03-26_08-33-37 Restart Xvfb...
<pre>2017-03-26_08-35-37 Restart Xvfb...
<pre>2017-03-26_08-37-37 Restart Xvfb...
<pre>2017-03-26_08-39-38 Restart Xvfb...
<pre>2017-03-26_08-41-38 Restart Xvfb...
<pre>2017-03-26_08-43-38 Restart Xvfb...
<pre>2017-03-26_08-45-38 Restart Xvfb...
<pre>2017-03-26_08-47-38 Restart Xvfb...
<pre>2017-03-26_08-49-38 Restart Xvfb...
<pre>2017-03-26_08-51-38 Restart Xvfb...
<pre>2017-03-26_08-53-38 Restart Xvfb...
<pre>2017-03-26_08-55-38 Restart Xvfb...
<pre>2017-03-26_08-57-38 Restart Xvfb...
<pre>2017-03-26_08-59-38 Restart Xvfb...
<pre>2017-03-26_09-01-38 Restart Xvfb...
<pre>2017-03-26_09-03-38 Restart Xvfb...
<pre>2017-03-26_09-05-38 Restart Xvfb...
<pre>2017-03-26_09-07-38 Restart Xvfb...
<pre>2017-03-26_09-09-38 Restart Xvfb...
<pre>2017-03-26_09-11-38 Restart Xvfb...
<pre>2017-03-26_09-13-38 Restart Xvfb...
<pre>2017-03-26_09-15-38 Restart Xvfb...
<pre>2017-03-26_09-17-38 Restart Xvfb...
<pre>2017-03-26_09-19-38 Restart Xvfb...
<pre>2017-03-26_09-21-38 Restart Xvfb...
<pre>2017-03-26_09-23-38 Restart Xvfb...
<pre>2017-03-26_09-25-38 Restart Xvfb...
<pre>2017-03-26_09-27-38 Restart Xvfb...
<pre>2017-03-26_09-29-38 Restart Xvfb...
<pre>2017-03-26_09-31-38 Restart Xvfb...
<pre>2017-03-26_09-33-38 Restart Xvfb...
<pre>2017-03-26_09-35-38 Restart Xvfb...
<pre>2017-03-26_09-37-38 Restart Xvfb...
<pre>2017-03-26_09-39-38 Restart Xvfb...
<pre>2017-03-26_09-41-38 Restart Xvfb...
<pre>2017-03-26_09-43-38 Restart Xvfb...
<pre>2017-03-26_09-45-38 Restart Xvfb...
<pre>2017-03-26_09-47-38 Restart Xvfb...
<pre>2017-03-26_09-49-38 Restart Xvfb...
<pre>2017-03-26_09-51-38 Restart Xvfb...
<pre>2017-03-26_09-53-38 Restart Xvfb...
<pre>2017-03-26_09-55-38 Restart Xvfb...
2017-03-26 09:56:59 reset updateRequest
2017-03-26 09:57:02  - 23147  http://www.lymphomahub.com/
2017-03-26 09:57:04  - 23147  http://www.lymphomahub.com/
2017-03-26 09:57:07  - 23147  http://www.lymphomahub.com/about
2017-03-26 09:57:09  - 23147  http://www.lymphomahub.com/about
2017-03-26 09:57:13  - 23147  http://www.lymphomahub.com/terms
2017-03-26 09:57:13  - 23147  http://www.lymphomahub.com/terms
2017-03-26 09:57:17  - 23147  http://www.lymphomahub.com/undefined
2017-03-26 09:57:17  - 23147  http://www.lymphomahub.com/undefined
2017-03-26 09:57:18  - 23147  http://www.lymphomahub.com/therapies
2017-03-26 09:57:18  - 23147  http://www.lymphomahub.com/therapies
2017-03-26 09:57:27  - 23147  http://www.lymphomahub.com/newsletter
2017-03-26 09:57:28  - 23147  http://www.lymphomahub.com/newsletter
2017-03-26 09:57:32  - 23147  http://www.lymphomahub.com/cookie-policy
2017-03-26 09:57:32  - 23147  http://www.lymphomahub.com/cookie-policy
2017-03-26 09:57:36  - 23147  http://www.lymphomahub.com/therapies/afm13
2017-03-26 09:57:36  - 23147  http://www.lymphomahub.com/therapies/afm13
<pre>2017-03-26_09-57-38 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/afm13?_prerender {"code":"ECONNRESET"}
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/afm13?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_09-59-38 Restart Xvfb...
2017-03-26 09:59:41  - 23147  http://www.lymphomahub.com/therapies/afm13
2017-03-26 09:59:41  - 23147  http://www.lymphomahub.com/therapies/afm13
2017-03-26 09:59:46  - 23147  http://www.lymphomahub.com/therapies/afm11
2017-03-26 09:59:51  - 23147  http://www.lymphomahub.com/therapies/ags67e
2017-03-26 09:59:55  - 23147  http://www.lymphomahub.com/therapies/cc-292
2017-03-26 09:59:59  - 23147  http://www.lymphomahub.com/therapies/cc-223
2017-03-26 10:00:04  - 23147  http://www.lymphomahub.com/therapies/sd-101
2017-03-26 10:00:14  - 23147  http://www.lymphomahub.com/therapies/rp6530
2017-03-26 10:00:22  - 23147  http://www.lymphomahub.com/therapies/abt199
2017-03-26 10:00:23  - 23147  http://www.lymphomahub.com/therapies/mor208
2017-03-26 10:00:27  - 23147  http://www.lymphomahub.com/therapies/cc-122
2017-03-26 10:00:32  - 23147  http://www.lymphomahub.com/therapies/at-101
2017-03-26 10:00:36  - 23147  http://www.lymphomahub.com/therapies/bl8040
2017-03-26 10:00:40  - 23147  http://www.lymphomahub.com/therapies/bcl201
2017-03-26 10:00:44  - 23147  http://www.lymphomahub.com/therapies/azd3965
2017-03-26 10:00:48  - 23147  http://www.lymphomahub.com/therapies/imgn529
2017-03-26 10:00:53  - 23147  http://www.lymphomahub.com/therapies/azd2014
2017-03-26 10:00:57  - 23147  http://www.lymphomahub.com/therapies/mt-3724
2017-03-26 10:01:02  - 23147  http://www.lymphomahub.com/therapies/actr087
2017-03-26 10:01:06  - 23147  http://www.lymphomahub.com/therapies/epz6438
2017-03-26 10:01:10  - 23147  http://www.lymphomahub.com/therapies/kte-c19
2017-03-26 10:01:14  - 23147  http://www.lymphomahub.com/about/secretariat
2017-03-26 10:01:18  - 23147  http://www.lymphomahub.com/therapies/alt-803
2017-03-26 10:01:22  - 23147  http://www.lymphomahub.com/therapies/regn1979
2017-03-26 10:01:26  - 23147  http://www.lymphomahub.com/therapies/immu-114
2017-03-26 10:01:30  - 23147  http://www.lymphomahub.com/therapies/incb7839
2017-03-26 10:01:34  - 23147  http://www.lymphomahub.com/therapies/adct-301
<pre>2017-03-26_10-01-38 Restart Xvfb...
2017-03-26 10:01:39  - 23147  http://www.lymphomahub.com/therapies/ixazomib
<pre>2017-03-26_10-03-38 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/ixazomib?_prerender {"code":"ECONNRESET"}
2017-03-26 10:03:44  - 23147  http://www.lymphomahub.com/therapies/ixazomib
2017-03-26 10:03:48  - 23147  http://www.lymphomahub.com/therapies/avelumab
2017-03-26 10:03:52  - 23147  http://www.lymphomahub.com/therapies/bi836826
2017-03-26 10:03:57  - 23147  http://www.lymphomahub.com/therapies/medi-570
2017-03-26 10:04:01  - 23147  http://www.lymphomahub.com/therapies/ds-3201b
2017-03-26 10:04:06  - 23147  http://www.lymphomahub.com/therapies/sea-cd40
2017-03-26 10:04:10  - 23147  http://www.lymphomahub.com/therapies/adct-402
2017-03-26 10:04:14  - 23147  http://www.lymphomahub.com/therapies/acy-1215
2017-03-26 10:04:19  - 23147  http://www.lymphomahub.com/therapies/cudc-907
2017-03-26 10:04:23  - 23147  http://www.lymphomahub.com/therapies/tgr-1202
2017-03-26 10:04:27  - 23147  http://www.lymphomahub.com/therapies/axitinib
2017-03-26 10:04:32  - 23147  http://www.lymphomahub.com/therapies/imatinib
2017-03-26 10:04:36  - 23147  http://www.lymphomahub.com/therapies/edo-s101
2017-03-26 10:04:40  - 23147  http://www.lymphomahub.com/therapies/btct4465a
2017-03-26 10:04:44  - 23147  http://www.lymphomahub.com/therapies/alisertib
2017-03-26 10:04:49  - 23147  http://www.lymphomahub.com/therapies/lirilumab
2017-03-26 10:04:53  - 23147  http://www.lymphomahub.com/therapies/ibrutinib
2017-03-26 10:04:54  - 23147  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-03-26 10:04:58  - 23147  http://www.lymphomahub.com/therapies/rituximab
2017-03-26 10:05:03  - 23147  http://www.lymphomahub.com/therapies/veliparib
2017-03-26 10:05:07  - 23147  http://www.lymphomahub.com/therapies/sunitinib
2017-03-26 10:05:11  - 23147  http://www.lymphomahub.com/therapies/nivolumab
2017-03-26 10:05:12  - 23147  http://www.lymphomahub.com/therapies/sirolimus
2017-03-26 10:05:16  - 23147  http://www.lymphomahub.com/medical-information
2017-03-26 10:05:20  - 23147  http://www.lymphomahub.com/therapies/selinexor
2017-03-26 10:05:25  - 23147  http://www.lymphomahub.com/therapies/abc294640
2017-03-26 10:05:29  - 23147  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-03-26 10:05:33  - 23147  http://www.lymphomahub.com/therapies/tenofovir
2017-03-26 10:05:38  - 23147  http://www.lymphomahub.com/therapies/betalutin
<pre>2017-03-26_10-05-38 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/betalutin?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_10-07-38 Restart Xvfb...
2017-03-26 10:07:43  - 23147  http://www.lymphomahub.com/therapies/betalutin
2017-03-26 10:07:47  - 23147  http://www.lymphomahub.com/therapies/chidamide
2017-03-26 10:07:51  - 23147  http://www.lymphomahub.com/therapies/duvelisib
2017-03-26 10:07:56  - 23147  http://www.lymphomahub.com/therapies/dasatinib
2017-03-26 10:08:00  - 23147  http://www.lymphomahub.com/therapies/everolimus
2017-03-26 10:08:05  - 23147  http://www.lymphomahub.com/therapies/incb039110
2017-03-26 10:08:09  - 23147  http://www.lymphomahub.com/therapies/durvalumab
2017-03-26 10:08:14  - 23147  http://www.lymphomahub.com/therapies/romidepsin
2017-03-26 10:08:18  - 23147  http://www.lymphomahub.com/therapies/bortezomib
2017-03-26 10:08:22  - 23147  http://www.lymphomahub.com/therapies/idelalisib
2017-03-26 10:08:23  - 23147  http://www.lymphomahub.com/therapies/tipifarnib
2017-03-26 10:08:27  - 23147  http://www.lymphomahub.com/therapies/ipilimumab
2017-03-26 10:08:31  - 23147  http://www.lymphomahub.com/therapies/crizotinib
2017-03-26 10:08:35  - 23147  http://www.lymphomahub.com/therapies/gsk2816126
2017-03-26 10:08:40  - 23147  http://www.lymphomahub.com/therapies/copanlisib
2017-03-26 10:08:44  - 23147  http://www.lymphomahub.com/therapies/buparlisib
2017-03-26 10:08:48  - 23147  http://www.lymphomahub.com/therapies/belinostat
2017-03-26 10:08:53  - 23147  http://www.lymphomahub.com/therapies/vorinostat
2017-03-26 10:08:57  - 23147  http://www.lymphomahub.com/therapies/plerixafor
2017-03-26 10:08:58  - 23147  http://www.lymphomahub.com/therapies/ofatumumab
2017-03-26 10:09:02  - 23147  http://www.lymphomahub.com/therapies/pf-06801591
2017-03-26 10:09:06  - 23147  http://www.lymphomahub.com/therapies/tocilizumab
2017-03-26 10:09:11  - 23147  http://www.lymphomahub.com/therapies/msc2490484a
2017-03-26 10:09:15  - 23147  http://www.lymphomahub.com/therapies/carfilzomib
2017-03-26 10:09:19  - 23147  http://www.lymphomahub.com/therapies/ruxolitinib
2017-03-26 10:09:24  - 23147  http://www.lymphomahub.com/therapies/palbociclib
2017-03-26 10:09:28  - 23147  http://www.lymphomahub.com/therapies/fenretinide
2017-03-26 10:09:32  - 23147  http://www.lymphomahub.com/therapies/daratumumab
2017-03-26 10:09:36  - 23147  http://www.lymphomahub.com/therapies/pf-05082566
<pre>2017-03-26_10-09-38 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/pf-05082566?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_10-11-38 Restart Xvfb...
2017-03-26 10:11:42  - 23147  http://www.lymphomahub.com/therapies/pf-05082566
2017-03-26 10:11:46  - 23147  http://www.lymphomahub.com/therapies/ramucirumab
2017-03-26 10:11:50  - 23147  http://www.lymphomahub.com/therapies/tositumomab
2017-03-26 10:11:54  - 23147  http://www.lymphomahub.com/therapies/ublituximab
2017-03-26 10:11:59  - 23147  http://www.lymphomahub.com/therapies/epacadostat
2017-03-26 10:12:03  - 23147  http://www.lymphomahub.com/therapies/alemtuzumab
2017-03-26 10:12:04  - 23147  http://www.lymphomahub.com/therapies/otlertuzumab
2017-03-26 10:12:08  - 23147  http://www.lymphomahub.com/therapies/panobinostat
2017-03-26 10:12:12  - 23147  http://www.lymphomahub.com/therapies/mocetinostat
2017-03-26 10:12:17  - 23147  http://www.lymphomahub.com/therapies/atezolizumab
2017-03-26 10:12:21  - 23147  http://www.lymphomahub.com/therapies/temsirolimus
2017-03-26 10:12:25  - 23147  http://www.lymphomahub.com/therapies/lenalidomide
2017-03-26 10:12:30  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab
2017-03-26 10:12:34  - 23147  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-03-26 10:12:38  - 23147  http://www.lymphomahub.com/therapies/blinatumomab
2017-03-26 10:12:42  - 23147  http://www.lymphomahub.com/therapies/jnj-64052781
2017-03-26 10:12:47  - 23147  http://www.lymphomahub.com/therapies/entospletinib
2017-03-26 10:12:51  - 23147  http://www.lymphomahub.com/therapies/pembrolizumab
2017-03-26 10:12:55  - 23147  http://www.lymphomahub.com/therapies/acalabrutinib
2017-03-26 10:12:59  - 23147  http://www.lymphomahub.com/about/innovation-committee
2017-03-26 10:13:04  - 23147  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-03-26 10:13:05  - 23147  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-03-26 10:13:09  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-03-26 10:13:13  - 23147  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-03-26 10:13:17  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-03-26 10:13:22  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-03-26 10:13:22  - 23147  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-03-26 10:13:27  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-03-26 10:13:31  - 23147  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-03-26 10:13:35  - 23147  http://www.lymphomahub.com/about/secretariat/terri-heasman
<pre>2017-03-26_10-13-38 Restart Xvfb...
2017-03-26 10:13:39  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board
2017-03-26 10:13:43  - 23147  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-03-26 10:13:47  - 23147  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-03-26 10:13:51  - 23147  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-03-26 10:13:54  - 23147  http://www.lymphomahub.com/about/executive-steering-committee
2017-03-26 10:13:58  - 23147  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-03-26 10:14:02  - 23147  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-03-26 10:14:07  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-03-26 10:14:11  - 23147  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-03-26 10:14:14  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-03-26 10:14:20  - 23147  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-03-26 10:14:23  - 23147  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-03-26 10:14:24  - 23147  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-03-26 10:14:28  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-03-26 10:14:32  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-03-26 10:14:37  - 23147  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-03-26 10:14:41  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-03-26 10:14:45  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-03-26 10:14:49  - 23147  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-03-26 10:14:53  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-03-26 10:14:57  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-03-26 10:15:01  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-03-26 10:15:04  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-03-26 10:15:08  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-03-26 10:15:12  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-03-26 10:15:16  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-03-26 10:15:19  - 23147  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-03-26 10:15:24  - 23147  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-03-26 10:15:28  - 23147  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-03-26 10:15:33  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-03-26 10:15:36  - 23147  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
<pre>2017-03-26_10-15-38 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_10-17-38 Restart Xvfb...
2017-03-26 10:17:41  - 23147  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-03-26 10:17:45  - 23147  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-03-26 10:17:50  - 23147  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-03-26 10:17:54  - 23147  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-03-26 10:17:59  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-03-26 10:18:02  - 23147  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-03-26 10:18:07  - 23147  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-03-26 10:18:11  - 23147  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-03-26 10:18:16  - 23147  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-03-26 10:18:21  - 23147  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-03-26 10:18:25  - 23147  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-03-26 10:18:30  - 23147  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-03-26 10:18:34  - 23147  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-03-26 10:18:39  - 23147  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-03-26 10:18:43  - 23147  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-03-26 10:18:47  - 23147  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-03-26 10:18:52  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-03-26 10:18:55  - 23147  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-03-26 10:19:00  - 23147  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-03-26 10:19:04  - 23147  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-03-26 10:19:09  - 23147  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-03-26 10:19:13  - 23147  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-03-26 10:19:18  - 23147  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-03-26 10:19:22  - 23147  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-03-26 10:19:26  - 23147  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-03-26 10:19:31  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-03-26 10:19:34  - 23147  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
<pre>2017-03-26_10-19-39 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_10-21-39 Restart Xvfb...
2017-03-26 10:21:40  - 23147  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-03-26 10:21:43  - 23147  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-03-26 10:21:47  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-03-26 10:21:51  - 23147  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-03-26 10:21:56  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-03-26 10:21:59  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-03-26 10:22:03  - 23147  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-03-26 10:22:08  - 23147  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-03-26 10:22:12  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-03-26 10:22:16  - 23147  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-03-26 10:22:20  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-03-26 10:22:24  - 23147  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-03-26 10:22:28  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-03-26 10:22:33  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-03-26 10:22:37  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-03-26 10:22:41  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-03-26 10:22:45  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-03-26 10:22:49  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-03-26 10:22:53  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-03-26 10:22:56  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-03-26 10:23:01  - 23147  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-03-26 10:23:05  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-03-26 10:23:10  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-03-26 10:23:14  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-03-26 10:23:18  - 23147  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-26 10:23:19  - 23147  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-03-26 10:23:23  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-03-26 10:23:27  - 23147  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-03-26 10:23:32  - 23147  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-03-26 10:23:37  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
<pre>2017-03-26_10-23-39 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_10-25-39 Restart Xvfb...
2017-03-26 10:25:42  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-03-26 10:25:46  - 23147  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-03-26 10:25:50  - 23147  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-03-26 10:25:55  - 23147  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-03-26 10:25:59  - 23147  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-03-26 10:26:04  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-03-26 10:26:08  - 23147  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-03-26 10:26:13  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-03-26 10:26:17  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-03-26 10:26:22  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-03-26 10:26:26  - 23147  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-03-26 10:26:31  - 23147  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-03-26 10:26:36  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-03-26 10:26:40  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-03-26 10:26:45  - 23147  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-03-26 10:26:49  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-03-26 10:26:54  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-03-26 10:26:58  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-03-26 10:27:03  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-03-26 10:27:07  - 23147  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-26 10:27:12  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-03-26 10:27:16  - 23147  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-03-26 10:27:21  - 23147  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-03-26 10:27:26  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-03-26 10:27:30  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-03-26 10:27:34  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
<pre>2017-03-26_10-27-39 Restart Xvfb...
2017-03-26 10:27:39  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-03-26 10:27:44  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-03-26 10:27:48  - 23147  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-03-26 10:27:53  - 23147  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-03-26 10:27:57  - 23147  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-03-26 10:28:02  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-03-26 10:28:06  - 23147  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-03-26 10:28:11  - 23147  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-03-26 10:28:16  - 23147  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-03-26 10:28:16  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-03-26 10:28:20  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-03-26 10:28:25  - 23147  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-03-26 10:28:30  - 23147  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-03-26 10:28:34  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-03-26 10:28:38  - 23147  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-03-26 10:28:43  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-03-26 10:28:47  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-03-26 10:28:52  - 23147  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-03-26 10:28:56  - 23147  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-03-26 10:29:01  - 23147  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-03-26 10:29:05  - 23147  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-03-26 10:29:10  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-03-26 10:29:14  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-03-26 10:29:19  - 23147  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-03-26 10:29:23  - 23147  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-03-26 10:29:27  - 23147  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-03-26 10:29:32  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-03-26 10:29:37  - 23147  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
<pre>2017-03-26_10-29-39 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_10-31-39 Restart Xvfb...
2017-03-26 10:31:42  - 23147  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-03-26 10:31:46  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-03-26 10:31:51  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-03-26 10:31:55  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-03-26 10:32:00  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-03-26 10:32:05  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-03-26 10:32:08  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-03-26 10:32:13  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-03-26 10:32:17  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-03-26 10:32:20  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-03-26 10:32:25  - 23147  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-03-26 10:32:25  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-03-26 10:32:29  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-03-26 10:32:33  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-03-26 10:32:37  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-03-26 10:32:41  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-03-26 10:32:44  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-03-26 10:32:48  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-03-26 10:32:51  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-03-26 10:32:55  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-03-26 10:32:59  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-03-26 10:33:02  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-03-26 10:33:06  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-03-26 10:33:09  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-03-26 10:33:13  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-03-26 10:33:16  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-03-26 10:33:20  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-03-26 10:33:25  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-03-26 10:33:28  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-03-26 10:33:32  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-03-26 10:33:36  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
<pre>2017-03-26_10-33-39 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_10-35-39 Restart Xvfb...
2017-03-26 10:35:41  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-03-26 10:35:44  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-03-26 10:35:48  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-03-26 10:35:52  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-03-26 10:35:55  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-03-26 10:35:59  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-03-26 10:36:02  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-03-26 10:36:06  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-03-26 10:36:10  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-03-26 10:36:14  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-03-26 10:36:17  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-03-26 10:36:21  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-03-26 10:36:24  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-03-26 10:36:28  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-03-26 10:36:32  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-03-26 10:36:35  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-03-26 10:36:39  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-03-26 10:36:43  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-03-26 10:36:46  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-03-26 10:36:50  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-03-26 10:36:54  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-03-26 10:36:57  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-03-26 10:37:01  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-03-26 10:37:04  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-03-26 10:37:08  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-03-26 10:37:12  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-03-26 10:37:15  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-03-26 10:37:19  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-03-26 10:37:23  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-03-26 10:37:26  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-03-26 10:37:30  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-03-26 10:37:35  - 23147  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
<pre>2017-03-26_10-37-39 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_10-39-39 Restart Xvfb...
2017-03-26 10:39:40  - 23147  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-03-26 10:39:44  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-03-26 10:39:49  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-03-26 10:39:53  - 23147  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-03-26 10:39:54  - 23147  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-03-26 10:39:58  - 23147  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-03-26 10:40:03  - 23147  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-03-26 10:40:08  - 23147  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-03-26 10:40:12  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-03-26 10:40:17  - 23147  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-03-26 10:40:21  - 23147  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-03-26 10:40:26  - 23147  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-03-26 10:40:30  - 23147  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-03-26 10:40:35  - 23147  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-03-26 10:40:39  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-03-26 10:40:44  - 23147  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-03-26 10:40:48  - 23147  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-03-26 10:40:52  - 23147  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-03-26 10:40:57  - 23147  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-03-26 10:41:01  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-03-26 10:41:05  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-03-26 10:41:10  - 23147  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-03-26 10:41:14  - 23147  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-03-26 10:41:19  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-03-26 10:41:23  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-03-26 10:41:27  - 23147  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-26 10:41:32  - 23147  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-03-26 10:41:36  - 23147  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
<pre>2017-03-26_10-41-39 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_10-43-39 Restart Xvfb...
2017-03-26 10:43:41  - 23147  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-03-26 10:43:45  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-03-26 10:43:50  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-03-26 10:43:54  - 23147  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-03-26 10:43:59  - 23147  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-03-26 10:44:03  - 23147  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-03-26 10:44:08  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-03-26 10:44:12  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-03-26 10:44:16  - 23147  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-26 10:44:21  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-03-26 10:44:25  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-03-26 10:44:30  - 23147  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-03-26 10:44:34  - 23147  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-03-26 10:44:38  - 23147  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-03-26 10:44:42  - 23147  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-03-26 10:44:47  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-03-26 10:44:51  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-03-26 10:44:55  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-03-26 10:45:00  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-03-26 10:45:05  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-03-26 10:45:09  - 23147  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-03-26 10:45:13  - 23147  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-03-26 10:45:18  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-03-26 10:45:22  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-03-26 10:45:26  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-03-26 10:45:31  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-03-26 10:45:35  - 23147  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
<pre>2017-03-26_10-45-39 Restart Xvfb...
2017-03-26 10:45:39  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
<pre>2017-03-26_10-47-39 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl?_prerender {"code":"ECONNRESET"}
2017-03-26 10:47:44  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-03-26 10:47:49  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-03-26 10:47:54  - 23147  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-03-26 10:47:58  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-03-26 10:48:03  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-03-26 10:48:07  - 23147  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-03-26 10:48:12  - 23147  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-03-26 10:48:16  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-03-26 10:48:21  - 23147  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-03-26 10:48:25  - 23147  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-03-26 10:48:29  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-03-26 10:48:34  - 23147  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-03-26 10:48:38  - 23147  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-03-26 10:48:43  - 23147  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-03-26 10:48:47  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-03-26 10:48:51  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-03-26 10:48:56  - 23147  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-03-26 10:49:00  - 23147  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-03-26 10:49:05  - 23147  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-03-26 10:49:10  - 23147  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-03-26 10:49:14  - 23147  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-03-26 10:49:19  - 23147  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-03-26 10:49:23  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-03-26 10:49:27  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-03-26 10:49:32  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-03-26 10:49:36  - 23147  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
<pre>2017-03-26_10-49-39 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_10-51-39 Restart Xvfb...
2017-03-26 10:51:41  - 23147  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-03-26 10:51:45  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-03-26 10:51:50  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-03-26 10:51:54  - 23147  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-03-26 10:51:58  - 23147  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-03-26 10:52:03  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-03-26 10:52:08  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-03-26 10:52:12  - 23147  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-03-26 10:52:16  - 23147  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-03-26 10:52:21  - 23147  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-03-26 10:52:25  - 23147  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-03-26 10:52:29  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-03-26 10:52:33  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-03-26 10:52:38  - 23147  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-03-26 10:52:42  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-03-26 10:52:47  - 23147  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-03-26 10:52:51  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-03-26 10:52:55  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-03-26 10:53:00  - 23147  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-03-26 10:53:04  - 23147  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-03-26 10:53:09  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-03-26 10:53:13  - 23147  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-03-26 10:53:18  - 23147  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-03-26 10:53:22  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-03-26 10:53:27  - 23147  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-03-26 10:53:31  - 23147  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-03-26 10:53:36  - 23147  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
<pre>2017-03-26_10-53-39 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_10-55-39 Restart Xvfb...
2017-03-26 10:55:41  - 23147  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-03-26 10:55:45  - 23147  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-03-26 10:55:50  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-03-26 10:55:54  - 23147  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-03-26 10:55:58  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-03-26 10:56:03  - 23147  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-03-26 10:56:07  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-03-26 10:56:12  - 23147  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-03-26 10:56:16  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-03-26 10:56:20  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-03-26 10:56:25  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-03-26 10:56:30  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-03-26 10:56:34  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-03-26 10:56:38  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-03-26 10:56:43  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-03-26 10:56:47  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-03-26 10:56:52  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-03-26 10:56:56  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-03-26 10:57:01  - 23147  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-03-26 10:57:05  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-03-26 10:57:09  - 23147  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-03-26 10:57:14  - 23147  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-03-26 10:57:18  - 23147  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-03-26 10:57:23  - 23147  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-03-26 10:57:27  - 23147  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-03-26 10:57:32  - 23147  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-03-26 10:57:36  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
<pre>2017-03-26_10-57-39 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_10-59-39 Restart Xvfb...
2017-03-26 10:59:41  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-03-26 10:59:45  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-03-26 10:59:50  - 23147  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-03-26 10:59:54  - 23147  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-03-26 10:59:59  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-03-26 11:00:04  - 23147  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-03-26 11:00:09  - 23147  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-03-26 11:00:20  - 23147  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-03-26 11:00:24  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-03-26 11:00:32  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-03-26 11:00:36  - 23147  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-03-26 11:00:41  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-03-26 11:00:45  - 23147  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-03-26 11:00:50  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-03-26 11:00:54  - 23147  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-03-26 11:00:58  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-03-26 11:01:03  - 23147  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-03-26 11:01:07  - 23147  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-03-26 11:01:11  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-03-26 11:01:16  - 23147  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-03-26 11:01:19  - 23147  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-03-26 11:01:24  - 23147  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-03-26 11:01:28  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-03-26 11:01:33  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-03-26 11:01:37  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
<pre>2017-03-26_11-01-39 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_11-03-39 Restart Xvfb...
2017-03-26 11:03:42  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-03-26 11:03:47  - 23147  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-03-26 11:03:51  - 23147  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-03-26 11:03:56  - 23147  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-03-26 11:04:00  - 23147  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-03-26 11:04:04  - 23147  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-03-26 11:04:08  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-03-26 11:04:13  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-03-26 11:04:17  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-03-26 11:04:21  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-03-26 11:04:26  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-03-26 11:04:31  - 23147  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-03-26 11:04:35  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-03-26 11:04:40  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-03-26 11:04:44  - 23147  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-03-26 11:04:48  - 23147  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-03-26 11:04:52  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-03-26 11:04:56  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-03-26 11:05:01  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-03-26 11:05:06  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-03-26 11:05:11  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-03-26 11:05:15  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-03-26 11:05:19  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-03-26 11:05:23  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-03-26 11:05:28  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-03-26 11:05:32  - 23147  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-03-26 11:05:36  - 23147  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
<pre>2017-03-26_11-05-39 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_11-07-39 Restart Xvfb...
2017-03-26 11:07:41  - 23147  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-03-26 11:07:46  - 23147  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-03-26 11:07:50  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-03-26 11:07:55  - 23147  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-03-26 11:07:59  - 23147  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-03-26 11:08:03  - 23147  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-03-26 11:08:08  - 23147  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-03-26 11:08:12  - 23147  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-03-26 11:08:17  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-03-26 11:08:21  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-03-26 11:08:26  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-03-26 11:08:30  - 23147  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-03-26 11:08:35  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-03-26 11:08:39  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-03-26 11:08:44  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-03-26 11:08:48  - 23147  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-03-26 11:08:52  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-03-26 11:08:56  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-03-26 11:09:01  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-03-26 11:09:05  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-03-26 11:09:09  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-03-26 11:09:14  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-03-26 11:09:18  - 23147  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-03-26 11:09:22  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-03-26 11:09:27  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-03-26 11:09:30  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-03-26 11:09:35  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
<pre>2017-03-26_11-09-39 Restart Xvfb...
2017-03-26 11:09:39  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-03-26 11:09:43  - 23147  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-03-26 11:09:48  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-03-26 11:09:52  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-03-26 11:09:56  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-03-26 11:10:00  - 23147  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-03-26 11:10:05  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-03-26 11:10:09  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-03-26 11:10:14  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-03-26 11:10:18  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-03-26 11:10:22  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-03-26 11:10:26  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-03-26 11:10:30  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-03-26 11:10:34  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-03-26 11:10:38  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-03-26 11:10:42  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-03-26 11:10:47  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-03-26 11:10:51  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-03-26 11:10:54  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-03-26 11:10:58  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-03-26 11:11:02  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-03-26 11:11:06  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-03-26 11:11:10  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-03-26 11:11:14  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-03-26 11:11:19  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-03-26 11:11:23  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-03-26 11:11:27  - 23147  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-03-26 11:11:31  - 23147  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-03-26 11:11:35  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
<pre>2017-03-26_11-11-39 Restart Xvfb...
2017-03-26 11:11:39  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-03-26 11:11:43  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-03-26 11:11:48  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-03-26 11:11:52  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-03-26 11:11:56  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-03-26 11:12:01  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-03-26 11:12:06  - 23147  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-03-26 11:12:10  - 23147  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-03-26 11:12:14  - 23147  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-03-26 11:12:18  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-03-26 11:12:22  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-03-26 11:12:26  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-03-26 11:12:30  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-03-26 11:12:34  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-03-26 11:12:38  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-26 11:12:42  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-26 11:12:46  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-26 11:12:50  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-26 11:12:54  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-03-26 11:12:58  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-26 11:13:02  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-26 11:13:06  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-03-26 11:13:10  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-03-26 11:13:14  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-03-26 11:13:18  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-03-26 11:13:22  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-03-26 11:13:27  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-03-26 11:13:31  - 23147  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-03-26 11:13:35  - 23147  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-03-26 11:13:39  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
<pre>2017-03-26_11-13-39 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_11-15-39 Restart Xvfb...
2017-03-26 11:15:44  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-03-26 11:15:48  - 23147  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-03-26 11:15:52  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-03-26 11:15:56  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-03-26 11:16:00  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-03-26 11:16:04  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-03-26 11:16:08  - 23147  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-03-26 11:16:12  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-03-26 11:16:16  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-03-26 11:16:20  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-03-26 11:16:24  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-03-26 11:16:28  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-03-26 11:16:32  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-26 11:16:36  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-26 11:16:39  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-26 11:16:43  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-26 11:16:47  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-26 11:16:52  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-03-26 11:16:56  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-26 11:17:00  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-26 11:17:04  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-26 11:17:08  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-26 11:17:12  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-03-26 11:17:16  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-26 11:17:20  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-26 11:17:24  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-26 11:17:28  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-03-26 11:17:32  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
<pre>2017-03-26_11-17-39 Restart Xvfb...
<pre>2017-03-26_11-19-39 Restart Xvfb...
<pre>2017-03-26_11-21-39 Restart Xvfb...
<pre>2017-03-26_11-23-39 Restart Xvfb...
<pre>2017-03-26_11-25-39 Restart Xvfb...
<pre>2017-03-26_11-27-39 Restart Xvfb...
<pre>2017-03-26_11-29-39 Restart Xvfb...
<pre>2017-03-26_11-31-39 Restart Xvfb...
<pre>2017-03-26_11-33-39 Restart Xvfb...
<pre>2017-03-26_11-35-39 Restart Xvfb...
<pre>2017-03-26_11-37-39 Restart Xvfb...
<pre>2017-03-26_11-39-39 Restart Xvfb...
<pre>2017-03-26_11-41-39 Restart Xvfb...
<pre>2017-03-26_11-43-39 Restart Xvfb...
<pre>2017-03-26_11-45-39 Restart Xvfb...
<pre>2017-03-26_11-47-40 Restart Xvfb...
<pre>2017-03-26_11-49-40 Restart Xvfb...
<pre>2017-03-26_11-51-40 Restart Xvfb...
<pre>2017-03-26_11-53-40 Restart Xvfb...
<pre>2017-03-26_11-55-40 Restart Xvfb...
<pre>2017-03-26_11-57-40 Restart Xvfb...
<pre>2017-03-26_11-59-40 Restart Xvfb...
<pre>2017-03-26_12-01-40 Restart Xvfb...
<pre>2017-03-26_12-03-40 Restart Xvfb...
<pre>2017-03-26_12-05-40 Restart Xvfb...
<pre>2017-03-26_12-07-40 Restart Xvfb...
<pre>2017-03-26_12-09-40 Restart Xvfb...
<pre>2017-03-26_12-11-40 Restart Xvfb...
<pre>2017-03-26_12-13-40 Restart Xvfb...
<pre>2017-03-26_12-15-40 Restart Xvfb...
<pre>2017-03-26_12-17-40 Restart Xvfb...
<pre>2017-03-26_12-19-40 Restart Xvfb...
<pre>2017-03-26_12-21-40 Restart Xvfb...
<pre>2017-03-26_12-23-40 Restart Xvfb...
<pre>2017-03-26_12-25-40 Restart Xvfb...
<pre>2017-03-26_12-27-40 Restart Xvfb...
<pre>2017-03-26_12-29-40 Restart Xvfb...
<pre>2017-03-26_12-31-40 Restart Xvfb...
<pre>2017-03-26_12-33-40 Restart Xvfb...
<pre>2017-03-26_12-35-40 Restart Xvfb...
<pre>2017-03-26_12-37-40 Restart Xvfb...
<pre>2017-03-26_12-39-40 Restart Xvfb...
<pre>2017-03-26_12-41-40 Restart Xvfb...
<pre>2017-03-26_12-43-40 Restart Xvfb...
<pre>2017-03-26_12-45-40 Restart Xvfb...
<pre>2017-03-26_12-47-40 Restart Xvfb...
<pre>2017-03-26_12-49-40 Restart Xvfb...
<pre>2017-03-26_12-51-40 Restart Xvfb...
<pre>2017-03-26_12-53-40 Restart Xvfb...
<pre>2017-03-26_12-55-40 Restart Xvfb...
2017-03-26 12:56:59 reset updateRequest
2017-03-26 12:57:03  - 23147  http://www.lymphomahub.com/
2017-03-26 12:57:04  - 23147  http://www.lymphomahub.com/
2017-03-26 12:57:08  - 23147  http://www.lymphomahub.com/about
2017-03-26 12:57:09  - 23147  http://www.lymphomahub.com/about
2017-03-26 12:57:15  - 23147  http://www.lymphomahub.com/terms
2017-03-26 12:57:18  - 23147  http://www.lymphomahub.com/undefined
2017-03-26 12:57:18  - 23147  http://www.lymphomahub.com/therapies
2017-03-26 12:57:24  - 23147  http://www.lymphomahub.com/newsletter
2017-03-26 12:57:27  - 23147  http://www.lymphomahub.com/cookie-policy
2017-03-26 12:57:30  - 23147  http://www.lymphomahub.com/therapies/afm13
2017-03-26 12:57:35  - 23147  http://www.lymphomahub.com/therapies/afm11
2017-03-26 12:57:39  - 23147  http://www.lymphomahub.com/therapies/ags67e
<pre>2017-03-26_12-57-40 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/ags67e?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_12-59-40 Restart Xvfb...
2017-03-26 12:59:44  - 23147  http://www.lymphomahub.com/therapies/ags67e
2017-03-26 12:59:49  - 23147  http://www.lymphomahub.com/therapies/cc-292
2017-03-26 12:59:53  - 23147  http://www.lymphomahub.com/therapies/cc-223
2017-03-26 12:59:57  - 23147  http://www.lymphomahub.com/therapies/sd-101
2017-03-26 13:00:02  - 23147  http://www.lymphomahub.com/therapies/rp6530
2017-03-26 13:00:06  - 23147  http://www.lymphomahub.com/therapies/abt199
2017-03-26 13:00:10  - 23147  http://www.lymphomahub.com/therapies/mor208
2017-03-26 13:00:17  - 23147  http://www.lymphomahub.com/therapies/cc-122
2017-03-26 13:00:21  - 23147  http://www.lymphomahub.com/therapies/at-101
2017-03-26 13:00:26  - 23147  http://www.lymphomahub.com/therapies/bl8040
2017-03-26 13:00:31  - 23147  http://www.lymphomahub.com/therapies/bcl201
2017-03-26 13:00:35  - 23147  http://www.lymphomahub.com/therapies/azd3965
2017-03-26 13:00:42  - 23147  http://www.lymphomahub.com/therapies/imgn529
2017-03-26 13:00:46  - 23147  http://www.lymphomahub.com/therapies/azd2014
2017-03-26 13:00:50  - 23147  http://www.lymphomahub.com/therapies/mt-3724
2017-03-26 13:00:54  - 23147  http://www.lymphomahub.com/therapies/actr087
2017-03-26 13:00:59  - 23147  http://www.lymphomahub.com/therapies/epz6438
2017-03-26 13:01:04  - 23147  http://www.lymphomahub.com/therapies/kte-c19
2017-03-26 13:01:08  - 23147  http://www.lymphomahub.com/about/secretariat
2017-03-26 13:01:11  - 23147  http://www.lymphomahub.com/therapies/alt-803
2017-03-26 13:01:16  - 23147  http://www.lymphomahub.com/therapies/regn1979
2017-03-26 13:01:20  - 23147  http://www.lymphomahub.com/therapies/immu-114
2017-03-26 13:01:24  - 23147  http://www.lymphomahub.com/therapies/incb7839
2017-03-26 13:01:28  - 23147  http://www.lymphomahub.com/therapies/adct-301
2017-03-26 13:01:33  - 23147  http://www.lymphomahub.com/therapies/ixazomib
2017-03-26 13:01:37  - 23147  http://www.lymphomahub.com/therapies/avelumab
<pre>2017-03-26_13-01-40 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/avelumab?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_13-03-40 Restart Xvfb...
2017-03-26 13:03:42  - 23147  http://www.lymphomahub.com/therapies/avelumab
2017-03-26 13:03:46  - 23147  http://www.lymphomahub.com/therapies/bi836826
2017-03-26 13:03:50  - 23147  http://www.lymphomahub.com/therapies/medi-570
2017-03-26 13:03:55  - 23147  http://www.lymphomahub.com/therapies/ds-3201b
2017-03-26 13:03:59  - 23147  http://www.lymphomahub.com/therapies/sea-cd40
2017-03-26 13:04:03  - 23147  http://www.lymphomahub.com/therapies/adct-402
2017-03-26 13:04:08  - 23147  http://www.lymphomahub.com/therapies/acy-1215
2017-03-26 13:04:12  - 23147  http://www.lymphomahub.com/therapies/cudc-907
2017-03-26 13:04:16  - 23147  http://www.lymphomahub.com/therapies/tgr-1202
2017-03-26 13:04:20  - 23147  http://www.lymphomahub.com/therapies/axitinib
2017-03-26 13:04:25  - 23147  http://www.lymphomahub.com/therapies/imatinib
2017-03-26 13:04:29  - 23147  http://www.lymphomahub.com/therapies/edo-s101
2017-03-26 13:04:34  - 23147  http://www.lymphomahub.com/therapies/btct4465a
2017-03-26 13:04:38  - 23147  http://www.lymphomahub.com/therapies/alisertib
2017-03-26 13:04:42  - 23147  http://www.lymphomahub.com/therapies/lirilumab
2017-03-26 13:04:47  - 23147  http://www.lymphomahub.com/therapies/ibrutinib
2017-03-26 13:04:47  - 23147  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-03-26 13:04:52  - 23147  http://www.lymphomahub.com/therapies/rituximab
2017-03-26 13:04:56  - 23147  http://www.lymphomahub.com/therapies/veliparib
2017-03-26 13:05:01  - 23147  http://www.lymphomahub.com/therapies/sunitinib
2017-03-26 13:05:05  - 23147  http://www.lymphomahub.com/therapies/nivolumab
2017-03-26 13:05:06  - 23147  http://www.lymphomahub.com/therapies/sirolimus
2017-03-26 13:05:10  - 23147  http://www.lymphomahub.com/medical-information
2017-03-26 13:05:14  - 23147  http://www.lymphomahub.com/therapies/selinexor
2017-03-26 13:05:19  - 23147  http://www.lymphomahub.com/therapies/abc294640
2017-03-26 13:05:23  - 23147  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-03-26 13:05:27  - 23147  http://www.lymphomahub.com/therapies/tenofovir
2017-03-26 13:05:32  - 23147  http://www.lymphomahub.com/therapies/betalutin
2017-03-26 13:05:36  - 23147  http://www.lymphomahub.com/therapies/chidamide
2017-03-26 13:05:40  - 23147  http://www.lymphomahub.com/therapies/duvelisib
<pre>2017-03-26_13-05-40 Restart Xvfb...
2017-03-26 13:05:44  - 23147  http://www.lymphomahub.com/therapies/dasatinib
2017-03-26 13:05:49  - 23147  http://www.lymphomahub.com/therapies/everolimus
2017-03-26 13:05:53  - 23147  http://www.lymphomahub.com/therapies/incb039110
2017-03-26 13:05:58  - 23147  http://www.lymphomahub.com/therapies/durvalumab
2017-03-26 13:06:02  - 23147  http://www.lymphomahub.com/therapies/romidepsin
2017-03-26 13:06:07  - 23147  http://www.lymphomahub.com/therapies/bortezomib
2017-03-26 13:06:11  - 23147  http://www.lymphomahub.com/therapies/idelalisib
2017-03-26 13:06:12  - 23147  http://www.lymphomahub.com/therapies/tipifarnib
2017-03-26 13:06:17  - 23147  http://www.lymphomahub.com/therapies/ipilimumab
2017-03-26 13:06:21  - 23147  http://www.lymphomahub.com/therapies/crizotinib
2017-03-26 13:06:25  - 23147  http://www.lymphomahub.com/therapies/gsk2816126
2017-03-26 13:06:29  - 23147  http://www.lymphomahub.com/therapies/copanlisib
2017-03-26 13:06:33  - 23147  http://www.lymphomahub.com/therapies/buparlisib
2017-03-26 13:06:38  - 23147  http://www.lymphomahub.com/therapies/belinostat
2017-03-26 13:06:42  - 23147  http://www.lymphomahub.com/therapies/vorinostat
2017-03-26 13:06:46  - 23147  http://www.lymphomahub.com/therapies/plerixafor
2017-03-26 13:06:47  - 23147  http://www.lymphomahub.com/therapies/ofatumumab
2017-03-26 13:06:52  - 23147  http://www.lymphomahub.com/therapies/pf-06801591
2017-03-26 13:06:56  - 23147  http://www.lymphomahub.com/therapies/tocilizumab
2017-03-26 13:07:00  - 23147  http://www.lymphomahub.com/therapies/msc2490484a
2017-03-26 13:07:04  - 23147  http://www.lymphomahub.com/therapies/carfilzomib
2017-03-26 13:07:08  - 23147  http://www.lymphomahub.com/therapies/ruxolitinib
2017-03-26 13:07:13  - 23147  http://www.lymphomahub.com/therapies/palbociclib
2017-03-26 13:07:17  - 23147  http://www.lymphomahub.com/therapies/fenretinide
2017-03-26 13:07:21  - 23147  http://www.lymphomahub.com/therapies/daratumumab
2017-03-26 13:07:26  - 23147  http://www.lymphomahub.com/therapies/pf-05082566
2017-03-26 13:07:30  - 23147  http://www.lymphomahub.com/therapies/ramucirumab
2017-03-26 13:07:34  - 23147  http://www.lymphomahub.com/therapies/tositumomab
2017-03-26 13:07:38  - 23147  http://www.lymphomahub.com/therapies/ublituximab
<pre>2017-03-26_13-07-40 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/ublituximab?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_13-09-40 Restart Xvfb...
2017-03-26 13:09:43  - 23147  http://www.lymphomahub.com/therapies/ublituximab
2017-03-26 13:09:47  - 23147  http://www.lymphomahub.com/therapies/epacadostat
2017-03-26 13:09:51  - 23147  http://www.lymphomahub.com/therapies/alemtuzumab
2017-03-26 13:09:52  - 23147  http://www.lymphomahub.com/therapies/otlertuzumab
2017-03-26 13:09:56  - 23147  http://www.lymphomahub.com/therapies/panobinostat
2017-03-26 13:10:00  - 23147  http://www.lymphomahub.com/therapies/mocetinostat
2017-03-26 13:10:04  - 23147  http://www.lymphomahub.com/therapies/atezolizumab
2017-03-26 13:10:09  - 23147  http://www.lymphomahub.com/therapies/temsirolimus
2017-03-26 13:10:13  - 23147  http://www.lymphomahub.com/therapies/lenalidomide
2017-03-26 13:10:17  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab
2017-03-26 13:10:23  - 23147  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-03-26 13:10:27  - 23147  http://www.lymphomahub.com/therapies/blinatumomab
2017-03-26 13:10:32  - 23147  http://www.lymphomahub.com/therapies/jnj-64052781
2017-03-26 13:10:36  - 23147  http://www.lymphomahub.com/therapies/entospletinib
2017-03-26 13:10:40  - 23147  http://www.lymphomahub.com/therapies/pembrolizumab
2017-03-26 13:10:44  - 23147  http://www.lymphomahub.com/therapies/acalabrutinib
2017-03-26 13:10:48  - 23147  http://www.lymphomahub.com/about/innovation-committee
2017-03-26 13:10:52  - 23147  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-03-26 13:10:52  - 23147  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-03-26 13:10:57  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-03-26 13:11:01  - 23147  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-03-26 13:11:06  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-03-26 13:11:10  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-03-26 13:11:11  - 23147  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-03-26 13:11:15  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-03-26 13:11:20  - 23147  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-03-26 13:11:24  - 23147  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-03-26 13:11:27  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board
2017-03-26 13:11:31  - 23147  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-03-26 13:11:36  - 23147  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-03-26 13:11:39  - 23147  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
<pre>2017-03-26_13-11-40 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about/secretariat/anne-villeneuve?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_13-13-40 Restart Xvfb...
2017-03-26 13:13:44  - 23147  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-03-26 13:13:50  - 23147  http://www.lymphomahub.com/about/executive-steering-committee
2017-03-26 13:13:53  - 23147  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-03-26 13:13:57  - 23147  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-03-26 13:14:02  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-03-26 13:14:06  - 23147  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-03-26 13:14:09  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-03-26 13:14:14  - 23147  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-03-26 13:14:18  - 23147  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-03-26 13:14:18  - 23147  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-03-26 13:14:22  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-03-26 13:14:26  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-03-26 13:14:31  - 23147  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-03-26 13:14:35  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-03-26 13:14:39  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-03-26 13:14:44  - 23147  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-03-26 13:14:47  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-03-26 13:14:51  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-03-26 13:14:55  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-03-26 13:14:58  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-03-26 13:15:02  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-03-26 13:15:06  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-03-26 13:15:10  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-03-26 13:15:14  - 23147  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-03-26 13:15:18  - 23147  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-03-26 13:15:22  - 23147  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-03-26 13:15:27  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-03-26 13:15:30  - 23147  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-03-26 13:15:34  - 23147  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-03-26 13:15:39  - 23147  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
<pre>2017-03-26_13-15-40 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_13-17-40 Restart Xvfb...
2017-03-26 13:17:44  - 23147  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-03-26 13:17:47  - 23147  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-03-26 13:17:52  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-03-26 13:17:56  - 23147  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-03-26 13:18:00  - 23147  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-03-26 13:18:04  - 23147  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-03-26 13:18:09  - 23147  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-03-26 13:18:14  - 23147  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-03-26 13:18:18  - 23147  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-03-26 13:18:23  - 23147  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-03-26 13:18:27  - 23147  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-03-26 13:18:32  - 23147  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-03-26 13:18:36  - 23147  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-03-26 13:18:40  - 23147  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-03-26 13:18:44  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-03-26 13:18:48  - 23147  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-03-26 13:18:53  - 23147  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-03-26 13:18:57  - 23147  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-03-26 13:19:01  - 23147  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-03-26 13:19:06  - 23147  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-03-26 13:19:10  - 23147  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-03-26 13:19:14  - 23147  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-03-26 13:19:19  - 23147  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-03-26 13:19:23  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-03-26 13:19:27  - 23147  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-03-26 13:19:32  - 23147  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-03-26 13:19:36  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-03-26 13:19:39  - 23147  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
<pre>2017-03-26_13-19-40 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_13-21-40 Restart Xvfb...
2017-03-26 13:21:45  - 23147  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-03-26 13:21:49  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-03-26 13:21:53  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-03-26 13:21:57  - 23147  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-03-26 13:22:01  - 23147  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-03-26 13:22:06  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-03-26 13:22:10  - 23147  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-03-26 13:22:14  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-03-26 13:22:17  - 23147  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-03-26 13:22:22  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-03-26 13:22:26  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-03-26 13:22:30  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-03-26 13:22:34  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-03-26 13:22:38  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-03-26 13:22:41  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-03-26 13:22:45  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-03-26 13:22:49  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-03-26 13:22:53  - 23147  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-03-26 13:22:58  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-03-26 13:23:03  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-03-26 13:23:07  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-03-26 13:23:12  - 23147  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-26 13:23:12  - 23147  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-03-26 13:23:16  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-03-26 13:23:20  - 23147  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-03-26 13:23:25  - 23147  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-03-26 13:23:29  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-03-26 13:23:34  - 23147  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-03-26 13:23:38  - 23147  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
<pre>2017-03-26_13-23-40 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_13-25-41 Restart Xvfb...
2017-03-26 13:25:43  - 23147  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-03-26 13:25:47  - 23147  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-03-26 13:25:51  - 23147  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-03-26 13:25:56  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-03-26 13:26:00  - 23147  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-03-26 13:26:05  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-03-26 13:26:09  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-03-26 13:26:14  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-03-26 13:26:19  - 23147  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-03-26 13:26:23  - 23147  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-03-26 13:26:27  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-03-26 13:26:32  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-03-26 13:26:36  - 23147  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-03-26 13:26:41  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-03-26 13:26:45  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-03-26 13:26:49  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-03-26 13:26:54  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-03-26 13:26:58  - 23147  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-26 13:27:03  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-03-26 13:27:08  - 23147  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-03-26 13:27:12  - 23147  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-03-26 13:27:17  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-03-26 13:27:21  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-03-26 13:27:25  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-03-26 13:27:29  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-03-26 13:27:34  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-03-26 13:27:38  - 23147  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
<pre>2017-03-26_13-27-41 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_13-29-41 Restart Xvfb...
2017-03-26 13:29:43  - 23147  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-03-26 13:29:48  - 23147  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-03-26 13:29:52  - 23147  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-03-26 13:29:56  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-03-26 13:30:01  - 23147  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-03-26 13:30:06  - 23147  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-03-26 13:30:11  - 23147  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-03-26 13:30:14  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-03-26 13:30:20  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-03-26 13:30:24  - 23147  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-03-26 13:30:29  - 23147  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-03-26 13:30:33  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-03-26 13:30:37  - 23147  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-03-26 13:30:42  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-03-26 13:30:46  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-03-26 13:30:51  - 23147  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-03-26 13:30:55  - 23147  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-03-26 13:31:00  - 23147  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-03-26 13:31:04  - 23147  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-03-26 13:31:09  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-03-26 13:31:13  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-03-26 13:31:18  - 23147  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-03-26 13:31:22  - 23147  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-03-26 13:31:26  - 23147  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-03-26 13:31:31  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-03-26 13:31:35  - 23147  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-03-26 13:31:40  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
<pre>2017-03-26_13-31-41 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_13-33-41 Restart Xvfb...
2017-03-26 13:33:45  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-03-26 13:33:49  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-03-26 13:33:53  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-03-26 13:33:58  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-03-26 13:34:03  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-03-26 13:34:06  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-03-26 13:34:10  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-03-26 13:34:14  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-03-26 13:34:18  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-03-26 13:34:22  - 23147  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-03-26 13:34:23  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-03-26 13:34:27  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-03-26 13:34:31  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-03-26 13:34:35  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-03-26 13:34:38  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-03-26 13:34:42  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-03-26 13:34:46  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-03-26 13:34:49  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-03-26 13:34:53  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-03-26 13:34:57  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-03-26 13:35:00  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-03-26 13:35:04  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-03-26 13:35:07  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-03-26 13:35:11  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-03-26 13:35:15  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-03-26 13:35:18  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-03-26 13:35:23  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-03-26 13:35:26  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-03-26 13:35:30  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-03-26 13:35:34  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-03-26 13:35:37  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-03-26 13:35:41  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
<pre>2017-03-26_13-35-41 Restart Xvfb...
2017-03-26 13:35:44  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-03-26 13:35:48  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-03-26 13:35:51  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-03-26 13:35:55  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-03-26 13:35:58  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-03-26 13:36:02  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-03-26 13:36:06  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-03-26 13:36:09  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-03-26 13:36:13  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-03-26 13:36:16  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-03-26 13:36:20  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-03-26 13:36:23  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-03-26 13:36:27  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-03-26 13:36:31  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-03-26 13:36:34  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-03-26 13:36:38  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-03-26 13:36:42  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-03-26 13:36:45  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-03-26 13:36:49  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-03-26 13:36:52  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-03-26 13:36:56  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-03-26 13:36:59  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-03-26 13:37:03  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-03-26 13:37:06  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-03-26 13:37:10  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-03-26 13:37:14  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-03-26 13:37:17  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-03-26 13:37:21  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-03-26 13:37:26  - 23147  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-03-26 13:37:30  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-03-26 13:37:35  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-03-26 13:37:39  - 23147  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-03-26 13:37:40  - 23147  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
<pre>2017-03-26_13-37-41 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_13-39-41 Restart Xvfb...
2017-03-26 13:39:45  - 23147  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-03-26 13:39:49  - 23147  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-03-26 13:39:54  - 23147  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-03-26 13:39:58  - 23147  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-03-26 13:40:03  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-03-26 13:40:08  - 23147  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-03-26 13:40:12  - 23147  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-03-26 13:40:17  - 23147  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-03-26 13:40:21  - 23147  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-03-26 13:40:26  - 23147  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-03-26 13:40:30  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-03-26 13:40:34  - 23147  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-03-26 13:40:39  - 23147  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-03-26 13:40:43  - 23147  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-03-26 13:40:48  - 23147  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-03-26 13:40:52  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-03-26 13:40:56  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-03-26 13:41:01  - 23147  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-03-26 13:41:06  - 23147  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-03-26 13:41:10  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-03-26 13:41:14  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-03-26 13:41:19  - 23147  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-26 13:41:23  - 23147  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-03-26 13:41:28  - 23147  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-03-26 13:41:32  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-03-26 13:41:36  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
<pre>2017-03-26_13-41-41 Restart Xvfb...
2017-03-26 13:41:41  - 23147  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-03-26 13:41:45  - 23147  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-03-26 13:41:49  - 23147  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-03-26 13:41:54  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-03-26 13:41:58  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-03-26 13:42:03  - 23147  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-26 13:42:07  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-03-26 13:42:12  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-03-26 13:42:16  - 23147  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-03-26 13:42:21  - 23147  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-03-26 13:42:25  - 23147  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-03-26 13:42:29  - 23147  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-03-26 13:42:34  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-03-26 13:42:38  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-03-26 13:42:43  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-03-26 13:42:47  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-03-26 13:42:52  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-03-26 13:42:56  - 23147  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-03-26 13:43:00  - 23147  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-03-26 13:43:05  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-03-26 13:43:09  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-03-26 13:43:13  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-03-26 13:43:18  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-03-26 13:43:22  - 23147  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-03-26 13:43:27  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-03-26 13:43:31  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-03-26 13:43:36  - 23147  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-03-26 13:43:40  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
<pre>2017-03-26_13-43-41 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_13-45-41 Restart Xvfb...
2017-03-26 13:45:45  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-03-26 13:45:50  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-03-26 13:45:54  - 23147  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-03-26 13:45:59  - 23147  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-03-26 13:46:03  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-03-26 13:46:08  - 23147  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-03-26 13:46:12  - 23147  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-03-26 13:46:16  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-03-26 13:46:21  - 23147  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-03-26 13:46:25  - 23147  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-03-26 13:46:30  - 23147  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-03-26 13:46:34  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-03-26 13:46:39  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-03-26 13:46:43  - 23147  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-03-26 13:46:48  - 23147  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-03-26 13:46:52  - 23147  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-03-26 13:46:56  - 23147  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-03-26 13:47:01  - 23147  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-03-26 13:47:05  - 23147  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-03-26 13:47:09  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-03-26 13:47:14  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-03-26 13:47:18  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-03-26 13:47:23  - 23147  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-03-26 13:47:27  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-03-26 13:47:32  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-03-26 13:47:36  - 23147  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-03-26 13:47:41  - 23147  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
<pre>2017-03-26_13-47-41 Restart Xvfb...
2017-03-26 13:47:45  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-03-26 13:47:50  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-03-26 13:47:54  - 23147  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-03-26 13:47:58  - 23147  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-03-26 13:48:03  - 23147  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-03-26 13:48:07  - 23147  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-03-26 13:48:11  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-03-26 13:48:16  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-03-26 13:48:20  - 23147  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-03-26 13:48:25  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-03-26 13:48:29  - 23147  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-03-26 13:48:33  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-03-26 13:48:38  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-03-26 13:48:42  - 23147  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-03-26 13:48:47  - 23147  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-03-26 13:48:51  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-03-26 13:48:55  - 23147  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-03-26 13:49:00  - 23147  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-03-26 13:49:04  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-03-26 13:49:09  - 23147  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-03-26 13:49:13  - 23147  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-03-26 13:49:19  - 23147  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-03-26 13:49:24  - 23147  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-03-26 13:49:28  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-03-26 13:49:32  - 23147  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-03-26 13:49:37  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
<pre>2017-03-26_13-49-41 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_13-51-41 Restart Xvfb...
2017-03-26 13:51:42  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-03-26 13:51:46  - 23147  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-03-26 13:51:51  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-03-26 13:51:55  - 23147  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-03-26 13:52:00  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-03-26 13:52:04  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-03-26 13:52:09  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-03-26 13:52:14  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-03-26 13:52:18  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-03-26 13:52:23  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-03-26 13:52:28  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-03-26 13:52:32  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-03-26 13:52:36  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-03-26 13:52:41  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-03-26 13:52:45  - 23147  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-03-26 13:52:49  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-03-26 13:52:53  - 23147  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-03-26 13:52:57  - 23147  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-03-26 13:53:02  - 23147  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-03-26 13:53:06  - 23147  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-03-26 13:53:11  - 23147  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-03-26 13:53:16  - 23147  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-03-26 13:53:20  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-03-26 13:53:24  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-03-26 13:53:29  - 23147  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-03-26 13:53:34  - 23147  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-03-26 13:53:38  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
<pre>2017-03-26_13-53-41 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_13-55-41 Restart Xvfb...
2017-03-26 13:55:43  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-03-26 13:55:47  - 23147  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-03-26 13:55:52  - 23147  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-03-26 13:55:56  - 23147  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-03-26 13:56:00  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-03-26 13:56:05  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-03-26 13:56:09  - 23147  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-03-26 13:56:14  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-03-26 13:56:18  - 23147  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-03-26 13:56:22  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-03-26 13:56:27  - 23147  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-03-26 13:56:31  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-03-26 13:56:36  - 23147  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-03-26 13:56:40  - 23147  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-03-26 13:56:44  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-03-26 13:56:48  - 23147  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-03-26 13:56:52  - 23147  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-03-26 13:56:57  - 23147  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-03-26 13:57:01  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-03-26 13:57:06  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-03-26 13:57:10  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-03-26 13:57:14  - 23147  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-03-26 13:57:18  - 23147  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-03-26 13:57:23  - 23147  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-03-26 13:57:27  - 23147  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-03-26 13:57:31  - 23147  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-03-26 13:57:35  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-03-26 13:57:40  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
<pre>2017-03-26_13-57-41 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_13-59-41 Restart Xvfb...
2017-03-26 13:59:45  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-03-26 13:59:50  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-03-26 13:59:54  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-03-26 13:59:58  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-03-26 14:00:03  - 23147  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-03-26 14:00:07  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-03-26 14:00:12  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-03-26 14:00:16  - 23147  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-03-26 14:00:24  - 23147  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-03-26 14:00:28  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-03-26 14:00:32  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-03-26 14:00:36  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-03-26 14:00:41  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-03-26 14:00:45  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-03-26 14:00:49  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-03-26 14:00:53  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-03-26 14:00:58  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-03-26 14:01:02  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-03-26 14:01:06  - 23147  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-03-26 14:01:11  - 23147  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-03-26 14:01:15  - 23147  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-03-26 14:01:19  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-03-26 14:01:23  - 23147  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-03-26 14:01:27  - 23147  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-03-26 14:01:32  - 23147  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-03-26 14:01:36  - 23147  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-03-26 14:01:41  - 23147  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
<pre>2017-03-26_14-01-41 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_14-03-41 Restart Xvfb...
2017-03-26 14:03:46  - 23147  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-03-26 14:03:50  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-03-26 14:03:55  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-03-26 14:03:59  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-03-26 14:04:03  - 23147  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-03-26 14:04:08  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-03-26 14:04:12  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-03-26 14:04:17  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-03-26 14:04:21  - 23147  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-03-26 14:04:26  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-03-26 14:04:30  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-03-26 14:04:34  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-03-26 14:04:38  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-03-26 14:04:42  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-03-26 14:04:47  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-03-26 14:04:51  - 23147  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-03-26 14:04:56  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-03-26 14:05:00  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-03-26 14:05:04  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-03-26 14:05:09  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-03-26 14:05:13  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-03-26 14:05:18  - 23147  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-03-26 14:05:22  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-03-26 14:05:26  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-03-26 14:05:30  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-03-26 14:05:34  - 23147  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-03-26 14:05:39  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
<pre>2017-03-26_14-05-41 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_14-07-41 Restart Xvfb...
2017-03-26 14:07:44  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-03-26 14:07:49  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-03-26 14:07:53  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-03-26 14:07:58  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-03-26 14:08:02  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-03-26 14:08:06  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-03-26 14:08:10  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-03-26 14:08:14  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-03-26 14:08:18  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-03-26 14:08:22  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-03-26 14:08:27  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-03-26 14:08:31  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-03-26 14:08:34  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-03-26 14:08:39  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-03-26 14:08:43  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-03-26 14:08:47  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-03-26 14:08:51  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-03-26 14:08:55  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-03-26 14:09:00  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-03-26 14:09:04  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-03-26 14:09:08  - 23147  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-03-26 14:09:12  - 23147  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-03-26 14:09:16  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-03-26 14:09:20  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-03-26 14:09:24  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-03-26 14:09:28  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-03-26 14:09:33  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-03-26 14:09:37  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
<pre>2017-03-26_14-09-41 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_14-11-41 Restart Xvfb...
2017-03-26 14:11:42  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-03-26 14:11:47  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-03-26 14:11:51  - 23147  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-03-26 14:11:55  - 23147  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-03-26 14:11:59  - 23147  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-03-26 14:12:03  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-03-26 14:12:07  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-03-26 14:12:11  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-03-26 14:12:15  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-03-26 14:12:20  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-03-26 14:12:23  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-26 14:12:27  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-26 14:12:31  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-26 14:12:35  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-26 14:12:39  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-03-26 14:12:43  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-26 14:12:47  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-26 14:12:51  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-03-26 14:12:55  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-03-26 14:12:59  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-03-26 14:13:03  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-03-26 14:13:07  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-03-26 14:13:11  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-03-26 14:13:15  - 23147  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-03-26 14:13:19  - 23147  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-03-26 14:13:23  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-03-26 14:13:27  - 23147  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-03-26 14:13:31  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-03-26 14:13:35  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-03-26 14:13:39  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
<pre>2017-03-26_14-13-41 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_14-15-41 Restart Xvfb...
2017-03-26 14:15:44  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-03-26 14:15:49  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-03-26 14:15:53  - 23147  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-03-26 14:15:56  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-03-26 14:16:01  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-03-26 14:16:05  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-03-26 14:16:09  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-03-26 14:16:13  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-03-26 14:16:17  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-26 14:16:21  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-26 14:16:26  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-26 14:16:30  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-26 14:16:34  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-26 14:16:38  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-03-26 14:16:42  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-26 14:16:46  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-26 14:16:50  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-26 14:16:54  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-26 14:16:58  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-03-26 14:17:02  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-26 14:17:07  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-26 14:17:11  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-26 14:17:15  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-03-26 14:17:19  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
<pre>2017-03-26_14-17-41 Restart Xvfb...
<pre>2017-03-26_14-19-41 Restart Xvfb...
<pre>2017-03-26_14-21-41 Restart Xvfb...
<pre>2017-03-26_14-23-41 Restart Xvfb...
<pre>2017-03-26_14-25-41 Restart Xvfb...
<pre>2017-03-26_14-27-41 Restart Xvfb...
<pre>2017-03-26_14-29-41 Restart Xvfb...
<pre>2017-03-26_14-31-41 Restart Xvfb...
<pre>2017-03-26_14-33-41 Restart Xvfb...
<pre>2017-03-26_14-35-41 Restart Xvfb...
<pre>2017-03-26_14-37-41 Restart Xvfb...
<pre>2017-03-26_14-39-41 Restart Xvfb...
<pre>2017-03-26_14-41-41 Restart Xvfb...
<pre>2017-03-26_14-43-41 Restart Xvfb...
<pre>2017-03-26_14-45-41 Restart Xvfb...
<pre>2017-03-26_14-47-41 Restart Xvfb...
<pre>2017-03-26_14-49-41 Restart Xvfb...
<pre>2017-03-26_14-51-41 Restart Xvfb...
<pre>2017-03-26_14-53-41 Restart Xvfb...
<pre>2017-03-26_14-55-42 Restart Xvfb...
<pre>2017-03-26_14-57-42 Restart Xvfb...
<pre>2017-03-26_14-59-42 Restart Xvfb...
<pre>2017-03-26_15-01-42 Restart Xvfb...
<pre>2017-03-26_15-03-42 Restart Xvfb...
<pre>2017-03-26_15-05-42 Restart Xvfb...
<pre>2017-03-26_15-07-42 Restart Xvfb...
<pre>2017-03-26_15-09-42 Restart Xvfb...
<pre>2017-03-26_15-11-42 Restart Xvfb...
<pre>2017-03-26_15-13-42 Restart Xvfb...
<pre>2017-03-26_15-15-42 Restart Xvfb...
<pre>2017-03-26_15-17-42 Restart Xvfb...
<pre>2017-03-26_15-19-42 Restart Xvfb...
<pre>2017-03-26_15-21-42 Restart Xvfb...
<pre>2017-03-26_15-23-42 Restart Xvfb...
<pre>2017-03-26_15-25-42 Restart Xvfb...
<pre>2017-03-26_15-27-42 Restart Xvfb...
<pre>2017-03-26_15-29-42 Restart Xvfb...
<pre>2017-03-26_15-31-42 Restart Xvfb...
<pre>2017-03-26_15-33-42 Restart Xvfb...
<pre>2017-03-26_15-35-42 Restart Xvfb...
<pre>2017-03-26_15-37-42 Restart Xvfb...
<pre>2017-03-26_15-39-42 Restart Xvfb...
<pre>2017-03-26_15-41-42 Restart Xvfb...
<pre>2017-03-26_15-43-42 Restart Xvfb...
<pre>2017-03-26_15-45-42 Restart Xvfb...
<pre>2017-03-26_15-47-42 Restart Xvfb...
<pre>2017-03-26_15-49-42 Restart Xvfb...
<pre>2017-03-26_15-51-42 Restart Xvfb...
<pre>2017-03-26_15-53-42 Restart Xvfb...
<pre>2017-03-26_15-55-42 Restart Xvfb...
2017-03-26 15:56:59 reset updateRequest
2017-03-26 15:57:00  - 23147  http://www.lymphomahub.com/
2017-03-26 15:57:04  - 23147  http://www.lymphomahub.com/
2017-03-26 15:57:05  - 23147  http://www.lymphomahub.com/about
2017-03-26 15:57:09  - 23147  http://www.lymphomahub.com/about
2017-03-26 15:57:11  - 23147  http://www.lymphomahub.com/terms
2017-03-26 15:57:13  - 23147  http://www.lymphomahub.com/terms
2017-03-26 15:57:15  - 23147  http://www.lymphomahub.com/undefined
2017-03-26 15:57:16  - 23147  http://www.lymphomahub.com/therapies
2017-03-26 15:57:17  - 23147  http://www.lymphomahub.com/therapies
2017-03-26 15:57:26  - 23147  http://www.lymphomahub.com/newsletter
2017-03-26 15:57:27  - 23147  http://www.lymphomahub.com/newsletter
2017-03-26 15:57:30  - 23147  http://www.lymphomahub.com/cookie-policy
2017-03-26 15:57:31  - 23147  http://www.lymphomahub.com/cookie-policy
2017-03-26 15:57:34  - 23147  http://www.lymphomahub.com/therapies/afm13
2017-03-26 15:57:35  - 23147  http://www.lymphomahub.com/therapies/afm13
2017-03-26 15:57:40  - 23147  http://www.lymphomahub.com/therapies/afm11
2017-03-26 15:57:40  - 23147  http://www.lymphomahub.com/therapies/afm11
<pre>2017-03-26_15-57-42 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/afm11?_prerender {"code":"ECONNRESET"}
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/afm11?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_15-59-42 Restart Xvfb...
2017-03-26 15:59:45  - 23147  http://www.lymphomahub.com/therapies/afm11
2017-03-26 15:59:45  - 23147  http://www.lymphomahub.com/therapies/afm11
2017-03-26 15:59:50  - 23147  http://www.lymphomahub.com/therapies/ags67e
2017-03-26 15:59:55  - 23147  http://www.lymphomahub.com/therapies/cc-292
2017-03-26 15:59:59  - 23147  http://www.lymphomahub.com/therapies/cc-223
2017-03-26 16:00:04  - 23147  http://www.lymphomahub.com/therapies/sd-101
2017-03-26 16:00:08  - 23147  http://www.lymphomahub.com/therapies/rp6530
2017-03-26 16:00:13  - 23147  http://www.lymphomahub.com/therapies/abt199
2017-03-26 16:00:13  - 23147  http://www.lymphomahub.com/therapies/mor208
2017-03-26 16:00:18  - 23147  http://www.lymphomahub.com/therapies/cc-122
2017-03-26 16:00:25  - 23147  http://www.lymphomahub.com/therapies/at-101
2017-03-26 16:00:29  - 23147  http://www.lymphomahub.com/therapies/bl8040
2017-03-26 16:00:33  - 23147  http://www.lymphomahub.com/therapies/bcl201
2017-03-26 16:00:38  - 23147  http://www.lymphomahub.com/therapies/azd3965
2017-03-26 16:00:42  - 23147  http://www.lymphomahub.com/therapies/imgn529
2017-03-26 16:00:46  - 23147  http://www.lymphomahub.com/therapies/azd2014
2017-03-26 16:00:51  - 23147  http://www.lymphomahub.com/therapies/mt-3724
2017-03-26 16:00:55  - 23147  http://www.lymphomahub.com/therapies/actr087
2017-03-26 16:01:00  - 23147  http://www.lymphomahub.com/therapies/epz6438
2017-03-26 16:01:04  - 23147  http://www.lymphomahub.com/therapies/kte-c19
2017-03-26 16:01:08  - 23147  http://www.lymphomahub.com/about/secretariat
2017-03-26 16:01:12  - 23147  http://www.lymphomahub.com/therapies/alt-803
2017-03-26 16:01:16  - 23147  http://www.lymphomahub.com/therapies/regn1979
2017-03-26 16:01:20  - 23147  http://www.lymphomahub.com/therapies/immu-114
2017-03-26 16:01:25  - 23147  http://www.lymphomahub.com/therapies/incb7839
2017-03-26 16:01:29  - 23147  http://www.lymphomahub.com/therapies/adct-301
2017-03-26 16:01:33  - 23147  http://www.lymphomahub.com/therapies/ixazomib
2017-03-26 16:01:37  - 23147  http://www.lymphomahub.com/therapies/avelumab
2017-03-26 16:01:42  - 23147  http://www.lymphomahub.com/therapies/bi836826
<pre>2017-03-26_16-01-42 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/bi836826?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_16-03-42 Restart Xvfb...
2017-03-26 16:03:47  - 23147  http://www.lymphomahub.com/therapies/bi836826
2017-03-26 16:03:51  - 23147  http://www.lymphomahub.com/therapies/medi-570
2017-03-26 16:03:55  - 23147  http://www.lymphomahub.com/therapies/ds-3201b
2017-03-26 16:04:00  - 23147  http://www.lymphomahub.com/therapies/sea-cd40
2017-03-26 16:04:04  - 23147  http://www.lymphomahub.com/therapies/adct-402
2017-03-26 16:04:08  - 23147  http://www.lymphomahub.com/therapies/acy-1215
2017-03-26 16:04:13  - 23147  http://www.lymphomahub.com/therapies/cudc-907
2017-03-26 16:04:17  - 23147  http://www.lymphomahub.com/therapies/tgr-1202
2017-03-26 16:04:21  - 23147  http://www.lymphomahub.com/therapies/axitinib
2017-03-26 16:04:25  - 23147  http://www.lymphomahub.com/therapies/imatinib
2017-03-26 16:04:30  - 23147  http://www.lymphomahub.com/therapies/edo-s101
2017-03-26 16:04:34  - 23147  http://www.lymphomahub.com/therapies/btct4465a
2017-03-26 16:04:39  - 23147  http://www.lymphomahub.com/therapies/alisertib
2017-03-26 16:04:43  - 23147  http://www.lymphomahub.com/therapies/lirilumab
2017-03-26 16:04:48  - 23147  http://www.lymphomahub.com/therapies/ibrutinib
2017-03-26 16:04:48  - 23147  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-03-26 16:04:53  - 23147  http://www.lymphomahub.com/therapies/rituximab
2017-03-26 16:04:57  - 23147  http://www.lymphomahub.com/therapies/veliparib
2017-03-26 16:05:01  - 23147  http://www.lymphomahub.com/therapies/sunitinib
2017-03-26 16:05:05  - 23147  http://www.lymphomahub.com/therapies/nivolumab
2017-03-26 16:05:06  - 23147  http://www.lymphomahub.com/therapies/sirolimus
2017-03-26 16:05:11  - 23147  http://www.lymphomahub.com/medical-information
2017-03-26 16:05:14  - 23147  http://www.lymphomahub.com/therapies/selinexor
2017-03-26 16:05:19  - 23147  http://www.lymphomahub.com/therapies/abc294640
2017-03-26 16:05:23  - 23147  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-03-26 16:05:27  - 23147  http://www.lymphomahub.com/therapies/tenofovir
2017-03-26 16:05:31  - 23147  http://www.lymphomahub.com/therapies/betalutin
2017-03-26 16:05:36  - 23147  http://www.lymphomahub.com/therapies/chidamide
2017-03-26 16:05:40  - 23147  http://www.lymphomahub.com/therapies/duvelisib
<pre>2017-03-26_16-05-42 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/duvelisib?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_16-07-42 Restart Xvfb...
2017-03-26 16:07:45  - 23147  http://www.lymphomahub.com/therapies/duvelisib
2017-03-26 16:07:49  - 23147  http://www.lymphomahub.com/therapies/dasatinib
2017-03-26 16:07:53  - 23147  http://www.lymphomahub.com/therapies/everolimus
2017-03-26 16:07:58  - 23147  http://www.lymphomahub.com/therapies/incb039110
2017-03-26 16:08:02  - 23147  http://www.lymphomahub.com/therapies/durvalumab
2017-03-26 16:08:06  - 23147  http://www.lymphomahub.com/therapies/romidepsin
2017-03-26 16:08:11  - 23147  http://www.lymphomahub.com/therapies/bortezomib
2017-03-26 16:08:15  - 23147  http://www.lymphomahub.com/therapies/idelalisib
2017-03-26 16:08:16  - 23147  http://www.lymphomahub.com/therapies/tipifarnib
2017-03-26 16:08:20  - 23147  http://www.lymphomahub.com/therapies/ipilimumab
2017-03-26 16:08:24  - 23147  http://www.lymphomahub.com/therapies/crizotinib
2017-03-26 16:08:28  - 23147  http://www.lymphomahub.com/therapies/gsk2816126
2017-03-26 16:08:33  - 23147  http://www.lymphomahub.com/therapies/copanlisib
2017-03-26 16:08:37  - 23147  http://www.lymphomahub.com/therapies/buparlisib
2017-03-26 16:08:41  - 23147  http://www.lymphomahub.com/therapies/belinostat
2017-03-26 16:08:45  - 23147  http://www.lymphomahub.com/therapies/vorinostat
2017-03-26 16:08:50  - 23147  http://www.lymphomahub.com/therapies/plerixafor
2017-03-26 16:08:51  - 23147  http://www.lymphomahub.com/therapies/ofatumumab
2017-03-26 16:08:55  - 23147  http://www.lymphomahub.com/therapies/pf-06801591
2017-03-26 16:09:00  - 23147  http://www.lymphomahub.com/therapies/tocilizumab
2017-03-26 16:09:04  - 23147  http://www.lymphomahub.com/therapies/msc2490484a
2017-03-26 16:09:08  - 23147  http://www.lymphomahub.com/therapies/carfilzomib
2017-03-26 16:09:13  - 23147  http://www.lymphomahub.com/therapies/ruxolitinib
2017-03-26 16:09:17  - 23147  http://www.lymphomahub.com/therapies/palbociclib
2017-03-26 16:09:21  - 23147  http://www.lymphomahub.com/therapies/fenretinide
2017-03-26 16:09:26  - 23147  http://www.lymphomahub.com/therapies/daratumumab
2017-03-26 16:09:30  - 23147  http://www.lymphomahub.com/therapies/pf-05082566
2017-03-26 16:09:34  - 23147  http://www.lymphomahub.com/therapies/ramucirumab
2017-03-26 16:09:38  - 23147  http://www.lymphomahub.com/therapies/tositumomab
<pre>2017-03-26_16-09-42 Restart Xvfb...
2017-03-26 16:09:43  - 23147  http://www.lymphomahub.com/therapies/ublituximab
2017-03-26 16:09:47  - 23147  http://www.lymphomahub.com/therapies/epacadostat
2017-03-26 16:09:51  - 23147  http://www.lymphomahub.com/therapies/alemtuzumab
2017-03-26 16:09:52  - 23147  http://www.lymphomahub.com/therapies/otlertuzumab
2017-03-26 16:09:56  - 23147  http://www.lymphomahub.com/therapies/panobinostat
2017-03-26 16:10:00  - 23147  http://www.lymphomahub.com/therapies/mocetinostat
2017-03-26 16:10:05  - 23147  http://www.lymphomahub.com/therapies/atezolizumab
2017-03-26 16:10:09  - 23147  http://www.lymphomahub.com/therapies/temsirolimus
2017-03-26 16:10:13  - 23147  http://www.lymphomahub.com/therapies/lenalidomide
2017-03-26 16:10:17  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab
2017-03-26 16:10:22  - 23147  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-03-26 16:10:26  - 23147  http://www.lymphomahub.com/therapies/blinatumomab
2017-03-26 16:10:30  - 23147  http://www.lymphomahub.com/therapies/jnj-64052781
2017-03-26 16:10:34  - 23147  http://www.lymphomahub.com/therapies/entospletinib
2017-03-26 16:10:39  - 23147  http://www.lymphomahub.com/therapies/pembrolizumab
2017-03-26 16:10:43  - 23147  http://www.lymphomahub.com/therapies/acalabrutinib
2017-03-26 16:10:47  - 23147  http://www.lymphomahub.com/about/innovation-committee
2017-03-26 16:10:51  - 23147  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-03-26 16:10:51  - 23147  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-03-26 16:10:55  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-03-26 16:11:00  - 23147  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-03-26 16:11:04  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-03-26 16:11:09  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-03-26 16:11:10  - 23147  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-03-26 16:11:14  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-03-26 16:11:18  - 23147  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-03-26 16:11:22  - 23147  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-03-26 16:11:26  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board
2017-03-26 16:11:30  - 23147  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-03-26 16:11:34  - 23147  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-03-26 16:11:38  - 23147  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-03-26 16:11:41  - 23147  http://www.lymphomahub.com/about/executive-steering-committee
<pre>2017-03-26_16-11-42 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about/executive-steering-committee?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_16-13-42 Restart Xvfb...
2017-03-26 16:13:47  - 23147  http://www.lymphomahub.com/about/executive-steering-committee
2017-03-26 16:13:52  - 23147  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-03-26 16:13:55  - 23147  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-03-26 16:14:01  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-03-26 16:14:04  - 23147  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-03-26 16:14:08  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-03-26 16:14:13  - 23147  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-03-26 16:14:17  - 23147  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-03-26 16:14:17  - 23147  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-03-26 16:14:21  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-03-26 16:14:25  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-03-26 16:14:30  - 23147  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-03-26 16:14:34  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-03-26 16:14:38  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-03-26 16:14:43  - 23147  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-03-26 16:14:46  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-03-26 16:14:50  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-03-26 16:14:53  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-03-26 16:14:57  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-03-26 16:15:01  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-03-26 16:15:05  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-03-26 16:15:08  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-03-26 16:15:12  - 23147  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-03-26 16:15:17  - 23147  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-03-26 16:15:21  - 23147  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-03-26 16:15:25  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-03-26 16:15:29  - 23147  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-03-26 16:15:33  - 23147  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-03-26 16:15:37  - 23147  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-03-26 16:15:42  - 23147  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
<pre>2017-03-26_16-15-42 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_16-17-42 Restart Xvfb...
2017-03-26 16:17:47  - 23147  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-03-26 16:17:51  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-03-26 16:17:55  - 23147  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-03-26 16:18:00  - 23147  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-03-26 16:18:04  - 23147  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-03-26 16:18:09  - 23147  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-03-26 16:18:14  - 23147  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-03-26 16:18:18  - 23147  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-03-26 16:18:23  - 23147  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-03-26 16:18:28  - 23147  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-03-26 16:18:32  - 23147  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-03-26 16:18:36  - 23147  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-03-26 16:18:40  - 23147  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-03-26 16:18:45  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-03-26 16:18:48  - 23147  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-03-26 16:18:53  - 23147  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-03-26 16:18:58  - 23147  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-03-26 16:19:02  - 23147  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-03-26 16:19:06  - 23147  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-03-26 16:19:11  - 23147  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-03-26 16:19:15  - 23147  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-03-26 16:19:19  - 23147  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-03-26 16:19:24  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-03-26 16:19:27  - 23147  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-03-26 16:19:32  - 23147  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-03-26 16:19:36  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-03-26 16:19:40  - 23147  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
<pre>2017-03-26_16-19-42 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_16-21-42 Restart Xvfb...
2017-03-26 16:21:45  - 23147  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-03-26 16:21:49  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-03-26 16:21:52  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-03-26 16:21:56  - 23147  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-03-26 16:22:01  - 23147  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-03-26 16:22:06  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-03-26 16:22:10  - 23147  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-03-26 16:22:14  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-03-26 16:22:18  - 23147  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-03-26 16:22:22  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-03-26 16:22:26  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-03-26 16:22:31  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-03-26 16:22:35  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-03-26 16:22:38  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-03-26 16:22:42  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-03-26 16:22:46  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-03-26 16:22:50  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-03-26 16:22:55  - 23147  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-03-26 16:22:59  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-03-26 16:23:04  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-03-26 16:23:08  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-03-26 16:23:13  - 23147  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-26 16:23:13  - 23147  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-03-26 16:23:18  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-03-26 16:23:22  - 23147  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-03-26 16:23:27  - 23147  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-03-26 16:23:31  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-03-26 16:23:36  - 23147  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-03-26 16:23:40  - 23147  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
<pre>2017-03-26_16-23-42 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_16-25-42 Restart Xvfb...
2017-03-26 16:25:45  - 23147  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-03-26 16:25:49  - 23147  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-03-26 16:25:54  - 23147  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-03-26 16:25:58  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-03-26 16:26:02  - 23147  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-03-26 16:26:07  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-03-26 16:26:11  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-03-26 16:26:16  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-03-26 16:26:20  - 23147  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-03-26 16:26:24  - 23147  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-03-26 16:26:29  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-03-26 16:26:33  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-03-26 16:26:38  - 23147  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-03-26 16:26:42  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-03-26 16:26:47  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-03-26 16:26:51  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-03-26 16:26:56  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-03-26 16:27:01  - 23147  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-26 16:27:05  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-03-26 16:27:10  - 23147  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-03-26 16:27:14  - 23147  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-03-26 16:27:19  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-03-26 16:27:23  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-03-26 16:27:28  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-03-26 16:27:32  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-03-26 16:27:37  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-03-26 16:27:41  - 23147  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
<pre>2017-03-26_16-27-42 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_16-29-42 Restart Xvfb...
2017-03-26 16:29:46  - 23147  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-03-26 16:29:51  - 23147  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-03-26 16:29:56  - 23147  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-03-26 16:30:01  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-03-26 16:30:08  - 23147  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-03-26 16:30:15  - 23147  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-03-26 16:30:19  - 23147  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-03-26 16:30:19  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-03-26 16:30:24  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-03-26 16:30:28  - 23147  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-03-26 16:30:35  - 23147  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-03-26 16:30:40  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-03-26 16:30:44  - 23147  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-03-26 16:30:49  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-03-26 16:30:53  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-03-26 16:30:58  - 23147  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-03-26 16:31:02  - 23147  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-03-26 16:31:06  - 23147  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-03-26 16:31:11  - 23147  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-03-26 16:31:15  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-03-26 16:31:20  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-03-26 16:31:25  - 23147  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-03-26 16:31:29  - 23147  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-03-26 16:31:34  - 23147  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-03-26 16:31:38  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-03-26 16:31:42  - 23147  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
<pre>2017-03-26_16-31-42 Restart Xvfb...
2017-03-26 16:31:47  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-03-26 16:31:51  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-03-26 16:31:55  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-03-26 16:32:00  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-03-26 16:32:06  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-03-26 16:32:09  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-03-26 16:32:13  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-03-26 16:32:17  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-03-26 16:32:21  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-03-26 16:32:25  - 23147  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-03-26 16:32:26  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-03-26 16:32:30  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-03-26 16:32:34  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-03-26 16:32:38  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-03-26 16:32:41  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-03-26 16:32:45  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-03-26 16:32:49  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-03-26 16:32:52  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-03-26 16:32:56  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-03-26 16:33:00  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-03-26 16:33:03  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-03-26 16:33:07  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-03-26 16:33:11  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-03-26 16:33:15  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-03-26 16:33:18  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-03-26 16:33:22  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-03-26 16:33:26  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-03-26 16:33:30  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-03-26 16:33:33  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-03-26 16:33:37  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-03-26 16:33:40  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
<pre>2017-03-26_16-33-43 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_16-35-43 Restart Xvfb...
2017-03-26 16:35:45  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-03-26 16:35:49  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-03-26 16:35:52  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-03-26 16:35:56  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-03-26 16:35:59  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-03-26 16:36:04  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-03-26 16:36:08  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-03-26 16:36:11  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-03-26 16:36:17  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-03-26 16:36:23  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-03-26 16:36:27  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-03-26 16:36:31  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-03-26 16:36:35  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-03-26 16:36:39  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-03-26 16:36:42  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-03-26 16:36:46  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-03-26 16:36:49  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-03-26 16:36:56  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-03-26 16:36:59  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-03-26 16:37:03  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-03-26 16:37:07  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-03-26 16:37:11  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-03-26 16:37:14  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-03-26 16:37:21  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-03-26 16:37:25  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-03-26 16:37:28  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-03-26 16:37:32  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-03-26 16:37:35  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-03-26 16:37:39  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
<pre>2017-03-26_16-37-43 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_16-39-43 Restart Xvfb...
2017-03-26 16:39:44  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-03-26 16:39:48  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-03-26 16:39:52  - 23147  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-03-26 16:39:56  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-03-26 16:40:01  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-03-26 16:40:06  - 23147  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-03-26 16:40:07  - 23147  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-03-26 16:40:11  - 23147  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-03-26 16:40:16  - 23147  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-03-26 16:40:20  - 23147  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-03-26 16:40:24  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-03-26 16:40:29  - 23147  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-03-26 16:40:33  - 23147  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-03-26 16:40:38  - 23147  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-03-26 16:40:43  - 23147  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-03-26 16:40:47  - 23147  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-03-26 16:40:51  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-03-26 16:40:56  - 23147  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-03-26 16:41:00  - 23147  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-03-26 16:41:05  - 23147  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-03-26 16:41:10  - 23147  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-03-26 16:41:14  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-03-26 16:41:18  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-03-26 16:41:23  - 23147  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-03-26 16:41:27  - 23147  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-03-26 16:41:31  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-03-26 16:41:36  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-03-26 16:41:40  - 23147  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
<pre>2017-03-26_16-41-43 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_16-43-43 Restart Xvfb...
2017-03-26 16:43:45  - 23147  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-26 16:43:50  - 23147  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-03-26 16:43:54  - 23147  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-03-26 16:43:58  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-03-26 16:44:03  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-03-26 16:44:08  - 23147  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-03-26 16:44:12  - 23147  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-03-26 16:44:16  - 23147  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-03-26 16:44:21  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-03-26 16:44:25  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-03-26 16:44:30  - 23147  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-26 16:44:34  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-03-26 16:44:38  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-03-26 16:44:43  - 23147  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-03-26 16:44:47  - 23147  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-03-26 16:44:51  - 23147  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-03-26 16:44:56  - 23147  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-03-26 16:45:00  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-03-26 16:45:05  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-03-26 16:45:09  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-03-26 16:45:14  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-03-26 16:45:18  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-03-26 16:45:23  - 23147  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-03-26 16:45:27  - 23147  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-03-26 16:45:31  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-03-26 16:45:36  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-03-26 16:45:40  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
<pre>2017-03-26_16-45-43 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_16-47-43 Restart Xvfb...
2017-03-26 16:47:45  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-03-26 16:47:49  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-03-26 16:47:54  - 23147  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-03-26 16:47:58  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-03-26 16:48:02  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-03-26 16:48:07  - 23147  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-03-26 16:48:11  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-03-26 16:48:16  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-03-26 16:48:20  - 23147  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-03-26 16:48:25  - 23147  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-03-26 16:48:29  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-03-26 16:48:33  - 23147  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-03-26 16:48:37  - 23147  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-03-26 16:48:42  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-03-26 16:48:46  - 23147  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-03-26 16:48:50  - 23147  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-03-26 16:48:55  - 23147  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-03-26 16:48:59  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-03-26 16:49:03  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-03-26 16:49:08  - 23147  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-03-26 16:49:12  - 23147  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-03-26 16:49:17  - 23147  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-03-26 16:49:21  - 23147  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-03-26 16:49:25  - 23147  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-03-26 16:49:30  - 23147  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-03-26 16:49:34  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-03-26 16:49:38  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
<pre>2017-03-26_16-49-43 Restart Xvfb...
2017-03-26 16:49:43  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-03-26 16:49:47  - 23147  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-03-26 16:49:52  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-03-26 16:49:56  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-03-26 16:50:01  - 23147  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-03-26 16:50:06  - 23147  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-03-26 16:50:10  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-03-26 16:50:15  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-03-26 16:50:19  - 23147  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-03-26 16:50:23  - 23147  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-03-26 16:50:28  - 23147  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-03-26 16:50:32  - 23147  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-03-26 16:50:36  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-03-26 16:50:40  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-03-26 16:50:45  - 23147  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-03-26 16:50:49  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-03-26 16:50:53  - 23147  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-03-26 16:50:58  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-03-26 16:51:02  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-03-26 16:51:07  - 23147  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-03-26 16:51:11  - 23147  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-03-26 16:51:15  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-03-26 16:51:20  - 23147  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-03-26 16:51:24  - 23147  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-03-26 16:51:28  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-03-26 16:51:33  - 23147  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-03-26 16:51:37  - 23147  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-03-26 16:51:42  - 23147  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
<pre>2017-03-26_16-51-43 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_16-53-43 Restart Xvfb...
2017-03-26 16:53:47  - 23147  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-03-26 16:53:51  - 23147  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-03-26 16:53:56  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-03-26 16:54:01  - 23147  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-03-26 16:54:05  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-03-26 16:54:10  - 23147  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-03-26 16:54:14  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-03-26 16:54:19  - 23147  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-03-26 16:54:23  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-03-26 16:54:28  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-03-26 16:54:33  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-03-26 16:54:37  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-03-26 16:54:42  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-03-26 16:54:46  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-03-26 16:54:50  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-03-26 16:54:55  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-03-26 16:54:59  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-03-26 16:55:04  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-03-26 16:55:09  - 23147  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-03-26 16:55:13  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-03-26 16:55:17  - 23147  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-03-26 16:55:21  - 23147  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-03-26 16:55:26  - 23147  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-03-26 16:55:31  - 23147  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-03-26 16:55:35  - 23147  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-03-26 16:55:40  - 23147  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
<pre>2017-03-26_16-55-43 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_16-57-43 Restart Xvfb...
2017-03-26 16:57:45  - 23147  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-03-26 16:57:49  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-03-26 16:57:54  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-03-26 16:57:58  - 23147  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-03-26 16:58:03  - 23147  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-03-26 16:58:07  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-03-26 16:58:12  - 23147  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-03-26 16:58:17  - 23147  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-03-26 16:58:21  - 23147  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-03-26 16:58:26  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-03-26 16:58:30  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-03-26 16:58:34  - 23147  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-03-26 16:58:38  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-03-26 16:58:43  - 23147  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-03-26 16:58:47  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-03-26 16:58:52  - 23147  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-03-26 16:58:56  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-03-26 16:59:00  - 23147  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-03-26 16:59:05  - 23147  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-03-26 16:59:09  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-03-26 16:59:14  - 23147  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-03-26 16:59:17  - 23147  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-03-26 16:59:22  - 23147  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-03-26 16:59:26  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-03-26 16:59:31  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-03-26 16:59:35  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-03-26 16:59:39  - 23147  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
<pre>2017-03-26_16-59-43 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_17-01-43 Restart Xvfb...
2017-03-26 17:01:44  - 23147  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-03-26 17:01:49  - 23147  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-03-26 17:01:53  - 23147  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-03-26 17:01:58  - 23147  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-03-26 17:02:02  - 23147  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-03-26 17:02:06  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-03-26 17:02:11  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-03-26 17:02:15  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-03-26 17:02:19  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-03-26 17:02:24  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-03-26 17:02:28  - 23147  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-03-26 17:02:32  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-03-26 17:02:37  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-03-26 17:02:41  - 23147  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-03-26 17:02:46  - 23147  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-03-26 17:02:50  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-03-26 17:02:54  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-03-26 17:02:58  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-03-26 17:03:03  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-03-26 17:03:07  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-03-26 17:03:12  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-03-26 17:03:16  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-03-26 17:03:20  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-03-26 17:03:25  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-03-26 17:03:29  - 23147  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-03-26 17:03:33  - 23147  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-03-26 17:03:38  - 23147  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-03-26 17:03:42  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
<pre>2017-03-26_17-03-43 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_17-05-43 Restart Xvfb...
2017-03-26 17:05:47  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-03-26 17:05:51  - 23147  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-03-26 17:05:55  - 23147  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-03-26 17:06:00  - 23147  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-03-26 17:06:04  - 23147  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-03-26 17:06:09  - 23147  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-03-26 17:06:13  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-03-26 17:06:17  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-03-26 17:06:22  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-03-26 17:06:26  - 23147  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-03-26 17:06:31  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-03-26 17:06:35  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-03-26 17:06:40  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-03-26 17:06:44  - 23147  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-03-26 17:06:48  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-03-26 17:06:52  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-03-26 17:06:56  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-03-26 17:07:00  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-03-26 17:07:05  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-03-26 17:07:10  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-03-26 17:07:14  - 23147  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-03-26 17:07:18  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-03-26 17:07:23  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-03-26 17:07:27  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-03-26 17:07:31  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-03-26 17:07:35  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-03-26 17:07:40  - 23147  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
<pre>2017-03-26_17-07-43 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_17-09-43 Restart Xvfb...
2017-03-26 17:09:45  - 23147  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-03-26 17:09:49  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-03-26 17:09:53  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-03-26 17:09:57  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-03-26 17:10:02  - 23147  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-03-26 17:10:07  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-03-26 17:10:11  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-03-26 17:10:16  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-03-26 17:10:20  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-03-26 17:10:24  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-03-26 17:10:28  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-03-26 17:10:32  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-03-26 17:10:36  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-03-26 17:10:40  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-03-26 17:10:45  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-03-26 17:10:49  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-03-26 17:10:53  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-03-26 17:10:57  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-03-26 17:11:01  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-03-26 17:11:05  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-03-26 17:11:09  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-03-26 17:11:13  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-03-26 17:11:18  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-03-26 17:11:22  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-03-26 17:11:26  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-03-26 17:11:30  - 23147  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-03-26 17:11:34  - 23147  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-03-26 17:11:38  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-03-26 17:11:42  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
<pre>2017-03-26_17-11-43 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_17-13-43 Restart Xvfb...
2017-03-26 17:13:48  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-03-26 17:13:52  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-03-26 17:13:56  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-03-26 17:14:01  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-03-26 17:14:05  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-03-26 17:14:10  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-03-26 17:14:15  - 23147  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-03-26 17:14:19  - 23147  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-03-26 17:14:23  - 23147  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-03-26 17:14:27  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-03-26 17:14:31  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-03-26 17:14:35  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-03-26 17:14:39  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-03-26 17:14:44  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-03-26 17:14:48  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-26 17:14:52  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-26 17:14:56  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-26 17:15:00  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-26 17:15:04  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-03-26 17:15:08  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-26 17:15:12  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-26 17:15:16  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-03-26 17:15:20  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-03-26 17:15:24  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-03-26 17:15:28  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-03-26 17:15:32  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-03-26 17:15:37  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-03-26 17:15:40  - 23147  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
<pre>2017-03-26_17-15-43 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_17-17-43 Restart Xvfb...
2017-03-26 17:17:46  - 23147  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-03-26 17:17:49  - 23147  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-03-26 17:17:53  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-03-26 17:17:57  - 23147  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-03-26 17:18:01  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-03-26 17:18:05  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-03-26 17:18:10  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-03-26 17:18:14  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-03-26 17:18:18  - 23147  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-03-26 17:18:22  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-03-26 17:18:26  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-03-26 17:18:30  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-03-26 17:18:34  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-03-26 17:18:38  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-03-26 17:18:42  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-26 17:18:46  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-26 17:18:50  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-26 17:18:54  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-26 17:18:58  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-26 17:19:03  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-03-26 17:19:07  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-26 17:19:11  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-26 17:19:14  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-26 17:19:18  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-26 17:19:22  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-03-26 17:19:26  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-26 17:19:30  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-26 17:19:34  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-26 17:19:38  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-03-26 17:19:42  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
<pre>2017-03-26_17-19-43 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_17-21-43 Restart Xvfb...
2017-03-26 17:21:47  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
<pre>2017-03-26_17-23-43 Restart Xvfb...
<pre>2017-03-26_17-25-43 Restart Xvfb...
<pre>2017-03-26_17-27-43 Restart Xvfb...
<pre>2017-03-26_17-29-43 Restart Xvfb...
<pre>2017-03-26_17-31-43 Restart Xvfb...
<pre>2017-03-26_17-33-43 Restart Xvfb...
<pre>2017-03-26_17-35-43 Restart Xvfb...
<pre>2017-03-26_17-37-43 Restart Xvfb...
<pre>2017-03-26_17-39-43 Restart Xvfb...
<pre>2017-03-26_17-41-43 Restart Xvfb...
<pre>2017-03-26_17-43-43 Restart Xvfb...
<pre>2017-03-26_17-45-43 Restart Xvfb...
<pre>2017-03-26_17-47-43 Restart Xvfb...
<pre>2017-03-26_17-49-43 Restart Xvfb...
<pre>2017-03-26_17-51-43 Restart Xvfb...
<pre>2017-03-26_17-53-43 Restart Xvfb...
<pre>2017-03-26_17-55-43 Restart Xvfb...
<pre>2017-03-26_17-57-43 Restart Xvfb...
<pre>2017-03-26_17-59-44 Restart Xvfb...
<pre>2017-03-26_18-01-44 Restart Xvfb...
<pre>2017-03-26_18-03-44 Restart Xvfb...
<pre>2017-03-26_18-05-44 Restart Xvfb...
<pre>2017-03-26_18-07-44 Restart Xvfb...
<pre>2017-03-26_18-09-44 Restart Xvfb...
<pre>2017-03-26_18-11-44 Restart Xvfb...
<pre>2017-03-26_18-13-44 Restart Xvfb...
<pre>2017-03-26_18-15-44 Restart Xvfb...
<pre>2017-03-26_18-17-44 Restart Xvfb...
<pre>2017-03-26_18-19-44 Restart Xvfb...
<pre>2017-03-26_18-21-44 Restart Xvfb...
<pre>2017-03-26_18-23-44 Restart Xvfb...
<pre>2017-03-26_18-25-44 Restart Xvfb...
<pre>2017-03-26_18-27-44 Restart Xvfb...
<pre>2017-03-26_18-29-44 Restart Xvfb...
<pre>2017-03-26_18-31-44 Restart Xvfb...
<pre>2017-03-26_18-33-44 Restart Xvfb...
<pre>2017-03-26_18-35-44 Restart Xvfb...
<pre>2017-03-26_18-37-44 Restart Xvfb...
<pre>2017-03-26_18-39-44 Restart Xvfb...
<pre>2017-03-26_18-41-44 Restart Xvfb...
<pre>2017-03-26_18-43-44 Restart Xvfb...
<pre>2017-03-26_18-45-44 Restart Xvfb...
<pre>2017-03-26_18-47-44 Restart Xvfb...
<pre>2017-03-26_18-49-44 Restart Xvfb...
<pre>2017-03-26_18-51-44 Restart Xvfb...
<pre>2017-03-26_18-53-44 Restart Xvfb...
<pre>2017-03-26_18-55-44 Restart Xvfb...
2017-03-26 18:56:59 reset updateRequest
2017-03-26 18:57:04  - 23147  http://www.lymphomahub.com/
2017-03-26 18:57:04  - 23147  http://www.lymphomahub.com/
2017-03-26 18:57:09  - 23147  http://www.lymphomahub.com/about
2017-03-26 18:57:10  - 23147  http://www.lymphomahub.com/about
2017-03-26 18:57:16  - 23147  http://www.lymphomahub.com/terms
2017-03-26 18:57:19  - 23147  http://www.lymphomahub.com/undefined
2017-03-26 18:57:20  - 23147  http://www.lymphomahub.com/therapies
2017-03-26 18:57:26  - 23147  http://www.lymphomahub.com/newsletter
2017-03-26 18:57:29  - 23147  http://www.lymphomahub.com/cookie-policy
2017-03-26 18:57:32  - 23147  http://www.lymphomahub.com/therapies/afm13
2017-03-26 18:57:36  - 23147  http://www.lymphomahub.com/therapies/afm11
2017-03-26 18:57:41  - 23147  http://www.lymphomahub.com/therapies/ags67e
<pre>2017-03-26_18-57-44 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/ags67e?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_18-59-44 Restart Xvfb...
2017-03-26 18:59:46  - 23147  http://www.lymphomahub.com/therapies/ags67e
2017-03-26 18:59:50  - 23147  http://www.lymphomahub.com/therapies/cc-292
2017-03-26 18:59:54  - 23147  http://www.lymphomahub.com/therapies/cc-223
2017-03-26 18:59:58  - 23147  http://www.lymphomahub.com/therapies/sd-101
2017-03-26 19:00:03  - 23147  http://www.lymphomahub.com/therapies/rp6530
2017-03-26 19:00:07  - 23147  http://www.lymphomahub.com/therapies/abt199
2017-03-26 19:00:08  - 23147  http://www.lymphomahub.com/therapies/mor208
2017-03-26 19:00:12  - 23147  http://www.lymphomahub.com/therapies/cc-122
2017-03-26 19:00:20  - 23147  http://www.lymphomahub.com/therapies/at-101
2017-03-26 19:00:24  - 23147  http://www.lymphomahub.com/therapies/bl8040
2017-03-26 19:00:29  - 23147  http://www.lymphomahub.com/therapies/bcl201
2017-03-26 19:00:35  - 23147  http://www.lymphomahub.com/therapies/azd3965
2017-03-26 19:00:40  - 23147  http://www.lymphomahub.com/therapies/imgn529
2017-03-26 19:00:44  - 23147  http://www.lymphomahub.com/therapies/azd2014
2017-03-26 19:00:48  - 23147  http://www.lymphomahub.com/therapies/mt-3724
2017-03-26 19:00:53  - 23147  http://www.lymphomahub.com/therapies/actr087
2017-03-26 19:00:57  - 23147  http://www.lymphomahub.com/therapies/epz6438
2017-03-26 19:01:01  - 23147  http://www.lymphomahub.com/therapies/kte-c19
2017-03-26 19:01:06  - 23147  http://www.lymphomahub.com/about/secretariat
2017-03-26 19:01:09  - 23147  http://www.lymphomahub.com/therapies/alt-803
2017-03-26 19:01:14  - 23147  http://www.lymphomahub.com/therapies/regn1979
2017-03-26 19:01:18  - 23147  http://www.lymphomahub.com/therapies/immu-114
2017-03-26 19:01:22  - 23147  http://www.lymphomahub.com/therapies/incb7839
2017-03-26 19:01:27  - 23147  http://www.lymphomahub.com/therapies/adct-301
2017-03-26 19:01:31  - 23147  http://www.lymphomahub.com/therapies/ixazomib
2017-03-26 19:01:35  - 23147  http://www.lymphomahub.com/therapies/avelumab
2017-03-26 19:01:39  - 23147  http://www.lymphomahub.com/therapies/bi836826
2017-03-26 19:01:43  - 23147  http://www.lymphomahub.com/therapies/medi-570
<pre>2017-03-26_19-01-44 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/medi-570?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_19-03-44 Restart Xvfb...
2017-03-26 19:03:48  - 23147  http://www.lymphomahub.com/therapies/medi-570
2017-03-26 19:03:53  - 23147  http://www.lymphomahub.com/therapies/ds-3201b
2017-03-26 19:03:57  - 23147  http://www.lymphomahub.com/therapies/sea-cd40
2017-03-26 19:04:01  - 23147  http://www.lymphomahub.com/therapies/adct-402
2017-03-26 19:04:06  - 23147  http://www.lymphomahub.com/therapies/acy-1215
2017-03-26 19:04:10  - 23147  http://www.lymphomahub.com/therapies/cudc-907
2017-03-26 19:04:15  - 23147  http://www.lymphomahub.com/therapies/tgr-1202
2017-03-26 19:04:19  - 23147  http://www.lymphomahub.com/therapies/axitinib
2017-03-26 19:04:23  - 23147  http://www.lymphomahub.com/therapies/imatinib
2017-03-26 19:04:27  - 23147  http://www.lymphomahub.com/therapies/edo-s101
2017-03-26 19:04:32  - 23147  http://www.lymphomahub.com/therapies/btct4465a
2017-03-26 19:04:36  - 23147  http://www.lymphomahub.com/therapies/alisertib
2017-03-26 19:04:40  - 23147  http://www.lymphomahub.com/therapies/lirilumab
2017-03-26 19:04:45  - 23147  http://www.lymphomahub.com/therapies/ibrutinib
2017-03-26 19:04:45  - 23147  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-03-26 19:04:49  - 23147  http://www.lymphomahub.com/therapies/rituximab
2017-03-26 19:04:54  - 23147  http://www.lymphomahub.com/therapies/veliparib
2017-03-26 19:04:58  - 23147  http://www.lymphomahub.com/therapies/sunitinib
2017-03-26 19:05:03  - 23147  http://www.lymphomahub.com/therapies/nivolumab
2017-03-26 19:05:04  - 23147  http://www.lymphomahub.com/therapies/sirolimus
2017-03-26 19:05:08  - 23147  http://www.lymphomahub.com/medical-information
2017-03-26 19:05:13  - 23147  http://www.lymphomahub.com/therapies/selinexor
2017-03-26 19:05:18  - 23147  http://www.lymphomahub.com/therapies/abc294640
2017-03-26 19:05:22  - 23147  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-03-26 19:05:26  - 23147  http://www.lymphomahub.com/therapies/tenofovir
2017-03-26 19:05:31  - 23147  http://www.lymphomahub.com/therapies/betalutin
2017-03-26 19:05:35  - 23147  http://www.lymphomahub.com/therapies/chidamide
2017-03-26 19:05:39  - 23147  http://www.lymphomahub.com/therapies/duvelisib
2017-03-26 19:05:43  - 23147  http://www.lymphomahub.com/therapies/dasatinib
<pre>2017-03-26_19-05-44 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/dasatinib?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_19-07-44 Restart Xvfb...
2017-03-26 19:07:49  - 23147  http://www.lymphomahub.com/therapies/dasatinib
2017-03-26 19:07:53  - 23147  http://www.lymphomahub.com/therapies/everolimus
2017-03-26 19:07:57  - 23147  http://www.lymphomahub.com/therapies/incb039110
2017-03-26 19:08:02  - 23147  http://www.lymphomahub.com/therapies/durvalumab
2017-03-26 19:08:06  - 23147  http://www.lymphomahub.com/therapies/romidepsin
2017-03-26 19:08:10  - 23147  http://www.lymphomahub.com/therapies/bortezomib
2017-03-26 19:08:15  - 23147  http://www.lymphomahub.com/therapies/idelalisib
2017-03-26 19:08:15  - 23147  http://www.lymphomahub.com/therapies/tipifarnib
2017-03-26 19:08:20  - 23147  http://www.lymphomahub.com/therapies/ipilimumab
2017-03-26 19:08:24  - 23147  http://www.lymphomahub.com/therapies/crizotinib
2017-03-26 19:08:28  - 23147  http://www.lymphomahub.com/therapies/gsk2816126
2017-03-26 19:08:33  - 23147  http://www.lymphomahub.com/therapies/copanlisib
2017-03-26 19:08:37  - 23147  http://www.lymphomahub.com/therapies/buparlisib
2017-03-26 19:08:41  - 23147  http://www.lymphomahub.com/therapies/belinostat
2017-03-26 19:08:45  - 23147  http://www.lymphomahub.com/therapies/vorinostat
2017-03-26 19:08:50  - 23147  http://www.lymphomahub.com/therapies/plerixafor
2017-03-26 19:08:50  - 23147  http://www.lymphomahub.com/therapies/ofatumumab
2017-03-26 19:08:55  - 23147  http://www.lymphomahub.com/therapies/pf-06801591
2017-03-26 19:08:59  - 23147  http://www.lymphomahub.com/therapies/tocilizumab
2017-03-26 19:09:04  - 23147  http://www.lymphomahub.com/therapies/msc2490484a
2017-03-26 19:09:08  - 23147  http://www.lymphomahub.com/therapies/carfilzomib
2017-03-26 19:09:12  - 23147  http://www.lymphomahub.com/therapies/ruxolitinib
2017-03-26 19:09:16  - 23147  http://www.lymphomahub.com/therapies/palbociclib
2017-03-26 19:09:21  - 23147  http://www.lymphomahub.com/therapies/fenretinide
2017-03-26 19:09:25  - 23147  http://www.lymphomahub.com/therapies/daratumumab
2017-03-26 19:09:29  - 23147  http://www.lymphomahub.com/therapies/pf-05082566
2017-03-26 19:09:33  - 23147  http://www.lymphomahub.com/therapies/ramucirumab
2017-03-26 19:09:37  - 23147  http://www.lymphomahub.com/therapies/tositumomab
2017-03-26 19:09:42  - 23147  http://www.lymphomahub.com/therapies/ublituximab
<pre>2017-03-26_19-09-44 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/ublituximab?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_19-11-44 Restart Xvfb...
2017-03-26 19:11:47  - 23147  http://www.lymphomahub.com/therapies/ublituximab
2017-03-26 19:11:51  - 23147  http://www.lymphomahub.com/therapies/epacadostat
2017-03-26 19:11:55  - 23147  http://www.lymphomahub.com/therapies/alemtuzumab
2017-03-26 19:11:55  - 23147  http://www.lymphomahub.com/therapies/otlertuzumab
2017-03-26 19:12:00  - 23147  http://www.lymphomahub.com/therapies/panobinostat
2017-03-26 19:12:04  - 23147  http://www.lymphomahub.com/therapies/mocetinostat
2017-03-26 19:12:08  - 23147  http://www.lymphomahub.com/therapies/atezolizumab
2017-03-26 19:12:13  - 23147  http://www.lymphomahub.com/therapies/temsirolimus
2017-03-26 19:12:18  - 23147  http://www.lymphomahub.com/therapies/lenalidomide
2017-03-26 19:12:22  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab
2017-03-26 19:12:26  - 23147  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-03-26 19:12:30  - 23147  http://www.lymphomahub.com/therapies/blinatumomab
2017-03-26 19:12:34  - 23147  http://www.lymphomahub.com/therapies/jnj-64052781
2017-03-26 19:12:39  - 23147  http://www.lymphomahub.com/therapies/entospletinib
2017-03-26 19:12:43  - 23147  http://www.lymphomahub.com/therapies/pembrolizumab
2017-03-26 19:12:48  - 23147  http://www.lymphomahub.com/therapies/acalabrutinib
2017-03-26 19:12:52  - 23147  http://www.lymphomahub.com/about/innovation-committee
2017-03-26 19:12:57  - 23147  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-03-26 19:12:57  - 23147  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-03-26 19:13:02  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-03-26 19:13:06  - 23147  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-03-26 19:13:10  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-03-26 19:13:14  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-03-26 19:13:15  - 23147  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-03-26 19:13:19  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-03-26 19:13:23  - 23147  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-03-26 19:13:28  - 23147  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-03-26 19:13:31  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board
2017-03-26 19:13:35  - 23147  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-03-26 19:13:40  - 23147  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-03-26 19:13:43  - 23147  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
<pre>2017-03-26_19-13-44 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about/secretariat/anne-villeneuve?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_19-15-44 Restart Xvfb...
2017-03-26 19:15:49  - 23147  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-03-26 19:15:52  - 23147  http://www.lymphomahub.com/about/executive-steering-committee
2017-03-26 19:15:56  - 23147  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-03-26 19:16:00  - 23147  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-03-26 19:16:04  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-03-26 19:16:08  - 23147  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-03-26 19:16:12  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-03-26 19:16:17  - 23147  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-03-26 19:16:20  - 23147  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-03-26 19:16:21  - 23147  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-03-26 19:16:24  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-03-26 19:16:29  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-03-26 19:16:33  - 23147  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-03-26 19:16:37  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-03-26 19:16:42  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-03-26 19:16:46  - 23147  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-03-26 19:16:50  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-03-26 19:16:54  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-03-26 19:16:57  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-03-26 19:17:01  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-03-26 19:17:05  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-03-26 19:17:09  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-03-26 19:17:13  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-03-26 19:17:17  - 23147  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-03-26 19:17:21  - 23147  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-03-26 19:17:25  - 23147  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-03-26 19:17:30  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-03-26 19:17:34  - 23147  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-03-26 19:17:37  - 23147  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-03-26 19:17:42  - 23147  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
<pre>2017-03-26_19-17-44 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_19-19-44 Restart Xvfb...
2017-03-26 19:19:47  - 23147  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-03-26 19:19:50  - 23147  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-03-26 19:19:55  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-03-26 19:19:59  - 23147  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-03-26 19:20:04  - 23147  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-03-26 19:20:09  - 23147  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-03-26 19:20:13  - 23147  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-03-26 19:20:18  - 23147  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-03-26 19:20:22  - 23147  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-03-26 19:20:27  - 23147  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-03-26 19:20:31  - 23147  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-03-26 19:20:35  - 23147  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-03-26 19:20:40  - 23147  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-03-26 19:20:44  - 23147  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-03-26 19:20:48  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-03-26 19:20:52  - 23147  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-03-26 19:20:57  - 23147  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-03-26 19:21:01  - 23147  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-03-26 19:21:05  - 23147  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-03-26 19:21:10  - 23147  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-03-26 19:21:14  - 23147  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-03-26 19:21:18  - 23147  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-03-26 19:21:22  - 23147  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-03-26 19:21:27  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-03-26 19:21:30  - 23147  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-03-26 19:21:35  - 23147  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-03-26 19:21:39  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-03-26 19:21:43  - 23147  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
<pre>2017-03-26_19-21-44 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_19-23-44 Restart Xvfb...
2017-03-26 19:23:48  - 23147  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-03-26 19:23:53  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-03-26 19:23:56  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-03-26 19:24:00  - 23147  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-03-26 19:24:05  - 23147  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-03-26 19:24:09  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-03-26 19:24:13  - 23147  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-03-26 19:24:17  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-03-26 19:24:21  - 23147  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-03-26 19:24:25  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-03-26 19:24:29  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-03-26 19:24:34  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-03-26 19:24:37  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-03-26 19:24:41  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-03-26 19:24:45  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-03-26 19:24:49  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-03-26 19:24:53  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-03-26 19:24:58  - 23147  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-03-26 19:25:02  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-03-26 19:25:07  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-03-26 19:25:12  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-03-26 19:25:16  - 23147  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-26 19:25:17  - 23147  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-03-26 19:25:21  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-03-26 19:25:25  - 23147  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-03-26 19:25:30  - 23147  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-03-26 19:25:35  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-03-26 19:25:39  - 23147  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-03-26 19:25:43  - 23147  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
<pre>2017-03-26_19-25-44 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_19-27-44 Restart Xvfb...
2017-03-26 19:27:48  - 23147  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-03-26 19:27:53  - 23147  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-03-26 19:27:57  - 23147  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-03-26 19:28:02  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-03-26 19:28:07  - 23147  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-03-26 19:28:12  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-03-26 19:28:16  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-03-26 19:28:20  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-03-26 19:28:25  - 23147  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-03-26 19:28:29  - 23147  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-03-26 19:28:34  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-03-26 19:28:38  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-03-26 19:28:43  - 23147  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-03-26 19:28:47  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-03-26 19:28:52  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-03-26 19:28:56  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-03-26 19:29:01  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-03-26 19:29:05  - 23147  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-26 19:29:10  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-03-26 19:29:14  - 23147  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-03-26 19:29:19  - 23147  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-03-26 19:29:23  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-03-26 19:29:28  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-03-26 19:29:32  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-03-26 19:29:37  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-03-26 19:29:41  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
<pre>2017-03-26_19-29-44 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_19-31-44 Restart Xvfb...
2017-03-26 19:31:46  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-03-26 19:31:50  - 23147  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-03-26 19:31:55  - 23147  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-03-26 19:31:59  - 23147  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-03-26 19:32:04  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-03-26 19:32:09  - 23147  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-03-26 19:32:13  - 23147  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-03-26 19:32:18  - 23147  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-03-26 19:32:18  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-03-26 19:32:23  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-03-26 19:32:27  - 23147  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-03-26 19:32:32  - 23147  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-03-26 19:32:36  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-03-26 19:32:41  - 23147  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-03-26 19:32:45  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-03-26 19:32:49  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-03-26 19:32:54  - 23147  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-03-26 19:32:58  - 23147  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-03-26 19:33:03  - 23147  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-03-26 19:33:07  - 23147  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-03-26 19:33:12  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-03-26 19:33:16  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-03-26 19:33:21  - 23147  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-03-26 19:33:25  - 23147  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-03-26 19:33:30  - 23147  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-03-26 19:33:34  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-03-26 19:33:39  - 23147  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-03-26 19:33:43  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
<pre>2017-03-26_19-33-44 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_19-35-45 Restart Xvfb...
2017-03-26 19:35:48  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-03-26 19:35:53  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-03-26 19:35:57  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-03-26 19:36:02  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-03-26 19:36:06  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-03-26 19:36:10  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-03-26 19:36:14  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-03-26 19:36:18  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-03-26 19:36:22  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-03-26 19:36:26  - 23147  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-03-26 19:36:26  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-03-26 19:36:31  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-03-26 19:36:35  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-03-26 19:36:39  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-03-26 19:36:43  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-03-26 19:36:46  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-03-26 19:36:50  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-03-26 19:36:54  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-03-26 19:36:57  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-03-26 19:37:01  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-03-26 19:37:05  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-03-26 19:37:08  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-03-26 19:37:12  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-03-26 19:37:15  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-03-26 19:37:19  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-03-26 19:37:23  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-03-26 19:37:27  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-03-26 19:37:31  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-03-26 19:37:35  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-03-26 19:37:39  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-03-26 19:37:42  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
<pre>2017-03-26_19-37-45 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_19-39-45 Restart Xvfb...
2017-03-26 19:39:48  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-03-26 19:39:51  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-03-26 19:39:55  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-03-26 19:39:58  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-03-26 19:40:02  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-03-26 19:40:06  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-03-26 19:40:10  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-03-26 19:40:13  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-03-26 19:40:17  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-03-26 19:40:21  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-03-26 19:40:24  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-03-26 19:40:28  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-03-26 19:40:32  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-03-26 19:40:36  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-03-26 19:40:39  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-03-26 19:40:43  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-03-26 19:40:46  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-03-26 19:40:50  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-03-26 19:40:53  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-03-26 19:40:57  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-03-26 19:41:01  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-03-26 19:41:05  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-03-26 19:41:08  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-03-26 19:41:12  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-03-26 19:41:16  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-03-26 19:41:19  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-03-26 19:41:23  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-03-26 19:41:26  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-03-26 19:41:30  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-03-26 19:41:34  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-03-26 19:41:39  - 23147  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-03-26 19:41:43  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
<pre>2017-03-26_19-41-45 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_19-43-45 Restart Xvfb...
2017-03-26 19:43:48  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-03-26 19:43:53  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-03-26 19:43:58  - 23147  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-03-26 19:43:58  - 23147  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-03-26 19:44:03  - 23147  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-03-26 19:44:08  - 23147  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-03-26 19:44:12  - 23147  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-03-26 19:44:18  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-03-26 19:44:22  - 23147  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-03-26 19:44:27  - 23147  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-03-26 19:44:31  - 23147  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-03-26 19:44:35  - 23147  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-03-26 19:44:40  - 23147  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-03-26 19:44:44  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-03-26 19:44:48  - 23147  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-03-26 19:44:53  - 23147  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-03-26 19:44:57  - 23147  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-03-26 19:45:01  - 23147  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-03-26 19:45:06  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-03-26 19:45:10  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-03-26 19:45:15  - 23147  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-03-26 19:45:19  - 23147  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-03-26 19:45:24  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-03-26 19:45:28  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-03-26 19:45:33  - 23147  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-26 19:45:37  - 23147  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-03-26 19:45:42  - 23147  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
<pre>2017-03-26_19-45-45 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_19-47-45 Restart Xvfb...
2017-03-26 19:47:47  - 23147  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-03-26 19:47:51  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-03-26 19:47:56  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-03-26 19:48:00  - 23147  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-03-26 19:48:05  - 23147  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-03-26 19:48:10  - 23147  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-03-26 19:48:14  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-03-26 19:48:19  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-03-26 19:48:23  - 23147  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-26 19:48:27  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-03-26 19:48:32  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-03-26 19:48:37  - 23147  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-03-26 19:48:41  - 23147  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-03-26 19:48:45  - 23147  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-03-26 19:48:50  - 23147  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-03-26 19:48:54  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-03-26 19:48:59  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-03-26 19:49:03  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-03-26 19:49:08  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-03-26 19:49:12  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-03-26 19:49:17  - 23147  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-03-26 19:49:22  - 23147  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-03-26 19:49:26  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-03-26 19:49:31  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-03-26 19:49:35  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-03-26 19:49:40  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-03-26 19:49:44  - 23147  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
<pre>2017-03-26_19-49-45 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_19-51-45 Restart Xvfb...
2017-03-26 19:51:49  - 23147  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-03-26 19:51:54  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-03-26 19:51:59  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-03-26 19:52:03  - 23147  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-03-26 19:52:08  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-03-26 19:52:12  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-03-26 19:52:17  - 23147  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-03-26 19:52:21  - 23147  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-03-26 19:52:26  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-03-26 19:52:30  - 23147  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-03-26 19:52:35  - 23147  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-03-26 19:52:39  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-03-26 19:52:43  - 23147  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-03-26 19:52:48  - 23147  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-03-26 19:52:52  - 23147  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-03-26 19:52:57  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-03-26 19:53:02  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-03-26 19:53:07  - 23147  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-03-26 19:53:11  - 23147  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-03-26 19:53:16  - 23147  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-03-26 19:53:20  - 23147  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-03-26 19:53:25  - 23147  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-03-26 19:53:29  - 23147  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-03-26 19:53:34  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-03-26 19:53:38  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-03-26 19:53:42  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
<pre>2017-03-26_19-53-45 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_19-55-45 Restart Xvfb...
2017-03-26 19:55:47  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-03-26 19:55:51  - 23147  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-03-26 19:55:56  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-03-26 19:56:01  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-03-26 19:56:05  - 23147  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-03-26 19:56:10  - 23147  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-03-26 19:56:14  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-03-26 19:56:18  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-03-26 19:56:23  - 23147  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-03-26 19:56:27  - 23147  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-03-26 19:56:32  - 23147  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-03-26 19:56:36  - 23147  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-03-26 19:56:41  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-03-26 19:56:45  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-03-26 19:56:49  - 23147  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-03-26 19:56:54  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-03-26 19:56:58  - 23147  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-03-26 19:57:03  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-03-26 19:57:07  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-03-26 19:57:12  - 23147  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-03-26 19:57:16  - 23147  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-03-26 19:57:21  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-03-26 19:57:25  - 23147  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-03-26 19:57:30  - 23147  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-03-26 19:57:34  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-03-26 19:57:39  - 23147  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-03-26 19:57:43  - 23147  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
<pre>2017-03-26_19-57-45 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_19-59-45 Restart Xvfb...
2017-03-26 19:59:48  - 23147  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-03-26 19:59:53  - 23147  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-03-26 19:59:58  - 23147  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-03-26 20:00:02  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-03-26 20:00:10  - 23147  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-03-26 20:00:16  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-03-26 20:00:21  - 23147  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-03-26 20:00:25  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-03-26 20:00:31  - 23147  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-03-26 20:00:35  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-03-26 20:00:40  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-03-26 20:00:45  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-03-26 20:00:49  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-03-26 20:00:54  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-03-26 20:00:58  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-03-26 20:01:03  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-03-26 20:01:07  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-03-26 20:01:12  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-03-26 20:01:16  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-03-26 20:01:21  - 23147  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-03-26 20:01:25  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-03-26 20:01:29  - 23147  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-03-26 20:01:33  - 23147  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-03-26 20:01:38  - 23147  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-03-26 20:01:42  - 23147  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
<pre>2017-03-26_20-01-45 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_20-03-45 Restart Xvfb...
2017-03-26 20:03:47  - 23147  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-03-26 20:03:51  - 23147  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-03-26 20:03:56  - 23147  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-03-26 20:04:01  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-03-26 20:04:05  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-03-26 20:04:10  - 23147  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-03-26 20:04:14  - 23147  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-03-26 20:04:18  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-03-26 20:04:23  - 23147  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-03-26 20:04:28  - 23147  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-03-26 20:04:32  - 23147  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-03-26 20:04:36  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-03-26 20:04:41  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-03-26 20:04:45  - 23147  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-03-26 20:04:50  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-03-26 20:04:54  - 23147  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-03-26 20:04:58  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-03-26 20:05:03  - 23147  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-03-26 20:05:07  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-03-26 20:05:12  - 23147  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-03-26 20:05:16  - 23147  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-03-26 20:05:20  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-03-26 20:05:25  - 23147  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-03-26 20:05:29  - 23147  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-03-26 20:05:33  - 23147  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-03-26 20:05:38  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-03-26 20:05:42  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
<pre>2017-03-26_20-05-45 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_20-07-45 Restart Xvfb...
2017-03-26 20:07:47  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-03-26 20:07:51  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-03-26 20:07:55  - 23147  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-03-26 20:07:59  - 23147  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-03-26 20:08:04  - 23147  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-03-26 20:08:09  - 23147  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-03-26 20:08:12  - 23147  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-03-26 20:08:16  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-03-26 20:08:21  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-03-26 20:08:25  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-03-26 20:08:30  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-03-26 20:08:34  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-03-26 20:08:38  - 23147  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-03-26 20:08:43  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-03-26 20:08:47  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-03-26 20:08:52  - 23147  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-03-26 20:08:56  - 23147  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-03-26 20:09:01  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-03-26 20:09:05  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-03-26 20:09:10  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-03-26 20:09:14  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-03-26 20:09:19  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-03-26 20:09:23  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-03-26 20:09:27  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-03-26 20:09:31  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-03-26 20:09:36  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-03-26 20:09:40  - 23147  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-03-26 20:09:44  - 23147  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
<pre>2017-03-26_20-09-45 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_20-11-45 Restart Xvfb...
2017-03-26 20:11:49  - 23147  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-03-26 20:11:54  - 23147  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-03-26 20:11:58  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-03-26 20:12:02  - 23147  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-03-26 20:12:06  - 23147  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-03-26 20:12:11  - 23147  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-03-26 20:12:16  - 23147  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-03-26 20:12:21  - 23147  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-03-26 20:12:25  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-03-26 20:12:30  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-03-26 20:12:34  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-03-26 20:12:39  - 23147  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-03-26 20:12:43  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-03-26 20:12:47  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-03-26 20:12:52  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-03-26 20:12:56  - 23147  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-03-26 20:13:01  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-03-26 20:13:05  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-03-26 20:13:09  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-03-26 20:13:13  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-03-26 20:13:17  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-03-26 20:13:22  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-03-26 20:13:26  - 23147  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-03-26 20:13:30  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-03-26 20:13:35  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-03-26 20:13:39  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-03-26 20:13:43  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
<pre>2017-03-26_20-13-45 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_20-15-45 Restart Xvfb...
2017-03-26 20:15:48  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-03-26 20:15:53  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-03-26 20:15:57  - 23147  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-03-26 20:16:02  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-03-26 20:16:06  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-03-26 20:16:10  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-03-26 20:16:14  - 23147  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-03-26 20:16:19  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-03-26 20:16:24  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-03-26 20:16:29  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-03-26 20:16:33  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-03-26 20:16:37  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-03-26 20:16:41  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-03-26 20:16:45  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-03-26 20:16:49  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-03-26 20:16:53  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-03-26 20:16:57  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-03-26 20:17:02  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-03-26 20:17:06  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-03-26 20:17:10  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-03-26 20:17:14  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-03-26 20:17:18  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-03-26 20:17:22  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-03-26 20:17:26  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-03-26 20:17:30  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-03-26 20:17:35  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-03-26 20:17:39  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-03-26 20:17:42  - 23147  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
<pre>2017-03-26_20-17-45 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_20-19-45 Restart Xvfb...
2017-03-26 20:19:48  - 23147  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-03-26 20:19:51  - 23147  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-03-26 20:19:55  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-03-26 20:20:00  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-03-26 20:20:04  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-03-26 20:20:09  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-03-26 20:20:13  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-03-26 20:20:18  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-03-26 20:20:22  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-03-26 20:20:27  - 23147  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-03-26 20:20:31  - 23147  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-03-26 20:20:35  - 23147  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-03-26 20:20:39  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-03-26 20:20:43  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-03-26 20:20:47  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-03-26 20:20:51  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-03-26 20:20:55  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-03-26 20:20:59  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-26 20:21:04  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-26 20:21:08  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-26 20:21:11  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-26 20:21:15  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-03-26 20:21:19  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-26 20:21:23  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-26 20:21:28  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-03-26 20:21:32  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-03-26 20:21:35  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-03-26 20:21:39  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-03-26 20:21:44  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
<pre>2017-03-26_20-21-45 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_20-23-45 Restart Xvfb...
2017-03-26 20:23:49  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-03-26 20:23:53  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-03-26 20:23:57  - 23147  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-03-26 20:24:01  - 23147  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-03-26 20:24:05  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-03-26 20:24:10  - 23147  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-03-26 20:24:14  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-03-26 20:24:18  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-03-26 20:24:23  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-03-26 20:24:27  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-03-26 20:24:31  - 23147  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-03-26 20:24:35  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-03-26 20:24:39  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-03-26 20:24:42  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-03-26 20:24:46  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-03-26 20:24:50  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-03-26 20:24:54  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-26 20:24:58  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-26 20:25:02  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-26 20:25:06  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-26 20:25:10  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-26 20:25:14  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-03-26 20:25:18  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-26 20:25:22  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-26 20:25:25  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-26 20:25:30  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-26 20:25:34  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-03-26 20:25:37  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-26 20:25:42  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
<pre>2017-03-26_20-25-45 Restart Xvfb...
2017-03-26 20:25:45  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-26 20:25:49  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-03-26 20:25:53  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
<pre>2017-03-26_20-27-45 Restart Xvfb...
<pre>2017-03-26_20-29-45 Restart Xvfb...
<pre>2017-03-26_20-31-45 Restart Xvfb...
<pre>2017-03-26_20-33-45 Restart Xvfb...
<pre>2017-03-26_20-35-45 Restart Xvfb...
<pre>2017-03-26_20-37-45 Restart Xvfb...
<pre>2017-03-26_20-39-45 Restart Xvfb...
<pre>2017-03-26_20-41-45 Restart Xvfb...
<pre>2017-03-26_20-43-45 Restart Xvfb...
<pre>2017-03-26_20-45-45 Restart Xvfb...
<pre>2017-03-26_20-47-45 Restart Xvfb...
<pre>2017-03-26_20-49-45 Restart Xvfb...
<pre>2017-03-26_20-51-45 Restart Xvfb...
<pre>2017-03-26_20-53-45 Restart Xvfb...
<pre>2017-03-26_20-55-45 Restart Xvfb...
<pre>2017-03-26_20-57-45 Restart Xvfb...
<pre>2017-03-26_20-59-45 Restart Xvfb...
<pre>2017-03-26_21-01-45 Restart Xvfb...
<pre>2017-03-26_21-03-46 Restart Xvfb...
<pre>2017-03-26_21-05-46 Restart Xvfb...
<pre>2017-03-26_21-07-46 Restart Xvfb...
<pre>2017-03-26_21-09-46 Restart Xvfb...
<pre>2017-03-26_21-11-46 Restart Xvfb...
<pre>2017-03-26_21-13-46 Restart Xvfb...
<pre>2017-03-26_21-15-46 Restart Xvfb...
<pre>2017-03-26_21-17-46 Restart Xvfb...
<pre>2017-03-26_21-19-46 Restart Xvfb...
<pre>2017-03-26_21-21-46 Restart Xvfb...
<pre>2017-03-26_21-23-46 Restart Xvfb...
<pre>2017-03-26_21-25-46 Restart Xvfb...
<pre>2017-03-26_21-27-46 Restart Xvfb...
<pre>2017-03-26_21-29-46 Restart Xvfb...
<pre>2017-03-26_21-31-46 Restart Xvfb...
<pre>2017-03-26_21-33-46 Restart Xvfb...
<pre>2017-03-26_21-35-46 Restart Xvfb...
<pre>2017-03-26_21-37-46 Restart Xvfb...
<pre>2017-03-26_21-39-46 Restart Xvfb...
<pre>2017-03-26_21-41-46 Restart Xvfb...
<pre>2017-03-26_21-43-46 Restart Xvfb...
<pre>2017-03-26_21-45-46 Restart Xvfb...
<pre>2017-03-26_21-47-46 Restart Xvfb...
<pre>2017-03-26_21-49-46 Restart Xvfb...
<pre>2017-03-26_21-51-46 Restart Xvfb...
<pre>2017-03-26_21-53-46 Restart Xvfb...
<pre>2017-03-26_21-55-46 Restart Xvfb...
2017-03-26 21:56:59 reset updateRequest
2017-03-26 21:56:59  - 23147  http://www.lymphomahub.com/
2017-03-26 21:57:03  - 23147  http://www.lymphomahub.com/about
2017-03-26 21:57:04  - 23147  http://www.lymphomahub.com/about
2017-03-26 21:57:10  - 23147  http://www.lymphomahub.com/terms
2017-03-26 21:57:13  - 23147  http://www.lymphomahub.com/undefined
2017-03-26 21:57:14  - 23147  http://www.lymphomahub.com/therapies
2017-03-26 21:57:20  - 23147  http://www.lymphomahub.com/newsletter
2017-03-26 21:57:23  - 23147  http://www.lymphomahub.com/cookie-policy
2017-03-26 21:57:26  - 23147  http://www.lymphomahub.com/therapies/afm13
2017-03-26 21:57:31  - 23147  http://www.lymphomahub.com/therapies/afm11
2017-03-26 21:57:35  - 23147  http://www.lymphomahub.com/therapies/ags67e
2017-03-26 21:57:39  - 23147  http://www.lymphomahub.com/therapies/cc-292
2017-03-26 21:57:44  - 23147  http://www.lymphomahub.com/therapies/cc-223
<pre>2017-03-26_21-57-46 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/cc-223?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_21-59-46 Restart Xvfb...
2017-03-26 21:59:49  - 23147  http://www.lymphomahub.com/therapies/cc-223
2017-03-26 21:59:53  - 23147  http://www.lymphomahub.com/therapies/sd-101
2017-03-26 21:59:57  - 23147  http://www.lymphomahub.com/therapies/rp6530
2017-03-26 22:00:02  - 23147  http://www.lymphomahub.com/therapies/abt199
2017-03-26 22:00:06  - 23147  http://www.lymphomahub.com/therapies/mor208
2017-03-26 22:00:12  - 23147  http://www.lymphomahub.com/therapies/cc-122
2017-03-26 22:00:19  - 23147  http://www.lymphomahub.com/therapies/at-101
2017-03-26 22:00:26  - 23147  http://www.lymphomahub.com/therapies/bl8040
2017-03-26 22:00:34  - 23147  http://www.lymphomahub.com/therapies/bcl201
2017-03-26 22:00:38  - 23147  http://www.lymphomahub.com/therapies/azd3965
2017-03-26 22:00:43  - 23147  http://www.lymphomahub.com/therapies/imgn529
2017-03-26 22:00:47  - 23147  http://www.lymphomahub.com/therapies/azd2014
2017-03-26 22:00:52  - 23147  http://www.lymphomahub.com/therapies/mt-3724
2017-03-26 22:00:56  - 23147  http://www.lymphomahub.com/therapies/actr087
2017-03-26 22:01:01  - 23147  http://www.lymphomahub.com/therapies/epz6438
2017-03-26 22:01:05  - 23147  http://www.lymphomahub.com/therapies/kte-c19
2017-03-26 22:01:09  - 23147  http://www.lymphomahub.com/about/secretariat
2017-03-26 22:01:13  - 23147  http://www.lymphomahub.com/therapies/alt-803
2017-03-26 22:01:17  - 23147  http://www.lymphomahub.com/therapies/regn1979
2017-03-26 22:01:21  - 23147  http://www.lymphomahub.com/therapies/immu-114
2017-03-26 22:01:26  - 23147  http://www.lymphomahub.com/therapies/incb7839
2017-03-26 22:01:30  - 23147  http://www.lymphomahub.com/therapies/adct-301
2017-03-26 22:01:34  - 23147  http://www.lymphomahub.com/therapies/ixazomib
2017-03-26 22:01:38  - 23147  http://www.lymphomahub.com/therapies/avelumab
2017-03-26 22:01:42  - 23147  http://www.lymphomahub.com/therapies/bi836826
<pre>2017-03-26_22-01-46 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/bi836826?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_22-03-46 Restart Xvfb...
2017-03-26 22:03:48  - 23147  http://www.lymphomahub.com/therapies/bi836826
2017-03-26 22:03:51  - 23147  http://www.lymphomahub.com/therapies/medi-570
2017-03-26 22:03:56  - 23147  http://www.lymphomahub.com/therapies/ds-3201b
2017-03-26 22:04:00  - 23147  http://www.lymphomahub.com/therapies/sea-cd40
2017-03-26 22:04:04  - 23147  http://www.lymphomahub.com/therapies/adct-402
2017-03-26 22:04:09  - 23147  http://www.lymphomahub.com/therapies/acy-1215
2017-03-26 22:04:13  - 23147  http://www.lymphomahub.com/therapies/cudc-907
2017-03-26 22:04:17  - 23147  http://www.lymphomahub.com/therapies/tgr-1202
2017-03-26 22:04:22  - 23147  http://www.lymphomahub.com/therapies/axitinib
2017-03-26 22:04:26  - 23147  http://www.lymphomahub.com/therapies/imatinib
2017-03-26 22:04:30  - 23147  http://www.lymphomahub.com/therapies/edo-s101
2017-03-26 22:04:35  - 23147  http://www.lymphomahub.com/therapies/btct4465a
2017-03-26 22:04:39  - 23147  http://www.lymphomahub.com/therapies/alisertib
2017-03-26 22:04:43  - 23147  http://www.lymphomahub.com/therapies/lirilumab
2017-03-26 22:04:48  - 23147  http://www.lymphomahub.com/therapies/ibrutinib
2017-03-26 22:04:48  - 23147  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-03-26 22:04:53  - 23147  http://www.lymphomahub.com/therapies/rituximab
2017-03-26 22:04:57  - 23147  http://www.lymphomahub.com/therapies/veliparib
2017-03-26 22:05:01  - 23147  http://www.lymphomahub.com/therapies/sunitinib
2017-03-26 22:05:06  - 23147  http://www.lymphomahub.com/therapies/nivolumab
2017-03-26 22:05:07  - 23147  http://www.lymphomahub.com/therapies/sirolimus
2017-03-26 22:05:11  - 23147  http://www.lymphomahub.com/medical-information
2017-03-26 22:05:15  - 23147  http://www.lymphomahub.com/therapies/selinexor
2017-03-26 22:05:20  - 23147  http://www.lymphomahub.com/therapies/abc294640
2017-03-26 22:05:24  - 23147  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-03-26 22:05:29  - 23147  http://www.lymphomahub.com/therapies/tenofovir
2017-03-26 22:05:33  - 23147  http://www.lymphomahub.com/therapies/betalutin
2017-03-26 22:05:37  - 23147  http://www.lymphomahub.com/therapies/chidamide
2017-03-26 22:05:41  - 23147  http://www.lymphomahub.com/therapies/duvelisib
2017-03-26 22:05:46  - 23147  http://www.lymphomahub.com/therapies/dasatinib
<pre>2017-03-26_22-05-46 Restart Xvfb...
2017-03-26 22:05:50  - 23147  http://www.lymphomahub.com/therapies/everolimus
2017-03-26 22:05:54  - 23147  http://www.lymphomahub.com/therapies/incb039110
2017-03-26 22:05:59  - 23147  http://www.lymphomahub.com/therapies/durvalumab
2017-03-26 22:06:03  - 23147  http://www.lymphomahub.com/therapies/romidepsin
2017-03-26 22:06:07  - 23147  http://www.lymphomahub.com/therapies/bortezomib
2017-03-26 22:06:12  - 23147  http://www.lymphomahub.com/therapies/idelalisib
2017-03-26 22:06:12  - 23147  http://www.lymphomahub.com/therapies/tipifarnib
2017-03-26 22:06:17  - 23147  http://www.lymphomahub.com/therapies/ipilimumab
2017-03-26 22:06:21  - 23147  http://www.lymphomahub.com/therapies/crizotinib
2017-03-26 22:06:25  - 23147  http://www.lymphomahub.com/therapies/gsk2816126
2017-03-26 22:06:30  - 23147  http://www.lymphomahub.com/therapies/copanlisib
2017-03-26 22:06:34  - 23147  http://www.lymphomahub.com/therapies/buparlisib
2017-03-26 22:06:39  - 23147  http://www.lymphomahub.com/therapies/belinostat
2017-03-26 22:06:45  - 23147  http://www.lymphomahub.com/therapies/vorinostat
2017-03-26 22:06:49  - 23147  http://www.lymphomahub.com/therapies/plerixafor
2017-03-26 22:06:50  - 23147  http://www.lymphomahub.com/therapies/ofatumumab
2017-03-26 22:06:54  - 23147  http://www.lymphomahub.com/therapies/pf-06801591
2017-03-26 22:06:58  - 23147  http://www.lymphomahub.com/therapies/tocilizumab
2017-03-26 22:07:03  - 23147  http://www.lymphomahub.com/therapies/msc2490484a
2017-03-26 22:07:07  - 23147  http://www.lymphomahub.com/therapies/carfilzomib
2017-03-26 22:07:11  - 23147  http://www.lymphomahub.com/therapies/ruxolitinib
2017-03-26 22:07:15  - 23147  http://www.lymphomahub.com/therapies/palbociclib
2017-03-26 22:07:19  - 23147  http://www.lymphomahub.com/therapies/fenretinide
2017-03-26 22:07:24  - 23147  http://www.lymphomahub.com/therapies/daratumumab
2017-03-26 22:07:28  - 23147  http://www.lymphomahub.com/therapies/pf-05082566
2017-03-26 22:07:33  - 23147  http://www.lymphomahub.com/therapies/ramucirumab
2017-03-26 22:07:37  - 23147  http://www.lymphomahub.com/therapies/tositumomab
2017-03-26 22:07:41  - 23147  http://www.lymphomahub.com/therapies/ublituximab
2017-03-26 22:07:45  - 23147  http://www.lymphomahub.com/therapies/epacadostat
<pre>2017-03-26_22-07-46 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/epacadostat?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_22-09-46 Restart Xvfb...
2017-03-26 22:09:50  - 23147  http://www.lymphomahub.com/therapies/epacadostat
2017-03-26 22:09:55  - 23147  http://www.lymphomahub.com/therapies/alemtuzumab
2017-03-26 22:09:55  - 23147  http://www.lymphomahub.com/therapies/otlertuzumab
2017-03-26 22:10:00  - 23147  http://www.lymphomahub.com/therapies/panobinostat
2017-03-26 22:10:04  - 23147  http://www.lymphomahub.com/therapies/mocetinostat
2017-03-26 22:10:08  - 23147  http://www.lymphomahub.com/therapies/atezolizumab
2017-03-26 22:10:13  - 23147  http://www.lymphomahub.com/therapies/temsirolimus
2017-03-26 22:10:17  - 23147  http://www.lymphomahub.com/therapies/lenalidomide
2017-03-26 22:10:21  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab
2017-03-26 22:10:26  - 23147  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-03-26 22:10:30  - 23147  http://www.lymphomahub.com/therapies/blinatumomab
2017-03-26 22:10:34  - 23147  http://www.lymphomahub.com/therapies/jnj-64052781
2017-03-26 22:10:38  - 23147  http://www.lymphomahub.com/therapies/entospletinib
2017-03-26 22:10:42  - 23147  http://www.lymphomahub.com/therapies/pembrolizumab
2017-03-26 22:10:47  - 23147  http://www.lymphomahub.com/therapies/acalabrutinib
2017-03-26 22:10:51  - 23147  http://www.lymphomahub.com/about/innovation-committee
2017-03-26 22:10:55  - 23147  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-03-26 22:10:55  - 23147  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-03-26 22:11:00  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-03-26 22:11:04  - 23147  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-03-26 22:11:09  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-03-26 22:11:13  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-03-26 22:11:14  - 23147  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-03-26 22:11:18  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-03-26 22:11:22  - 23147  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-03-26 22:11:26  - 23147  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-03-26 22:11:30  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board
2017-03-26 22:11:34  - 23147  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-03-26 22:11:39  - 23147  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-03-26 22:11:42  - 23147  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-03-26 22:11:46  - 23147  http://www.lymphomahub.com/about/executive-steering-committee
<pre>2017-03-26_22-11-46 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about/executive-steering-committee?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_22-13-46 Restart Xvfb...
2017-03-26 22:13:51  - 23147  http://www.lymphomahub.com/about/executive-steering-committee
2017-03-26 22:13:56  - 23147  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-03-26 22:14:00  - 23147  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-03-26 22:14:04  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-03-26 22:14:08  - 23147  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-03-26 22:14:12  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-03-26 22:14:17  - 23147  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-03-26 22:14:21  - 23147  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-03-26 22:14:21  - 23147  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-03-26 22:14:25  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-03-26 22:14:30  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-03-26 22:14:34  - 23147  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-03-26 22:14:38  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-03-26 22:14:42  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-03-26 22:14:47  - 23147  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-03-26 22:14:50  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-03-26 22:14:54  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-03-26 22:14:58  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-03-26 22:15:02  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-03-26 22:15:05  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-03-26 22:15:09  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-03-26 22:15:13  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-03-26 22:15:17  - 23147  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-03-26 22:15:21  - 23147  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-03-26 22:15:26  - 23147  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-03-26 22:15:29  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-03-26 22:15:33  - 23147  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-03-26 22:15:36  - 23147  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-03-26 22:15:41  - 23147  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-03-26 22:15:46  - 23147  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
<pre>2017-03-26_22-15-46 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_22-17-46 Restart Xvfb...
2017-03-26 22:17:51  - 23147  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-03-26 22:17:56  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-03-26 22:17:59  - 23147  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-03-26 22:18:04  - 23147  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-03-26 22:18:08  - 23147  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-03-26 22:18:13  - 23147  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-03-26 22:18:18  - 23147  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-03-26 22:18:23  - 23147  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-03-26 22:18:27  - 23147  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-03-26 22:18:32  - 23147  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-03-26 22:18:36  - 23147  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-03-26 22:18:40  - 23147  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-03-26 22:18:45  - 23147  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-03-26 22:18:50  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-03-26 22:18:53  - 23147  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-03-26 22:18:58  - 23147  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-03-26 22:19:02  - 23147  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-03-26 22:19:07  - 23147  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-03-26 22:19:11  - 23147  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-03-26 22:19:15  - 23147  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-03-26 22:19:19  - 23147  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-03-26 22:19:24  - 23147  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-03-26 22:19:28  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-03-26 22:19:32  - 23147  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-03-26 22:19:37  - 23147  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-03-26 22:19:41  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-03-26 22:19:45  - 23147  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
<pre>2017-03-26_22-19-46 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_22-21-46 Restart Xvfb...
2017-03-26 22:21:50  - 23147  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-03-26 22:21:55  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-03-26 22:21:58  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-03-26 22:22:02  - 23147  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-03-26 22:22:07  - 23147  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-03-26 22:22:11  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-03-26 22:22:15  - 23147  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-03-26 22:22:19  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-03-26 22:22:23  - 23147  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-03-26 22:22:27  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-03-26 22:22:31  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-03-26 22:22:36  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-03-26 22:22:39  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-03-26 22:22:43  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-03-26 22:22:47  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-03-26 22:22:51  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-03-26 22:22:55  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-03-26 22:22:59  - 23147  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-03-26 22:23:04  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-03-26 22:23:09  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-03-26 22:23:13  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-03-26 22:23:18  - 23147  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-26 22:23:19  - 23147  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-03-26 22:23:23  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-03-26 22:23:27  - 23147  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-03-26 22:23:32  - 23147  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-03-26 22:23:36  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-03-26 22:23:40  - 23147  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-03-26 22:23:45  - 23147  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
<pre>2017-03-26_22-23-46 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_22-25-46 Restart Xvfb...
2017-03-26 22:25:50  - 23147  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-03-26 22:25:55  - 23147  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-03-26 22:26:00  - 23147  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-03-26 22:26:04  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-03-26 22:26:08  - 23147  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-03-26 22:26:13  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-03-26 22:26:17  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-03-26 22:26:22  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-03-26 22:26:26  - 23147  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-03-26 22:26:30  - 23147  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-03-26 22:26:35  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-03-26 22:26:39  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-03-26 22:26:44  - 23147  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-03-26 22:26:48  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-03-26 22:26:52  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-03-26 22:26:57  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-03-26 22:27:01  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-03-26 22:27:06  - 23147  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-26 22:27:10  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-03-26 22:27:15  - 23147  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-03-26 22:27:20  - 23147  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-03-26 22:27:24  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-03-26 22:27:28  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-03-26 22:27:33  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-03-26 22:27:37  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-03-26 22:27:42  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-03-26 22:27:46  - 23147  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
<pre>2017-03-26_22-27-46 Restart Xvfb...
2017-03-26 22:27:51  - 23147  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-03-26 22:27:55  - 23147  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-03-26 22:28:00  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-03-26 22:28:04  - 23147  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-03-26 22:28:09  - 23147  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-03-26 22:28:14  - 23147  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-03-26 22:28:14  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-03-26 22:28:19  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-03-26 22:28:23  - 23147  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-03-26 22:28:28  - 23147  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-03-26 22:28:32  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-03-26 22:28:36  - 23147  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-03-26 22:28:40  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-03-26 22:28:45  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-03-26 22:28:49  - 23147  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-03-26 22:28:53  - 23147  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-03-26 22:28:58  - 23147  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-03-26 22:29:02  - 23147  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-03-26 22:29:07  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-03-26 22:29:11  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-03-26 22:29:15  - 23147  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-03-26 22:29:20  - 23147  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-03-26 22:29:24  - 23147  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-03-26 22:29:29  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-03-26 22:29:33  - 23147  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-03-26 22:29:37  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-03-26 22:29:42  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-03-26 22:29:46  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
<pre>2017-03-26_22-29-46 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_22-31-46 Restart Xvfb...
2017-03-26 22:31:51  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-03-26 22:31:57  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-03-26 22:32:01  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-03-26 22:32:05  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-03-26 22:32:09  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-03-26 22:32:13  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-03-26 22:32:16  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-03-26 22:32:21  - 23147  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-03-26 22:32:21  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-03-26 22:32:26  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-03-26 22:32:30  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-03-26 22:32:34  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-03-26 22:32:38  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-03-26 22:32:41  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-03-26 22:32:45  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-03-26 22:32:48  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-03-26 22:32:52  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-03-26 22:32:56  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-03-26 22:32:59  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-03-26 22:33:03  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-03-26 22:33:07  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-03-26 22:33:10  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-03-26 22:33:14  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-03-26 22:33:18  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-03-26 22:33:22  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-03-26 22:33:26  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-03-26 22:33:30  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-03-26 22:33:33  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-03-26 22:33:37  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-03-26 22:33:41  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-03-26 22:33:44  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
<pre>2017-03-26_22-33-46 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_22-35-47 Restart Xvfb...
2017-03-26 22:35:49  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-03-26 22:35:53  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-03-26 22:35:57  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-03-26 22:36:00  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-03-26 22:36:04  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-03-26 22:36:08  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-03-26 22:36:11  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-03-26 22:36:15  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-03-26 22:36:18  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-03-26 22:36:22  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-03-26 22:36:26  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-03-26 22:36:29  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-03-26 22:36:33  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-03-26 22:36:37  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-03-26 22:36:40  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-03-26 22:36:44  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-03-26 22:36:48  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-03-26 22:36:51  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-03-26 22:36:55  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-03-26 22:36:58  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-03-26 22:37:02  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-03-26 22:37:06  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-03-26 22:37:10  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-03-26 22:37:13  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-03-26 22:37:17  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-03-26 22:37:21  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-03-26 22:37:24  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-03-26 22:37:28  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-03-26 22:37:33  - 23147  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-03-26 22:37:37  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-03-26 22:37:41  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-03-26 22:37:46  - 23147  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-03-26 22:37:46  - 23147  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
<pre>2017-03-26_22-37-47 Restart Xvfb...
2017-03-26 22:37:51  - 23147  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-03-26 22:37:55  - 23147  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-03-26 22:38:00  - 23147  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-03-26 22:38:04  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-03-26 22:38:09  - 23147  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-03-26 22:38:14  - 23147  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-03-26 22:38:18  - 23147  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-03-26 22:38:22  - 23147  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-03-26 22:38:27  - 23147  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-03-26 22:38:31  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-03-26 22:38:35  - 23147  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-03-26 22:38:40  - 23147  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-03-26 22:38:44  - 23147  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-03-26 22:38:49  - 23147  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-03-26 22:38:53  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-03-26 22:38:58  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-03-26 22:39:02  - 23147  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-03-26 22:39:06  - 23147  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-03-26 22:39:11  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-03-26 22:39:15  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-03-26 22:39:20  - 23147  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-26 22:39:24  - 23147  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-03-26 22:39:29  - 23147  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-03-26 22:39:33  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-03-26 22:39:38  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-03-26 22:39:42  - 23147  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-03-26 22:39:46  - 23147  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
<pre>2017-03-26_22-39-47 Restart Xvfb...
2017-03-26 22:39:51  - 23147  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-03-26 22:39:55  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-03-26 22:40:00  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-03-26 22:40:04  - 23147  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-26 22:40:09  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-03-26 22:40:13  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-03-26 22:40:17  - 23147  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-03-26 22:40:22  - 23147  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-03-26 22:40:26  - 23147  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-03-26 22:40:31  - 23147  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-03-26 22:40:35  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-03-26 22:40:40  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-03-26 22:40:44  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-03-26 22:40:48  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-03-26 22:40:53  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-03-26 22:40:57  - 23147  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-03-26 22:41:02  - 23147  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-03-26 22:41:06  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-03-26 22:41:11  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-03-26 22:41:15  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-03-26 22:41:19  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-03-26 22:41:24  - 23147  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-03-26 22:41:28  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-03-26 22:41:33  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-03-26 22:41:37  - 23147  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-03-26 22:41:42  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-03-26 22:41:46  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
<pre>2017-03-26_22-41-47 Restart Xvfb...
2017-03-26 22:41:51  - 23147  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-03-26 22:41:56  - 23147  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-03-26 22:42:00  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-03-26 22:42:04  - 23147  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-03-26 22:42:09  - 23147  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-03-26 22:42:13  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-03-26 22:42:17  - 23147  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-03-26 22:42:22  - 23147  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-03-26 22:42:26  - 23147  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-03-26 22:42:31  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-03-26 22:42:35  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-03-26 22:42:39  - 23147  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-03-26 22:42:44  - 23147  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-03-26 22:42:48  - 23147  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-03-26 22:42:53  - 23147  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-03-26 22:42:57  - 23147  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-03-26 22:43:01  - 23147  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-03-26 22:43:06  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-03-26 22:43:10  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-03-26 22:43:15  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-03-26 22:43:19  - 23147  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-03-26 22:43:23  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-03-26 22:43:28  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-03-26 22:43:32  - 23147  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-03-26 22:43:37  - 23147  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-03-26 22:43:41  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-03-26 22:43:46  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
<pre>2017-03-26_22-43-47 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_22-45-47 Restart Xvfb...
2017-03-26 22:45:51  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-03-26 22:45:55  - 23147  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-03-26 22:46:00  - 23147  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-03-26 22:46:04  - 23147  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-03-26 22:46:08  - 23147  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-03-26 22:46:12  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-03-26 22:46:17  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-03-26 22:46:21  - 23147  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-03-26 22:46:26  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-03-26 22:46:30  - 23147  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-03-26 22:46:35  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-03-26 22:46:39  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-03-26 22:46:44  - 23147  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-03-26 22:46:48  - 23147  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-03-26 22:46:53  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-03-26 22:46:57  - 23147  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-03-26 22:47:01  - 23147  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-03-26 22:47:06  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-03-26 22:47:10  - 23147  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-03-26 22:47:14  - 23147  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-03-26 22:47:19  - 23147  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-03-26 22:47:23  - 23147  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-03-26 22:47:28  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-03-26 22:47:32  - 23147  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-03-26 22:47:37  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-03-26 22:47:41  - 23147  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-03-26 22:47:46  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
<pre>2017-03-26_22-47-47 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_22-49-47 Restart Xvfb...
2017-03-26 22:49:51  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-03-26 22:49:55  - 23147  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-03-26 22:50:00  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-03-26 22:50:04  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-03-26 22:50:09  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-03-26 22:50:14  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-03-26 22:50:18  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-03-26 22:50:22  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-03-26 22:50:27  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-03-26 22:50:31  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-03-26 22:50:36  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-03-26 22:50:40  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-03-26 22:50:45  - 23147  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-03-26 22:50:49  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-03-26 22:50:53  - 23147  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-03-26 22:50:57  - 23147  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-03-26 22:51:02  - 23147  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-03-26 22:51:06  - 23147  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-03-26 22:51:11  - 23147  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-03-26 22:51:15  - 23147  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-03-26 22:51:20  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-03-26 22:51:24  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-03-26 22:51:28  - 23147  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-03-26 22:51:33  - 23147  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-03-26 22:51:37  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-03-26 22:51:42  - 23147  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-03-26 22:51:46  - 23147  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
<pre>2017-03-26_22-51-47 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_22-53-47 Restart Xvfb...
2017-03-26 22:53:51  - 23147  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-03-26 22:53:56  - 23147  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-03-26 22:54:01  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-03-26 22:54:05  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-03-26 22:54:10  - 23147  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-03-26 22:54:14  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-03-26 22:54:18  - 23147  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-03-26 22:54:23  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-03-26 22:54:27  - 23147  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-03-26 22:54:32  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-03-26 22:54:36  - 23147  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-03-26 22:54:40  - 23147  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-03-26 22:54:44  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-03-26 22:54:49  - 23147  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-03-26 22:54:52  - 23147  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-03-26 22:54:57  - 23147  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-03-26 22:55:01  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-03-26 22:55:06  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-03-26 22:55:10  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-03-26 22:55:14  - 23147  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-03-26 22:55:18  - 23147  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-03-26 22:55:23  - 23147  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-03-26 22:55:27  - 23147  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-03-26 22:55:31  - 23147  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-03-26 22:55:35  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-03-26 22:55:40  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-03-26 22:55:44  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
<pre>2017-03-26_22-55-47 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_22-57-47 Restart Xvfb...
2017-03-26 22:57:50  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-03-26 22:57:53  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-03-26 22:57:58  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-03-26 22:58:02  - 23147  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-03-26 22:58:07  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-03-26 22:58:11  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-03-26 22:58:16  - 23147  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-03-26 22:58:20  - 23147  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-03-26 22:58:24  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-03-26 22:58:28  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-03-26 22:58:32  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-03-26 22:58:37  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-03-26 22:58:41  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-03-26 22:58:46  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-03-26 22:58:50  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-03-26 22:58:54  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-03-26 22:58:58  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-03-26 22:59:03  - 23147  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-03-26 22:59:07  - 23147  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-03-26 22:59:11  - 23147  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-03-26 22:59:15  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-03-26 22:59:20  - 23147  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-03-26 22:59:24  - 23147  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-03-26 22:59:28  - 23147  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-03-26 22:59:33  - 23147  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-03-26 22:59:37  - 23147  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-03-26 22:59:41  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-03-26 22:59:46  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
<pre>2017-03-26_22-59-47 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_23-01-47 Restart Xvfb...
2017-03-26 23:01:51  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-03-26 23:01:55  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-03-26 23:02:00  - 23147  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-03-26 23:02:04  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-03-26 23:02:09  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-03-26 23:02:13  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-03-26 23:02:17  - 23147  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-03-26 23:02:22  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-03-26 23:02:26  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-03-26 23:02:30  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-03-26 23:02:34  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-03-26 23:02:39  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-03-26 23:02:43  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-03-26 23:02:47  - 23147  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-03-26 23:02:51  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-03-26 23:02:56  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-03-26 23:03:00  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-03-26 23:03:04  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-03-26 23:03:08  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-03-26 23:03:13  - 23147  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-03-26 23:03:17  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-03-26 23:03:21  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-03-26 23:03:25  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-03-26 23:03:29  - 23147  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-03-26 23:03:34  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-03-26 23:03:38  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-03-26 23:03:43  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
<pre>2017-03-26_23-03-47 Restart Xvfb...
2017-03-26 23:03:47  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-03-26 23:03:51  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-03-26 23:03:55  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-03-26 23:03:59  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-03-26 23:04:03  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-03-26 23:04:07  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-03-26 23:04:11  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-03-26 23:04:16  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-03-26 23:04:20  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-03-26 23:04:23  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-03-26 23:04:27  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-03-26 23:04:31  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-03-26 23:04:35  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-03-26 23:04:39  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-03-26 23:04:43  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-03-26 23:04:48  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-03-26 23:04:51  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-03-26 23:04:55  - 23147  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-03-26 23:04:59  - 23147  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-03-26 23:05:03  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-03-26 23:05:08  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-03-26 23:05:12  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-03-26 23:05:16  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-03-26 23:05:21  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-03-26 23:05:25  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-03-26 23:05:30  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-03-26 23:05:34  - 23147  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-03-26 23:05:38  - 23147  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-03-26 23:05:42  - 23147  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-03-26 23:05:46  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
<pre>2017-03-26_23-05-47 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_23-07-47 Restart Xvfb...
2017-03-26 23:07:51  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-03-26 23:07:55  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-03-26 23:07:59  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-03-26 23:08:03  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-03-26 23:08:08  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-03-26 23:08:12  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-26 23:08:16  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-26 23:08:20  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-26 23:08:23  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-26 23:08:28  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-03-26 23:08:32  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-26 23:08:35  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-26 23:08:39  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-03-26 23:08:43  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-03-26 23:08:47  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-03-26 23:08:51  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-03-26 23:08:55  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-03-26 23:08:59  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-03-26 23:09:04  - 23147  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-03-26 23:09:08  - 23147  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-03-26 23:09:12  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-03-26 23:09:16  - 23147  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-03-26 23:09:20  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-03-26 23:09:24  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-03-26 23:09:28  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-03-26 23:09:32  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-03-26 23:09:36  - 23147  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-03-26 23:09:40  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-03-26 23:09:44  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
<pre>2017-03-26_23-09-47 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-?_prerender {"code":"ECONNRESET"}
<pre>2017-03-26_23-11-47 Restart Xvfb...
2017-03-26 23:11:49  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-03-26 23:11:53  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-03-26 23:11:57  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-03-26 23:12:02  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-03-26 23:12:06  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-26 23:12:10  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-26 23:12:14  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-26 23:12:18  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-26 23:12:22  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-26 23:12:25  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-03-26 23:12:29  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-26 23:12:33  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-26 23:12:37  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-26 23:12:41  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-26 23:12:45  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-03-26 23:12:49  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-26 23:12:53  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-26 23:12:57  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-26 23:13:01  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-03-26 23:13:05  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
<pre>2017-03-26_23-13-47 Restart Xvfb...
<pre>2017-03-26_23-15-47 Restart Xvfb...
<pre>2017-03-26_23-17-47 Restart Xvfb...
<pre>2017-03-26_23-19-47 Restart Xvfb...
<pre>2017-03-26_23-21-47 Restart Xvfb...
<pre>2017-03-26_23-23-47 Restart Xvfb...
<pre>2017-03-26_23-25-47 Restart Xvfb...
<pre>2017-03-26_23-27-47 Restart Xvfb...
<pre>2017-03-26_23-29-47 Restart Xvfb...
<pre>2017-03-26_23-31-47 Restart Xvfb...
<pre>2017-03-26_23-33-47 Restart Xvfb...
<pre>2017-03-26_23-35-47 Restart Xvfb...
<pre>2017-03-26_23-37-47 Restart Xvfb...
<pre>2017-03-26_23-39-47 Restart Xvfb...
<pre>2017-03-26_23-41-47 Restart Xvfb...
<pre>2017-03-26_23-43-47 Restart Xvfb...
<pre>2017-03-26_23-45-47 Restart Xvfb...
<pre>2017-03-26_23-47-47 Restart Xvfb...
<pre>2017-03-26_23-49-47 Restart Xvfb...
<pre>2017-03-26_23-51-47 Restart Xvfb...
<pre>2017-03-26_23-53-47 Restart Xvfb...
<pre>2017-03-26_23-55-47 Restart Xvfb...
<pre>2017-03-26_23-57-47 Restart Xvfb...
<pre>2017-03-26_23-59-47 Restart Xvfb...
<pre>2017-03-27_00-01-47 Restart Xvfb...
<pre>2017-03-27_00-03-47 Restart Xvfb...
<pre>2017-03-27_00-05-47 Restart Xvfb...
<pre>2017-03-27_00-07-47 Restart Xvfb...
<pre>2017-03-27_00-09-47 Restart Xvfb...
<pre>2017-03-27_00-11-47 Restart Xvfb...
<pre>2017-03-27_00-13-47 Restart Xvfb...
<pre>2017-03-27_00-15-48 Restart Xvfb...
<pre>2017-03-27_00-17-48 Restart Xvfb...
<pre>2017-03-27_00-19-48 Restart Xvfb...
<pre>2017-03-27_00-21-48 Restart Xvfb...
<pre>2017-03-27_00-23-48 Restart Xvfb...
<pre>2017-03-27_00-25-48 Restart Xvfb...
<pre>2017-03-27_00-27-48 Restart Xvfb...
<pre>2017-03-27_00-29-48 Restart Xvfb...
<pre>2017-03-27_00-31-48 Restart Xvfb...
<pre>2017-03-27_00-33-48 Restart Xvfb...
<pre>2017-03-27_00-35-48 Restart Xvfb...
<pre>2017-03-27_00-37-48 Restart Xvfb...
<pre>2017-03-27_00-39-48 Restart Xvfb...
<pre>2017-03-27_00-41-48 Restart Xvfb...
<pre>2017-03-27_00-43-48 Restart Xvfb...
<pre>2017-03-27_00-45-48 Restart Xvfb...
<pre>2017-03-27_00-47-48 Restart Xvfb...
<pre>2017-03-27_00-49-48 Restart Xvfb...
<pre>2017-03-27_00-51-48 Restart Xvfb...
<pre>2017-03-27_00-53-48 Restart Xvfb...
<pre>2017-03-27_00-55-48 Restart Xvfb...
2017-03-27 00:56:59 reset updateRequest
2017-03-27 00:57:02  - 23147  http://www.lymphomahub.com/
2017-03-27 00:57:04  - 23147  http://www.lymphomahub.com/
2017-03-27 00:57:06  - 23147  http://www.lymphomahub.com/about
2017-03-27 00:57:08  - 23147  http://www.lymphomahub.com/about
2017-03-27 00:57:13  - 23147  http://www.lymphomahub.com/terms
2017-03-27 00:57:16  - 23147  http://www.lymphomahub.com/undefined
2017-03-27 00:57:17  - 23147  http://www.lymphomahub.com/therapies
2017-03-27 00:57:22  - 23147  http://www.lymphomahub.com/newsletter
2017-03-27 00:57:25  - 23147  http://www.lymphomahub.com/cookie-policy
2017-03-27 00:57:28  - 23147  http://www.lymphomahub.com/therapies/afm13
2017-03-27 00:57:33  - 23147  http://www.lymphomahub.com/therapies/afm11
2017-03-27 00:57:37  - 23147  http://www.lymphomahub.com/therapies/ags67e
2017-03-27 00:57:42  - 23147  http://www.lymphomahub.com/therapies/cc-292
2017-03-27 00:57:46  - 23147  http://www.lymphomahub.com/therapies/cc-223
<pre>2017-03-27_00-57-48 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/cc-223?_prerender {"code":"ECONNRESET"}
<pre>2017-03-27_00-59-48 Restart Xvfb...
2017-03-27 00:59:51  - 23147  http://www.lymphomahub.com/therapies/cc-223
2017-03-27 00:59:56  - 23147  http://www.lymphomahub.com/therapies/sd-101
2017-03-27 01:00:00  - 23147  http://www.lymphomahub.com/therapies/rp6530
2017-03-27 01:00:05  - 23147  http://www.lymphomahub.com/therapies/abt199
2017-03-27 01:00:07  - 23147  http://www.lymphomahub.com/therapies/mor208
2017-03-27 01:00:12  - 23147  http://www.lymphomahub.com/therapies/cc-122
2017-03-27 01:00:16  - 23147  http://www.lymphomahub.com/therapies/at-101
2017-03-27 01:00:21  - 23147  http://www.lymphomahub.com/therapies/bl8040
2017-03-27 01:00:27  - 23147  http://www.lymphomahub.com/therapies/bcl201
2017-03-27 01:00:31  - 23147  http://www.lymphomahub.com/therapies/azd3965
2017-03-27 01:00:36  - 23147  http://www.lymphomahub.com/therapies/imgn529
2017-03-27 01:00:40  - 23147  http://www.lymphomahub.com/therapies/azd2014
2017-03-27 01:00:44  - 23147  http://www.lymphomahub.com/therapies/mt-3724
2017-03-27 01:00:48  - 23147  http://www.lymphomahub.com/therapies/actr087
2017-03-27 01:00:52  - 23147  http://www.lymphomahub.com/therapies/epz6438
2017-03-27 01:00:57  - 23147  http://www.lymphomahub.com/therapies/kte-c19
2017-03-27 01:01:01  - 23147  http://www.lymphomahub.com/about/secretariat
2017-03-27 01:01:05  - 23147  http://www.lymphomahub.com/therapies/alt-803
2017-03-27 01:01:09  - 23147  http://www.lymphomahub.com/therapies/regn1979
2017-03-27 01:01:13  - 23147  http://www.lymphomahub.com/therapies/immu-114
2017-03-27 01:01:18  - 23147  http://www.lymphomahub.com/therapies/incb7839
2017-03-27 01:01:22  - 23147  http://www.lymphomahub.com/therapies/adct-301
2017-03-27 01:01:26  - 23147  http://www.lymphomahub.com/therapies/ixazomib
2017-03-27 01:01:30  - 23147  http://www.lymphomahub.com/therapies/avelumab
2017-03-27 01:01:34  - 23147  http://www.lymphomahub.com/therapies/bi836826
2017-03-27 01:01:39  - 23147  http://www.lymphomahub.com/therapies/medi-570
2017-03-27 01:01:43  - 23147  http://www.lymphomahub.com/therapies/ds-3201b
2017-03-27 01:01:47  - 23147  http://www.lymphomahub.com/therapies/sea-cd40
<pre>2017-03-27_01-01-48 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/sea-cd40?_prerender {"code":"ECONNRESET"}
<pre>2017-03-27_01-03-48 Restart Xvfb...
2017-03-27 01:03:52  - 23147  http://www.lymphomahub.com/therapies/sea-cd40
2017-03-27 01:03:57  - 23147  http://www.lymphomahub.com/therapies/adct-402
2017-03-27 01:04:01  - 23147  http://www.lymphomahub.com/therapies/acy-1215
2017-03-27 01:04:05  - 23147  http://www.lymphomahub.com/therapies/cudc-907
2017-03-27 01:04:09  - 23147  http://www.lymphomahub.com/therapies/tgr-1202
2017-03-27 01:04:14  - 23147  http://www.lymphomahub.com/therapies/axitinib
2017-03-27 01:04:18  - 23147  http://www.lymphomahub.com/therapies/imatinib
2017-03-27 01:04:22  - 23147  http://www.lymphomahub.com/therapies/edo-s101
2017-03-27 01:04:26  - 23147  http://www.lymphomahub.com/therapies/btct4465a
2017-03-27 01:04:31  - 23147  http://www.lymphomahub.com/therapies/alisertib
2017-03-27 01:04:35  - 23147  http://www.lymphomahub.com/therapies/lirilumab
2017-03-27 01:04:39  - 23147  http://www.lymphomahub.com/therapies/ibrutinib
2017-03-27 01:04:40  - 23147  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-03-27 01:04:44  - 23147  http://www.lymphomahub.com/therapies/rituximab
2017-03-27 01:04:48  - 23147  http://www.lymphomahub.com/therapies/veliparib
2017-03-27 01:04:52  - 23147  http://www.lymphomahub.com/therapies/sunitinib
2017-03-27 01:04:57  - 23147  http://www.lymphomahub.com/therapies/nivolumab
2017-03-27 01:04:57  - 23147  http://www.lymphomahub.com/therapies/sirolimus
2017-03-27 01:05:01  - 23147  http://www.lymphomahub.com/medical-information
2017-03-27 01:05:05  - 23147  http://www.lymphomahub.com/therapies/selinexor
2017-03-27 01:05:10  - 23147  http://www.lymphomahub.com/therapies/abc294640
2017-03-27 01:05:14  - 23147  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-03-27 01:05:18  - 23147  http://www.lymphomahub.com/therapies/tenofovir
2017-03-27 01:05:22  - 23147  http://www.lymphomahub.com/therapies/betalutin
2017-03-27 01:05:27  - 23147  http://www.lymphomahub.com/therapies/chidamide
2017-03-27 01:05:31  - 23147  http://www.lymphomahub.com/therapies/duvelisib
2017-03-27 01:05:35  - 23147  http://www.lymphomahub.com/therapies/dasatinib
2017-03-27 01:05:39  - 23147  http://www.lymphomahub.com/therapies/everolimus
2017-03-27 01:05:44  - 23147  http://www.lymphomahub.com/therapies/incb039110
2017-03-27 01:05:48  - 23147  http://www.lymphomahub.com/therapies/durvalumab
<pre>2017-03-27_01-05-48 Restart Xvfb...
2017-03-27 01:05:52  - 23147  http://www.lymphomahub.com/therapies/romidepsin
2017-03-27 01:05:57  - 23147  http://www.lymphomahub.com/therapies/bortezomib
2017-03-27 01:06:01  - 23147  http://www.lymphomahub.com/therapies/idelalisib
2017-03-27 01:06:02  - 23147  http://www.lymphomahub.com/therapies/tipifarnib
2017-03-27 01:06:06  - 23147  http://www.lymphomahub.com/therapies/ipilimumab
2017-03-27 01:06:11  - 23147  http://www.lymphomahub.com/therapies/crizotinib
2017-03-27 01:06:15  - 23147  http://www.lymphomahub.com/therapies/gsk2816126
2017-03-27 01:06:19  - 23147  http://www.lymphomahub.com/therapies/copanlisib
2017-03-27 01:06:23  - 23147  http://www.lymphomahub.com/therapies/buparlisib
2017-03-27 01:06:27  - 23147  http://www.lymphomahub.com/therapies/belinostat
2017-03-27 01:06:32  - 23147  http://www.lymphomahub.com/therapies/vorinostat
2017-03-27 01:06:36  - 23147  http://www.lymphomahub.com/therapies/plerixafor
2017-03-27 01:06:37  - 23147  http://www.lymphomahub.com/therapies/ofatumumab
2017-03-27 01:06:41  - 23147  http://www.lymphomahub.com/therapies/pf-06801591
2017-03-27 01:06:45  - 23147  http://www.lymphomahub.com/therapies/tocilizumab
2017-03-27 01:06:50  - 23147  http://www.lymphomahub.com/therapies/msc2490484a
2017-03-27 01:06:54  - 23147  http://www.lymphomahub.com/therapies/carfilzomib
2017-03-27 01:06:58  - 23147  http://www.lymphomahub.com/therapies/ruxolitinib
2017-03-27 01:07:02  - 23147  http://www.lymphomahub.com/therapies/palbociclib
2017-03-27 01:07:07  - 23147  http://www.lymphomahub.com/therapies/fenretinide
2017-03-27 01:07:11  - 23147  http://www.lymphomahub.com/therapies/daratumumab
2017-03-27 01:07:15  - 23147  http://www.lymphomahub.com/therapies/pf-05082566
2017-03-27 01:07:19  - 23147  http://www.lymphomahub.com/therapies/ramucirumab
2017-03-27 01:07:23  - 23147  http://www.lymphomahub.com/therapies/tositumomab
2017-03-27 01:07:28  - 23147  http://www.lymphomahub.com/therapies/ublituximab
2017-03-27 01:07:32  - 23147  http://www.lymphomahub.com/therapies/epacadostat
2017-03-27 01:07:36  - 23147  http://www.lymphomahub.com/therapies/alemtuzumab
2017-03-27 01:07:37  - 23147  http://www.lymphomahub.com/therapies/otlertuzumab
2017-03-27 01:07:41  - 23147  http://www.lymphomahub.com/therapies/panobinostat
2017-03-27 01:07:45  - 23147  http://www.lymphomahub.com/therapies/mocetinostat
<pre>2017-03-27_01-07-48 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/mocetinostat?_prerender {"code":"ECONNRESET"}
<pre>2017-03-27_01-09-48 Restart Xvfb...
2017-03-27 01:09:50  - 23147  http://www.lymphomahub.com/therapies/mocetinostat
2017-03-27 01:09:54  - 23147  http://www.lymphomahub.com/therapies/atezolizumab
2017-03-27 01:09:58  - 23147  http://www.lymphomahub.com/therapies/temsirolimus
2017-03-27 01:10:03  - 23147  http://www.lymphomahub.com/therapies/lenalidomide
2017-03-27 01:10:08  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab
2017-03-27 01:10:12  - 23147  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-03-27 01:10:16  - 23147  http://www.lymphomahub.com/therapies/blinatumomab
2017-03-27 01:10:20  - 23147  http://www.lymphomahub.com/therapies/jnj-64052781
2017-03-27 01:10:24  - 23147  http://www.lymphomahub.com/therapies/entospletinib
2017-03-27 01:10:29  - 23147  http://www.lymphomahub.com/therapies/pembrolizumab
2017-03-27 01:10:33  - 23147  http://www.lymphomahub.com/therapies/acalabrutinib
2017-03-27 01:10:37  - 23147  http://www.lymphomahub.com/about/innovation-committee
2017-03-27 01:10:41  - 23147  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-03-27 01:10:41  - 23147  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-03-27 01:10:46  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-03-27 01:10:50  - 23147  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-03-27 01:10:54  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-03-27 01:10:58  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-03-27 01:10:59  - 23147  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-03-27 01:11:03  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-03-27 01:11:08  - 23147  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-03-27 01:11:12  - 23147  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-03-27 01:11:16  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board
2017-03-27 01:11:20  - 23147  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-03-27 01:11:24  - 23147  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-03-27 01:11:28  - 23147  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-03-27 01:11:31  - 23147  http://www.lymphomahub.com/about/executive-steering-committee
2017-03-27 01:11:35  - 23147  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-03-27 01:11:39  - 23147  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-03-27 01:11:44  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-03-27 01:11:47  - 23147  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
<pre>2017-03-27_01-11-48 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede?_prerender {"code":"ECONNRESET"}
<pre>2017-03-27_01-13-48 Restart Xvfb...
2017-03-27 01:13:53  - 23147  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-03-27 01:13:58  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-03-27 01:14:02  - 23147  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-03-27 01:14:06  - 23147  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-03-27 01:14:07  - 23147  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-03-27 01:14:10  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-03-27 01:14:15  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-03-27 01:14:19  - 23147  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-03-27 01:14:23  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-03-27 01:14:27  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-03-27 01:14:32  - 23147  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-03-27 01:14:36  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-03-27 01:14:40  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-03-27 01:14:43  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-03-27 01:14:47  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-03-27 01:14:51  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-03-27 01:14:54  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-03-27 01:14:58  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-03-27 01:15:02  - 23147  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-03-27 01:15:06  - 23147  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-03-27 01:15:11  - 23147  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-03-27 01:15:15  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-03-27 01:15:19  - 23147  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-03-27 01:15:23  - 23147  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-03-27 01:15:27  - 23147  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-03-27 01:15:32  - 23147  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-03-27 01:15:36  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-03-27 01:15:40  - 23147  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-03-27 01:15:44  - 23147  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
<pre>2017-03-27_01-15-48 Restart Xvfb...
2017-03-27 01:15:48  - 23147  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
<pre>2017-03-27_01-17-48 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/?_prerender {"code":"ECONNRESET"}
2017-03-27 01:17:54  - 23147  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-03-27 01:17:58  - 23147  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-03-27 01:18:03  - 23147  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-03-27 01:18:08  - 23147  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-03-27 01:18:12  - 23147  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-03-27 01:18:17  - 23147  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-03-27 01:18:21  - 23147  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-03-27 01:18:25  - 23147  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-03-27 01:18:30  - 23147  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-03-27 01:18:34  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-03-27 01:18:37  - 23147  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-03-27 01:18:42  - 23147  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-03-27 01:18:46  - 23147  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-03-27 01:18:51  - 23147  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-03-27 01:18:55  - 23147  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-03-27 01:18:59  - 23147  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-03-27 01:19:03  - 23147  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-03-27 01:19:08  - 23147  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-03-27 01:19:12  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-03-27 01:19:16  - 23147  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-03-27 01:19:20  - 23147  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-03-27 01:19:25  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-03-27 01:19:29  - 23147  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-03-27 01:19:33  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-03-27 01:19:37  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-03-27 01:19:40  - 23147  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-03-27 01:19:45  - 23147  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
<pre>2017-03-27_01-19-48 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/fl-international-prognostic-index?_prerender {"code":"ECONNRESET"}
<pre>2017-03-27_01-21-48 Restart Xvfb...
2017-03-27 01:21:50  - 23147  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-03-27 01:21:54  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-03-27 01:21:58  - 23147  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-03-27 01:22:02  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-03-27 01:22:06  - 23147  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-03-27 01:22:10  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-03-27 01:22:14  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-03-27 01:22:19  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-03-27 01:22:22  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-03-27 01:22:26  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-03-27 01:22:30  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-03-27 01:22:34  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-03-27 01:22:37  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-03-27 01:22:42  - 23147  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-03-27 01:22:46  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-03-27 01:22:51  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-03-27 01:22:55  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-03-27 01:23:00  - 23147  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-27 01:23:00  - 23147  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-03-27 01:23:05  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-03-27 01:23:09  - 23147  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-03-27 01:23:14  - 23147  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-03-27 01:23:18  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-03-27 01:23:22  - 23147  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-03-27 01:23:27  - 23147  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-03-27 01:23:31  - 23147  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-03-27 01:23:35  - 23147  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-03-27 01:23:40  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-03-27 01:23:44  - 23147  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
<pre>2017-03-27_01-23-48 Restart Xvfb...
2017-03-27 01:23:48  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-03-27 01:23:53  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-03-27 01:23:57  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-03-27 01:24:02  - 23147  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-03-27 01:24:06  - 23147  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-03-27 01:24:11  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-03-27 01:24:15  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-03-27 01:24:20  - 23147  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-03-27 01:24:24  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-03-27 01:24:28  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-03-27 01:24:33  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-03-27 01:24:37  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-03-27 01:24:42  - 23147  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-27 01:24:46  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-03-27 01:24:50  - 23147  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-03-27 01:24:55  - 23147  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-03-27 01:24:59  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-03-27 01:25:04  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-03-27 01:25:09  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-03-27 01:25:13  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-03-27 01:25:17  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-03-27 01:25:22  - 23147  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-03-27 01:25:26  - 23147  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-03-27 01:25:31  - 23147  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-03-27 01:25:35  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-03-27 01:25:40  - 23147  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-03-27 01:25:44  - 23147  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
<pre>2017-03-27_01-25-48 Restart Xvfb...
2017-03-27 01:25:49  - 23147  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-03-27 01:25:49  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-03-27 01:25:53  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-03-27 01:25:58  - 23147  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-03-27 01:26:03  - 23147  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-03-27 01:26:07  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-03-27 01:26:11  - 23147  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-03-27 01:26:16  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-03-27 01:26:20  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-03-27 01:26:25  - 23147  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-03-27 01:26:29  - 23147  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-03-27 01:26:34  - 23147  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-03-27 01:26:38  - 23147  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-03-27 01:26:42  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-03-27 01:26:47  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-03-27 01:26:52  - 23147  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-03-27 01:26:56  - 23147  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-03-27 01:27:00  - 23147  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-03-27 01:27:05  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-03-27 01:27:09  - 23147  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-03-27 01:27:14  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-03-27 01:27:18  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-03-27 01:27:22  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-03-27 01:27:28  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-03-27 01:27:32  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-03-27 01:27:36  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-03-27 01:27:39  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-03-27 01:27:43  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-03-27 01:27:47  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
<pre>2017-03-27_01-27-48 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma?_prerender {"code":"ECONNRESET"}
<pre>2017-03-27_01-29-48 Restart Xvfb...
2017-03-27 01:29:52  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-03-27 01:29:57  - 23147  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-03-27 01:29:57  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-03-27 01:30:02  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-03-27 01:30:07  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-03-27 01:30:10  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-03-27 01:30:14  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-03-27 01:30:18  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-03-27 01:30:22  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-03-27 01:30:25  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-03-27 01:30:29  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-03-27 01:30:33  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-03-27 01:30:36  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-03-27 01:30:40  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-03-27 01:30:43  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-03-27 01:30:47  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-03-27 01:30:51  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-03-27 01:30:55  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-03-27 01:31:00  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-03-27 01:31:04  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-03-27 01:31:07  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-03-27 01:31:11  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-03-27 01:31:15  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-03-27 01:31:18  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-03-27 01:31:22  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-03-27 01:31:26  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-03-27 01:31:29  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-03-27 01:31:33  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-03-27 01:31:36  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-03-27 01:31:40  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-03-27 01:31:44  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-03-27 01:31:47  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
<pre>2017-03-27_01-31-48 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/?_prerender {"code":"ECONNRESET"}
<pre>2017-03-27_01-33-48 Restart Xvfb...
2017-03-27 01:33:52  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-03-27 01:33:56  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-03-27 01:34:00  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-03-27 01:34:04  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-03-27 01:34:07  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-03-27 01:34:11  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-03-27 01:34:14  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-03-27 01:34:18  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-03-27 01:34:22  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-03-27 01:34:25  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-03-27 01:34:29  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-03-27 01:34:32  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-03-27 01:34:36  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-03-27 01:34:39  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-03-27 01:34:43  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-03-27 01:34:47  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-03-27 01:34:50  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-03-27 01:34:54  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-03-27 01:34:58  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-03-27 01:35:01  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-03-27 01:35:05  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-03-27 01:35:10  - 23147  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-03-27 01:35:14  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-03-27 01:35:19  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-03-27 01:35:23  - 23147  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-03-27 01:35:24  - 23147  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-03-27 01:35:28  - 23147  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-03-27 01:35:33  - 23147  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-03-27 01:35:37  - 23147  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-03-27 01:35:41  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-03-27 01:35:46  - 23147  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
<pre>2017-03-27_01-35-48 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl?_prerender {"code":"ECONNRESET"}
<pre>2017-03-27_01-37-48 Restart Xvfb...
2017-03-27 01:37:51  - 23147  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-03-27 01:37:55  - 23147  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-03-27 01:38:00  - 23147  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-03-27 01:38:04  - 23147  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-03-27 01:38:08  - 23147  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-03-27 01:38:13  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-03-27 01:38:17  - 23147  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-03-27 01:38:22  - 23147  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-03-27 01:38:26  - 23147  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-03-27 01:38:30  - 23147  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-03-27 01:38:35  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-03-27 01:38:39  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-03-27 01:38:44  - 23147  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-03-27 01:38:48  - 23147  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-03-27 01:38:52  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-03-27 01:38:57  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-03-27 01:39:01  - 23147  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-27 01:39:06  - 23147  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-03-27 01:39:10  - 23147  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-03-27 01:39:14  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-03-27 01:39:19  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-03-27 01:39:23  - 23147  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-03-27 01:39:27  - 23147  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-03-27 01:39:32  - 23147  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-03-27 01:39:36  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-03-27 01:39:40  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-03-27 01:39:45  - 23147  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
<pre>2017-03-27_01-39-48 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma?_prerender {"code":"ECONNRESET"}
<pre>2017-03-27_01-41-48 Restart Xvfb...
2017-03-27 01:41:50  - 23147  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-27 01:41:55  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-03-27 01:41:59  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-03-27 01:42:04  - 23147  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-03-27 01:42:08  - 23147  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-03-27 01:42:12  - 23147  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-03-27 01:42:17  - 23147  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-03-27 01:42:21  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-03-27 01:42:25  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-03-27 01:42:30  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-03-27 01:42:34  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-03-27 01:42:39  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-03-27 01:42:43  - 23147  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-03-27 01:42:47  - 23147  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-03-27 01:42:51  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-03-27 01:42:56  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-03-27 01:43:00  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-03-27 01:43:04  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-03-27 01:43:09  - 23147  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-03-27 01:43:13  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-03-27 01:43:18  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-03-27 01:43:22  - 23147  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-03-27 01:43:27  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-03-27 01:43:31  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-03-27 01:43:36  - 23147  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-03-27 01:43:40  - 23147  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-03-27 01:43:44  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
<pre>2017-03-27_01-43-48 Restart Xvfb...
2017-03-27 01:43:49  - 23147  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-03-27 01:43:53  - 23147  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-03-27 01:43:57  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-03-27 01:44:02  - 23147  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-03-27 01:44:07  - 23147  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-03-27 01:44:11  - 23147  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-03-27 01:44:15  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-03-27 01:44:20  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-03-27 01:44:24  - 23147  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-03-27 01:44:29  - 23147  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-03-27 01:44:33  - 23147  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-03-27 01:44:38  - 23147  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-03-27 01:44:42  - 23147  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-03-27 01:44:47  - 23147  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-03-27 01:44:51  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-03-27 01:44:56  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-03-27 01:45:00  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-03-27 01:45:05  - 23147  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-03-27 01:45:09  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-03-27 01:45:14  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-03-27 01:45:18  - 23147  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-03-27 01:45:22  - 23147  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-03-27 01:45:26  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-03-27 01:45:31  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-03-27 01:45:35  - 23147  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-03-27 01:45:40  - 23147  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-03-27 01:45:44  - 23147  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-03-27 01:45:48  - 23147  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
<pre>2017-03-27_01-45-48 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct?_prerender {"code":"ECONNRESET"}
<pre>2017-03-27_01-47-48 Restart Xvfb...
2017-03-27 01:47:53  - 23147  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-03-27 01:47:57  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-03-27 01:48:02  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-03-27 01:48:06  - 23147  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-03-27 01:48:11  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-03-27 01:48:15  - 23147  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-03-27 01:48:20  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-03-27 01:48:24  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-03-27 01:48:29  - 23147  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-03-27 01:48:33  - 23147  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-03-27 01:48:38  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-03-27 01:48:42  - 23147  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-03-27 01:48:46  - 23147  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-03-27 01:48:51  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-03-27 01:48:55  - 23147  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-03-27 01:48:59  - 23147  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-03-27 01:49:04  - 23147  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-03-27 01:49:08  - 23147  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-03-27 01:49:13  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-03-27 01:49:17  - 23147  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-03-27 01:49:21  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-03-27 01:49:26  - 23147  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-03-27 01:49:30  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-03-27 01:49:34  - 23147  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-03-27 01:49:39  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-03-27 01:49:43  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-03-27 01:49:48  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
<pre>2017-03-27_01-49-49 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145?_prerender {"code":"ECONNRESET"}
<pre>2017-03-27_01-51-49 Restart Xvfb...
2017-03-27 01:51:53  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-03-27 01:51:58  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-03-27 01:52:02  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-03-27 01:52:07  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-03-27 01:52:12  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-03-27 01:52:16  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-03-27 01:52:20  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-03-27 01:52:25  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-03-27 01:52:29  - 23147  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-03-27 01:52:34  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-03-27 01:52:38  - 23147  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-03-27 01:52:42  - 23147  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-03-27 01:52:47  - 23147  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-03-27 01:52:51  - 23147  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-03-27 01:52:55  - 23147  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-03-27 01:53:00  - 23147  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-03-27 01:53:04  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-03-27 01:53:09  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-03-27 01:53:13  - 23147  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-03-27 01:53:17  - 23147  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-03-27 01:53:22  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-03-27 01:53:27  - 23147  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-03-27 01:53:31  - 23147  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-03-27 01:53:35  - 23147  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-03-27 01:53:40  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-03-27 01:53:44  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
<pre>2017-03-27_01-53-49 Restart Xvfb...
2017-03-27 01:53:49  - 23147  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-03-27 01:53:53  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-03-27 01:53:58  - 23147  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-03-27 01:54:02  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-03-27 01:54:07  - 23147  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-03-27 01:54:11  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-03-27 01:54:15  - 23147  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-03-27 01:54:20  - 23147  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-03-27 01:54:24  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-03-27 01:54:28  - 23147  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-03-27 01:54:32  - 23147  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-03-27 01:54:36  - 23147  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-03-27 01:54:41  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-03-27 01:54:45  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-03-27 01:54:49  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-03-27 01:54:54  - 23147  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-03-27 01:54:58  - 23147  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-03-27 01:55:02  - 23147  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-03-27 01:55:07  - 23147  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-03-27 01:55:11  - 23147  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-03-27 01:55:15  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-03-27 01:55:19  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-03-27 01:55:24  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-03-27 01:55:27  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-03-27 01:55:32  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-03-27 01:55:36  - 23147  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-03-27 01:55:40  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-03-27 01:55:45  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
<pre>2017-03-27_01-55-49 Restart Xvfb...
2017-03-27 01:55:49  - 23147  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-03-27 01:55:54  - 23147  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-03-27 01:55:57  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-03-27 01:56:01  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-03-27 01:56:06  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-03-27 01:56:10  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-03-27 01:56:15  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-03-27 01:56:19  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-03-27 01:56:23  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-03-27 01:56:28  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-03-27 01:56:32  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-03-27 01:56:36  - 23147  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-03-27 01:56:41  - 23147  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-03-27 01:56:45  - 23147  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-03-27 01:56:49  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-03-27 01:56:53  - 23147  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-03-27 01:56:57  - 23147  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-03-27 01:57:02  - 23147  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-03-27 01:57:07  - 23147  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-03-27 01:57:11  - 23147  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-03-27 01:57:16  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-03-27 01:57:20  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-03-27 01:57:24  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-03-27 01:57:28  - 23147  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-03-27 01:57:33  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-03-27 01:57:37  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-03-27 01:57:42  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-03-27 01:57:46  - 23147  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
<pre>2017-03-27_01-57-49 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl?_prerender {"code":"ECONNRESET"}
<pre>2017-03-27_01-59-49 Restart Xvfb...
2017-03-27 01:59:51  - 23147  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-03-27 01:59:55  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-03-27 01:59:59  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-03-27 02:00:04  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-03-27 02:00:08  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-03-27 02:00:13  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-03-27 02:00:23  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-03-27 02:00:28  - 23147  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-03-27 02:00:33  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-03-27 02:00:38  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-03-27 02:00:42  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-03-27 02:00:46  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-03-27 02:00:51  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-03-27 02:00:56  - 23147  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-03-27 02:01:00  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-03-27 02:01:04  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-03-27 02:01:09  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-03-27 02:01:13  - 23147  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-03-27 02:01:17  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-03-27 02:01:22  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-03-27 02:01:26  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-03-27 02:01:31  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-03-27 02:01:35  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-03-27 02:01:39  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-03-27 02:01:43  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-03-27 02:01:47  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
<pre>2017-03-27_02-01-49 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-?_prerender {"code":"ECONNRESET"}
<pre>2017-03-27_02-03-49 Restart Xvfb...
2017-03-27 02:03:52  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-03-27 02:03:56  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-03-27 02:04:01  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-03-27 02:04:05  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-03-27 02:04:09  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-03-27 02:04:13  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-03-27 02:04:17  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-03-27 02:04:21  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-03-27 02:04:25  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-03-27 02:04:29  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-03-27 02:04:33  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-03-27 02:04:38  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-03-27 02:04:42  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-03-27 02:04:46  - 23147  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-03-27 02:04:50  - 23147  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-03-27 02:04:54  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-03-27 02:04:58  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-03-27 02:05:02  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-03-27 02:05:07  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-03-27 02:05:11  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-03-27 02:05:16  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-03-27 02:05:20  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-03-27 02:05:24  - 23147  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-03-27 02:05:28  - 23147  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-03-27 02:05:32  - 23147  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-03-27 02:05:36  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-03-27 02:05:41  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-03-27 02:05:44  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-03-27 02:05:49  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
<pre>2017-03-27_02-05-49 Restart Xvfb...
2017-03-27 02:05:53  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-03-27 02:05:57  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-27 02:06:01  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-27 02:06:06  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-27 02:06:09  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-27 02:06:13  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-03-27 02:06:17  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-27 02:06:21  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-27 02:06:25  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-03-27 02:06:29  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-03-27 02:06:33  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-03-27 02:06:37  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-03-27 02:06:41  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-03-27 02:06:46  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-03-27 02:06:50  - 23147  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-03-27 02:06:54  - 23147  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-03-27 02:06:58  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-03-27 02:07:02  - 23147  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-03-27 02:07:06  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-03-27 02:07:10  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-03-27 02:07:14  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-03-27 02:07:18  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-03-27 02:07:22  - 23147  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-03-27 02:07:26  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-03-27 02:07:30  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-03-27 02:07:34  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-03-27 02:07:38  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-03-27 02:07:42  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-03-27 02:07:46  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
<pre>2017-03-27_02-07-49 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-?_prerender {"code":"ECONNRESET"}
<pre>2017-03-27_02-09-49 Restart Xvfb...
2017-03-27 02:09:51  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-27 02:09:55  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-27 02:09:59  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-27 02:10:03  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-27 02:10:07  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-27 02:10:12  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-03-27 02:10:16  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-27 02:10:20  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-27 02:10:24  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-27 02:10:28  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-27 02:10:32  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-03-27 02:10:36  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-27 02:10:40  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-27 02:10:44  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-27 02:10:48  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-03-27 02:10:52  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
<pre>2017-03-27_02-11-49 Restart Xvfb...
<pre>2017-03-27_02-13-49 Restart Xvfb...
<pre>2017-03-27_02-15-49 Restart Xvfb...
<pre>2017-03-27_02-17-49 Restart Xvfb...
<pre>2017-03-27_02-19-49 Restart Xvfb...
<pre>2017-03-27_02-21-49 Restart Xvfb...
<pre>2017-03-27_02-23-49 Restart Xvfb...
<pre>2017-03-27_02-25-49 Restart Xvfb...
<pre>2017-03-27_02-27-49 Restart Xvfb...
<pre>2017-03-27_02-29-49 Restart Xvfb...
<pre>2017-03-27_02-31-49 Restart Xvfb...
<pre>2017-03-27_02-33-49 Restart Xvfb...
<pre>2017-03-27_02-35-49 Restart Xvfb...
<pre>2017-03-27_02-37-49 Restart Xvfb...
<pre>2017-03-27_02-39-49 Restart Xvfb...
<pre>2017-03-27_02-41-49 Restart Xvfb...
<pre>2017-03-27_02-43-49 Restart Xvfb...
<pre>2017-03-27_02-45-49 Restart Xvfb...
<pre>2017-03-27_02-47-49 Restart Xvfb...
<pre>2017-03-27_02-49-49 Restart Xvfb...
<pre>2017-03-27_02-51-49 Restart Xvfb...
<pre>2017-03-27_02-53-49 Restart Xvfb...
<pre>2017-03-27_02-55-49 Restart Xvfb...
<pre>2017-03-27_02-57-49 Restart Xvfb...
<pre>2017-03-27_02-59-49 Restart Xvfb...
<pre>2017-03-27_03-01-49 Restart Xvfb...
<pre>2017-03-27_03-03-49 Restart Xvfb...
<pre>2017-03-27_03-05-49 Restart Xvfb...
<pre>2017-03-27_03-07-49 Restart Xvfb...
<pre>2017-03-27_03-09-49 Restart Xvfb...
<pre>2017-03-27_03-11-49 Restart Xvfb...
<pre>2017-03-27_03-13-49 Restart Xvfb...
<pre>2017-03-27_03-15-49 Restart Xvfb...
<pre>2017-03-27_03-17-49 Restart Xvfb...
<pre>2017-03-27_03-19-49 Restart Xvfb...
<pre>2017-03-27_03-21-49 Restart Xvfb...
<pre>2017-03-27_03-23-49 Restart Xvfb...
<pre>2017-03-27_03-25-49 Restart Xvfb...
<pre>2017-03-27_03-27-49 Restart Xvfb...
<pre>2017-03-27_03-29-49 Restart Xvfb...
<pre>2017-03-27_03-31-49 Restart Xvfb...
<pre>2017-03-27_03-33-50 Restart Xvfb...
<pre>2017-03-27_03-35-50 Restart Xvfb...
<pre>2017-03-27_03-37-50 Restart Xvfb...
<pre>2017-03-27_03-39-50 Restart Xvfb...
<pre>2017-03-27_03-41-50 Restart Xvfb...
<pre>2017-03-27_03-43-50 Restart Xvfb...
<pre>2017-03-27_03-45-50 Restart Xvfb...
<pre>2017-03-27_03-47-50 Restart Xvfb...
<pre>2017-03-27_03-49-50 Restart Xvfb...
<pre>2017-03-27_03-51-50 Restart Xvfb...
<pre>2017-03-27_03-53-50 Restart Xvfb...
<pre>2017-03-27_03-55-50 Restart Xvfb...
2017-03-27 03:56:59 reset updateRequest
2017-03-27 03:56:59  - 23147  http://www.lymphomahub.com/
2017-03-27 03:57:04  - 23147  http://www.lymphomahub.com/about
2017-03-27 03:57:10  - 23147  http://www.lymphomahub.com/terms
2017-03-27 03:57:13  - 23147  http://www.lymphomahub.com/undefined
2017-03-27 03:57:14  - 23147  http://www.lymphomahub.com/therapies
2017-03-27 03:57:20  - 23147  http://www.lymphomahub.com/newsletter
2017-03-27 03:57:23  - 23147  http://www.lymphomahub.com/cookie-policy
2017-03-27 03:57:26  - 23147  http://www.lymphomahub.com/therapies/afm13
2017-03-27 03:57:30  - 23147  http://www.lymphomahub.com/therapies/afm11
2017-03-27 03:57:35  - 23147  http://www.lymphomahub.com/therapies/ags67e
2017-03-27 03:57:39  - 23147  http://www.lymphomahub.com/therapies/cc-292
2017-03-27 03:57:44  - 23147  http://www.lymphomahub.com/therapies/cc-223
2017-03-27 03:57:48  - 23147  http://www.lymphomahub.com/therapies/sd-101
<pre>2017-03-27_03-57-50 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/sd-101?_prerender {"code":"ECONNRESET"}
<pre>2017-03-27_03-59-50 Restart Xvfb...
2017-03-27 03:59:53  - 23147  http://www.lymphomahub.com/therapies/sd-101
2017-03-27 03:59:58  - 23147  http://www.lymphomahub.com/therapies/rp6530
2017-03-27 04:00:02  - 23147  http://www.lymphomahub.com/therapies/abt199
2017-03-27 04:00:03  - 23147  http://www.lymphomahub.com/therapies/mor208
2017-03-27 04:00:09  - 23147  http://www.lymphomahub.com/therapies/cc-122
2017-03-27 04:00:14  - 23147  http://www.lymphomahub.com/therapies/at-101
2017-03-27 04:00:21  - 23147  http://www.lymphomahub.com/therapies/bl8040
2017-03-27 04:00:25  - 23147  http://www.lymphomahub.com/therapies/bcl201
2017-03-27 04:00:32  - 23147  http://www.lymphomahub.com/therapies/azd3965
2017-03-27 04:00:37  - 23147  http://www.lymphomahub.com/therapies/imgn529
2017-03-27 04:00:42  - 23147  http://www.lymphomahub.com/therapies/azd2014
2017-03-27 04:00:46  - 23147  http://www.lymphomahub.com/therapies/mt-3724
2017-03-27 04:00:50  - 23147  http://www.lymphomahub.com/therapies/actr087
2017-03-27 04:00:55  - 23147  http://www.lymphomahub.com/therapies/epz6438
2017-03-27 04:00:59  - 23147  http://www.lymphomahub.com/therapies/kte-c19
2017-03-27 04:01:04  - 23147  http://www.lymphomahub.com/about/secretariat
2017-03-27 04:01:07  - 23147  http://www.lymphomahub.com/therapies/alt-803
2017-03-27 04:01:12  - 23147  http://www.lymphomahub.com/therapies/regn1979
2017-03-27 04:01:16  - 23147  http://www.lymphomahub.com/therapies/immu-114
2017-03-27 04:01:20  - 23147  http://www.lymphomahub.com/therapies/incb7839
2017-03-27 04:01:24  - 23147  http://www.lymphomahub.com/therapies/adct-301
2017-03-27 04:01:28  - 23147  http://www.lymphomahub.com/therapies/ixazomib
2017-03-27 04:01:33  - 23147  http://www.lymphomahub.com/therapies/avelumab
2017-03-27 04:01:37  - 23147  http://www.lymphomahub.com/therapies/bi836826
2017-03-27 04:01:41  - 23147  http://www.lymphomahub.com/therapies/medi-570
2017-03-27 04:01:46  - 23147  http://www.lymphomahub.com/therapies/ds-3201b
<pre>2017-03-27_04-01-50 Restart Xvfb...
2017-03-27 04:01:50  - 23147  http://www.lymphomahub.com/therapies/sea-cd40
2017-03-27 04:01:54  - 23147  http://www.lymphomahub.com/therapies/adct-402
2017-03-27 04:01:58  - 23147  http://www.lymphomahub.com/therapies/acy-1215
2017-03-27 04:02:03  - 23147  http://www.lymphomahub.com/therapies/cudc-907
2017-03-27 04:02:07  - 23147  http://www.lymphomahub.com/therapies/tgr-1202
2017-03-27 04:02:12  - 23147  http://www.lymphomahub.com/therapies/axitinib
2017-03-27 04:02:16  - 23147  http://www.lymphomahub.com/therapies/imatinib
2017-03-27 04:02:20  - 23147  http://www.lymphomahub.com/therapies/edo-s101
2017-03-27 04:02:25  - 23147  http://www.lymphomahub.com/therapies/btct4465a
2017-03-27 04:02:29  - 23147  http://www.lymphomahub.com/therapies/alisertib
2017-03-27 04:02:33  - 23147  http://www.lymphomahub.com/therapies/lirilumab
2017-03-27 04:02:37  - 23147  http://www.lymphomahub.com/therapies/ibrutinib
2017-03-27 04:02:38  - 23147  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-03-27 04:02:43  - 23147  http://www.lymphomahub.com/therapies/rituximab
2017-03-27 04:02:47  - 23147  http://www.lymphomahub.com/therapies/veliparib
2017-03-27 04:02:52  - 23147  http://www.lymphomahub.com/therapies/sunitinib
2017-03-27 04:02:56  - 23147  http://www.lymphomahub.com/therapies/nivolumab
2017-03-27 04:02:57  - 23147  http://www.lymphomahub.com/therapies/sirolimus
2017-03-27 04:03:01  - 23147  http://www.lymphomahub.com/medical-information
2017-03-27 04:03:05  - 23147  http://www.lymphomahub.com/therapies/selinexor
2017-03-27 04:03:09  - 23147  http://www.lymphomahub.com/therapies/abc294640
2017-03-27 04:03:14  - 23147  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-03-27 04:03:18  - 23147  http://www.lymphomahub.com/therapies/tenofovir
2017-03-27 04:03:22  - 23147  http://www.lymphomahub.com/therapies/betalutin
2017-03-27 04:03:26  - 23147  http://www.lymphomahub.com/therapies/chidamide
2017-03-27 04:03:31  - 23147  http://www.lymphomahub.com/therapies/duvelisib
2017-03-27 04:03:35  - 23147  http://www.lymphomahub.com/therapies/dasatinib
2017-03-27 04:03:40  - 23147  http://www.lymphomahub.com/therapies/everolimus
2017-03-27 04:03:44  - 23147  http://www.lymphomahub.com/therapies/incb039110
2017-03-27 04:03:48  - 23147  http://www.lymphomahub.com/therapies/durvalumab
<pre>2017-03-27_04-03-50 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/durvalumab?_prerender {"code":"ECONNRESET"}
<pre>2017-03-27_04-05-50 Restart Xvfb...
2017-03-27 04:05:54  - 23147  http://www.lymphomahub.com/therapies/durvalumab
2017-03-27 04:05:58  - 23147  http://www.lymphomahub.com/therapies/romidepsin
2017-03-27 04:06:02  - 23147  http://www.lymphomahub.com/therapies/bortezomib
2017-03-27 04:06:07  - 23147  http://www.lymphomahub.com/therapies/idelalisib
2017-03-27 04:06:08  - 23147  http://www.lymphomahub.com/therapies/tipifarnib
2017-03-27 04:06:12  - 23147  http://www.lymphomahub.com/therapies/ipilimumab
2017-03-27 04:06:16  - 23147  http://www.lymphomahub.com/therapies/crizotinib
2017-03-27 04:06:21  - 23147  http://www.lymphomahub.com/therapies/gsk2816126
2017-03-27 04:06:25  - 23147  http://www.lymphomahub.com/therapies/copanlisib
2017-03-27 04:06:30  - 23147  http://www.lymphomahub.com/therapies/buparlisib
2017-03-27 04:06:34  - 23147  http://www.lymphomahub.com/therapies/belinostat
2017-03-27 04:06:39  - 23147  http://www.lymphomahub.com/therapies/vorinostat
2017-03-27 04:06:43  - 23147  http://www.lymphomahub.com/therapies/plerixafor
2017-03-27 04:06:44  - 23147  http://www.lymphomahub.com/therapies/ofatumumab
2017-03-27 04:06:48  - 23147  http://www.lymphomahub.com/therapies/pf-06801591
2017-03-27 04:06:52  - 23147  http://www.lymphomahub.com/therapies/tocilizumab
2017-03-27 04:06:57  - 23147  http://www.lymphomahub.com/therapies/msc2490484a
2017-03-27 04:07:01  - 23147  http://www.lymphomahub.com/therapies/carfilzomib
2017-03-27 04:07:05  - 23147  http://www.lymphomahub.com/therapies/ruxolitinib
2017-03-27 04:07:10  - 23147  http://www.lymphomahub.com/therapies/palbociclib
2017-03-27 04:07:14  - 23147  http://www.lymphomahub.com/therapies/fenretinide
2017-03-27 04:07:19  - 23147  http://www.lymphomahub.com/therapies/daratumumab
2017-03-27 04:07:23  - 23147  http://www.lymphomahub.com/therapies/pf-05082566
2017-03-27 04:07:27  - 23147  http://www.lymphomahub.com/therapies/ramucirumab
2017-03-27 04:07:31  - 23147  http://www.lymphomahub.com/therapies/tositumomab
2017-03-27 04:07:36  - 23147  http://www.lymphomahub.com/therapies/ublituximab
2017-03-27 04:07:40  - 23147  http://www.lymphomahub.com/therapies/epacadostat
2017-03-27 04:07:44  - 23147  http://www.lymphomahub.com/therapies/alemtuzumab
2017-03-27 04:07:45  - 23147  http://www.lymphomahub.com/therapies/otlertuzumab
2017-03-27 04:07:49  - 23147  http://www.lymphomahub.com/therapies/panobinostat
<pre>2017-03-27_04-07-50 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/panobinostat?_prerender {"code":"ECONNRESET"}
<pre>2017-03-27_04-09-50 Restart Xvfb...
2017-03-27 04:09:54  - 23147  http://www.lymphomahub.com/therapies/panobinostat
2017-03-27 04:10:00  - 23147  http://www.lymphomahub.com/therapies/mocetinostat
2017-03-27 04:10:04  - 23147  http://www.lymphomahub.com/therapies/atezolizumab
2017-03-27 04:10:09  - 23147  http://www.lymphomahub.com/therapies/temsirolimus
2017-03-27 04:10:13  - 23147  http://www.lymphomahub.com/therapies/lenalidomide
2017-03-27 04:10:18  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab
2017-03-27 04:10:22  - 23147  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-03-27 04:10:27  - 23147  http://www.lymphomahub.com/therapies/blinatumomab
2017-03-27 04:10:31  - 23147  http://www.lymphomahub.com/therapies/jnj-64052781
2017-03-27 04:10:35  - 23147  http://www.lymphomahub.com/therapies/entospletinib
2017-03-27 04:10:39  - 23147  http://www.lymphomahub.com/therapies/pembrolizumab
2017-03-27 04:10:44  - 23147  http://www.lymphomahub.com/therapies/acalabrutinib
2017-03-27 04:10:48  - 23147  http://www.lymphomahub.com/about/innovation-committee
2017-03-27 04:10:51  - 23147  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-03-27 04:10:52  - 23147  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-03-27 04:10:56  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-03-27 04:11:01  - 23147  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-03-27 04:11:05  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-03-27 04:11:09  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-03-27 04:11:10  - 23147  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-03-27 04:11:14  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-03-27 04:11:19  - 23147  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-03-27 04:11:23  - 23147  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-03-27 04:11:27  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board
2017-03-27 04:11:31  - 23147  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-03-27 04:11:36  - 23147  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-03-27 04:11:39  - 23147  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-03-27 04:11:43  - 23147  http://www.lymphomahub.com/about/executive-steering-committee
2017-03-27 04:11:47  - 23147  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
<pre>2017-03-27_04-11-50 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien?_prerender {"code":"ECONNRESET"}
<pre>2017-03-27_04-13-50 Restart Xvfb...
2017-03-27 04:13:52  - 23147  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-03-27 04:13:58  - 23147  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-03-27 04:14:02  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-03-27 04:14:06  - 23147  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-03-27 04:14:10  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-03-27 04:14:15  - 23147  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-03-27 04:14:18  - 23147  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-03-27 04:14:19  - 23147  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-03-27 04:14:23  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-03-27 04:14:27  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-03-27 04:14:32  - 23147  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-03-27 04:14:36  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-03-27 04:14:41  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-03-27 04:14:45  - 23147  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-03-27 04:14:49  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-03-27 04:14:53  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-03-27 04:14:57  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-03-27 04:15:01  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-03-27 04:15:04  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-03-27 04:15:08  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-03-27 04:15:12  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-03-27 04:15:16  - 23147  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-03-27 04:15:20  - 23147  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-03-27 04:15:25  - 23147  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-03-27 04:15:29  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-03-27 04:15:33  - 23147  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-03-27 04:15:36  - 23147  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-03-27 04:15:41  - 23147  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-03-27 04:15:45  - 23147  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-03-27 04:15:50  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
<pre>2017-03-27_04-15-50 Restart Xvfb...
2017-03-27 04:15:54  - 23147  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-03-27 04:15:58  - 23147  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-03-27 04:16:03  - 23147  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-03-27 04:16:08  - 23147  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-03-27 04:16:12  - 23147  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-03-27 04:16:17  - 23147  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-03-27 04:16:21  - 23147  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-03-27 04:16:25  - 23147  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-03-27 04:16:30  - 23147  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-03-27 04:16:34  - 23147  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-03-27 04:16:38  - 23147  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-03-27 04:16:43  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-03-27 04:16:46  - 23147  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-03-27 04:16:51  - 23147  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-03-27 04:16:55  - 23147  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-03-27 04:17:00  - 23147  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-03-27 04:17:04  - 23147  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-03-27 04:17:09  - 23147  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-03-27 04:17:12  - 23147  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-03-27 04:17:17  - 23147  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-03-27 04:17:21  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-03-27 04:17:25  - 23147  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-03-27 04:17:30  - 23147  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-03-27 04:17:34  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-03-27 04:17:38  - 23147  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-03-27 04:17:42  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-03-27 04:17:46  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-03-27 04:17:50  - 23147  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
<pre>2017-03-27_04-17-50 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker?_prerender {"code":"ECONNRESET"}
<pre>2017-03-27_04-19-50 Restart Xvfb...
2017-03-27 04:19:55  - 23147  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-03-27 04:19:59  - 23147  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-03-27 04:20:04  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-03-27 04:20:07  - 23147  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-03-27 04:20:12  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-03-27 04:20:16  - 23147  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-03-27 04:20:20  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-03-27 04:20:24  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-03-27 04:20:29  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-03-27 04:20:32  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-03-27 04:20:36  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-03-27 04:20:40  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-03-27 04:20:44  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-03-27 04:20:48  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-03-27 04:20:52  - 23147  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-03-27 04:20:57  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-03-27 04:21:01  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-03-27 04:21:06  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-03-27 04:21:10  - 23147  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-27 04:21:11  - 23147  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-03-27 04:21:15  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-03-27 04:21:20  - 23147  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-03-27 04:21:24  - 23147  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-03-27 04:21:29  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-03-27 04:21:33  - 23147  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-03-27 04:21:38  - 23147  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-03-27 04:21:42  - 23147  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-03-27 04:21:46  - 23147  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
<pre>2017-03-27_04-21-50 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools?_prerender {"code":"ECONNRESET"}
<pre>2017-03-27_04-23-50 Restart Xvfb...
2017-03-27 04:23:51  - 23147  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-03-27 04:23:55  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-03-27 04:24:00  - 23147  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-03-27 04:24:05  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-03-27 04:24:09  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-03-27 04:24:14  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-03-27 04:24:18  - 23147  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-03-27 04:24:23  - 23147  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-03-27 04:24:27  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-03-27 04:24:32  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-03-27 04:24:36  - 23147  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-03-27 04:24:41  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-03-27 04:24:45  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-03-27 04:24:50  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-03-27 04:24:55  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-03-27 04:24:59  - 23147  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-27 04:25:04  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-03-27 04:25:08  - 23147  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-03-27 04:25:13  - 23147  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-03-27 04:25:17  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-03-27 04:25:22  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-03-27 04:25:26  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-03-27 04:25:31  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-03-27 04:25:35  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-03-27 04:25:39  - 23147  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-03-27 04:25:44  - 23147  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-03-27 04:25:48  - 23147  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
<pre>2017-03-27_04-25-50 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value?_prerender {"code":"ECONNRESET"}
<pre>2017-03-27_04-27-50 Restart Xvfb...
2017-03-27 04:27:54  - 23147  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-03-27 04:27:58  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-03-27 04:28:03  - 23147  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-03-27 04:28:08  - 23147  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-03-27 04:28:13  - 23147  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-03-27 04:28:13  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-03-27 04:28:18  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-03-27 04:28:22  - 23147  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-03-27 04:28:27  - 23147  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-03-27 04:28:32  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-03-27 04:28:36  - 23147  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-03-27 04:28:41  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-03-27 04:28:45  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-03-27 04:28:50  - 23147  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-03-27 04:28:54  - 23147  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-03-27 04:28:59  - 23147  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-03-27 04:29:03  - 23147  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-03-27 04:29:08  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-03-27 04:29:13  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-03-27 04:29:18  - 23147  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-03-27 04:29:23  - 23147  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-03-27 04:29:27  - 23147  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-03-27 04:29:32  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-03-27 04:29:36  - 23147  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-03-27 04:29:40  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-03-27 04:29:45  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-03-27 04:29:49  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
<pre>2017-03-27_04-29-50 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/?_prerender {"code":"ECONNRESET"}
<pre>2017-03-27_04-31-50 Restart Xvfb...
2017-03-27 04:31:54  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-03-27 04:32:00  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-03-27 04:32:04  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-03-27 04:32:07  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-03-27 04:32:11  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-03-27 04:32:15  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-03-27 04:32:19  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-03-27 04:32:23  - 23147  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-03-27 04:32:24  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-03-27 04:32:29  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-03-27 04:32:33  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-03-27 04:32:36  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-03-27 04:32:40  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-03-27 04:32:44  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-03-27 04:32:47  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-03-27 04:32:51  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-03-27 04:32:54  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-03-27 04:32:58  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-03-27 04:33:02  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-03-27 04:33:05  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-03-27 04:33:09  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-03-27 04:33:13  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-03-27 04:33:16  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-03-27 04:33:20  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-03-27 04:33:25  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-03-27 04:33:28  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-03-27 04:33:32  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-03-27 04:33:35  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-03-27 04:33:39  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-03-27 04:33:43  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-03-27 04:33:47  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
<pre>2017-03-27_04-33-50 Restart Xvfb...
2017-03-27 04:33:51  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-03-27 04:33:54  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-03-27 04:33:58  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-03-27 04:34:01  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-03-27 04:34:05  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-03-27 04:34:08  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-03-27 04:34:12  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-03-27 04:34:16  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-03-27 04:34:19  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-03-27 04:34:23  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-03-27 04:34:26  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-03-27 04:34:30  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-03-27 04:34:34  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-03-27 04:34:38  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-03-27 04:34:41  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-03-27 04:34:45  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-03-27 04:34:48  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-03-27 04:34:52  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-03-27 04:34:56  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-03-27 04:34:59  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-03-27 04:35:03  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-03-27 04:35:07  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-03-27 04:35:10  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-03-27 04:35:14  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-03-27 04:35:18  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-03-27 04:35:21  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-03-27 04:35:25  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-03-27 04:35:29  - 23147  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-03-27 04:35:34  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-03-27 04:35:39  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-03-27 04:35:43  - 23147  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-03-27 04:35:44  - 23147  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-03-27 04:35:49  - 23147  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
<pre>2017-03-27_04-35-50 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm?_prerender {"code":"ECONNRESET"}
<pre>2017-03-27_04-37-50 Restart Xvfb...
2017-03-27 04:37:54  - 23147  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-03-27 04:37:58  - 23147  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-03-27 04:38:03  - 23147  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-03-27 04:38:07  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-03-27 04:38:12  - 23147  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-03-27 04:38:16  - 23147  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-03-27 04:38:21  - 23147  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-03-27 04:38:26  - 23147  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-03-27 04:38:30  - 23147  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-03-27 04:38:35  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-03-27 04:38:39  - 23147  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-03-27 04:38:44  - 23147  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-03-27 04:38:48  - 23147  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-03-27 04:38:53  - 23147  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-03-27 04:38:57  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-03-27 04:39:01  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-03-27 04:39:06  - 23147  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-03-27 04:39:10  - 23147  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-03-27 04:39:15  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-03-27 04:39:19  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-03-27 04:39:24  - 23147  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-27 04:39:28  - 23147  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-03-27 04:39:33  - 23147  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-03-27 04:39:37  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-03-27 04:39:42  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-03-27 04:39:46  - 23147  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
<pre>2017-03-27_04-39-50 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response?_prerender {"code":"ECONNRESET"}
<pre>2017-03-27_04-41-50 Restart Xvfb...
2017-03-27 04:41:51  - 23147  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-03-27 04:41:55  - 23147  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-03-27 04:42:00  - 23147  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-03-27 04:42:04  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-03-27 04:42:09  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-03-27 04:42:13  - 23147  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-27 04:42:18  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-03-27 04:42:22  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-03-27 04:42:27  - 23147  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-03-27 04:42:31  - 23147  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-03-27 04:42:36  - 23147  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-03-27 04:42:40  - 23147  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-03-27 04:42:44  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-03-27 04:42:49  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-03-27 04:42:53  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-03-27 04:42:58  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-03-27 04:43:02  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-03-27 04:43:07  - 23147  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-03-27 04:43:11  - 23147  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-03-27 04:43:15  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-03-27 04:43:20  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-03-27 04:43:24  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-03-27 04:43:29  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-03-27 04:43:33  - 23147  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-03-27 04:43:37  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-03-27 04:43:42  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-03-27 04:43:46  - 23147  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
<pre>2017-03-27_04-43-50 Restart Xvfb...
2017-03-27 04:43:51  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
<pre>2017-03-27_04-45-50 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl?_prerender {"code":"ECONNRESET"}
2017-03-27 04:45:56  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-03-27 04:46:00  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-03-27 04:46:05  - 23147  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-03-27 04:46:10  - 23147  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-03-27 04:46:14  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-03-27 04:46:18  - 23147  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-03-27 04:46:23  - 23147  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-03-27 04:46:27  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-03-27 04:46:32  - 23147  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-03-27 04:46:36  - 23147  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-03-27 04:46:41  - 23147  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-03-27 04:46:45  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-03-27 04:46:49  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-03-27 04:46:54  - 23147  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-03-27 04:46:58  - 23147  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-03-27 04:47:03  - 23147  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-03-27 04:47:08  - 23147  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-03-27 04:47:12  - 23147  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-03-27 04:47:17  - 23147  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-03-27 04:47:21  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-03-27 04:47:25  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-03-27 04:47:30  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-03-27 04:47:34  - 23147  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-03-27 04:47:39  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-03-27 04:47:43  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-03-27 04:47:47  - 23147  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
<pre>2017-03-27_04-47-50 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot?_prerender {"code":"ECONNRESET"}
<pre>2017-03-27_04-49-50 Restart Xvfb...
2017-03-27 04:49:53  - 23147  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-03-27 04:49:57  - 23147  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-03-27 04:50:01  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-03-27 04:50:06  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-03-27 04:50:10  - 23147  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-03-27 04:50:15  - 23147  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-03-27 04:50:20  - 23147  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-03-27 04:50:23  - 23147  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-03-27 04:50:28  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-03-27 04:50:32  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-03-27 04:50:37  - 23147  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-03-27 04:50:41  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-03-27 04:50:46  - 23147  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-03-27 04:50:50  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-03-27 04:50:55  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-03-27 04:50:59  - 23147  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-03-27 04:51:03  - 23147  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-03-27 04:51:08  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-03-27 04:51:13  - 23147  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-03-27 04:51:17  - 23147  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-03-27 04:51:22  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-03-27 04:51:26  - 23147  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-03-27 04:51:30  - 23147  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-03-27 04:51:35  - 23147  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-03-27 04:51:39  - 23147  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-03-27 04:51:44  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-03-27 04:51:48  - 23147  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
<pre>2017-03-27_04-51-50 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker?_prerender {"code":"ECONNRESET"}
<pre>2017-03-27_04-53-50 Restart Xvfb...
2017-03-27 04:53:54  - 23147  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-03-27 04:53:58  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-03-27 04:54:03  - 23147  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-03-27 04:54:07  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-03-27 04:54:11  - 23147  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-03-27 04:54:16  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-03-27 04:54:20  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-03-27 04:54:25  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-03-27 04:54:29  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-03-27 04:54:34  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-03-27 04:54:39  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-03-27 04:54:43  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-03-27 04:54:47  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-03-27 04:54:52  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-03-27 04:54:56  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-03-27 04:55:01  - 23147  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-03-27 04:55:05  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-03-27 04:55:09  - 23147  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-03-27 04:55:14  - 23147  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-03-27 04:55:19  - 23147  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-03-27 04:55:23  - 23147  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-03-27 04:55:28  - 23147  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-03-27 04:55:32  - 23147  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-03-27 04:55:37  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-03-27 04:55:41  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-03-27 04:55:46  - 23147  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-03-27 04:55:50  - 23147  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
<pre>2017-03-27_04-55-51 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial?_prerender {"code":"ECONNRESET"}
<pre>2017-03-27_04-57-51 Restart Xvfb...
2017-03-27 04:57:55  - 23147  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-03-27 04:58:00  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-03-27 04:58:04  - 23147  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-03-27 04:58:09  - 23147  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-03-27 04:58:13  - 23147  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-03-27 04:58:18  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-03-27 04:58:22  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-03-27 04:58:27  - 23147  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-03-27 04:58:32  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-03-27 04:58:36  - 23147  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-03-27 04:58:40  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-03-27 04:58:45  - 23147  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-03-27 04:58:50  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-03-27 04:58:54  - 23147  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-03-27 04:58:59  - 23147  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-03-27 04:59:03  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-03-27 04:59:07  - 23147  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-03-27 04:59:11  - 23147  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-03-27 04:59:16  - 23147  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-03-27 04:59:20  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-03-27 04:59:25  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-03-27 04:59:29  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-03-27 04:59:33  - 23147  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-03-27 04:59:38  - 23147  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-03-27 04:59:42  - 23147  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-03-27 04:59:47  - 23147  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-03-27 04:59:50  - 23147  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
<pre>2017-03-27_04-59-51 Restart Xvfb...
2017-03-27 04:59:54  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-03-27 04:59:59  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-03-27 05:00:04  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-03-27 05:00:08  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-03-27 05:00:12  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-03-27 05:00:17  - 23147  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-03-27 05:00:22  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-03-27 05:00:29  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-03-27 05:00:33  - 23147  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-03-27 05:00:38  - 23147  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-03-27 05:00:42  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-03-27 05:00:46  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-03-27 05:00:50  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-03-27 05:00:55  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-03-27 05:00:59  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-03-27 05:01:04  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-03-27 05:01:08  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-03-27 05:01:13  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-03-27 05:01:17  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-03-27 05:01:21  - 23147  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-03-27 05:01:25  - 23147  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-03-27 05:01:30  - 23147  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-03-27 05:01:34  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-03-27 05:01:38  - 23147  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-03-27 05:01:42  - 23147  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-03-27 05:01:47  - 23147  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
<pre>2017-03-27_05-01-51 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided?_prerender {"code":"ECONNRESET"}
<pre>2017-03-27_05-03-51 Restart Xvfb...
2017-03-27 05:03:52  - 23147  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-03-27 05:03:56  - 23147  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-03-27 05:04:01  - 23147  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-03-27 05:04:05  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-03-27 05:04:10  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-03-27 05:04:14  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-03-27 05:04:18  - 23147  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-03-27 05:04:23  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-03-27 05:04:28  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-03-27 05:04:32  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-03-27 05:04:36  - 23147  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-03-27 05:04:41  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-03-27 05:04:45  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-03-27 05:04:50  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-03-27 05:04:54  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-03-27 05:04:58  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-03-27 05:05:02  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-03-27 05:05:06  - 23147  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-03-27 05:05:11  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-03-27 05:05:16  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-03-27 05:05:20  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-03-27 05:05:24  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-03-27 05:05:29  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-03-27 05:05:33  - 23147  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-03-27 05:05:37  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-03-27 05:05:41  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-03-27 05:05:45  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-03-27 05:05:50  - 23147  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
<pre>2017-03-27_05-05-51 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma?_prerender {"code":"ECONNRESET"}
<pre>2017-03-27_05-07-51 Restart Xvfb...
2017-03-27 05:07:55  - 23147  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-03-27 05:07:59  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-03-27 05:08:04  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-03-27 05:08:08  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-03-27 05:08:13  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-03-27 05:08:17  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-03-27 05:08:21  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-03-27 05:08:25  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-03-27 05:08:29  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-03-27 05:08:33  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-03-27 05:08:41  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-03-27 05:08:45  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-03-27 05:08:49  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-03-27 05:08:53  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-03-27 05:08:57  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-03-27 05:09:01  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-03-27 05:09:05  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-03-27 05:09:09  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-03-27 05:09:14  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-03-27 05:09:18  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-03-27 05:09:22  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-03-27 05:09:26  - 23147  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-03-27 05:09:30  - 23147  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-03-27 05:09:34  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-03-27 05:09:39  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-03-27 05:09:43  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-03-27 05:09:47  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
<pre>2017-03-27_05-09-51 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma?_prerender {"code":"ECONNRESET"}
<pre>2017-03-27_05-11-51 Restart Xvfb...
2017-03-27 05:11:52  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-03-27 05:11:56  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-03-27 05:12:01  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-03-27 05:12:05  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-03-27 05:12:10  - 23147  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-03-27 05:12:14  - 23147  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-03-27 05:12:18  - 23147  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-03-27 05:12:22  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-03-27 05:12:26  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-03-27 05:12:30  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-03-27 05:12:34  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-03-27 05:12:38  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-03-27 05:12:42  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-27 05:12:46  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-27 05:12:50  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-27 05:12:54  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-27 05:12:58  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-03-27 05:13:02  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-27 05:13:06  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-27 05:13:10  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-03-27 05:13:14  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-03-27 05:13:18  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-03-27 05:13:22  - 23147  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-03-27 05:13:26  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-03-27 05:13:30  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-03-27 05:13:34  - 23147  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-03-27 05:13:38  - 23147  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-03-27 05:13:42  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-03-27 05:13:46  - 23147  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-03-27 05:13:50  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
<pre>2017-03-27_05-13-51 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-?_prerender {"code":"ECONNRESET"}
<pre>2017-03-27_05-15-51 Restart Xvfb...
2017-03-27 05:15:55  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-03-27 05:15:59  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-03-27 05:16:04  - 23147  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-03-27 05:16:08  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-03-27 05:16:12  - 23147  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-03-27 05:16:16  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-03-27 05:16:20  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-03-27 05:16:24  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-03-27 05:16:28  - 23147  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-03-27 05:16:32  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-03-27 05:16:36  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-27 05:16:39  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-27 05:16:43  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-27 05:16:47  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-27 05:16:51  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-27 05:16:55  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-03-27 05:16:59  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-27 05:17:03  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-27 05:17:07  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-27 05:17:11  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-27 05:17:15  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-03-27 05:17:19  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-27 05:17:23  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-27 05:17:26  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-27 05:17:30  - 23147  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-03-27 05:17:34  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
<pre>2017-03-27_05-17-51 Restart Xvfb...
<pre>2017-03-27_05-19-51 Restart Xvfb...
<pre>2017-03-27_05-21-51 Restart Xvfb...
<pre>2017-03-27_05-23-51 Restart Xvfb...
<pre>2017-03-27_05-25-51 Restart Xvfb...
<pre>2017-03-27_05-27-51 Restart Xvfb...
<pre>2017-03-27_05-29-51 Restart Xvfb...
<pre>2017-03-27_05-31-51 Restart Xvfb...
<pre>2017-03-27_05-33-51 Restart Xvfb...
<pre>2017-03-27_05-35-51 Restart Xvfb...
<pre>2017-03-27_05-37-51 Restart Xvfb...
<pre>2017-03-27_05-39-51 Restart Xvfb...
<pre>2017-03-27_05-41-51 Restart Xvfb...
<pre>2017-03-27_05-43-51 Restart Xvfb...
<pre>2017-03-27_05-45-51 Restart Xvfb...
<pre>2017-03-27_05-47-51 Restart Xvfb...
<pre>2017-03-27_05-49-51 Restart Xvfb...
<pre>2017-03-27_05-51-51 Restart Xvfb...
<pre>2017-03-27_05-53-51 Restart Xvfb...
<pre>2017-03-27_05-55-51 Restart Xvfb...
<pre>2017-03-27_05-57-51 Restart Xvfb...
<pre>2017-03-27_05-59-51 Restart Xvfb...
<pre>2017-03-27_06-01-51 Restart Xvfb...
<pre>2017-03-27_06-03-51 Restart Xvfb...
<pre>2017-03-27_06-05-51 Restart Xvfb...
<pre>2017-03-27_06-07-51 Restart Xvfb...
<pre>2017-03-27_06-09-51 Restart Xvfb...
<pre>2017-03-27_06-11-51 Restart Xvfb...
<pre>2017-03-27_06-13-51 Restart Xvfb...
<pre>2017-03-27_06-15-51 Restart Xvfb...
<pre>2017-03-27_06-17-51 Restart Xvfb...
<pre>2017-03-27_06-19-51 Restart Xvfb...
<pre>2017-03-27_06-21-51 Restart Xvfb...
<pre>2017-03-27_06-23-51 Restart Xvfb...
<pre>2017-03-27_06-25-51 Restart Xvfb...
<pre>2017-03-27_06-27-51 Restart Xvfb...
<pre>2017-03-27_06-29-51 Restart Xvfb...
<pre>2017-03-27_06-31-51 Restart Xvfb...
<pre>2017-03-27_06-33-51 Restart Xvfb...
<pre>2017-03-27_06-35-51 Restart Xvfb...
<pre>2017-03-27_06-37-51 Restart Xvfb...
<pre>2017-03-27_06-39-51 Restart Xvfb...
<pre>2017-03-27_06-41-51 Restart Xvfb...
<pre>2017-03-27_06-43-51 Restart Xvfb...
<pre>2017-03-27_06-45-51 Restart Xvfb...
<pre>2017-03-27_06-47-51 Restart Xvfb...
<pre>2017-03-27_06-49-52 Restart Xvfb...
<pre>2017-03-27_06-51-52 Restart Xvfb...
<pre>2017-03-27_06-53-52 Restart Xvfb...
<pre>2017-03-27_06-55-52 Restart Xvfb...
2017-03-27 06:56:59 reset updateRequest
2017-03-27 06:57:01  - 23147  http://www.lymphomahub.com/
2017-03-27 06:57:04  - 23147  http://www.lymphomahub.com/
2017-03-27 06:57:06  - 23147  http://www.lymphomahub.com/about
2017-03-27 06:57:08  - 23147  http://www.lymphomahub.com/about
2017-03-27 06:57:12  - 23147  http://www.lymphomahub.com/terms
2017-03-27 06:57:16  - 23147  http://www.lymphomahub.com/undefined
2017-03-27 06:57:16  - 23147  http://www.lymphomahub.com/therapies
2017-03-27 06:57:22  - 23147  http://www.lymphomahub.com/newsletter
2017-03-27 06:57:25  - 23147  http://www.lymphomahub.com/cookie-policy
2017-03-27 06:57:28  - 23147  http://www.lymphomahub.com/therapies/afm13
2017-03-27 06:57:33  - 23147  http://www.lymphomahub.com/therapies/afm11
2017-03-27 06:57:37  - 23147  http://www.lymphomahub.com/therapies/ags67e
2017-03-27 06:57:41  - 23147  http://www.lymphomahub.com/therapies/cc-292
2017-03-27 06:57:46  - 23147  http://www.lymphomahub.com/therapies/cc-223
2017-03-27 06:57:50  - 23147  http://www.lymphomahub.com/therapies/sd-101
<pre>2017-03-27_06-57-52 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/sd-101?_prerender {"code":"ECONNRESET"}
<pre>2017-03-27_06-59-52 Restart Xvfb...
2017-03-27 06:59:55  - 23147  http://www.lymphomahub.com/therapies/sd-101
2017-03-27 07:00:00  - 23147  http://www.lymphomahub.com/therapies/rp6530
2017-03-27 07:00:04  - 23147  http://www.lymphomahub.com/therapies/abt199
2017-03-27 07:00:05  - 23147  http://www.lymphomahub.com/therapies/mor208
2017-03-27 07:00:09  - 23147  http://www.lymphomahub.com/therapies/cc-122
2017-03-27 07:00:15  - 23147  http://www.lymphomahub.com/therapies/at-101
2017-03-27 07:00:23  - 23147  http://www.lymphomahub.com/therapies/bl8040
2017-03-27 07:00:28  - 23147  http://www.lymphomahub.com/therapies/bcl201
2017-03-27 07:00:32  - 23147  http://www.lymphomahub.com/therapies/azd3965
2017-03-27 07:00:36  - 23147  http://www.lymphomahub.com/therapies/imgn529
2017-03-27 07:00:40  - 23147  http://www.lymphomahub.com/therapies/azd2014
2017-03-27 07:00:45  - 23147  http://www.lymphomahub.com/therapies/mt-3724
2017-03-27 07:00:49  - 23147  http://www.lymphomahub.com/therapies/actr087
2017-03-27 07:00:53  - 23147  http://www.lymphomahub.com/therapies/epz6438
2017-03-27 07:00:58  - 23147  http://www.lymphomahub.com/therapies/kte-c19
2017-03-27 07:01:03  - 23147  http://www.lymphomahub.com/about/secretariat
2017-03-27 07:01:06  - 23147  http://www.lymphomahub.com/therapies/alt-803
2017-03-27 07:01:11  - 23147  http://www.lymphomahub.com/therapies/regn1979
2017-03-27 07:01:15  - 23147  http://www.lymphomahub.com/therapies/immu-114
2017-03-27 07:01:19  - 23147  http://www.lymphomahub.com/therapies/incb7839
2017-03-27 07:01:24  - 23147  http://www.lymphomahub.com/therapies/adct-301
2017-03-27 07:01:28  - 23147  http://www.lymphomahub.com/therapies/ixazomib
2017-03-27 07:01:32  - 23147  http://www.lymphomahub.com/therapies/avelumab
2017-03-27 07:01:36  - 23147  http://www.lymphomahub.com/therapies/bi836826
2017-03-27 07:01:41  - 23147  http://www.lymphomahub.com/therapies/medi-570
2017-03-27 07:01:45  - 23147  http://www.lymphomahub.com/therapies/ds-3201b
2017-03-27 07:01:49  - 23147  http://www.lymphomahub.com/therapies/sea-cd40
<pre>2017-03-27_07-01-52 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/sea-cd40?_prerender {"code":"ECONNRESET"}
<pre>2017-03-27_07-03-52 Restart Xvfb...
2017-03-27 07:03:54  - 23147  http://www.lymphomahub.com/therapies/sea-cd40
2017-03-27 07:03:58  - 23147  http://www.lymphomahub.com/therapies/adct-402
2017-03-27 07:04:03  - 23147  http://www.lymphomahub.com/therapies/acy-1215
2017-03-27 07:04:07  - 23147  http://www.lymphomahub.com/therapies/cudc-907
2017-03-27 07:04:11  - 23147  http://www.lymphomahub.com/therapies/tgr-1202
2017-03-27 07:04:15  - 23147  http://www.lymphomahub.com/therapies/axitinib
2017-03-27 07:04:20  - 23147  http://www.lymphomahub.com/therapies/imatinib
2017-03-27 07:04:24  - 23147  http://www.lymphomahub.com/therapies/edo-s101
2017-03-27 07:04:28  - 23147  http://www.lymphomahub.com/therapies/btct4465a
2017-03-27 07:04:33  - 23147  http://www.lymphomahub.com/therapies/alisertib
2017-03-27 07:04:37  - 23147  http://www.lymphomahub.com/therapies/lirilumab
2017-03-27 07:04:42  - 23147  http://www.lymphomahub.com/therapies/ibrutinib
2017-03-27 07:04:42  - 23147  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-03-27 07:04:47  - 23147  http://www.lymphomahub.com/therapies/rituximab
2017-03-27 07:04:51  - 23147  http://www.lymphomahub.com/therapies/veliparib
2017-03-27 07:04:55  - 23147  http://www.lymphomahub.com/therapies/sunitinib
2017-03-27 07:05:00  - 23147  http://www.lymphomahub.com/therapies/nivolumab
2017-03-27 07:05:00  - 23147  http://www.lymphomahub.com/therapies/sirolimus
2017-03-27 07:05:05  - 23147  http://www.lymphomahub.com/medical-information
2017-03-27 07:05:09  - 23147  http://www.lymphomahub.com/therapies/selinexor
2017-03-27 07:05:14  - 23147  http://www.lymphomahub.com/therapies/abc294640
2017-03-27 07:05:19  - 23147  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-03-27 07:05:23  - 23147  http://www.lymphomahub.com/therapies/tenofovir
2017-03-27 07:05:27  - 23147  http://www.lymphomahub.com/therapies/betalutin
2017-03-27 07:05:31  - 23147  http://www.lymphomahub.com/therapies/chidamide
2017-03-27 07:05:36  - 23147  http://www.lymphomahub.com/therapies/duvelisib
2017-03-27 07:05:40  - 23147  http://www.lymphomahub.com/therapies/dasatinib
2017-03-27 07:05:44  - 23147  http://www.lymphomahub.com/therapies/everolimus
2017-03-27 07:05:49  - 23147  http://www.lymphomahub.com/therapies/incb039110
<pre>2017-03-27_07-05-52 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/incb039110?_prerender {"code":"ECONNRESET"}
<pre>2017-03-27_07-07-52 Restart Xvfb...
2017-03-27 07:07:54  - 23147  http://www.lymphomahub.com/therapies/incb039110
2017-03-27 07:07:58  - 23147  http://www.lymphomahub.com/therapies/durvalumab
2017-03-27 07:08:02  - 23147  http://www.lymphomahub.com/therapies/romidepsin
2017-03-27 07:08:07  - 23147  http://www.lymphomahub.com/therapies/bortezomib
2017-03-27 07:08:11  - 23147  http://www.lymphomahub.com/therapies/idelalisib
2017-03-27 07:08:12  - 23147  http://www.lymphomahub.com/therapies/tipifarnib
2017-03-27 07:08:16  - 23147  http://www.lymphomahub.com/therapies/ipilimumab
2017-03-27 07:08:20  - 23147  http://www.lymphomahub.com/therapies/crizotinib
2017-03-27 07:08:25  - 23147  http://www.lymphomahub.com/therapies/gsk2816126
2017-03-27 07:08:29  - 23147  http://www.lymphomahub.com/therapies/copanlisib
2017-03-27 07:08:33  - 23147  http://www.lymphomahub.com/therapies/buparlisib
2017-03-27 07:08:37  - 23147  http://www.lymphomahub.com/therapies/belinostat
2017-03-27 07:08:42  - 23147  http://www.lymphomahub.com/therapies/vorinostat
2017-03-27 07:08:46  - 23147  http://www.lymphomahub.com/therapies/plerixafor
2017-03-27 07:08:47  - 23147  http://www.lymphomahub.com/therapies/ofatumumab
2017-03-27 07:08:51  - 23147  http://www.lymphomahub.com/therapies/pf-06801591
2017-03-27 07:08:56  - 23147  http://www.lymphomahub.com/therapies/tocilizumab
2017-03-27 07:09:00  - 23147  http://www.lymphomahub.com/therapies/msc2490484a
2017-03-27 07:09:05  - 23147  http://www.lymphomahub.com/therapies/carfilzomib
2017-03-27 07:09:09  - 23147  http://www.lymphomahub.com/therapies/ruxolitinib
2017-03-27 07:09:13  - 23147  http://www.lymphomahub.com/therapies/palbociclib
2017-03-27 07:09:18  - 23147  http://www.lymphomahub.com/therapies/fenretinide
2017-03-27 07:09:22  - 23147  http://www.lymphomahub.com/therapies/daratumumab
2017-03-27 07:09:26  - 23147  http://www.lymphomahub.com/therapies/pf-05082566
2017-03-27 07:09:30  - 23147  http://www.lymphomahub.com/therapies/ramucirumab
2017-03-27 07:09:35  - 23147  http://www.lymphomahub.com/therapies/tositumomab
2017-03-27 07:09:39  - 23147  http://www.lymphomahub.com/therapies/ublituximab
2017-03-27 07:09:43  - 23147  http://www.lymphomahub.com/therapies/epacadostat
2017-03-27 07:09:47  - 23147  http://www.lymphomahub.com/therapies/alemtuzumab
2017-03-27 07:09:48  - 23147  http://www.lymphomahub.com/therapies/otlertuzumab
<pre>2017-03-27_07-09-52 Restart Xvfb...
2017-03-27 07:09:52  - 23147  http://www.lymphomahub.com/therapies/panobinostat
2017-03-27 07:09:56  - 23147  http://www.lymphomahub.com/therapies/mocetinostat
2017-03-27 07:10:01  - 23147  http://www.lymphomahub.com/therapies/atezolizumab
2017-03-27 07:10:05  - 23147  http://www.lymphomahub.com/therapies/temsirolimus
2017-03-27 07:10:09  - 23147  http://www.lymphomahub.com/therapies/lenalidomide
2017-03-27 07:10:14  - 23147  http://www.lymphomahub.com/therapies/obinutuzumab
2017-03-27 07:10:18  - 23147  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-03-27 07:10:22  - 23147  http://www.lymphomahub.com/therapies/blinatumomab
2017-03-27 07:10:27  - 23147  http://www.lymphomahub.com/therapies/jnj-64052781
2017-03-27 07:10:31  - 23147  http://www.lymphomahub.com/therapies/entospletinib
2017-03-27 07:10:35  - 23147  http://www.lymphomahub.com/therapies/pembrolizumab
2017-03-27 07:10:39  - 23147  http://www.lymphomahub.com/therapies/acalabrutinib
2017-03-27 07:10:44  - 23147  http://www.lymphomahub.com/about/innovation-committee
2017-03-27 07:10:47  - 23147  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-03-27 07:10:48  - 23147  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-03-27 07:10:52  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-03-27 07:10:56  - 23147  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-03-27 07:11:01  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-03-27 07:11:05  - 23147  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-03-27 07:11:06  - 23147  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-03-27 07:11:10  - 23147  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-03-27 07:11:15  - 23147  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-03-27 07:11:19  - 23147  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-03-27 07:11:23  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board
2017-03-27 07:11:27  - 23147  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-03-27 07:11:31  - 23147  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-03-27 07:11:35  - 23147  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-03-27 07:11:38  - 23147  http://www.lymphomahub.com/about/executive-steering-committee
2017-03-27 07:11:42  - 23147  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-03-27 07:11:46  - 23147  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-03-27 07:11:50  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
<pre>2017-03-27_07-11-52 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim?_prerender {"code":"ECONNRESET"}
<pre>2017-03-27_07-13-52 Restart Xvfb...
2017-03-27 07:13:56  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-03-27 07:14:01  - 23147  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-03-27 07:14:05  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-03-27 07:14:09  - 23147  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-03-27 07:14:13  - 23147  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-03-27 07:14:13  - 23147  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-03-27 07:14:17  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-03-27 07:14:22  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-03-27 07:14:28  - 23147  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-03-27 07:14:31  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-03-27 07:14:36  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-03-27 07:14:40  - 23147  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-03-27 07:14:44  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-03-27 07:14:48  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-03-27 07:14:51  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-03-27 07:14:55  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-03-27 07:14:59  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-03-27 07:15:03  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-03-27 07:15:07  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-03-27 07:15:10  - 23147  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-03-27 07:15:15  - 23147  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-03-27 07:15:19  - 23147  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-03-27 07:15:24  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-03-27 07:15:27  - 23147  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-03-27 07:15:31  - 23147  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-03-27 07:15:36  - 23147  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-03-27 07:15:40  - 23147  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-03-27 07:15:45  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-03-27 07:15:48  - 23147  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
<pre>2017-03-27_07-15-52 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/?_prerender {"code":"ECONNRESET"}
<pre>2017-03-27_07-17-52 Restart Xvfb...
2017-03-27 07:17:54  - 23147  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-03-27 07:17:57  - 23147  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-03-27 07:18:02  - 23147  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-03-27 07:18:06  - 23147  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-03-27 07:18:11  - 23147  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-03-27 07:18:15  - 23147  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-03-27 07:18:20  - 23147  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-03-27 07:18:24  - 23147  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-03-27 07:18:29  - 23147  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-03-27 07:18:33  - 23147  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-03-27 07:18:37  - 23147  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-03-27 07:18:42  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-03-27 07:18:46  - 23147  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-03-27 07:18:50  - 23147  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-03-27 07:18:55  - 23147  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-03-27 07:19:00  - 23147  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-03-27 07:19:04  - 23147  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-03-27 07:19:09  - 23147  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-03-27 07:19:13  - 23147  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-03-27 07:19:17  - 23147  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-03-27 07:19:21  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-03-27 07:19:25  - 23147  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-03-27 07:19:29  - 23147  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-03-27 07:19:34  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-03-27 07:19:37  - 23147  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-03-27 07:19:42  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-03-27 07:19:46  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-03-27 07:19:50  - 23147  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
<pre>2017-03-27_07-19-52 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker?_prerender {"code":"ECONNRESET"}
<pre>2017-03-27_07-21-52 Restart Xvfb...
2017-03-27 07:21:55  - 23147  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-03-27 07:21:59  - 23147  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-03-27 07:22:04  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-03-27 07:22:08  - 23147  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-03-27 07:22:12  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-03-27 07:22:16  - 23147  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-03-27 07:22:20  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-03-27 07:22:24  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-03-27 07:22:29  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-03-27 07:22:32  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-03-27 07:22:36  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-03-27 07:22:40  - 23147  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-03-27 07:22:44  - 23147  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-03-27 07:22:48  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-03-27 07:22:52  - 23147  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-03-27 07:22:57  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-03-27 07:23:01  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-03-27 07:23:06  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-03-27 07:23:10  - 23147  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-27 07:23:11  - 23147  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-03-27 07:23:15  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-03-27 07:23:20  - 23147  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-03-27 07:23:24  - 23147  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-03-27 07:23:29  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-03-27 07:23:33  - 23147  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-03-27 07:23:38  - 23147  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-03-27 07:23:42  - 23147  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-03-27 07:23:47  - 23147  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-03-27 07:23:51  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
<pre>2017-03-27_07-23-52 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl?_prerender {"code":"ECONNRESET"}
<pre>2017-03-27_07-25-52 Restart Xvfb...
2017-03-27 07:25:56  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-03-27 07:26:01  - 23147  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-03-27 07:26:05  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-03-27 07:26:10  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-03-27 07:26:14  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-03-27 07:26:19  - 23147  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-03-27 07:26:24  - 23147  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-03-27 07:26:28  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-03-27 07:26:33  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-03-27 07:26:37  - 23147  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-03-27 07:26:42  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-03-27 07:26:46  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-03-27 07:26:51  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-03-27 07:26:55  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-03-27 07:27:00  - 23147  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-27 07:27:05  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-03-27 07:27:09  - 23147  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-03-27 07:27:14  - 23147  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-03-27 07:27:18  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-03-27 07:27:22  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-03-27 07:27:27  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-03-27 07:27:31  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-03-27 07:27:36  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-03-27 07:27:40  - 23147  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-03-27 07:27:45  - 23147  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-03-27 07:27:49  - 23147  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
<pre>2017-03-27_07-27-52 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value?_prerender {"code":"ECONNRESET"}
<pre>2017-03-27_07-29-52 Restart Xvfb...
2017-03-27 07:29:54  - 23147  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-03-27 07:29:58  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-03-27 07:30:03  - 23147  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-03-27 07:30:08  - 23147  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-03-27 07:30:12  - 23147  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-03-27 07:30:13  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-03-27 07:30:17  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-03-27 07:30:22  - 23147  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-03-27 07:30:27  - 23147  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-03-27 07:30:31  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-03-27 07:30:36  - 23147  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-03-27 07:30:40  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-03-27 07:30:45  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-03-27 07:30:49  - 23147  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-03-27 07:30:54  - 23147  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-03-27 07:30:58  - 23147  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-03-27 07:31:02  - 23147  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-03-27 07:31:07  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-03-27 07:31:12  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-03-27 07:31:16  - 23147  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-03-27 07:31:21  - 23147  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-03-27 07:31:25  - 23147  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-03-27 07:31:30  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-03-27 07:31:34  - 23147  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-03-27 07:31:39  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-03-27 07:31:44  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-03-27 07:31:47  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
<pre>2017-03-27_07-31-52 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/?_prerender {"code":"ECONNRESET"}
<pre>2017-03-27_07-33-52 Restart Xvfb...
2017-03-27 07:33:52  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-03-27 07:33:58  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-03-27 07:34:03  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-03-27 07:34:06  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-03-27 07:34:10  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-03-27 07:34:14  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-03-27 07:34:18  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-03-27 07:34:22  - 23147  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-03-27 07:34:23  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-03-27 07:34:27  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-03-27 07:34:31  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-03-27 07:34:35  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-03-27 07:34:39  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-03-27 07:34:42  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-03-27 07:34:46  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-03-27 07:34:49  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-03-27 07:34:53  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-03-27 07:34:57  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-03-27 07:35:00  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-03-27 07:35:04  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-03-27 07:35:08  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-03-27 07:35:11  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-03-27 07:35:15  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-03-27 07:35:19  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-03-27 07:35:23  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-03-27 07:35:27  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-03-27 07:35:30  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-03-27 07:35:34  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-03-27 07:35:37  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-03-27 07:35:41  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-03-27 07:35:44  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-03-27 07:35:48  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-03-27 07:35:51  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
<pre>2017-03-27_07-35-52 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/?_prerender {"code":"ECONNRESET"}
<pre>2017-03-27_07-37-52 Restart Xvfb...
2017-03-27 07:37:56  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-03-27 07:38:00  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-03-27 07:38:04  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-03-27 07:38:07  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-03-27 07:38:11  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-03-27 07:38:15  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-03-27 07:38:18  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-03-27 07:38:22  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-03-27 07:38:26  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-03-27 07:38:29  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-03-27 07:38:33  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-03-27 07:38:36  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-03-27 07:38:40  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-03-27 07:38:44  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-03-27 07:38:47  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-03-27 07:38:51  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-03-27 07:38:55  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-03-27 07:38:58  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-03-27 07:39:02  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-03-27 07:39:05  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-03-27 07:39:09  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-03-27 07:39:13  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-03-27 07:39:16  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-03-27 07:39:20  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-03-27 07:39:23  - 23147  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-03-27 07:39:27  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-03-27 07:39:32  - 23147  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-03-27 07:39:36  - 23147  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-03-27 07:39:41  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-03-27 07:39:46  - 23147  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-03-27 07:39:46  - 23147  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-03-27 07:39:51  - 23147  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
<pre>2017-03-27_07-39-52 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm?_prerender {"code":"ECONNRESET"}
<pre>2017-03-27_07-41-52 Restart Xvfb...
2017-03-27 07:41:56  - 23147  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-03-27 07:42:01  - 23147  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-03-27 07:42:05  - 23147  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-03-27 07:42:09  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-03-27 07:42:14  - 23147  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-03-27 07:42:18  - 23147  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-03-27 07:42:23  - 23147  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-03-27 07:42:27  - 23147  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-03-27 07:42:32  - 23147  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-03-27 07:42:36  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-03-27 07:42:41  - 23147  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-03-27 07:42:45  - 23147  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-03-27 07:42:50  - 23147  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-03-27 07:42:54  - 23147  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-03-27 07:42:59  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-03-27 07:43:03  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-03-27 07:43:08  - 23147  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-03-27 07:43:12  - 23147  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-03-27 07:43:17  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-03-27 07:43:21  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-03-27 07:43:26  - 23147  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-27 07:43:30  - 23147  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-03-27 07:43:34  - 23147  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-03-27 07:43:39  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-03-27 07:43:43  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-03-27 07:43:48  - 23147  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
<pre>2017-03-27_07-43-52 Restart Xvfb...
2017-03-27 07:43:52  - 23147  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-03-27 07:43:57  - 23147  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-03-27 07:44:01  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-03-27 07:44:06  - 23147  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-03-27 07:44:10  - 23147  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-27 07:44:15  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-03-27 07:44:19  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-03-27 07:44:23  - 23147  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-03-27 07:44:28  - 23147  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-03-27 07:44:33  - 23147  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-03-27 07:44:37  - 23147  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-03-27 07:44:41  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-03-27 07:44:46  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-03-27 07:44:50  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-03-27 07:44:55  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-03-27 07:44:59  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-03-27 07:45:04  - 23147  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-03-27 07:45:09  - 23147  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-03-27 07:45:13  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-03-27 07:45:17  - 23147  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-03-27 07:45:21  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-03-27 07:45:26  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-03-27 07:45:30  - 23147  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-03-27 07:45:34  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-03-27 07:45:39  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-03-27 07:45:43  - 23147  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-03-27 07:45:48  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
<pre>2017-03-27_07-45-52 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl?_prerender {"code":"ECONNRESET"}
<pre>2017-03-27_07-47-52 Restart Xvfb...
2017-03-27 07:47:54  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-03-27 07:47:58  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-03-27 07:48:03  - 23147  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-03-27 07:48:07  - 23147  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-03-27 07:48:12  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-03-27 07:48:16  - 23147  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-03-27 07:48:20  - 23147  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-03-27 07:48:25  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-03-27 07:48:29  - 23147  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-03-27 07:48:34  - 23147  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-03-27 07:48:39  - 23147  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-03-27 07:48:43  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-03-27 07:48:47  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-03-27 07:48:52  - 23147  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-03-27 07:48:56  - 23147  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-03-27 07:49:01  - 23147  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-03-27 07:49:06  - 23147  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-03-27 07:49:11  - 23147  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-03-27 07:49:16  - 23147  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-03-27 07:49:21  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-03-27 07:49:25  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-03-27 07:49:30  - 23147  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-03-27 07:49:34  - 23147  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-03-27 07:49:38  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-03-27 07:49:43  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-03-27 07:49:47  - 23147  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-03-27 07:49:51  - 23147  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
<pre>2017-03-27_07-49-52 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator?_prerender {"code":"ECONNRESET"}
<pre>2017-03-27_07-51-52 Restart Xvfb...
2017-03-27 07:51:57  - 23147  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-03-27 07:52:01  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-03-27 07:52:06  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-03-27 07:52:11  - 23147  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-03-27 07:52:16  - 23147  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-03-27 07:52:20  - 23147  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-03-27 07:52:24  - 23147  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-03-27 07:52:29  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-03-27 07:52:33  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-03-27 07:52:38  - 23147  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-03-27 07:52:42  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-03-27 07:52:47  - 23147  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-03-27 07:52:51  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-03-27 07:52:55  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-03-27 07:53:00  - 23147  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-03-27 07:53:04  - 23147  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-03-27 07:53:09  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-03-27 07:53:13  - 23147  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-03-27 07:53:18  - 23147  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-03-27 07:53:22  - 23147  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-03-27 07:53:26  - 23147  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-03-27 07:53:31  - 23147  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-03-27 07:53:36  - 23147  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-03-27 07:53:40  - 23147  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-03-27 07:53:45  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-03-27 07:53:49  - 23147  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
<pre>2017-03-27_07-53-52 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker?_prerender {"code":"ECONNRESET"}
<pre>2017-03-27_07-55-52 Restart Xvfb...
2017-03-27 07:55:54  - 23147  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-03-27 07:55:59  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-03-27 07:56:04  - 23147  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-03-27 07:56:08  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-03-27 07:56:12  - 23147  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-03-27 07:56:17  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-03-27 07:56:22  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-03-27 07:56:26  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-03-27 07:56:31  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-03-27 07:56:35  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-03-27 07:56:40  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-03-27 07:56:44  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-03-27 07:56:48  - 23147  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-03-27 07:56:53  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-03-27 07:56:57  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-03-27 07:57:02  - 23147  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-03-27 07:57:06  - 23147  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-03-27 07:57:10  - 23147  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-03-27 07:57:14  - 23147  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-03-27 07:57:19  - 23147  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-03-27 07:57:24  - 23147  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-03-27 07:57:28  - 23147  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-03-27 07:57:32  - 23147  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-03-27 07:57:37  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-03-27 07:57:41  - 23147  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-03-27 07:57:46  - 23147  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-03-27 07:57:50  - 23147  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
<pre>2017-03-27_07-57-52 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial?_prerender {"code":"ECONNRESET"}
<pre>2017-03-27_07-59-52 Restart Xvfb...
2017-03-27 07:59:55  - 23147  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-03-27 08:00:00  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-03-27 08:00:05  - 23147  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-03-27 08:00:09  - 23147  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-03-27 08:00:14  - 23147  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-03-27 08:00:18  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-03-27 08:00:28  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-03-27 08:00:32  - 23147  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-03-27 08:00:38  - 23147  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-03-27 08:00:43  - 23147  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-03-27 08:00:47  - 23147  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-03-27 08:00:52  - 23147  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-03-27 08:00:57  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-03-27 08:01:01  - 23147  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-03-27 08:01:06  - 23147  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-03-27 08:01:10  - 23147  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-03-27 08:01:15  - 23147  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-03-27 08:01:19  - 23147  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-03-27 08:01:23  - 23147  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-03-27 08:01:29  - 23147  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-03-27 08:01:33  - 23147  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-03-27 08:01:37  - 23147  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-03-27 08:01:42  - 23147  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-03-27 08:01:46  - 23147  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-03-27 08:01:51  - 23147  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
<pre>2017-03-27_08-01-52 Restart Xvfb...
